question_text,nct_id,retrieval_score,matching_terms,trial_title,brief_summary,interventions,trial_phase,trial_age_range,diseases_targeted,inclusion_criteria,exclusion_criteria,prior_therapies,gender,model_grade,reasoning,patient_diseases_targeted,patient_biomarkers,patient_inclusion_criteria,patient_exclusion_criteria,patient_prior_therapies,patient_disease_stage,patient_line_of_therapy,patient_age,patient_age_unit,patient_sex,patient_trial_phase_preference,judge_accuracy,judge_correct_grade,judge_comment,human_grade,human_notes
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT00102648,0.8363864421844482,Recurrent Glioblastoma,Phase I/Ib Study of Sarasar and Temodar in Patients with Recurrent or Temodar-Refractory Glioblastoma Multiforme,"This phase I trial studies the side effects and best dose of lonafarnib when given together with temozolomide and to see how well they work in treating patients with glioblastoma multiforme that is has come back or did not respond to previous treatment with temozolomide. Lonafarnib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killi...","{'id': 205501910, 'name': 'Lonafarnib', 'description': 'Given PO', 'other_names': ['4-[2-[4-[(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide', 'Sarasar', 'SCH 66336', 'SCH-66336', 'SCH66336'], 'intervention_type': 'DRUG'}; {'id': 205501911, 'name': 'Temozolomide', 'description': 'Given PO', 'other_names': ['CCRG-81045', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'M & B 39831', 'M and B 39831', 'Methazolastone', 'RP-46161', 'SCH 52365', 'Temcad', 'Temodal', 'Temodar', 'Temomedac'], 'intervention_type': 'DRUG'}",PHASE1,18 years,Glioblastoma (recurrent); Gliosarcoma (recurrent),"Histologically proven supratentorial glioblastoma multiforme or gliosarcoma | Radiographic evidence of tumor recurrence or progression by MRI/CT after radiation therapy | Imaging within 14 days prior to registration with stable or decreasing steroid dose for >=5 days | Post-resection patients: >=2 weeks from surgery, recovered with adequate wound healing | Post-resection imaging: CT/MRI within 96 hours post-op or >=4 weeks post-op (within 14 days of registration) with stable steroids for 5 days | Karnofsky performance status >=60 | Recovered from prior therapy toxicities | Washouts: >=4 weeks from prior cytotoxic therapy; >=2 weeks from vincristine; >=6 weeks from nitrosoureas; >=3 weeks from procarbazine; >=1 week from non-cytotoxic agents","Current use of enzyme-inducing anticonvulsants (primidone, carbamazepine, phenobarbital, phenytoin) or not off them for at least 72 hours prior to treatment | History of another cancer (except non-melanoma skin cancer or cervical carcinoma in situ) unless in complete remission and off all therapy for >=3 years | Uncontrolled active infection | Serious intercurrent medical illness or conditions that could obscure toxicity or alter drug metabolism | Any prior treatment with farnesyl transferase inhibitors | Prior recurrence while receiving a farnesyl transferase inhibitor | Use of oral contraceptives or other hormonal birth control methods (e.g., depot medroxyprogesterone)",Prior temozolomide required; No prior farnesyl transferase inhibitor therapy allowed; Up to 2 prior chemotherapy regimens for recurrent/progressive disease allowed; Phase 1b expansion: at least 2 cycles of adjuvant temozolomide required; Washout: >=4 weeks from prior cytotoxic therapy; Washout: >=2 weeks from vincristine; Washout: >=6 weeks from nitrosoureas; Washout: >=3 weeks from procarbazine; Washout: >=1 week from non-cytotoxic agents,ALL,A,"Disease and setting match (recurrent GBM), and prior-exposure requirements are met (completed concurrent/adjuvant temozolomide with adequate washout), with age and sex eligible and no disqualifying exclusions reported. Other operational criteria (e.g., imaging timing, steroid stability, KPS) are unspecified but no conflicts are evident.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"No hard exclusions identified. Disease and recurrent setting match; prior temozolomide requirement and washout are satisfied; age/sex eligible. Other criteria (e.g., supratentorial location, KPS, steroid stability) are unknown but not mismatches. With ≥2 core anchors matched (stage/setting and line/prior), A is appropriate.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT00565851,0.7943270802497864,Recurrent Clear Cell Ovarian Carcinoma,"A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)","This randomized phase III trial studies carboplatin, paclitaxel and gemcitabine hydrochloride when given together with or without bevacizumab after surgery to see how well it works in treating patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer that has come back. Drugs used in chemotherapy, such as carboplatin, paclitaxel and gemcitabine hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from divid...","{'id': 206095314, 'name': 'Bevacizumab', 'description': 'Given IV', 'other_names': ['Anti-VEGF', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF rhuMAb', 'Avastin', 'Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'rhuMab-VEGF'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206095315, 'name': 'Carboplatin', 'description': 'Given IV', 'other_names': ['Blastocarb', 'Carboplat', 'Carboplatin Hexal', 'Carboplatino', 'Carboplatinum', 'Carbosin', 'Carbosol', 'Carbotec', 'CBDCA', 'Displata', 'Ercar', 'JM-8', 'JM8', 'Nealorin', 'Novoplatinum', 'Paraplatin', 'Paraplatin AQ', 'Paraplatine', 'Platinwas', 'Ribocarbo'], 'intervention_type': 'DRUG'}; {'id': 206095316, 'name': 'Docetaxel', 'description': 'Given IV', 'other_names': ['Docecad', 'RP 56976', 'RP-56976', 'RP56976', 'Taxotere', 'Taxotere Injection Concentrate'], 'intervention_type': 'DRUG'}; {'id': 206095317, 'name': 'Gemcitabine Hydrochloride', 'description': 'Given IV', 'other_names': ['dFdCyd', 'Difluorodeoxycytidine Hydrochloride', 'Gemcitabine HCI', 'Gemzar', 'LY 188011', 'LY-188011', 'LY188011'], 'intervention_type': 'DRUG'}; {'id': 206095318, 'name': 'Laboratory Biomarker Analysis', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206095319, 'name': 'Paclitaxel', 'description': 'Given IV', 'other_names': ['Taxol', 'Taxol Konzentrat', 'Anzatax', 'Asotax', 'Bristaxol', 'Praxel'], 'intervention_type': 'DRUG'}; {'id': 206095320, 'name': 'Quality-of-Life Assessment', 'description': 'Ancillary studies', 'other_names': ['Quality of Life Assessment'], 'intervention_type': 'OTHER'}",PHASE3,18 years,Ovarian Carcinoma (recurrent); Fallopian Tube Carcinoma (recurrent); Primary Peritoneal Carcinoma (recurrent),"Candidate for cytoreductive surgery when applicable per protocol/randomization plan | Histologic epithelial ovarian, primary peritoneal, or fallopian tube carcinoma, recurrent | Eligible epithelial histologies include serous, endometrioid, mucinous, clear cell, transitional cell, undifferentiated, malignant Brenner tumor, mixed epithelial, or adenocarcinoma NOS | Complete response to front-line platinum-taxane therapy (>=3 cycles) | Treatment-free interval without progression >=6 months after completion of front-line chemotherapy (platinum and taxane) | Maintenance biologic or hormonal therapy allowed if recurrence >6 months and >=4 weeks since last biologic infusion | Clinically evident recurrent disease | Measurable disease per RECIST with at least one lesion: >=20 mm by conventional imaging/MRI/CT or >=10 mm by spiral CT | ANC >=1500/µL | Platelets >=100000/µL | Creatinine <=1.5 x ULN | Total bilirubin <=1.5 x ULN | AST <=2.5 x ULN | Alkaline phosphatase <=2.5 x ULN | Urine protein-to-creatinine ratio <1.0 mg/dL (if receiving bevacizumab) | ECOG 0–2","More than one prior chemotherapy regimen (maintenance not counted as a separate regimen) | Concurrent immunotherapy or radiotherapy | Prior radiotherapy to any portion of the abdominal cavity or pelvis | Prior secondary cytoreductive surgery for recurrent disease | Requirement for parenteral hydration or nutrition with evidence of partial bowel obstruction or perforation | Prior chemotherapy for other abdominal or pelvic tumors (except ovarian, fallopian tube, primary peritoneal) | Synchronous or prior primary endometrial cancer unless all met: stage <= IB; no more than superficial myometrial invasion without vascular/lymphatic invasion; no poorly differentiated subtypes (papillary serous, clear cell, FIGO grade 3) | Uncontrolled infection | Severe uncontrolled comorbid medical conditions limiting compliance or increasing risk | Peripheral neuropathy >= grade 2 | History of hypersensitivity to carboplatin and/or paclitaxel unless successfully desensitized | Hypersensitivity to CHO cell products or other recombinant antibodies (applies to bevacizumab recipients) | Pregnant or breastfeeding; inadequate contraception | Other invasive malignancy within 5 years (except non-melanoma skin cancer) or prior cancer therapy contraindicating protocol therapy | Active bleeding or high-risk bleeding conditions/coagulopathy (applies to bevacizumab recipients) | CNS disease (including brain metastases), uncontrolled seizures, or stroke within 5 years (applies to bevacizumab recipients) | Significant cardiovascular disease, including conduction abnormalities (PR >0.24 s or 2nd/3rd-degree AV block), uncontrolled hypertension (systolic >150 mmHg or diastolic >90 mmHg), myocardial infarction/cardiac arrhythmia/unstable angina within 6 months, NYHA class >= II heart failure, serious arrhythmia requiring medication, peripheral vascular disease grade >= II, or cerebrovascular accident within 6 months (applies to bevacizumab recipients) | Major surgery, open biopsy, dental extractions/procedures resulting in open wound, or significant traumatic injury within 28 days before treatment; vascular access device placement or core biopsy within 7 days before treatment",Complete response to front-line platinum-taxane therapy (>=3 cycles) required; Treatment-free interval >=6 months from completion of front-line platinum and taxane chemotherapy; Front-line therapy may have included bevacizumab; Maintenance cytotoxic chemotherapy must be discontinued >=6 months before documentation of recurrence; Maintenance biological or hormonal therapy allowed if recurrence >6 months and >=4 weeks since last biologic infusion,FEMALE,A,"Disease and histology match (recurrent epithelial ovarian, clear cell included), and age/sex and prior first-line platinum-taxane±bevacizumab are compatible. Platinum-sensitivity interval, measurable disease, and performance/labs are unspecified but not known mismatches.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),INCORRECT,B,"No hard exclusions. Disease and setting (recurrent epithelial ovarian, clear cell allowed) match. However, key line-of-therapy requirements—complete response to front-line platinum-taxane and ≥6-month platinum-free interval (platinum-sensitive)—are unknown, as is measurable disease. Thus only one core anchor (stage/setting) clearly matches; line/prior is not definitively met. Per rubric this is a B, not A.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02142803,0.8482123017311096,Recurrent Clear Cell Ovarian Carcinoma,A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors,"This phase I trial studies the side effects and best dose of raptor/rictor-mammalian target of rapamycin (mTOR) (TORC1/2) inhibitor MLN0128 when given in combination with bevacizumab in treating patients with glioblastoma, a type of brain tumor, or a solid tumor that has spread and not responded to standard treatment. TORC1/2 inhibitor MLN0128 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, may interfere wi...","{'id': 205773755, 'name': 'Bevacizumab', 'description': 'Given IV', 'other_names': ['ABP 215', 'ABP-215', 'ABP215', 'Alymsys', 'Anti-VEGF', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF Monoclonal Antibody SIBP04', 'Anti-VEGF rhuMAb', 'Avastin', 'Bevacizumab-bvzr', 'Bevacizumab-equi', 'Bevacizumab-maly', 'Bevacizumab-onbe', 'Bevacizumab-tnjn', 'BP102', 'BP102 Biosimilar', 'CT P16', 'CT-P16', 'CTP16', 'Equidacent', 'FKB 238', 'FKB-238', 'FKB238', 'HD204', 'Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer', 'MB 02', 'MB-02', 'MB02', 'Mvasi', 'MYL-1402O', 'Onbevzi', 'Oyavas', 'PF 06439535', 'PF-06439535', 'PF06439535', 'QL1101', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'rhuMab-VEGF', 'SCT501', 'SIBP 04', 'SIBP-04', 'SIBP04', 'Vegzelma', 'Zirabev', 'Avzivi', 'Aybintio', 'BAT 1706', 'BAT-1706', 'BAT1706', 'BAT1706 Biosimilar', 'Bevacizumab awwb', 'Bevacizumab Biosimilar ABP 215', 'Bevacizumab Biosimilar BAT1706', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar GB-222', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar MB02', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar QL1101', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab-adcd', 'Bevacizumab-awwb', 'Bevacizumab-aybi'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205773756, 'name': 'Laboratory Biomarker Analysis', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 205773757, 'name': 'Pharmacological Study', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 205773758, 'name': 'Sapanisertib', 'description': 'Given PO', 'other_names': ['INK-128', 'INK128', 'MLN-0128', 'MLN0128', 'TAK-228'], 'intervention_type': 'DRUG'}",PHASE1,18 years,Glioblastoma; Endometrial Clear Cell Carcinoma; Endometrial Serous Carcinoma; Ovarian Clear Cell Carcinoma; Ovarian Endometrioid Carcinoma; Ovarian Mucinous Carcinoma; Ovarian Serous Carcinoma; Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Malignant Uterine Corpus Neoplasm,"Histologically/cytologically confirmed recurrent glioblastoma or advanced solid tumor where bevacizumab has shown benefit and no standard/curative options remain | Measurable or evaluable disease (RECIST 1.1 for non-GBM; RANO for GBM) | Prior therapy: Stage 1 and Stage 2 endometrial/ovarian cohorts allow unlimited prior therapy; Stage 2 GBM: no more than 2 prior relapses (intent: no more than 3 prior therapies total) | Recovery from prior therapy toxicities to grade <= 1 or baseline | Washouts before day 1: 12 weeks from completion of radiation for recurrent GBM (unless surgical diagnosis of recurrence or new non-irradiated lesion) | Washouts before day 1: 6 weeks from nitrosourea chemotherapy | Washouts before day 1: 3 weeks from non-nitrosourea chemotherapy | Washouts before day 1: 4 weeks from an investigational (non-FDA-approved) agent or 5 half-lives (whichever is shorter) | Washouts before day 1: 2 weeks from a non-cytotoxic FDA-approved agent or 5 half-lives (whichever is shorter) | ECOG performance status <= 2 (Karnofsky >= 60%) | Absolute neutrophil count >= 1,500/µL | Platelets >= 100,000/µL | Hemoglobin >= 9.0 g/dL | Total bilirubin < 1.5 x ULN (direct bilirubin normal; exception: Gilbert's disease) | AST <= 2.5 x ULN (<= 5 x ULN with liver metastases) | ALT <= 2.5 x ULN (<= 5 x ULN with liver metastases) | Creatinine < 1.5 x ULN or creatinine clearance >= 50 mL/min | Fasting serum glucose <= 130 mg/dL | Fasting triglycerides <= 300 mg/dL | Solid tumor patients off corticosteroids prior to registration; GBM: on stable or decreasing corticosteroid dose >= 5 days before baseline imaging; new/increased steroids require new baseline imaging | Able to swallow whole capsules | Stage 2 GBM: archival tissue (block or 30 unstained slides) available | Stage 2 endometrial/ovarian: at least one lesion amenable to biopsy | Stage 2 solid tumor histologies limited to specified endometrial (papillary serous, endometrioid, clear cell) and ovarian/fallopian/primary peritoneal (high-grade serous, clear cell, endometrioid, mucinous) carcinoma","Concurrent investigational agents | Allergy to compounds similar to sapanisertib or bevacizumab | Stage 2: prior mTOR/PI3K/Akt inhibitors not allowed (allowed in Stage 1 only) | Stage 2 GBM: prior bevacizumab/VEGFR inhibitors not allowed (allowed in Stage 1 and Stage 2 endometrial/ovarian) | Stage 1 solid tumor and Stage 2 endometrial/ovarian: symptomatic or progressing CNS metastases (treated, asymptomatic, stable >= 1 month allowed) | Concurrent enzyme-inducing antiepileptic drugs (must be off >= 10 days); non-enzyme–inducing AEDs allowed | Strong CYP3A4/CYP2C19 inhibitors/inducers require caution; avoid if possible | Concurrent herbal supplements or non-traditional medications (must stop before registration) | Concurrent anticoagulants other than LMWH (must stop before registration); if recently on warfarin, INR <= 2 required | Significant intracranial hemorrhage within 6 weeks or on screening MRI | Uncontrolled intercurrent illness (active infection, symptomatic CHF, unstable angina, significant arrhythmia, psychiatric illness limiting compliance) | Cardiac exclusions within 6 months: LVEF <= 55%, NYHA class >= 3 heart failure, significant ischemic changes, complete LBBB, bifascicular block, congenital long QT, QTcF > 450 ms, inotropic support (excluding digoxin), clinically significant tachyarrhythmias or cardiac arrest, clinically significant bradycardia, unstable atrial fibrillation (>100 bpm), arrhythmia requiring ICD, angina within 12 months, acute MI within 12 months, significant valvular disease, ischemic events requiring therapy or revascularization, pacemaker placement, pulmonary embolism, ischemic cerebrovascular events or revascularization | GI impairment that may alter absorption (e.g., active ulcerative disease, uncontrolled N/V/D, malabsorption, small bowel resection requiring nutritional support) | Use of hematopoietic growth factors <= 2 weeks before start (ESAs allowed if started >= 2 weeks prior) | Pregnant or nursing women | HIV-positive on combination antiretroviral therapy with strong CYP inhibitors are ineligible (eligible if CD4 adequate and ART without strong CYP inhibitors) | Uncontrolled hypertension (SBP >= 160 mmHg or DBP >= 90 mmHg) | Pulmonary hypertension | Uncontrolled asthma or O2 saturation < 90% on room air | Poorly controlled diabetes (HbA1c > 7%) | Proteinuria: if urine dipstick >= 2+, 24-hour urine protein must be < 1000 mg for enrollment | Serious or non-healing wound, ulcer, or bone fracture | History of abdominal fistula, GI perforation, or intra-abdominal abscess within 6 months | Recent invasive procedures: major surgery/open biopsy/significant trauma within 28 days; anticipated major surgery; core biopsy within 7 days | Significant vascular disease within 6 months (e.g., aortic aneurysm requiring repair, recent peripheral arterial thrombosis) | Bleeding diathesis or coagulopathy | Hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies",Stage 1 and Stage 2 endometrial/ovarian: unlimited prior therapy allowed; Stage 2 GBM: no more than 2 prior relapses (no more than 3 prior therapies total including initial); Recovery from prior therapy toxicities to grade <= 1 required before enrollment; Washout: >= 12 weeks since radiation for recurrent GBM (unless surgical diagnosis of recurrence or new non-irradiated lesion); Washout: >= 6 weeks since nitrosourea chemotherapy; Washout: >= 3 weeks since non-nitrosourea chemotherapy; Washout: >= 4 weeks or 5 half-lives (whichever shorter) since investigational non-FDA-approved agent; Washout: >= 2 weeks or 5 half-lives (whichever shorter) since non-cytotoxic FDA-approved agent,ALL,A,"Disease and histologic subtype (recurrent ovarian clear cell carcinoma) match the trial’s endometrial/ovarian cohorts, and the recurrent/advanced setting aligns with allowed stage/setting. Prior therapies (carboplatin/paclitaxel/bevacizumab) are permitted for endometrial/ovarian cohorts; age and sex meet criteria, with no explicit exclusions identified.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,"Disease (ovarian clear cell) matches listed cohorts; recurrent/advanced setting aligns; prior therapies (including bevacizumab) are allowed for endometrial/ovarian cohorts; age/sex within limits; no explicit exclusions identified. Any additional requirements (e.g., no standard options, biopsy-amenable lesion, labs) are unknown and not hard exclusions. ≥2 core anchors match (stage/setting and line/prior; histology subtype), so A is appropriate.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT02192359,0.8363864421844482,Recurrent Glioblastoma,A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination With Intravenous Irinotecan in Patients With Recurrent High-Grade Gliomas,This phase I trial studies the side effects and best dose of carboxylesterase-expressing allogeneic neural stem cells when given together with irinotecan hydrochloride in treating patients with high-grade gliomas that have come back. Placing genetically modified neural stem cells into brain tumor cells may make the tumor more sensitive to irinotecan hydrochloride. Irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving carboxy...,"{'id': 205921738, 'name': 'Carboxylesterase-expressing Allogeneic Neural Stem Cells', 'description': 'Given intracranially', 'other_names': ['CE-secreting Allogeneic NSCs', 'hCE1m6-NSC'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205921739, 'name': 'Irinotecan', 'description': 'Given IV', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205921740, 'name': 'Irinotecan Hydrochloride', 'description': 'Given IV', 'other_names': ['Campto', 'Camptosar', 'Camptothecin 11', 'Camptothecin-11', 'CPT 11', 'CPT-11', 'Irinomedac', 'U-101440E', 'Irinotecan Hydrochloride Trihydrate', 'Irinotecan Monohydrochloride Trihydrate'], 'intervention_type': 'DRUG'}; {'id': 205921741, 'name': 'Laboratory Biomarker Analysis', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 205921742, 'name': 'Pharmacological Study', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}",PHASE1,18 years to 69 years,Anaplastic Astrocytoma (recurrent); Anaplastic Oligoastrocytoma (recurrent); Anaplastic Oligodendroglioma (recurrent); Glioblastoma (recurrent); Gliosarcoma (recurrent),"Karnofsky performance status >= 70% | Life expectancy >= 3 months | Histologically confirmed grade III or IV glioma or prior grade II glioma now with radiographic high-grade (grade III or IV) | Radiographic evidence of recurrent tumor | Recurrent or progressive high-grade glioma after prior brain radiation and temozolomide | Requires craniotomy for tumor resection or stereotactic brain biopsy | No anticipated connection between post-resection cavity and cerebral ventricles | Medically able to undergo neurosurgery | Any number of prior therapies permitted with washouts: >= 6 weeks from nitrosoureas; >= 4 weeks from non-nitrosourea cytotoxic chemotherapy (23 days from last daily temozolomide in 5/28 regimen); >= 2 weeks from last targeted agent (>= 4 weeks for bevacizumab) | Toxicities from prior therapy improved to grade 0 or 1 | ANC >= 1,500/µL | Platelets > 100,000/µL | Total bilirubin <= 2.0 mg/dL | AST <= 4 x ULN | Serum creatinine <= 1.5 x ULN | Homozygous negative for UGT1A1*28 | Absence of anti-HLA class I antibodies specific for the NSCs | Negative pregnancy test (women of childbearing potential) | Effective contraception during study (women of childbearing potential and sexually active men) | For enrollment at dose level >= 2: presence of supratentorial disease amenable to resection or biopsy for Rickham reservoir/catheter placement","Prior therapy with neural stem cells | Use of CYP3A4 inducers (including enzyme-inducing anticonvulsants) within 2 weeks prior to start of study treatment | Use of moderate to strong CYP3A4 inhibitors within 2 weeks prior to start of study treatment | Use of drugs that inhibit UGT1A1 (e.g., atazanavir, gemfibrozil, indinavir, ketoconazole) within 2 weeks prior to start of study treatment | Use of systemic immunosuppressive agents other than corticosteroids (e.g., cyclosporine, tacrolimus) | Flucytosine within 2 weeks prior to start of study treatment | Use of herbal medications | Concurrent use or planned use of other investigational agents or anti-tumor therapy (biologic, chemotherapy, or radiation) | Known HIV infection or hepatitis C infection | Unable to undergo MRI with contrast | Known chronic or active CNS viral infections | Clinically significant uncontrolled illness | Active infection requiring antibiotics | Diagnosis of Gilbert's disease | History of allergic reactions to compounds similar to irinotecan | Known sensitivity to any study products | Any other active malignancy | Pregnant or breastfeeding | Serious medical or psychiatric illness that may interfere with safety monitoring or treatment completion | Investigator deems participant may be unable to comply with study procedures",Prior brain radiation and temozolomide required; Any number of prior therapies permitted; Washout: >= 6 weeks from nitrosoureas; Washout: >= 4 weeks from non-nitrosourea cytotoxic chemotherapy (23 days from last daily temozolomide in 5/28 regimen); Washout: >= 2 weeks from last targeted agent (>= 4 weeks for bevacizumab),ALL,A,"Disease and recurrent setting match, and prior RT/temozolomide exposure aligns with trial requirements; age/sex are within range with no explicit exclusions. Some required criteria (KPS ≥70, need for surgery/biopsy, UGT1A1*28 status, anti-HLA antibodies) are unknown but not conflicting.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"No hard exclusions: disease matches (recurrent GBM is included), age/sex fit, and no explicit exclusion conflicts are known. Core anchors: stage/setting (recurrent) matches and prior-exposure/line (post-RT/TMZ) matches—meeting ≥2 anchors with no identified soft mismatch. Other required factors (KPS threshold, need for surgery/biopsy, UGT1A1*28, anti-HLA antibodies) are unknown, treated as neutral per rubric. Grade A is appropriate.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02208375,0.7943270802497864,Recurrent Clear Cell Ovarian Carcinoma,"A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","This phase Ib/II trial studies the side effects and best dose of olaparib and vistusertib (AZD2014) or olaparib and capivasertib (AZD5363) when given together in treating patients with endometrial, triple negative breast cancer, ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent). Olaparib, vistusertib, and capivasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.","{'id': 206627702, 'name': 'Capivasertib', 'description': 'Given PO', 'other_names': ['AZD5363'], 'intervention_type': 'DRUG'}; {'id': 206627703, 'name': 'Laboratory Biomarker Analysis', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206627704, 'name': 'Olaparib', 'description': 'Given PO', 'other_names': ['AZD2281', 'KU-0059436', 'Lynparza', 'PARP Inhibitor AZD2281'], 'intervention_type': 'DRUG'}; {'id': 206627705, 'name': 'Pharmacological Study', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206627706, 'name': 'Vistusertib', 'description': 'Given PO', 'other_names': ['AZD 2014', 'AZD-2014', 'AZD2014'], 'intervention_type': 'DRUG'}",PHASE1,18 years,Endometrial Adenocarcinoma (recurrent); High-Grade Serous Ovarian Carcinoma (recurrent); Primary Peritoneal Carcinoma (recurrent); Fallopian Tube Carcinoma (recurrent); Ovarian Carcinoma (recurrent); Triple-Negative Breast Cancer (metastatic),"Recurrent endometrial adenocarcinoma (no carcinosarcoma) with no curative option | Recurrent high-grade serous ovarian, primary peritoneal, or fallopian tube carcinoma; or deleterious BRCA-mutant recurrent ovarian/primary peritoneal/fallopian tube cancer | Metastatic triple-negative breast cancer (ER and PR < 10% by IHC and HER2 negative) | Unlimited prior regimens allowed; frontline therapy for metastatic disease allowed | Measurable disease by RECIST 1.1 or assessable disease (e.g., effusion/ascites per CA125 GCIG criteria) | ECOG performance status 0-1 | Women of childbearing potential: negative pregnancy test and agree to effective contraception during treatment and for 30 days after last dose | Able to swallow and tolerate oral medications; no GI illnesses precluding absorption | Life expectancy > 4 months | Absolute neutrophil count >= 1,500/µL | Hemoglobin >= 10 g/dL | Platelets >= 100,000/µL | Blasts < 4% on hematologic studies | Total bilirubin <= 1.5 x ULN | AST/ALT <= 2.5 x ULN (<= 5 x ULN if liver involvement) | Creatinine clearance > 50 mL/min (Cockcroft-Gault) | Type II diabetes eligible if diet-controlled with HbA1c < 8% | FOR EXPANSION PHASE ONLY: Measurable disease accessible for biopsy | FOR EXPANSION PHASE ONLY: Archival tumor specimens available","Receipt of other investigational agents or additional anti-cancer agents | Endometrial carcinosarcoma | Ovarian cancer histology other than high-grade serous without a deleterious BRCA mutation | Recurrences amenable to potentially curative radiation therapy or surgery | History of other malignancy within 5 years except adequately treated basal/squamous skin cancer or in situ cervical cancer (dual primaries of endometrial, ovarian, or breast cancer allowed) | History of myelodysplastic syndrome | Symptomatic, uncontrolled spinal cord compression and/or brain metastases | Prior chemotherapy, biologic therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents, or investigational agents within 28 days before starting study treatment (palliative focal RT excepted as noted) | Prohibited corticosteroids within 14 days prior to starting study treatment | Major surgery within 28 days or minor surgery within 2 weeks prior to study entry, or not recovered from surgery | QTcF >= 470 ms at 2 or more time points within 24 hours or family history of long QT syndrome | Blood transfusion required within 28 days prior to study start | Receipt of hematopoietic growth factors (e.g., G-CSF, GM-CSF) within 2 weeks prior to study start | Concomitant prohibited medications/substances within specified washout periods | Known hypersensitivity to olaparib, capivasertib (AZD5363), vistusertib (AZD2014), or their excipients; or to drugs of similar class | Intolerable adverse events to prior PARP, mTOR, PI3K, or AKT inhibitors per investigator | Within 12 months: CABG, angioplasty, vascular stent, myocardial infarction, angina pectoris, CHF NYHA >= 2, ventricular arrhythmias requiring continuous therapy, uncontrolled supraventricular arrhythmias including atrial fibrillation, hemorrhagic or thrombotic stroke including TIA or other CNS bleeding | Abnormal ECHO or MUGA with LVEF < 50% | Torsades de pointes within 12 months | Uncontrolled hypotension (SBP < 90 mmHg and/or DBP < 50 mmHg) | Proteinuria (>= 3+ dipstick or 300 mg/dL on urinalysis or > 500 mg/24 hours) | Type I diabetes or uncontrolled type II diabetes (HbA1c > 8%) | Severe or uncontrolled systemic disease (e.g., severe hepatic impairment, interstitial lung disease, uncontrolled chronic renal disease), unstable/uncompensated respiratory or cardiac conditions, uncontrolled hypertension (>= 140/90), active bleeding diathesis, or active infection including hepatitis B, hepatitis C, or HIV | Investigator deems patient unsuitable or unlikely to comply | FOR EXPANSION PHASE ONLY: No accessible tumor for biopsy | No archival tumor specimens available",Unlimited prior chemotherapy allowed; Prior PARP inhibitor allowed if not discontinued for toxicity (progression allowed); Prior mTOR inhibitor allowed if not discontinued for toxicity (progression allowed); Prior AKT inhibitor allowed if not discontinued for toxicity (progression allowed); Frontline therapy for metastatic disease permitted; No anticancer therapy or investigational agents within 28 days before study start; No prohibited corticosteroids within 14 days before study start; No hematopoietic growth factors within 14 days before study start; No major surgery within 28 days or minor surgery within 2 weeks before study start,FEMALE,A,"Recurrent ovarian cancer with a BRCA1 mutation qualifies for the BRCA-mutant ovarian cohort; stage/setting (recurrent) and prior therapies are allowed, and pleural effusion counts as assessable disease. Age and sex meet requirements with no conflicting exclusions evident.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,No hard exclusions. Disease matches via the BRCA-mutant recurrent ovarian cohort. Stage/setting (recurrent) and line/prior exposure are compatible; required biomarker (BRCA1+) is satisfied. No soft conflicts identified. Grade A is appropriate.,,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT02266745,0.8316181302070618,Castration-Resistant Prostate Cancer,"A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts","This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study to be conducted in two parts: the Dose Escalation Phase and the Dose Expansion Phase. The Dose Escalation Phase will determine the Maximum Tolerated Dose (MTD) and recommended Phase 2 dose(s) (RP2D) of PT-112 Injection and evaluate its safety and tolerability, and PK (pharmacokinetics). The Dose Escalation Phase is complete and no longer enrolling. The Dose Expansion Phase has two cohorts: one cohort for the ...","{'id': 205812227, 'name': 'PT-112 Injection', 'description': None, 'other_names': ['PT-112'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Metastatic Castration-Resistant Prostate Cancer,"Male >= 18 years of age | Histologically or cytologically confirmed adenocarcinoma of the prostate | Metastatic castration-resistant prostate cancer with documented metastatic lesions on bone scan or CT/MRI | Received at least three prior intended life-prolonging therapies for metastatic disease | ECOG 0-1 | Progressive disease by RECIST v1.1 or PCWG3 or by informative tumor markers | Adequate organ function | If known history of brain metastases, disease must be stable",Cytotoxic chemotherapy within 21 days prior to initiation of study drug | Immunomodulatory drug therapy within 14 days prior to initiation of study drug | Anti-neoplastic hormonal therapy within 14 days prior to initiation of study drug | Immunosuppressive therapy within 14 days prior to initiation of study drug | Corticosteroids within 14 days prior to initiation of study drug | Growth factor treatment within 14 days prior to initiation of study drug | Inadequate bone marrow reserve | Radiotherapy within 14 days prior to baseline | Radiotherapy to >25% of active bone marrow | Major surgery within 28 days prior to initiation of study drug,At least three prior intended life-prolonging therapies for metastatic disease; Washout: cytotoxic chemotherapy >= 21 days before study drug; Washout: immunomodulatory drugs >= 14 days before study drug; Washout: anti-neoplastic hormonal therapy >= 14 days before study drug; Washout: immunosuppressive therapy >= 14 days before study drug; Washout: corticosteroids >= 14 days before study drug; Washout: growth factors >= 14 days before study drug; Washout: radiotherapy >= 14 days before baseline; Washout: major surgery >= 28 days before study drug,MALE,A,"Disease and stage match (metastatic CRPC), patient is an eligible male age, and has ≥3 prior life-prolonging therapies (ADT, abiraterone, enzalutamide); metastatic pattern (bone and liver) is allowed and no explicit exclusions are evident.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions. Disease and stage (metastatic CRPC) match. Line/prior exposure matches the trial’s requirement of ≥3 prior life-prolonging therapies (ADT, abiraterone, enzalutamide). Other criteria (ECOG, washouts) are unknown and not disqualifying per rubric. Thus ≥2 core anchors match with no soft conflicts → A.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT02337686,0.8363864421844482,Recurrent Glioblastoma,Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma,"This phase II trial studies the effects of pembrolizumab on the body, or pharmacodynamics, in patients with glioblastoma that has come back. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.","{'id': 206515690, 'name': 'Laboratory Biomarker Analysis', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206515691, 'name': 'Pembrolizumab', 'description': 'Given IV', 'other_names': ['Keytruda', 'Lambrolizumab', 'MK-3475', 'SCH 900475'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206515692, 'name': 'Pharmacological Study', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206515693, 'name': 'Therapeutic Conventional Surgery', 'description': 'Undergo surgery', 'other_names': [], 'intervention_type': 'PROCEDURE'}",PHASE2,18 years,Glioblastoma (recurrent); Gliosarcoma (recurrent),Histologically confirmed WHO grade IV malignant glioma (glioblastoma or gliosarcoma) | First or second relapse requiring reoperation for tumor progression | Measurable disease with minimal volume >= 1 cm^3 | Archival or newly obtained tumor tissue available | Karnofsky performance status >= 60% | Stable corticosteroid dose for 5 days (<= 2 mg dexamethasone/day),"Prior bevacizumab treatment | Tumor primarily localized to brainstem or spinal cord | Prior interstitial brachytherapy, implanted chemotherapy, or locally delivered therapeutics (including convection-enhanced delivery) | Participation in investigational agent/device within 4 weeks | Immunodeficiency or systemic steroids > 2 mg dexamethasone/day or other immunosuppressive therapy within 7 days | Prior monoclonal antibody within 4 weeks or unresolved toxicities (> grade 1) from prior agents | Prior chemotherapy, targeted therapy, or radiation within 2 weeks or unresolved toxicities (> grade 1) | Concurrent active malignancy requiring treatment (except certain skin/cervical in situ cancers) | Carcinomatous meningitis, extracranial disease, or multifocal disease | Active autoimmune disease requiring systemic treatment within 3 months or history of severe autoimmune disease | Interstitial lung disease or active non-infectious pneumonitis | Active infection requiring systemic therapy | Psychiatric or substance abuse disorder interfering with study requirements | Pregnant or breastfeeding | Prior therapy with anti–PD-1, anti–PD-L1, anti–PD-L2, anti-CD137, or CTLA-4 antibodies (e.g., ipilimumab) | Known HIV infection | Known hepatitis B or hepatitis C infection | Live vaccine within 30 days prior to first dose","Washout >= 2 weeks since prior chemotherapy, targeted therapy, or radiation; Washout >= 4 weeks since prior monoclonal antibody therapy; Washout >= 4 weeks since investigational agent/device",ALL,A,"Disease and recurrent setting match, and prior-exposure requirements are compatible (no prior PD-1/Bevacizumab, adequate washout presumed). Age/sex fit; items like need for reoperation, measurable volume, steroid dose, and tissue availability are unknown but not conflicting.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"No hard exclusions identified. Disease matches (recurrent GBM) and core anchors match for stage/setting (recurrent) and line/prior exposure (first relapse; no prior PD-1/bevacizumab; adequate washout). Other requirements (reoperation, steroids, tissue, measurable disease) are unknown but not conflicting. Grade A per rubric.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT02412553,0.6685259342193604,Fistulizing Crohn's Disease,,"The study is proposed as a 2-year single site, open-label clinical trial of enteral nutrition or the specific carbohydrate diet in patients with active CD or UC. Patients seeking care in the outpatient clinics of the Division of Gastroenterology at Massachusetts General Hospital will be approached for participation in the trial during their routine outpatient appointments. All patients are required to have a diagnosis of CD or UC confirmed using standard clinical, endoscopic, and histologic c...","{'id': 205404636, 'name': 'Specific carbohydrate diet', 'description': None, 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 205404637, 'name': 'Elemental diet', 'description': None, 'other_names': [], 'intervention_type': 'OTHER'}",NA,18 years to 90 years,Crohn's Disease; Ulcerative Colitis,Age >= 18 years | Established diagnosis of small bowel or colonic Crohn's disease or ulcerative colitis | Active Crohn's disease or ulcerative colitis with objective evidence on colonoscopy within 1 month | Current IBD medications stable during the study period (corticosteroid taper permitted) | Harvey Bradshaw Index > 4 at baseline (week 0) or SCCAI > 3,"Pregnant or breastfeeding | Celiac disease or positive screen for celiac disease (elevated tissue transglutaminase antibodies) | Untreated infection (e.g., Clostridium difficile) | Presence of stoma or J pouch | Enterocutaneous, abdominal, or pelvic fistulae with abscesses or fistulae likely to require surgery during the study period | Bowel surgery within 12 weeks prior to screening or planned/likely during the study period | Fixed symptomatic stenosis of small bowel or colon | Chronic daily use of narcotics for chronic pain | Use of oral or intravenous antibiotics within 4 weeks prior to screening | Use of tube or enteral feeding, elemental diet, or parenteral alimentation within 2 weeks prior to screening",(none),ALL,A,"Disease and age match an adult active Crohn's cohort, and there are no restrictions on prior biologic exposure. No explicit exclusions are triggered, though timing of recent IV antibiotics and current absence of abscess would need confirmation at screening.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,A,No hard exclusions are definitively triggered (antibiotics timing and current abscess status are unknown). Disease matches Crohn’s. Core anchors: Stage/setting (active disease) matches and Line/prior exposure is compatible. No soft conflicts on core anchors. Grade A is appropriate per rubric.,,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT02420847,0.8805802464485168,Metastatic Urothelial Carcinoma,"A Phase I Two-Dimensional Dose-Finding Study of Ixazomib in Combination With Gemcitabine and Doxorubicin, Followed by a Phase II Extension to Assess the Efficacy of This Combination in Metastatic, Surgically Unresectable Urothelial Cancer","This phase I/II trial studies the side effects and best dose of ixazomib citrate, gemcitabine hydrochloride, and doxorubicin hydrochloride when given together in treating patients with urothelial cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery. Ixazomib citrate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as gemcitabine hydrochloride and doxorubicin hydrochloride, work in dif...","{'id': 205717675, 'name': 'Doxorubicin Hydrochloride', 'description': 'Given IV', 'other_names': ['5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)', 'ADM', 'Adriacin', 'Adriamycin', 'Adriamycin Hydrochloride', 'Adriamycin PFS', 'Adriamycin RDF', 'ADRIAMYCIN, HYDROCHLORIDE', 'Adriamycine', 'Adriblastina', 'Adriblastine', 'Adrimedac', 'Chloridrato de Doxorrubicina', 'DOX', 'DOXO-CELL', 'Doxolem', 'Doxorubicin HCl', 'Doxorubicin.HCl', 'Doxorubin', 'Farmiblastina', 'FI 106', 'FI-106', 'hydroxydaunorubicin', 'Rubex'], 'intervention_type': 'DRUG'}; {'id': 205717676, 'name': 'Gemcitabine Hydrochloride', 'description': 'Given IV', 'other_names': ['dFdCyd', 'Difluorodeoxycytidine Hydrochloride', 'FF 10832', 'FF-10832', 'FF10832', 'Gemcitabine HCI', 'Gemzar', 'LY-188011', 'LY188011'], 'intervention_type': 'DRUG'}; {'id': 205717677, 'name': 'Ixazomib Citrate', 'description': 'Given PO', 'other_names': ['MLN-9708', 'MLN9708', 'Ninlaro'], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,18 years,Urothelial Carcinoma (metastatic); Urothelial Carcinoma (unresectable),"Histologically confirmed metastatic or locally unresectable urothelial (transitional cell) carcinoma; variant histology allowed with urothelial component | Measurable or evaluable disease | At least one prior therapy unless not candidates for or refuse cisplatin-based therapy | Phase I: any number of prior regimens allowed | Phase II: no prior proteasome inhibitor (e.g., bortezomib, carfilzomib) and no prior gemcitabine >= 800 mg/m^2 plus doxorubicin >= 30 mg/m^2 in the same regimen | Prior neoadjuvant chemotherapy failure eligible | If prior ischemic heart disease or >= 200 mg/m^2 prior doxorubicin, left ventricular ejection fraction >= 45% | ALT <= 3 x ULN | AST <= 3 x ULN | ECOG performance status <= 2; PS 3 allowed if due to malignancy","Platelet count < 100 x 10^9/L | Absolute neutrophil count < 1.0 x 10^9/L | Creatinine clearance < 30 mL/min | Peripheral neuropathy >= grade 3 or grade 2 with pain | Total bilirubin >= 1.5 x ULN | Allergy to study drugs or excipients | Pregnant or breastfeeding | Participation in other investigational trials within 30 days | Myocardial infarction within 6 months, NYHA class III/IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, acute ischemia or active conduction abnormalities | Symptomatic congestive heart failure | Claudication limiting activity | Cerebrovascular event within the last year (including TIA) | Unstable angina | Active brain metastases (previously treated and stable allowed) | Radiotherapy within 28 days (14 days if small field) | Another malignancy within 2 years unless meeting specified exceptions | Strong CYP1A2/3A inhibitors or strong CYP3A inducers within 14 days of first ixazomib dose; use of Ginkgo biloba or St. John's wort | Not recovered to <= grade 1 from prior chemotherapy toxicities | Major surgery within 14 days | Infection requiring current IV antibiotics | Active systemic infection, active hepatitis B or C, or HIV positive | Serious medical or psychiatric illness interfering with protocol treatment | GI disease or procedure interfering with oral absorption of ixazomib","At least one prior systemic therapy required unless cisplatin-ineligible or refuse cisplatin-based therapy; Phase I: any number of prior regimens permitted, including prior bortezomib or gemcitabine+doxorubicin; Phase II: exclude prior proteasome inhibitor therapy and exclude prior combination gemcitabine >= 800 mg/m^2 plus doxorubicin >= 30 mg/m^2; Prior neoadjuvant chemotherapy allowed; Radiotherapy washout: >= 28 days (>= 14 days if small field); Other investigational agents washout: >= 30 days; Major surgery washout: >= 14 days; Recovered to <= grade 1 from prior chemotherapy toxicities before enrollment",ALL,A,"Metastatic urothelial carcinoma matches the trial setting, and prior therapies (neoadjuvant gemcitabine/cisplatin; enfortumab vedotin+pembrolizumab) meet requirements with no prior proteasome inhibitor or gemcitabine+doxorubicin. No explicit exclusions are triggered (renal function above the CrCl <30 mL/min cutoff; no disallowed metastasis pattern stated).",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,A,"No hard exclusions apply (disease matches; age/sex ok; CrCl cutoff is <30 and patient eGFR 35 suggests not excluded; even if treated as unknown, not an exclusion). Core anchors: Stage/setting matches (metastatic); Line/prior exposure compatible (prior therapies allowed; no prior proteasome inhibitor or gemcitabine+doxorubicin); no biomarker requirement; metastasis pattern acceptable (no active brain mets). This yields ≥2 core anchors matched with no soft conflicts → Grade A. The grader’s reasoning aligns with the rubric.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT02444741,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,Phase I/II Trial of MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With NSCLC,"This randomized phase I/II trial studies the side effects and best dose of pembrolizumab when given together with stereotactic body radiation therapy or non-stereotactic wide-field radiation therapy (conventional radiation therapy) and to see how well they work in treating patients with non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and s...","{'id': 206422164, 'name': '3-Dimensional Conformal Radiation Therapy', 'description': 'Undergo 3D-CRT', 'other_names': ['3-dimensional radiation therapy', '3D Conformal', '3D CONFORMAL RADIATION THERAPY', '3D CRT', '3D-CRT', 'Conformal Therapy', 'Radiation Conformal Therapy', 'Radiation, 3D Conformal'], 'intervention_type': 'RADIATION'}; {'id': 206422165, 'name': 'Intensity-Modulated Radiation Therapy', 'description': 'Undergo IMRT', 'other_names': ['IMRT', 'Intensity Modulated RT', 'Intensity-Modulated Radiotherapy', 'Radiation, Intensity-Modulated Radiotherapy'], 'intervention_type': 'RADIATION'}; {'id': 206422166, 'name': 'Laboratory Biomarker Analysis', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206422167, 'name': 'Pembrolizumab', 'description': 'Given IV', 'other_names': ['Keytruda', 'Lambrolizumab', 'MK-3475', 'SCH 900475'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206422168, 'name': 'Proton Beam Radiation Therapy', 'description': 'Undergo PBRT', 'other_names': ['PBRT', 'Proton', 'Proton Radiation Therapy', 'Radiation, Proton Beam'], 'intervention_type': 'RADIATION'}; {'id': 206422169, 'name': 'Radiation Therapy', 'description': 'Undergo low dose radiation therapy', 'other_names': ['Radiation Therapy, NOS', 'Radiotherapeutics', 'Radiotherapy', 'RT', 'Therapy, Radiation', 'Cancer Radiotherapy', 'ENERGY_TYPE', 'Irradiate', 'Irradiated', 'Irradiation', 'Radiation'], 'intervention_type': 'RADIATION'}; {'id': 206422170, 'name': 'Stereotactic Body Radiation Therapy', 'description': 'Undergo SBRT', 'other_names': ['SABR', 'SBRT', 'Stereotactic Ablative Body Radiation Therapy'], 'intervention_type': 'RADIATION'}",PHASE1/PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic); Solid Tumor,"Pathologically confirmed non-small cell lung cancer; for Group 5, any solid tumor histology | Stage IV metastatic disease (Phase II) | At least one thoracic or liver lesion amenable to radiation; for Group 5, at least one site safely treatable with SBRT or WFRT (not restricted to lung/liver) | At least one additional non-contiguous lesion amenable to radiographic evaluation | Measurable disease per immune-related response criteria (irRC) | ECOG performance status 0–1 | Absolute neutrophil count (ANC) >= 1500 /µL | Platelets >= 100000 /µL | Hemoglobin >= 9 g/dL | Serum creatinine <= 1.5 x ULN or creatinine clearance >= 60 mL/min | Total bilirubin <= 1.5 x ULN or direct bilirubin <= ULN if total bilirubin > 1.5 x ULN | AST and ALT <= 2.5 x ULN (<= 5 x ULN with liver metastases) | INR or PT <= 1.5 x ULN unless on anticoagulation (therapeutic range allowed) | aPTT <= 1.5 x ULN unless on anticoagulation (therapeutic range allowed) | Brain metastases allowed if asymptomatic, stable, and not requiring systemic corticosteroids within 14 days before starting pembrolizumab | Prior radiation to other sites allowed with no washout if at least one measurable site remains unirradiated","Participation in another investigational study or use of an investigational device within 4 weeks or 5 half-lives (whichever is shorter) | Immunodeficiency or systemic steroid/immunosuppressive therapy within 7 days before first dose (except physiological steroid replacement) | Active scleroderma, lupus, or other autoimmune disease that precludes safe radiation therapy | Prior radiation to all available thoracic and liver lesions such that additional radiation therapy is unsafe | Prior monoclonal antibody within 4 weeks or 5 half-lives before day 1, or unresolved adverse events > grade 1 from prior therapies | Prior chemotherapy or targeted small molecule therapy within 2 weeks before day 1, or unresolved adverse events > grade 1 (except <= grade 2 neuropathy) | Known additional malignancy that is progressing or requires active treatment (exceptions: certain skin cancers or in situ cervical cancer after curative therapy) | Active CNS metastases or carcinomatous meningitis (previously treated brain metastases allowed if stable >= 4 weeks and off steroids >= 7 days) | Active autoimmune disease requiring systemic treatment within the past 3 months or history of clinically severe autoimmune disease (exceptions: vitiligo, resolved childhood asthma/atopy, hypothyroidism on replacement, Sjogren's; intermittent bronchodilators or local steroid injections allowed) | Interstitial lung disease or active, non-infectious pneumonitis | Active infection requiring systemic therapy or hospital admission | Condition or laboratory abnormality that may confound results or interfere with participation per investigator | Psychiatric or substance abuse disorders interfering with trial requirements | Pregnant or breastfeeding | Known HIV infection | Active hepatitis B or hepatitis C infection | Receipt of a live vaccine within 30 days before first dose | Symptomatic brain metastasis | Prior dose-limiting toxicity to radiation or to prior PD-1/PD-L1 inhibitor therapy",Prior radiation therapy to other sites allowed with no washout if at least one measurable site remains unirradiated,ALL,A,"Disease and setting match (metastatic NSCLC), and prior therapy is compatible (EGFR TKI allowed with washout); ECOG 0 and age ≥18 fit. Other specifics (lab values, measurable/SBRT-amenable lesions, brain mets status) are not provided but do not present a conflict.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,A,"No hard exclusions. Stage/setting (metastatic NSCLC) matches and prior exposure is compatible with washout; metastatic pattern acceptable. Measurable disease/SBRT-amenable lesions and brain mets status are unknown, not soft conflicts on core anchors. With ≥2 core anchors matched and no soft mismatches, A is appropriate.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT02496663,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,A Phase I Trial of Osimertinib (AZD9291) and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor,"This phase I trial studies the safety, side effects and best dose of necitumumab when given together with osimertinib in treating patients with EGFR-mutant non-small cell lung cancer that is stage IV or has come back after a period of improvement (recurrent) and who have progressed on a previous EGFR tyrosine kinase inhibitor. Immunotherapy with monoclonal antibodies, such as necitumumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and ...","{'id': 206424114, 'name': 'Biospecimen Collection', 'description': 'Undergo blood sample collection', 'other_names': ['Biological Sample Collection', 'Biospecimen Collected', 'Specimen Collection'], 'intervention_type': 'PROCEDURE'}; {'id': 206424115, 'name': 'Computed Tomography', 'description': 'Undergo CT scan', 'other_names': ['tomography', 'CAT', 'CAT Scan', 'Computed Axial Tomography', 'Computerized Axial Tomography', 'Computerized axial tomography (procedure)', 'Computerized Tomography', 'Computerized Tomography (CT) scan', 'CT', 'CT Scan', 'Diagnostic CAT Scan', 'Diagnostic CAT Scan Service Type'], 'intervention_type': 'PROCEDURE'}; {'id': 206424116, 'name': 'Echocardiography Test', 'description': 'Undergo ECHO', 'other_names': ['EC', 'Echocardiography'], 'intervention_type': 'PROCEDURE'}; {'id': 206424117, 'name': 'Magnetic Resonance Elastography', 'description': 'Undergo MRI', 'other_names': ['MRE'], 'intervention_type': 'PROCEDURE'}; {'id': 206424118, 'name': 'Multigated Acquisition Scan', 'description': 'Undergo MUGA', 'other_names': ['Blood Pool Scan', 'Equilibrium Radionuclide Angiography', 'Gated Blood Pool Imaging', 'Gated Heart Pool Scan', 'MUGA', 'MUGA Scan', 'Multi-Gated Acquisition Scan', 'Radionuclide Ventriculogram Scan', 'Radionuclide Ventriculography', 'RNV Scan', 'RNVG', 'SYMA Scanning', 'Synchronized Multigated Acquisition Scanning'], 'intervention_type': 'PROCEDURE'}; {'id': 206424119, 'name': 'Necitumumab', 'description': 'Given IV', 'other_names': ['Anti-Epidermal Growth Factor Receptor Monoclonal Antibody IMC-11F8', 'IMC 11F8', 'IMC-11F8', 'IMC11F8', 'Portrazza'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206424120, 'name': 'Osimertinib', 'description': 'Given PO', 'other_names': ['AZD 9291', 'AZD-9291', 'AZD9291', 'Mereletinib'], 'intervention_type': 'DRUG'}",PHASE1,18 years,Non-Small Cell Lung Cancer (metastatic); Non-Small Cell Lung Cancer (recurrent),"Histologically confirmed non-small cell lung cancer, stage IV or recurrent/metastatic | Measurable disease per RECIST 1.1 | EGFR activating mutation: exon 21 L858R and/or exon 19 deletion and/or exon 18 G719X and/or exon 21 L861Q or EGFR exon 20 insertion (for cohort D) | Dose escalation cohort: progressive disease on at least one prior EGFR-TKI | Dose Expansion Cohort A: progression on erlotinib, gefitinib or afatinib as last systemic treatment | Dose Expansion Cohort A: EGFR T790M negative on post-progression biopsy confirmed by central testing | Dose Expansion Cohort A: treatment naive to 3rd-generation EGFR-TKIs and EGFR monoclonal antibodies | Dose Expansion Cohort B: progression on a 3rd-generation EGFR-TKI (e.g., osimertinib, rociletinib, HM61713) | Dose Expansion Cohort B: treatment naive to an EGFR monoclonal antibody | Dose Expansion Cohort B: EGFR T790M negative on post-progression biopsy confirmed by central testing | Dose Expansion Cohort C: progression on a 3rd-generation EGFR-TKI (e.g., osimertinib, rociletinib, HM61713) | Dose Expansion Cohort C: treatment naive to an EGFR monoclonal antibody | Dose Expansion Cohort C: EGFR T790M preserved (positive) on post-progression biopsy confirmed by central testing | Dose Expansion Cohort D: EGFR exon 20 insertion by CLIA-certified test | Dose Expansion Cohort D: progressive disease on or after platinum-based chemotherapy | Dose Expansion Cohort D: treatment naive to 3rd-generation and beyond EGFR-TKIs and EGFR monoclonal antibody | Dose Expansion Cohort E: progressive disease on first-line osimertinib for metastatic NSCLC | Dose Expansion Cohort E: treatment naive to EGFR monoclonal antibody | Adequate archival tissue after progression on previous EGFR-TKI or willingness for fresh biopsy (mandatory for cohorts A, B, C) | Any number of prior therapies allowed | Age >= 18 years | ECOG performance status <= 1 | Ability to swallow tablets | Life expectancy > 3 months | Absolute neutrophil count >= 1,500/µL | Platelets >= 100,000/µL | Total bilirubin <= 1.5 x ULN | AST/ALT <= 3.0 x ULN | Creatinine <= 1.5 x ULN or creatinine clearance >= 50 mL/min | Women of childbearing potential: negative pregnancy test within 7 days prior to treatment | Untreated brain metastases allowed if clinically asymptomatic and stable | Previously symptomatic brain metastases eligible if treated, asymptomatic at enrollment, off corticosteroids >= 7 days, and stable on imaging | Last chemotherapy completed >= 3 weeks prior to study drugs | Last radiotherapy completed >= 2 weeks prior to study drugs | Recovered from prior treatment adverse events to <= grade 1 (except alopecia and sensory neuropathy <= grade 2)","Major surgery within 21 days before starting protocol treatment | Current or recent use of another investigational agent without adequate washout (>= 5 half-lives or 3 months, whichever is greater) | Prior EGFR-TKI must be discontinued >= 7 days prior to enrollment (except cohorts B, C, and E on osimertinib) | History of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonitis requiring steroids | Clinically active interstitial lung disease | Concomitant use of potent CYP3A4 inducers (within 3 weeks prior to first dose) | Active malignancy other than NSCLC or prior curatively treated malignancy at high risk of relapse during study | Uncontrolled intercurrent illness (including active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia) | Gastrointestinal disease limiting absorption of osimertinib (e.g., malabsorption syndrome, inflammatory bowel disease) | Psychiatric illness or social situations limiting compliance | QTcF > 470 msec | Clinically important ECG abnormalities in rhythm, conduction or morphology (e.g., complete left bundle branch block, second/third degree heart block) | Risk factors for QTc prolongation or arrhythmic events (e.g., heart failure, hypokalemia, congenital long QT syndrome, family history of long QT or sudden death < 40 years, or concomitant QT-prolonging drugs causing torsades de pointes) | Left ventricular ejection fraction < 50% | Pregnancy or breastfeeding | HIV-positive on combination antiretroviral therapy (due to potential pharmacokinetic interactions with osimertinib)","Progression on prior EGFR-TKI required (per cohort); Progression on erlotinib, gefitinib, or afatinib as last treatment (Cohort A); Progression on a 3rd-generation EGFR-TKI (e.g., osimertinib, rociletinib, HM61713) (Cohorts B, C); Prior platinum-based chemotherapy required (Cohort D, EGFR exon 20 insertion); Treatment naive to 3rd-generation EGFR-TKI (as specified for dose escalation and Cohort D); Treatment naive to EGFR monoclonal antibody (as specified for Cohorts A, B, C, E and Cohort D); Any number of prior systemic therapies allowed; Washout: chemotherapy >= 3 weeks before study drugs; Washout: radiotherapy >= 2 weeks before study drugs; Discontinue prior EGFR-TKI >= 7 days before enrollment (except cohorts B, C, E may continue osimertinib); Discontinue investigational agents >= 5 half-lives or 3 months before initiation",ALL,A,"Metastatic EGFR exon 19–mutant NSCLC with progression on first-line osimertinib matches Cohort E; age ≥18 and ECOG 0 meet trial criteria, and no conflicting exclusions are evident.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,A,"Disease matches (metastatic EGFR-mutant NSCLC). Stage/setting matches (metastatic). Line/prior exposure matches (progression on first-line osimertinib aligns with Cohort E). Required biomarker (EGFR exon 19 del) satisfied. No explicit exclusions identified. Thus ≥2 core anchors (including stage and line) match, supporting grade A.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT02503722,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,A Phase 1 Trial of MLN0128 (TAK-228) in Combination With Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor,This phase I trial studies the side effects and best dose of sapanisertib when given together with osimertinib in treating patients with stage IV EGFR mutation positive non-small cell lung cancer that has progressed after treatment with an EGFR tyrosine kinase inhibitor. Sapanisertib and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.,"{'id': 206019917, 'name': 'Laboratory Biomarker Analysis', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206019918, 'name': 'Osimertinib', 'description': 'Given PO', 'other_names': ['AZD 9291', 'AZD-9291', 'AZD9291', 'Mereletinib'], 'intervention_type': 'DRUG'}; {'id': 206019919, 'name': 'Pharmacological Study', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206019920, 'name': 'Sapanisertib', 'description': 'Given PO', 'other_names': ['INK-128', 'INK128', 'MLN-0128', 'MLN0128', 'TAK-228'], 'intervention_type': 'DRUG'}",PHASE1,18 years,Non-Small Cell Lung Cancer (metastatic),"Stage IV or recurrent/metastatic histologically or cytologically confirmed non-squamous non-small cell lung cancer | EGFR activating mutation required: Exon 21 L858R or Exon 19 deletion | Progressive disease on first-line osimertinib for advanced/metastatic disease | Measurable disease per RECIST 1.1 by CT/MRI within 28 days prior to start | Dose expansion: progression on first-line osimertinib as last prior systemic therapy | Dose expansion: treatment-naive to other third-generation EGFR-TKIs and mTOR inhibitors | Dose expansion: no other systemic therapies after first-line osimertinib | Brain metastases allowed if treated or not requiring local therapy, asymptomatic, off corticosteroids and anti-epileptics >=7 days, and stable on imaging | ECOG performance status <=1 (Karnofsky >=70%) | ANC >= 1500/µL | Hemoglobin >= 9 g/dL | Platelets >= 100000/µL | Creatinine clearance > 50 mL/min | Total bilirubin <= 1.5 x ULN | AST <= 2.5 x ULN | ALT <= 2.5 x ULN | Fasting plasma glucose <= 130 mg/dL | HbA1c <= 7.0% | Fasting triglycerides <= 300 mg/dL | Cholesterol <= 300 mg/dL | QTcF <= 470 msec | Prior EGFR inhibitor washout >= 7 days and toxicities resolved to <= grade 1 (except alopecia) | Chemotherapy washout >= 21 days and toxicities resolved to <= grade 1 (except <= grade 2 neuropathy or alopecia) | Major surgery washout >= 21 days with complete wound healing and toxicities < grade 1 | Radiation therapy washout >= 14 days with resolution of radiation toxicity (excluding alopecia) | Investigational drug washout >= 3 months or >= 5 half-lives, whichever is longer","Uncontrolled diabetes mellitus (fasting plasma glucose > 130 mg/dL) | History of interstitial lung disease, drug-induced ILD, or radiation pneumonitis requiring steroids, or clinically active ILD | Active infections | Gastrointestinal disease limiting swallowing or absorption (refractory N/V, chronic GI disease, inflammatory bowel disease, malabsorption) | Enteric stoma or significant bowel resection | Prior corneal ulceration | Severe or uncontrolled liver disease including active hepatitis B or C (excluding cured hepatitis C) | Active bleeding diathesis | Uncontrolled hypertension (systolic > 180 mmHg or diastolic > 95 mmHg) | Pulmonary hypertension | Uncontrolled asthma or oxygen saturation < 90% on room air | Significant valvular heart disease (severe regurgitation or stenosis) or history of valve replacement | Clinically important ECG abnormalities (e.g., symptomatic bradycardia, complete LBBB, 2nd/3rd degree heart block) | Within 6 months: need for inotropic support (excluding digoxin) or serious uncontrolled arrhythmia | Within 6 months: pacemaker placement for rhythm control | Within 6 months: ischemic myocardial event or coronary revascularization | Within 6 months: ischemic cerebrovascular event or cerebrovascular revascularization | NYHA class III or IV heart failure | Symptomatic PE or asymptomatic PE within the last 3 months | Baseline QTcF >= 470 msec, congenital long QT syndrome, torsades de pointes, or other risk factors for QT prolongation | Left ventricular ejection fraction below lower limit of normal | Active malignancy other than NSCLC or prior curatively treated malignancy at high risk of relapse during study (except localized basal or squamous cell skin cancer) | Concurrent anti-cancer therapy | Hypersensitivity to sapanisertib (MLN0128/TAK-228) or osimertinib (AZD9291) | Pregnancy or breastfeeding | Inability to discontinue strong CYP3A4/3A5, CYP2C19, or CYP2C9 inhibitors/inducers, and sensitive substrates of CYP3A4/5 or CYP1A2 at least 3 weeks prior to registration | Systemic corticosteroids within 1 week before first dose (excluding inhaled or low-dose hormone replacement) | Consumption of grapefruit or Seville orange products within 7 days before first dose and during study | HIV-positive on combination antiretroviral therapy | Concomitant proton pump inhibitor use (must discontinue >= 1 week before MLN0128)","Progression on first-line osimertinib required; Dose expansion: no systemic therapy after first-line osimertinib; Dose expansion: no prior third-generation EGFR-TKI (other than osimertinib); Dose expansion: no prior mTOR inhibitors; Prior EGFR inhibitor washout >= 7 days with toxicities resolved to <= grade 1 (except alopecia); Prior chemotherapy washout >= 21 days with toxicities resolved to <= grade 1 (except <= grade 2 neuropathy or alopecia); Major surgery washout >= 21 days with complete wound healing and toxicities < grade 1; Radiation therapy washout >= 14 days with resolution of radiation toxicity (excluding alopecia); Investigational agent washout >= 3 months or >= 5 half-lives, whichever is longer",ALL,A,"Metastatic NSCLC with EGFR exon 19 deletion matches the required population, and he has progressed after first-line osimertinib with ECOG 0. No exclusion criteria are evident, and key eligibility (stage, biomarker, and prior-exposure setting) aligns.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,A,"Disease and stage match (metastatic NSCLC), required EGFR exon 19 biomarker is present, and no hard exclusions are evident. Line/prior exposure likely matches (progression on first-line osimertinib is suggested by new lesions), but even if treated as unknown, there are ≥2 core anchors (stage and biomarker) without soft conflicts, supporting grade A. The grader’s conclusion is consistent with the rubric.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT02658279,0.9180995225906372,Recurrent Glioblastoma,"A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype","The purpose of this study is to test if the study drug called pembrolizumab could control the growth or shrink the cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by half, or prevent it from growing for at least 6 months. Pembrolizumab is an antibody that targets the immune system and activates it to stop cancer growth and/or kill cancer cells.","{'id': 205991849, 'name': 'Pembrolizumab', 'description': None, 'other_names': ['(MK-3475)'], 'intervention_type': 'DRUG'}",NA,18 years,Recurrent Malignant Glioma,"Histologically confirmed malignant glioma | WHO grade IV glioblastoma or variants | WHO grade III anaplastic astrocytoma or oligodendroglial tumor | WHO grade II glioma with contrast enhancement on MRI | Recurrent tumor after prior therapy including at least radiation therapy and one cytotoxic chemotherapy | Hypermutator phenotype defined as >=30 nonsynonymous somatic mutations by CLIA-certified NGS (or per PI approval, mutation in mismatch repair gene or other hypermutator-associated genes, or presence of microsatellite instability) | Age >= 18 years | >=12 weeks since prior radiation therapy unless histopathologic confirmation of recurrence or new enhancement outside radiation field | >=4 weeks since last investigational agent or any other treatment prior to first dose of pembrolizumab | Recovered to <= Grade 1 from adverse events of prior therapy | Karnofsky performance status >= 70 | Adequate organ function | Negative pregnancy test for females of childbearing potential | Agreement to use effective contraception","Requirement for escalating or chronic supraphysiologic corticosteroids (>10 mg/day prednisone equivalent) for disease control at registration | Prior treatment with anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti-PD-L2 agents | Hypersensitivity to pembrolizumab or its excipients | Immunodeficiency including HIV/AIDS | Active hepatitis B or active hepatitis C infection | Known history of active tuberculosis | Additional malignancy that is progressing or requires active treatment (except certain skin cancers or in situ cervical cancer) | Active autoimmune disease requiring systemic treatment in the past 2 years | History or evidence of active non-infectious pneumonitis | Active infection requiring systemic therapy | Pregnant or breastfeeding | Unable to undergo brain MRI | Live vaccine within 30 days before start of study therapy | Prior treatment with bevacizumab",Must have received prior radiation therapy; Must have received at least one prior cytotoxic chemotherapy; >=12 weeks since prior radiation therapy unless pathologic confirmation of recurrence or new enhancement outside radiation field; >=4 weeks since last investigational agent or any other treatment; Recovered to <= Grade 1 from prior therapy adverse events; Prior surgical resection for recurrence allowed,ALL,A,Recurrent GBM with prior RT+temozolomide matches the trial’s disease setting and prior-therapy requirements; age/sex fit and no exclusions are evident. The required hypermutator phenotype is currently unknown (needs confirmation) but this is not an explicit mismatch.,Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),INCORRECT,B,"Disease and stage/setting match and prior-therapy requirements align, but the trial requires a hypermutator phenotype and the patient’s status is unknown. Per rubric, required biomarkers must be satisfied for an A. With no soft conflicts and at least one core anchor matched, B is appropriate.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT02713269,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,A Phase II Clinical Trial Evaluating the Efficacy of Combining Thermal Ablation and Spine Stereotactic Radiosurgery for Patients With Spine Metastases With Moderate to Severe Epidural Involvement,"This phase II clinical trial studies how well thermal ablation and spine stereotactic radiosurgery work in treating patients with cancer that has spread to the spine (spine metastases) and is at risk for compressing the spinal cord. Thermal ablation uses a laser to heat tumor tissue and helps to shrink the tumor by destroying tumor cells. Stereotactic radiosurgery delivers a large dose of radiation in a short time precisely to the tumor, sparing healthy surrounding tissue. Combining thermal a...","{'id': 206403064, 'name': 'Computed Tomography', 'description': 'Undergo CT scan', 'other_names': ['CAT', 'CAT Scan', 'Computerized Axial Tomography', 'computerized tomography', 'CT', 'CT SCAN', 'tomography'], 'intervention_type': 'PROCEDURE'}; {'id': 206403065, 'name': 'Quality-of-Life Assessment', 'description': 'Ancillary studies', 'other_names': ['Quality of Life Assessment'], 'intervention_type': 'OTHER'}; {'id': 206403066, 'name': 'Questionnaire Administration', 'description': 'Ancillary studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206403067, 'name': 'Stereotactic Radiosurgery', 'description': 'Undergo CT-guided SSRS', 'other_names': ['Stereotactic External Beam Irradiation', 'stereotactic external-beam radiation therapy', 'stereotactic radiation therapy', 'Stereotactic Radiotherapy', 'stereotaxic radiation therapy', 'stereotaxic radiosurgery'], 'intervention_type': 'RADIATION'}; {'id': 206403068, 'name': 'Thermal Ablation Therapy', 'description': 'Undergo thermal ablation therapy', 'other_names': ['thermal ablation'], 'intervention_type': 'PROCEDURE'}",PHASE2,18 years,Breast Cancer (metastatic); Non-Small Cell Lung Cancer (metastatic); Prostate Carcinoma (metastatic); Kidney Carcinoma (metastatic); Melanoma (metastatic); Sarcoma (metastatic); Thyroid Carcinoma (metastatic); Head and Neck Carcinoma (metastatic); Cancer of Unknown Primary (metastatic); Digestive System Neoplasm (metastatic); Spinal Cord Compression,"Age >= 18 years | Histologically confirmed solid malignant tumor excluding radiosensitive histologies | Epidural spinal cord compression grade 1C, 2, or 3 by MRI | Target vertebral body site between T2 and T12 | <= 3 contiguous or discontiguous vertebral levels to be irradiated in a single session or up to 3 sessions | Motor strength >= 4/5 in affected extremities | ECOG <=2 or Karnofsky >=50% | Life expectancy > 3 months | Inoperable disease due to patient refusal, neurosurgical evaluation, or medical reasons | Agreement to use adequate contraception during study participation | Prior conventional radiation to the same site allowed if interval > 3 months | No other viable treatment options per multidisciplinary spine SSRS tumor board","Primary tumors of radiosensitive histology: lymphoma, multiple myeloma, small cell carcinoma, germ cell tumors | Prior conventional irradiation to the spine site with interval < 3 months | Lesions located outside T2 to T12 | Prior surgery to the same spine levels | Inability to lie flat on a treatment table for > 60 minutes | Unable to undergo MRI of the spine | Pregnancy | Frank spinal cord compression or compression from bone components with acute neurological deficits | Motor strength < 4/5 in affected extremities",Prior conventional radiation to the same site allowed if > 3 months interval,ALL,A,"Disease and setting match (metastatic NSCLC), and age/ECOG and prior therapy exposure are compatible with the trial. Eligibility will hinge on confirming T2–T12 spine metastases with moderate–severe epidural involvement by MRI, which is not provided but not a conflict.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),INCORRECT,B,"No hard exclusions. Disease matches. Only one CORE ANCHOR clearly matches: stage/setting (metastatic). Line/prior is not specified by the trial and patient prior therapy doesn’t create a defined match; biomarker/subtype (epidural ESCC grade 1C–3) and metastatic pattern constraints (T2–T12 spine involvement, ≤3 levels) are unknown. Age/ECOG are not CORE ANCHORS. Therefore exactly 1 anchor match → Grade B, not A.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT02720874,1.0,Rheumatoid Arthritis,Multidisciplinary Approach to Patient-Physician Partnership In Treating To Target In Rheumatoid Arthritis,"This research will evaluate a multifaceted patient-centered intervention in a sample of socioeconomically disadvantaged Hispanic adults with rheumatoid arthritis (RA) that capitalizes on a partnership between the extended rheumatology healthcare team and each patient in order to promote understanding, uptake and adherence to the principles of treat-to-target strategy. The primary hypothesis of this study is that the addition of a multifaceted intervention incorporating integrated multidiscipl...","{'id': 205447623, 'name': 'Rheumatoid arthritis educational booklet', 'description': 'Participants will receive a low-literacy rheumatoid arthritis educational booklet that provides general disease state information.', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}; {'id': 205447624, 'name': 'Multidisciplinary rheumatologic care', 'description': 'At each regularly scheduled clinic appointment, participants will receive treatment from their assigned rheumatologist, undergo an in-clinic physical therapy evaluation and, if indicated, a psychological evaluation. Physical therapy and psychology follow-up sessions will occur as directed by the individual services.', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}; {'id': 205447625, 'name': 'Nurse education and monthly calls', 'description': 'Participants will meet one-on-one with a rheumatology nurse for a tailored educational session encompassing disease state education, an introduction of the treat to target concept, an overview of treatment options, and goal setting and planning. During monthly follow-up calls, participant educational needs will be addressed; goal setting, planning and review will also be conducted.', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}; {'id': 205447626, 'name': 'Monthly healthcare coordinator calls', 'description': 'During monthly calls with the healthcare coordinator, specific questions and concerns raised by participants may be addressed. The primary purpose of these calls is to control for potential benefit derived from time on the phone with a health professional.', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}; {'id': 205447627, 'name': 'Technology-based symptom monitoring and reporting', 'description': 'When at home patient self-monitoring reports indicate a significant increase in RA disease activity, participants will be promptly contacted and scheduled for an ad hoc evaluation with their treating rheumatologist.', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}",NA,18 years,Rheumatoid Arthritis,Rheumatoid arthritis per 2010 American College of Rheumatology revised diagnostic criteria | Moderate or higher disease activity: Clinical Disease Activity Index (CDAI) > 10 and Routine Assessment Patient Index Data (RAPID3) > 2,"Irreversible articular damage (including subluxations, arthrodesis, fusion, or prosthesis) | American College of Rheumatology Functional Class IV | Overlapping autoimmune or mixed connective tissue syndromes | Chronic infection | Advanced or decompensated heart failure | Chronic kidney disease higher than class II | Cancer unless in remission for >= 5 years | Any uncontrolled medical condition interfering with the study protocol | At risk for suicide",(none),ALL,A,"Disease matches RA, and the patient has active disease consistent with the trial’s moderate-or-higher activity setting; age and sex fit. Prior therapies are allowed (no restrictions stated), and no explicit exclusions are identified from the available data.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),INCORRECT,B,"No hard exclusions. Disease matches and active disease suggests a stage/setting match. Line/prior exposure is unspecified in the trial (cannot be counted as a match), and CDAI/RAPID3 requirements are unknown from the patient data. With exactly one core anchor match and no soft conflicts, the correct grade is B, not A.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT02795052,1.0,Dementia,Neurologic Bone Marrow Derived Stem Cell Treatment Study,This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/,"{'id': 206037463, 'name': 'Intravenous and Intranasal BMSC', 'description': 'Autologous Bone Marrow Derived Stem Cells provided intravenous and intranasal (lower 1/3 of nose)', 'other_names': ['IV and IN BMSC'], 'intervention_type': 'PROCEDURE'}",NA,18 years,Amyotrophic Lateral Sclerosis; Alzheimer Disease; CADASIL; Cerebral Hemorrhage; Cerebral Infarction; Cerebral Ischemia; Chronic Traumatic Encephalopathy; Cognitive Impairment; Dementia; Diabetic Neuropathy; Frontotemporal Dementia; Lewy Body Disease; Lewy Body Variant of Alzheimer Disease; Multiple System Atrophy; Neuropathy; Parkinson Disease; Progressive Supranuclear Palsy; Stroke; Traumatic Brain Injury,"Documented functional damage to the central or peripheral nervous system unlikely to improve with current standard of care | >= 6 months since disease onset | If on pharmacologic or surgical therapy, clinically stable and unlikely to have reversal of neurologic damage from that therapy | Investigator assessment that there is potential for improvement with BMSC and minimal risk from the procedure | Age > 18 years | Medically stable and able to be cleared by a primary care practitioner for the procedure",Not medically stable or at significant risk to health from undergoing the procedure | Pregnant at the time of treatment or planning pregnancy within 3 months post-treatment,Current pharmacologic or surgical therapy allowed if stable,ALL,A,"Disease (dementia) is included; age and sex fit. Onset >6 months and no conflicting prior-therapy requirements (none, and stable therapy allowed); no required biomarkers and no explicit exclusions apply.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),INCORRECT,C,"No hard exclusions. Disease matches, but the trial provides no clear constraints on stage/setting (beyond general chronicity), line-of-therapy/prior exposure, biomarkers, or metastatic pattern. Thus 0 core anchors clearly match (age/sex/onset are not counted anchors). With no soft conflicts, the correct grade is C, not A.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT02974621,0.8363864421844482,Recurrent Glioblastoma,A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy,"This randomized phase II trial studies how well cediranib maleate and olaparib work compared to bevacizumab in treating patients with glioblastoma that has come back (recurrent). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.","{'id': 206251023, 'name': 'Bevacizumab', 'description': 'Given IV', 'other_names': ['Bevacizumab Biosimilar LY01008', 'ABP 215', 'ABP-215', 'ABP215', 'Alymsys', 'Anti-VEGF', 'Anti-VEGF Humanized Monoclonal Antibody', 'Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer', 'MB 02', 'MB-02', 'MB02', 'Mvasi', 'MYL-1402O', 'Onbevzi', 'Oyavas', 'PF 06439535', 'PF-06439535', 'PF06439535', 'QL1101', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'rhuMab-VEGF', 'SCT501', 'SIBP 04', 'SIBP-04', 'SIBP04', 'Vegzelma', 'Zirabev', 'Anti-VEGF Monoclonal Antibody SIBP04', 'Anti-VEGF rhuMAb', 'Avastin', 'Avzivi', 'Aybintio', 'BAT 1706', 'BAT-1706', 'BAT1706', 'BAT1706 Biosimilar', 'Bevacizumab awwb', 'Bevacizumab Biosimilar ABP 215', 'Bevacizumab Biosimilar BAT1706', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar GB-222', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar MB02', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar QL1101', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab-adcd', 'Bevacizumab-awwb', 'Bevacizumab-aybi', 'Bevacizumab-bvzr', 'Bevacizumab-equi', 'Bevacizumab-maly', 'Bevacizumab-onbe', 'Bevacizumab-tnjn', 'BP102', 'BP102 Biosimilar', 'CT P16', 'CT-P16', 'CTP16', 'Equidacent', 'FKB 238', 'FKB-238', 'FKB238', 'HD204'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206251024, 'name': 'Cediranib', 'description': 'Given PO', 'other_names': ['AZ-D2171', 'AZD 2171', 'AZD2171'], 'intervention_type': 'DRUG'}; {'id': 206251025, 'name': 'Cediranib Maleate', 'description': 'Given PO', 'other_names': ['AZD2171', 'AZD2171 Maleate', 'Recentin'], 'intervention_type': 'DRUG'}; {'id': 206251026, 'name': 'Olaparib', 'description': 'Given PO', 'other_names': ['AZD 2281', 'AZD-2281', 'AZD2281', 'KU 0059436', 'KU-0059436', 'KU0059436', 'Lynparza', 'Olanib', 'Olaparix', 'PARP Inhibitor AZD2281'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Glioblastoma (recurrent),"Progressive disease on contrast-enhanced CT/MRI per RANO or recurrent glioblastoma on biopsy | Previous therapy with at least radiotherapy and temozolomide | >=12 weeks from radiotherapy unless progression is outside the high-dose field or biopsy confirms progression | Only first or second recurrence eligible | Washout: >=5 half-lives from investigational agents | Washout: >=4 weeks from cytotoxic therapy (>=23 days for temozolomide; >=6 weeks for nitrosoureas) | Washout: >=6 weeks from antibodies | Washout: >=4 weeks or >=5 half-lives (whichever is shorter) from other systemic anti-tumor therapies | May start treatment 1 day after discontinuation of the Optune device | Adverse events from prior therapy resolved to <= grade 1 (except alopecia) | Karnofsky performance status >= 60% | Life expectancy >= 3 months | Leukocytes >= 3,000/µL | Absolute neutrophil count >= 1,500/µL | Platelets >= 100,000/µL | Hemoglobin >= 10.0 g/dL without transfusion in the prior 28 days | Total bilirubin <= 1.5 x ULN | AST <= 2.5 x ULN | ALT <= 2.5 x ULN | Creatinine <= 1 x ULN or creatinine clearance >= 60 mL/min | Urine protein/creatinine ratio < 1 or urine dipstick protein <= 2+ | Baseline brain CT or MRI within 14 days prior to start of study drug | Corticosteroid dose stable or decreasing for at least 5 days before baseline MRI","Prior use of PARP inhibitors | Prior therapy affecting the VEGF pathway (e.g., thalidomide, bevacizumab, sunitinib, sorafenib) | Allergic reactions to compounds similar to olaparib, cediranib, or bevacizumab | Uncontrolled hypertension (systolic BP > 140 mmHg or diastolic BP > 90 mmHg) or need for more than three antihypertensive medications | History of hypertensive crisis or hypertensive encephalopathy | Abdominal fistula or gastrointestinal perforation within 6 months | Intra-abdominal abscess within 6 months | History of pneumonitis | Current signs/symptoms of bowel obstruction or within 3 months | Dependency on IV hydration or total parenteral nutrition | Myelodysplastic syndrome or acute myeloid leukemia | Active or recent invasive malignancy other than allowed exceptions (limited-stage basal/squamous cell skin cancer, carcinoma in situ of breast/cervix, or prior cancer cured with no recurrence for 3 years) | Myocardial infarction within 6 months | Unstable angina | Cerebrovascular accident within 6 months | NYHA class II or greater heart failure | Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) or clinically significant peripheral vascular disease | Left ventricular ejection fraction below institutional normal or < 55% if unspecified | QTc > 470 msec or family history of long QT syndrome | Major surgery, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib; anticipated need for major surgery | Uncontrolled intercurrent illness (including active infection, symptomatic heart failure, unstable angina, significant arrhythmia, or psychiatric illness limiting compliance) | Concurrent use of strong CYP3A4 inhibitors/inducers or moderate CYP3A4 inhibitors | Pregnant or breastfeeding | HIV-positive on combination antiretroviral therapy | Concurrent anti-cancer therapy while on study treatment | Concurrent use of herbal supplements (e.g., cannabis, St. John's wort, kava, ephedra, ginkgo, DHEA, yohimbe, saw palmetto, ginseng) during the study | Evidence of coagulopathy or bleeding diathesis (therapeutic anticoagulation permitted)",Prior radiotherapy and temozolomide required; Only first or second recurrence permitted; Washout >= 5 half-lives from investigational agents; Washout >= 4 weeks from cytotoxic therapy (>= 23 days for temozolomide; >= 6 weeks for nitrosoureas); Washout >= 6 weeks from antibodies; Washout >= 4 weeks or >= 5 half-lives (whichever is shorter) from other systemic anti-tumor therapies; May start one day after discontinuing Optune device,ALL,A,"Recurrent glioblastoma with prior radiotherapy and temozolomide, first recurrence, and no prior VEGF/PARP therapy matches the trial’s key inclusion criteria. Age and sex are eligible, and no explicit exclusions are triggered based on available information.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches (recurrent GBM). Stage/setting matches (recurrent). Line/prior exposure compatible (prior RT/TMZ required; no prior VEGF/PARP). No identified soft conflicts. ≥2 core anchors match, satisfying A per rubric.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT03026062,0.8482123017311096,Recurrent Clear Cell Ovarian Carcinoma,Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer,"This phase II trial studies how well durvalumab and tremelimumab work in treating participants with ovarian, primary peritoneal, or fallopian tube cancer that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether give durvalumab and tremelimumab in combination or sequentia...","{'id': 206204147, 'name': 'Durvalumab', 'description': 'Given IV', 'other_names': ['Imfinzi', 'Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer', 'MEDI-4736', 'MEDI4736'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206204148, 'name': 'Tremelimumab', 'description': 'Given IV', 'other_names': ['Anti-CTLA4 Human Monoclonal Antibody CP-675,206', 'CP-675', 'CP-675,206', 'CP-675206', 'Ticilimumab'], 'intervention_type': 'BIOLOGICAL'}",PHASE2,18 years,Ovarian Clear Cell Carcinoma; Primary Peritoneal Carcinoma (clear cell); Fallopian Tube Carcinoma (clear cell); Uterine Serous Carcinoma,"Age >= 18 years | ECOG performance status 0–1 | Adequate organ and marrow function | Non-reproductive potential or negative serum pregnancy test | Histologically confirmed recurrent high grade epithelial ovarian, primary peritoneal, or fallopian tube cancer with clear cell histology or mixed carcinoma with a clear cell component | Expansion cohort: recurrent uterine serous carcinoma with somatic testing demonstrating a nonsynonymous PPP2R1A mutation | Platinum-resistant or refractory disease | Measurable disease per modified RECIST 1.1","Any previous treatment with PD-1/PD-L1 inhibitors (including durvalumab) or anti-CTLA-4 therapy (including tremelimumab) | History of another primary malignancy unless in remission >= 5 years or adequately treated non-melanoma skin cancer, lentigo maligna, or carcinoma in situ | Current or prior use of systemic immunosuppressive medication within 28 days before first dose (exceptions apply) | Unresolved toxicity > CTCAE grade 1 from prior anticancer therapy (excluding alopecia) | Any prior grade >= 3 immune-related adverse event or unresolved immune-related adverse event > grade 1 | Active or prior autoimmune disease within the past 2 years (exceptions apply) | Active or prior inflammatory bowel disease | History of primary immunodeficiency | History of allogeneic organ transplant | Hypersensitivity to durvalumab, tremelimumab, or any excipient | Uncontrolled intercurrent illness including active infection, symptomatic CHF, uncontrolled hypertension, unstable angina, cardiac arrhythmia, active peptic ulcer or gastritis, active bleeding diathesis, active hepatitis B or C, or HIV | QTc >= 470 ms (Fridericia) on 3 ECGs | Known history of tuberculosis | History of leptomeningeal carcinomatosis or brain metastasis | Unresolved partial or complete bowel obstruction | Live attenuated vaccination within 30 days before or after durvalumab or tremelimumab | Pregnant or breastfeeding or of reproductive potential not using effective birth control | Uncontrolled seizures","At least one prior line of platinum-based chemotherapy (required for uterine serous carcinoma cohort); Washout from prior anticancer therapy >= 28 days before first dose; Washout from prior tyrosine kinase inhibitors >= 21 days before first dose; Washout from prior nitrosoureas, mitomycin C, or bevacizumab >= 6 weeks before first dose",FEMALE,A,"Disease and histology match (recurrent clear cell ovarian carcinoma), age/sex fit, and prior-exposure compatibility aligns (no prior PD-1/PD-L1 or CTLA-4). Platinum-resistance status and RECIST measurability are not specified but present no explicit conflicts.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,"No hard exclusions. Disease and clear cell histology match. Stage/setting matches (recurrent). Line/prior exposure compatible (no prior PD-1/CTLA-4); platinum-resistant status is unknown, which should be treated neutrally. Required histology biomarker satisfied. With ≥2 anchors matched and no soft conflicts, A is appropriate.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT03170960,1.0,Castration-Resistant Prostate Cancer,A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,"This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometri...","{'id': 205866952, 'name': 'cabozantinib', 'description': 'Supplied as 60-mg and 20-mg tablets; administered orally daily at dose levels of 20 mg, 40 mg, or 60 mg.', 'other_names': ['Cabometyx', 'XL184'], 'intervention_type': 'DRUG'}; {'id': 205866953, 'name': 'atezolizumab', 'description': 'Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).', 'other_names': ['Tecentriq'], 'intervention_type': 'DRUG'}; {'id': 205866954, 'name': 'cabozantinib', 'description': 'Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage', 'other_names': ['Cabometyx', 'XL184'], 'intervention_type': 'DRUG'}; {'id': 205866955, 'name': 'cabozantinib', 'description': 'Supplied as 60-mg and 20-mg tablets; administered orally daily at 60 mg qd', 'other_names': ['Cabometyx', 'XL184'], 'intervention_type': 'DRUG'}",PHASE1,18 years,Castration-Resistant Prostate Cancer; Colorectal Cancer; Differentiated Thyroid Cancer; Endometrial Cancer; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Head and Neck Cancer; Hepatocellular Carcinoma; Lower Esophageal Cancer; Non-Small Cell Lung Cancer; Ovarian Cancer; Renal Cell Carcinoma; Triple Negative Breast Cancer; Urothelial Carcinoma,"Histologically or cytologically and radiologically confirmed inoperable, locally advanced, metastatic, or recurrent solid tumor per cohort definitions | Measurable disease per RECIST 1.1 | Tumor tissue available (archival or recent biopsy) | Recovery to baseline or <= Grade 1 from prior treatment toxicities unless clinically nonsignificant/stable on supportive therapy | Age >= 18 years | ECOG performance status 0–1 | Adequate organ and marrow function | Use of effective contraception if of childbearing potential or sexually active | Negative pregnancy test for females of childbearing potential","Prior treatment with cabozantinib or immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, anti-PD-L1, anti-PD-L2) except in specified cohorts (5, 7, 9, 11, 17, 19, 20) | Known brain metastases or cranial epidural disease unless adequately treated and stable for >= 4 weeks prior to first dose | Concomitant anticoagulation with oral anticoagulants | Systemic steroid therapy >10 mg daily prednisone equivalent or other immunosuppressive therapy within 2 weeks prior to first dose | Receipt of a live attenuated vaccine within 30 days before first dose | Uncontrolled significant intercurrent or recent illness, including active or history of autoimmune disease or immune deficiency | Interstitial lung disease (idiopathic pulmonary fibrosis, organizing pneumonia) or pneumonitis | Active infection requiring systemic treatment | HIV infection or AIDS-related illness | Acute or chronic hepatitis B or C infection | Positive test for tuberculosis | Moderate to severe hepatic impairment (Child-Pugh B or C) | Pregnant or lactating | Allergy or hypersensitivity to components of study treatments | Another malignancy diagnosed within 2 years prior to first dose","Prior platinum-based chemotherapy for urothelial carcinoma (specific cohorts); Up to one prior VEGFR-targeting TKI allowed for non–clear cell RCC (Expansion Cohort 10); No prior systemic anticancer therapy required for selected cohorts (e.g., clear cell RCC, HCC, PD-L1 positive NSCLC); Progression after prior immune checkpoint inhibitor required for selected UC and NSCLC cohorts; Prior EGFR-targeting TKI with subsequent progression required for EGFR-mutant NSCLC cohort; Prior systemic chemotherapy containing fluoropyrimidine with oxaliplatin or irinotecan required for CRC cohort; At least one prior systemic therapy required for TNBC cohort; Platinum-resistant or refractory OC after up to two prior lines; At least one prior systemic therapy required for EC cohort; Prior enzalutamide and/or abiraterone for metastatic CRPC (specific cohort); Exactly one prior novel hormonal therapy for mCRPC cohorts; Prior docetaxel for mCRPC required in a specific cohort",ALL,A,"Disease and stage match metastatic CRPC, and the patient’s prior enzalutamide/abiraterone exposure fits an mCRPC cohort requiring prior novel hormonal therapy. No explicit exclusions are triggered; other criteria (ECOG, measurable disease) are unspecified.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),INCORRECT,D,"No hard exclusions. Disease and metastatic setting match. However, for mCRPC cohorts the trial specifies exactly one prior novel hormonal therapy; the patient has two (abiraterone and enzalutamide), creating a specific line/prior-exposure mismatch (soft). Therefore grade should be D, not A.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03337698,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)","This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in participants with metastatic non-small cell lung cancer (NSCLC). Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of participants with tumor PD-L1 expression who have received no prior systemic therapy for metastatic NSCLC, and Cohort 2 will consist of participants who experienced disease progression during or following treatment with a platinum-con...","{'id': 206121907, 'name': 'Atezolizumab', 'description': 'Atezolizumab is administered by IV on Day 1 of each 21 day cycle or on Days 1 and 15 of each 28 day cycle.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206121908, 'name': 'Cobimetinib', 'description': 'Cobimetinib is administered orally on Days 1-21 of a 28 day cycle.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206121909, 'name': 'RO6958688', 'description': 'Cycle 1:\n\nRO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle at increasing dosage.\n\nSubsequent cycles:\n\nRO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206121910, 'name': 'Docetaxel', 'description': 'Docetaxel is administered by IV on Day 1 of each 21 day cycle.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206121911, 'name': 'CPI-444', 'description': 'CPI-444 is administered orally twice daily on Days 1- 21, of a 21 day cycle.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206121912, 'name': 'Pemetrexed', 'description': 'Pemetrexed is administered by IV on Day 1 of a 21 day cycle.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206121913, 'name': 'Carboplatin', 'description': 'Carboplatin is administered by IV on day 1 of the first 4 or 6 cycles out of a 21 day cycle.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206121914, 'name': 'Gemcitabine', 'description': 'Gemcitabine is administered by IV on Days 1 and 8 of the first 4 or 6 cycles out of a 21 day cycle.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206121915, 'name': 'Linagliptin', 'description': 'Linagliptin is administered orally once daily on Days 1 to 21 out of a 21 day cycle.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206121916, 'name': 'Tocilizumab', 'description': 'Tocilizumab is administered for the management of cytokine-release syndrome in the RO6958688-containing arms.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206121917, 'name': 'Ipatasertib', 'description': 'Ipatasertib will be administered orally once a day on Days 1-21 of each 28-day cycle.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206121918, 'name': 'Bevacizumab', 'description': 'Bevacizumab is administered by IV on Day 1 of each 21-day cycle.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206121919, 'name': 'Sacituzumab Govitecan', 'description': 'Sacituzumab Govitecan is administered by IV on Day 1 and 8 of each 21-day cycle.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206121920, 'name': 'Radiation', 'description': 'Radiotherapy up to 21 days', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206121921, 'name': 'Evolocumab', 'description': 'Evolocumab is administered subcutaneously at a dose of 140 mg on Days 1 and 15 of each 28-day cycle.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206121922, 'name': 'Tiragolumab', 'description': 'Tiragolumab is administered on Day 1 of each 21 day cycle.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206121923, 'name': 'XL092', 'description': 'XL092 is administered orally once a day on Day 1 to Day 21 of a 21 day cycle.', 'other_names': ['Zanzalintinib'], 'intervention_type': 'DRUG'}; {'id': 206121924, 'name': 'Camonsertib', 'description': 'Camonsertib is administered orally on Days 1-3, Days 8-10 of a 21 day cycle.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic),"ECOG performance status 0–1 | Life expectancy >= 3 months | Histologically or cytologically confirmed metastatic non-squamous or squamous NSCLC | Measurable disease (at least one target lesion) | Adequate hematologic and end-organ function | Tumor accessible for biopsy | No prior systemic therapy for metastatic NSCLC (Cohort 1) | High tumor PD-L1 expression: TPS >= 50% or TC3 (Cohort 1) | Disease progression during or following treatment for metastatic or locally advanced, inoperable NSCLC (Cohort 2)","Prior allogeneic stem cell or solid organ transplantation | Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently) | Symptomatic, untreated, or actively progressing CNS metastases | History of leptomeningeal disease | Active or history of autoimmune disease or immune deficiency | History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT | History of malignancy other than NSCLC within 2 years prior to screening | Active tuberculosis | Severe infection within 4 weeks prior to initiation of study treatment","No prior systemic therapy for metastatic NSCLC (Cohort 1); Progression during or after treatment for metastatic or locally advanced, inoperable NSCLC (Cohort 2)",ALL,A,"Metastatic NSCLC with ECOG 0 matches the study setting, and prior systemic therapy (osimertinib) with apparent progression fits Cohort 2. Age and sex are eligible, and no trial exclusions are triggered based on available data; PD-L1 is only required for the treatment‑naïve cohort.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches metastatic NSCLC. Stage/setting matches. Prior therapy with osimertinib and new numerous lesions reasonably indicate progression, satisfying Cohort 2 line/prior anchor. PD-L1 requirement applies only to treatment-naïve cohort. No soft conflicts identified. Grade A is appropriate per rubric.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT03355976,0.8482123017311096,Recurrent Clear Cell Ovarian Carcinoma,BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas,"Preclinical and early-phase clinical data suggest that immune modulation represents a treatment strategy that is worthy of further investigation in relapsed epithelial ovarian cancer. One method by which tumor cells may evade immune surveillance is by activation of the programmed cell death (PD-1) pathway, mediated by expression of PD-1 on the surface of T lymphocytes, which conveys an inhibitory signal after binding to its ligand PD-L1 on the surface of tumor cells. Nivolumab and Ipilimumab ...","{'id': 206068075, 'name': 'Nivolumab', 'description': '240mg flat dose every 2 weeks', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206068076, 'name': 'Ipilimumab', 'description': 'Ipilimumab 1mg/kg every 6 weeks', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,18 years,Ovarian Clear Cell Carcinoma; Fallopian Tube Clear Cell Carcinoma; Primary Peritoneal Clear Cell Carcinoma; Clear Cell Carcinoma (extra-renal),"Recurrent, advanced, or metastatic pure clear cell carcinoma of ovarian, fallopian tube, primary peritoneal, or extra-renal origin | Measurable disease by RECIST: >=20 mm by conventional imaging or >=10 mm by spiral CT/MRI/clinical calipers | Progressed after >=1 prior platinum- and taxane-based regimen (ovarian/fallopian tube/primary peritoneal) | Extra-renal clear cell cancer: progressed after >=1 prior systemic regimen for advanced/metastatic disease | Age >=18 years | ECOG performance status 0-1 | Adequate organ and marrow function | Adequate thyroid function (TSH within normal range) | Resting oxygen saturation >=92% at rest","Prior therapy with nivolumab, anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 | Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C); endocrine therapy within 7 days | Not recovered from clinically significant adverse events to < grade 2 from prior therapies | Concurrent investigational agents | Known brain metastases | History of severe hypersensitivity reaction to any monoclonal antibody | Uncontrolled intercurrent illness (active infection requiring antibiotics, symptomatic CHF, unstable angina, serious arrhythmia, or significant psychiatric illness) | Pregnancy or breastfeeding | Other invasive malignancy within 3 years (exceptions for low-risk conditions as specified) | Prior chemotherapy within the last 3 years for cancers other than clear cell cancer | HIV infection not meeting: stable HAART, CD4 >350/µL, and undetectable viral load | Hepatitis B or C with detectable viral load or not definitively treated >=6 months | Active autoimmune disease or history likely to recur affecting vital organs or requiring immunosuppression | Systemic corticosteroids >10 mg prednisone equivalents daily or other immunosuppressive medications within 14 days prior to day 1 | Planned concomitant, non-protocol anti-cancer therapy | Grade >=2 peripheral neuropathy",Prior platinum- and taxane-based chemotherapy required (ovarian/fallopian tube/primary peritoneal); At least one prior systemic regimen required (extra-renal clear cell carcinoma); Washout: chemotherapy or radiotherapy >=4 weeks (>=6 weeks for nitrosoureas or mitomycin C); Washout: endocrine therapy >=7 days,ALL,A,"Disease and setting match (recurrent ovarian clear cell carcinoma), and she has progressed after prior platinum/taxane therapy without prior PD-1/CTLA-4 exposure. Age and sex meet requirements, and no explicit exclusions are evident from the available data.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,"Disease matches ovarian clear cell; setting is recurrent; prior platinum/taxane exposure satisfied; no PD-1/CTLA-4 exposure; age/sex within bounds. No explicit exclusions from provided data; measurable disease and other labs are unknown, not mismatches. ≥2 core anchors match (stage/setting and line/prior), so A is appropriate.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03377023,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer,"The main purpose of this study is to see if the combination of nivolumab, ipilimumab and nintedanib is effective in people with non- small cell lung cancer. Researchers also want to find out if the combination of nivolumab, ipilimumab and nintedanib is safe and tolerable.","{'id': 206035679, 'name': 'Nivolumab', 'description': 'Intravenous nivolumab every 2 weeks.', 'other_names': ['Opdivo®'], 'intervention_type': 'DRUG'}; {'id': 206035680, 'name': 'Ipilimumab', 'description': 'Intravenous ipilimumab every 6 weeks.', 'other_names': ['Yervoy®'], 'intervention_type': 'DRUG'}; {'id': 206035681, 'name': 'Nintedanib', 'description': 'Nintedanib 100-200 mg capsules by mouth twice daily for two-week cycles.', 'other_names': ['Vargatef®', 'Ofev®', 'BIBF1120'], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic),"Histologic or cytologic diagnosis of advanced/metastatic Non-Small Cell Lung Cancer with no curative options | Age >= 18 years | Life expectancy >= 3 months | ECOG performance status 0–1 | Phase 1: Treatment-naive or previously treated with chemotherapy, immunotherapy, or targeted therapy for NSCLC allowed | Neoadjuvant/adjuvant chemo/radiation allowed if recurrence > 6 months after completion (considered treatment-naive in Stage IV) | Driver-positive NSCLC allowed if prior FDA-approved targeted therapy received (e.g., EGFR, ALK, ROS1, BRAF V600E) | Phase 2 Arm A: Newly diagnosed/treatment-naive; prior neoadjuvant/adjuvant allowed if recurrence > 6 months | Phase 2 Arm B: Prior immunotherapy exposure required (primary refractory or relapsed after initial disease control) | At least one measurable lesion per RECIST v1.1 | QTcB < 470 ms (males) or < 480 ms (females) | Adequate organ and marrow function | Negative pregnancy test for women of childbearing potential","Concurrent use of other anticancer agents (chemotherapy, targeted therapy, radiotherapy, or immunotherapy) not specified in protocol | Participation in another clinical trial with a non–FDA-approved medication within 4 weeks | Chemo- or immunotherapy, monoclonal antibodies, or small molecule TKIs within 2 weeks prior to study treatment | Radiotherapy (except brain/extremities or stereotactic) within 2 weeks prior to study treatment | In immunotherapy-pretreated patients: prior dose-limiting toxicity to immunotherapy including grade 3/4 or irreversible immune-related adverse events, steroid-refractory grade >= 3 irAEs, or neurologic irAEs with significant sequelae | Prior treatment with nintedanib | Known hypersensitivity to nintedanib, nivolumab, ipilimumab, peanut, or soy, or excipients | Unresolved > CTCAE grade 2 toxicity from prior therapy (except allowable irreversible toxicities such as hearing loss, peripheral neuropathy, alopecia) | History of leptomeningeal carcinomatosis | Radiotherapy to a target lesion within 3 months prior to baseline imaging unless progression is demonstrated | Active brain metastases or symptomatic/uncontrolled CNS metastases | Current or prior use of immunosuppressive medication within 7 days before first dose of nivolumab or ipilimumab (with specified exceptions) | Active or prior documented autoimmune disease within the past 2 years (with specified exceptions) | Centrally located tumors with radiographic evidence of major blood vessel invasion | History or evidence of active, non-infectious pneumonitis | Therapeutic anticoagulation requiring INR monitoring or antiplatelet therapy (except low-dose aspirin < 325 mg/day or low-dose heparin/flushes) | Major surgery or significant injury within 4 weeks with incomplete wound healing or planned surgery during treatment | Clinically significant hemorrhagic or thromboembolic event within 6 months | Known inherited bleeding or thrombotic disorders | Significant cardiovascular disease (uncontrolled hypertension, unstable angina, recent MI < 3 months, CHF > NYHA II, serious arrhythmia) | Coagulation abnormalities: INR > 2 or PT/PTT > 50% above ULN | Another active malignancy within 2 years (except specified in situ or skin cancers) | Active serious infection requiring systemic therapy | Active hepatitis B or C infection | Known active primary immunodeficiency | History of allogeneic organ transplant | Live attenuated vaccination within 30 days before entry or during treatment window | GI disorders that would interfere with absorption of oral study drug | Serious non-oncologic illness or laboratory abnormality increasing study risk per investigator | Sexually active patients unwilling to use effective contraception during and after study therapy | Pregnancy or breastfeeding | Active alcohol or drug abuse | Significant weight loss > 20% of body weight within 6 months | History of active tuberculosis","Phase 1: Prior chemotherapy, immunotherapy, or targeted therapy for NSCLC allowed; Neoadjuvant/adjuvant chemo/radiation allowed if recurrence > 6 months after completion; Phase 2 Arm A: Treatment-naive; Phase 2 Arm B: Prior immunotherapy required (primary refractory or relapsed after initial disease control); Driver-positive NSCLC: must have received prior FDA-approved targeted therapy (e.g., EGFR, ALK, ROS1, BRAF V600E)",ALL,A,"Disease and setting match (metastatic NSCLC), and prior therapy is compatible with Phase 1 (driver-positive NSCLC with prior EGFR TKI); ECOG 0 and age ≥18 also fit. No explicit exclusions are triggered based on available data (no prior nintedanib; CNS/other exclusionary factors not stated).",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),INCORRECT,F,"Hard exclusion present: the trial excludes concurrent use of other anticancer agents and TKIs within 2 weeks prior to study treatment. The patient is currently on osimertinib, directly conflicting with this criterion. While disease and stage align and prior EGFR TKI fits Phase 1, the explicit exclusion overrides, so the correct grade is F, not A.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT03460977,0.8316181302070618,Castration-Resistant Prostate Cancer,"A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF 06821497 (MEVROMETOSTAT) IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)","A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 (Mevrometostat) in Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL).","{'id': 205738910, 'name': 'Mervometostat (PF-06821497)', 'description': 'Oral continuous', 'other_names': ['EZH2i'], 'intervention_type': 'DRUG'}; {'id': 205738911, 'name': 'Enzalutamide', 'description': 'Oral continuous', 'other_names': ['Xtandi'], 'intervention_type': 'DRUG'}",PHASE1,18 years,Follicular Lymphoma; Metastatic Castration-Resistant Prostate Cancer; Small Cell Lung Cancer,"Histologically or cytologically confirmed advanced/metastatic disease of the specified tumor types by study part. | Metastatic castration-resistant prostate cancer with prior abiraterone and/or enzalutamide and evidence of progression per PCWG3 (part-dependent; includes Japan and China cohorts). | mCRPC may have received up to 1 prior line of chemotherapy (part-dependent). | Part 2B/2C: mCRPC with prior abiraterone, up to 1 prior chemotherapy line, no prior enzalutamide/apalutamide/darolutamide, and progression per PCWG3. | Radiographic evidence of disease required (Part 2B/2C). | CRPC resistant/intolerant to SOC or lacking available beneficial SOC; refusal of SOC may be eligible (cohort-dependent). | ECOG performance status 0–1.","More than the allowed prior chemotherapy regimens: Part 1C/Japan/China (CRPC) >2 regimens; Part 2A (mCRPC) >1 regimen; Part 2B (mCRPC) >1 regimen. | Prior irradiation to >25% of bone marrow. | QTcF >480 msec at screening. | Uncontrolled hypertension >150/90 mmHg despite optimal therapy. | Known or suspected hypersensitivity to mevrometostat (PF-06821497) or components, or to enzalutamide (for CRPC cohorts). | Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease, or prior gastric resection/lap band surgery; GERD on proton pump inhibitors allowed. | Current use or anticipated need for strong CYP3A4/5 inducers or inhibitors, including within 10 days or 5 half-lives before first dose.",Prior treatment with abiraterone and/or enzalutamide required with documented progression (PCWG3) for mCRPC.; Up to 1 prior line of chemotherapy allowed in some parts; up to 2 prior chemotherapy regimens allowed in specific cohorts (cohort-dependent).,ALL,A,"Disease and setting match mCRPC, and the patient (66M) meets line-of-therapy requirements with prior abiraterone and enzalutamide and progression, as well as age criteria. No explicit exclusions are evident; while some cohorts prohibit prior enzalutamide, other parts allow it.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions. Disease and metastatic setting match. Prior-exposure anchor matches (prior abiraterone and enzalutamide with progression). Biomarker not required; mets pattern unrestricted. Cohort-specific prohibition of prior enzalutamide does not preclude eligibility since other cohorts allow it. Unknowns (PCWG3 documentation, ECOG) are neutral. Thus ≥2 core anchors match with no soft conflicts → A.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03547973,0.9586746692657471,Metastatic Urothelial Carcinoma,A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer,The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).,"{'id': 206376431, 'name': 'Sacituzumab Govitecan-hziy', 'description': 'Administered intravenously.', 'other_names': ['IMMU-132', 'Trodelvy™'], 'intervention_type': 'DRUG'}; {'id': 206376432, 'name': 'Pembrolizumab', 'description': 'Administered per package insert', 'other_names': ['KEYTRUDA®'], 'intervention_type': 'DRUG'}; {'id': 206376433, 'name': 'Cisplatin', 'description': 'Administered per package insert', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206376434, 'name': 'Avelumab', 'description': 'Administered per package insert', 'other_names': ['BAVENCIO®'], 'intervention_type': 'DRUG'}; {'id': 206376435, 'name': 'Zimberelimab', 'description': 'Administered intravenously', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206376436, 'name': 'Carboplatin', 'description': 'Administered per package insert', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206376437, 'name': 'Gemcitabine', 'description': 'Administered per package insert', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206376438, 'name': 'Domvanalimab', 'description': 'Administered intravenously', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206376439, 'name': 'Enfortumab Vedotin', 'description': 'Administered intravenously', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,18 years,Metastatic Urothelial Cancer,"Age >= 18 years | ECOG performance status 0–1 | Adequate renal and hepatic function | Adequate hematologic parameters without transfusional support | Life expectancy >= 3 months | Cohorts 4 and 6: Measurable disease by RECIST 1.1 | Cohorts 1, 2, 3, 5: Creatinine clearance >= 30 mL/min | Cohort 4: No prior platinum-based chemotherapy in the metastatic or unresectable locally advanced setting | Cohort 4: Creatinine clearance >= 50 mL/min; if receiving cisplatin 70 mg/m2 Day 1 q21d, creatinine clearance >= 60 mL/min; if creatinine clearance 50–59 mL/min, receive split-dose cisplatin | Cohorts 4, 5, 6, 7: Archival tumor tissue (muscle-invasive or metastatic urothelial carcinoma) or biopsy of metastatic urothelial carcinoma | Cohort 5: Completed 4–6 cycles of gemcitabine + cisplatin with CR/PR/SD and treatment-free interval of 4–10 weeks | Cohort 6: Cisplatin-ineligible; no prior therapy for metastatic or unresectable locally advanced disease; CPI-naive or >12 months from completion of adjuvant therapy | Cohort 7: No prior systemic therapy for locally advanced or metastatic urothelial cancer (recurrence >12 months after curative therapy allowed) | Cohort 7: Measurable disease by RECIST 1.1","Pregnant or lactating | Active second malignancy | Known active hepatitis B or hepatitis C | Known active central nervous system metastases and/or carcinomatous meningitis | Other concurrent medical or psychiatric conditions that would preclude study participation | Prior anti-cancer monoclonal antibody within 4 weeks before Day 1 or unresolved > Grade 1 toxicities from prior therapy | Cohorts 3–6: Active autoimmune disease requiring systemic treatment in past 2 years | Cohorts 3–6: Receipt of a live vaccine within 30 days prior to first dose | Cohorts 3–6: History or evidence of interstitial lung disease or non-infectious pneumonitis | Cohort 3: Prior anti-PD-1/PD-L1 therapy | Cohort 4: Refractory to platinum in neoadjuvant/adjuvant setting (relapse <= 12 months after completion) | Cohorts 4, 5, 6: If prior checkpoint inhibitor, treatment-free interval must be >12 months between last dose and date of recurrence | Cohort 7: Prior anticancer therapy within 12 months before C1D1 or prior radiation within 2 weeks before C1D1 | Cohort 7: History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced or idiopathic pneumonitis, or active pneumonitis on screening CT | Cohort 7: Child-Pugh class B or C hepatic impairment | Cohort 7: Uncontrolled diabetes | Cohort 7: Active keratitis or corneal ulcerations | Cohort 7: Ongoing sensory or motor neuropathy Grade >= 2",Cohort 1: Prior platinum-containing therapy and prior anti-PD-1/PD-L1 therapy with progression/recurrence; Cohort 2: Platinum-ineligible for first-line metastatic disease and progression after first-line anti-PD-1/PD-L1 therapy; no prior platinum for recurrent/metastatic/advanced disease; Cohort 3: Prior platinum-containing therapy with progression/recurrence; Cohort 4: No prior platinum-based chemotherapy in the metastatic or unresectable locally advanced setting; Cohort 5: Completed 4–6 cycles of gemcitabine + cisplatin without progressive disease; Cohort 6: No prior therapy for metastatic or unresectable locally advanced disease; CPI-naive or >12 months since completion of adjuvant therapy; Cohort 7: No prior systemic therapy for locally advanced or metastatic disease (curative-intent therapy allowed if recurrence >12 months),ALL,A,"Metastatic urothelial cancer matches, and Cohort 1 specifically requires prior platinum and prior PD-1/PD-L1 therapy with progression, which the patient has; creatinine clearance ~35 mL/min meets the ≥30 mL/min threshold, and age/sex fit. No explicit exclusions are triggered; other requirements (ECOG, timing of last therapy) are unknown.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,A,No hard exclusions. Disease matches. Stage/setting matches (metastatic). Line/prior exposure matches via Cohort 1 (prior platinum and prior PD-1 with progression). Renal function meets cohort threshold (>=30 mL/min). No identified soft mismatches. Grade A per rubric.,,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03589339,0.8805802464485168,Metastatic Urothelial Carcinoma,A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy,"The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.","{'id': 205979917, 'name': 'NBTXR3', 'description': 'Single intra Tumoral injection', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205979918, 'name': 'SABR', 'description': 'Radiotherapy given as a definite number of fractions at the dose defined for each radiation field', 'other_names': ['Stereotaxic Ablative Radiotherapy', 'Stereotaxic Body Radiation Therapy'], 'intervention_type': 'RADIATION'}; {'id': 205979919, 'name': 'Nivolumab', 'description': 'Anti-PD-1 monotherapy', 'other_names': ['Opdivo'], 'intervention_type': 'DRUG'}; {'id': 205979920, 'name': 'Pembrolizumab', 'description': 'Anti-PD-1 monotherapy', 'other_names': ['Keytruda'], 'intervention_type': 'DRUG'}",PHASE1,18 years,Head and Neck Squamous Cell Carcinoma (recurrent/metastatic); Non-Small Cell Lung Cancer (metastatic); Melanoma (metastatic); Renal Cell Carcinoma (metastatic); Triple-Negative Breast Cancer (metastatic); Urothelial Carcinoma (metastatic); Cervical Cancer (metastatic); Hepatocellular Carcinoma (metastatic),"Biopsy-confirmed cancer indicated for anti-PD-1 therapy | Inoperable locoregional recurrent or recurrent/metastatic head and neck squamous cell carcinoma with a lesion amenable to irradiation (head and neck region, lung, or liver) | Metastatic disease to lung (including involved/mediastinal lymph nodes) or liver with a lesion in a previously non-irradiated field (dose escalation cohorts 2–3) | At least one measurable lesion per RECIST 1.1 that is amenable to intratumoral injection | Prior anti-PD-1 exposure status meeting cohort criteria (anti-PD-1 naive or primary/secondary resistance as specified) | ECOG performance status 0–2 | Life expectancy >12 weeks | Adequate organ and bone marrow function | Negative pregnancy test <= 7 days prior to NBTXR3 injection for women of child-bearing potential",History of immune-related adverse events from anti-PD-1/L1 that led to termination and precludes further PD-1 exposure | Symptomatic central nervous system metastases or carcinomatous meningitis | Active autoimmune disease requiring systemic treatment within the past 1 year | Known HIV infection | Active hepatitis B or hepatitis C infection | Active infection requiring intravenous antibiotics | Receipt of a live virus vaccine within 30 days prior to study treatment | History of pneumonitis requiring steroids or current pneumonitis | Extensive metastatic disease burden (>5 lesions overall including the primary tumor) | Locoregional recurrent HNSCC with ulceration | Prior checkpoint inhibitor within 2 weeks before NBTXR3 injection | Prior systemic anti-neoplastic therapy (including investigational agents) within 4 weeks before NBTXR3 injection | Unresolved adverse events from prior anti-neoplastic therapies and/or interventions (including radiation) > Grade 1 or not at baseline at screening | Clinically significant cardiac arrhythmias | NYHA Class III or IV heart failure within 6 months prior to screening | Pregnant or nursing female | Women of child-bearing potential and men who are sexually active not willing/able to use acceptable contraception | Any condition for which participation would not be in the participant's best interest,Prior anti-PD-1 therapy allowed; participants may be anti-PD-1 naive or have primary/secondary resistance per cohort; Expansion Cohorts 1 and 3 require prior anti-PD-1 primary or secondary resistance; Expansion Cohort 2 requires anti-PD-1 naive; Washout: no prior checkpoint inhibitor within 2 weeks before NBTXR3 injection; Washout: no prior systemic anti-neoplastic therapy (including investigational agents) within 4 weeks before NBTXR3 injection; Prior radiation allowed; injectable lesion may be in a previously irradiated field for specified HNSCC cohorts,ALL,A,"Disease and setting match (metastatic urothelial carcinoma), and prior anti-PD-1 exposure is allowed with cohorts for resistance, fitting the patient’s post–second-line status; age/sex are within limits. Final eligibility hinges on having a lesion amenable to intratumoral injection/radiotherapy and meeting organ function/ECOG requirements.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches (metastatic urothelial carcinoma). Stage/setting matches and prior exposure/line compatibility matches (prior PD-1 allowed with resistant cohorts). Other requirements (injectable lesion, organ function/ECOG) are unknown, not mismatches. ≥2 core anchors match → A. Grader’s reasoning aligns with rubric.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT03681028,0.8363864421844482,Recurrent Glioblastoma,Pilot Study Testing Feasibility of Individualized Therapy for Recurrent Glioblastoma,"The current study will test the ability and likelihood of successfully implementing individualized combination treatment recommendations for adult patients with surgically-resectable recurrent glioblastoma in a timely fashion. Collected tumor tissue and blood will be examined using a new diagnostic testing called University of California, San Francisco (UCSF) 500 Cancer Gene Panel which is done at the UCSF Clinical Cancer Genomics Laboratory. The UCSF 500 Cancer Gene Panel will help identify ...","{'id': 206359044, 'name': 'Individualized therapy', 'description': '1. For a given proposed individualized combination of drugs the first priority to establish doses will be to identify the same combination of drugs in a peer-reviewed journal article or presented as a reviewed abstract.\n2. When a proposed individualized combination of drugs has not previously been reported, the process to establish doses will be to then identify individual members of the proposed combination that have been used in combination with other cytotoxic agents similar to those being considered for combination therapy.\n3. When a proposed individualized combination of drugs has no available combination data, dosing guidelines will start with the FDA-approved package insert recommended dose.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,18 years,Glioblastoma (recurrent); Gliosarcoma (recurrent),"Age >= 18 years | Histologically proven recurrent glioblastoma or gliosarcoma (WHO grade IV) that is surgically resectable | Surgeon anticipates resection of at least 500 mg of tumor | Karnofsky Performance Scale >= 70% | Estimated life expectancy >= 3 months | Received appropriate prior therapy for GBM at initial diagnosis, including radiation therapy | Adequate bone marrow function | Adequate hepatic function | Adequate renal function | Able to undergo MRI for tumor evaluation | Women of child-bearing potential: negative pregnancy test within 7 days prior to surgery | Women and men agree to use adequate contraception during treatment and for 3 months after completion | No New York Heart Association class II or greater congestive heart failure | No history of myocardial infarction or unstable angina within 12 months prior to enrollment","Chemotherapy or radiotherapy <= 4 weeks prior to registration (exceptions: >= 23 days from last temozolomide; >= 6 weeks from last nitrosourea) | Not recovered to grade 1 or baseline from adverse effects of prior radiotherapy or chemotherapy | Less than 12 weeks from initial course of radiation | Multifocal tumor, primarily infratentorial or posterior fossa tumor, or leptomeningeal dissemination | Active malignancy other than GBM, excluding non-melanoma skin cancer or carcinoma in situ of cervix, prostate, or breast, unless disease-free/in remission for >= 2 years | Known HIV-positive | Uncontrolled concurrent illness, including psychiatric illness, that would limit compliance | Any acute or chronic medical or psychiatric condition or laboratory abnormality increasing risk or interfering with trial, per investigator judgment",Prior radiation therapy for GBM required at initial diagnosis; Any number of prior therapies allowed; No chemotherapy or radiotherapy within 4 weeks before registration (>= 23 days for temozolomide; >= 6 weeks for nitrosourea),ALL,A,"Disease and recurrent setting align, with prior standard RT/TMZ completed and adequate washout since last therapy; age and sex meet criteria and no explicit exclusions are triggered. Surgical resectability and KPS are not specified but there is no conflict with these requirements.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),INCORRECT,B,"Disease matches and prior exposure/washout align (Line/prior anchor = match). However, a key part of Stage/setting is surgical resectability, which is required by the trial and is unknown for the patient; KPS is also required and unspecified. With only one confirmed CORE ANCHOR match and no soft conflicts, the rubric supports grade B, not A.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03808662,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,Precision Radiation for OligoMetastatIc and MetaStatic DiseasE (PROMISE)-004: Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression,The purpose of this study is determine if receiving stereotactic body radiation(SBRT) when participants' metastatic tumors have just begun to grow increase the length of time before disease gets worse,"{'id': 206380145, 'name': 'Sterotactic Body Radiotherapy/SBRT', 'description': 'In general, it is recommended using 9-10 Gy x 3 or 10 Gy x 5 fractions given every other day. Physicians should try to give the highest BED whenever possible while respecting normal tissue tolerance. All lesions are recommended to receive a biologically effective dose (BED) of 60 Gy or higher (BED10≥70), assuming α/β ratio of 10 and using the linear-quadratic model: BED = nd x \\[1 + d/(α/β)\\] where n is number of fractions and d is dose per fraction. Sometimes BED ≥80 Gy is preferred, with lower doses ≥50 Gy allowed at the discretion of the treating physician for concerns about normal tissue toxicity.', 'other_names': [], 'intervention_type': 'RADIATION'}; {'id': 206380146, 'name': 'Standard of care', 'description': 'Standard of care per physician discretion', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic); Triple-Negative Breast Cancer; Breast Cancer (metastatic),"Age >= 18 | Metastatic disease confirmed on imaging and histology | Oligoprogression with progression in up to 5 lesions per RECIST or PERCIST definitions | Maximum 5 progressing metastases in any single extracranial organ system | All sites of oligoprogression can be safely treated with local therapy | No restriction on total number of metastases | Patients may have >5 total metastases provided only 1–5 lesions are progressive | Brain metastases permitted; brain lesions may be treated before randomization without counting toward the 5 progressive lesions | Symptomatic metastatic sites requiring urgent palliative radiation may be treated before randomization without counting toward the 5 progressive lesions | Prior systemic therapy: received at least first-line treatment (cytotoxic or targeted, including maintenance) | Patients who received prior immunotherapy are allowed | Patients who had prior radiation near or overlapping oligoprogressive sites are allowed | For NSCLC: either no known EGFR mutation or ALK/ROS1 rearrangement, or if present, progression on first-line tyrosine kinase inhibitor | Other local therapies (surgery or ablation) may be used if deemed more suitable after discussion with the investigator","Pregnancy | Leptomeningeal disease | Serious comorbidities precluding radiotherapy (e.g., ataxia-telangiectasia, scleroderma) | Any condition that in the investigator's judgment makes the patient inappropriate for the study",At least first-line prior systemic therapy required; Prior immunotherapy allowed; Prior radiation near or overlapping progressive sites allowed; Brain stereotactic radiation permitted prior to randomization; Palliative radiation for symptomatic sites permitted prior to randomization; For NSCLC with EGFR/ALK/ROS1 alterations: prior first-line tyrosine kinase inhibitor with progression required,ALL,A,"Metastatic NSCLC with EGFR exon 19 deletion and progression after first-line osimertinib meets stage/setting and prior-therapy requirements, and age/ECOG fit. The trial’s oligoprogression limit (≤5 progressive lesions) is not clearly violated since the number of progressive lesions is unspecified, so no soft conflict is confirmed.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),INCORRECT,D,"Disease, stage (metastatic), and prior therapy (EGFR-mutant NSCLC with progression after first-line TKI) match, but the trial requires oligoprogression (≤5 progressive lesions). The patient’s “recent MRI shows numerous lesions” after prior complete response implies more than 5 progressive lesions, a metastatic-pattern soft mismatch. Per rubric, any clear soft mismatch → D, not A.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT03896568,0.8363864421844482,Recurrent Glioblastoma,"Phase I Clinical Trial of Allogeneic Bone Marrow Human Mesenchymal Stem Cells Loaded With A Tumor Selective Oncolytic Adenovirus, DNX-2401, Administered Via Intra-Arterial Injection in Patients With Recurrent High-Grade Glioma",This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurrent). Oncolytic adenovirus DNX-2401 is made from the common cold virus that has been changed in the laboratory to make it less likely to cause an infection (such as a cold). The virus is also changed to target brain cancer cells and attack them.,"{'id': 205889785, 'name': 'Oncolytic Adenovirus Ad5-DNX-2401', 'description': 'Given IA', 'other_names': ['Ad5-Delta24RGD', 'DNX-2401', 'DNX2401', 'Oncolytic Ad5-Delta 24RGD', 'Oncolytic Adenovirus Ad5-Delta 24RGD'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205889786, 'name': 'Therapeutic Conventional Surgery', 'description': 'Undergo surgery', 'other_names': [], 'intervention_type': 'PROCEDURE'}",PHASE1,18 years,"Glioblastoma (recurrent); Gliosarcoma (recurrent); Anaplastic Astrocytoma (recurrent); Astrocytoma (grade 4, IDH-mutant)","Recurrent glioblastoma or gliosarcoma | Recurrent anaplastic astrocytoma (IDH1 wild-type) with enhancing mass 1.0-5.0 cm on MRI | Recurrent IDH-mutant grade 4 astrocytoma with enhancing mass 1.0-5.0 cm on MRI | Unequivocal tumor recurrence/progression on MRI after prior surgery/biopsy/chemotherapy or radiation; baseline MRI within 24 days | Age >= 18 years | Able to undergo endovascular treatment; internal carotid artery <50% occluded by Doppler | Tumor diameter 1.0-5.0 cm | Karnofsky performance score >= 70% | Life expectancy >= 16 weeks | Adequate bone marrow: ANC > 1500/µL, platelets > 75,000/µL | Adequate liver function: AST/ALT and bilirubin < 2 x ULN | Adequate renal function: creatinine < 2.0 x ULN | PT/INR or PTT <= 1.5 x ULN | Chemotherapy washout: >=4 weeks from cytotoxics (>=3 weeks from procarbazine or temozolomide; >=2 weeks from vincristine) | >=6 weeks from nitrosoureas (CCNU, BCNU) | >=4 weeks from any targeted investigational agent | >=1 week from non-cytotoxic agents | >=8 weeks from radiotherapy (>=4 weeks if new lesion outside prior field or biopsy confirms recurrence) | Willing to forego other anti-tumor drug or radiation therapy while enrolled | Women of childbearing potential: negative pregnancy test | Effective contraception during study and for 6 months after administration","Histology other than GBM, gliosarcoma, IDH wild-type anaplastic astrocytoma grade III, or IDH-mutant astrocytoma grade 4 | Tumor below tentorium, beyond cranial vault, or within posterior fossa | Leptomeningeal disease | Inability to obtain vascular access for percutaneous procedure | Ipsilateral carotid stenosis >50% by Doppler | Thrombophilia or primary hematologic disease | Transfusions or G-CSF for cytopenias < 28 days before Day 0 | Biologic/immunotherapy within 2 weeks of baseline | Inflammatory or autoimmune disorders (clinical or laboratory evidence) | MRI contraindications or non-evaluable by MRI | Pregnant or nursing | Active uncontrolled infection or unstable/severe intercurrent condition; fever >= 38.0 C | Any condition precluding surgery or endovascular treatment | Alcohol or substance abuse within 12 months with health consequences | Immunocompromised state, active hepatitis, HIV seropositivity, or LFTs > 2 x ULN | Bleeding diathesis or anticoagulant/bleeding risk medications that cannot be stopped prior to surgery | Medical or psychological conditions interfering with participation or consent | CNS infections or primary CNS diseases interfering with evaluation (e.g., encephalitis, multiple sclerosis) | Known Li-Fraumeni syndrome or germline RB1 pathway deficit | Significant systemic/major illnesses (e.g., CHF, ischemic heart disease, cerebrovascular disease, kidney disease, renal failure, active liver disease, organ transplant, significant psychiatric disorder) | Enrollment in a concomitant therapeutic clinical study | Any condition preventing protocol compliance | For biological endpoint phase: high likelihood of BM-hMSC-DNX2401 injection into ventricles after resection per surgeon","Prior surgery/biopsy/chemotherapy or radiation with subsequent recurrence required; Washout: >=4 weeks from cytotoxic agents (>=3 weeks from procarbazine or temozolomide; >=2 weeks from vincristine); Washout: >=6 weeks from nitrosoureas (CCNU, BCNU); Washout: >=4 weeks from targeted investigational agents; Washout: >=1 week from non-cytotoxic agents; >=8 weeks from radiotherapy (>=4 weeks if new lesion outside prior field or biopsy confirms recurrence); Must forego other cytotoxic and non-cytotoxic anti-tumor therapy and radiation while on study",ALL,A,"Disease and recurrent setting match, and prior surgery/chemoradiation/adjuvant temozolomide with adequate washout align with trial requirements; age and performance status meet thresholds with no exclusions evident. Some items (tumor size 1–5 cm, vascular patency, labs, and tumor location) are unknown but not conflicting.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease and recurrent setting clearly match. Prior surgery/chemoradiation/temozolomide with sufficient washout meet trial’s prior-exposure requirements. Other criteria (tumor size, KPS vs ECOG, vascular/labs/location) are unknown but not conflicting. ≥2 core anchors (stage/setting and line/prior) match, so A is appropriate.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT04003649,0.8363864421844482,Recurrent Glioblastoma,A Phase 1 Study to Evaluate IL13Rα2-Targeted Chimeric Antigen Receptor (CAR) T Cells Combined With Checkpoint Inhibition for Patients With Resectable Recurrent Glioblastoma,"This phase I trial studies the side effects and how well IL13Ralpha2-CAR T cells work when given alone or together with nivolumab and ipilimumab in treating patients with glioblastoma that has come back (recurrent) or does not respond to treatment (refractory). Biological therapies, such as IL13Ralpha2-CAR T cells, use substances made from living organisms that may attack specific glioma cells and stop them from growing or kill them. Immunotherapy with monoclonal antibodies, such as nivolumab...","{'id': 206256087, 'name': 'IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells', 'description': 'Given ITV/ITC', 'other_names': ['IL13 [EQ]BBzeta/truncated CD19[t]+ Naive and Memory T Cells', 'IL13 [EQ]BBzeta/truncated CD19[t]+ TN/MEM Cells', 'IL13Ra2-specific-hinge-optimized-4-1BB-CAR/truncated CD19-expressing Autologous TN/MEM Lymphocytes'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206256088, 'name': 'Ipilimumab', 'description': 'Given IV', 'other_names': ['MDX-010', 'Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody', 'BMS-734016', 'MDX-CTLA4', 'Yervoy'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206256089, 'name': 'Nivolumab', 'description': 'Given IV', 'other_names': ['BMS-936558', 'MDX-1106', 'NIVO', 'ONO-4538', 'Opdivo'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206256090, 'name': 'Quality-of-Life Assessment', 'description': 'Ancillary studies', 'other_names': ['Quality of Life Assessment'], 'intervention_type': 'OTHER'}; {'id': 206256091, 'name': 'Questionnaire Administration', 'description': 'Ancillary studies', 'other_names': [], 'intervention_type': 'OTHER'}",PHASE1,18 years,Glioblastoma (recurrent); Glioblastoma (refractory),"Age >= 18 years | ECOG <= 2 | Karnofsky >= 60% | Life expectancy >= 4 weeks | Histologically confirmed WHO grade IV glioblastoma or prior grade II/III glioma with progression consistent with grade IV glioblastoma after standard therapy | Relapsed/refractory measurable disease after standard therapy | >= 12 weeks after completion of front-line radiation therapy | IL13Ralpha2-positive tumor by IHC (H-score > 50) | WBC > 2000/µL or ANC >= 1000/µL (within 14 days prior to leukapheresis) | Platelets >= 75000/µL | Fasting blood glucose within ULN | Total bilirubin <= 1.5 x ULN | AST <= 2.5 x ULN | ALT <= 2.5 x ULN | Serum creatinine <= 1.6 mg/dL | Oxygen saturation >= 95% on room air | Seronegative for HIV Ag/Ab combo | Hepatitis C antibody negative or, if positive, HCV RNA negative | Hepatitis B surface antigen negative | Hepatitis A virus IgM antibody negative | Women of childbearing potential: negative pregnancy test | Agreement to use effective contraception during study and for at least 5 months after last nivolumab dose and/or 3 months after last CAR T cell cycle","Prior CTLA-4, PD-1, or PD-L1 inhibitor therapy | Steroid-dependent requiring > 6 mg dexamethasone per day at enrollment | Unresolved toxicities from prior therapy | History of or active autoimmune disease | Uncontrolled seizure activity or clinically evident progressive encephalopathy | History of allergic reactions to compounds similar to study agents | Active diarrhea | Clinically significant uncontrolled illness | Active infection requiring antibiotics | Known HIV, hepatitis B, or hepatitis C infection | Other active malignancy | Pregnant or breastfeeding | Any condition that contraindicates participation due to safety concerns per investigator | Inability to comply with study procedures",Completed standard therapy for glioblastoma; Radiographic progression after standard therapy; At least 12 weeks since completion of front-line radiation therapy,ALL,A,"Disease and setting match (recurrent GBM) and prior therapy/exposure requirements are met (post-standard chemoradiation/temozolomide, no prior PD-1/PD-L1, age/ECOG fit, >12 weeks since RT). IL13Rα2 positivity and resectability are not provided but are not confirmed mismatches.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches (recurrent GBM). Stage/setting matches (recurrent) and line/prior exposure matches (post standard chemoradiation, no prior PD-1/PD-L1, >12 weeks since RT). Required biomarker (IL13Rα2) and resectability are unknown, which per rubric are neutral (not soft mismatches). With ≥2 core anchors matched and no soft conflicts, grade A is appropriate.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04090528,1.0,Castration-Resistant Prostate Cancer,"Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer","This trial will evaluate the use of one versus two DNA vaccines, delivered concurrently with PD-1 blockade using pembrolizumab followed by treatment with pembrolizumab alone, and delivered over a prolonged period of time (for a maximum of 2 years (32 cycles) or until radiographic progression) on the treatment of castrate-resistant, metastatic prostate cancer. The hypothesis to be tested is that delivering two vaccines with PD-1 blockade will elicit a greater frequency and magnitude of tumor-d...","{'id': 205955877, 'name': 'pTVG-HP', 'description': 'pTVG-HP is a plasmid DNA, produced in E. coli, that encodes the complementary deoxyribonucleic acid (cDNA) for human prostatic acid phosphatase (PAP).', 'other_names': [], 'intervention_type': 'BIOLOGICAL'}; {'id': 205955878, 'name': 'pTVG-AR', 'description': 'pTVG-AR is a plasmid DNA', 'other_names': [], 'intervention_type': 'BIOLOGICAL'}; {'id': 205955879, 'name': 'Pembrolizumab', 'description': 'Pembrolizumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.', 'other_names': ['Keytruda'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Castration-Resistant Prostate Cancer,"Histologically confirmed adenocarcinoma of the prostate | Metastatic disease on imaging (soft tissue and/or bone metastases) | Castration-resistant disease with ongoing androgen deprivation therapy (surgical castration or GnRH analogue/antagonist; continue during study) | Serum testosterone < 50 ng/dL within 6 weeks of day 1 | Progressive disease on ADT per PCWG3/RECIST: PSA progression: >=2 consecutive rises >=1 week apart with final PSA > 2.0 ng/mL | Progressive disease on ADT per RECIST 1.1: > 50% increase in sum of cross products of measurable lesions or new measurable lesions (target LN short axis >= 15 mm) | Progressive bone disease on ADT: >=2 new areas of uptake on bone scan or NaF PET/CT consistent with metastases | Prior nonsteroidal antiandrogen allowed with washout: off >=28 days (flutamide, apalutamide, enzalutamide or other 2nd-generation AR antagonists) or >=6 weeks (bicalutamide, nilutamide); no antiandrogen withdrawal responders until PSA rises above nadir | Prior abiraterone or enzalutamide permitted if weaned to <=5 mg prednisone daily for >=28 days before day 1 | Life expectancy >= 6 months | ECOG performance status 0–2 | Adequate hematologic, renal, liver, and coagulation function within 6 weeks of day 1 per protocol thresholds | No known history of HIV-1/2, HTLV-1, or active hepatitis B or C | >=4 weeks since any prior treatments and recovered to < Grade 2 from acute toxicities unless chronic","Small cell or other non-adenocarcinoma prostate cancer histology unless tumor expresses PAP | Concurrent investigational agents or anticancer therapy other than standard ADT | Rapidly progressive symptomatic metastatic disease requiring increased opioid analgesics within 1 month (PI approval required if on opioids) | Prohibited within 28 days before day 1 or during study: systemic corticosteroids >5 mg prednisone daily (non-systemic allowed) | Prohibited within 28 days: PC-SPES | Prohibited within 28 days: megestrol | Prohibited within 28 days: ketoconazole | Prohibited within 28 days: diethylstilbestrol | Prohibited within 28 days: abiraterone | Prohibited within 28 days: enzalutamide | Prohibited within 28 days: apalutamide | Prohibited within 28 days: radium-223 | 5-alpha-reductase inhibitors should not be started on study; continuation allowed if started >=28 days before registration | External beam radiation therapy within 4 weeks of registration or anticipated need for RT within 3 months | Major surgery within 4 weeks of registration | Prior cytotoxic chemotherapy within 28 days of registration | Prior anti-PD-1, anti-PD-L1, anti-PD-L2, or other T-cell stimulatory/inhibitory agents (e.g., CTLA-4, OX-40, CD137) | History of life-threatening autoimmune disease | History of non-infectious pneumonitis requiring corticosteroids or current pneumonitis | History of severe allergic reactions to tetanus vaccine | Prior splenectomy or diagnosis of immunodeficiency | Other active malignancy except non-melanoma skin cancer or superficial (non–muscle-invasive) bladder cancer; other cancers allowed if adequately treated and >3 years recurrence-free | Known brain metastases or carcinomatous meningitis | Live vaccine within 30 days before first dose (e.g., MMR, varicella/zoster, yellow fever, BCG, typhoid; inactivated influenza allowed; intranasal live attenuated not allowed) | Any antibiotic therapy within 1 month of day 1 or anticipated need within 1 month of beginning treatment | Active autoimmune disease requiring systemic treatment within the past 2 years (replacement therapy allowed) | Medical conditions that could compromise safety/adherence or confound results per investigator | Psychiatric or substance abuse disorders interfering with study requirements","Ongoing androgen deprivation therapy required during study (surgical castration or GnRH analogue/antagonist); Prior nonsteroidal antiandrogen allowed with washout: >=28 days (flutamide, apalutamide, enzalutamide or other 2nd-generation AR antagonists) or >=6 weeks (bicalutamide, nilutamide); Prior abiraterone or enzalutamide permitted if prednisone <=5 mg daily for >=28 days before day 1; >=4 weeks since any prior treatments and recovered to < Grade 2 from acute toxicities",MALE,A,"Male, 66, with metastatic castration-resistant prostate cancer fits the stage/setting; prior ADT, abiraterone, and enzalutamide are permitted with appropriate washouts and no prior PD‑1 exposure is noted. No required biomarkers are unmet and no explicit exclusions are identified from the available data.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches (mCRPC). Stage/setting matches (metastatic CRPC), and line/prior exposure is compatible (prior ARSIs allowed; no prior PD-1 noted). Metastatic pattern acceptable (liver/bone allowed; no brain mets stated). Required biomarkers not applicable. Thus ≥2 core anchors match with no soft conflicts → A.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT04092270,0.9288163185119629,Recurrent Clear Cell Ovarian Carcinoma,A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC),"This phase I trial studies the side effects and best dose of peposertib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with high or low grade ovarian cancer that has come back after a period of improvement (recurrent). Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tum...","{'id': 206423339, 'name': 'Biospecimen Collection', 'description': 'Undergo blood sample collection', 'other_names': ['Biological Sample Collection', 'Biospecimen Collected', 'Specimen Collection'], 'intervention_type': 'PROCEDURE'}; {'id': 206423340, 'name': 'Computed Tomography', 'description': 'Undergo CT scan', 'other_names': ['CAT', 'CAT Scan', 'Computed Axial Tomography', 'Computerized Axial Tomography', 'Computerized axial tomography (procedure)', 'Computerized Tomography', 'Computerized Tomography (CT) scan', 'CT', 'CT Scan', 'Diagnostic CAT Scan', 'Diagnostic CAT Scan Service Type', 'tomography'], 'intervention_type': 'PROCEDURE'}; {'id': 206423341, 'name': 'Echocardiography Test', 'description': 'Undergo ECHO', 'other_names': ['EC', 'Echocardiography'], 'intervention_type': 'PROCEDURE'}; {'id': 206423342, 'name': 'Magnetic Resonance Imaging', 'description': 'Undergo MRI', 'other_names': ['Magnetic Resonance', 'Magnetic Resonance Imaging (MRI)', 'Magnetic resonance imaging (procedure)', 'Magnetic Resonance Imaging Scan', 'Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance', 'MR', 'MR Imaging', 'MRI', 'MRI Scan', 'MRIs', 'NMR Imaging', 'NMRI', 'Nuclear Magnetic Resonance Imaging', 'sMRI', 'Structural MRI'], 'intervention_type': 'PROCEDURE'}; {'id': 206423343, 'name': 'Multigated Acquisition Scan', 'description': 'Undergo MUGA scan', 'other_names': ['Blood Pool Scan', 'Equilibrium Radionuclide Angiography', 'Gated Blood Pool Imaging', 'Gated Heart Pool Scan', 'MUGA', 'MUGA Scan', 'Multi-Gated Acquisition Scan', 'Radionuclide Ventriculogram Scan', 'Radionuclide Ventriculography', 'RNV Scan', 'RNVG', 'SYMA Scanning', 'Synchronized Multigated Acquisition Scanning'], 'intervention_type': 'PROCEDURE'}; {'id': 206423344, 'name': 'Pegylated Liposomal Doxorubicin Hydrochloride', 'description': 'Given IV', 'other_names': ['Evacet', 'LipoDox', 'Lipodox 50', 'Liposomal Adriamycin', 'Pegylated Doxorubicin HCl Liposome', 'Pegylated Liposomal Doxorubicin', 'S-Liposomal Doxorubicin', 'Stealth Liposomal Doxorubicin', 'TLC D-99', 'Liposomal Doxorubicin Hydrochloride', 'Liposomal-Encapsulated Doxorubicin', 'ATI-0918', 'Caelyx', 'Dox-SL', 'Doxil', 'Doxilen', 'Doxorubicin HCl Liposomal', 'Doxorubicin HCl Liposome', 'Doxorubicin Hydrochloride Liposome', 'Duomeisu'], 'intervention_type': 'DRUG'}; {'id': 206423345, 'name': 'Peposertib', 'description': 'Given PO', 'other_names': ['3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-', 'M 3814', 'M-3814', 'M3814', 'MSC 2490484A', 'MSC-2490484A', 'MSC2490484A', 'Nedisertib'], 'intervention_type': 'DRUG'}",PHASE1,18 years,Endometrial Endometrioid Adenocarcinoma (FIGO Grade 1); Endometrial Endometrioid Adenocarcinoma (FIGO Grade 2); Endometrial High Grade Endometrioid Adenocarcinoma; Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian High Grade Serous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Undifferentiated Carcinoma; Platinum-Sensitive Ovarian Carcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Primary Peritoneal Transitional Cell Carcinoma; Primary Peritoneal Undifferentiated Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Ovarian Carcinosarcoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Ovarian Low Grade Serous Adenocarcinoma; Recurrent Ovarian Mucinous Adenocarcinoma; Recurrent Ovarian Transitional Cell Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma,"Recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer (dose-escalation). | Expansion cohorts: recurrent or persistent low grade serous ovarian cancer (LGSOC) or high grade serous ovarian cancer (HGSOC). | Measurable disease per RECIST 1.1. | Prior therapy: at least one prior line of platinum-based chemotherapy required. | Prior therapy: unlimited additional lines of chemotherapy, targeted, biologic, or hormonal therapy allowed. | Washout: prior anti-cancer therapy discontinued >= 4 weeks, one cycle, or 5 half-lives (whichever is shortest) before study treatment. | Age >= 18 years. | Platinum-sensitive ovarian cancer eligible for dose expansion if PLD is appropriate. | ECOG performance status <= 2 (Karnofsky >= 60%). | Cardiac ejection fraction >= lower limit of normal. | Hemoglobin >= 9 g/dL. | Absolute neutrophil count >= 1,500/µL. | Platelets >= 100,000/µL. | Total bilirubin <= 1.5 x ULN. | AST/ALT <= 3 x ULN. | Alkaline phosphatase <= 2.5 x ULN. | Creatinine clearance > 30 mL/min. | HIV-infected patients eligible if on effective ART with undetectable viral load within 6 months. | Chronic hepatitis B eligible if viral load undetectable on suppressive therapy, if indicated. | Hepatitis C eligible if cured or on treatment with undetectable viral load. | Treated brain metastases eligible if no progression on follow-up imaging, off steroids, and clinically stable. | Women of childbearing potential: negative urine or serum pregnancy test within 72 hours prior to first dose. | Contraception required during treatment and for 6 months after last dose. | Prior or concurrent malignancy allowed if it will not interfere with assessment of safety or efficacy. | Cardiac risk assessment NYHA class 2B or better. | Availability of archival FFPE tissue (within past 36 months) for DNA/RNA analysis.","Eligible for available therapies known to confer clinical benefit (dose-escalation phase). | Inability to swallow or absorb oral medication (e.g., drainage PEG). | Prior anthracycline exposure for ovarian cancer (doxorubicin or pegylated liposomal doxorubicin). | Unresolved toxicities from prior therapy > grade 1 (except alopecia, thyroid dysfunction, or neuropathy). | Receipt of other investigational agents within 28 days prior to start of treatment. | Allergic reactions to compounds similar to peposertib or pegylated liposomal doxorubicin. | Unable to discontinue interacting medications or herbal supplements with peposertib (strong CYP3A4/5, CYP2C9, CYP2C19 modulators; narrow TI substrates of CYP3A4/5, CYP1A2, CYP2B6; narrow TI transport substrates of P-gp, BCRP, OCT1, OATP1B1, OATP1B3). | Unable to discontinue proton-pump inhibitors >= 5 days prior to treatment (calcium carbonate allowed). | Concurrent sorivudine or brivudine use. | Live attenuated vaccine within 30 days prior to peposertib dosing. | Uncontrolled intercurrent illness, including active infection. | Psychiatric illness or social situations limiting compliance. | Pregnant or breastfeeding. | Significant uncontrolled cardiac conduction abnormalities.","At least one prior line of platinum-based chemotherapy required.; Unlimited additional prior lines of chemotherapy, targeted therapy, biologic therapy, or hormonal therapy allowed.; Washout required: prior anti-cancer therapy stopped >= 4 weeks, one cycle, or 5 half-lives before study start (whichever is shortest).",FEMALE,A,"Disease and setting match (recurrent epithelial ovarian cancer, clear cell histology included in dose-escalation), and the patient meets prior-therapy requirements (≥1 prior platinum regimen), age, and sex criteria. No known exclusions apply (no prior anthracycline, biomarker not required).",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,No hard exclusions. Disease matches (recurrent clear cell ovarian carcinoma included). Stage/setting matches (recurrent). Prior therapy requirement met (≥1 prior platinum). Age and sex fit. No soft mismatches identified. Therefore ≥2 core anchors (stage/setting and line/prior) match → Grade A is appropriate.,,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT04221503,0.8363864421844482,Recurrent Glioblastoma,A Phase II Study Evaluating the Efficacy and Safety of Niraparib and Tumor-Treating Fields in Recurrent Glioblastoma,Evaluating the efficacy and safety of niraparib and Tumor-Treating Fields (TTFields) in recurrent glioblastoma (GBM).,"{'id': 206008011, 'name': 'Niraparib', 'description': 'Niraparib (\\[3S\\]-3-\\[4-{7-(aminocarbonyl)-2H-indazol-2-yl} phenyl\\] piperidine \\[tosylate monohydrate salt\\]) is an orally available, potent, highly selective poly (adenosine diphosphate \\[ADP\\]-ribose) polymerase (PARP) -1 and -2 inhibitor. The niraparib drug product is provided as 100-mg capsules filled with a dry blend of niraparib tosylate monohydrate, lactose monohydrate, and magnesium stearate in a hard gelatin capsule.', 'other_names': ['ZEJULA'], 'intervention_type': 'DRUG'}; {'id': 206008012, 'name': 'Optune', 'description': 'Optune, which is manufactured by Novocure, is a portable battery or power supply operated device which produces alternating electrical fields, called tumor treatment fields (""TTFields"") within the human body. TTFields are applied to the patient by electrically-insulated surface transducer arrays. TTFields disrupt the rapid cell division exhibited by cancer cells.', 'other_names': ['Tumor Treatment Fields (TTFields)'], 'intervention_type': 'DEVICE'}; {'id': 206008013, 'name': 'Planned surgical resection', 'description': 'Surgery of supratentorial glioblastoma (GBM).', 'other_names': ['Tumor Resection'], 'intervention_type': 'PROCEDURE'}",PHASE2,22 years,Glioblastoma (recurrent),Histopathologically or molecularly proven recurrent glioblastoma following prior radiation therapy (40–75 Gy) | MGMT methylation status available from a prior GBM specimen | Measurable contrast-enhancing disease >= 1 cm x 1 cm by MRI within 28 days of treatment start | Recovered from severe toxicity of prior therapy | Able to swallow oral medications | Karnofsky performance status >= 60% | Life expectancy > 3 months | Adequate hematologic parameters | Adequate hepatic function within 7 days prior to start | Adequate renal function within 7 days prior to start | Cohort B: surgery clinically indicated | Cohort B: archived tumor tissue available from a previous glioblastoma surgery,"Age < 22 years | Prior treatment with tumor-treating fields (Optune) within the past 6 months | Prior treatment with a PARP inhibitor | History or current diagnosis of myelodysplastic syndrome or acute myeloid leukemia | Infratentorial tumor | Grade 3 or 4 anemia, neutropenia, or thrombocytopenia due to prior chemotherapy persisting > 4 weeks and related to the most recent treatment | Serious uncontrolled medical disorder, nonmalignant systemic disease, or active uncontrolled infection | Implanted pacemaker, defibrillator, deep brain stimulator, or other implanted electronic devices in the brain; programmable shunt | Skull defects | Hypersensitivity to conductive hydrogels or to niraparib components or excipients | Gastrointestinal disorders or abnormalities that would interfere with absorption of study treatment | Simultaneous enrollment in another interventional clinical trial",Prior radiation therapy 40–75 Gy; Recovered from severe toxicity of prior therapy; Unlimited prior relapses allowed,ALL,A,"Disease and setting match recurrent glioblastoma after prior chemoradiation, age meets the ≥22 requirement, and prior therapies are compatible with the trial’s allowances. No conflicting exclusions are documented; MGMT status availability, KPS, and measurable disease are unspecified but not mismatches.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"No hard exclusions identified. Disease and recurrent setting match; prior radiation/temozolomide exposure is compatible and no disallowed prior PARP/TTFields noted. MGMT status availability, KPS, and measurable disease are unknown but not mismatches. At least two core anchors (stage/setting and line/prior) match, with no soft conflicts, supporting grade A.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT04263831,0.6691051721572876,Fistulizing Crohn's Disease,Low Dose IL-2 for the Treatment of Crohn's Disease,The purpose of this study is to determine the safety and maximum effective dose (MED) of Interleukin-2 in subjects with moderate-to-severe crohn's disease.,"{'id': 206165142, 'name': 'Interleukin-2 (aldesleukin).', 'description': 'Description of intervention is covered in ""Arm"", above.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,12 years to 80 years,Crohn Disease,"Age 12-80 years. | Crohn disease diagnosed by standard clinical, radiologic, endoscopic, and histologic criteria. | Moderate-to-severe disease activity (CDAI 220-450). | Endoscopic inflammation accessible by ileocolonoscopy or ileoscopy with SES-CD >= 6 (or >= 4 for isolated ileal disease). | Ileostomy or colostomy subset permitted; ileostomy assessed as isolated ileal disease for SES-CD. | Failure to tolerate or respond to at least one conventional therapy or corticosteroid-dependent disease. | Stable doses of concomitant medications. | Negative pregnancy test for women of childbearing potential; effective contraception during treatment and for 6 months after.","Ulcerative colitis or indeterminate colitis. | Immediate need for surgical, endoscopic, or radiologic intervention for perforation, sepsis, or intra-abdominal or perianal abscess. | History of colorectal cancer or dysplasia. | Positive stool test for Clostridium difficile by GDH/EIA method. | Current medically significant infection. | Hemoglobin < 7.0 g/dL. | White blood cell count < 2.5 x 10^3/µL. | Platelets < 50 x 10^3/µL. | Creatinine >= 2 x ULN. | Total bilirubin > 2.0 mg/dL. | ALT > 2 x ULN. | Abnormal thyroid function tests. | Positive serology for HIV, hepatitis B virus, or hepatitis C virus. | Positive tuberculosis screening test. | Malignancy within the last 5 years, excluding non-melanoma skin cancer. | Allergy to any component of the study drug. | Pregnant or lactating women. | Prior exposure to interleukin-2. | Uncontrolled angina or symptomatic congestive heart failure (NYHA Class III or IV).","Failure or intolerance to at least one conventional therapy (e.g., corticosteroids, 5-aminosalicylates, azathioprine/6-mercaptopurine, TNF antagonists, anti-integrins, ustekinumab) or corticosteroid dependence.; Washout: no biologic medication within 4 weeks before first study dose.; Washout: no other investigational agent (IND) within 5 half-lives before baseline.",ALL,A,"Disease matches Crohn’s with moderate-to-severe activity (CDAI 350), age/sex within range, and prior failure of infliximab/ustekinumab meets the trial’s prior-therapy requirement. No explicit exclusions are triggered; SES-CD/endoscopic status and washout timing are unknown but not conflicting.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches Crohn’s; stage/severity (CDAI 350 within 220–450) matches; prior therapy failure matches the trial’s requirement. Other criteria (SES-CD, washout) are unknown, not conflicting. ≥2 core anchors matched with no soft conflicts → A per rubric.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT04388852,0.9999872446060181,Metastatic Urothelial Carcinoma,"DS3201 With Ipilimumab in Patients With Metastatic Aggressive Variant Prostate (AVPC), Urothelial (UC), and Renal Cell (RCC) Carcinomas","This phase Ib trial studies the side effects and best dose of DS3201 when given together with and ipilimumab for the treatment of patients with prostate, urothelial, or renal cell cancer that has spread to other places in the body (metastatic). DS3201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of t...","{'id': 206418308, 'name': 'Ipilimumab', 'description': 'Given IV', 'other_names': ['Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody', 'BMS-734016', 'Ipilimumab Biosimilar CS1002', 'MDX-010', 'MDX-CTLA4', 'Yervoy'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206418309, 'name': 'Valemetostat', 'description': 'Given PO', 'other_names': ['DS 3201', 'DS-3201', 'DS3201'], 'intervention_type': 'DRUG'}",PHASE1,18 years,Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Urothelial Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma,"ECOG performance status 0-1 | Histologically or cytologically confirmed prostate carcinoma, urothelial carcinoma, or clear cell renal cell carcinoma; variant prostate histologies (small cell/neuroendocrine) permitted | Metastatic disease by CT/MRI and/or bone scan, or locally advanced not amenable to locoregional therapy | Prostate carcinoma: castration-resistant disease and maintain castrate testosterone (<= 50 ng/dL or <= 2.0 nM) throughout the study; small cell histology exempt from progression on prior ADT but must maintain castrate levels | Aggressive variant prostate carcinoma requires molecular signature: loss or mutation in at least 2 of TP53, RB1, PTEN by CLIA-certified testing | Renal cell carcinoma: progressive disease during or after at least one anti-angiogenic agent and one PD-1 or PD-L1 inhibitor | Urothelial carcinoma: progressive disease during or after at least one PD-1 or PD-L1 inhibitor and prior platinum chemotherapy or platinum-ineligible | AVPC patients may have received prior PD-1 or PD-L1 inhibitor but not required | Evidence of disease progression by RECIST; for AVPC, rising PSA per PCWG3 may qualify if AVPC molecular criteria met | Known brain metastases allowed if stable >= 4 weeks after local therapy, off steroids or on stable/decreasing dose <= 10 mg prednisone equivalent daily, and without confounding neurologic dysfunction | Recovery from prior surgery, radiotherapy, chemotherapy, or other anti-cancer therapy to baseline or <= grade 1 (other low-grade toxicities may be allowed if clinically insignificant) | Ability to swallow and retain oral medications | Disease site accessible for serial biopsies","Pregnant or lactating | Carcinomatous meningitis | Prior treatment with an EZH2 inhibitor | PD-1, PD-L1, PD-L2, or CTLA-4 inhibitor within 4 weeks prior to day 1 | Monoclonal antibody within 4 weeks prior to day 1 | Investigational drug within 2 weeks prior to day 1 | Chemotherapy within 2 weeks prior to day 1 | Radiation therapy or radionuclide therapy within 2 weeks prior to day 1 | Receipt of live virus vaccine within 30 days prior to day 1 | Untreated symptomatic spinal cord compression or brain metastases | History of immune-related adverse event leading to permanent discontinuation of prior immunotherapy | History of >= grade 3 immune-related adverse event within past 16 weeks, any grade 4 life-threatening irAE, or neurologic/ocular irAE of any grade with prior immunotherapy (endocrine AEs allowed if on stable replacement, no adrenal crisis, asymptomatic) | Active, known, or suspected autoimmune disease (exceptions: vitiligo, type 1 diabetes, residual hypothyroidism on replacement, psoriasis/eczema not requiring systemic treatment, or conditions not expected to recur) | Requires chronic systemic corticosteroids > 10 mg prednisone equivalents daily or other immunosuppressive medications (physiologic adrenal replacement > 10 mg allowed without active autoimmune disease; inhaled/intranasal/intra-articular/topical allowed) | History of interstitial lung disease, idiopathic pulmonary fibrosis, or active pneumonitis on screening CT | Clinically significant cardiovascular disease: MI or stroke within 6 months; unstable angina within 3 months; CHF NYHA class 3-4; clinically significant ventricular arrhythmias; uncontrolled hypertension (SBP >= 140 mmHg or DBP >= 90 mmHg); baseline ECG abnormalities including QTc > 470 msec, complete LBBB, ischemic ST-T changes, second- or third-degree AV block, or serious brady-/tachyarrhythmias | Active hepatitis B (positive HBsAg) or active hepatitis C (detectable HCV RNA) | Known HIV infection | Gastrointestinal disorder that negatively affects absorption (e.g., short bowel syndrome, severe diarrhea, TPN requirement) | Additional malignancy that is progressing, requires active treatment, or has >= 30% probability of recurrence within 24 months (exceptions: non-melanoma skin cancer after curative therapy, Ta urothelial carcinoma, stage 0 CLL) | Any other severe/uncontrolled medical condition that could compromise participation | Unwilling or unable to comply with the study protocol",Renal cell carcinoma: prior treatment with at least one anti-angiogenic agent; Renal cell carcinoma: prior treatment with a PD-1 or PD-L1 inhibitor; Urothelial carcinoma: prior treatment with a PD-1 or PD-L1 inhibitor; Urothelial carcinoma: prior platinum-based chemotherapy or platinum-ineligible; Prostate cancer: maintain castrate testosterone during study; Washout: PD-1/PD-L1/PD-L2 or CTLA-4 inhibitors within 4 weeks prior to day 1 not allowed; Washout: monoclonal antibody within 4 weeks prior to day 1 not allowed; Washout: investigational drug within 2 weeks prior to day 1 not allowed; Washout: chemotherapy within 2 weeks prior to day 1 not allowed; Washout: radiation or radionuclide therapy within 2 weeks prior to day 1 not allowed,ALL,A,"Disease and setting match (metastatic urothelial carcinoma with progression), and prior-exposure requirements are met (prior platinum and PD-1 therapy). Age/sex fit, and no explicit exclusions are evident from the provided data.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,A,No hard exclusions identified. Disease (metastatic urothelial carcinoma) matches. Core anchors: Stage/setting matches (metastatic) and prior-exposure/line requirements are satisfied (prior platinum and PD-1). No specific soft mismatches are evident from provided data. Grade A is appropriate per rubric.,,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04388852,0.9548177123069763,Castration-Resistant Prostate Cancer,"DS3201 With Ipilimumab in Patients With Metastatic Aggressive Variant Prostate (AVPC), Urothelial (UC), and Renal Cell (RCC) Carcinomas","This phase Ib trial studies the side effects and best dose of DS3201 when given together with and ipilimumab for the treatment of patients with prostate, urothelial, or renal cell cancer that has spread to other places in the body (metastatic). DS3201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of t...","{'id': 206418308, 'name': 'Ipilimumab', 'description': 'Given IV', 'other_names': ['Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody', 'BMS-734016', 'Ipilimumab Biosimilar CS1002', 'MDX-010', 'MDX-CTLA4', 'Yervoy'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206418309, 'name': 'Valemetostat', 'description': 'Given PO', 'other_names': ['DS 3201', 'DS-3201', 'DS3201'], 'intervention_type': 'DRUG'}",PHASE1,18 years,Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Urothelial Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma,"ECOG performance status 0-1 | Histologically or cytologically confirmed prostate carcinoma, urothelial carcinoma, or clear cell renal cell carcinoma; variant prostate histologies (small cell/neuroendocrine) permitted | Metastatic disease by CT/MRI and/or bone scan, or locally advanced not amenable to locoregional therapy | Prostate carcinoma: castration-resistant disease and maintain castrate testosterone (<= 50 ng/dL or <= 2.0 nM) throughout the study; small cell histology exempt from progression on prior ADT but must maintain castrate levels | Aggressive variant prostate carcinoma requires molecular signature: loss or mutation in at least 2 of TP53, RB1, PTEN by CLIA-certified testing | Renal cell carcinoma: progressive disease during or after at least one anti-angiogenic agent and one PD-1 or PD-L1 inhibitor | Urothelial carcinoma: progressive disease during or after at least one PD-1 or PD-L1 inhibitor and prior platinum chemotherapy or platinum-ineligible | AVPC patients may have received prior PD-1 or PD-L1 inhibitor but not required | Evidence of disease progression by RECIST; for AVPC, rising PSA per PCWG3 may qualify if AVPC molecular criteria met | Known brain metastases allowed if stable >= 4 weeks after local therapy, off steroids or on stable/decreasing dose <= 10 mg prednisone equivalent daily, and without confounding neurologic dysfunction | Recovery from prior surgery, radiotherapy, chemotherapy, or other anti-cancer therapy to baseline or <= grade 1 (other low-grade toxicities may be allowed if clinically insignificant) | Ability to swallow and retain oral medications | Disease site accessible for serial biopsies","Pregnant or lactating | Carcinomatous meningitis | Prior treatment with an EZH2 inhibitor | PD-1, PD-L1, PD-L2, or CTLA-4 inhibitor within 4 weeks prior to day 1 | Monoclonal antibody within 4 weeks prior to day 1 | Investigational drug within 2 weeks prior to day 1 | Chemotherapy within 2 weeks prior to day 1 | Radiation therapy or radionuclide therapy within 2 weeks prior to day 1 | Receipt of live virus vaccine within 30 days prior to day 1 | Untreated symptomatic spinal cord compression or brain metastases | History of immune-related adverse event leading to permanent discontinuation of prior immunotherapy | History of >= grade 3 immune-related adverse event within past 16 weeks, any grade 4 life-threatening irAE, or neurologic/ocular irAE of any grade with prior immunotherapy (endocrine AEs allowed if on stable replacement, no adrenal crisis, asymptomatic) | Active, known, or suspected autoimmune disease (exceptions: vitiligo, type 1 diabetes, residual hypothyroidism on replacement, psoriasis/eczema not requiring systemic treatment, or conditions not expected to recur) | Requires chronic systemic corticosteroids > 10 mg prednisone equivalents daily or other immunosuppressive medications (physiologic adrenal replacement > 10 mg allowed without active autoimmune disease; inhaled/intranasal/intra-articular/topical allowed) | History of interstitial lung disease, idiopathic pulmonary fibrosis, or active pneumonitis on screening CT | Clinically significant cardiovascular disease: MI or stroke within 6 months; unstable angina within 3 months; CHF NYHA class 3-4; clinically significant ventricular arrhythmias; uncontrolled hypertension (SBP >= 140 mmHg or DBP >= 90 mmHg); baseline ECG abnormalities including QTc > 470 msec, complete LBBB, ischemic ST-T changes, second- or third-degree AV block, or serious brady-/tachyarrhythmias | Active hepatitis B (positive HBsAg) or active hepatitis C (detectable HCV RNA) | Known HIV infection | Gastrointestinal disorder that negatively affects absorption (e.g., short bowel syndrome, severe diarrhea, TPN requirement) | Additional malignancy that is progressing, requires active treatment, or has >= 30% probability of recurrence within 24 months (exceptions: non-melanoma skin cancer after curative therapy, Ta urothelial carcinoma, stage 0 CLL) | Any other severe/uncontrolled medical condition that could compromise participation | Unwilling or unable to comply with the study protocol",Renal cell carcinoma: prior treatment with at least one anti-angiogenic agent; Renal cell carcinoma: prior treatment with a PD-1 or PD-L1 inhibitor; Urothelial carcinoma: prior treatment with a PD-1 or PD-L1 inhibitor; Urothelial carcinoma: prior platinum-based chemotherapy or platinum-ineligible; Prostate cancer: maintain castrate testosterone during study; Washout: PD-1/PD-L1/PD-L2 or CTLA-4 inhibitors within 4 weeks prior to day 1 not allowed; Washout: monoclonal antibody within 4 weeks prior to day 1 not allowed; Washout: investigational drug within 2 weeks prior to day 1 not allowed; Washout: chemotherapy within 2 weeks prior to day 1 not allowed; Washout: radiation or radionuclide therapy within 2 weeks prior to day 1 not allowed,ALL,A,"Disease matches metastatic castration-resistant prostate cancer, and prior therapies (ADT, abiraterone, enzalutamide) are compatible with the trial’s prostate cohort requirements. No disqualifying exclusions are evident; AVPC molecular signature is only required for the AVPC subset and is not mandated for general CRPC.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches metastatic CRPC cohort. Stage/setting aligns (metastatic CRPC), and prior therapies (ADT, abiraterone, enzalutamide) are compatible with trial allowances; no required biomarker for the CRPC cohort (AVPC signature applies only to AVPC subset). No soft conflicts on core anchors. Grade A is appropriate.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT04417088,0.8363864421844482,Recurrent Glioblastoma,Assessment of Safety and Feasibility of Exablate Type 2 for Blood-Brain Barrier Disruption (BBBD) With Microbubble Resonators for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin Monotherapy,The purpose of this study is to evaluate the safety and feasibility of the Exablate Model 4000 Type 2 system when used as a tool to open the blood-brain-barrier (BBB) in subjects with recurrent glioblastoma (rGBM) undergoing carboplatin monotherapy.,"{'id': 205255338, 'name': 'Carboplatin', 'description': 'Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205255339, 'name': 'Exablate BBBD', 'description': 'BBB opening via Exablate Neuro Type 2 system with microbubble resonators.', 'other_names': ['Exablate Neuro'], 'intervention_type': 'DEVICE'}",PHASE1/PHASE2,18 years to 80 years,Glioblastoma (recurrent),Age 18–80 years | Histologically confirmed glioblastoma | Planned carboplatin monotherapy | Disease progression after first-line chemoradiation | Recovered to grade 0–1 or baseline from prior therapy toxicities,"Acute intracranial hemorrhage | Ferrous metallic implanted objects in the skull or brain | Prior toxicity with carboplatin chemotherapy | Pregnant or breastfeeding | Cerebellar, spinal cord, or brainstem tumor | Active hepatitis B, hepatitis C, or HIV infection | Significant depression not adequately controlled | Prior anti-VEGF therapy (e.g., bevacizumab) | Cardiac disease or unstable hemodynamics | Severe hypertension | Bleeding disorder or coagulopathy or history of spontaneous tumor hemorrhage | Active drug or alcohol use disorder | Known sensitivity to gadolinium-based contrast agents | Known sensitivity or contraindications to ultrasound contrast agent or perflutren | Unable to undergo MRI or MRI contraindications | Inability to lie supine and still or severe claustrophobia not manageable with medication | Severely impaired renal function | Right-to-left or bidirectional cardiac shunt | Cranial or systemic infection requiring antibiotics | Concurrent additional malignancy that is progressing or requires active treatment",Progression after first-line chemoradiation required,ALL,A,"Recurrent glioblastoma after first-line chemoradiation matches the trial’s disease/setting and prior-therapy requirements, and the patient’s age/sex are within limits with no exclusions evident. Planned carboplatin monotherapy is unspecified but not a known conflict, so ≥2 core anchors match.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"Disease and recurrent setting match; patient progressed after first-line chemoradiation (line/prior anchor match); age/sex within limits; no explicit exclusions. Planned carboplatin monotherapy is unknown but not a mismatch, so ≥2 core anchors match with no soft conflicts. Grade A is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT04539964,1.0,Rheumatoid Arthritis,Vagus Nerve Stimulation Using the SetPoint System for Moderate to Severe Rheumatoid Arthritis: The RESET-RA Study,"The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically placed under general anesthesia on the vagus nerve through a small incision on the left side of the ...","{'id': 206507368, 'name': 'Implant Procedure', 'description': 'The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.', 'other_names': ['Surgical placement of vagus nerve stimulator inside the neck'], 'intervention_type': 'PROCEDURE'}; {'id': 206507369, 'name': 'Conventional Synthetic DMARD', 'description': 'All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent', 'other_names': ['Background therapy with conventional synthetic DMARD'], 'intervention_type': 'DRUG'}; {'id': 206507370, 'name': 'Active stimulation', 'description': 'Active stimulation for 1 min once per day', 'other_names': [], 'intervention_type': 'DEVICE'}; {'id': 206507371, 'name': 'Non-active stimulation', 'description': 'Non-active stimulation for 1 min once per day', 'other_names': [], 'intervention_type': 'DEVICE'}",PHASE3,22 years to 75 years,Rheumatoid Arthritis,"Age 22-75 years | Active moderate or severe rheumatoid arthritis with >=4/28 tender and >=4/28 swollen joints | Inadequate response, loss of response, or intolerance to >=1 biologic or targeted synthetic DMARD, including JAK inhibitors | Receiving at least 1 conventional synthetic DMARD for >=12 weeks and on a stable dose and route for >=4 weeks prior to screening and able to continue the same stable dose through Week 12","Untreated or poorly controlled psychiatric illness | History of substance abuse | Significant immunodeficiency due to underlying illness | History of stroke or transient ischemic attack | Cerebrovascular fibromuscular dysplasia | Clinically significant cardiovascular disease | Multiple sclerosis | Alzheimer's disease | Parkinson's disease | Uncontrolled fibromyalgia | History of left or right carotid surgery | History of unilateral or bilateral vagotomy | Partial or complete splenectomy | Recurrent vasovagal syncope episodes | Current, regular use of tobacco products | Hypersensitivity or allergy to MRI contrast agents | Unable to perform MRI","Inadequate response, loss of response, or intolerance to >=1 biologic or targeted synthetic DMARD (including JAK inhibitors) required; On conventional synthetic DMARD >=12 weeks with stable dose and route for >=4 weeks prior to screening; continue stable dose through Week 12",ALL,A,"Disease matches and the patient has active moderate–severe RA with inadequate response to multiple biologics, meeting key prior-therapy requirements; age and sex fit the trial. No explicit exclusions are evident from the provided data.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,A,"No hard exclusions. Disease matches. Stage/setting (active moderate–severe RA) and line/prior exposure (inadequate response to multiple biologics) both match, satisfying ≥2 core anchors. Other inclusion details (current csDMARD stability) are unknown, not a soft mismatch. Grade A is appropriate.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT04559230,0.8363864421844482,Recurrent Glioblastoma,"A Phase II, Multicenter, Prospective Study of Sacituzumab Govitecan in Recurrent Glioblastoma","This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with recurrent brain tumor, known as Glioblastoma (GBM) having high levels of a protein, Trophoblast cell surface antigen 2 (Trop-2), expression on treatment with Sacituzumab Govitecan (SG) versus lomustine only which has been used in the past.","{'id': 206509260, 'name': 'Sacituzumab Govitecan', 'description': 'Sacituzumab Govitecan will be administered by IV infusion over 3 hours for first administration and over 1 hour if tolerated. Subjects will be allowed to continue treatment until they have evidence of significant treatment-related toxicity or progressive disease.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,18 years,Glioblastoma (recurrent),"Age >= 18 years | Histologically confirmed IDH wild-type glioblastoma; molecular GBM per cIMPACT-NOW 3 allowed; gliosarcoma and epithelioid glioblastoma allowed | Progression after standard chemoradiation with temozolomide if MGMT methylated; if MGMT unmethylated, must have received standard-dose radiation | Prior tumor-treating fields allowed and not considered an additional line of therapy | No additional lines of therapy given for recurrent disease | Surgery for recurrence allowed if >= 2 weeks before enrollment with MRI within 48 hours post-surgery | No radiotherapy within the 3 months prior to the diagnosis of progression | Willing to forego tumor-treating field therapy during study participation | Stable or decreasing corticosteroid dose for >= 7 days prior to baseline MRI | Recovered from prior therapy toxicities to grade 0–1 (except neuropathy <= grade 2 and alopecia) | ECOG <=2 | Life expectancy >= 6 months | Bilirubin <= 1.5 x ULN | AST <= 3.0 x ULN | ALT <= 3.0 x ULN | Creatinine clearance >= 30 mL/min | ANC >= 1500/µL | Platelets >= 100000/µL | Hemoglobin >= 9.0 g/dL | Availability of tumor tissue for central review/biomarker testing | Measurable recurrent or residual disease by RANO; multifocal and infratentorial disease allowed | Positive Trop-2 expression (H-score >= 200) by central review","Prior treatment with bevacizumab or other VEGF/VEGFR pathway inhibitors | Use of warfarin or other coumarin anticoagulants if unable to switch to low molecular weight heparin before first dose | Evidence of acute intracranial or intratumoral hemorrhage on MRI or CT (resolving changes, punctate hemorrhage, or hemosiderin allowed) | Unable to undergo MRI (e.g., pacemaker) | Use of enzyme-inducing antiepileptic drugs within 14 days before study drug (e.g., carbamazepine, phenytoin, phenobarbital, primidone) | Pregnant or breastfeeding | Uncontrolled hypertension (>150 mmHg systolic or >100 mmHg diastolic on >=2 readings at screening) despite optimal therapy | Non-healing wound, ulcer, or bone fracture | Significant cardiac arrhythmias | Untreated hypothyroidism | Unhealed rectal or perirectal abscess | Uncontrolled active infection | Symptomatic congestive heart failure or unstable angina within 3 months | Any history of cardiac arrhythmia or heart block | Stroke or transient ischemic attack within 6 months | Prior non-standard radiation therapy (brachytherapy, systemic radioisotope therapy, intra-operative radiotherapy); stereotactic radiosurgery allowed | Systemic therapy (including investigational agents and small-molecule kinase inhibitors) or non-cytotoxic hormonal therapy within 7 days or 5 half-lives (whichever is shorter) before first dose | Biologic agents (antibodies, immune modulators, vaccines, cytokines) within 21 days before first dose | Nitrosoureas or mitomycin C within 42 days before first dose | Metronomic/protracted low-dose chemotherapy within 14 days before first dose | Other cytotoxic chemotherapy within 28 days before first dose | Prior treatment with carmustine wafers | Radiographic or clinical leptomeningeal disease",Prior standard-dose radiation required; Prior temozolomide required if MGMT methylated; Prior tumor-treating fields allowed; Surgery for recurrence allowed if >= 2 weeks before enrollment; Washout: systemic therapy within 7 days or 5 half-lives (whichever shorter) before first dose; Washout: biologic agents within 21 days before first dose; Washout: nitrosoureas or mitomycin C within 42 days before first dose; Washout: metronomic/protracted low-dose chemotherapy within 14 days before first dose; Washout: other cytotoxic chemotherapy within 28 days before first dose,ALL,A,"Disease and setting match (recurrent IDH-wildtype GBM), and prior therapy/line requirements are met (post standard chemoradiation and TMZ with no therapy for recurrence). No exclusions are evident; Trop-2 positivity and other labs are unknown and would need confirmation.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),INCORRECT,B,"No hard exclusions. Disease and recurrent setting match. Prior therapy/line likely compatible, but the trial requires Trop-2 positivity, which is unknown for the patient. Since A requires required biomarkers to be satisfied, A is not appropriate. With one clear core anchor (stage/setting) and no soft conflicts, B is the correct grade.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT04590508,0.6691051721572876,Fistulizing Crohn's Disease,A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease,"A pilot study to assess the safety and tolerability of an orally administered natural product derived from hops, called xanthohumol, in humans with Crohn's Disease, in order to identify a biological signature of xanthohumol exposure, and to characterize the role of xanthohumol metabolism by intestinal microorganisms in that signature within adults with Crohn's Disease.","{'id': 205499770, 'name': 'Xanthohumol', 'description': 'The xanthohumol supplement will be administered in a capsule and taken orally.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205499771, 'name': 'Placebo', 'description': 'The placebo will be administered in a capsule and taken orally.', 'other_names': [], 'intervention_type': 'OTHER'}",PHASE2,21 years to 50 years,Crohn Disease,Age 21-50 years | Active Crohn's disease with CDAI >150 | Non-smoker (including tobacco and cannabis) | Individuals of child-bearing potential must use an intrauterine device or two concurrent forms of contraception during study participation,"Highly variable dosing of anti-inflammatory medications (dose changes more than once per week) | Use of dietary supplements containing xanthohumol, flavonoids, or other anti-inflammatories within 14 days prior to screening (e.g., curcumin, turmeric, fenugreek, hops, rosemary, ginger, white willow, devil's claw, fish oil >1 g/day, quercetin) | Current or typical alcohol intake >2 drinks/day, >14 drinks/week, or >4 drinks in a single day within the past 14 days | Currently receiving or received intravenous nutrition support within the last 14 days | Current or recent (within 14 days) use of anticoagulant or antiplatelet prescription medications | Current or recent (within 14 days) use of oral or intravenous antibiotic, antiparasitic, or antifungal medications | Initiation of or changes to supplements or medications within 14 days prior to screening | Initiation of or changes to an exercise regimen within 14 days prior to screening | Initiation of or changes to a food plan within 14 days prior to screening | Participation in a significant diet or weight loss program within 14 days prior to screening | Hospitalization within 3 months prior to screening | Gastrointestinal surgery within 3 months prior to screening | Malignancy within the last 5 years (except basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma in situ) | Lactating, pregnant, or planning pregnancy within the next 4 months | Smoking tobacco or nicotine products (combusted or vaporized) | Use of illicit drugs within 14 days of screening | Use of inhaled or ingested cannabis products, including cannabidiol (CBD) | Currently participating in another interventional research study or participated within 14 days prior to screening | No active primary care provider or gastroenterologist managing Crohn's disease","Washout >=14 days from dietary supplements containing xanthohumol, flavonoids, or other anti-inflammatories before screening",ALL,A,"Disease matches; the patient is 32 with active Crohn’s (CDAI 350) meeting inclusion, and prior infliximab/ustekinumab exposure is allowed, satisfying stage/setting and prior-therapy compatibility. Some protocol exclusions (e.g., non-smoking status and no antibiotic use within 14 days) are unknown and would need confirmation.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,A,"No hard exclusions are confirmed (recent antibiotics timing is unknown; smoking status unknown). Disease matches Crohn’s; stage/setting matches (active disease with CDAI>150); prior-exposure/line is compatible (no restrictions on prior biologics). With ≥2 core anchors matching and no soft conflicts, grade A is appropriate.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT04590664,0.8363864421844482,Recurrent Glioblastoma,A Phase 1 / 2 Study of Visudyne (Liposomal Verteporfin) in Persons with Recurrent High Grade EGFR-Mutated Glioblastoma,This phase I/II trial studies the side effects and best dose of Visudyne (liposomal verteporfin) and to see how well it works in treating patients with high grade EGFR-mutated glioblastoma that has come back (recurrent). Visudyne is FDA approved in combination with light to treat eye diseases. In this study we use Visudyne by itself like chemotherapy to kill tumor cells which may be sensitive to verteporfin.,"{'id': 205981389, 'name': 'Verteporfin', 'description': 'Given IV', 'other_names': ['Benzoporphyrin Derivative Monoacid Ring A', 'BPD-MA', 'Visudyne'], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,18 years,Glioblastoma (recurrent),Recurrent or progressive grade 4 glioma (glioblastoma) after standard first-line therapy including radiation and temozolomide | EGFR mutation or EGFR amplification required | MRI evidence of progression | Willing to have central venous access placed | ECOG performance status 0-3 | Non-neurologic comorbidities grade <=2 | Neurologic comorbidities up to grade 3 allowed if due to brain pathology | Reasonable expectation to complete 6 weeks (1 cycle) of treatment | >=7 days since discontinuation of prior chemotherapy or non-bevacizumab therapies for glioma | Prior brain radiation required and completed >=90 days before first study treatment | >=21 days since major surgery | Participants using tumor-treating fields (Optune) may continue | Females of childbearing potential must have a negative pregnancy test prior to therapy | Females of childbearing potential and men agree to use effective contraception during treatment and for 8 weeks after,"Clinical progression without MRI change | Edema likely due to late radiation effect without confirmed tumor progression | Pregnant or breastfeeding | Baseline comorbidities or laboratory abnormalities grade >=3 (except alopecia), excluding allowed neurologic deficits from tumor | Inability to comply with safety monitoring requirements | Any condition that precludes safe performance of study procedures or compromises consent ability | Hereditary porphyria",Received prior standard first-line therapy including radiation and temozolomide; Completed prior brain radiation >= 90 days before study treatment; Washout: >=7 days since prior chemotherapy or non-bevacizumab therapies; >=21 days since major surgery; Bevacizumab may be continued during study participation; Tumor treating fields (Optune) may be continued,ALL,A,Recurrent glioblastoma after standard RT/TMZ with ECOG 1 and age 40 matches the stage/setting and prior-therapy requirements. Trial requires EGFR mutation/amplification; patient’s EGFR status is unknown and would need confirmation but is not an explicit exclusion.,Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),INCORRECT,B,"Disease and stage/setting match; prior standard RT/TMZ exposure is compatible. However, the trial requires EGFR mutation/amplification, which is unknown for the patient. Per rubric, an A requires required biomarkers to be satisfied when applicable. With biomarker status unknown and no soft conflicts, the appropriate grade is B (good match with exactly one core anchor clearly met for sure, given uncertainty on the required biomarker anchor).",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04592237,0.9548177123069763,Castration-Resistant Prostate Cancer,Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers,"This phase II trial studies the effect of cabazitaxel, carboplatin, and cetrelimab followed by niraparib with or without cetrelimab in treating patients with aggressive variant prostate cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as cabazitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. PARPs are proteins that help repai...","{'id': 206231625, 'name': 'Cabazitaxel', 'description': 'Given IV', 'other_names': ['Jevtana', 'RPR-116258A', 'Taxoid XRP6258', 'XRP-6258'], 'intervention_type': 'DRUG'}; {'id': 206231626, 'name': 'Carboplatin', 'description': 'Given IV', 'other_names': ['Paraplatin', 'Blastocarb', 'Carboplat', 'Carboplatin Hexal', 'Carboplatino', 'Carboplatinum', 'Carbosin', 'Carbosol', 'Carbotec', 'CBDCA', 'Displata', 'Ercar', 'JM-8', 'Nealorin', 'Novoplatinum', 'Paraplatin AQ', 'Paraplatine', 'Platinwas', 'Ribocarbo'], 'intervention_type': 'DRUG'}; {'id': 206231627, 'name': 'Cetrelimab', 'description': 'Given IV', 'other_names': ['JNJ 63723283', 'JNJ-63723283', 'JNJ63723283', 'WHO 10757'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206231628, 'name': 'Niraparib', 'description': 'Given PO', 'other_names': ['MK-4827', 'MK4827'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Small Cell Carcinoma; Stage IV Prostate Cancer,"Histologically or cytologically confirmed prostate carcinoma | Metastatic disease documented on imaging (bone scan, CT and/or MRI) | Meets at least one aggressive variant prostate carcinoma (AVPC) criterion | Histologically proven small cell (neuroendocrine) prostate carcinoma (AVPC criterion) | Exclusive visceral metastases (AVPC criterion) | Predominantly lytic bone metastases by x-ray or CT (AVPC criterion) | Bulky (>= 5 cm) lymphadenopathy or high-grade tumor mass in prostate/pelvis (AVPC criterion) | Low PSA (<= 10 ng/mL) at initial presentation or at symptomatic progression in the castrate-setting plus high-volume (>= 20) bone metastases (AVPC criterion) | Elevated LDH (>= 2 x ULN) or elevated CEA (>= 2 x ULN) without other etiologies (AVPC criterion) | Short interval (<= 180 days) to castration-resistant progression after initiation of hormonal therapy (AVPC criterion) | Loss or mutation in at least 2 of TP53, RB1, and PTEN by CLIA-certified testing, IHC and/or DNA sequencing (AVPC criterion) | Castration-resistant progression per RECIST without PSA rising to >= 1.0 ng/mL per PCWG3 (AVPC criterion) | Documented progressive disease by PSA progression (3 measurements >= 7 days apart with last >= 1.0 ng/mL), or new/increasing measurable disease (RECIST), or >= 2 new bone lesions (PCWG3), or increasing symptoms attributed to progression | Surgically or medically castrated with baseline testosterone <= 50 ng/dL | ECOG performance status <= 2 | Hemoglobin >= 10.0 g/dL (>= 8 g/dL if due to marrow infiltration) | Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1.0 x 10^9/L if due to marrow infiltration) | White blood cells (WBC) > 3 x 10^9/L (> 2 x 10^9/L if due to marrow infiltration) | Platelet count >= 100 x 10^9/L (>= 50 x 10^9/L if due to marrow infiltration) | Total bilirubin <= 1.5 x ULN (except Gilbert syndrome) | AST and ALT <= 2.5 x ULN (<= 5 x ULN with liver metastases) | Calculated creatinine clearance (Cockcroft-Gault) >= 30 mL/min | No features suggestive of MDS/AML on peripheral blood smear | Able to swallow study drugs whole (tablet/capsule)","Any prior treatment for CRPC with carboplatin, cisplatin, cabazitaxel, a PARP inhibitor, or an anti-PD-1/PD-L1 inhibitor | More than one prior line of chemotherapy | Unresolved toxicity from prior therapy > CTCAE grade 2 (except allowed ongoing LHRH therapy, bisphosphonates, or RANK ligand inhibitors) | Any unresolved CTCAE grade >= 2 toxicity from previous anti-cancer therapy (irreversible toxicities not expected to be exacerbated may be allowed) | History or current diagnosis of myelodysplastic syndrome or acute myeloid leukemia | Active uncontrolled infection | Active or symptomatic viral hepatitis or chronic liver disease | History of pneumonitis or extensive bilateral non-malignant lung disease | Another malignancy with >= 30% probability of recurrence within 24 months (except adequately treated non-melanoma skin cancer, curatively treated in-situ cervical cancer, or Ta urothelial carcinoma) | Serious underlying medical or psychiatric condition that would make study drug hazardous or confound adverse event interpretation (e.g., uncontrolled ventricular arrhythmia, recent myocardial infarction, superior vena cava syndrome, uncontrolled seizures, history of allogeneic transplant, primary immunodeficiency) | Unable to swallow oral medication or gastrointestinal disorders likely to interfere with absorption | Symptomatic uncontrolled brain metastases or spinal cord compression | Known hypersensitivity to niraparib, carboplatin, cabazitaxel, or anti-PD-1/PD-L1 inhibitors | Current or prior use of systemic immunosuppressive medication within 28 days before first cetrelimab dose (with specified corticosteroid exceptions) | Active or prior documented autoimmune or inflammatory disorders requiring systemic therapy (with specified exceptions such as vitiligo, alopecia, controlled hypothyroidism, certain inactive diseases, or celiac disease controlled by diet) | Receipt of live attenuated vaccine within 30 days prior to cetrelimab | Compulsory detention for treatment of psychiatric or physical illness",(none),MALE,A,"Stage/setting matches (metastatic CRPC) and prior therapies are compatible (no prior platinum, cabazitaxel, PARP, or PD-1/PD-L1; age/sex fit). AVPC criterion status is unknown, which is not a hard exclusion and presents no clear soft mismatch.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),INCORRECT,B,"Disease and stage/setting match, and prior-exposure compatibility appears acceptable (no excluded agents). However, the trial requires meeting at least one AVPC criterion; the patient’s AVPC status is unknown. Per rubric, A requires required biomarker/subtype to be satisfied when applicable, which is not confirmed here. With one core anchor clearly matched (stage/setting) and prior exposure compatible, the correct grade is B, not A.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04606446,1.0,Castration-Resistant Prostate Cancer,"A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS","This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other agents","{'id': 206510420, 'name': 'PF-07248144', 'description': 'KAT6 Inhibitor', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206510421, 'name': 'Fulvestrant', 'description': 'Endocrine Therapy', 'other_names': ['Faslodex'], 'intervention_type': 'DRUG'}; {'id': 206510422, 'name': 'Letrozole', 'description': 'Endocrine Therapy', 'other_names': ['Femara'], 'intervention_type': 'DRUG'}; {'id': 206510423, 'name': 'Palbociclib', 'description': 'CDK4/6 Inhibitor', 'other_names': ['Ibrance'], 'intervention_type': 'DRUG'}; {'id': 206510424, 'name': 'PF-07220060', 'description': 'CDK4 inhibitor', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206510425, 'name': 'PF-07850327, ARV-471, vepdegestrant', 'description': 'PROTAC (PROteolysis Targeting Chimera) ER degrader', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,18 years,"Castration-Resistant Prostate Cancer; Breast Cancer (ER+, HER2-); Non-Small Cell Lung Cancer","Histological or cytological diagnosis of locally advanced or metastatic ER+ HER2- breast cancer, castration-resistant prostate cancer, or non-small cell lung cancer (Part 1A) | For combination dose escalation (Parts 1B, 1C, 1D, 1E): ER+ HER2- breast cancer progressed after at least 1 prior line of endocrine therapy and a CDK4/6 inhibitor in the advanced/metastatic setting | For Part 2A (monotherapy): ER+ HER2- breast cancer progressed after at least 1 prior line of a CDK4/6 inhibitor and 1 line of endocrine therapy | For Part 2B (with fulvestrant): ER+ HER2- breast cancer with progression after at least 1 prior CDK4/6 inhibitor and at least 1 prior endocrine therapy; no more than 3 prior systemic therapy lines including up to 1 line of cytotoxic chemotherapy for visceral disease; prior fulvestrant allowed but not required | For Part 2D (with PF-07220060 and fulvestrant): ER+ HER2- breast cancer with progression after at least 1 prior CDK4/6 inhibitor and at least 1 prior endocrine therapy; no more than 3 prior systemic therapy lines including up to 1 line of cytotoxic chemotherapy for visceral disease; prior fulvestrant allowed but not required | For Part 2E (with vepdegestrant): ER+ HER2- breast cancer with progression after at least 1 prior CDK4/6 inhibitor and at least 1 prior endocrine therapy; no more than 3 prior systemic therapy lines including up to 1 line of cytotoxic chemotherapy for visceral disease; prior fulvestrant may have been received | ER-positive tumor documentation (>=1% positive stained cells) for ER+ HER2- breast cancer cohorts | HER2-negative tumor documentation for ER+ HER2- breast cancer cohorts (IHC 0/1+ or ISH negative: HER2/CEP17 ratio <2 or HER2 copy number <4) | Willing to undergo medically induced menopause with an LHRH agonist if female of childbearing potential with ER+ HER2- breast cancer | At least 1 measurable lesion per RECIST 1.1 not previously irradiated | ECOG performance status 0 or 1 | Age >= 18 years | Adequate renal, hepatic, and bone marrow function | Acute effects of prior therapy resolved to baseline or <= Grade 1 (except AEs not constituting a safety risk)","Unmanageable ascites | Any other active malignancy within 3 years except adequately treated basal/squamous cell skin cancer or carcinoma in situ | Major surgery, radiation therapy, or systemic anti-cancer therapy within 3 weeks prior to study entry | Prior irradiation to >25% of bone marrow | Clinically relevant ECG abnormalities including QTc >470 ms, complete left bundle branch block, second- or third-degree AV block, ST elevation, or changes suggesting myocardial infarction or active ischemia | Therapeutic anticoagulation (low molecular weight heparin allowed; vitamin K antagonists or factor Xa inhibitors may be allowed after discussion with sponsor) | Known or suspected hypersensitivity or severe allergy to PF-07248144 or its excipients | Active inflammatory gastrointestinal disease, refractory or unresolved chronic diarrhea, or prior gastric resection/lap band or other GI conditions/surgeries that may significantly alter absorption | Pregnant or breastfeeding","Progression after at least 1 prior line of endocrine therapy and a CDK4/6 inhibitor for ER+ HER2- breast cancer (advanced/metastatic setting); No more than 3 prior systemic therapy lines in the advanced/metastatic setting for specified breast cancer cohorts, including up to 1 line of cytotoxic chemotherapy for visceral disease; Prior fulvestrant allowed (not required) in specified breast cancer cohorts; Resected/treated prior cancers allowed if not active within 3 years per criteria; Washout >= 3 weeks from major surgery, radiation therapy, or systemic anti-cancer therapy before study entry",ALL,A,"The trial includes metastatic castration-resistant prostate cancer; the patient is a 66-year-old male with metastatic CRPC and prior AR-targeted therapies, matching the disease and stage with compatible prior exposure. Other requirements (ECOG, measurable disease, organ function) are unknown and do not create explicit conflicts.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,A,"Disease matches (CRPC included); stage/setting matches (metastatic); prior therapy exposure is compatible (no disallowance for CRPC). No hard exclusions identified; other inclusion items (ECOG, measurable disease) are unknown and not disqualifying. Meets ≥2 core anchors with no soft conflicts → A.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT04692493,1.0,Rheumatoid Arthritis,A Real-World Comparative Effectiveness Trial of Treatment Strategies in Patients With Rheumatoid Arthritis: The RA-PRO Pragmatic Trial (RA-PROPR),"The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive anoth...","{'id': 206486775, 'name': 'targeted synthetic DMARD class', 'description': 'Switching to a targeted synthetic DMARD (choice from targeted synthetic DMARDs; currently available are tofacitinib, baricitinib, upadacitinib) in people with active RA despite current treatment', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206486776, 'name': 'non-TNFi-biologic class', 'description': 'Switching to a non-TNFi-biologic (choice from non-TNFi-biologics; currently available are rituximab, abatacept, tocilizumab, or sarilumab) in people with active RA despite current treatment,', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,18 years,Rheumatoid Arthritis,"Active, disabling rheumatoid arthritis with CDAI >= 10 | HAQ >= 0.5 | Inadequate response to or discontinuation of a TNF inhibitor biologic due to intolerability or toxicity | If receiving glucocorticoids (<= 10 mg/day prednisone equivalent) or NSAIDs, on stable doses for >= 2 weeks prior to randomization","Prior treatment with more than three biologics (TNFi or non-TNFi) | Prior treatment with a targeted synthetic DMARD | Concomitant use of leflunomide, sulfasalazine, cyclosporine, or azathioprine within 2 months before randomization | History of sensitivity to all four non-TNFi biologics or to a targeted synthetic DMARD | Glucocorticoid injection (intravenous, intramuscular, or intraarticular) within 1 month prior to study entry | Live vaccine within 90 days prior to study entry | Acute or chronic infections requiring parenteral antibiotics or hospitalization within 1 month prior to study entry | Oral antibiotics for infection within 2 weeks prior to study entry | History of HIV infection | History of any opportunistic infection | New York Heart Association Class III or IV heart failure | Latent tuberculosis for which anti-tubercular treatment has not been started | Untreated hepatitis B infection | Untreated hepatitis C infection | History of deep venous thrombosis | History of pulmonary embolism | Pregnant or nursing | History of herpes zoster or shingles in the previous 12 months without subsequent herpes zoster vaccination",Prior TNF inhibitor therapy with inadequate response or discontinued due to intolerability/toxicity,ALL,A,"Disease matches and the patient has active RA with prior inadequate response to a TNF inhibitor (adalimumab), fitting the line/prior-exposure requirements; age/sex are eligible and prior biologics (two) and no tsDMARD do not trigger exclusions. No explicit exclusion is evident from available data.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),INCORRECT,B,"No hard exclusions. Disease matches and prior TNFi failure matches the Line/prior anchor. Other anchors are unknown/not applicable (CDAI/HAQ not provided; no stage/met constraints). With exactly one core anchor match and no soft conflicts, the correct grade is B, not A.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04754425,0.929232120513916,Castration-Resistant Prostate Cancer,A Study of Erdafitinib in Castration-Resistant Prostate Cancer Patients Evaluating Markers of Bone Remodeling and FGF Signaling in Plasma and Bone Marrow,"This phase II trial studies the effect of erdafitinib in treating patients with prostate cancer that grows and continues to spread despite the surgical removal of the testes or drugs to block androgen production (castration-resistant). Erdafitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erdafitinib may help control disease in patients with castration-resistant prostate cancer. In addition, studying samples of blood, tissue, plasma, and...","{'id': 205951300, 'name': 'Biopsy', 'description': 'Undergo biopsy', 'other_names': ['BIOPSY_TYPE', 'Bx'], 'intervention_type': 'PROCEDURE'}; {'id': 205951301, 'name': 'Biospecimen Collection', 'description': 'Undergo collection of blood and bone marrow', 'other_names': [], 'intervention_type': 'PROCEDURE'}; {'id': 205951302, 'name': 'Erdafitinib', 'description': 'Given PO', 'other_names': ['Balversa', 'JNJ-42756493'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Castration-Resistant Prostate Cancer (metastatic); Prostate Small Cell Neuroendocrine Carcinoma (metastatic),"Age >= 18 years | Histologically confirmed prostate adenocarcinoma or small cell carcinoma with skeletal metastases | ECOG <=2 | Serum testosterone <= 50 ng/mL and maintenance of castration with LHRH agonist/antagonist or orchiectomy | Documented progressive disease by PSA progression, RECIST 1.1 non-bone disease, or >= 2 new bone lesions (PCWG3) | Prior treatment with a second-generation androgen receptor-targeted agent required (up to two agents) | Prior immunotherapy (e.g., sipuleucel-T, checkpoint inhibitors) or radium-223 allowed | Chemotherapy-naive or up to two prior cytotoxic chemotherapy regimens; last dose >= 3 weeks before study start | Able to swallow oral tablets/capsules","Radiation therapy to primary tumor or metastatic sites within 2 weeks of cycle 1 day 1 | Treatment with another investigational agent or therapeutic clinical study participation within 30 days prior to randomization | Active second malignancy requiring radiotherapy or systemic treatment within the past 1 year, or >= 30% risk of recurrence within 24 months (except non-melanoma skin cancer or Ta urothelial carcinoma) | Chronically uncontrolled hypertension despite therapy (systolic >160 mmHg or diastolic >100 mmHg) | Corneal or retinal abnormality likely to increase risk of eye toxicity, or untreated mature/hypermature senile cataract impairing Amsler grid interpretation | History of central serous retinopathy | History of retinal vascular occlusion | Active wet age-related macular degeneration | Diabetic retinopathy with macular edema (non-proliferative) | Uncontrolled glaucoma | Corneal pathology such as keratitis, keratoconjunctivitis, keratopathy, corneal abrasion, inflammation, or ulceration | Any underlying medical or psychiatric condition that makes study drug hazardous or obscures adverse event interpretation | Unstable angina, myocardial infarction, ventricular fibrillation, Torsades de Pointes, cardiac arrest, or congestive heart failure class III–V within 3 months | Cerebrovascular accident or transient ischemic attack within 3 months | Mobitz II second-degree heart block or third-degree heart block | QTc > 480 ms (Fridericia) confirmed by triplicate at screening | Pulmonary embolism or other venous thromboembolism within 2 months | Known active HIV/AIDS unless on stable ART >= 6 months, no opportunistic infections for 6 months, and CD4 > 350 | Known active hepatitis B or C infection | Not recovered from reversible toxicity of prior anticancer therapy (except non-clinically significant toxicities) | Impaired wound healing (e.g., skin/decubitus ulcers, chronic leg ulcers, known gastric ulcers, or unhealed incisions) | Major surgery within 4 weeks before randomization | Untreated symptomatic spinal cord compression",Prior second-generation androgen receptor-targeted therapy required; Up to two prior cytotoxic chemotherapy regimens allowed; Last cytotoxic chemotherapy dose >= 3 weeks before study treatment; Prior immunotherapy allowed; Prior radium-223 allowed; Ongoing LHRH therapy or prior orchiectomy to maintain castration required,MALE,A,"Disease and stage match metastatic CRPC, with required skeletal metastases present, and the patient meets age/sex criteria and prior AR-targeted therapy exposure (abiraterone and enzalutamide up to two agents). Other requirements (e.g., ECOG, testosterone level, ocular/cardiac history) are not provided but no explicit exclusions are evident from the available data.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches metastatic CRPC with skeletal mets; male, age within range; prior second-gen AR therapy satisfied. At least two core anchors match (stage/setting and line/prior; metastatic pattern also fits). No soft conflicts identified. Grade A is appropriate.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT04919629,0.8971775770187378,Recurrent Clear Cell Ovarian Carcinoma,Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion,"This phase II trial studies the effect of APL-2 when given in combination with either pembrolizumab or pembrolizumab and bevacizumab compared with bevacizumab alone in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent) and a buildup of fluid and cancer cells (malignant effusion). APL-2 may limit tumor progression, decrease malignant effusion production, and improve the immune system's response against cancer cells. Immunotherapy with mo...","{'id': 205998900, 'name': 'Bevacizumab', 'description': 'Given IV', 'other_names': ['ABP 215', 'SIBP 04', 'SIBP-04', 'SIBP04', 'Vegzelma', 'Zirabev', 'Anti-VEGF', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF Monoclonal Antibody SIBP04', 'Anti-VEGF rhuMAb', 'Avastin', 'BAT 1706', 'BAT-1706', 'BAT1706', 'BAT1706 Biosimilar', 'Bevacizumab awwb', 'Bevacizumab Biosimilar ABP 215', 'Bevacizumab Biosimilar BAT1706', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar GB-222', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar QL1101', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab-adcd', 'Bevacizumab-awwb', 'Bevacizumab-bvzr', 'BP102', 'BP102 Biosimilar', 'CT-P16', 'HD204', 'Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer', 'Mvasi', 'MYL-1402O', 'QL1101', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'rhuMab-VEGF', 'SCT501'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205998901, 'name': 'Biopsy', 'description': 'Undergo tumor biopsy', 'other_names': ['BIOPSY_TYPE', 'Bx'], 'intervention_type': 'PROCEDURE'}; {'id': 205998902, 'name': 'Biospecimen Collection', 'description': 'Undergo blood sample collection', 'other_names': ['Biological Sample Collection', 'Biospecimen Collected', 'Specimen Collection'], 'intervention_type': 'PROCEDURE'}; {'id': 205998903, 'name': 'Pegcetacoplan', 'description': 'Given IV and SC', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205998904, 'name': 'Pembrolizumab', 'description': 'Given IV', 'other_names': ['BCD-201', 'Keytruda', 'Lambrolizumab', 'MK-3475', 'Pembrolizumab Biosimilar BCD-201', 'SCH 900475'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205998905, 'name': 'Questionnaire Administration', 'description': 'Ancillary studies', 'other_names': [], 'intervention_type': 'OTHER'}",PHASE2,18 years,Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Ovarian Carcinosarcoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal Clear Cell Adenocarcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,"Age >= 18 years | Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (serous, clear cell, endometrioid, mixed or poorly differentiated, or carcinosarcoma) | Symptomatic ascites or pleural effusion requiring >= 1 drainage within 4 weeks or indwelling drainage catheter in place | ECOG 0-1 | Life expectancy >= 3 months | No known absolute contraindication to bevacizumab and/or pembrolizumab","Receiving additional anticancer therapy or used an investigational drug or device within 3 weeks before first dose | Immunodeficiency or systemic steroid/immunosuppressive therapy within 7 days before first dose | Active autoimmune disease requiring systemic treatment within the past 3 months | Active infection requiring systemic therapy | Uncontrolled hypertension (systolic > 150 mmHg or diastolic > 90 mmHg) | Myocardial infarction or unstable angina within 6 months | New York Heart Association (NYHA) class II or higher congestive heart failure | Peripheral vascular disease grade II or higher | Clinically significant peripheral artery disease (e.g., claudication) within 6 months | Pregnancy or lactation | History of non-infectious pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease | Known HIV infection | Active hepatitis B (HBsAg positive and/or detectable HBV DNA) or active hepatitis C (anti-HCV Ab positive with detectable HCV RNA) | Receipt of investigational (non-licensed) vaccines | Additional malignancy that is progressing or required active treatment within the past 2 years (except certain skin cancers or carcinoma in situ, excluding bladder CIS) | Any condition, therapy, or laboratory abnormality that could confound results or is not in the patient's best interest per investigator",No prior pembrolizumab or other immune checkpoint inhibitor within 9 weeks prior to enrollment; No other anticancer therapy within 3 weeks before first dose; No investigational drug or device within 3 weeks before first dose,FEMALE,A,"Disease and setting match (recurrent epithelial ovarian cancer with malignant pleural effusion) and prior therapy compatibility is met (no prior checkpoint inhibitor; prior bevacizumab allowed). Age/sex fit; no explicit exclusions identified, though drainage frequency for effusion is unspecified.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,"No hard exclusions. Disease matches (recurrent epithelial ovarian/clear cell with malignant effusion) and core anchors met: stage/setting (recurrent) and prior exposure compatibility (no prior IO; prior bev allowed). Effusion drainage requirement is unknown, not a soft mismatch. Age/sex fit; no explicit exclusions noted.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT04925960,0.5075228214263916,PMM2-CDG,"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of Oral Epalrestat Therapy in Pediatric Subjects With Phosphomannomutase 2-congenital Disorder of Glycosylation (PMM2-CDG)","This is a prospective, single-center, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and clinical and metabolic improvement of pediatric subjects with PMM2-CDG on oral epalrestat therapy vs. placebo.","{'id': 205234005, 'name': 'Epalrestat', 'description': ""Epalrestat is a noncompetitive and reversible aldose reductase inhibitor (ARI) used for the treatment of diabetic neuropathy in Japan. The drug's ability to safely improve symptoms of neuropathy alone by reducing oxidative stress, increasing glutathione levels, and reducing intracellular sorbitol accumulation make it a desirable medication for PMM2-CDG patients who commonly suffer with various neuropathies. However, work recently conducted by Perlara, a public benefit company with the mandate to screen existing commercially available drugs for possible application in rare diseases, has demonstrated that Epalrestat can also elevate the level PMM2 produced endogenously. This may reduce the severity of the morbidities associated with PMM2-CDG."", 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205234006, 'name': 'Placebo', 'description': 'The placebo capsule with be identical in appearance to the Epalrestat capsule. It will contain microcrystalline cellulose filler in a gelatin capsule.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,2 years to 17 years,Phosphomannomutase 2 Congenital Disorder of Glycosylation,Age >= 2 and < 18 years | Molecularly confirmed biallelic PMM2 pathogenic variants | Negative urine pregnancy test (females of child-bearing potential) | Agrees to effective contraception or abstinence from prior to randomization through 3 months after treatment (subjects of child-bearing potential),"Other known congenital disorders of glycosylation | Allergy to aldose reductase inhibitors | Hypersensitivity to epalrestat | AST > 5 x ULN within 6 months prior to screening | ALT > 5 x ULN within 6 months prior to screening | Total bilirubin > 2 x ULN within 6 months prior to screening | Albumin < 2.8 mmol/L at screening | Liver fibrosis by elastography (Fibroscan > 7 kPa) at screening | Serum creatinine > 0.5 mg/dL (<= 6 years) | Serum creatinine > 0.7 mg/dL (7-10 years) | Serum creatinine > 1.24 mg/dL (>= 11 years) | Platelet count < 125 x10^9/L | Hemoglobin < 10 g/dL | Any other clinically significant laboratory abnormality per investigator | Use of an investigational drug (including acetazolamide) within 28 days | Use of an investigational biologic within 12 months | Concurrent or planned participation in another interventional protocol or use of other unapproved therapeutics | Any other medical condition that interferes with protocol compliance, compromises safety, or interferes with interpretation of results",Washout from investigational drugs >= 28 days; Washout from investigational biologics >= 12 months,ALL,A,"Disease and required biomarker (biallelic PMM2 variants) match, and the patient’s age (8) and sex are eligible. Line/prior exposure is compatible (no prior investigational therapy), with no identified soft conflicts.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,A,No hard exclusions. Disease matches. Core anchors: (1) Line/prior exposure compatible (no investigational therapy) and (2) required biomarker (biallelic PMM2) satisfied. Stage/setting is neutral/unknown; no soft conflicts identified. Meets A per rubric.,,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT04991870,0.8363864421844482,Recurrent Glioblastoma,A Phase I Clinical Trial With a Window-of-Opportunity Component of Engineered NK Cells Containing Deleted TGF-ßR2 and NR3C1 in Recurrent Grade 4 Astrocytoma (Glioblastoma),"This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer (NK) cells containing deleted TGF-betaR2 and NR3C1 (cord blood \[CB\]-NK-TGF-betaR2-/NR3C1-) in treating patients with glioblastoma that has come back (recurrent). CB-NK-TGF-betaR2-/NR3C1- cells are genetically changed immune cells that may help to control the disease.","{'id': 206583361, 'name': 'Cord Blood-derived Expanded Allogeneic Natural Killer Cells', 'description': 'Given CB-NK-TGF-betaR2-/NR3C1- intratumorally', 'other_names': ['Allogeneic CB-derived Ex vivo-expanded NK Cells', 'Umbilical Cord Blood-derived Expanded Allogeneic Natural Killer Cells', 'CB-derived Expanded Allogeneic NK Cells', 'UCB-derived Expanded Allogeneic NK Cells'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206583362, 'name': 'Resection', 'description': 'Undergo surgical resection', 'other_names': ['Surgical Resection'], 'intervention_type': 'PROCEDURE'}",PHASE1,12 years,Glioblastoma (recurrent); Gliosarcoma (recurrent),"Age >= 12 years | Histologically confirmed supratentorial WHO grade 4 recurrent astrocytoma, including recurrent glioblastoma (IDH-wildtype), recurrent IDH-mutant grade 4 astrocytoma, or recurrent gliosarcoma | Prior radiation therapy and temozolomide required | Karnofsky Performance Score >70% (Lansky >70% if <16 years) | >= 12 weeks since conformal radiation unless RANO early progression criteria are met | Baseline brain MRI with advanced brain tumor imaging within 30 days prior to registration | If recent surgery: >= 3 weeks from resection or >= 1 week from stereotactic biopsy and recovered from complications | Adequate hematologic function | Adequate hepatic function | Adequate renal function | Surgical cohort: at least 1 cm^2 of contrast-enhancing disease resectable by neurosurgeon","Prior therapy with Gliadel | Prior therapy with bevacizumab | Prior interstitial brachytherapy, implanted chemotherapy, or locally delivered therapeutics | Participation in another investigational study or device within 4 weeks of last dose | Planning to continue or start Optune during this trial | Severe hypersensitivity to monoclonal antibodies, history of anaphylaxis, or uncontrolled asthma within 5 months | Known HIV infection | Known HTLV-1 or HTLV-2 infection | Active hepatitis B infection | Active hepatitis C infection | Diagnosis of immunodeficiency or use of immunosuppressive therapy within 7 days prior to registration | Chemotherapy or targeted small molecule therapy within 2 weeks prior to Day 0 (<= Grade 2 neuropathy excepted) | Major surgery (other than craniotomy) without adequate recovery prior to starting therapy | Radiation therapy within 12 weeks prior to registration unless RANO early progression criteria are met | Immune checkpoint inhibitor therapy (anti-PD-1, anti-PD-L1, anti-CTLA-4) within 3 months prior to registration | Another malignancy that is progressing or requires active treatment (specified exceptions allowed by PI) | Known gliomatosis cerebri | Extracranial disease | Tumor localized primarily to brainstem or spinal cord | Brain midline shift >0.5 cm or pending herniation on baseline MRI | Tumor size >5 cm in greatest diameter | Active autoimmune disease requiring systemic treatment within past 3 months or history of clinically severe autoimmune disease, or syndrome requiring systemic steroids or immunosuppressive agents (specified exceptions allowed) | Evidence of interstitial lung disease or active non-infectious pneumonitis | Active infection requiring systemic therapy or that may interfere with participation per investigator | Any condition, therapy, or laboratory abnormality that could confound results or is not in participant's best interest per investigator | Psychiatric or substance abuse disorders interfering with trial requirements | Pregnant, breastfeeding, or planning to conceive or father a child during the study and for 3 months after last dose | Live vaccine within 30 days prior to first dose | Contraindication to MRI | Bleeding diathesis or coagulopathy | On full-dose anticoagulants or antiplatelet therapy that cannot be held | Significant hemorrhage on baseline MRI (>1 cm acute blood) | Prior organ transplantation, including allogeneic stem-cell transplantation (except transplants not requiring immunosuppression) | Multifocal glioblastoma requiring distinct radiotherapy ports (satellite lesions within same port permitted)",Prior radiation therapy required; Prior temozolomide required; Washout: >= 12 weeks since radiation unless RANO early progression criteria are met; Washout: >= 2 weeks since chemotherapy or targeted small molecule therapy; Washout: >= 4 weeks since investigational agent or device; Washout: >= 3 weeks since surgical resection; Washout: >= 1 week since stereotactic biopsy; No immunosuppressive therapy within 7 days prior to registration; No immune checkpoint inhibitor therapy within 3 months prior to registration; Not using Optune during trial participation,ALL,A,"Recurrent IDH-wildtype glioblastoma with prior surgery, radiation, and temozolomide matches the trial’s disease setting and required prior therapies; age and performance status also fit. No explicit exclusions (e.g., prior bevacizumab/Optune, immunotherapy) are present, and unreported location/size criteria are neutral rather than conflicts.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"No hard exclusions identified. Disease matches (recurrent GBM). Stage/setting matches (recurrent) and prior therapy requirements (RT + temozolomide) are satisfied, meeting ≥2 core anchors. Age/sex fit and no soft mismatches noted; unknown exclusionary details (e.g., bevacizumab, tumor size/location) remain neutral. Grade A is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05003310,1.0,Rheumatoid Arthritis,Multipart Exploratory Study to Evaluate Splenic Nerve Stimulation in Patients With Rheumatoid Arthritis,"This study will evaluate the safety, tolerability, and effects of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which consists of a lead, implantable pulse generator, external components and accessories. The study will consist of 4 study periods, including a Randomized Control Trial period (Period 1), an Open Label period (Period 2), a Treat-to-target period (Period 3), and a Long-term Follow-up period (Period 4). Participants eligible for implant will have activ...","{'id': 205483473, 'name': 'Active Stimulation', 'description': 'Stimulation will be turned ON and applied during each day of the period.', 'other_names': [], 'intervention_type': 'DEVICE'}; {'id': 205483474, 'name': 'Sham Stimulation', 'description': 'Sham stimulation will be provided during the period', 'other_names': [], 'intervention_type': 'DEVICE'}; {'id': 205483475, 'name': 'Baricitinib', 'description': 'Baricitinib (2 mg) is administered daily during the period.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205483476, 'name': 'Background Treatment', 'description': 'Stable dose of standard background treatment (e.g., csDMARD therapy)', 'other_names': [], 'intervention_type': 'DRUG'}",NA,22 years to 75 years,Rheumatoid Arthritis,Rheumatoid arthritis >= 6 months per 2010 ACR/EULAR criteria | Age 22-75 years | Active rheumatoid arthritis | Inadequate response to at least 2 biologic DMARDs and/or JAK inhibitors including at least one TNF inhibitor | Appropriate washout from previously used biologic DMARDs or JAK inhibitor | Currently receiving standard-dose conventional synthetic DMARD(s) or documented failure due to ineffectiveness or intolerance,"Significant psychiatric disease or substance abuse | History of unilateral or bilateral vagotomy | Active or latent tuberculosis | Known HIV infection | Current acute or chronic hepatitis B or hepatitis C | Previous hepatitis B infection | Positive SARS-CoV-2 PCR at screening | Currently implanted electrically active medical devices (e.g., pacemaker, ICD) | Previous splenectomy",Inadequate response to >=2 biologic DMARDs and/or JAK inhibitors including >=1 TNF inhibitor; Washout required from previously used biologic DMARDs or JAK inhibitor; On current conventional synthetic DMARD(s) or documented failure due to ineffectiveness or intolerance,ALL,A,"Disease matches RA; patient is 55 (within 22–75), has active RA, and has inadequate response to ≥2 biologic DMARDs including a TNF inhibitor (adalimumab), aligning with trial requirements. No explicit exclusion conflicts are provided.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),INCORRECT,B,"No hard exclusions. Disease matches. The only clear CORE ANCHOR match is line/prior-exposure (inadequate response to ≥2 biologics including a TNF inhibitor). Age fit and “active RA” are not core anchors per rubric. With exactly 1 anchor match and no soft conflicts, the correct grade is B, not A.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT05032040,0.8316181302070618,Castration-Resistant Prostate Cancer,A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer,"This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.","{'id': 205983743, 'name': 'vudalimab', 'description': 'Monoclonal bispecific antibody', 'other_names': [], 'intervention_type': 'BIOLOGICAL'}",PHASE2,18 years,Cervical Carcinoma; Clear Cell Carcinoma; Endometrial Cancer; Metastatic Castration-Resistant Prostate Cancer; Ovarian Cancer,"Age >= 18 years | Cancer progressed after standard-of-care therapy approved for that indication | Histologically confirmed persistent or recurrent clear cell carcinoma of the ovary, peritoneum, or endometrium after platinum-based systemic chemotherapy | Histologically confirmed persistent or recurrent high-grade serous carcinoma of the ovary, fallopian tube, or peritoneum after platinum-based systemic chemotherapy (excluding carcinosarcoma) | Recurrent or metastatic cervical carcinoma previously treated with standard-of-care systemic chemotherapy and FDA-approved immunotherapy if eligible | Advanced endometrial carcinoma that is microsatellite stable (MSS)/MMR proficient, not a candidate for curative surgery or radiation, progressed after <= 1 prior line of systemic therapy, and prior treatment with an FDA-approved combination of a checkpoint inhibitor and a targeted agent | Metastatic castration-resistant prostate cancer with castrate level of testosterone < 50 ng/dL after surgical castration or on medical androgen ablation | Documented progressive mCRPC by at least one of: PSA progression (>= 2 rises >= 1 week apart), soft-tissue progression per RECIST 1.1, or progression of bone disease or >= 2 new bone lesions on bone scan | Measurable disease by RECIST 1.1 in Stage 1; mCRPC without measurable disease eligible in Stage 2 | Adequate available archival tumor tissue and/or adequate predose fresh tumor biopsy | ECOG performance status 0–1","Receiving other anticancer therapies (mCRPC may continue LHRH analogue therapy) | More than 2 prior chemotherapy regimens for cervical cancer, clear cell carcinoma, HGSOC, or mCRPC cohorts | Progression on more than 2 prior androgen receptor signaling inhibitor therapies (mCRPC cohort) | Prior treatment with a CTLA-4–targeted agent | Prior treatment with PD-1/PD-L1/PD-L2–directed therapy (except permitted in MSS endometrial cancer and cervical cancer per approved settings) | Any anticancer therapy within 2 weeks before start of study drug | History of life-threatening (Grade 4) immune-mediated adverse event with prior immunotherapy | Failure to recover from immunotherapy-related toxicity to <= Grade 1 (except controlled endocrinopathy on hormone replacement) | Failure to recover from other cancer therapy–related toxicity to <= Grade 2 | Active central nervous system metastases or carcinomatous meningitis | Active known or suspected autoimmune disease requiring systemic therapy (with specified exceptions such as vitiligo, type 1 diabetes, controlled hypothyroidism, adrenal insufficiency on low-dose steroids, certain skin conditions without systemic therapy, or arthritis controlled without systemic therapy) | Systemic corticosteroids or other immunosuppressive medications within 14 days prior to first dose (with specified exceptions) | Receipt of an organ allograft | History of small or large bowel obstruction within 3 months (palliative diverting ostomy allowed if symptom-free > 3 months) | Ongoing bowel perforation, bowel fistula, or intra-abdominal abscess | Refractory ascites requiring drainage more often than every 4 weeks | Histologic diagnosis of ovarian carcinosarcoma | Symptomatic spinal cord compression or impending cord compression | Serious uncontrolled medical disorder that could pose risk or interfere with study | Serious bacterial, viral, parasitic, or systemic fungal infection within 30 days prior to first dose | Receipt of a live-virus vaccine within 30 days prior to first dose (non-live seasonal flu and COVID-19 vaccines permitted with timing restrictions) | HIV-positive with CD4 < 350 cells/µL, HIV viral load > 400 copies/mL, AIDS-defining opportunistic infection within 12 months, or not on established ART >= 4 weeks prior to dosing | Positive test for hepatitis C RNA | Positive hepatitis B surface antigen or core antibody (unless HBsAg negative and HBV DNA negative with ongoing monitoring) | Pregnant or breastfeeding | Positive urine pregnancy test","Progressed after standard-of-care therapy for the tumor type; Platinum-based systemic chemotherapy required for clear cell and high-grade serous ovarian/fallopian tube/peritoneal carcinoma cohorts; Prior FDA-approved immunotherapy required for recurrent or metastatic cervical cancer if eligible; Prior FDA-approved combination of a checkpoint inhibitor and a targeted agent required for MSS endometrial cancer cohort; No more than 2 prior chemotherapy regimens for cervical, clear cell, HGSOC, or mCRPC cohorts; No other anticancer therapy within 2 weeks before study drug; LHRH analogue therapy may be continued in mCRPC",ALL,A,"Disease and setting match the mCRPC cohort; age/sex fit, and prior therapy history (ADT with abiraterone and enzalutamide progression) aligns with requirements without violating limits on ARSI or chemotherapy exposure. No disallowed prior PD-1/CTLA-4 or other explicit exclusions are evident; eligibility depends on standard requirements like castrate testosterone and ECOG 0–1.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions identified. Disease matches mCRPC cohort; stage/setting match and prior-exposure compatibility (≤2 ARSIs, no excessive chemo) provide ≥2 core anchor matches. No soft conflicts noted. Unknowns like castrate testosterone and ECOG are not grounds for F and don’t create a soft mismatch. Grade A is appropriate per rubric.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05039281,0.8363864421844482,Recurrent Glioblastoma,Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (Anti-PD-L1) in Combination With Cabozantinib in Patients With Recurrent Glioblastoma (rGBM),"This phase I/II trial tests the safety and side effects of atezolizumab in combination with cabozantinib and whether they work to shrink tumors in patients with glioblastoma that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ...","{'id': 205869154, 'name': 'Atezolizumab', 'description': 'Given IV', 'other_names': ['RO5541267', 'Tecentriq', 'MPDL 3280A', 'MPDL 328OA', 'MPDL-3280A', 'MPDL3280A', 'MPDL328OA', 'RG7446'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205869155, 'name': 'Cabozantinib', 'description': 'Given PO', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,18 years,Glioblastoma (recurrent); Gliosarcoma (recurrent),"Age >= 18 years | Histologically confirmed WHO grade IV glioma (glioblastoma or gliosarcoma) | Previously treated with radiation and temozolomide | >= 12 weeks since completion of concurrent chemoradiation | Karnofsky performance status >= 60% | First or second recurrence | ANC >= 1,500/µL | Platelets >= 100,000/µL | Hemoglobin >= 9 g/dL | Serum creatinine <= 1.5 x ULN or creatinine clearance >= 60 mL/min | Urine protein/creatinine ratio <= 1 mg/mg or 24-hour urine protein <= 1 g | Total bilirubin <= 1.5 x ULN (or direct bilirubin <= ULN) | AST <= 2.5 x ULN and ALT <= 2.5 x ULN | Serum albumin >= 2.8 g/dL | INR or aPTT <= 1.3 x ULN","Prior interstitial brachytherapy, implanted chemotherapy, or locally delivered therapeutics (including Gliadel wafers or convection-enhanced delivery) | Radiation therapy for bone metastasis within 2 weeks or other radiation within 4 weeks; radionuclide therapy within 6 weeks before first dose | Clinically relevant ongoing complications from prior radiation therapy | History of cavitating pulmonary lesions or known endotracheal/endobronchial disease | Malignancy other than study disease within 5 years (except certain in situ/skin cancers or CLL Rai 0 under surveillance) | Leptomeningeal disease, gliomatosis cerebri, extracranial disease, or multifocal glioblastoma | History of interstitial lung disease or active, non-infectious pneumonitis | Active infection requiring systemic therapy | History of idiopathic pulmonary fibrosis, organizing pneumonia, or active pneumonitis (radiation fibrosis allowed) | HIV infection, active hepatitis B, or active hepatitis C (exceptions for resolved HBV or HCV RNA negative) | Active tuberculosis | Severe infections within 4 weeks; signs or symptoms of infection within 2 weeks; systemic antibiotics within 2 weeks before cycle 1 day 1 (prophylaxis allowed) | Need for major surgery within 2 weeks or minor surgery within 10 days before first dose; incomplete wound healing | Live attenuated vaccine within 4 weeks before first dose or during study (and for 5 months after atezolizumab) | Concomitant chemotherapy, hormonal therapy, immunotherapy, or radiotherapy while on study | Prior anti-PD-1 or anti-PD-L1 therapy | Prior anti-angiogenic (e.g., anti-VEGF) therapy | Systemic anticancer therapy (cytotoxic, biologic, investigational) within 4 weeks before first dose | Small molecule kinase inhibitor within 2 weeks before first dose | Systemic immunostimulatory agents (e.g., IFN, IL-2) within 6 weeks or 5 half-lives (whichever is shorter) before first dose | Systemic immunosuppressive medications within 2 weeks before first dose (specified exceptions allowed) | Severe allergic or hypersensitivity reactions to chimeric/humanized antibodies, fusion proteins, or components of cabozantinib | Prior allogeneic bone marrow or solid organ transplantation | Recent intracranial hemorrhage on postoperative MRI (minor stable findings allowed) | Lesions invading or encasing major blood vessels (intrahepatic vasculature invasion permitted) | QTcF > 500 ms | Inability to swallow tablets | Inadequately controlled hypertension (systolic > 140 mmHg or diastolic > 90 mmHg) | History or active nephrotic syndrome | Prior hypertensive crisis or hypertensive encephalopathy | Congestive heart failure NYHA grade >= II | Myocardial infarction or unstable angina within 6 months | Stroke or transient ischemic attack within 6 months | Significant vascular disease within 6 months (e.g., aortic aneurysm requiring repair, recent peripheral arterial thrombosis) | Clinically significant hematuria, hematemesis, or hemoptysis (> 0.5 teaspoon) within 12 weeks; significant bleeding history or bleeding diathesis/coagulopathy | Major surgery, open biopsy, intracranial biopsy, ventriculoperitoneal shunt, or significant traumatic injury within 28 days before enrollment | Core biopsy (excluding intracranial) or other minor procedure within 10 days before enrollment; central venous access within 2 days before cabozantinib | History of abdominal fistula, bowel obstruction, GI perforation, or intra-abdominal abscess within 6 months | Tumor invading the GI tract; active peptic ulcer disease; inflammatory bowel disease; diverticulitis; cholecystitis; symptomatic cholangitis or appendicitis; acute pancreatitis; acute pancreatic or bile duct obstruction; gastric outlet obstruction | History of intracranial abscess within 6 months | Serious non-healing wound, active ulcer, or untreated bone fracture | Uncompensated or symptomatic hypothyroidism | Moderate to severe hepatic impairment (Child-Pugh B or C) | Concomitant anticoagulation with warfarin, dabigatran, betrixaban, or platelet inhibitors (e.g., clopidogrel) (specified LMWH/Xa inhibitor exceptions allowed)",Prior radiation therapy and temozolomide required; At least 12 weeks since completion of concurrent chemoradiation; No systemic anticancer therapy within 4 weeks prior to first dose; No small molecule kinase inhibitor within 2 weeks prior to first dose; No radionuclide therapy within 6 weeks prior to first dose; No radiation therapy for bone metastasis within 2 weeks or other radiation within 4 weeks prior to first dose; No systemic immunostimulatory agents within 6 weeks or 5 half-lives prior to first dose; No systemic immunosuppressive medications within 2 weeks prior to first dose,ALL,A,"Recurrent GBM after RT/TMZ (first recurrence), age 40, aligns with trial disease/setting and prior-therapy requirements; no prior PD-1/PD-L1 or anti-angiogenic therapy reported. The interval since chemoradiation exceeds 12 weeks (completed adjuvant TMZ and recurred 3 months later), and no explicit exclusions are evident.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"No hard exclusions identified. Disease matches (recurrent GBM), age/sex within bounds, prior RT/TMZ as required, and recurrence setting aligns (first/second recurrence acceptable; narrative implies first). No prior PD-1/PD-L1 or anti-angiogenic therapy listed. ≥12 weeks since chemoradiation is logically satisfied given completion of adjuvant TMZ and later recurrence. At least two core anchors (stage/setting and prior-exposure) match with no soft conflicts. Grade A is appropriate.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT05039801,0.8482123017311096,Recurrent Clear Cell Ovarian Carcinoma,"A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors","To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.","{'id': 206419214, 'name': 'Bevacizumab', 'description': 'Given IV', 'other_names': ['ABP 215', 'Anti-VEGF', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF Monoclonal Antibody SIBP04', 'Anti-VEGF rhuMAb', 'Avastin', 'Bevacizumab awwb', 'Bevacizumab Biosimilar ABP 215', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar GB-222', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar QL1101', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab-awwb', 'Bevacizumab-bvzr', 'BP102', 'BP102 Biosimilar', 'HD204', 'Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer', 'Mvasi', 'MYL-1402O', 'QL1101', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'rhuMab-VEGF', 'SCT501', 'SIBP 04', 'SIBP-04', 'SIBP04', 'Zirabev'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206419215, 'name': 'Glutaminase-1 Inhibitor IACS-6274', 'description': 'Given by PO', 'other_names': ['GLS1 Inhibitor IACS-6274', 'IACS 6274', 'IACS-6274', 'IACS6274', 'IPN 60090', 'IPN-60090', 'IPN60090'], 'intervention_type': 'DRUG'}; {'id': 206419216, 'name': 'Paclitaxel', 'description': 'Given by IV (vein)', 'other_names': ['Anzatax', 'Asotax', 'Bristaxol', 'Praxel', 'Taxol', 'Taxol Konzentrat'], 'intervention_type': 'DRUG'}; {'id': 206419217, 'name': 'Capivasertib', 'description': 'Given by PO', 'other_names': ['AZD5363'], 'intervention_type': 'DRUG'}",PHASE1,18 years,Endometrial Carcinoma; Head and Neck Squamous Cell Carcinoma; Melanoma; Ovarian Clear Cell Carcinoma; Ovarian High Grade Serous Carcinoma; Chondrosarcoma; Non-Small Cell Lung Cancer,Age >=18 years | Histologically or cytologically confirmed advanced solid tumor per part-specific cohorts | Measurable and/or non-measurable lesion assessable by CT or MRI | ECOG performance status <=1 with no deterioration over 2 weeks prior to baseline | Adequate organ function | Left ventricular ejection fraction >=50% | Received at least one prior line of therapy for advanced disease and refractory or ineligible to available therapies,"Prior malignancy within 2 years except certain cured in situ or skin cancers | Primary CNS malignancy or symptomatic CNS metastases (unless treated and stable; steroid washout required) | Unstable cardiac arrhythmia within 6 months | QTcF >450 ms (males) or >470 ms (females) | Recent significant cardiovascular events within 6 months (e.g., MI, unstable angina, CABG, symptomatic peripheral vascular disease, NYHA class III/IV heart failure) | Major surgery within 28 days before first dose or need for major surgery during study | Significant acute or chronic infections | Strong CYP3A4 inducers/inhibitors within 2 weeks of first dose; St. John's Wort within 3 weeks; enzalutamide within 4 weeks | Strong CYP2D6 inhibitors or sensitive CYP3A4 substrates within 7 days of first dose | Radiotherapy within 4 weeks prior to start of study drug (palliative RT allowed if completed >=2 weeks and no further RT planned to same lesion) | History of severe allergy to compounds similar to study drugs | Inability to swallow oral medications or GI conditions precluding adequate absorption | Part B: Severe hypersensitivity to monoclonal antibodies; hypersensitivity to paclitaxel or bevacizumab | Part B: Bowel obstruction or high risk GI conditions (e.g., fistula, perforation, abscess); recto-sigmoid involvement or symptoms of obstruction | Part B: Proteinuria with urine protein:creatinine ratio >=1.0 or dipstick >=2+ (unless 24-hour urine <2 g/24 h) | Part B: Increased bleeding risk or significant cardiovascular disease within 6 months | Part B: Pre-existing peripheral neuropathy >=Grade 2 | Part B: Requires paracentesis within 2 weeks prior to enrollment | Part C: Hypersensitivity to capivasertib | Part C: Diabetes mellitus type I or II or HbA1c >8% | Part C: Severe or uncontrolled liver disease; AST or ALT >2.5 x ULN; total bilirubin >1.5 x ULN | Part C: Clinically significant cardiovascular disease or risk of QT prolongation; mean resting QTc >470 ms; symptomatic or uncontrolled arrhythmias | Part C: Active tuberculosis infection | Part C: Active hepatitis B or C infection | Part C: HIV with viral load >400 copies/mL and CD4 <350 cells/µL or recent AIDS-defining infection; exclusion if on ART with strong CYP3A4/5 interaction | Concurrent anticancer therapy or concomitant medications that may interfere with study drugs","At least one prior line of therapy for advanced disease and refractory or ineligible to available therapies; Prior chemotherapy, radiotherapy, immunotherapy, or investigational therapy completed >=3 weeks or >=5 half-lives with toxicities <= Grade 1; Melanoma cohort: prior PD-1 or PD-L1 therapy for >=12 weeks or 2 response evaluations; Ovarian cancer Part B: recurrent platinum-resistant disease with platinum-free interval <6 months and <5 prior lines of therapy; Radiotherapy washout: >=4 weeks before start of study drug (>=2 weeks if palliative and no further RT planned to same lesion)",ALL,A,"Disease matches an included cohort (ovarian clear cell), and the patient has recurrent/advanced disease with prior platinum-based therapy, meeting stage/setting and prior-therapy requirements. Age/sex fit and no explicit exclusions are evident from the provided data.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),INCORRECT,B,"No hard exclusions. Disease matches and stage/setting (advanced/recurrent) matches. However, the trial requires ≥1 prior line for advanced disease and refractory/ineligible status (and ovarian cohort may require platinum-resistant), which are not confirmed from the patient data. Thus only one core anchor is definitively met; the grader over-claimed prior-therapy compatibility. Correct grade per rubric is B, not A.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05091866,0.8363864421844482,Recurrent Glioblastoma,Pilot Study of Subcutaneously Administered Natural Progesterone for the Treatment of Recurrent GBM,"This early phase I trial identifies the best dose, possible benefits and/or side effects of natural progesterone in treating patients with glioblastoma that has come back (recurrent). Progesterone is a type of hormone made by the body that plays a role in the menstrual cycle and pregnancy. Progesterone may help control tumor growth and spread in patients with glioblastoma.","{'id': 205898946, 'name': 'Quality-of-Life Assessment', 'description': 'Ancillary studies', 'other_names': ['Quality of Life Assessment'], 'intervention_type': 'OTHER'}; {'id': 205898947, 'name': 'Questionnaire Administration', 'description': 'Ancillary studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 205898948, 'name': 'Therapeutic Progesterone', 'description': 'Given SC', 'other_names': ['Corlutina', 'Corluvite', 'Corpus luteum hormone', 'Cyclogest', 'Gestiron', 'Gestone', 'Lipo-Lutin', 'Luteohormone', 'Lutocyclin', 'Lutocylin M', 'Lutogyl', 'Lutromone', 'Progestasert', 'Progesterone', 'Progestin', 'Progestogel', 'Progestol', 'Progeston', 'Prolidon', 'Proluton', 'Syngesterone', 'Utrogestan'], 'intervention_type': 'BIOLOGICAL'}",EARLY_PHASE1,18 years,Glioblastoma (recurrent); Gliosarcoma,"Pathologic confirmation of glioblastoma or gliosarcoma at initial or subsequent surgery | Up to two prior salvage agents for treatment of recurrent GBM allowed | Age >= 18 years | Measurable recurrent GBM with >= 1 cm^3 contrast-enhancing disease on MRI within 14 days prior to therapy | Life expectancy >= 12 weeks | Karnofsky Performance Status >= 60 | WBC >= 3,000/µL | ANC >= 1,500/µL | Platelets >= 75,000/µL | Hemoglobin >= 9.0 g/dL | AST <= 2 x ULN | ALT <= 2 x ULN | Bilirubin <= 2 x ULN | Creatinine <= 1.5 mg/dL","MRI-incompatible implants or metal making MRI unsafe (e.g., pacemakers, aneurysm clips, neurostimulators, cochlear implants, metal in ocular structures, certain occupational metal exposure) | Significant uncontrolled medical illnesses that would compromise tolerance of therapy | History of severe hepatic dysfunction or liver disease | History of idiopathic jaundice, severe pruritus, or pemphigoid gestationis during pregnancy | History of breast or genital tract cancer | History of any other invasive cancer (except non-melanoma skin cancer and carcinoma in situ) unless in complete remission and off therapy for >= 3 years | Active infection or serious intercurrent medical illness | Receipt of any anti-tumor agents (including investigational) within 4 weeks prior to starting progesterone | Currently receiving anticoagulation therapy | Active or recent (within 6 months) thromboembolic disease | Current therapy with estrogen or progesterone (including hormonal contraceptives); must discontinue >= 7 days prior to initiation | Known allergy to progesterone | Active vaginal bleeding in females | Enrollment on another therapeutic trial receiving anti-tumor therapy",Up to two prior salvage agents for recurrent GBM allowed; Washout >= 4 weeks from prior anti-tumor therapy before starting progesterone; Discontinue estrogen/progesterone therapy (including hormonal contraceptives) >= 7 days before initiation,ALL,A,"Recurrent glioblastoma matches the trial disease and the setting, and prior therapy history with >4-week washout is compatible; age and sex are allowed. Performance status is likely adequate (ECOG 1 ~ KPS ≥60), with no conflicting exclusions noted; measurable disease and labs are unspecified but not hard exclusions.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease and recurrent setting match. Line/prior exposure compatible (standard prior therapy, >4-week washout implied). No required biomarkers. No identified soft conflicts. Meets ≥2 core anchors (stage/setting and line/prior), so A is appropriate.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT05107674,0.9999872446060181,Metastatic Urothelial Carcinoma,"A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types","This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.","{'id': 206205261, 'name': 'NX-1607', 'description': 'Oral NX-1607', 'other_names': ['Cbl-b Inhibitor'], 'intervention_type': 'DRUG'}; {'id': 206205262, 'name': 'Paclitaxel', 'description': 'Paclitaxel IV', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,18 years,Cervical Cancer; Diffuse Large B-Cell Lymphoma; Gastric Cancer; Gastroesophageal Junction Cancer; Head and Neck Squamous Cell Carcinoma; Malignant Pleural Mesothelioma; Metastatic Castration-Resistant Prostate Cancer; Metastatic Urothelial Carcinoma; Melanoma (metastatic or unresectable); Microsatellite Stable Colorectal Carcinoma; Non-Small Cell Lung Cancer; Ovarian Cancer (epithelial); Richter Transformation; Triple Negative Breast Cancer,"Age >= 18 years | Measurable disease by disease-specific response criteria | Metastatic or unresectable disease and no suitable standard treatment options | ECOG performance status 0–1 | Minimum of 3 weeks or 5 half-lives (whichever is shorter) since last systemic cancer therapy | Minimum of 2 weeks since last radiotherapy | Minimum of 6 weeks since last nitrosoureas, antibody-drug conjugate, or radio-immuno-conjugate therapy | Adequate organ and bone marrow function without growth factors (limited exception for DLBCL) | Histologic/cytologic diagnosis of one of the specified malignancies (EOC, gastric/GEJ cancer, HNSCC, melanoma, NSCLC, mCRPC, MPM, TNBC, urothelial cancer, cervical cancer, MSS CRC, DLBCL including DLBCL-RT) | Accessible tumor (all cohorts) or lymph node (DLBCL only) for biopsy in Phase 1b","Active untreated brain metastases | Uncontrolled intercurrent illness (e.g., poorly controlled hypertension or diabetes, active infection requiring systemic therapy) | Primary refractory EOC (no response to first platinum regimen or relapse < 6 months after completion) | Psychiatric illness limiting compliance | Unresolved toxicities from prior therapy > Grade 1 (except Grade 2 alopecia or peripheral neuropathy, or patients on endocrine replacement therapy) | History of Grade >= 3 immune-related adverse events with prior immunotherapy | History of uveitis or active autoimmune disease requiring systemic treatment within 2 years (replacement therapy allowed) | Inability to swallow capsules or significant GI disease affecting absorption (e.g., malabsorption, resection of stomach/small bowel, ulcerative colitis, symptomatic IBD, bowel obstruction) | Known hypersensitivity to NX-1607 components | Pregnant or breastfeeding | Major surgery within 4 weeks before first dose or not fully recovered; planned major surgery during study or within 4 weeks after last dose | Live vaccine within 28 days or COVID-19 vaccine within 14 days prior to first NX-1607 dose | Active second malignancy except specified low-risk or remission conditions | HIV-1/2 infection unless well controlled (e.g., CD4 > 350/mm3 and undetectable viral load) | Active hepatitis A (IgM positive), hepatitis B (HBsAg positive), or hepatitis C (HCV RNA positive); HCV with undetectable virus after treatment is eligible; prior HBV exposure allowed if PCR negative | Systemic corticosteroids > 20 mg prednisone equivalent within 15 days (except prophylaxis for contrast reactions or with paclitaxel) or other immunosuppressive drugs within 30 days | Use of high-dose biotin (> 30 mcg/day) within 1 day prior to screening | Significant cardiovascular events within 6 months (myocardial infarction, unstable angina, symptomatic ischemic heart disease, NYHA Class III/IV heart failure, thromboembolic events, or other significant cardiac conditions) | Autologous or allogeneic stem cell transplant within 100 days prior to first dose | Receipt of an investigational product or device within 3 weeks or 5 half-lives (whichever is shorter) prior to first dose | Use of strong or moderate CYP3A4 inducers/inhibitors within specified windows (strong: within 14 days; moderate: within 7 days; or 5 half-lives, whichever is longer) | Prior CAR-T therapy within 30 days prior to first dose","Received and progressed after or are not candidates for standard treatments; Minimum washout: 3 weeks or 5 half-lives (whichever is shorter) since last systemic cancer therapy; Minimum washout: 2 weeks since last radiotherapy; Minimum washout: 6 weeks since last nitrosoureas, antibody-drug conjugate, or radio-immuno-conjugate therapy; Checkpoint inhibitor (PD-1/PD-L1/CTLA-4) washout >= 3 weeks before first dose; Autologous or allogeneic stem cell transplant washout >= 100 days before first dose; CAR-T therapy washout >= 30 days before first dose; Avoid strong CYP3A4 inducers for >= 14 days and moderate CYP3A4 inducers for >= 7 days (or 5 half-lives, whichever longer) before first dose; similar for inhibitors; mCRPC: at least 2 prior lines in advanced setting including androgen receptor-directed therapy and a taxane; MSS CRC: previously treated with >= 2 lines including a fluoropyrimidine, irinotecan, and/or oxaliplatin (and EGFR inhibitor if RAS wild-type)",ALL,A,"Disease and stage match (metastatic urothelial carcinoma), and the patient is post–second line with no suitable standard options, aligning with trial prior-treatment requirements. No explicit exclusions are triggered from the provided data (age/sex fit; no required biomarkers), while other criteria (ECOG, organ function thresholds, washouts) are unknown.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,A,"No hard exclusions apply. Disease matches (metastatic urothelial carcinoma). Stage/setting matches (metastatic/unresectable required). Line/prior-exposure compatible (post–second line, no suitable standard options). No required biomarker. No metastatic pattern restrictions violated. Other criteria (ECOG, washouts, organ function thresholds) are unknown, not conflicts. Thus ≥2 core anchors match with no soft conflicts → A.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05139056,0.8363864421844482,Recurrent Glioblastoma,A Phase I Study of Multiple Doses of Neural Stem Cell-Based Oncolytic Virotherapy (NSC-CRAd-S-pk7) Administered Intracerebrally to Patients With Recurrent High-Grade Gliomas,"This phase I trial studies the effect of multiple doses of NSC-CRAd-S-pk7 in treating patients with high-grade gliomas that have come back (recurrent). NSC-CRAd-S-pk7 consists of neural stem cells that carry a virus, which can kill cancer cells. Giving multiple doses of NSC-CRAd-S-pk7 may kill more tumor cells.","{'id': 206130491, 'name': 'Neural Stem Cells-expressing CRAd-S-pk7', 'description': 'Given intracerebrally', 'other_names': ['CRAd-S-pk7 loaded NSCs', 'NSC-CRAd-S-pk7', 'NSC-CRAd-S-pk7 Virotherapeutic', 'NSCs loaded with CRAd-S-pk7', 'SC-CRAd-Survivin-pk7'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206130492, 'name': 'Resection', 'description': 'Undergo surgical resection', 'other_names': ['Surgical Resection'], 'intervention_type': 'PROCEDURE'}",PHASE1,18 years,Anaplastic Astrocytoma (recurrent); Anaplastic Oligoastrocytoma (recurrent); Anaplastic Oligodendroglioma (recurrent); Glioblastoma (recurrent); Gliosarcoma (recurrent); Malignant Glioma (recurrent),"Age >= 18 years | Karnofsky performance status >= 70% | Life expectancy >= 3 months | Histologically confirmed grade III or IV glioma, or prior grade II glioma now with radiographic findings consistent with high-grade glioma | Evidence of recurrent supratentorial tumor(s); infratentorial tumor allowed if supratentorial disease amenable to intracavitary Rickham catheter placement | Recurrent/progressive high-grade glioma after prior brain radiation and temozolomide | Requires surgery for tumor resection | No anticipated connection between the post-resection cavity and cerebral ventricles | Absolute neutrophil count >= 1000/µL | Platelet count >= 100000/µL | Total bilirubin <= 2.0 mg/dL | AST <= 4 x ULN | Serum creatinine <= 1 x ULN | >= 6 weeks since nitrosourea-containing chemotherapy | >= 4 weeks since non-nitrosourea cytotoxic chemotherapy (temozolomide exception: >= 23 days after standard 5/28 regimen) | >= 2 weeks since last targeted agent | >= 4 weeks since last bevacizumab","Anti-HLA antibodies specific for HLA Class I antigens (A*01, A*31, B*07, B*15, C*07) expressed by the neural stem cells | Receiving radiation, chemotherapy, or another investigational agent | Prior therapy with neural stem cells | Unresolved toxicity > grade 1 from prior therapies (except alopecia) | Unable to undergo brain MRI | Chronic or active viral infections of the CNS | Coagulopathy or bleeding disorder | Uncontrolled illness including ongoing or active infection | Another active malignancy | Pregnant or breastfeeding | Serious medical or psychiatric illness that could interfere with safety monitoring or completion of treatment",Prior brain radiation required; Prior temozolomide required; >= 6 weeks since nitrosourea-containing chemotherapy; >= 4 weeks since non-nitrosourea cytotoxic chemotherapy (temozolomide exception: >= 23 days after standard 5/28 regimen); >= 2 weeks since last targeted agent; >= 4 weeks since last bevacizumab; No limit to number of prior therapies during treatment schedule escalation,ALL,A,"Recurrent glioblastoma after prior radiation and temozolomide matches the trial’s disease and prior-therapy requirements; age and performance status are compatible with inclusion. Some procedural/lab details (e.g., candidacy for re-resection, supratentorial location, labs/HLA) are unspecified but not hard mismatches.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches (recurrent GBM). Core anchors: Stage/setting matches (recurrent), and Line/prior exposure matches (prior RT and temozolomide with adequate washout). Biomarker and mets/location requirements are unspecified but not conflicting. With ≥2 anchors matching and no soft mismatches, A is appropriate.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT05154994,0.8805802464485168,Metastatic Urothelial Carcinoma,RESOLVE : A Phase I Trial of Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma,"This phase I trial studies the side effects and best dose of belinostat when given together with durvalumab in treating patients with urothelial cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and has spread to nearby tissue or lymph nodes (locally advanced). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow a...","{'id': 206272120, 'name': 'Belinostat', 'description': 'Given IV', 'other_names': ['Beleodaq', 'PXD 101', 'PXD101'], 'intervention_type': 'DRUG'}; {'id': 206272121, 'name': 'Durvalumab', 'description': 'Given IV', 'other_names': ['MEDI-4736', 'MEDI4736', 'Imfinzi', 'Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer'], 'intervention_type': 'BIOLOGICAL'}",PHASE1,18 years,Urothelial Carcinoma (metastatic); Urothelial Carcinoma (locally advanced); Urothelial Carcinoma (unresectable),"Age >= 18 years | Histologically confirmed urothelial carcinoma with metastatic disease or unresectable, locally advanced disease | Variant histology permitted (e.g., neuroendocrine, sarcomatoid, squamous differentiation) | Progressed on at least one prior therapy or declined standard therapy or not a suitable candidate for standard therapy | May have progressed on prior immune checkpoint inhibitor therapy | Body weight > 30 kg | Measurable disease per RECIST 1.1 by CT or MRI | ECOG performance status <= 1 | Absolute neutrophil count >= 1500/µL | Platelet count >= 100,000/µL | Hemoglobin >= 10 g/dL | Total bilirubin <= 1.5 x ULN | AST <= 3 x ULN (<= 5 x ULN with liver metastases) | ALT <= 3 x ULN (<= 5 x ULN with liver metastases) | Estimated creatinine clearance >= 30 mL/min (Cockcroft-Gault) | Negative pregnancy test if applicable; effective contraception during treatment and for at least 4 months after last dose | Recovery to baseline or <= grade 1 from prior treatment toxicities unless clinically non-significant/stable on supportive therapy | Estimated life expectancy >= 12 weeks","UGT1A1 genotypes associated with reduced function (homozygous UGT1A1*28 or heterozygous/homozygous UGT1A1*60) or Gilbert syndrome | Systemic antineoplastic or investigational therapy within <= 14 days or within 5 half-lives before starting study treatment | Prior treatment with durvalumab | Radiotherapy within <= 14 days before first dose (localized palliative bone RT allowed) | Major surgery within <= 3 weeks before starting study drug or not fully recovered | Active/progressive additional malignancy requiring treatment | Known brain metastases or cranial epidural disease unless adequately treated and stable >= 4 weeks and off corticosteroids | Congestive heart failure NYHA class 3 or 4, unstable angina, or serious cardiac arrhythmias | Stroke/TIA, myocardial infarction, other ischemic events, or thromboembolic event within 3 months | Uncontrolled hypertension (sustained systolic >= 160 mmHg or diastolic >= 100 mmHg despite optimal management) | Prolonged QTc > 480 msec or concomitant medications with torsades risk that cannot be discontinued | Adrenal insufficiency | Interstitial lung disease | Congenital long QT syndrome | Current or required use of valproic acid during the study | Active or prior autoimmune or inflammatory disorders requiring systemic therapy (exceptions include vitiligo, alopecia, stable hypothyroidism on replacement, chronic skin conditions not requiring systemic therapy, inactive disease >= 5 years with PI approval, celiac disease controlled by diet) | Prior randomization/treatment in a durvalumab clinical study | History of prior anti–PD-1, anti–PD-L1, or anti–CTLA-4 with toxicity leading to permanent discontinuation, unresolved AEs, prior >= grade 3 immune-related AE (except controlled endocrine <= grade 2), need for additional immunosuppression beyond corticosteroids, recurrence on rechallenge, or current need for > 10 mg prednisone equivalent daily | Current or prior use of systemic immunosuppressive medication within 14 days of C1D1 (except permitted physiologic/locally administered steroids or premedication) | Active primary immunodeficiency | HIV infection with detectable viral load at screening | Active infection including tuberculosis, hepatitis B (HBsAg positive), or hepatitis C with detectable RNA | Live attenuated vaccine within 4 weeks of C1D1 or while on trial | Severe hypersensitivity to study drugs or components, including severe reactions to monoclonal antibodies | Use of prohibited medications without adequate washout (>= 5 half-lives or as clinically indicated) | Any condition that, in the investigator's judgment, poses safety risk or interferes with study compliance (e.g., extensive peritoneal carcinomatosis)",Progressed on >= 1 prior therapy; May have progressed on prior immune checkpoint inhibitor therapy; Washout from systemic antineoplastic or investigational therapy: >= 14 days or >= 5 half-lives before starting study treatment; Radiotherapy washout: > 14 days before first dose,ALL,A,"Metastatic urothelial carcinoma progressed after ≥2 lines aligns with the trial’s metastatic/unresectable setting and prior-therapy requirement, and prior PD-1 exposure is allowed. Age/sex fit, and eGFR 35 mL/min meets the ≥30 mL/min threshold, with no explicit exclusions identified from the provided data.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,A,"No hard exclusions identified. Disease matches. Stage/setting (metastatic) and line/prior exposure (progressed after ≥1 prior; prior PD-1 allowed) both match, meeting ≥2 core anchors. Renal function threshold is met. No soft mismatches noted. Grade A is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05197049,0.6691051721572876,Fistulizing Crohn's Disease,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Crohn's Disease",The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.,"{'id': 206131065, 'name': 'Guselkumab Dose 1', 'description': 'Guselkumab (Dose 1) will be administered by subcutaneous (SC) injection.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206131066, 'name': 'Guselkumab Dose 2', 'description': 'Guselkumab (Dose 2) will be administered by SC injection.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206131067, 'name': 'Guselkumab Dose 3', 'description': 'Guselkumab (Dose 3) will be administered by SC injection.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206131068, 'name': 'Placebo', 'description': 'Placebo will be administered by SC injection.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,18 years,Crohn Disease,"Crohn disease diagnosis for >= 3 months | Moderate to severe Crohn disease per CDAI, stool frequency, abdominal pain score, and SES-CD | Intolerance or inadequate response to conventional or biologic therapy for Crohn disease",Ulcerative colitis or indeterminate colitis | Crohn disease complications requiring surgical intervention or that confound efficacy assessments | Unstable doses of concomitant Crohn disease therapy,Intolerance or inadequate response to conventional or biologic therapy for Crohn disease,ALL,A,"Disease matches (Crohn’s), with moderate-to-severe activity and inadequate response to biologics aligning with inclusion, and age/sex within bounds. No explicit exclusion is triggered by the provided data, despite fistulizing perianal disease.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,A,"Disease matches (Crohn). Patient meets moderate–severe activity and inadequate response to biologics; age/sex within bounds. No explicit exclusion is clearly triggered—perianal fistula with seton does not unambiguously satisfy “requiring surgical intervention” per provided data. ≥2 core anchors (stage/setting and line/prior) match, so A is appropriate.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05226494,0.8363864421844482,Recurrent Glioblastoma,A Phase 1 Trial to Evaluate the Safety and Tolerability of Fb-PMT in Patients With Recurrent Glioblastoma,"Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be effective in heterogeneous, treatment-resistant tumors such as Glioblastoma. fb-PMT also is actively transported across the blood-brain barrier into the brain. This study is being conducted to determine the dose level for further clinical development of fb-PMT to treat recurrent Glioblastoma.","{'id': 206556366, 'name': 'fb-PMT', 'description': 'Daily dosing based on patient weight', 'other_names': ['NP-100', 'NP751'], 'intervention_type': 'DRUG'}",PHASE1,18 years,Glioblastoma (recurrent),Histologically proven intracranial glioblastoma with first or second recurrence | Stable or decreasing dose of corticosteroids if taken prior to screening | Prior completion of and recovery from surgery/biopsy and radiotherapy for glioblastoma | Confirmation of true progressive disease if previously treated with interstitial brachytherapy or stereotactic radiosurgery | Life expectancy > 3 months | Karnofsky Performance Status >= 70 | Hypertension well controlled (<= 95th percentile) on stable doses of medication | Adequate bone marrow and organ function at screening,"Uncontrolled significant medical illness that may obscure toxicity, alter drug metabolism, or compromise study participation | History of another cancer unless in complete remission and off all therapy for that disease for >= 3 months prior to first dose | Use of bevacizumab or any experimental drug or therapy within 28 days before study treatment | Prior therapy with fb-PMT or related drugs | Currently pregnant or breastfeeding | Active infection or serious intercurrent medical illness | Surgery within the preceding 28 days that has not fully healed | Serious or non-healing wound, ulcer, or bone fracture | Known bleeding diathesis or coagulopathy, or a history of bleeding diathesis within 28 days of study treatment | Known thrombophilic condition (protein S, protein C, or antithrombin III deficiency; Factor V Leiden; Factor II G20210A mutation; homocysteinemia; antiphospholipid antibody syndrome) | Evidence of new central nervous system hemorrhage on baseline MRI obtained within 14 days prior to enrollment | Clinically significant cardiovascular event (uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction) within 6 months of screening | New York Heart Association class > 2 heart disease | QTc interval > 450 msec in males or > 470 msec in females at screening | Concomitant medications that prolong the QT/QTc interval or risk inducing Torsades de Pointes | Use of concomitant OATP1B1, OATP1B3, or BSEP inhibitors within 14 days or five half-lives (whichever is longer) before starting study drug | Abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 6 months prior to enrollment | Significant vascular disease (e.g., aortic aneurysm requiring surgical repair, deep venous or arterial thrombosis) within the last 6 months | History of stroke, myocardial infarction, transient ischemic attack, severe or unstable angina, peripheral vascular disease, or grade II or greater congestive heart failure within the past 6 months | History of Torsades de Pointes or risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)",Prior surgery/biopsy and radiotherapy completed and recovered; Washout >= 28 days since bevacizumab or any experimental therapy before study treatment,ALL,A,"Disease and setting match (first recurrence GBM), and prior therapies/line of therapy are compatible with the trial’s allowances. Age and sex meet eligibility, and no exclusion criteria are triggered based on the provided profile.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,No hard exclusions. Disease and recurrent setting match; prior surgery/radiation/temozolomide are allowed with no disallowed exposures noted; age and sex fit. At least two core anchors match (stage/setting and line/prior). No soft conflicts identified.,,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05236036,1.0,Recurrent Glioblastoma,A Phase 1/1b Adaptive Dose Escalation Study of Mycophenolate Mofetil (MMF) in Combination With Standard of Care for Patients With Glioblastoma,"This phase I/Ib trial tests the safety, side effects, and best dose of mycophenolate mofetil in combination with temozolomide and/or radiation therapy (standard of care) in treating patients with glioblastoma. Mycophenolate mofetil is an immunosuppressant drug that is typically used to prevent organ rejection in transplant recipients. However, mycophenolate mofetil may also help chemotherapy with temozolomide work better by making tumor cells more sensitive to the drug. The purpose of this tr...","{'id': 206229958, 'name': 'Mycophenolate Mofetil', 'description': 'Given PO', 'other_names': ['CellCept', 'MMF'], 'intervention_type': 'DRUG'}; {'id': 206229959, 'name': 'Quality-of-Life Assessment', 'description': 'Ancillary studies', 'other_names': ['Quality of Life Assessment'], 'intervention_type': 'OTHER'}; {'id': 206229960, 'name': 'Radiation Therapy', 'description': 'Receive radiation therapy', 'other_names': ['ENERGY_TYPE', 'Irradiate', 'Irradiated', 'Irradiation', 'Radiation', 'Radiation Therapy, NOS', 'Radiotherapeutics', 'Radiotherapy', 'RT', 'Therapy, Radiation', 'Cancer Radiotherapy'], 'intervention_type': 'RADIATION'}; {'id': 206229961, 'name': 'Temozolomide', 'description': 'Given Orally (PO)', 'other_names': ['CCRG-81045', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'M & B 39831', 'M and B 39831', 'Methazolastone', 'RP-46161', 'SCH 52365', 'Temcad', 'Temodal', 'Temodar', 'Temomedac', 'TMZ'], 'intervention_type': 'DRUG'}",PHASE1,18 years,Glioblastoma (IDH-wildtype); Recurrent Glioblastoma; Astrocytoma,"Histologically confirmed glioblastoma, IDH wild-type (IHC R132H negative or sequencing); astrocytoma with molecular features of GBM eligible | Newly diagnosed glioblastoma with prior surgical resection or biopsy; cohort-specific requirements per Group 1-3 | Group 2: Documented MGMT-unmethylated glioblastoma | Group S: Newly suspected or recurrent glioblastoma and scheduled for standard-of-care surgical resection or biopsy | Stable or decreasing corticosteroids at <= 8 mg dexamethasone daily for >= 7 days prior to registration | Age >= 18 years | Karnofsky performance status >= 70% | WBC >= 3,000/µL (within 14 days) | ANC >= 1,500/µL (within 14 days) | Hemoglobin >= 8 g/dL (within 14 days) | Platelets >= 100,000/µL (within 14 days) | Total bilirubin <= 2 x ULN (within 14 days) | AST/ALT <= 3 x ULN (within 14 days) | Creatinine <= 1.5 x ULN (within 14 days) | INR <= 1.5 x ULN (within 14 days) | PT/PTT <= 1.5 x ULN (within 14 days) | Females of childbearing potential: negative pregnancy test within 14 days prior to registration","Receiving other investigational agents (COVID-19 vaccine or treatment allowed) | Prior or concurrent malignancy that may interfere with study treatment or safety (per investigator discretion) | History of allergic reactions to temozolomide or mycophenolate mofetil or similar compounds | Spinal cord and diffuse leptomeningeal disease glioblastoma | Live vaccination within 2 weeks before initiation of MMF and/or TMZ | Current viral-vector based therapy | Uncontrolled epilepsy | Uncontrolled intercurrent illness | Concurrent malignancy outside of glioblastoma requiring tumor-directed treatment | Known hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency (e.g., Lesch-Nyhan or Kelley-Seegmiller syndromes) | Known concurrent shingles, herpes, or cytomegalovirus (CMV) infection | Known concurrent opportunistic fungal infection | Known concurrent or history of unexplained opportunistic infection | Known immunodeficiency that could predispose to opportunistic infections | Psychiatric illness or social conditions limiting compliance or compromising safety | Pregnant or nursing | Unable to swallow oral medication or conditions affecting absorption of oral medication | Known history of HIV, HBV, or HCV infection",Prior surgical resection or biopsy required for Groups 1-3; Group 1: Prior chemoradiation completed; Group 2: Surgical resection or biopsy only (no prior chemoradiation); Group 3: Surgical resection or biopsy only; Group S: Planned standard-of-care surgical resection or biopsy,ALL,A,"Disease and setting match (recurrent IDH-wildtype GBM), required biomarker (IDH-wildtype) is satisfied, and prior chemoradiation/temozolomide are compatible with allowed cohorts. Age/sex fit, and no explicit exclusions are triggered based on available data.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches (recurrent GBM, IDH-wildtype). Core anchors: Stage/setting matches (recurrent cohort exists) and required biomarker matches (IDH-wildtype). No identified soft conflicts; surgery scheduling and labs are unknown, not mismatches. Thus A is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05274243,1.0,Rheumatoid Arthritis,2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis,"This is a phase 2 study to determine 2-HOBA's tolerability, safety, and effect on isoLG-adducts in patients with rheumatoid arthritis (RA) patients. Up to 32 subjects will be randomized to 750mg 2-HOBA or matching placebo three times a day for 4 weeks. As primary outcome measures investigators will compare tolerability and adverse events and changes in isoLG adducts in active and placebo arms. Among prespecified exploratory outcomes investigators will compare changes in markers of inflammatio...","{'id': 206583343, 'name': '2-HOBA', 'description': '2-HOBA acetate (2-Hydroxybenzlamine acetate) 750mg (provided as three 250mg capsules) three times per day for 4 weeks', 'other_names': ['2-hydroxybenzylamine', 'salicylamine', 'IUPAC name: 2-(aminomethyl)phenol'], 'intervention_type': 'DRUG'}; {'id': 206583344, 'name': 'Placebo', 'description': 'Placebo (provided as three capsules) three times a day for 4 weeks', 'other_names': [], 'intervention_type': 'OTHER'}",PHASE2,18 years,Rheumatoid Arthritis,Age >= 18 years | Rheumatoid arthritis meeting 2010 ACR/EULAR classification criteria | >= 4 tender or swollen joints,Pregnant or breastfeeding | Active cancer except non-melanoma skin cancer | Active infection | Concomitant inflammatory autoimmune disease | Major surgery within <= 3 months | Aspirin allergy | Use of monoamine oxidase inhibitors (MAO-I) | Creatinine clearance < 30 mL/min | Prior diagnosis of liver cirrhosis | AST > 1.5 x ULN | ALT > 1.5 x ULN | Total bilirubin >= 1.5 mg/dL,Stable dose of DMARDs for >= 4 weeks prior to enrollment; Stable dose of glucocorticoids for >= 4 weeks prior to enrollment; Discontinue NSAIDs for 2 weeks prior to study and throughout the study,ALL,A,"Disease matches, and the patient is an adult with active RA and prior DMARD/biologic exposure, aligning with the study’s setting and prior-therapy allowances. No explicit exclusion conflicts are evident from the provided data, though some specifics (ACR/EULAR criteria, joint counts, labs/meds) are not specified.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,A,"No hard exclusions. Disease matches. Stage/setting aligns (active RA) and prior-therapy exposure is compatible (no prohibition of prior biologics; stable DMARDs allowed). Other specifics (ACR/EULAR, joint counts, labs/meds) are unknown but not disqualifying. Thus ≥2 anchors (including line/prior) → A.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT05296512,0.8482123017311096,Recurrent Clear Cell Ovarian Carcinoma,A Phase II Trial of Pembrolizumab and Lenvatinib in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary,This research study is being done to test the efficacy and safety of combining the study drugs pembrolizumab and lenvatinib in patients with clear cell ovarian cancer. The names of the study drugs involved in this study are: * Lenvatinib * Pembrolizumab,"{'id': 205793371, 'name': 'Lenvatinib', 'description': 'Lenvatinib is an oral capsule medication that will be taken by mouth once daily, every day of each 21-day treatment cycle. Treatment will be administered on an outpatient basis.', 'other_names': ['Lenvatinib mesilate', 'Lenvima'], 'intervention_type': 'DRUG'}; {'id': 205793372, 'name': 'Pembrolizumab', 'description': 'Pembrolizumab will be administered intravenously (IV) on Day 1 of every 21-day treatment cycle. Treatment will be administered on an outpatient basis.\n\nPembrolizumab will be given up to 35 cycles (approximately 24 months). Participants who stop pembrolizumab treatment with SD or better may be eligible for up to an additional 17 cycles (approximately 12 months) of pembrolizumab treatment (""Pembrolizumab Re-Treatment"") if they progress after stopping pembrolizumab and while receiving lenvatinib.', 'other_names': ['Keytruda'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Ovarian Clear Cell Carcinoma,"Histologically or cytologically confirmed recurrent or persistent ovarian clear cell carcinoma (>=50% clear cell histology) | Measurable disease per RECIST v1.1 | At least one prior platinum-based chemotherapeutic regimen for primary management | Prior bevacizumab allowed | Prior immune checkpoint inhibitor therapy (PD-1/PD-L1/CTLA-4) allowed for up to 30% of participants | Unlimited prior lines for recurrent or persistent disease allowed | Age >= 18 years | ECOG performance status 0–1 (Karnofsky >=70%) | Adequate organ and marrow function per protocol-specified laboratory thresholds | Adequately controlled blood pressure <=140/90 mmHg at screening with no change in antihypertensives within 2 weeks prior to Cycle 1 Day 1 | Brain metastases allowed if clinically stable after local therapy, asymptomatic, radiologically stable for >=4 weeks, and off steroids for >=4 weeks | Other malignancy allowed if it will not interfere with safety or efficacy assessment | Archival tumor tissue available (preferably most recent FFPE; 27 slides requested; fewer may be acceptable upon discussion) | Women of childbearing potential must have negative pregnancy test at Screening and Cycle 1 Day 1 and agree to use adequate contraception; men must agree to contraception","Prior use of lenvatinib | Systemic immunosuppressive therapy (e.g., prednisone >10 mg/day or equivalent) within 2 weeks prior to study treatment, except physiologic replacement or inhaled steroids or prophylactic corticosteroids | Anticancer therapy (chemotherapy, radiotherapy, or investigational therapy) within 4 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C) | Radiation therapy within 2 weeks prior to start; must have recovered from radiation toxicities; no radiation pneumonitis; palliative non-CNS radiation <=2 weeks allowed with >=1 week washout | Use of herbal supplements (e.g., cannabis, St. John's wort, ginkgo biloba, ginseng, saw palmetto, ephedra) within 1 week prior to study treatment | Residual toxicities from prior therapy > Grade 1 (except alopecia and peripheral neuropathy) | Live or live-attenuated vaccine within 30 days prior to first dose | Major surgery within 4 weeks or minor surgery (except port placement) within 1 week prior to study treatment | Proteinuria >=1 g/24 hours on 24-hour urine collection | Evidence of bowel involvement | Gastrointestinal disorders interfering with oral medication absorption or inability to swallow oral medications; enteric tube feeding, TPN, or IV fluid dependence | Significant cardiovascular impairment including uncontrolled hypertension, NYHA class II or higher heart failure, unstable angina, myocardial infarction within 6 months, or serious arrhythmia within 6 months | QTcF >450 ms (males) or >470 ms (females) | Clinically significant bleeding within 4 weeks prior to treatment | Active autoimmune disease requiring systemic treatment within the past 2 years | Diagnosis of immunodeficiency | Known HIV infection | Known active hepatitis B or C infection (history of HCV allowed if treated and cured with undetectable viral load) | History of allogeneic tissue or solid organ transplant | History of non-infectious pneumonitis/interstitial lung disease requiring steroids, or current pneumonitis/interstitial lung disease | Uncontrolled intercurrent illness including active infection or serious non-healing wounds or ulcers | Psychiatric illness or social situations limiting compliance | Allergic reactions to compounds similar to lenvatinib, pembrolizumab, or their excipients | Pregnancy or breastfeeding",Prior platinum-based chemotherapy required; Prior bevacizumab allowed; Prior immune checkpoint inhibitor therapy allowed (up to 30% of participants); Unlimited prior lines for recurrent or persistent disease allowed; Washout: anticancer therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C); Washout: radiation therapy >=2 weeks prior; palliative non-CNS radiation <=2 weeks allowed with >=1 week washout,FEMALE,A,"The patient has recurrent ovarian clear cell carcinoma with prior platinum-based chemotherapy and bevacizumab, matching the trial’s disease and prior-therapy requirements; age and sex also fit. No explicit exclusions are triggered based on available data.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,"Disease matches recurrent ovarian clear cell carcinoma; stage/setting matches (recurrent), prior platinum/bevacizumab exposure fits line/prior requirements, and required clear cell subtype is satisfied. No hard exclusions identified and no clear soft mismatches from available data. Therefore A is appropriate.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05303467,0.8363864421844482,Recurrent Glioblastoma,FRONTIER: A Feasibility Study to Evaluate the Safety of the TheRaSphere GliOblastoma (GBM) Device iN PaTIEnts With Recurrent GBM,"The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.","{'id': 205831688, 'name': 'TheraSphere GBM', 'description': 'Single treatment of TheraSphere GBM device', 'other_names': ['TheraSphere™ GBM Y-90 Glass Microspheres (TheraSphere GBM)'], 'intervention_type': 'DEVICE'}",PHASE1,18 years,Glioblastoma; Glioblastoma (recurrent),"Age >= 18 years | Life expectancy >= 12 weeks | Histologically confirmed glioblastoma per 2021 WHO criteria | Radiographic progression/recurrence with measurable disease (>= 1 cm and <= 5 cm bidirectional diameters) by contrast-enhanced MRI per RANO | Prior surgery and combined radiotherapy and chemotherapy ± Tumor Treating Fields | Prior cranial radiation dose < 66 Gy | WHO performance status <=2 | Interval since completion of cranial radiotherapy > 6 months, or >= 12 weeks with tissue-confirmed recurrence/progression outside prior radiation field | Washout: >= 4 weeks since last temozolomide dose | Washout: >= 6 weeks since last lomustine or other nitrosourea dose | Washout: >= 2 weeks since last small-molecule targeted agent (e.g., TKI) | Washout: >= 6 weeks since last intravenous bevacizumab or other antibody-based VEGF therapy | If on steroids, stable or decreasing dose equivalent to dexamethasone <= 6 mg/day for >= 7 days prior to registration | Adequate organ and bone marrow function | Negative pregnancy test within 14 days prior to registration (for females of childbearing potential) | Angiographic mapping: neurovascular anatomy allows safe microcatheter placement (up to two locations) to infuse TheraSphere GBM to treat all T1-enhancing target lesion | Angiographic mapping: total treatment volume <= 150 cc","Bilateral gadolinium-enhancing disease | Tumor located in the posterior fossa | Tumor involving critical subcortical structures (thalamus/hypothalamus, midbrain, brainstem, corticospinal tract, internal capsule, cerebral peduncle) | Tumor approximating or invading the brainstem | Tumor approximating or invading the optic chiasm | Leptomeningeal disease | Extracranial metastatic disease | More than 1 prior course of external beam cranial radiotherapy | Prior radiosurgery | Prior brachytherapy | Prior hypofractionated radiotherapy | More than 2 prior systemic treatment protocols (excluding maintenance temozolomide) | Prior intra-arterial cerebral infusion therapy | More than 2 prior GBM-related surgical procedures | Prior thoracic radiation therapy | At increased risk of wound dehiscence (e.g., brain surgery within last 3 months, poor skin condition, previously infected surgical field) | Uncontrolled epilepsy | Hypertension grade >= 3 without adequate control on medications | Symptomatic or unstable cardiac disease | Known right-to-left intracardiac shunts | Severe pulmonary hypertension (pulmonary artery pressure > 90 mmHg) | Pulmonary insufficiency with PaO2 < 60 mmHg | Pulmonary insufficiency with oxygen saturation < 90% | Ongoing or active bacterial infection requiring systemic treatment | Ongoing or active viral infection requiring systemic treatment (including HIV) | Pneumonitis | Psychiatric illness or social situation limiting compliance | Peripheral neuropathy >= grade 1 | Any other illness or condition that would interfere with study compliance, safety, endpoints, or longevity per investigator | Currently pregnant or breastfeeding (unless agrees to stop breastfeeding) | Active other malignancy within 1 year prior to registration (except adequately treated non-melanoma skin cancer, lentigo maligna, or carcinoma in situ; or recurrent glioblastoma) | History of ischemic cerebral disease | At risk of cerebral herniation | Contraindication to contrast-enhanced MRI | History of hypersensitivity to iodinated contrast | History of hypersensitivity to gadolinium-based contrast | Receipt of other investigational agents within 4 weeks of treatment | Concurrent participation in another investigational trial that may confound results (without written approval) | Angiographic mapping: significant vascular disease precluding safe/feasible vascular access | Angiographic mapping: significant arteriovenous shunting precluding safe/feasible vascular access | Angiographic mapping: anatomic tortuosity precluding safe/feasible vascular access","Prior surgery required; Prior cranial radiotherapy required; Prior chemotherapy required; Prior Tumor Treating Fields allowed; Washout: >= 4 weeks since last temozolomide; Washout: >= 6 weeks since last lomustine or other nitrosourea; Washout: >= 2 weeks since last small-molecule targeted agent (e.g., TKI); Washout: >= 6 weeks since last intravenous bevacizumab or other antibody-based VEGF therapy",ALL,A,"Recurrent glioblastoma matches the trial disease/setting; the patient had prior surgery and chemoradiation with temozolomide and is ≥18 with ECOG 1, and recurrence occurred ≥3 months after finishing TMZ (meeting washout). No explicit exclusions are evident; required WHO GBM histology is consistent with IDH-wildtype, while imaging/anatomic mapping details are unknown but not hard conflicts.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"No hard exclusions identified. Disease and recurrent setting match; prior surgery/chemoradiation aligns with trial requirements (line/prior exposure). IDH-wildtype is consistent with WHO 2021 GBM. Washout from temozolomide (≥3 months) meets ≥4-week requirement. Imaging/location/angiographic mapping details are unknown but not conflicts. With ≥2 core anchors matched and no soft mismatches, Grade A is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05347095,0.6739141345024109,Fistulizing Crohn's Disease,"A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease","The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety of guselkumab.","{'id': 206132018, 'name': 'Guselkumab', 'description': 'Guselkumab will be administered subcutaneously/IV infusion.', 'other_names': ['CNTO1959'], 'intervention_type': 'DRUG'}; {'id': 206132019, 'name': 'Placebo', 'description': 'Matching placebo will be administered subcutaneously/IV infusion.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,18 years,Perianal Crohn's Disease,"Diagnosis of Crohn's disease for >= 3 months | At least one active draining perianal fistula confirmed by screening MRI | Previously had inadequate initial response, loss of response, or intolerance to therapy from up to 2 classes of advanced drug therapies approved for Crohn's disease (e.g., infliximab, adalimumab, certolizumab pegol, vedolizumab or approved biosimilars) or a JAK inhibitor licensed for Crohn's disease (e.g., upadacitinib)","Very severe luminal Crohn's disease activity | History of rectovaginal fistulas, rectal and/or anal stenosis, stoma or functioning ostomy, undrained abscess/collections, colonic mucosal dysplasia or pre-cancerous lesions not removed, demyelinating disease, or systemic lupus erythematosus | Complications of Crohn's disease anticipated to require surgery or preclude fistula evaluation (e.g., symptomatic strictures/stenoses, short gut syndrome) | Any medical contraindications preventing study participation | History of ongoing, chronic, or recurrent enteral or systemic infectious disease","Prior exposure to up to 2 classes of advanced therapies for Crohn's disease (anti-TNF agents, vedolizumab, or JAK inhibitor such as upadacitinib); Documented inadequate response, loss of response, or intolerance to the above therapies",ALL,A,"Disease and setting match (active draining perianal fistulizing Crohn’s), and prior exposure/inefficacy to advanced therapies (anti-TNF; plus ustekinumab) fits the “up to 2 classes” criterion; age/sex align and no explicit exclusions are evident from provided data.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,A,Disease matches (perianal fistulizing Crohn’s). Two core anchors align: stage/setting (active perianal fistula) and line/prior exposure (inadequate response to two classes: anti-TNF and ustekinumab). Age/sex permitted; no explicit exclusions apparent. Grade A per rubric.,,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT05415098,0.8482123017311096,Recurrent Clear Cell Ovarian Carcinoma,"A Phase I Study of Safety, Pharmacokinetic and Efficacy of Orally Administered APG-5918 in Patients With Advanced Solid Tumors or Hematologic Malignancies","This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918. APG-5918 will be administered orally. Patients will be treated in 28-day cycles.","{'id': 205861505, 'name': 'APG-5918', 'description': 'The investigational drug product is formulated as oral tablets of 50 mg or 200 mg that contain APG-5918 as the active ingredient. APG-5918 will be orally administered once every day on 28-day cycles.\n\nThe dosage of APG-5918 depends on the dose level to which the patient is assigned. Each dose of APG-5918 will be taken orally in fasted condition in the study.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,18 years,B-Cell Lymphoma; Non-Hodgkin Lymphoma; Castration-Resistant Prostate Cancer; Gastric Cancer; Ovarian Clear Cell Carcinoma; Mesothelioma; Nasopharyngeal Carcinoma; Epithelioid Sarcoma; Sarcoma,"ECOG performance status 0–1 (dose escalation) or 0–2 (dose expansion) | Life expectancy >3 months | Histologically or cytologically confirmed locally advanced or metastatic solid tumor or relapsed/refractory non-Hodgkin lymphoma after progression on available therapies with clinical benefit | Measurable disease per RECIST 1.1 for solid tumors | Measurable disease per Cheson criteria for non-Hodgkin lymphoma | B-cell lymphoma: documented EZH2 mutation status or willingness to undergo EZH2 testing | Sarcoma: epithelioid sarcoma or sarcoma with aberrant SMARCB1 preferred | Prostate cancer: evidence of castration resistance with elevated PSA per PCWG3 and serum testosterone <=50 ng/dL | Adequate hematologic, hepatic, and renal function | PT and aPTT <=2 x ULN | Troponin <=2 x ULN | QTcF <=470 ms (mean of triplicate) | Stable brain metastases with controlled neurologic symptoms | Use of effective contraception during treatment and for >=3 months after last dose","Concurrent anti-cancer therapy (chemotherapy, radiotherapy, surgery, immunotherapy, targeted or biologic therapy); except thyroid hormones or estrogen replacement; anti-androgen/agonists allowed to maintain castrate testosterone | Investigational therapy within 14 days or 5 half-lives before first dose | Steroid therapy for anti-neoplastic intent within 7 days before first dose | Unresolved toxicities from prior therapy to < Grade 2 (except alopecia or leukoderma) | Gastrointestinal conditions that could affect absorption of APG-5918 | Therapeutic anticoagulation or antiplatelet agents (except low-dose for catheter patency) | Biologics (G-CSF, GM-CSF, erythropoietin) within 7 days before first dose | Major surgery within 28 days or minor surgery within 14 days before study entry, or inadequate recovery from surgery | Severe cardiac conditions: NYHA class III/IV, significant arrhythmia, CHF, cardiomyopathy | Unstable angina, MI, or coronary revascularization within <=3 months before treatment | LVEF <50% | Poorly controlled hypertension or history of poor adherence to antihypertensives | Symptomatic brain metastases; requirement for steroids for CNS tumor within <=28 days | Active symptomatic fungal, bacterial, or viral infection (well-controlled HIV, HBV, HCV allowed) | Prior treatment with EED inhibitors | Concurrent treatment with QT-prolonging drugs | History of Torsades de Pointes | Allergy/hypersensitivity to APG-5918-like compounds or other EED inhibitors | Other malignancy except cured >3 years, or completely resected basal/squamous skin cancer or carcinoma in situ | Non-Hodgkin lymphoma with prior allogeneic stem cell transplant | Severe/uncontrolled medical conditions that could affect safety or assessments | Long-term steroid therapy above 10 mg prednisone equivalent daily (topical/inhaled allowed) | Pregnant or lactating",Progression after available standard therapies known to confer clinical benefit; No investigational therapy within 14 days or 5 half-lives before first dose; No concurrent anticancer therapy during study treatment; No steroid therapy for anti-neoplastic intent within 7 days before first dose,ALL,A,"Disease matches (ovarian clear cell carcinoma included). The patient is an adult female with recurrent disease after standard therapy, fitting the post-progression setting; no required biomarkers for this cohort and no evident age/sex or explicit exclusion conflicts.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,"Disease matches (ovarian clear cell included). Stage/setting aligns (advanced/recurrent), and line/prior exposure fits the trial’s post-progression requirement after standard therapy. No hard exclusions are known. Measurable disease status is unknown and not a core anchor. Thus ≥2 anchors match with no soft conflicts → A.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT05415098,1.0,Castration-Resistant Prostate Cancer,"A Phase I Study of Safety, Pharmacokinetic and Efficacy of Orally Administered APG-5918 in Patients With Advanced Solid Tumors or Hematologic Malignancies","This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918. APG-5918 will be administered orally. Patients will be treated in 28-day cycles.","{'id': 205861505, 'name': 'APG-5918', 'description': 'The investigational drug product is formulated as oral tablets of 50 mg or 200 mg that contain APG-5918 as the active ingredient. APG-5918 will be orally administered once every day on 28-day cycles.\n\nThe dosage of APG-5918 depends on the dose level to which the patient is assigned. Each dose of APG-5918 will be taken orally in fasted condition in the study.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,18 years,B-Cell Lymphoma; Non-Hodgkin Lymphoma; Castration-Resistant Prostate Cancer; Gastric Cancer; Ovarian Clear Cell Carcinoma; Mesothelioma; Nasopharyngeal Carcinoma; Epithelioid Sarcoma; Sarcoma,"ECOG performance status 0–1 (dose escalation) or 0–2 (dose expansion) | Life expectancy >3 months | Histologically or cytologically confirmed locally advanced or metastatic solid tumor or relapsed/refractory non-Hodgkin lymphoma after progression on available therapies with clinical benefit | Measurable disease per RECIST 1.1 for solid tumors | Measurable disease per Cheson criteria for non-Hodgkin lymphoma | B-cell lymphoma: documented EZH2 mutation status or willingness to undergo EZH2 testing | Sarcoma: epithelioid sarcoma or sarcoma with aberrant SMARCB1 preferred | Prostate cancer: evidence of castration resistance with elevated PSA per PCWG3 and serum testosterone <=50 ng/dL | Adequate hematologic, hepatic, and renal function | PT and aPTT <=2 x ULN | Troponin <=2 x ULN | QTcF <=470 ms (mean of triplicate) | Stable brain metastases with controlled neurologic symptoms | Use of effective contraception during treatment and for >=3 months after last dose","Concurrent anti-cancer therapy (chemotherapy, radiotherapy, surgery, immunotherapy, targeted or biologic therapy); except thyroid hormones or estrogen replacement; anti-androgen/agonists allowed to maintain castrate testosterone | Investigational therapy within 14 days or 5 half-lives before first dose | Steroid therapy for anti-neoplastic intent within 7 days before first dose | Unresolved toxicities from prior therapy to < Grade 2 (except alopecia or leukoderma) | Gastrointestinal conditions that could affect absorption of APG-5918 | Therapeutic anticoagulation or antiplatelet agents (except low-dose for catheter patency) | Biologics (G-CSF, GM-CSF, erythropoietin) within 7 days before first dose | Major surgery within 28 days or minor surgery within 14 days before study entry, or inadequate recovery from surgery | Severe cardiac conditions: NYHA class III/IV, significant arrhythmia, CHF, cardiomyopathy | Unstable angina, MI, or coronary revascularization within <=3 months before treatment | LVEF <50% | Poorly controlled hypertension or history of poor adherence to antihypertensives | Symptomatic brain metastases; requirement for steroids for CNS tumor within <=28 days | Active symptomatic fungal, bacterial, or viral infection (well-controlled HIV, HBV, HCV allowed) | Prior treatment with EED inhibitors | Concurrent treatment with QT-prolonging drugs | History of Torsades de Pointes | Allergy/hypersensitivity to APG-5918-like compounds or other EED inhibitors | Other malignancy except cured >3 years, or completely resected basal/squamous skin cancer or carcinoma in situ | Non-Hodgkin lymphoma with prior allogeneic stem cell transplant | Severe/uncontrolled medical conditions that could affect safety or assessments | Long-term steroid therapy above 10 mg prednisone equivalent daily (topical/inhaled allowed) | Pregnant or lactating",Progression after available standard therapies known to confer clinical benefit; No investigational therapy within 14 days or 5 half-lives before first dose; No concurrent anticancer therapy during study treatment; No steroid therapy for anti-neoplastic intent within 7 days before first dose,ALL,A,"Disease and setting match (metastatic castration‑resistant prostate cancer), and the patient has progressed after standard therapies (abiraterone, enzalutamide), aligning with trial requirements. Other specifics (ECOG, measurable disease, testosterone level) are not provided but do not present conflicts.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches (CRPC). Stage/setting matches (metastatic/advanced). Line/prior exposure matches (progressed after standard therapies like abiraterone/enzalutamide). Required subtype (castration-resistant) satisfied. Other criteria (ECOG, measurable disease, testosterone) are unknown, not soft mismatches. Thus ≥2 core anchors match → A.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT05489211,0.8316181302070618,Castration-Resistant Prostate Cancer,"A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours","TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.","{'id': 205944560, 'name': 'Datopotamab deruxtecan (Dato-DXd)', 'description': 'Intravenous (IV) Antibody drug conjugate', 'other_names': ['DS-1062a'], 'intervention_type': 'DRUG'}; {'id': 205944561, 'name': 'Capecitabine', 'description': 'Administered orally', 'other_names': ['Xeloda'], 'intervention_type': 'DRUG'}; {'id': 205944562, 'name': '5-Fluorouracil', 'description': 'Administered as an IV', 'other_names': ['Adrucil'], 'intervention_type': 'DRUG'}; {'id': 205944563, 'name': 'Volrustomig', 'description': 'Administered as an IV', 'other_names': ['MEDI5752'], 'intervention_type': 'DRUG'}; {'id': 205944564, 'name': 'Carboplatin', 'description': 'Administered as an IV', 'other_names': ['Paraplatin'], 'intervention_type': 'DRUG'}; {'id': 205944565, 'name': 'Leucovorin LV', 'description': 'Administered as an IV', 'other_names': ['Folinic acid'], 'intervention_type': 'DRUG'}; {'id': 205944566, 'name': 'Bevacizumab', 'description': 'Administered as an IV', 'other_names': ['Avastin'], 'intervention_type': 'DRUG'}; {'id': 205944567, 'name': 'Rilvegostomig', 'description': 'Administered as an IV', 'other_names': ['AZD2936'], 'intervention_type': 'DRUG'}; {'id': 205944568, 'name': 'Prednisone/ prednisolone', 'description': 'Administered orally', 'other_names': ['Prednisolone'], 'intervention_type': 'DRUG'}; {'id': 205944569, 'name': 'Cisplatin', 'description': 'Administered as an IV', 'other_names': ['Platinol'], 'intervention_type': 'DRUG'}",PHASE2,18 years to 130 years,Biliary Tract Cancer; Colorectal Cancer; Endometrial Cancer; Gastric Cancer; Metastatic Castration-Resistant Prostate Cancer; Ovarian Cancer; Urothelial Cancer,Age >= 18 years | Advanced or metastatic malignancy | ECOG performance status 0–1 with no deterioration over 2 weeks prior to baseline/first dose | Tumor sample available for tissue-based analysis | At least 1 measurable lesion not previously irradiated (Substudy 3 may enroll with non-measurable bone metastatic disease) | Adequate bone marrow reserve and organ function | Life expectancy >= 12 weeks,"Any disease or condition that makes participation undesirable or would jeopardize protocol compliance per investigator | History of another primary malignancy except adequately resected basal cell carcinoma or in situ squamous cell carcinoma of the skin, or other solid malignancy treated with curative intent | Persistent toxicities from prior anticancer therapy (excluding alopecia) not yet improved | Irreversible toxicity not expected to be exacerbated by study intervention (e.g., hearing loss) per investigator | Spinal cord compression or brain metastases unless treated | Leptomeningeal carcinomatosis | Clinically significant corneal disease | Active hepatitis or uncontrolled hepatitis B or C infection | Uncontrolled infection requiring IV antimicrobials | Known HIV infection that is not well controlled | Active tuberculosis infection | Mean resting QTcF > 470 ms or history/risk factors for long QT/TdP | Uncontrolled or significant cardiac diseases | History of non-infectious interstitial lung disease/pneumonitis requiring steroids or severe pulmonary function compromise | Prior exposure to chloroquine/hydroxychloroquine without adequate washout | Receipt of live, attenuated vaccine within 30 days prior to first dose | Prior anticancer therapies without adequate washout or any concurrent anticancer treatment | Palliative radiotherapy within <= 2 weeks or to > 30% of bone marrow within <= 4 weeks before first dose | Major surgery or significant traumatic injury within <= 3 weeks before first dose or anticipated need for major surgery during study | Prior treatment with TROP2-directed therapies or other ADCs with deruxtecan payload | Use of herbal or natural products intended as cancer treatment/prophylaxis that may interfere with study intervention | Previous treatment in the present study | Participation in another clinical study with an investigational intervention/device within 4 weeks prior to first dose or concurrent enrollment | Severe hypersensitivity to datopotamab deruxtecan or its excipients (including polysorbate 80) or other monoclonal antibodies | Females who are pregnant or breastfeeding",Washout required from prior anticancer therapies before enrollment; Palliative radiotherapy washout: > 2 weeks (limited field) and > 4 weeks if > 30% bone marrow irradiated; Major surgery washout: > 3 weeks before first dose; Live attenuated vaccines prohibited within 30 days before first dose,ALL,A,"Disease and metastatic castration-resistant setting match a listed trial cohort, and prior AR-targeted therapies are compatible with the protocol. Age/sex fit the criteria and there are no explicit exclusions noted, though ECOG, organ function, and measurability are not provided.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,A,"Disease (mCRPC) matches a listed cohort; metastatic setting aligns; prior AR-targeted therapies are allowed (no disallowed prior TROP2/deruxtecan ADC exposure). Age/sex within limits; no explicit exclusions known. At least two core anchors match (stage/setting and prior-exposure), with no soft conflicts. A is appropriate.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05549219,0.46250319480895996,PMM2-CDG,"A Phase 2, Randomized, Open-Label, 24-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult, Adolescent, and Pediatric Participants With PMM2-CDG","This is a Phase 2, randomized, open-label, 24-week treatment study to evaluate the potential pharmacodynamic (PD) activity, safety, tolerability, and pharmacokinetics (PK) of GLM101 in adult, adolescent, and pediatric, patients with a confirmed diagnosis of PMM2-CDG. The planned doses of GLM101 to be investigated are 10, 20, and 30 mg/kg. The study will consist of a Screening Period, a 24-week (6-month) Treatment Period, and a 30-day (1-month) Follow-Up Period.","{'id': 205716428, 'name': 'GLM101', 'description': 'GLM101 IV Infusion', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,2 years to 65 years,Phosphomannomutase 2 Deficiency,"Age 2–65 years (cohort dependent) | Molecularly confirmed PMM2-CDG (biallelic pathogenic/likely pathogenic PMM2 variants, or bi-allelic variants plus deficient PMM2 enzyme activity)","Diagnosis of a congenital disorder of glycosylation other than PMM2-CDG | Active infection requiring parenteral antibiotics/antivirals/antifungals or systemic steroids within 7 days prior to screening | Active COVID-19 or positive SARS-CoV-2 test at screening | ALT >3 x ULN | AST >3 x ULN | Total bilirubin >2 x ULN | INR >1.5 | History of severe allergic reaction to GLM101 or its excipients | Known poor venous access | History of liver transplant | Drug or alcohol use disorder within 12 months | Major surgery within 30 days prior to screening | Clinically significant lab abnormalities not related to PMM2-CDG | Positive pregnancy test (female) | Breastfeeding (female) | Hepatitis B surface antigen positive or hepatitis C antibody positive | Any illness that might impact infusion safety or evaluability per investigator/medical monitor | QTc >=450 ms or clinically significant ECG abnormalities | Uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric, or other significant disease | Participation in another interventional study or investigational product within 30 days or 5 half-lives | Weight >75 kg",(none),ALL,A,"Disease and required biomarker (biallelic PMM2 variants) match, and the patient is within the 2–65 year age range with no conflicting prior-therapy requirements. No explicit exclusion criteria are triggered based on available data.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),INCORRECT,B,"Disease and required biomarker match, and no hard exclusions. However, only one CORE ANCHOR (required biomarker) clearly matches; stage/setting and line/prior are unspecified (neutral), so A (which requires ≥2 anchors with at least one stage/line) is not met. Correct grade is B.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05627128,0.6691051721572876,Fistulizing Crohn's Disease,Anti-Inflammatory Diet (Dieta Antiinflamatoria or DAIN in Spanish): a Crohn's Disease Management Strategy Tailored for Puerto Ricans,The goal of the study is to test the efficacy of a dietary intervention in inducing clinical response and remission for patients with Crohn's disease in a randomized controlled trial. The intervention diet: DAIN has been adapted from the Inflammatory Bowel Disease Anti-Inflammatory Diet or IBD-AID™ taking into account the food availability and preferences of Puerto Ricans. DAIN also includes traditional foods commonly consumed in the typical Puerto Rican diet while maintaining the fundamental...,"{'id': 205977498, 'name': 'DAIN', 'description': ""Participants in the experimental arm will have access to the newly created DAIN curriculum including menus, recipes, and recorded 'how to' recipes. Participants in the experimental arm will also have once-per-week dietary counseling with DAIN-trained nutritionists and monthly cooking classes with a DAIN-trained chef."", 'other_names': [], 'intervention_type': 'OTHER'}",NA,21 years to 65 years,Crohn Disease,"Age 21–65 years | Confirmed Crohn disease with sCDAI < 450 | sIBDQ < 60 (moderate to severe impaired quality of life) | Stable doses of thiopurines, natalizumab, or methotrexate for >=12 weeks | Stable doses of anti-TNF agents, ustekinumab, or vedolizumab for >=8 weeks | Stable dose of 5-aminosalicylic acid for >=2 weeks | Stable dose of corticosteroids for >=1 week",Ostomy | Use of Specific Carbohydrate Diet or IBD-AID within 4 weeks | Use of prescribed probiotics within 4 weeks | Prednisone > 20 mg/day or equivalent | Recent Clostridioides difficile colitis | Pregnancy | Symptomatic or significant stricture or history of obstruction within the past 6 months,"Stable thiopurines, natalizumab, or methotrexate for >=12 weeks before screening; Stable anti-TNF, ustekinumab, or vedolizumab for >=8 weeks before screening; Stable 5-aminosalicylic acid for >=2 weeks before screening; Stable corticosteroids for >=1 week before screening",ALL,A,"Disease and setting align (active Crohn’s; age 32 within 21–65), and prior biologic exposure/refractoriness is allowed with no disallowed therapies. No explicit exclusions are triggered; sIBDQ status is unknown but not contradicted.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,A,"No hard exclusions identified. Disease matches Crohn’s; age/sex within limits. Stage/setting aligns (active Crohn’s) and prior exposure/line is compatible (no disallowed therapies or naïve requirements). Required sIBDQ is unknown but not a mismatch; ≥2 anchors match with no soft conflicts, supporting grade A.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05661084,1.0,Dementia,Multifocal Transcranial Current Stimulation for Cognitive and Motor Dysfunction in Dementia,"This project aims to examine the efficacy of remote, caregiver-led tES/brain stimulation intervention targeted to improve memory, mobility, and executive functioning among older adults with mild cognitive impairment or mild dementia.","{'id': 205753140, 'name': 'Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active)', 'description': 'Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex.', 'other_names': ['Transcranial electrical stimulation (tES)'], 'intervention_type': 'DEVICE'}; {'id': 205753141, 'name': 'Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (sham)', 'description': 'A sham transcranial electrical stimulation (tES) will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex. It will physically mimic active stimulation.', 'other_names': ['Transcranial electrical stimulation (sham condition)'], 'intervention_type': 'DEVICE'}; {'id': 205753142, 'name': 'Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham)', 'description': 'Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Active tACS to the left angular gyrus and sham tDCS to the prefrontal cortex.', 'other_names': ['tACS active; tDCS sham'], 'intervention_type': 'DEVICE'}; {'id': 205753143, 'name': 'Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active)', 'description': 'Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Sham tACS to the left angular gyrus and active tDCS to the prefrontal cortex.', 'other_names': ['tACS sham; tDCS active'], 'intervention_type': 'DEVICE'}",NA,55 years,Alzheimer Disease; Dementia,,"Major psychiatric comorbidity (e.g., major depressive disorder, schizophrenia, psychosis) | Blindness or other disabilities that prevent task performance | Contraindications to transcranial electrical stimulation, including a reported seizure within the past 2 years | Use of neuroactive drugs | Presence of implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant) | Active dermatological condition on the scalp (e.g., eczema) | Montreal Cognitive Assessment (MoCA) score <= 18 (participants) | Inability to understand study procedures after informed consent review | Caregiver: Mild cognitive impairment defined by MoCA <= 26 | Caregiver: Poor eyesight, severe arthritis in the hands, pain, deformity, or other condition interfering with administration of tES",(none),ALL,A,"Disease (dementia) matches, age 68 fits the ≥55 requirement, and there are no known explicit exclusions triggered (MoCA not provided, no neuroactive drugs or devices reported). Stage/setting is appropriate for symptomatic dementia, and there are no prior-therapy constraints conflicting with the patient.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),INCORRECT,B,"No hard exclusions. Disease matches. Only one CORE ANCHOR clearly matches (stage/setting). Line/prior exposure is unknown; biomarkers/metastatic pattern not applicable. Age fit is not a CORE ANCHOR. Therefore grade should be B, not A.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT05715216,0.8482123017311096,Recurrent Clear Cell Ovarian Carcinoma,"EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer","To learn if adding etigilimab to nivolumab therapy can help to control clear cell ovarian, fallopian tube, and primary peritoneal cancers that are resistant to platinum-based therapy","{'id': 205693483, 'name': 'Nivolumab', 'description': 'Given by IV (vein)', 'other_names': ['BMS-936558', 'Opdivo'], 'intervention_type': 'DRUG'}; {'id': 205693484, 'name': 'Etigilimab', 'description': 'Given by IV (vein)', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,18 years,Ovarian Clear Cell Carcinoma,"Age >= 18 years | Histologically confirmed recurrent clear cell ovarian, peritoneal, or fallopian tube cancer | Platinum-resistant or refractory disease (progression on platinum therapy or recurrence within 180 days of last platinum) | Measurable disease per RECIST 1.1 | ECOG performance status 0–1 | Adequate organ and marrow function | Postmenopausal or negative serum pregnancy test for women of childbearing potential | Previously treated, asymptomatic, or small brain metastases allowed if clinically stable >=4 weeks and off steroids >=14 days; asymptomatic brain metastases allowed with regular imaging","Participation in another interventional study within 28 days | Prior treatment with CD137 agonists, anti-TIGIT, anti-CTLA-4, or anti-PD-1/PD-L1 antibodies | Receipt of last dose of anticancer therapy within <=28 days or <=5 half-lives (whichever is shorter) before first dose | Unresolved >= Grade 2 toxicity from prior therapy (except alopecia, vitiligo, and allowed lab values) | Concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer | Major surgery within 28 days prior to first dose (palliative local surgery allowed) | History of allogeneic organ transplantation | Active or prior autoimmune or inflammatory disorders requiring systemic therapy (with specified exceptions such as vitiligo, alopecia, controlled hypothyroidism, chronic skin conditions, remote inactive disease, or celiac disease controlled by diet) | Uncontrolled intercurrent illness (e.g., active infection, symptomatic CHF, uncontrolled hypertension, unstable angina, significant arrhythmia, interstitial lung disease, serious chronic GI conditions with diarrhea, or significant psychiatric illness) | Active infection including tuberculosis, hepatitis B (HBsAg positive), hepatitis C (HCV RNA positive), or HIV infection | Another active malignancy within 5 years (except certain adequately treated cancers) | History of leptomeningeal carcinomatosis | Active brain metastases or spinal cord compression | QTcF >= 470 ms | Current or prior use of systemic immunosuppressive medication within 14 days before first dose (with specified exceptions) | Receipt of live attenuated vaccine within 30 days before first dose and during therapy up to 90 days after last dose | Pregnant or breastfeeding, or of reproductive potential unwilling to use effective contraception through 180 days after last dose | Allergy or hypersensitivity to study drugs or excipients | Unresolved partial or complete bowel obstruction | Any condition that, in the investigator's judgment, makes the patient unsuitable or unlikely to comply",Prior platinum-based therapy required (platinum-resistant or refractory); Washout from prior anticancer therapy >= 28 days or >= 5 half-lives before first dose,ALL,A,"Disease and stage/setting match (recurrent clear cell ovarian carcinoma), required histology is satisfied, and age/sex fit. Prior platinum-based therapy was given; platinum-resistant status is unspecified but not an explicit exclusion, and no other conflicts are evident.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,"No hard exclusions. Disease and recurrent setting match; required clear cell histology is satisfied. Platinum-resistant status is unknown (neutral, not a soft mismatch). With ≥2 anchors matched (stage/setting and required subtype) and no soft conflicts, Grade A is appropriate.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT05785741,1.0,Castration-Resistant Prostate Cancer,"A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects With Advanced/Metastatic Solid Tumors",This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.,"{'id': 205985475, 'name': 'DB-1310', 'description': 'Administered I.V.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205985476, 'name': 'Trastuzumab', 'description': 'Administered I.V.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205985477, 'name': 'Osimertinib', 'description': 'Oral', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,18 years,Non-Small Cell Lung Cancer; Esophageal Squamous Cell Carcinoma; Biliary Tract Cancer; Castration-Resistant Prostate Cancer; Head and Neck Squamous Cell Carcinoma; Breast Cancer (HER2-positive); Solid Tumor,"Age >= 18 years | Relapsed or progressed after standard systemic treatment, intolerant to standard therapy, or no standard therapy available | At least one measurable lesion per RECIST 1.1 | Life expectancy >= 3 months | ECOG performance status 0-1 | Left ventricular ejection fraction (LVEF) >= 50% | Adequate organ function | Adequate treatment washout before Cycle 1 Day 1 | Willing to provide tumor tissue for biomarker assessment (e.g., HER3 level) if feasible","Prior HER3-targeted therapy | Prior antibody-drug conjugate with topoisomerase I inhibitor (with protocol-specified exceptions) | History of symptomatic congestive heart failure (NYHA class II-IV) or serious cardiac arrhythmia requiring treatment | Myocardial infarction or unstable angina within 6 months | Clinically important ECG abnormalities (e.g., complete LBBB, second- or third-degree heart block, PR interval > 250 ms) | QTcF > 470 ms or inability to discontinue QT-prolonging drugs | Use of strong CYP3A4 inducers when receiving osimertinib combinations (per protocol cohorts) | History of or current ILD/pneumonitis or radiation pneumonitis requiring steroids; suspected ILD/pneumonitis not ruled out | Clinically significant pulmonary illness (e.g., recent pulmonary embolism, severe asthma/COPD, restrictive lung disease, significant pleural effusion) or prior complete pneumonectomy | Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals | Clinically significant corneal disease | Known HIV infection | Active viral hepatitis (with protocol-defined HBV/HCV exceptions) | Pregnant or lactating | Clinically active brain metastases (unless stable >= 4 weeks post-therapy and on stable/decreasing steroids <= 10 mg/day prednisone equivalent) | Unresolved toxicities from prior therapy > Grade 1 (except alopecia; certain chronic Grade 2 allowed per protocol) | Multiple primary malignancies within 3 years (with protocol-defined exceptions) | Substance abuse or other conditions increasing safety risk or interfering with study assessments | Known hypersensitivity to study drugs or excipients",Progressed on or after standard systemic therapy or no standard therapy available; Treatment washout required before Cycle 1 Day 1,ALL,A,"Disease matches (CRPC is included), and the patient has metastatic disease with progression after standard therapies, aligning with the trial’s advanced/relapsed setting. Age/sex fit, no required biomarker positivity, and no explicit exclusions are identified.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions. Disease (CRPC) is included. Stage/setting matches (metastatic/advanced), and prior therapy requirement matches (progressed after standard systemic therapy). No required biomarker. No metastatic pattern constraints conflicting. Meets ≥2 core anchors with no soft conflicts, so A is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05848258,1.0,Rheumatoid Arthritis,"An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis",The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).,"{'id': 206205547, 'name': 'LY3871801', 'description': 'Administered orally', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206205548, 'name': 'Placebo', 'description': 'Administered orally', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,18 years,Rheumatoid Arthritis,"Diagnosis of adult-onset rheumatoid arthritis for >= 3 months prior to screening per 2010 ACR/EULAR classification criteria | Moderately-to-severely active rheumatoid arthritis at screening and baseline with >= 6 swollen joints (66-joint count) and >= 6 tender joints (68-joint count) | History of inadequate response, intolerance, or loss of response to >= 1 csDMARD and to either 1 bDMARD or 1 tsDMARD","Class IV rheumatoid arthritis per ACR revised criteria | Poorly controlled diabetes or hypertension | Chronic kidney disease stage IIIa or IIIb, IV, or V | Symptomatic heart failure NYHA class II–IV | Myocardial infarction, unstable angina, stroke, or transient ischemic attack within 12 months before randomization | Severe chronic pulmonary disease requiring oxygen therapy | Major chronic inflammatory disease or connective tissue disease other than rheumatoid arthritis | Systemic lupus erythematosus | Psoriatic arthritis | Axial spondyloarthritis including ankylosing spondylitis and non-radiographic axial spondyloarthritis | Reactive arthritis | Gout | Scleroderma | Polymyositis | Dermatomyositis | Active fibromyalgia | Multiple sclerosis","Prior inadequate response, intolerance, or loss of response to >= 1 csDMARD and to either 1 bDMARD or 1 tsDMARD",ALL,A,"Disease matches RA, age/sex are eligible, and the patient has active disease consistent with the trial’s moderately-to-severely active RA requirement. She has inadequate response to a csDMARD (methotrexate) and multiple bDMARDs, meeting prior-therapy criteria, with no explicit exclusions identified.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,A,No hard exclusions. Disease matches RA. Stage/setting aligns (moderate-to-severe active RA; DAS28 5.5) and prior therapy criteria are met (failed csDMARD and multiple bDMARDs). Age/sex eligible. No soft conflicts identified; unknown joint counts/duration are not exclusions. Grade A is appropriate.,,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05869955,1.0,Rheumatoid Arthritis,"A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, or Rheumatoid Arthritis (Breakfree-1)","The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).","{'id': 206510372, 'name': 'CC-97540', 'description': 'Specified dose on specified days', 'other_names': ['BMS-986353'], 'intervention_type': 'DRUG'}; {'id': 206510373, 'name': 'Fludarabine', 'description': 'Specified dose on specified days', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206510374, 'name': 'Cyclophosphamide', 'description': 'Specified dose on specified days', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206510375, 'name': 'Tocilizumab', 'description': 'Specified dose on specified days', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,18 years,Systemic Lupus Erythematosus; Idiopathic Inflammatory Myopathy; Systemic Sclerosis; Rheumatoid Arthritis,"Systemic Lupus Erythematosus fulfilling 2019 EULAR/ACR classification criteria | SLE: Presence of anti-dsDNA, anti-histone, anti-chromatin, anti-Ro (SS-A), anti-La (SS-B), or anti-Sm antibodies at screening | SLE: Active disease with >= 1 major organ BILAG A (excluding musculoskeletal, mucocutaneous, and constitutional) | SLE: Inadequate response to glucocorticoids and to >= 2 prior treatments for >= 3 months (from: cyclophosphamide, mycophenolic acid/derivatives, belimumab, azathioprine, anifrolumab, methotrexate, rituximab, obinutuzumab, cyclosporin, tacrolimus, voclosporin) | Idiopathic Inflammatory Myopathy fulfilling 2017 EULAR/ACR criteria (probable or definite) | IIM subgroup: dermatomyositis, immune-mediated necrotizing myopathy, anti-synthetase syndrome, or polymyositis | IIM: Presence of >= 1 myositis-specific antibody, myositis-associated antibody, or ANA at or before screening | IIM: Severe or moderate muscle and/or skin involvement | IIM: Evidence of activity by active myositis-associated rash OR recent muscle biopsy OR elevated CK > 3 x ULN OR progressive interstitial lung disease on HRCT | IIM: Inadequate response to glucocorticoids and to >= 2 prior treatments for >= 3 months (from: azathioprine, methotrexate, cyclosporin A, tacrolimus, mycophenolate mofetil, cyclophosphamide, IVIG, JAK inhibitors, rituximab) | Systemic Sclerosis fulfilling 2013 EULAR/ACR classification criteria | SSc: ANA positive at or before screening | SSc: Diffuse cutaneous SSc OR diffuse/limited cutaneous SSc with progressive ILD | SSc: Inadequate response to >= 1 prior treatment for >= 3 months (from: mycophenolate, cyclophosphamide, rituximab, nintedanib, azathioprine, tocilizumab, IVIG) | Rheumatoid Arthritis: Minimum of 3 swollen joints and 3 tender joints on 66/68 joint count | RA: Inadequate response to >= 1 prior treatment for >= 3 months (from: mycophenolate, cyclophosphamide, rituximab, nintedanib, azathioprine, tocilizumab, IVIG)","Drug-induced SLE | Other systemic autoimmune diseases (e.g., multiple sclerosis, psoriasis, inflammatory bowel disease); exceptions: type I autoimmune diabetes mellitus, thyroid autoimmune disease, celiac disease, secondary Sjogren's syndrome | SLE overlap syndromes (e.g., rheumatoid arthritis, scleroderma, mixed connective tissue disease) | Present or recent clinically significant CNS pathology within 12 months | IIM: Inclusion body myositis, amyopathic dermatomyositis, any form of juvenile myositis | IIM: Myositis other than IIM (e.g., drug-induced myositis, polymyositis associated with HIV) | IIM: Severe muscle damage (Physician VAS for muscle damage > 7 cm on 10 cm scale), permanent weakness due to non-IIM cause, or myositis with cardiac involvement | SSc: Pulmonary arterial hypertension requiring active treatment | SSc: Rapidly progressive lower GI involvement requiring parenteral nutrition; active gastric antral vascular ectasia | SSc: Prior scleroderma renal crisis | RA: Prior history of or current inflammatory joint disease other than RA | RA: Joint damage and/or deformity that may confound accurate assessment of disease activity | Other protocol-defined inclusion/exclusion criteria apply",glucocorticoids; cyclophosphamide; mycophenolate; belimumab; azathioprine; anifrolumab; methotrexate; rituximab; obinutuzumab; cyclosporin; tacrolimus; voclosporin; intravenous immunoglobulin; JAK inhibitors; nintedanib; tocilizumab,ALL,A,"Disease matches RA cohort, and the patient has active, refractory RA with prior inadequate response to tocilizumab (listed) and other biologics, aligning with line-of-therapy requirements; age and sex are eligible with no explicit exclusions noted. While joint count specifics are not provided, no conflicts are identified.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,A,"No hard exclusions. Disease matches RA cohort. Stage/setting aligns (active, refractory RA) and line/prior-exposure aligns (inadequate response to tocilizumab from the allowed list). Joint count requirement is unknown but not a conflict. Thus ≥2 core anchors match with no soft mismatches → A.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT05920798,0.8471782803535461,Recurrent Clear Cell Ovarian Carcinoma,"MC220601, Folate Receptor Alpha Dendritic Cells (FRαDCs) Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer (FRAPPE)","This phase I/II trial tests the safety, side effects, best dose, and effectiveness of multi-epitope folate receptor alpha-loaded dendritic cell vaccine (FRalphaDC) with pembrolizumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer (collectively known as ovarian cancer) that that has come back (after a period of improvement) (recurrent). Ovarian cancer is the most lethal gynecologic malignancy in the United States. While the majority of patients achieve a remiss...","{'id': 206172865, 'name': 'Biopsy', 'description': 'Undergo biopsy', 'other_names': ['BIOPSY_TYPE', 'Bx'], 'intervention_type': 'PROCEDURE'}; {'id': 206172866, 'name': 'Biospecimen Collection', 'description': 'Undergo blood sample collection', 'other_names': ['Biological Sample Collection', 'Biospecimen Collected', 'Specimen Collection'], 'intervention_type': 'PROCEDURE'}; {'id': 206172867, 'name': 'Computed Tomography', 'description': 'Undergo CT', 'other_names': ['CAT', 'CAT Scan', 'Computed Axial Tomography', 'Computerized Axial Tomography', 'Computerized axial tomography (procedure)', 'Computerized Tomography', 'CT', 'CT Scan', 'tomography'], 'intervention_type': 'PROCEDURE'}; {'id': 206172868, 'name': 'Magnetic Resonance Imaging', 'description': 'Undergo MRI', 'other_names': ['Magnetic Resonance', 'Magnetic resonance imaging (procedure)', 'Magnetic Resonance Imaging Scan', 'Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance', 'MR', 'MR Imaging', 'MRI', 'MRI Scan', 'NMR Imaging', 'NMRI', 'Nuclear Magnetic Resonance Imaging'], 'intervention_type': 'PROCEDURE'}; {'id': 206172869, 'name': 'Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine', 'description': 'Given ID', 'other_names': ['FRalphaDC Vaccine', 'FRaDC Vaccine'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206172870, 'name': 'Pembrolizumab', 'description': 'Given IV', 'other_names': ['Keytruda', 'Lambrolizumab', 'MK-3475', 'SCH 900475'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206172871, 'name': 'Pheresis', 'description': 'Undergo apheresis', 'other_names': ['Apheresed', 'Apheresis', 'Blood Component Removal', 'Collection, Apheresis/Leukapheresis', 'Hemapheresis'], 'intervention_type': 'PROCEDURE'}",PHASE1/PHASE2,18 years,Ovarian Carcinoma (recurrent); Ovarian Clear Cell Adenocarcinoma (recurrent); Ovarian Endometrioid Adenocarcinoma (recurrent); Ovarian High Grade Serous Adenocarcinoma (recurrent); Ovarian Carcinosarcoma (recurrent); Fallopian Tube Carcinoma (recurrent); Fallopian Tube Clear Cell Adenocarcinoma (recurrent); Fallopian Tube Endometrioid Adenocarcinoma (recurrent); Fallopian Tube High Grade Serous Adenocarcinoma (recurrent); Fallopian Tube Carcinosarcoma; Primary Peritoneal Carcinoma (recurrent); Primary Peritoneal Clear Cell Adenocarcinoma (recurrent); Primary Peritoneal Endometrioid Adenocarcinoma (recurrent); Primary Peritoneal High Grade Serous Adenocarcinoma (recurrent); Primary Peritoneal Carcinosarcoma (recurrent),"Age >= 18 years | Histologically confirmed recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (high grade serous, endometrioid, or clear cell; mixed carcinomas/carcinosarcomas eligible if >= 50% high grade serous and/or endometrioid and/or clear cell) | Platinum-refractory, platinum-resistant, or platinum-sensitive recurrence | Measurable disease per RECIST v1.1 and/or CA-125-evaluable disease by GCIG | ECOG performance status 0-1 | Hemoglobin >= 8.5 g/dL | Absolute neutrophil count >= 1000/µL | Platelet count >= 75000/µL | Lymphocytes >= 300/µL | Monocytes >= 250/µL | Total bilirubin <= 1.5 x ULN (if Gilbert's, direct bilirubin <= ULN) | AST <= 3 x ULN | Creatinine clearance >= 30 mL/min","Pregnant or nursing | Persons of childbearing potential or able to father a child unwilling to use adequate contraception | Prior anti-PD-1 or anti-PD-L1 therapy for ovarian cancer | IV anti-cancer therapy <= 3 weeks or oral anti-cancer therapy <= 1 week prior to registration | Grade >= 2 ovarian cancer-related symptoms, or lesion > 5 cm (non-nodal long axis or nodal short axis), or disease likely to become symptomatic within 8 weeks | Significant comorbid illness that would interfere with study treatment or assessments | Uncontrolled HIV infection; HIV must be well controlled on ART with CD4 >= 350/µL and suppressed HIV RNA | Ongoing or active serious infection requiring systemic therapy | Current or prior immune-related pneumonitis or interstitial lung disease requiring steroids | Active autoimmune disease requiring systemic treatment within 2 years (except replacement therapy) | Active hepatitis B (unless on antivirals with undetectable HBV DNA) or active hepatitis C (unless successfully treated with undetectable HCV RNA) | Other active malignancy requiring palliative systemic therapy within 3 years or likely to require treatment in next 2 years (except non-melanoma skin cancer, papillary thyroid cancer not requiring therapy, or carcinoma in situ) | Myocardial infarction within 6 months or congestive heart failure requiring ongoing maintenance therapy for life-threatening ventricular arrhythmias | Systemic immunosuppressive medication within 7 days prior to registration (except permitted low-dose or inhaled steroids) | History of allogeneic stem cell transplant","Any number of prior therapies or maintenance regimens for ovarian cancer allowed; Eligible regardless of platinum status (platinum-refractory, -resistant, or -sensitive); Washout required: last IV anti-cancer therapy >= 3 weeks; last oral anti-cancer therapy >= 1 week before registration",FEMALE,A,"Recurrent ovarian clear cell carcinoma in a 36-year-old female matches the trial disease and setting, and prior therapies (carboplatin/paclitaxel/bevacizumab, no prior PD-1/PD-L1) are allowed. No hard exclusions are triggered; required subtype is met and other eligibility details are not contradicted.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,No hard exclusions. Disease matches recurrent ovarian clear cell carcinoma. Stage/setting matches (recurrent). Line/prior exposure compatible (any prior allowed; no prior PD-1). Required subtype satisfied. No soft conflicts identified. Grade A is appropriate.,,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT06039371,1.0,Castration-Resistant Prostate Cancer,SPECTRA: Supraphysiological Androgen to Enhance Treatment Activity,"This phase II trial studies how well giving testosterone at levels higher than normally found in the body (supraphysiological) works to enhance chemotherapy treatment, and Lutetium 177Lu-prostate specific-membrane antigen (PSMA)-617 (LuPSMA) in patients with prostate cancer that has progressed despite being previously treated with androgen therapies and has spread from where it first started (prostate) to other places in the body (metastatic castration-resistant prostate cancer). In patients ...","{'id': 206391130, 'name': 'Biopsy Procedure', 'description': 'Undergo a biopsy', 'other_names': ['Biopsy', 'BIOPSY_TYPE', 'Bx'], 'intervention_type': 'PROCEDURE'}; {'id': 206391131, 'name': 'Biospecimen Collection', 'description': 'Undergo blood sample collection', 'other_names': ['Biological Sample Collection', 'Biospecimen Collected', 'Specimen Collection'], 'intervention_type': 'PROCEDURE'}; {'id': 206391132, 'name': 'Bone Scan', 'description': 'Undergo bone scan', 'other_names': ['Bone Scintigraphy'], 'intervention_type': 'PROCEDURE'}; {'id': 206391133, 'name': 'Carboplatin', 'description': 'Given IV', 'other_names': ['Blastocarb', 'Carboplat', 'Carboplatin Hexal', 'Carboplatino', 'Carboplatinum', 'Carbosin', 'Carbosol', 'Carbotec', 'CBDCA', 'Displata', 'Ercar', 'JM-8', 'Nealorin', 'Novoplatinum', 'Paraplatin', 'Paraplatin AQ', 'Paraplatine', 'Platinwas', 'Ribocarbo'], 'intervention_type': 'DRUG'}; {'id': 206391134, 'name': 'Computed Tomography', 'description': 'Undergo CT', 'other_names': ['CAT', 'CAT Scan', 'Computed Axial Tomography', 'Computerized Axial Tomography', 'Computerized axial tomography (procedure)', 'Computerized Tomography', 'CT', 'CT Scan', 'tomography'], 'intervention_type': 'PROCEDURE'}; {'id': 206391135, 'name': 'Etoposide', 'description': 'Given PO', 'other_names': ['Demethyl Epipodophyllotoxin Ethylidine Glucoside', 'EPEG', 'Lastet', 'Toposar', 'Vepesid', 'VP 16', 'VP 16-213', 'VP-16', 'VP-16-213', 'VP16'], 'intervention_type': 'DRUG'}; {'id': 206391136, 'name': 'Quality-of-Life Assessment', 'description': 'Ancillary studies', 'other_names': ['Quality of Life Assessment'], 'intervention_type': 'OTHER'}; {'id': 206391137, 'name': 'Questionnaire Administration', 'description': 'Ancillary studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206391138, 'name': 'Testosterone Cypionate', 'description': 'Given IM', 'other_names': ['depAndro', 'Depo-Testosterone', 'Depotest', 'Depovirin', 'Pertestis', 'Virilon'], 'intervention_type': 'DRUG'}; {'id': 206391139, 'name': 'Radioconjugate', 'description': 'Given LuPSMA IV', 'other_names': ['Radio Conjugates'], 'intervention_type': 'OTHER'}; {'id': 206391140, 'name': 'Dual X-ray Absorptiometry', 'description': 'Undergo DEXA', 'other_names': ['BMD scan', 'bone mineral density scan', 'DEXA', 'DEXA scan', 'dual energy x-ray absorptiometric scan'], 'intervention_type': 'PROCEDURE'}; {'id': 206391141, 'name': 'Gallium Ga 68-PSMA-617', 'description': 'Given gallium 68Ga-PSMA-617', 'other_names': ['2247839-19-4', '68Ga-PSMA-617', 'Gallium-68 PSMA-617', 'VIPIVOTIDE TETRAXETAN GALLIUM GA-68'], 'intervention_type': 'OTHER'}; {'id': 206391142, 'name': 'Positron Emission Tomography', 'description': 'Undergo 68Ga-PSMA PET', 'other_names': ['Medical Imaging', 'PET', 'PET scan'], 'intervention_type': 'PROCEDURE'}; {'id': 206391143, 'name': 'Single Photon Emission Computed Tomography', 'description': 'Undergo SPECT/CT', 'other_names': ['Medical Imaging', 'SPECT'], 'intervention_type': 'PROCEDURE'}",PHASE2,18 years,Castration-Resistant Prostate Cancer; Prostate Adenocarcinoma (metastatic),"Age >= 18 years | Histologically confirmed adenocarcinoma of the prostate | Castration-resistant prostate cancer with PSA progression per PCWG3 and serum testosterone <= 50 ng/dL | PSA >= 2 ng/mL and rising on two successive measurements at least 2 weeks apart | Progressed on at least one prior next-generation androgen receptor–signaling inhibitor (e.g., abiraterone, enzalutamide) | Washout >= 2 weeks after most recent approved mCRPC therapy before cycle 1 day 1 | Wean off steroids >= 1 week prior to starting treatment if applicable | Cohort 3: PSMA expression on 68Ga-PSMA-11 PET per VISION criteria | No prior chemotherapy for mCRPC; prior docetaxel for hormone-sensitive disease allowed | Prior treatment with non-chemotherapy investigational agents permitted with washout >= 2 weeks | Hemoglobin >= 9 g/dL without transfusion in past 28 days | Absolute neutrophil count (ANC) >= 1500/µL | Platelet count >= 100000/µL | Total bilirubin <= 1.5 x ULN | AST/ALT <= 2.5 x ULN (<= 5 x ULN if liver metastases present) | Creatinine clearance >= 51 mL/min | ECOG performance status <= 2 | Life expectancy >= 16 weeks | At least one lesion assessable by CT, PET, MRI and/or bone scan suitable for repeated assessment | Willing to undergo metastatic biopsy with a lesion amenable to biopsy | Men and partners of childbearing potential agree to use two effective contraceptive methods during treatment and for 6 months after last dose","Other malignancy unless curatively treated with no evidence of disease for >= 2 years (except adequately treated non-melanoma skin cancer and non–muscle invasive bladder cancer) | Persistent toxicities > grade 2 from prior therapy (excluding alopecia) | Symptomatic uncontrolled brain metastases | Spinal cord compression without definitive treatment and stable disease for at least 28 days | Chronic corticosteroid use > 10 mg prednisone equivalent daily | Concurrent systemic anticancer therapy planned aside from LHRH analogue | Use of warfarin (LMWH and direct oral anticoagulants allowed with PI approval) | Major surgery within 2 weeks prior to starting study treatment and not recovered | Serious uncontrolled medical disorder or active uncontrolled infection | Uncontrolled ventricular arrhythmia | Uncontrolled major seizure disorder | Uncontrolled hypertension (BP >= 165/100) | History of prior stroke | Unstable spinal cord compression | Superior vena cava syndrome | Extensive interstitial bilateral lung disease | Psychiatric disorder prohibiting informed consent | Hypersensitivity to testosterone cypionate, etoposide, or carboplatin or their excipients | Known active hepatitis B or C infection | Condition that could interfere with patient safety or informed consent | Disease features that pose risk from testosterone therapy (e.g., femoral metastases at high fracture risk, spinal metastases with concern for cord compression, lymph node disease with concern for ureteral obstruction) | Pain attributable to prostate cancer | Tumor-related urinary outlet obstruction requiring catheterization for voiding | History of deep venous thrombosis or pulmonary embolism within 5 years and not on systemic anticoagulation | NYHA class III or IV heart failure | Myocardial infarction within 5 years",Progressed on at least one next-generation androgen receptor–signaling inhibitor; No prior chemotherapy for mCRPC; Prior docetaxel for hormone-sensitive prostate cancer allowed; Prior non-chemotherapy investigational agents allowed; Washout >= 2 weeks after most recent approved mCRPC therapy before C1D1; Washout >= 2 weeks after any investigational cancer agent before C1D1; Discontinue steroids or wean to <= physiologic dose at least 1 week before treatment start,MALE,A,"Disease and setting match mCRPC; the patient progressed on next‑generation ARSIs (abiraterone, enzalutamide), and PSMA PET avidity aligns with the PSMA+ cohort. No explicit exclusions are evident from available data (age/sex fit; no disqualifying prior mCRPC chemotherapy reported).",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,A,No hard exclusions identified. Disease matches mCRPC; stage/setting matches; prior-exposure matches (progressed on abiraterone/enzalutamide; no prior mCRPC chemo reported); PSMA PET positivity aligns with the PSMA cohort. Other required labs/PSA progression details are unknown but not disqualifying per rubric. Grade A is appropriate.,,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06094608,0.6691051721572876,Fistulizing Crohn's Disease,IBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms,This research study is testing whether changes in sleep timing and morning light treatment may have an impact on symptoms related to inflammatory bowel disease.,"{'id': 205707854, 'name': 'Morning light treatment', 'description': 'Light therapy via the Re-Timer. Participants will conduct light treatment in the mornings at home for one hour using Re-timer®.', 'other_names': ['Re-Timer®'], 'intervention_type': 'DEVICE'}; {'id': 205707855, 'name': 'Treatment-as-usual', 'description': 'Participants will not make modifications to their activities or sleep schedule.', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}",NA,18 years,Crohn Disease; Ulcerative Colitis,Biopsy-proven inflammatory bowel disease | Active IBD symptoms | Impaired IBD quality of life | Age >= 18 years,"Ileostomy, colostomy, ileoanal pouch, or ileorectal anastomoses | Planned imminent surgery | Short bowel syndrome | Other significant chronic disease | Retinal pathology | History of eye surgery | Taking photosensitizing medications | Recent history of light treatment | Lifetime psychotic disorder | Lifetime bipolar disorder | Acute suicidal ideation | Substance use disorder in the past 3 months | Cannabis use >1/week | High risk for or diagnosed obstructive sleep apnea | Narcolepsy | Severe hearing problem | Intellectual disability | Serious cognitive impairment | Pregnant, trying to get pregnant, or breastfeeding | Night work | Travel outside the eastern time zone in the past month",(none),ALL,A,"Disease matches (Crohn’s disease) and the patient has active symptoms; age/sex fit and prior biologic exposure is allowed. No explicit exclusions are triggered, though some inclusions (biopsy confirmation, impaired quality of life) are not documented.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),INCORRECT,B,"No hard exclusions identified. Disease matches and stage/setting (active IBD symptoms) matches. Other core anchors are not applicable/unknown: the trial has no line/prior restrictions (neutral, not a match), no biomarker requirement, and no mets pattern. Thus exactly 1 core anchor matches → Grade B. The grader incorrectly counted age/sex and permissive prior exposure as additional anchors and overgraded to A.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT06242470,1.0,Castration-Resistant Prostate Cancer,"A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors","The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatmen...","{'id': 206511499, 'name': 'MGC026 Dose Escalation', 'description': 'Escalating doses of MGC026', 'other_names': [], 'intervention_type': 'BIOLOGICAL'}; {'id': 206511500, 'name': 'MGC026 Dose for Expansion', 'description': 'MGC026 recommended dose for expansion', 'other_names': [], 'intervention_type': 'BIOLOGICAL'}",PHASE1,18 years,Squamous Cell Carcinoma of Head and Neck; Esophageal Squamous Cell Carcinoma; Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Bladder Cancer; Sarcoma; Endometrial Cancer; Melanoma; Castration-Resistant Prostate Cancer; Breast Cancer; Ovarian Cancer; Platinum-Resistant Ovarian Cancer; Cervical Cancer; Colorectal Cancer; Gastric Cancer; Gastroesophageal Cancer; Pancreatic Cancer; Clear Cell Renal Cell Carcinoma; Hepatocellular Carcinoma,"Age >= 18 years | Adequate performance status and laboratory parameters | Availability of archival tumor tissue or willingness to undergo fresh biopsy; eligibility allowed if biopsy unsafe after sponsor-investigator review | Unresectable, locally advanced or metastatic solid tumor from specified histologies (e.g., HNSCC, esophageal SCC, NSCLC [squamous and non-squamous], SCLC, bladder cancer, sarcoma, endometrial cancer, melanoma, castration-resistant prostate cancer, breast cancer, ovarian cancer, cervical cancer, colorectal cancer, gastric or gastroesophageal cancer, pancreatic carcinoma, clear cell renal cell carcinoma, hepatocellular carcinoma) | Measurable disease per RECIST v1.1; metastatic CRPC without measurable disease eligible | Use highly effective contraception during treatment and for 7 months after last dose | Not pregnant or breastfeeding","Medical or psychiatric condition that would impair ability to receive or comply with study treatment | Active malignancy requiring treatment within 2 years except adequately treated non-melanoma skin cancer, localized prostate cancer (Gleason score < 6), or carcinoma in situ | History of CNS metastases unless treated, asymptomatic, with no ongoing treatment and no progression on imaging; no history of leptomeningeal disease or cord compression at enrollment | Recent treatment with surgery, systemic cancer therapy, immunotherapy, CAR-T therapy, or anti-hormonal therapy within protocol-specified intervals | Prior treatment with any B7-H3–targeted agent or any ADC with a topoisomerase payload | Prior autologous or allogeneic stem cell or solid organ transplant | Clinically significant cardiovascular, pulmonary, or gastrointestinal disorders | Active viral, bacterial, or systemic fungal infection requiring parenteral therapy within 1 week of first dose | Known hepatitis B or C infection (HBsAg or HBcAb positive, or HCV PCR positive) | Known HIV infection or history of AIDS | History of primary immunodeficiency | Major trauma or major surgery within 4 weeks of first dose | Known hypersensitivity to recombinant proteins","Washout from prior surgery, systemic therapy, immunotherapy, CAR-T therapy, or anti-hormonal therapy per protocol-specified intervals",ALL,A,"Disease and stage match (metastatic CRPC), and the patient's age/sex fit. Prior ARSI therapies are allowed in this phase 1 study (no requirement for specific prior lines; disallowed prior B7-H3/topoisomerase-ADC not indicated), and no exclusion is evident from available data.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions. Disease (mCRPC) is included; stage/setting matches (metastatic). Line/prior exposure compatible (prior ARSI allowed; only prior B7-H3/topoisomerase-ADC excluded, not indicated). No soft mismatches identified. ≥2 core anchors match, so A is appropriate.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT06255782,1.0,Ornithine Transcarbamylase Deficiency,"A Phase 1/2/3 First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of a Single Intravenous (IV) Administration of ECUR-506 in Males Less Than 9 Months of Age With Genetically Confirmed Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency","Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for detoxification of ammonia. Individuals with OTC deficiency can build-up excess levels of ammonia in their blood, potentially resulting in devastating consequences, including cumulative and irreversible neurological damage, coma and death. The severe form of the condition emerges shortly after birth and is more common ...","{'id': 206177923, 'name': 'ECUR-506', 'description': 'ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene.', 'other_names': [], 'intervention_type': 'GENETIC'}",PHASE1/PHASE2,24 hour to 7 months,Ornithine Transcarbamylase Deficiency,Male sex | Gestational or adjusted gestational age >= 37 weeks | Age at screening 24 hours to 7 months | Weight >= 3.5 kg and <= 13.5 kg at screening | Has received age-appropriate vaccinations | Genetically confirmed ornithine transcarbamylase deficiency (OTCD) | Severe neonatal OTCD with hyperammonemic crisis and ammonia >560 µmol/L with clinical symptoms within first week of life | Current or historical biochemical profile consistent with OTCD,"Severe to profound hypoxic ischemic encephalopathy due to birth injury | Requiring urgent liver transplant due to liver failure | Contiguous gene deletion involving the OTC gene including at least CYBB or TSPAN7 | Known or suspected major organ injury, dysfunction, or anomalies | Vital sign abnormalities | Laboratory abnormalities outside normal ranges for urinalysis, complete blood count, or comprehensive metabolic panel attributable to comorbidities unrelated to OTCD | Treatment with any other gene therapy or gene editing therapy | Documented vertical transmission of hepatitis A, B, or C | Documented in-utero teratogen, substance, or alcohol exposure increasing risk of developmental delays, congenital anomalies, or significant medical complications",(none),MALE,A,"Disease, sex, and age match; the patient has genetically confirmed neonatal-onset OTC deficiency with a severe neonatal hyperammonemic crisis, and no disallowed prior therapies. Other required details (e.g., weight, gestational age ≥37 weeks, vaccination status, exact ammonia threshold) are unknown but not conflicting.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,A,"No hard exclusions (disease, sex, and age all match). Core anchors: Line/prior-exposure compatibility matches (no prior gene therapy) and required subtype/biomarker criteria are met (genetically confirmed OTCD; severe neonatal crisis stated). No soft conflicts identified; other inclusion details (weight, gestational age, ammonia threshold timing) are unknown and treated as neutral. Thus ≥2 anchors match including Line/prior → A.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT06367972,0.8805802464485168,Metastatic Urothelial Carcinoma,A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP),"To find out if local consolidation therapy (such as radiation therapy with or without other local therapies such as surgery, ablation \[the removal or destruction of a body part or tissue or its function\], or embolization \[a procedure that uses particles, such as tiny gelatin sponges or beads, to block a blood vessel\]) to all progressive sites of disease can help to control the disease compared with next-line systemic therapy.","{'id': 206232672, 'name': 'Local Consolidation Therapy', 'description': 'Participants may receive radiation therapy. The choice of LCT and radiation therapy regimen will be determined by a multidisciplinary team including the study doctor.', 'other_names': ['LCT'], 'intervention_type': 'PROCEDURE'}; {'id': 206232673, 'name': 'Next-line Systemic Therapy', 'description': 'The specific next-line systemic therapy will be determined by your doctor.', 'other_names': ['NLST'], 'intervention_type': 'PROCEDURE'}",PHASE2,18 years,Colorectal Cancer (metastatic); Renal Cell Carcinoma (metastatic); Breast Cancer (metastatic); Pancreatic Cancer (metastatic); Urothelial Carcinoma (metastatic); Prostate Cancer (metastatic); Esophageal Cancer (metastatic),"Age >= 18 | Histologically or cytologically confirmed stage IV cancer | ECOG <=2 | Candidate for local consolidation therapy to all progressive disease sites | Progressive disease defined by RECIST v1.1 from pre-baseline to baseline imaging | Progressive disease must be an active lesion (primary, regional nodal, and/or distant metastasis) | Candidate for radiation therapy to at least one site of disease | Between 1 and 5 progressive lesions; all progressive lesions amenable to local therapy | Baseline imaging within 4 weeks prior to randomization (PET/CT or CT chest/abdomen/pelvis; MRI as indicated); intracranial imaging recommended per histology | Pre-baseline imaging 6–16 weeks prior to baseline with comparable modality when possible | Immediate LCT to CNS or other symptomatic lesions before randomization allowed; such lesions count toward total lesion number | One of the following metastatic histologies: colorectal carcinoma, renal cell carcinoma, breast cancer, pancreatic cancer, urothelial (bladder) cancer, prostate cancer, esophageal cancer | Adequate organ function","Metastatic effusion (e.g., pleural effusion or ascites) of significant size | Leptomeningeal disease | Peritoneal carcinomatosis | Diffuse bone marrow involvement by biopsy from a site without radiologic bone metastasis | More than 4 prior lines of systemic therapy for metastatic disease | Active scleroderma, lupus, or other rheumatologic disease precluding safe radiotherapy | Concurrent other primary malignancy posing substantial competing risk of death | Known psychiatric or substance abuse disorder interfering with trial participation | Cognitive impairment precluding informed consent | Any condition that would interfere with study treatment or interpretation per investigator",(none),ALL,A,"Disease and metastatic setting match, and prior therapy exposure/line count are compatible (≤4 prior lines; PD-1/EV exposure allowed). No explicit exclusions are triggered; oligoprogressive LCT-amenable lesions and adequate organ function need confirmation but are not contradicted.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches metastatic urothelial carcinoma. Stage/setting (metastatic, progressive) matches; line/prior exposure compatible (<4 metastatic lines, no disallowed agents). Oligoprogressive/LCT-amenable status and organ function are unknown, not contradictions. Meets ≥2 core anchors without soft conflicts → A.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT06439836,0.8805802464485168,Metastatic Urothelial Carcinoma,Phase 1 Trial of CA-4948 in Combination With Pembrolizumab to Overcome Resistance to PD-1/PD-L1 Blockade in Metastatic Urothelial Cancer,"This phase I trial tests the safety, side effects, best dose, and effectiveness of emavusertib (CA-4948) in combination with pembrolizumab in treating patients with urothelial cancer that has spread from where it first started to other places in the body (metastatic) and that has a resistance to PD-1/PD-L1 immune checkpoint inhibitors. CA-4948, a kinase inhibitor, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodie...","{'id': 206424001, 'name': 'Biopsy Procedure', 'description': 'Undergo tumor biopsy', 'other_names': ['Biopsy', 'BIOPSY_TYPE', 'Bx'], 'intervention_type': 'PROCEDURE'}; {'id': 206424002, 'name': 'Biospecimen Collection', 'description': 'Undergo blood sample collection', 'other_names': ['Biological Sample Collection', 'Biospecimen Collected', 'Specimen Collection'], 'intervention_type': 'PROCEDURE'}; {'id': 206424003, 'name': 'Computed Tomography', 'description': 'Undergo CT', 'other_names': ['tomography', 'CAT', 'CAT Scan', 'Computed Axial Tomography', 'Computerized Axial Tomography', 'Computerized axial tomography (procedure)', 'Computerized Tomography', 'Computerized Tomography (CT) scan', 'CT', 'CT Scan', 'Diagnostic CAT Scan', 'Diagnostic CAT Scan Service Type'], 'intervention_type': 'PROCEDURE'}; {'id': 206424004, 'name': 'Emavusertib', 'description': 'Given PO', 'other_names': ['AU 4948', 'AU-4948', 'CA 4948', 'CA-4948', 'CA4948', 'Interleukin-1 Receptor-associated Kinase 4 Inhibitor CA-4948', 'IRAK4 Inhibitor CA-4948'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206424005, 'name': 'Magnetic Resonance Imaging', 'description': 'Undergo MRI', 'other_names': ['Magnetic Resonance', 'Magnetic Resonance Imaging (MRI)', 'Magnetic resonance imaging (procedure)', 'Magnetic Resonance Imaging Scan', 'Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance', 'MR', 'MR Imaging', 'MRI', 'MRI Scan', 'MRIs', 'NMR Imaging', 'NMRI', 'Nuclear Magnetic Resonance Imaging', 'sMRI', 'Structural MRI'], 'intervention_type': 'PROCEDURE'}; {'id': 206424006, 'name': 'Pembrolizumab', 'description': 'Given IV', 'other_names': ['BCD-201', 'GME 751', 'GME751', 'Keytruda', 'Lambrolizumab', 'MK 3475', 'MK-3475', 'MK3475', 'Pembrolizumab Biosimilar BCD-201', 'Pembrolizumab Biosimilar GME751', 'Pembrolizumab Biosimilar QL2107', 'Pembrolizumab Biosimilar RPH-075', 'Pembrolizumab Biosimilar SB27', 'QL2107', 'RPH 075', 'RPH-075', 'RPH075', 'SB 27', 'SB-27', 'SB27', 'SCH 900475', 'SCH-900475', 'SCH900475'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206424007, 'name': 'Positron Emission Tomography', 'description': 'Undergo PET', 'other_names': ['Medical Imaging, Positron Emission Tomography', 'PET', 'PET Scan', 'Positron emission tomography (procedure)', 'Positron Emission Tomography Scan', 'Positron-Emission Tomography', 'PT'], 'intervention_type': 'PROCEDURE'}",PHASE1,18 years,Urothelial Carcinoma (metastatic); Urothelial Carcinoma (unresectable),"Histologically confirmed urothelial cancer that is metastatic or unresectable and lacks effective standard options | Age >= 18 years | ECOG performance status <= 2 | Measurable metastatic or unresectable disease | Must have received prior PD-1 or PD-L1 inhibitor | Must have received at least one of: platinum-based chemotherapy or enfortumab vedotin | Primary resistance to PD-1/PD-L1 blockade per SITC consensus definitions | HIV-infected patients eligible if on effective antiretroviral therapy with undetectable viral load within 6 months | Previously treated brain metastases allowed if stable >= 4 weeks, no new/enlarging lesions, and off steroids >= 7 days | Prior or concurrent malignancy allowed if it will not interfere with safety or efficacy assessments","Unresolved toxicities from prior therapy > grade 1 (except grade <= 2 neuropathy or alopecia) | Chronic systemic corticosteroids > 10 mg prednisone equivalent daily or other immunosuppressive therapy within 7 days prior to first dose | Prior grade >= 3 immune-related adverse event with PD-1/PD-L1 blockade | Allergy to compounds similar to emavusertib or pembrolizumab | Uncontrolled intercurrent illness including interstitial lung disease or active non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina, or significant arrhythmia | Concurrent use of other investigational agents | Carcinomatous meningitis | Malabsorption syndrome or conditions interfering with intestinal absorption | Active autoimmune disease requiring systemic treatment in the past 2 years | History of pneumonitis requiring steroids or current pneumonitis | Live vaccine within 30 days before treatment start | Pregnant or breastfeeding | Active hepatitis B or active hepatitis C infection | Known active tuberculosis",Prior PD-1 or PD-L1 inhibitor required; Prior platinum-based chemotherapy or enfortumab vedotin (at least one) required,ALL,A,"The patient has metastatic urothelial carcinoma with prior PD-1 (pembrolizumab) and enfortumab vedotin/platinum exposure, matching stage/setting and prior-therapy requirements, and age/sex fit with no explicit exclusions noted. The ‘primary resistance to PD-1/PD-L1’ requirement is not documented but not contradicted.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),INCORRECT,C,"No hard exclusions. Stage/setting and prior-exposure anchors match, but the trial requires “primary resistance to PD-1/PD-L1,” which is unknown in the patient. For grade A, required biomarkers/subtype must be satisfied; here it’s not documented. With a key required feature unknown and no soft mismatch, the rubric indicates a C rather than A.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT06483334,0.9999872446060181,Metastatic Urothelial Carcinoma,"A Phase 1/2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab, as Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04C","This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the safety and preliminary efficacy of sacituzumab tirumotecan plus enfortumab vedotin (EV). Part 2 will be based on Part 1 results and will evaluate the efficacy, pharmacokinetics, and safety of sacituzumab tirumotecan plus EV in combination with pembrolizumab in participants with advanced urothelial carcinoma.","{'id': 205890243, 'name': 'Sacituzumab tirumotecan', 'description': 'IV infusion at different dose levels', 'other_names': ['MK-2870', 'SKB264'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205890244, 'name': 'Enfortumab Vedotin', 'description': 'IV infusion at different dose levels', 'other_names': ['PADCEV™'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205890245, 'name': 'Pembrolizumab', 'description': '200 mg IV infusion', 'other_names': ['MK-3475', 'KEYTRUDA'], 'intervention_type': 'BIOLOGICAL'}",PHASE1/PHASE2,18 years,Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma,Histologically documented locally advanced or metastatic urothelial carcinoma | Archival or newly obtained tumor tissue adequate for biomarker evaluation (prefer newly obtained if feasible) | Adverse events from prior anticancer therapy recovered to <= Grade 1 or baseline (endocrine AEs allowed if adequately treated) | Part 1: Prior platinum-based chemotherapy for la/mUC | Part 1: <= 2 prior lines of therapy for la/mUC (platinum-based chemotherapy followed by avelumab maintenance counts as 2 lines) | Part 2: No prior systemic therapy for la/mUC,"Additional malignancy that is progressing or required active treatment within the past 3 years | Active central nervous system metastases or carcinomatous meningitis | Peripheral neuropathy Grade >= 2 | History of severe dry eye syndrome, severe Meibomian gland disease, blepharitis, or corneal disease that prevents/delays corneal healing | Active inflammatory bowel disease requiring immunosuppressive medication or prior history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, chronic diarrhea) | Uncontrolled significant cardiovascular or cerebrovascular disease, or serious cardiovascular/cerebrovascular events within 6 months | Active keratitis or corneal ulcerations (superficial punctate keratitis allowed if adequately treated) | History of uncontrolled diabetes | Received an investigational agent or used an investigational device within 4 weeks prior to study intervention | Received a live or live-attenuated vaccine within 30 days prior to first dose | Part 2: Diagnosis of immunodeficiency or receiving chronic systemic steroids or other immunosuppressive therapy within 7 days before first dose (inhaled/topical steroids permitted; physiologic replacement allowed for adrenal insufficiency) | Part 2: Active autoimmune disease requiring systemic treatment in past 2 years except replacement therapy | Human immunodeficiency virus infection with history of Kaposi's sarcoma and/or Multicentric Castleman's Disease | Active hepatitis B or hepatitis C virus infection | History of noninfectious pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease | Active infection requiring systemic therapy | Part 2: History of allogeneic tissue/solid organ transplant | Not adequately recovered from major surgery or ongoing surgical complications",Part 1: Prior platinum-based chemotherapy required for la/mUC; Part 1: <= 2 prior lines of therapy for la/mUC; Part 2: No prior systemic therapy for la/mUC,ALL,A,"Disease and setting match (metastatic urothelial carcinoma), and Part 1 permits ≤2 prior lines; the patient is post–second line and prior EV/PD-1 exposure is not excluded. No exclusion criteria are triggered; prior platinum specifically for la/mUC is required but not documented (neoadjuvant platinum given), so eligibility appears feasible pending confirmation.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),INCORRECT,B,"No hard exclusions identified. Stage/setting matches (metastatic UC). However, the line/prior-exposure anchor is not clearly a match because Part 1 requires prior platinum for la/mUC, which is not documented (only neoadjuvant platinum listed). With that unknown, only one core anchor clearly matches, so the appropriate grade is B, not A.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT06660654,0.8387863039970398,Recurrent Clear Cell Ovarian Carcinoma,"REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants With Advanced/Metastatic Solid Tumors","This pan-tumor trial is designed as a signal-seeking trial to assess efficacy and safety of raludotatug deruxtecan (R-DXd) monotherapy in locally advanced or metastatic solid tumors with various cadherin-6 (CDH6) expression levels, including gynecological cancers (endometrial cancer, cervical cancer, and non-high-grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and clear cell renal cell carcinoma \[ccRCC\]).","{'id': 206205829, 'name': 'Raludotatug deruxtecan', 'description': 'IV administration Q3W', 'other_names': ['R-DXd'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Endometrial Cancer; Cervical Cancer; Clear Cell Ovarian Carcinoma; Endometrioid Ovarian Cancer (low grade); Serous Ovarian Cancer (low grade); Mucinous Ovarian Cancer; Urothelial Carcinoma; Clear Cell Renal Cell Carcinoma,"Age >= 18 years | At least 1 lesion not previously irradiated | Lesion amenable to biopsy and willingness to provide a pre-treatment biopsy | Measurable disease per RECIST 1.1 | Radiographic progression on or after the most recent line of systemic therapy | ECOG performance status 0–1 | Endometrial cancer: Pathologically or cytologically documented endometrial carcinoma (any histology) or carcinosarcoma, irrespective of MSI/MMR status | Endometrial cancer: Disease progression after 1–3 prior lines including platinum-based chemotherapy and an anti-PD-1–containing regimen (combined or sequential) in the advanced/metastatic setting | Cervical cancer: Pathologically or cytologically documented recurrent or persistent squamous, adenosquamous, or adenocarcinoma of the cervix | Cervical cancer: Disease progression after >=1 prior line of systemic therapy in the advanced or metastatic setting | Non-HGS ovarian cancer: Pathologically or cytologically documented unresectable or metastatic clear cell, low-grade endometrioid, low-grade serous, or mucinous ovarian cancer previously treated with >=1 prior line | Urothelial cancer: Pathologically or cytologically documented unresectable or metastatic urothelial carcinoma of bladder, renal pelvis, ureter, or urethra; histologic variants allowed if predominantly urothelial | Urothelial cancer: Relapsed/progressed after >=1 prior line (maximum 3) that contained anti-PD-(L)1 therapy in the perioperative or metastatic setting | ccRCC: Pathologically or cytologically documented unresectable or metastatic clear cell renal cell carcinoma | ccRCC: Previously treated with <=3 prior systemic regimens for advanced/metastatic RCC, including both a PD-(L)1 checkpoint inhibitor and a VEGF-TKI in sequence or combination","Clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis | Cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event within 6 months | Uncontrolled or significant cardiovascular disease | History of noninfectious ILD/pneumonitis requiring steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis on screening imaging | Clinically severe pulmonary compromise | Chronic steroid treatment >10 mg/day (with protocol-specified exceptions) | History of other active malignancy within 3 years, except those with negligible risk and treated with expected curative outcome | Unresolved toxicities from prior anticancer therapy (except alopecia) not resolved to <= Grade 1 or baseline per NCI-CTCAE v5.0 | Prior exposure to CDH6-targeted agents or to an ADC with an exatecan derivative topoisomerase I inhibitor (e.g., trastuzumab deruxtecan, datopotamab deruxtecan) | Ongoing uncontrolled systemic bacterial, fungal, or viral infection | Active or uncontrolled HIV, HBV, or HCV infection",Progression on or after the most recent line of systemic therapy; Endometrial cancer: 1–3 prior lines including platinum-based chemotherapy and an anti-PD-1–containing regimen; Cervical cancer: >=1 prior line of systemic therapy in advanced/metastatic setting; Non-HGS ovarian cancer: >=1 prior line of therapy; Urothelial cancer: >=1 prior line (max 3) including anti-PD-(L)1 therapy; ccRCC: <=3 prior systemic regimens including both a PD-(L)1 inhibitor and a VEGF-TKI,ALL,A,"Disease matches the trial’s clear cell ovarian carcinoma cohort, and the patient has recurrent/advanced disease after ≥1 prior systemic line (carboplatin/paclitaxel/bevacizumab), satisfying stage/setting and prior-therapy anchors. No exclusion conflicts are evident and no biomarker requirement applies to this cohort.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,Disease matches the clear cell ovarian cohort. Stage/setting is advanced/recurrent (pleural effusion) and prior systemic therapy (adjuvant carboplatin/paclitaxel/bevacizumab) satisfies the ≥1 prior line requirement—two core anchors match. No hard exclusions identified and no required biomarker. A is appropriate.,,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT06677190,0.8482123017311096,Recurrent Clear Cell Ovarian Carcinoma,A Phase II Trial of Belzutifan in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary,The purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with ovarian cancer. The name of the study drug involved in this study is: \- Belzutifan (a type of Hypoxia-Inducible Factor-2 alpha (HIF-2a) inhibitor),"{'id': 205850830, 'name': 'Belzutifan', 'description': 'A Hypoxia-Inducible Factor-2 alpha inhibitor, 40 mg immediate-release tablet, taken orally per protocol.', 'other_names': ['MK-6482', 'PT2977', 'NSC#825217', 'C17H12F3NO4S', '3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Ovarian Clear Cell Carcinoma,"Histologically or cytologically confirmed recurrent or persistent clear cell carcinoma of the ovary (if mixed histology then >=50% clear cell component). | Measurable disease per RECIST v1.1. | Received at least one prior platinum-based chemotherapy regimen for primary management. | Prior bevacizumab allowed. | Prior immunotherapy allowed. | Unlimited prior lines for recurrent or persistent disease allowed. | Age >=18 years. | ECOG performance status 0–1 (Karnofsky >=70%). | Adequate organ and marrow function per protocol-specified thresholds. | Brain metastases allowed if CNS therapy completed, clinically stable and radiologically stable >=4 weeks, and off steroids >=4 weeks. | Prior or concurrent malignancy allowed if it will not interfere with study assessments per investigator. | Archival tumor tissue available (preferably 17 slides; fewer may be acceptable after discussion). | Women of child-bearing potential must have a negative pregnancy test at screening and Cycle 1 Day 1 and agree to contraception; men must agree to contraception. | Ability to swallow oral medications.","Prior use of belzutifan or another HIF-2a inhibitor. | Pulse oximeter reading <92% at rest or requires intermittent or chronic supplemental oxygen. | Anti-cancer treatment (chemotherapy, radiotherapy, or other investigational therapy) within 4 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C). | Prior small molecule kinase inhibitor within 2 weeks prior to study entry. | Radiation therapy within 2 weeks of start; must have recovered from radiation toxicities; no steroid requirement; no history of radiation pneumonitis; palliative RT (<=2 weeks) to non-CNS disease allowed with >=1-week washout. | Use of specified herbal supplements within 1 week prior to treatment start. | Concomitant moderate or strong CYP3A4 inducers during treatment (unless appropriately substituted before first dose). | Participation in another interventional study or use of an investigational device within 4 weeks before first dose (follow-up phase allowed if >=4 weeks since last dose). | Toxicities from prior anticancer therapies not recovered to Grade 1 or baseline (except alopecia; endocrine AEs on replacement therapy and Grade 2 neuropathy allowed). | Receipt of live or live-attenuated vaccine within 30 days prior to first dose (non-live vaccines allowed). | Major surgery within 4 weeks or minor surgery (except port placement) within 1 week before treatment start. | Gastrointestinal disorder interfering with oral medication absorption or passage; inability to swallow; enteric tube, TPN, or IV fluid dependence. | Significant cardiovascular impairment (uncontrolled hypertension, CHF NYHA II or above, unstable angina, MI within 6 months, serious arrhythmia within 6 months). | Moderate to severe hepatic impairment (Child-Pugh B or C). | Receipt of colony-stimulating factors (e.g., G-CSF, GM-CSF, EPO) <=28 days prior to first dose. | Diagnosis of immunodeficiency. | Known HIV infection (including on antiretroviral therapy). | Known active HBV or HCV infection (allowed if prior HCV treated and cured with undetectable viral load). | Uncontrolled intercurrent illness including active infection or serious non-healing wounds/ulcers. | Psychiatric illness or social situation limiting compliance. | History of hypersensitivity to compounds with similar composition to belzutifan. | Pregnant or breastfeeding. | Any condition or laboratory abnormality that could confound results or interfere with participation per investigator judgment.","At least one prior platinum-based chemotherapy regimen required.; Prior bevacizumab allowed.; Prior immunotherapy allowed.; Washout: >=4 weeks from chemotherapy, radiotherapy, or other investigational therapy (>=6 weeks for nitrosoureas or mitomycin C).; Washout: >=2 weeks from prior small molecule kinase inhibitor.; Radiation washout: >=2 weeks; palliative RT (<=2 weeks) to non-CNS disease allowed with >=1-week washout.; No participation in another interventional study within 4 weeks before first dose.",FEMALE,A,"Recurrent ovarian clear cell carcinoma with prior platinum-taxane and bevacizumab matches the trial’s disease setting and prior-therapy requirements (age/sex also fit), and the clear cell subtype requirement is met. No explicit exclusions are evident; other specifics (e.g., measurable disease, ECOG, organ function) are unknown.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,"No hard exclusions. Disease matches (recurrent ovarian clear cell), stage/setting matches (recurrent), prior therapy requirement met (platinum-based; bev allowed), sex/age fit, and subtype requirement satisfied. No soft mismatches identified; other criteria (measurable disease, ECOG) are unknown and treated as neutral. Grade A is appropriate per rubric.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT06764771,0.8074830770492554,Recurrent Clear Cell Ovarian Carcinoma,A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors,"This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.","{'id': 206599301, 'name': 'BMS-986488', 'description': 'Specified dose on specified days', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206599302, 'name': 'Adagrasib', 'description': 'Specified dose on specified days', 'other_names': ['KRAZATI', 'BMS-986503', 'MRTX849'], 'intervention_type': 'DRUG'}; {'id': 206599303, 'name': 'Cetuximab', 'description': 'Specified dose on specified days', 'other_names': ['ERBITUX'], 'intervention_type': 'DRUG'}; {'id': 206599304, 'name': 'Nivolumab', 'description': 'Specified dose on specified days', 'other_names': ['OPDIVO', 'BMS-936558'], 'intervention_type': 'DRUG'}",PHASE1,18 years,Clear-Cell Renal Cell Carcinoma; Clear-Cell Ovarian Cancer; Non-Small Cell Lung Cancer; Colorectal Cancer; Pancreatic Ductal Adenocarcinoma,"Age >= 18 years | Histologically confirmed locally advanced unresectable or metastatic solid tumor | Part 1A tumor types: clear-cell renal cell carcinoma, clear-cell ovarian cancer, non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma | Parts 2A, 1D, 2D: clear-cell renal cell carcinoma | Part 1B: solid tumors with KRAS G12C mutation | Part 2B: non-small cell lung cancer with KRAS G12C mutation | Parts 1C, 2C: colorectal cancer with KRAS G12C mutation | ECOG 0–1 | Measurable disease per RECIST v1.1","Untreated central nervous system metastases | Leptomeningeal metastasis | Impaired cardiac function or clinically significant cardiac disease | For adagrasib combination cohorts (Parts 1B, 1C, 2B, 2C): history of pneumonitis or interstitial lung disease | For adagrasib combination cohorts (Parts 1B, 1C, 2B, 2C): history of severe cutaneous adverse reactions including Stevens-Johnson syndrome or toxic epidermal necrolysis",(none),ALL,A,"Disease matches the trial’s clear-cell ovarian cancer cohort, and the patient’s recurrent/advanced setting and prior therapies are compatible with this Phase 1 study. Age is within range and no exclusion criteria are triggered; biomarker requirements are not applicable for this cohort.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,"No hard exclusions. Disease matches (clear-cell ovarian cancer cohort). Stage/setting aligns (recurrent with cytology-positive pleural effusion → advanced/metastatic). Prior therapy is compatible for Phase 1; no disallowed exposures noted. At least two core anchors match (stage/setting and line/prior), with no soft conflicts. Grade A is appropriate.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT06892288,0.46250319480895996,PMM2-CDG,"A Phase 2b, Multicenter, Double-blind, Randomized, Placebo Controlled Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 Administered Intravenously to Participants With PMM2-CDG (POLAR Trial)","This study is evaluating the safety, effectiveness, and how the body absorbs, distributes, and eliminates GLM101, for participants with PMM2-CDG, including children, adolescents, and adults. Researchers will compare participants receiving GLM101 to those receiving a placebo to see if GLM101 improves symptoms of PMM2-CDG. The study includes two treatment parts: a 24-week double blind placebo-controlled treatment period (Part A), and a 24-week open-label phase where every participant will recei...","{'id': 206615058, 'name': 'GLM101 (Part A, Double-blind)', 'description': 'IV infusions, 30 mg/kg once weekly for 24 weeks, for participants randomized to GLM101 in Part A', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206615059, 'name': 'Placebo (Part A, Double-blind)', 'description': 'IV infusions, 30 mg/kg once weekly for 24 weeks, for participants randomized to Placebo in Part A', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206615060, 'name': 'GLM101 (Part B, Open-label)', 'description': 'IV infusions, 30 mg/kg once weekly from week 25 to 48, to all participants', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2/PHASE3,4 years,Phosphomannomutase 2 Deficiency,"Age >= 4 years at consent | Molecular diagnosis of PMM2-CDG with biallelic pathogenic/likely pathogenic variants or biallelic variants plus PMM2 enzyme activity consistent with PMM2-CDG | Able to complete the full ICARS assessment | Screening ICARS total score >= 20 and <= 80 | Women of childbearing potential: negative serum pregnancy test and use of effective contraception during treatment and for 50 days after last infusion | Females of non-childbearing potential: premenarchal, surgically sterile, or ovarian dysfunction with FSH > 40 IU/L and amenorrhea for 12 months | Sexually active males with female partners: use effective contraception during treatment and for 50 days after last infusion | Males agree to refrain from donating sperm during the study and for 50 days after last infusion","Uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric, or other significant disease per investigator | Diagnosis of a CDG other than PMM2-CDG | History of liver transplant | Active infection requiring parenteral antibiotics, antivirals, antifungals, or systemic steroids within 7 days prior to screening | History of drug or alcohol use disorder within 12 months prior to screening | Major surgical procedure within 30 days prior to screening or planned major surgery | Previous GLM101 administration | Participation in another interventional study or investigational drug/device use within 30 days or 5 half-lives before enrollment | Use of products or supplements containing mannose or biotin within 2 weeks prior to screening | ALT > 3 x ULN, AST > 3 x ULN, or total bilirubin > 2 x ULN, or INR > 1.5 | Screening laboratory value(s) clinically significant and not related to PMM2-CDG per investigator | Hepatitis B surface antigen positive or hepatitis C antibody positive | QTcF >= 450 ms or other clinically significant ECG abnormalities | Any illness that may impact GLM101 infusion safety or evaluability per investigator/Medical Monitor | Body weight > 75 kg | Known or suspected hypersensitivity to GLM101 or its components | Any other condition making the participant unsuitable per investigator",No investigational drug or device within 30 days or 5 half-lives (whichever is longer) before enrollment; No mannose or biotin supplements within 2 weeks prior to screening,ALL,A,Disease and biomarker match (PMM2-CDG with biallelic PMM2 variants); age 8 and premenarchal female fit eligibility; ICARS 35 meets 20–80 range; no prior therapies or stated exclusions conflict. No soft mismatches identified.,PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,A,"No hard exclusions. Disease matches (PMM2-CDG), required biomarker/diagnosis satisfied (biallelic PMM2), age within range, ICARS 35 within 20–80, sex allowed, and prior exposure compatible. At least two core anchors match (biomarker and line/prior), with no soft mismatches. Grade A is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06918808,0.7952461242675781,Fistulizing Crohn's Disease,A Phase 2a Study of Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product (DB-3Q) in Patients With Perianal Fistulizing Crohn's Disease,"This is a double-blind, randomized, placebo-controlled, sequential cohort, ascending dose clinical trial to evaluate the safety and determine the efficacy of ascending doses of DB-3Q for the treatment of Perianal Fistulizing Crohn's Disease.","{'id': 206470626, 'name': 'DB-3Q', 'description': 'DB-3Q (IMP) is the frozen liquid formulation of acellular secretome proteins and extracellular vesicles isolated from human bmMSC and processed under current Good Manufacturing Process standards.', 'other_names': [], 'intervention_type': 'BIOLOGICAL'}; {'id': 206470627, 'name': 'Placebo', 'description': '0.9% NaCl', 'other_names': [], 'intervention_type': 'BIOLOGICAL'}",PHASE2,18 years to 75 years,Perianal Fistula (Crohn's Disease),"Age 18-75 years | Crohn's Disease diagnosed for >= 6 months prior to Day 1 | Single and/or multi-tract perianal fistula(s) with 2 or fewer openings that are actively draining | Failed at least one medical therapy within the last year (e.g., antibiotics, immunomodulators, monoclonal antibodies, or small molecule inhibitors) | Previous failed surgical intervention (including seton placement >= 2 weeks prior to screening) or not a candidate for/willing to undergo surgical intervention | Medical therapy for Crohn's Disease stable for >= 2 months prior to Day 1","Pregnant or breastfeeding | Woman of childbearing potential without a documented negative urine or serum pregnancy test | Active perianal abscess or infection at screening or Day 1 | Clinically significant medical conditions within 6 months before Day 1 that could compromise safety | Confirmed HIV infection | Confirmed Hepatitis B infection | Confirmed Hepatitis C infection | History of cancer, including melanoma, within 1 year of screening (except localized non-melanoma skin cancers) | History of colorectal cancer within 2 years of screening | Use of investigational therapy or treatment within 30 days prior to Day 1 | Unwilling to use medically acceptable contraception during the study",Failed at least one prior medical therapy for Crohn's Disease within the last year; Previous failed surgical intervention for perianal fistula or not a candidate/willing; Current Crohn's Disease medical therapy stable for >= 2 months prior to Day 1; No investigational therapy within 30 days prior to Day 1,ALL,A,"Disease/setting match is strong (perianal fistulizing Crohn’s with active drainage and seton) and age/sex fit the trial. Prior biologic failures align with the requirement for failed medical therapy, seton placement matches surgical history expectations, and no explicit exclusions are evident (recent abscess appears treated, not active).",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches (perianal fistulizing Crohn’s). Stage/setting aligns (active draining perianal fistula). Line/prior exposure aligns (failed prior medical therapies; seton in place fits prior surgical intervention). No clear soft conflicts identified; unknowns (e.g., timing, number of fistula openings, stability of Crohn’s therapy) are not hard exclusions. Thus ≥2 core anchors match, satisfying an A grade.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT06999187,1.0,Castration-Resistant Prostate Cancer,"A Phase 1a/1b, Multicenter, Open-label, Dose Escalation/Expansion, Multiple-dose Study to Evaluate the Safety and Activity of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas","A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas","{'id': 206116890, 'name': 'DR-0202', 'description': 'DR-0202 is a bispecific antibody', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,18 years,Castration-Resistant Prostate Cancer; Cervical Cancer; Endometrial Cancer; Gastric Cancer; Gastroesophageal Junction Cancer; HER2-Negative Breast Cancer; Head and Neck Squamous Cell Carcinoma; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Ductal Adenocarcinoma; Triple Negative Breast Cancer; Urothelial Carcinoma,"Histologically confirmed epithelial cancer: breast (TNBC, HR+/HER2-/+), non-small cell lung cancer, cervical cancer, castration-resistant prostate cancer, pancreatic ductal adenocarcinoma, head and neck squamous cell carcinoma, endometrial cancer, ovarian cancer, gastric or gastroesophageal junction cancer, or urothelial carcinoma that is unresectable, locally advanced, or metastatic | Relapsed or refractory with at least 2 prior lines of therapy and no standard-of-care options available | Radiographically measurable disease | ECOG performance status 0–1 | Life expectancy >= 3 months | Adequate marrow, renal, and hepatic function | Taper of >= 2 weeks from high-dose systemic corticosteroids; low-dose corticosteroids <= 25 mg prednisone or equivalent daily permitted in consultation with the Medical Monitor | Willing to provide archival tumor tissue or agree to baseline biopsy if not available | Willing to undergo an on-treatment biopsy if clinically feasible and not contraindicated","Major surgery within 28 days prior to Day 1 | Insufficient washout from systemic therapy, including investigational agents, prior to C1D1 | Systemic chemotherapy or anticancer therapies within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to C1D1 | Antibody-based anticancer therapy within < 4 weeks prior to C1D1 | Prior Trop-2-directed therapy within 5 half-lives of the drug prior to C1D1 | Radiation therapy within 21 days prior to C1D1 | Untreated and symptomatic brain metastases or brain metastases requiring steroids or anticonvulsants | Active Grade >= 2 anorexia, nausea, vomiting, or signs of intestinal obstruction | Another malignancy, except adequately treated non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated with no evidence of disease for >= 1 year | Significant, uncontrolled concomitant disease that could affect compliance | Current or past CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease (with specified exceptions) | QTcF > 480 msec or history of additional risk factors for Torsades de Pointes | Uncontrolled or significant cardiovascular disease | Clinically significant abnormal ECG or myocardial infarction within 6 months prior to C1D1 | Prior solid organ transplantation | Known infection with HIV, HBV, or HCV unless meeting protocol-specified controlled criteria | Active infection requiring systemic treatment within 2 weeks prior to C1D1 | Active clinical interstitial pneumonitis or as confirmed by diagnostic imaging within 6 months prior to C1D1 | Other concurrent medical or psychiatric conditions that may confound study interpretation or prevent completion of study procedures","At least 2 prior lines of therapy required; Washout: systemic chemotherapy or anticancer therapies within 4 weeks or 5 half-lives (whichever is shorter) before C1D1; Washout: antibody-based anticancer therapy >= 4 weeks before C1D1; Washout: prior Trop-2-directed therapy within 5 half-lives before C1D1; Washout: radiation therapy within 21 days before C1D1; For CRPC, LHRH agents are allowed; Low-dose corticosteroids <= 25 mg prednisone or equivalent daily permitted",ALL,A,"Disease and setting match (metastatic CRPC is included), and the patient has ≥2 prior lines (abiraterone and enzalutamide) with LHRH therapy allowed. No explicit exclusion is evident from the available data.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions identified. Disease matches (CRPC included). Stage/setting matches (metastatic). Line/prior-therapy requirement met (≥2 prior lines: abiraterone and enzalutamide). Other criteria (ECOG, measurable disease, SOC availability) are unknown and treated as neutral. No soft mismatches noted. Grade A is appropriate per rubric.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT07077746,0.6691051721572876,Fistulizing Crohn's Disease,"A Randomized, Double-Blind, Phase 2, Efficacy and Safety Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Crohn's Disease","Methodology: Randomized, double-blind, efficacy and safety study of allogeneic HB-adMSCs vs placebo for the treatment of Crohn's Disease with a 16-week treatment period and a safety and efficacy follow up period for 52 weeks post first treatment. Treatment Duration: 16 weeks General Objectives: To assess the efficacy and safety of multiple intravenous infusions of allogeneic HB-adMSCs by improving signs and symptoms of Crohn's Disease in this subject population. Number of Subjects: 46 (23 in ...","{'id': 206206339, 'name': 'HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells', 'description': 'Allogeneic HB-adMSCs (Hope Biosciences adipose derived mesenchymal stem cells). Dose: 200 million cells (+/- 20%) suspended in 20mL 0.9% sodium chloride. Route: Intravenous. Regimen: Weeks 0, 2, 4, 8, 12, and 16. Preparation: HB-adMSCs syringe should be diluted in 250 mL 0.9% sodium chloride (for a total volume of 270 mL).', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206206340, 'name': '0.9% sodium chloride', 'description': '0.9% sodium chloride Dose: N/A - 20mL 0.9% sodium chloride. Route: Intravenous. Regimen: Weeks 0, 2, 4, 8, 12, and 16. Preparation: Placebo syringe should be diluted in 250 mL 0.9% sodium chloride (for a total volume of 270 mL).', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,18 years to 65 years,Crohn Disease,Age 18-65 years | Crohn Disease diagnosed >= 6 months prior to screening | CDAI 150-450 at screening | No current Crohn Disease treatment or on a stable Crohn Disease therapy regimen for >= 3 months prior to screening | Elevated CRP >= 1 mg/L and/or ESR > 15 mm/hr (male) or > 20 mm/hr (female) | Women of childbearing potential not pregnant and using effective contraception (or male partner uses contraception) during study and for 6 months after last dose,"WBC < 3000/µL or > 15000/µL | Absolute neutrophil count < 1500/µL | Sodium < 120 mEq/L or > 150 mEq/L | Fasting glucose > 150 mg/dL | Potassium < 3.5 mEq/L or > 6 mEq/L | BUN > 25 mg/dL | Creatinine > 2 mg/dL | BUN/Creatinine ratio > 50 | CDAI < 150 or > 450 at screening | Severe heart failure (NYHA Class III/IV) | Uncontrolled arrhythmias | Recent myocardial infarction (< 6 months from screening) | Uncontrolled hypertension | Severe COPD | Pulmonary fibrosis | History of pulmonary embolism or DVT within 6 months of screening | Significant uncontrolled concurrent medical conditions including Diabetes Mellitus, Rheumatoid Arthritis, Lupus, or Multiple Sclerosis | Any active malignancy, including cutaneous basal cell, squamous cell carcinoma, or melanoma | History of cancer within 5 years (unless curatively treated and without recurrence) | Alcohol or substance use disorder | Receipt of any investigational therapy or approved therapy for investigational use within 1 year prior to first dose (except COVID-19 vaccines) | Known chronic hepatitis B or C infection or HIV infection | Systemic infection requiring antibiotics, antivirals, or antifungals within 30 days prior to first dose | Planned donation of eggs or sperm during the study or within 6 months after the last infusion | Vital sign abnormalities at screening as determined by investigator | Any laboratory abnormality or medical condition that poses a safety risk or prevents study completion in the opinion of the investigator",Stable background Crohn Disease therapy for >= 3 months prior to screening allowed (or no current treatment),ALL,A,"Disease and setting match (active Crohn’s with CDAI 350; age 32 within 18–65), and prior biologic exposure is allowed. CRP/ESR status and whether recent IV antibiotics fell within 30 days are unknown and may affect screening but are not clear mismatches.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches (Crohn’s). Stage/setting matches (active disease, CDAI 350 within 150–450). Line/prior exposure is compatible (no restriction against prior infliximab/ustekinumab; stable or no current therapy allowed). CRP/ESR and antibiotic timing are unknown, not mismatches. Thus A per rubric.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT07145255,1.0,Castration-Resistant Prostate Cancer,"A Multicenter, Open-label Phase 1/2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors","This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.","{'id': 205738023, 'name': 'ADC', 'description': 'MBRC-201 ADC', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,18 years,Breast Cancer; Colorectal Cancer; Non-Small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma; Castration-Resistant Prostate Cancer,"Age >= 18 years | Histologic or cytologic malignant solid tumor with no standard-of-care options or ineligible/declines standard therapy | Phase 1a tumor types: mCRPC, breast cancer (TNBC, HR+/HER2-negative or HER2-low, HR-/HER2+), colorectal cancer, non-small cell lung cancer, or pancreatic ductal adenocarcinoma | Phase 1b Cohort A: mCRPC (adenocarcinoma) refractory to standard treatment; prior exposure to >=1 AR-targeted therapy required | Phase 1b Cohort B: Advanced metastatic non-small cell lung cancer refractory to standard treatment | Phase 1b Cohort C: Advanced metastatic breast cancer (TNBC, HR+/HER2-negative or HER2-low, HR-/HER2+) refractory to standard treatment | Phase 1b Cohort D: Advanced metastatic colorectal cancer or pancreatic ductal adenocarcinoma refractory to standard treatment | Tumor tissue FFPE sample available if feasible (may be waived with approval) | Phase 1a: evaluable or measurable disease per RECIST v1.1 | Phase 1b and Phase 2: measurable disease per RECIST v1.1 | ECOG <=2 | Life expectancy >= 3 months | Adequate organ and marrow function","Malignancy within 3 years other than allowed exceptions (e.g., cured non-melanoma skin cancer; localized prostate cancer cured or under active surveillance; other malignancy considered cured with minimal risk of recurrence) | Known or suspected hypersensitivity to MBRC-201 or its components | Active cerebral or meningeal disease related to malignancy; prior CNS disease allowed if treated and clinically stable without steroids >= 2 weeks before first dose | Uncontrolled viral, bacterial, or fungal infection within 2 weeks prior to first dose | Active or symptomatic hepatitis; active hepatitis C infection (PCR positive or on antiviral therapy within last 6 months) | HIV with AIDS-defining infection within 6 months, recent ART change (<3 months) with viral load > 500 copies/mL, ART that may interfere with study drug, or CD4 < 350/µL | Thromboembolic events or bleeding disorders within 14 days prior to first dose | Stroke, TIA, unstable angina, myocardial infarction, or NYHA class III–IV heart failure within 6 months prior to first dose | Baseline QTcF > 470 msec or risk factors for Torsades de pointes | Uncontrolled inflammatory bowel disease | History of ILD/pneumonitis requiring steroids, or active/suspected ILD/pneumonitis | Uncontrolled autoimmune disease or syndrome | Active ocular surface disease (e.g., confluent superficial keratitis, corneal epithelial defect, corneal ulcer, stromal opacity) that increases risk | Anticancer therapy within 14 days prior to first dose (small molecules, immunotherapy, chemotherapy, monoclonal antibodies, radiotherapy, other anticancer agents; specified hormonal therapies excepted) | Use of any investigational drug within 14 days prior to first dose | Phase 1b and Phase 2: prior treatment with an ADC with a camptothecin payload (e.g., trastuzumab deruxtecan, datopotamab deruxtecan, sacituzumab govitecan) | Current use of prohibited concomitant medications | Major surgery within 28 days prior to first dose | Unresolved toxicities from prior anticancer therapy > Grade 1 (except alopecia) | Any medical, psychiatric, or substance use disorder compromising consent or compliance | Any condition that may put the patient at significant risk, confound results, or interfere with participation | Serious underlying medical condition that would impair ability to receive or tolerate treatment and follow-up","mCRPC: prior exposure to >=1 androgen receptor-targeted therapy required (e.g., abiraterone, enzalutamide, apalutamide, darolutamide); Prior taxane or lutetium Lu 177 vipivotide tetraxetan allowed",ALL,A,"Disease matches mCRPC cohorts and the patient meets prior AR-targeted therapy requirements (abiraterone, enzalutamide); stage/setting is metastatic and refractory. Age/sex are compatible and no exclusion criteria are evident from available data.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches mCRPC cohort. Stage/setting (metastatic/refractory) and prior exposure (≥1 AR-targeted therapy) both match. Other requirements (e.g., measurable disease, adenocarcinoma histology, SOC status) are unknown, not mismatches. Grade A is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT00692939,0.6685259342193604,Fistulizing Crohn's Disease,Autologous Stem Cell Transplantation with CD34-Selected Peripheral Blood Stem Cells (PBSC) in Pediatric and Adult Patients with Severe Crohn's Disease,The objective of this study is to evaluate the safety and effectiveness of administering high-dose chemotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC) in pediatric and adult patients with severe Crohn's disease.,"{'id': 206002425, 'name': 'autologous CD34-selected peripheral blood stem cells transplant', 'description': 'high-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)', 'other_names': [], 'intervention_type': 'BIOLOGICAL'}; {'id': 206002426, 'name': 'Alemtuzumab', 'description': 'Transplant conditioning', 'other_names': ['Campath-1H'], 'intervention_type': 'DRUG'}; {'id': 206002427, 'name': 'ATG', 'description': 'Transplant conditioning', 'other_names': ['Anti-thymocyte globulin, rabbit; Thymoglobulin'], 'intervention_type': 'DRUG'}; {'id': 206002428, 'name': 'Melphalan', 'description': 'Transplant conditioning', 'other_names': ['L-phenylalanine mustard, phenylalanine mustard, L-PAM, or L-sarcolysin'], 'intervention_type': 'DRUG'}; {'id': 206002429, 'name': 'Thiotepa', 'description': 'Transplant conditioning', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206002430, 'name': 'Rituximab', 'description': 'Transplant conditioning', 'other_names': ['Rituxan'], 'intervention_type': 'DRUG'}; {'id': 206002431, 'name': 'Cyclophosphamide', 'description': 'Mobilization', 'other_names': ['Cytoxan'], 'intervention_type': 'DRUG'}; {'id': 206002432, 'name': 'G-CSF', 'description': 'Mobilization', 'other_names': ['Neupogen, Granix, Zarxio, Filgrastim'], 'intervention_type': 'DRUG'}; {'id': 206002433, 'name': 'Mesna', 'description': 'Mobilization', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,10 years to 60 years,Crohn's Disease,"Age 10–60 years | Severe, refractory Crohn's Disease appropriate for stem cell transplant therapy | Prior surgery with severe recurrent disease despite aggressive maintenance therapy | Diffuse small bowel and colonic disease refractory to aggressive medical treatment and not eligible for surgery without high risk of short bowel syndrome or other contraindications to surgery | Persistently high disease activity: HBI > 6 or CDAI > 250 or PCDAI > 45, or moderate disease (HBI <= 6, CDAI < 250, PCDAI 30–45) requiring daily corticosteroids and aggressive medical treatment to maintain status | Resistant complications unresponsive to medical management (e.g., multiple enteric fistulas, enterovesicular or enterovaginal fistulas, severe perianal disease, debilitating arthritis, severe skin lesions such as pyoderma, severe bony complications such as aseptic necrosis or pathologic fractures) | Severe complications from medical therapy (e.g., pancreatitis from 6-mercaptopurine, colitis from 5-ASA, severe hypersensitivity to TNF-alpha inhibitors, anti-integrin agents, or anti-IL12/23 agents) | Stoma present is allowed | No surgical therapeutic option due to risk of short bowel syndrome or patient refusal | Harvey Bradshaw Index > 5, or CDAI > 250, or PCDAI > 30 | Platelet count > 100,000/µL | Absolute neutrophil count > 1500/µL | Creatinine <= 2.0 mg/dL | No history of coronary artery disease; LVEF >= 40% or shortening fraction >= 26% | FEV1/FVC >= 60% predicted; DLCO >= 60% predicted | Negative pregnancy test for females of childbearing potential | Agreement to use effective contraception during treatment and for up to 24 months after PBSC transplant or while on any medication that may harm a pregnancy","No prior adequate dosing of 6-mercaptopurine, 5-ASA products, and metronidazole | Sustained corticosteroid-free response to anti-TNF-alpha, anti-integrin, or anti-IL12/23 therapy after a 4-month course | Toxic megacolon | Intestinal perforation | Conjugated bilirubin > 2.0 mg/dL | Pregnancy or nursing | HIV seropositive, HTLV seropositive, HBsAg positive, or HCV RNA positive by PCR | Active infection within two weeks of mobilization and high-dose chemotherapy | Other significant medical problems or abnormal findings that increase risk, interfere with compliance, or impact data quality in the investigator's opinion","Prior adequate dosing of 6-mercaptopurine, 5-ASA products, and metronidazole required; Prior surgery allowed",ALL,B,"Disease and severity match well (CDAI 350, severe perianal fistulizing disease; age 32 within 10–60). However, the trial requires prior adequate dosing of 6-mercaptopurine, 5-ASA, and metronidazole and specific organ function/infection criteria, which are unknown for this patient, so only one core anchor is confirmed.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,B,"No hard exclusions. Disease matches Crohn’s. Stage/severity clearly matches (severe, refractory, fistulizing). Line/prior exposure has a required prior dosing (6-MP, 5-ASA, metronidazole) that is unknown, so cannot be counted as a match. No soft mismatches identified. Exactly one core anchor confirmed → Grade B per rubric.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT01962415,0.6685259342193604,Fistulizing Crohn's Disease,"A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation","The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). After transplant, subjects will be followed for late effects and for ongoing graft success.","{'id': 206509891, 'name': 'Hydroxyurea', 'description': 'Oral administration', 'other_names': ['hydroxycarbamide', 'Hydrea', 'Droxia'], 'intervention_type': 'DRUG'}; {'id': 206509892, 'name': 'Alemtuzumab', 'description': 'Intravenous (IV) administration.', 'other_names': ['Campath'], 'intervention_type': 'DRUG'}; {'id': 206509893, 'name': 'Fludarabine', 'description': 'IV administration', 'other_names': ['Fludara'], 'intervention_type': 'DRUG'}; {'id': 206509894, 'name': 'Melphalan', 'description': 'IV administration', 'other_names': ['Melphalan hydrochloride', 'Alkeran'], 'intervention_type': 'DRUG'}; {'id': 206509895, 'name': 'Thiotepa', 'description': 'IV administration', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,2 months to 55 years,Primary Immunodeficiency; Congenital Bone Marrow Failure Syndrome; Inherited Metabolic Disorder; Hereditary Anemia; Crohn's Disease; Inflammatory Bowel Disease; Juvenile Rheumatoid Arthritis; Systemic Juvenile Idiopathic Arthritis,"Availability of a suitable graft: 4/6–6/6 HLA matched related or unrelated UCB unit with total nucleated cells >= 3 x 10^7/kg (or double units each >= 2 x 10^7/kg) or 8/8 or 7/8 HLA allele-matched unrelated donor bone marrow or peripheral blood progenitor graft | Serum creatinine <= 2.0 mg/dL | Creatinine clearance >= 50 mL/min | ALT <= 4 x ULN | AST <= 4 x ULN | Cardiac function adequate: shortening fraction > 26% or ejection fraction > 40% or > 80% of normal for age | Pulmonary function: FEV1/FVC >= 50% predicted for age | Pulmonary function: DLCO (hemoglobin-corrected) >= 50% predicted (adults, if obtainable) | Resting pulse oximetry >= 92% on room air | HIV negative | Negative pregnancy test if pubertal and/or menstruating | Non-malignant disorder amenable to HSCT, including primary immunodeficiency syndromes (e.g., SCID with NK activity, Omenn, BLS, CID, CVID, Wiskott-Aldrich, leukocyte adhesion deficiency, CGD, X-linked hyper IgM, IPEX, Chediak-Higashi, ALPS, HLH, lymphocyte signaling defects) | Congenital bone marrow failure syndromes (e.g., dyskeratosis congenita, congenital amegakaryocytic thrombocytopenia, osteopetrosis) | Inherited metabolic disorders (e.g., mucopolysaccharidoses [Hurler, Hunter], leukodystrophies [Krabbe, metachromatic leukodystrophy, X-linked adrenoleukodystrophy, HDLS], alpha mannosidosis, Gaucher disease) | Hereditary anemias (e.g., thalassemia major, sickle cell disease with qualifying complications, Diamond-Blackfan anemia, other congenital transfusion-dependent anemias) | Inflammatory conditions (e.g., Crohn's disease/Inflammatory Bowel Disease)","Allogeneic hematopoietic stem cell transplant within the previous 6 months | Active malignancy or myelodysplastic syndrome | Severe acquired aplastic anemia | Uncontrolled bacterial, viral, or fungal infection with progression of clinical symptoms despite therapy | Pregnancy or nursing | Poorly controlled pulmonary hypertension | Any condition that precludes serial follow-up",(none),ALL,B,"Disease matches (Crohn’s/IBD) and age/sex fit; no disallowed prior therapies. However, the transplant-specific setting (undergoing HSCT with suitable graft and required organ function) is unknown, so eligibility on that core criterion is uncertain.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),INCORRECT,C,"No hard exclusions. Disease matches and age/sex fit, but those are not core anchors. Stage/setting (HSCT candidate with suitable graft) is unknown; line/prior exposure not specified; other anchors not applicable. Thus 0 CORE ANCHOR matches and no soft conflict → C, not B.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT02038140,1.0,Rheumatoid Arthritis,Prospective Post Market Clinical Follow-Up (PMCF) Study of the Zimmer® Trabecular Metal™ Total Ankle,"The primary objective of this study is to obtain implant survivorship and clinical outcome data for commercially available Zimmer Trabecular Metal Total Ankle implants used in primary or revision total ankle arthroplasty. The assessment will include implant survivorship and clinical performance measured by pain and function, quality of life data, radiographic parameters and survivorship.","{'id': 205974295, 'name': 'Zimmer Trabecular Metal Total Ankle System', 'description': 'Primary or revision total ankle replacement', 'other_names': ['Primary Ankle Replacement', 'Total Ankle Arthroplasty', 'Total Ankle Replacement'], 'intervention_type': 'DEVICE'}",NA,18 years,Degenerative Arthritis; Post-traumatic Arthritis; Rheumatoid Arthritis,"Age > 18 years | Skeletally mature | Eligible for primary or revision total ankle arthroplasty for degenerative arthritis, rheumatoid arthritis, or post-traumatic arthritis","Ankle arthrodesis with malleolar exeresis compromising the affected limb | Severe neurological disease affecting the limb | Severe vascular disease affecting the limb | Loss of musculature or neuromuscular compromise affecting the limb | Severe instability, maltracking, or misalignment of the tibia and talus uncorrectable by surgery | Local or systemic infection that may affect the prosthetic joint | Previous history of infection in the affected joint | Pregnant | Insufficient bone stock or bone quality to fix components (e.g., osteoporosis, Charcot disease) | Known sensitivity or allergic reaction to implanted materials",(none),ALL,B,"Disease (rheumatoid arthritis) matches and prior treatments do not conflict with any trial restrictions; age and sex meet eligibility. However, the trial requires eligibility for total ankle arthroplasty, which is not specified for this patient.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),INCORRECT,C,"No hard exclusions. Disease (RA) matches, but stage/setting (eligibility for total ankle arthroplasty) is unknown, line/prior exposure not specified by trial, no required biomarkers, and mets pattern not applicable—so 0 CORE ANCHORS clearly match and no soft mismatch. Per rubric this is C, not B.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02101775,0.7943270802497864,Recurrent Clear Cell Ovarian Carcinoma,"A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers","This randomized phase II clinical trial studies how well gemcitabine hydrochloride and WEE1 inhibitor MK-1775 work compared to gemcitabine hydrochloride alone in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of time. Gemcitabine hydrochloride may prevent tumor cells from multiplying by damaging their deoxyribonucleic acid (DNA, molecules that contain instructions for the proper development and functioning of cells), which in tur...","{'id': 206131675, 'name': 'Adavosertib', 'description': 'Given PO', 'other_names': ['AZD 1775', 'AZD-1775', 'AZD1775', 'MK 1775', 'MK-1775', 'MK1775'], 'intervention_type': 'DRUG'}; {'id': 206131676, 'name': 'Gemcitabine Hydrochloride', 'description': 'Given IV', 'other_names': ['dFdCyd', 'Difluorodeoxycytidine Hydrochloride', 'Gemcitabine HCI', 'Gemzar', 'LY 188011', 'LY-188011', 'LY188011'], 'intervention_type': 'DRUG'}; {'id': 206131677, 'name': 'Laboratory Biomarker Analysis', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206131678, 'name': 'Pharmacological Study', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206131679, 'name': 'Placebo Administration', 'description': 'Given PO', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206131680, 'name': 'Questionnaire Administration', 'description': 'Ancillary studies', 'other_names': [], 'intervention_type': 'OTHER'}",PHASE2,18 years,Ovarian Carcinoma (recurrent); Primary Peritoneal Carcinoma (recurrent); Fallopian Tube Carcinoma (recurrent),"Histologically or cytologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma. | Platinum-resistant (platinum-free interval < 6 months) or platinum-refractory disease with radiologic or clinical progression. | Measurable disease per RECIST 1.1 with at least one lesion >= 10 mm. | Completed prior chemotherapy, radiotherapy, or major surgery >= 4 weeks before treatment; treatment toxicities <= grade 1 (except grade 2 alopecia or peripheral neuropathy). | Palliative radiation to < 10% of bone marrow allowed if completed >= 1 week before treatment; previously irradiated lesions excluded as targets unless progression documented. | ECOG <=2 (Karnofsky >=70% equivalent; protocol allows >=60%). | Life expectancy > 3 months. | Able to tolerate oral medication; no active bowel obstruction. | Disease amenable to biopsy; willing to undergo paired biopsies (pre-treatment within 28 days and on-treatment).","Prior gemcitabine for the treatment of recurrent disease. | Concurrent treatment with other investigational agents. | Clinically or radiologically unstable brain metastases (stable >= 3 months after treatment allowed; off or on stable steroids). | History of hypersensitivity to adavosertib (AZD1775/MK-1775), gemcitabine, or similar compounds. | Concomitant sensitive CYP3A4 substrates, CYP3A4 substrates with a narrow therapeutic index, or moderate/strong CYP3A4 inhibitors/inducers (unless discontinued >= 2 weeks prior and withheld until 2 weeks after last dose). | Pregnant or breastfeeding. | HIV-positive patients on combination antiretroviral therapy. | Uncontrolled intercurrent illness (e.g., myocardial infarction within 6 months, congestive heart failure, unstable angina, active cardiomyopathy, unstable ventricular arrhythmia, uncontrolled hypertension, uncontrolled psychotic disorders, serious infections, active peptic ulcer disease, active liver disease, cerebrovascular disease with prior stroke, or psychiatric/social conditions limiting compliance).","Prior platinum-based therapy required (platinum-resistant or platinum-refractory disease).; Any number of prior lines of therapy allowed.; Washout: >= 4 weeks since prior chemotherapy, radiotherapy, or major surgery; toxicities recovered to <= grade 1 (except grade 2 alopecia or peripheral neuropathy).; Palliative radiotherapy to < 10% of bone marrow allowed if completed >= 1 week before treatment; irradiated lesions not targetable unless progressed.",FEMALE,B,"Disease and stage/setting match (recurrent epithelial ovarian cancer in a 36-year-old female with prior platinum). However, platinum-resistant/refractory status and RECIST-measurable, biopsy-amenable disease are not specified, so key eligibility elements are unknown.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,B,"No hard exclusions. Disease matches (recurrent epithelial ovarian cancer). One core anchor matches (stage/setting = recurrent). Line/prior exposure (platinum-resistant/refractory) and measurable/biopsy-amenable disease are unknown, with no soft mismatches identified. Thus, grade B per rubric.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02446600,0.8971775770187378,Recurrent Clear Cell Ovarian Carcinoma,"A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","This phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may stop the growth of ovarian, fallopian tube, or primary peritoneal cancer by blocking ...","{'id': 206615874, 'name': 'Biospecimen Collection', 'description': 'Undergo blood sample collection', 'other_names': ['Biological Sample Collection', 'Biospecimen Collected', 'Specimen Collection'], 'intervention_type': 'PROCEDURE'}; {'id': 206615875, 'name': 'Carboplatin', 'description': 'Given IV', 'other_names': ['Blastocarb', 'Carboplat', 'Carboplatin Hexal', 'Carboplatino', 'Carboplatinum', 'Carbosin', 'Carbosol', 'Carbotec', 'CBDCA', 'Displata', 'Ercar', 'JM-8', 'JM8', 'Nealorin', 'Novoplatinum', 'Paraplatin', 'Paraplatin AQ', 'Paraplatine', 'Platinwas', 'Ribocarbo'], 'intervention_type': 'DRUG'}; {'id': 206615876, 'name': 'Cediranib Maleate', 'description': 'Given PO', 'other_names': ['AZD2171', 'AZD2171 Maleate', 'Recentin'], 'intervention_type': 'DRUG'}; {'id': 206615877, 'name': 'Computed Tomography', 'description': 'Undergo CT', 'other_names': ['CAT', 'CAT Scan', 'Computed Axial Tomography', 'Computerized Axial Tomography', 'Computerized axial tomography (procedure)', 'Computerized Tomography', 'Computerized Tomography (CT) scan', 'CT', 'CT Scan', 'tomography'], 'intervention_type': 'PROCEDURE'}; {'id': 206615878, 'name': 'Echocardiography Test', 'description': 'Undergo ECHO', 'other_names': ['EC', 'Echocardiography'], 'intervention_type': 'PROCEDURE'}; {'id': 206615879, 'name': 'Gemcitabine', 'description': 'Given IV', 'other_names': ['dFdC', 'dFdCyd', 'Difluorodeoxycytidine'], 'intervention_type': 'DRUG'}; {'id': 206615880, 'name': 'Gemcitabine Hydrochloride', 'description': 'Given IV', 'other_names': ['dFdCyd', 'Difluorodeoxycytidine Hydrochloride', 'Gemcitabine HCI', 'Gemzar', 'LY 188011', 'LY-188011', 'LY188011'], 'intervention_type': 'DRUG'}; {'id': 206615881, 'name': 'Laboratory Biomarker Analysis', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206615882, 'name': 'Magnetic Resonance Imaging', 'description': 'Undergo MRI', 'other_names': ['Magnetic Resonance', 'Magnetic Resonance Imaging (MRI)', 'Magnetic resonance imaging (procedure)', 'Magnetic Resonance Imaging Scan', 'Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance', 'MR', 'MR Imaging', 'MRI', 'MRI Scan', 'MRIs', 'NMR Imaging', 'NMRI', 'Nuclear Magnetic Resonance Imaging', 'sMRI', 'Structural MRI'], 'intervention_type': 'PROCEDURE'}; {'id': 206615883, 'name': 'Multigated Acquisition Scan', 'description': 'Undergo MUGA', 'other_names': ['Synchronized Multigated Acquisition Scanning', 'Blood Pool Scan', 'Equilibrium Radionuclide Angiography', 'Gated Blood Pool Imaging', 'Gated Heart Pool Scan', 'MUGA', 'MUGA Scan', 'Multi-Gated Acquisition Scan', 'Radionuclide Ventriculogram Scan', 'Radionuclide Ventriculography', 'RNV Scan', 'RNVG', 'SYMA Scanning'], 'intervention_type': 'PROCEDURE'}; {'id': 206615884, 'name': 'Olaparib', 'description': 'Given PO', 'other_names': ['AZD 2281', 'AZD-2281', 'AZD2281', 'KU 0059436', 'KU-0059436', 'KU0059436', 'Lynparza', 'Olanib', 'Olaparix', 'PARP Inhibitor AZD2281'], 'intervention_type': 'DRUG'}; {'id': 206615885, 'name': 'Paclitaxel', 'description': 'Given IV', 'other_names': ['Anzatax', 'Asotax', 'Bristaxol', 'Praxel', 'Taxol', 'Taxol Konzentrat'], 'intervention_type': 'DRUG'}; {'id': 206615886, 'name': 'Pegylated Liposomal Doxorubicin Hydrochloride', 'description': 'Given IV', 'other_names': ['ATI-0918', 'Caelyx', 'Dox-SL', 'Doxil', 'Doxilen', 'Doxorubicin HCl Liposomal', 'Doxorubicin HCl Liposome', 'Doxorubicin Hydrochloride Liposome', 'Duomeisu', 'Evacet', 'LipoDox', 'Lipodox 50', 'Liposomal Adriamycin', 'Liposomal Doxorubicin Hydrochloride', 'Liposomal-Encapsulated Doxorubicin', 'Pegylated Doxorubicin HCl Liposome', 'Pegylated Liposomal Doxorubicin', 'S-Liposomal Doxorubicin', 'Stealth Liposomal Doxorubicin', 'TLC D-99'], 'intervention_type': 'DRUG'}; {'id': 206615887, 'name': 'Pharmacological Study', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206615888, 'name': 'Quality-of-Life Assessment', 'description': 'Ancillary studies', 'other_names': ['Quality of Life Assessment'], 'intervention_type': 'OTHER'}",PHASE3,18 years,Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Tumor; Ovarian Seromucinous Carcinoma; Ovarian Serous Tumor; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Primary Peritoneal Carcinoma,"Platinum-sensitive recurrent high-grade serous or high-grade endometrioid ovarian, primary peritoneal, or fallopian tube cancer; other high-risk histologies (clear cell, mixed epithelial, undifferentiated, or transitional cell) allowed if deleterious germline BRCA1 or BRCA2 mutation is present | Platinum-sensitive disease: > 6 months since last platinum and complete clinical response to prior platinum; no progression through prior platinum therapy | Measurable disease by RECIST 1.1 OR evaluable disease with CA-125 doubled from nadir and > 2 x ULN | Prior chemotherapy must have included a first-line platinum-based regimen; unlimited prior platinum-based regimens in the recurrent setting allowed | Up to 1 prior non-platinum-based line in the recurrent setting allowed; prior hormonal therapy does not count toward this limit | ECOG performance status 0–2 (Karnofsky >= 60%) | Able to swallow and retain oral medications; no gastrointestinal illness precluding absorption | Blood pressure <= 140/90 mmHg on up to three antihypertensive medications; able and willing to record daily BP | Toxicities from prior therapy resolved to <= grade 1 (except alopecia); long-standing stable grade 2 neuropathy may be allowed (will not receive carboplatin/paclitaxel if randomized to that arm) | Adequately controlled thyroid function; TSH within normal limits without symptoms of thyroid dysfunction | Women of childbearing potential: negative pregnancy test and agreement to use two reliable forms of contraception | Age >= 18 years","Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to starting treatment, or unresolved toxicities from prior therapy > grade 1 | Hormonal therapy within 2 weeks prior to study entry (except raloxifene for bone health) | Concurrent investigational agents or investigational trial participation within 4 weeks | Medications that may markedly affect renal function (e.g., vancomycin, amphotericin, pentamidine) | Prior treatment affecting the VEGF pathway (e.g., thalidomide, sunitinib, pazopanib, sorafenib, nintedanib) in the recurrent setting; upfront bevacizumab allowed | Prior PARP inhibitor | CA-125–only disease without RECIST 1.1 measurable or otherwise evaluable disease | Untreated or symptomatic brain metastases, spinal cord compression, or leptomeningeal disease; treated brain metastases must be radiographically stable >= 6 months and asymptomatic | Strong CYP3A4 inhibitors or inducers; strong UGT/P-gp modulators should be used with caution | History of gastrointestinal perforation; abdominal fistula unless healed and no evidence for >= 6 months and low risk of recurrence | Intra-abdominal abscess within 3 months | Current signs/symptoms of bowel obstruction or within 3 months prior to starting study drugs | Dependency on IV hydration or total parenteral nutrition | Other invasive malignancy unless meeting specified curatively treated exceptions and disease-free >= 3 years | Myocardial infarction within 6 months, unstable angina, clinically significant ECG abnormalities, or NYHA class III/IV heart failure | Left ventricular ejection fraction below institutional normal or < 55% if no institutional threshold | History of stroke or transient ischemic attack within 6 months | Any prior hypertensive crisis or hypertensive encephalopathy | Clinically significant peripheral or other vascular disease (including aortic aneurysm or dissection) | Major surgery, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib | Uncontrolled intercurrent illness (active infection, symptomatic CHF, unstable angina, significant arrhythmia other than controlled AF, or psychiatric/social conditions limiting compliance) | Pregnancy or breastfeeding | Known HIV-positive status | Use of complementary or alternative medicines (natural herbal products or folk remedies) | Features suggestive of myelodysplastic syndrome or acute myelogenous leukemia on smear or marrow (if evaluated) | Prior allogeneic bone marrow transplant or double umbilical cord blood transplantation",Required prior first-line platinum-based chemotherapy (with or without IV consolidation); Unlimited prior platinum-based regimens in the recurrent setting allowed; Up to 1 prior non-platinum-based line in the recurrent setting allowed; Prior hormonal therapy allowed and does not count toward non-platinum limit; Washout: chemotherapy or radiotherapy >= 4 weeks (>= 6 weeks for nitrosoureas or mitomycin C) before study treatment; Washout: hormonal therapy >= 2 weeks before study entry,FEMALE,B,"Disease and setting are relevant and prior platinum-based therapy (with upfront bevacizumab) is compatible, and age/sex fit. However, platinum-sensitive status and, for clear cell histology, confirmation of a deleterious germline BRCA1/2 mutation are not established from the provided data.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,B,"No hard exclusions. Disease matches. Stage/setting (recurrent) matches. Line/prior is uncertain due to unknown platinum-sensitive status despite prior first-line platinum being compatible. Required biomarker for clear cell (deleterious germline BRCA) is not confirmed. With exactly one clear anchor match and no soft mismatch, B is appropriate.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02502266,0.7943270802497864,Recurrent Clear Cell Ovarian Carcinoma,"A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)","This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned (recurrent) after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory). Cediranib maleate and olaparib may ...","{'id': 206130346, 'name': 'Cediranib', 'description': 'Given PO', 'other_names': ['AZ-D2171', 'AZD 2171', 'AZD2171'], 'intervention_type': 'DRUG'}; {'id': 206130347, 'name': 'Cediranib Maleate', 'description': 'Given PO', 'other_names': ['AZD2171', 'AZD2171 Maleate', 'Recentin'], 'intervention_type': 'DRUG'}; {'id': 206130348, 'name': 'Computed Tomography', 'description': 'Undergo CT', 'other_names': ['CAT', 'CAT Scan', 'Computed Axial Tomography', 'Computerized Axial Tomography', 'Computerized axial tomography (procedure)', 'Computerized Tomography', 'Computerized Tomography (CT) scan', 'CT', 'CT Scan', 'Diagnostic CAT Scan', 'Diagnostic CAT Scan Service Type', 'tomography'], 'intervention_type': 'PROCEDURE'}; {'id': 206130349, 'name': 'Magnetic Resonance Imaging', 'description': 'Undergo MRI', 'other_names': ['Nuclear Magnetic Resonance Imaging', 'sMRI', 'Structural MRI', 'Magnetic Resonance', 'Magnetic Resonance Imaging (MRI)', 'Magnetic resonance imaging (procedure)', 'Magnetic Resonance Imaging Scan', 'Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance', 'MR', 'MR Imaging', 'MRI', 'MRI Scan', 'MRIs', 'NMR Imaging', 'NMRI'], 'intervention_type': 'PROCEDURE'}; {'id': 206130350, 'name': 'Olaparib', 'description': 'Given PO', 'other_names': ['AZD 2281', 'AZD-2281', 'AZD2281', 'KU 0059436', 'KU-0059436', 'KU0059436', 'Lynparza', 'Olanib', 'Olaparix', 'PARP Inhibitor AZD2281'], 'intervention_type': 'DRUG'}; {'id': 206130351, 'name': 'Paclitaxel', 'description': 'Given IV', 'other_names': ['Anzatax', 'Asotax', 'Bristaxol', 'Praxel', 'Taxol', 'Taxol Konzentrat'], 'intervention_type': 'DRUG'}; {'id': 206130352, 'name': 'Pegylated Liposomal Doxorubicin Hydrochloride', 'description': 'Given IV', 'other_names': ['ATI-0918', 'Caelyx', 'Dox-SL', 'Doxil', 'Doxilen', 'Doxorubicin HCl Liposomal', 'Doxorubicin HCl Liposome', 'Doxorubicin Hydrochloride Liposome', 'Duomeisu', 'Evacet', 'LipoDox', 'Lipodox 50', 'Liposomal Adriamycin', 'Liposomal Doxorubicin Hydrochloride', 'Liposomal-Encapsulated Doxorubicin', 'Pegylated Doxorubicin HCl Liposome', 'Pegylated Liposomal Doxorubicin', 'S-Liposomal Doxorubicin', 'Stealth Liposomal Doxorubicin', 'TLC D-99'], 'intervention_type': 'DRUG'}; {'id': 206130353, 'name': 'Questionnaire Administration', 'description': 'Ancillary studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206130354, 'name': 'Topotecan', 'description': 'Given IV', 'other_names': ['Hycamptamine', 'Topotecan Lactone'], 'intervention_type': 'DRUG'}; {'id': 206130355, 'name': 'Topotecan Hydrochloride', 'description': 'Given IV', 'other_names': ['Evotopin', 'Hycamptamine', 'Hycamtin', 'Nogitecan Hydrochloride', 'Potactasol', 'SKF S 104864 A', 'SKF S-104864-A', 'SKF S104864A', 'Topotec', 'Topotecan HCl', 'topotecan hydrochloride (oral)'], 'intervention_type': 'DRUG'}",PHASE2/PHASE3,18 years,Ovarian Carcinoma (recurrent); Primary Peritoneal Carcinoma (recurrent); Fallopian Tube Carcinoma (recurrent),"Histologically or cytologically confirmed ovarian, primary peritoneal, or fallopian tube cancer | Serous or endometrioid histology (high-grade for non-mutation carriers) | Clear cell, mixed epithelial, undifferentiated, or transitional cell histologies eligible only with a known deleterious germline BRCA1 or BRCA2 mutation | Recurrent platinum-resistant or platinum-refractory disease (progression on platinum or recurrence within 6 months of last platinum); rising CA-125 only is not sufficient | Phase II: measurable disease by RECIST 1.1 | Phase III: evaluable disease (RECIST 1.1 measurable or non-measurable disease or disease-related ascites/pleural effusion with CA-125 >= 2 x ULN) | No more than 3 prior treatment regimens (including primary therapy) with no more than 1 prior non-platinum regimen in the platinum-resistant/refractory setting | Hormonal single-agent therapies (tamoxifen, aromatase inhibitors) do not count toward line limit | No prior anti-angiogenic agent in the recurrent setting (prior bevacizumab allowed in upfront/maintenance) | No prior PARP inhibitor | ECOG performance status 0–2 | ANC >= 1,500/µL | Platelets >= 100,000/µL | Hemoglobin >= 10 g/dL | Total bilirubin <= 1.5 x ULN | AST <= 3 x ULN (<= 5 x ULN if intrahepatic liver metastases) | ALT <= 3 x ULN (<= 5 x ULN if intrahepatic liver metastases) | Creatinine <= 1.5 x ULN | Urine protein/creatinine ratio <= 1 or <= 2+ proteinuria on dipstick confirmed by 24-hour urine protein <= 500 mg/24 h | Toxicities from prior therapy resolved to <= grade 1 (except alopecia); stable long-standing grade 2 neuropathy may be allowed | Blood pressure controlled (<= 140/90 mmHg) on up to 3 antihypertensive medications and able to monitor BP | Thyroid-stimulating hormone within normal limits and no symptoms of thyroid dysfunction | Able to swallow and retain oral medications; no GI illnesses precluding absorption | Age >= 18 years | Women of child-bearing potential: negative pregnancy test and agreement to use two reliable forms of contraception (timing per drug-specific requirements)","Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to starting treatment or unresolved toxicities from prior therapy > grade 1 | Hormonal therapy within 2 weeks prior to study entry (raloxifene for bone health allowed absent interactions) | Investigational agents within 4 weeks prior to study entry | Prior anti-angiogenic therapy targeting VEGF/VEGFR or angiopoietin pathways in the recurrent setting (e.g., thalidomide, bevacizumab, sunitinib, sorafenib, pazopanib, cediranib, nintedanib, trebananib); upfront bevacizumab allowed | Prior PARP inhibitor use | CA-125 only disease without RECIST 1.1 measurable or otherwise evaluable disease | Major surgery, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib | Current signs/symptoms of bowel obstruction or bowel obstruction within 3 months prior to starting study drugs | History of intra-abdominal abscess within 3 months | History of gastrointestinal perforation; abdominal fistula unless repaired/healed with no evidence for >= 6 months and low risk of recurrence | Dependency on IV hydration or total parenteral nutrition | Concomitant or prior invasive malignancy except certain curatively treated in situ or early-stage cancers and cancers disease-free >= 5 years | Untreated brain metastases, spinal cord compression, symptomatic brain metastases, or leptomeningeal disease; treated brain metastases require stable imaging for >= 6 months and symptom resolution | History of myocardial infarction within 6 months, unstable angina, clinically significant ECG abnormalities, or NYHA class III/IV heart failure | Left ventricular ejection fraction below normal per institutional guidelines or < 55% if no institutional threshold | History of stroke or transient ischemic attack within 6 months | Clinically significant peripheral vascular disease or major vascular disease (e.g., aortic aneurysm or dissection) | Coagulopathy or bleeding diathesis (therapeutic anticoagulation permitted) | Evidence suggestive of myelodysplastic syndrome or acute myelogenous leukemia | Prior allogeneic bone marrow transplant or double umbilical cord blood transplant | Use of complementary or alternative medicines (natural herbal products/folk remedies) that might interfere with study treatments | Uncontrolled intercurrent illness including active infection, symptomatic congestive heart failure, unstable angina, significant cardiac arrhythmia (other than controlled atrial fibrillation), or psychiatric/social conditions limiting compliance | Known HIV infection (due to potential drug interactions and infection risks) | Concomitant strong CYP3A4 inhibitors or inducers (strong UGT/P-gp modulators to be used with caution) | Pregnancy or breastfeeding",No more than 3 prior regimens (including primary therapy); No more than 1 prior non-platinum therapy in the platinum-resistant/refractory setting; No prior anti-angiogenic therapy in the recurrent setting (upfront bevacizumab allowed); No prior PARP inhibitor; Washout: chemotherapy/radiotherapy >= 4 weeks (>= 6 weeks for nitrosoureas or mitomycin C); Washout: hormonal therapy >= 2 weeks; Washout: investigational agents >= 4 weeks,FEMALE,B,"Disease and recurrent setting align and prior/exposure limits fit (upfront bevacizumab allowed; no prior PARP; limited prior regimens), but key requirements are uncertain: platinum-resistant/refractory status, confirmation of a deleterious germline BRCA1 mutation for clear cell histology, and evaluable disease per trial (e.g., CA-125/measurable) are not specified.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),INCORRECT,A,"No hard exclusions. Stage/setting matches (recurrent) and line/prior-exposure is compatible (no prior PARP; bevacizumab only upfront; within line limits). Required BRCA germline deleterious status is unknown, which per rubric should not penalize; no soft mismatches identified. That yields ≥2 CORE ANCHOR matches, so grade should be A. The grader’s B was too conservative and cited evaluable disease, which isn’t a core anchor.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT02921477,1.0,Dementia,Open Label Study for the Use of Tyrosine Kinase Inhibitors for Treatment of Cognitive Decline Due to Degenerative Dementias,The present study is designed as an open label study of patients with mild cognitive impairment or dementia to evaluate longer term tolerability and potential efficacy of tyrosine kinase inhibitors. Baseline and outcome measures in this study utilize validated tests that are appropriate for repeated measures which are not affected by practice effects. Advantages of this study include the fact that the neuropsychological testing instruments and advanced MRI imaging protocols that have been in ...,"{'id': 205379130, 'name': 'bosutinib', 'description': None, 'other_names': ['bosulif', 'TKI'], 'intervention_type': 'DRUG'}",PHASE1,45 years to 89 years,Dementia; Mild Cognitive Impairment,"Cognitive decline with mild cognitive impairment through moderate dementia (CDR 0.5–2) | At least one abnormal brain imaging biomarker (e.g., MRI volumetrics, ASL perfusion, or MRS) at entry","History of hypersensitivity to bosutinib | Contraindications to lumbar puncture (e.g., bleeding abnormalities, anticoagulant use, local skin or spine abnormalities) | Reversible causes of cognitive impairment explaining status entirely (e.g., hypothyroidism, depression) | Advanced stages of any terminal illness or any active cancer that requires chemotherapy | Pre-existing renal impairment | Pre-existing hepatic impairment | QT prolongation | Significant cytopenia | Cardiovascular, cerebrovascular, or peripheral vascular arterial thrombosis | Pregnant, may become pregnant, or breastfeeding | Women of child-bearing potential and male participants with female partners who are of child-bearing potential | Unable to give informed consent or in vulnerable categories (e.g., prisoners)",(none),ALL,B,"Disease, age/sex, and stage (moderate dementia) match the trial’s inclusion range with no known exclusions. However, the required abnormal brain imaging biomarker (e.g., MRI volumetrics/ASL/MRS) is not provided for the patient, preventing a higher-confidence match.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,B,"No hard exclusions. Disease and stage match; age/sex within limits. Required abnormal brain imaging biomarker is unknown (not a definite mismatch), so only one core anchor (stage/setting) clearly matches with no soft conflicts. Grade B per rubric.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT03017131,0.7943270802497864,Recurrent Clear Cell Ovarian Carcinoma,A Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination With Decitabine in Patients With Recurrent or Treatment Refractory Ovarian Cancer,"This phase I trial studies the side effects of genetically modified T cells and decitabine in treating patients with recurrent or refractory epithelial or non-epithelial ovarian, primary peritoneal, or fallopian tube cancer that has come back or has not responded to previous treatments. White blood cells called T cells are collected via a process called leukapheresis, genetically modified to recognize and attack tumor cells, then given back to the patient. Decitabine may induce and increase t...","{'id': 205898327, 'name': 'Aldesleukin', 'description': 'Given SC', 'other_names': ['125-L-Serine-2-133-interleukin 2', 'Proleukin', 'r-serHuIL-2', 'Recombinant Human IL-2', 'Recombinant Human Interleukin-2'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205898328, 'name': 'Cyclophosphamide', 'description': 'Given IV', 'other_names': ['(-)-Cyclophosphamide', '2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate', 'Carloxan', 'Ciclofosfamida', 'Ciclofosfamide', 'Cicloxal', 'Clafen', 'Claphene', 'CP monohydrate', 'CTX', 'CYCLO-cell', 'Cycloblastin', 'Cycloblastine', 'Cyclophospham', 'Cyclophosphamid monohydrate', 'Cyclophosphamidum', 'Cyclophosphan', 'Cyclophosphane', 'Cyclophosphanum', 'Cyclostin', 'Cyclostine', 'Cytophosphan', 'Cytophosphane', 'Cytoxan', 'Fosfaseron', 'Genoxal', 'Genuxal', 'Ledoxina', 'Mitoxan', 'Neosar', 'Revimmune', 'Syklofosfamid', 'WR- 138719'], 'intervention_type': 'DRUG'}; {'id': 205898329, 'name': 'Decitabine', 'description': 'Given IV', 'other_names': [""5-Aza-2'-deoxycytidine"", 'Dacogen', 'Decitabine for Injection', 'Deoxyazacytidine', 'Dezocitidine'], 'intervention_type': 'DRUG'}; {'id': 205898330, 'name': 'Genetically Engineered NY-ESO-1-specific T Lymphocytes', 'description': 'Given IV and IP', 'other_names': [], 'intervention_type': 'BIOLOGICAL'}; {'id': 205898331, 'name': 'Laboratory Biomarker Analysis', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}",PHASE1,18 years,Ovarian Carcinoma (recurrent); Primary Peritoneal Carcinoma (recurrent); Fallopian Tube Carcinoma (recurrent),"Recurrent or refractory epithelial or non-epithelial ovarian, primary peritoneal, or fallopian tube carcinoma | Prior platinum-containing chemotherapy; platinum-refractory or resistant disease, or if platinum-sensitive, received >= 2 lines of chemotherapy | HLA-A*02:01 positive | ECOG performance status 0-1 | Life expectancy > 4 months | >= 4 weeks since prior chemotherapy, radiotherapy, immunotherapy, or investigational agents | Measurable disease by irRECIST | Adequate venous access for apheresis | Women of childbearing potential agree to use acceptable contraception | Leukocytes >= 3 x 10^9/L | Absolute neutrophil count >= 1 x 10^9/L | Platelets >= 100 x 10^9/L | Total bilirubin within normal limits | AST/ALT <= 2.5 x ULN | Creatinine <= 2 x ULN or creatinine clearance > 60 mL/min","Receiving other investigational agents | Active brain metastases | Allergic reactions to cyclophosphamide, decitabine, or similar agents | Prior malignancy (except non-melanoma skin cancer) within 3 years | Uncontrolled intercurrent illness including active infection or significant psychiatric illness | Chronic corticosteroids, hydroxyurea, or immunomodulating agents within 30 days (except inhaled steroids or brief oral courses < 7 days) | Active HIV infection | Active hepatitis B infection (HBsAg positive) | Active hepatitis C infection (HCV RNA positive) | Active cytomegalovirus infection (CMV IgG positive for active CMV) | Previous gene therapy using an integrating vector within 6 months | Pregnancy or breastfeeding | Significant cardiac disease (MI within 6 months, significant arrhythmia, or CHF class III/IV) | Pulmonary function abnormality with FEV1/FVC < 70% predicted","Prior platinum-containing chemotherapy required; If platinum-sensitive, must have received >= 2 prior lines of chemotherapy; Prior PARP inhibitors allowed; Prior bevacizumab allowed; Prior immunotherapy allowed; Washout >= 4 weeks from prior chemotherapy, radiotherapy, immunotherapy, or investigational agents",FEMALE,B,"Disease and setting match (recurrent ovarian cancer), and she has prior platinum therapy. However, HLA‑A*02:01 status and whether she is platinum‑resistant or, if platinum‑sensitive, has ≥2 prior lines are unknown, so only one core anchor clearly matches.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,B,"No hard exclusions. Disease and recurrent setting match. Line/prior-exposure is uncertain due to unknown platinum sensitivity and only one known prior line; required HLA-A*02:01 status is unknown. Thus exactly one core anchor clearly matches, supporting grade B.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT03048201,1.0,Rheumatoid Arthritis,Post-market Registry Study on the Physica System Total Knee Replacement,"The primary objective of this study is to obtain long-term implant survivorship (out to 10 years) and to assess clinical, patient-reported outcome measures, and radiographic data for the commercially available Physica system. For ancillary arm, from baseline to 5-year follow-up.","{'id': 205624305, 'name': 'Physica Kinematic Retaining Knee System', 'description': 'Modular total knee prosthesis with a Kinematic Retaining mechanism and posterior cruciate ligament (PCL) preservation', 'other_names': [], 'intervention_type': 'DEVICE'}; {'id': 205624306, 'name': 'Physica Cruciate Retaining Knee System', 'description': 'Total knee prosthesis with posterior cruciate ligament (PCL) preservation', 'other_names': [], 'intervention_type': 'DEVICE'}; {'id': 205624307, 'name': 'Physica Posterior Stabilized Knee System', 'description': 'Total knee prosthesis that sacrifices the posterior cruciate ligament (PCL) and replaces the functionality of the PCL with a post-cam mechanism.', 'other_names': [], 'intervention_type': 'DEVICE'}; {'id': 205624308, 'name': 'Physica Cruciate Retaining Knee System with LMC Liner', 'description': 'Total knee prosthesis with posterior cruciate ligament (PCL) preservation', 'other_names': [], 'intervention_type': 'DEVICE'}",NA,22 years,Avascular Necrosis; Knee Deformity; Degenerative Joint Disease (knee); Knee Osteoarthritis; Rheumatoid Arthritis; Traumatic Arthritis,Age > 22 years (skeletally mature) | Candidate for total knee replacement suitable for a Physica system configuration | Non-inflammatory degenerative joint disease of the knee | Knee osteoarthritis | Post-traumatic knee arthritis | Inflammatory arthritis | Functional knee deformity requiring correction | Intact and functional collateral ligaments | For Physica KR or CR: intact and functional posterior cruciate ligament | For Physica LMC: with or without a functioning posterior cruciate ligament | For Physica PS: absent or non-functioning posterior cruciate ligament and/or severe antero-posterior instability of the knee,"Severe knee joint instability due to absent collateral ligament integrity or function | Active or suspected infection (local to the knee or systemic) | Previous partial knee replacement (unicompartmental, bicompartmental, or patellofemoral), patellectomy, or high tibial osteotomy | Significant bone loss on femoral or tibial side | Current treatment for malignant or life-threatening non-malignant disorders | Known incompatibility or allergy to implant materials or metal hypersensitivity | Severe vascular insufficiency of lower limbs interfering with evaluation | Bone stock compromised by disease, infection, or prior implantation that cannot support/fix the prosthesis | Systemic or metabolic disorders causing progressive bone deterioration that may impair fixation and stability | Concomitant disease or dependence that might affect prosthesis performance | Clinically significant pathology that may affect evaluation (e.g., primary osteoporosis with significant bone loss, hemophilic disease, septicemia, persistent acute or chronic osteomyelitis) | Significant neurological or musculoskeletal disorders that may adversely affect gait and recovery | Neuromuscular or neurosensory deficit limiting assessment of device performance | Previous history of infection in the affected joint or other local/systemic infections that may affect the prosthetic joint | Psychiatric illness preventing study comprehension | Currently participating in other surgical intervention or pain management studies | Pregnant, nursing, or planning pregnancy",(none),ALL,B,"Disease matches (rheumatoid arthritis) and age fits, satisfying one core anchor. However, the trial requires candidacy for total knee replacement and specific knee/ligament criteria, which are not provided, so stage/setting and prior-exposure anchors are unknown.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),INCORRECT,C,"Age fit is not a CORE ANCHOR. Stage/setting (TKR candidacy) is unknown, line/prior exposure is not specified as required/forbidden, biomarkers and mets pattern are not applicable. No hard exclusions or clear soft mismatches. With 0 anchors matched/known, the correct grade is C, not B.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT03219359,0.6691051721572876,Fistulizing Crohn's Disease,Maintenance in Autologous Stem Cell Transplant for Crohn's Disease (MASCT - CD),"Crohn's Disease (CD) is an inflammatory bowel disease. It can lead to significant complications and discomfort in the stomach and intestines. Crohn's disease is a debilitating, incurable disease of immune cells; it affects almost 1 million people in the United States. CD is characterized by inflammation of the stomach and intestine as well as organs outside of the intestines such as the skin, eyes, and joints. Current therapies to treat CD aim to suppress the patient's immune cells but these ...","{'id': 205504852, 'name': 'Autologous stem cell transplant', 'description': 'Hematopoietic stem cell transplantation', 'other_names': ['Bone Marrow Transplant'], 'intervention_type': 'PROCEDURE'}; {'id': 205504853, 'name': 'Cyclophosphamide', 'description': 'Days 1 and 2: Cyclophosphamide 2gm/m2/day x 2 days (total dose 4gm/m2) Day 3 until leukapheresis: G-CSF 10μg/kg/day to CD34+ \\>20x104/ml then leukapheresis daily to collection goal', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205504854, 'name': 'Cyclophosphamide', 'description': 'Day -6 to -3: Cyclophosphamide 50 mg/kg/day (200 mg/kg total dose)', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205504855, 'name': 'Thymoglobulin', 'description': 'Day -3 to -1: 2.5 mg/kg/day (7.5 mg/kg total dose)', 'other_names': ['ATG'], 'intervention_type': 'DRUG'}; {'id': 205504856, 'name': 'Methylprednisolone', 'description': 'Day -3 to -1: 1 gram prior to each ATG dose', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205504857, 'name': 'Vedolizumab', 'description': 'Starting first day after discharge from transplant admission, then 2 weeks after 1st infusion, 4 weeks after 2nd infusion, followed by every 8 weeks for 52 weeks (8 doses)', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,18 years,Crohn Disease,"Diagnosis of Crohn's disease by standard criteria | Active disease with CDAI > 250 (ostomy patients: number of liquid stools score replaced by daily ostomy bag emptying frequency) | Active endoscopic disease with SES-CD > 3 in at least one bowel segment | Failure to respond, intolerance/adverse reaction, or refusal for: corticosteroids | Failure to respond, intolerance/adverse reaction, or refusal for: azathioprine | Failure to respond, intolerance/adverse reaction, or refusal for: 6-mercaptopurine or methotrexate | Failure to respond, intolerance/adverse reaction, or refusal for: anti-TNF agents (infliximab, adalimumab, certolizumab, golimumab) | Failure to respond, intolerance/adverse reaction, or refusal for: anti-integrin agents (natalizumab, vedolizumab) | Failure to respond, intolerance/adverse reaction, or refusal for: ustekinumab | No surgical therapeutic option due to risk of short bowel syndrome or patient refusal","History of significant toxicity to cyclophosphamide, antithymocyte globulin, or vedolizumab | Pregnant or breastfeeding | Age < 18 | Karnofsky Performance Score < 60 | Uncontrolled infection (presumed or documented) despite appropriate therapy for at least one month | Symptomatic coronary artery disease or uncontrolled congestive heart failure | HIV infected | Left ventricular ejection fraction < 30% or requiring supplemental continuous oxygen | DLCO < 35% or requiring supplementary oxygen | Insufficient stem cell collection (< 2 x 10^6/kg)","Failed corticosteroids; Failed azathioprine; Failed 6-mercaptopurine; Failed methotrexate; Failed anti-TNF therapy (e.g., infliximab, adalimumab, certolizumab, golimumab); Failed anti-integrin therapy (e.g., natalizumab, vedolizumab); Failed ustekinumab",ALL,B,"Disease and setting match (active Crohn’s with CDAI >250; age/sex eligible), and the patient is refractory to anti-TNF and ustekinumab. However, key inclusion requirements are undocumented (failure of steroids/immunomodulators/anti-integrin, SES-CD >3, and no surgical option), so eligibility is uncertain but not conflicting.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,B,"No hard exclusions apply. Disease matches. Stage/setting matches (active Crohn’s with CDAI >250). Line/prior-exposure requirements are only partially documented (steroids/immunomodulators/anti-integrin and SES-CD >3, no-surgery option unknown), so not a confirmed second anchor. No soft mismatches identified. Grade B per rubric.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT03414502,1.0,Rheumatoid Arthritis,Treatment of Rheumatoid Arthritis With Disease-modifying Antirheumatic Drugs (DMARDs): Predictors of Response,"Rheumatoid arthritis (RA) is a common disease with approximately 1% prevalence. RA is also a chronic, progressive disease with no cure. Current treatment goals are to minimize pain, limit joint damage, and prevent loss of function. Drugs used to treat RA include non-steroidal anti-inflammatory drugs (NSAIDS), glucocorticoids, and disease-modifying anti-rheumatic drugs (DMARDs), including biologics. Methotrexate (MTX) is the DMARD of choice in the treatment of RA, because it has been shown to ...","{'id': 206416558, 'name': 'Methotrexate', 'description': 'Starting dose of Methotrexate of 15 mg once a week plus folic acid 1mg daily.', 'other_names': ['Methotrexate (MTX)'], 'intervention_type': 'DRUG'}; {'id': 206416559, 'name': 'Abatacept', 'description': ""Starting dose may be adjusted as needed at investigator's discretion."", 'other_names': ['Orencia'], 'intervention_type': 'DRUG'}; {'id': 206416560, 'name': 'Adalimumab', 'description': ""Starting dose may be adjusted as needed at investigator's discretion."", 'other_names': ['Humira'], 'intervention_type': 'DRUG'}; {'id': 206416561, 'name': 'Azathioprine', 'description': ""Starting dose may be adjusted as needed at investigator's discretion."", 'other_names': ['Imuran'], 'intervention_type': 'DRUG'}; {'id': 206416562, 'name': 'Baricitinib', 'description': ""Starting dose may be adjusted as needed at investigator's discretion."", 'other_names': ['Olimuant'], 'intervention_type': 'DRUG'}; {'id': 206416563, 'name': 'Certolizumab', 'description': ""Starting dose may be adjusted as needed at investigator's discretion."", 'other_names': ['Cimzia'], 'intervention_type': 'DRUG'}; {'id': 206416564, 'name': 'Etanercept', 'description': ""Starting dose may be adjusted as needed at investigator's discretion."", 'other_names': ['Enbrel'], 'intervention_type': 'DRUG'}; {'id': 206416565, 'name': 'Golimumab', 'description': ""Starting dose may be adjusted as needed at investigator's discretion."", 'other_names': ['Simponi'], 'intervention_type': 'DRUG'}; {'id': 206416566, 'name': 'Hydroxychloroquine', 'description': ""Starting dose may be adjusted as needed at investigator's discretion."", 'other_names': ['Plaquenil'], 'intervention_type': 'DRUG'}; {'id': 206416567, 'name': 'Infliximab', 'description': ""Starting dose may be adjusted as needed at investigator's discretion."", 'other_names': ['Remicade'], 'intervention_type': 'DRUG'}; {'id': 206416568, 'name': 'Leflunomide', 'description': ""Starting dose may be adjusted as needed at investigator's discretion."", 'other_names': ['Arava'], 'intervention_type': 'DRUG'}; {'id': 206416569, 'name': 'Minocycline', 'description': ""Starting dose may be adjusted as needed at investigator's discretion."", 'other_names': ['Minocin'], 'intervention_type': 'DRUG'}; {'id': 206416570, 'name': 'Rituximab', 'description': ""Starting dose may be adjusted as needed at investigator's discretion."", 'other_names': ['Rituxin'], 'intervention_type': 'DRUG'}; {'id': 206416571, 'name': 'Sarilumab', 'description': ""Starting dose may be adjusted as needed at investigator's discretion."", 'other_names': ['Kevzara'], 'intervention_type': 'DRUG'}; {'id': 206416572, 'name': 'Sulfasalazine', 'description': ""Starting dose may be adjusted as needed at investigator's discretion."", 'other_names': ['Azulfidine'], 'intervention_type': 'DRUG'}; {'id': 206416573, 'name': 'Tofacitinib', 'description': ""Starting dose may be adjusted as needed at investigator's discretion."", 'other_names': ['Xeljanz'], 'intervention_type': 'DRUG'}",PHASE3,19 years,Rheumatoid Arthritis,"Diagnosed rheumatoid arthritis with >= 4 of 7 American College of Rheumatology criteria | > 19 years old at rheumatoid arthritis diagnosis | Active disease with at least 1 swollen joint | Starting new DMARD medication(s) (abatacept, adalimumab, azathioprine, baricitinib, certolizumab, etanercept, golimumab, hydroxychloroquine, infliximab, leflunomide, methotrexate, minocycline, rituximab, sarilumab, sulfasalazine, tofacitinib) | If on other DMARDs, must be on stable dose for >= 6 weeks | If on glucocorticoids, must be on stable dose for 2 weeks (< 10 mg prednisone/day or equivalent) | Hemoglobin > 9 g/dL | Platelets > 100 | Creatinine < 1.6 | AST or ALT <= 1.2 x ULN | Albumin up to 1.0 g/dL below lower limit of normal",Pregnant or breastfeeding | Men and women of childbearing potential unwilling to use effective contraception,Starting new DMARD therapy required; Other DMARDs allowed if on stable dose for >= 6 weeks; Glucocorticoids allowed if on stable dose for 2 weeks and < 10 mg prednisone/day or equivalent,ALL,B,"Disease matches and the patient has active RA, aligning with the trial’s active-disease setting. However, it’s not specified that she is starting a new DMARD (a requirement) or that she meets lab/contraception criteria, so key eligibility elements are unknown.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,B,"No hard exclusions. Disease matches. Stage/setting (active RA) matches. Line-of-therapy (starting a new DMARD) is unknown, and no other anchors apply; no soft mismatches identified. Exactly one core anchor match → B per rubric.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT03511625,1.0,Rheumatoid Arthritis,The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis: A Pilot Study,"Patients will be assigned to receive either Depo Medrol or Acthar treatment. A synovial biopsy, blood draws, synovial fluid aspiration, and physician assessments will be performed before and after initiating treatment.","{'id': 205652543, 'name': 'Acthar Injectable Product', 'description': 'Acthar is a non-specific melanocortin receptor agonist', 'other_names': ['repository corticotropin injection', 'H.P. Acthar Gel'], 'intervention_type': 'DRUG'}; {'id': 205652544, 'name': 'Depo medrol', 'description': 'Depo medrol is an anti-inflammatory glucocorticoid', 'other_names': ['methylprednisolone acetate injectable suspension'], 'intervention_type': 'DRUG'}",PHASE3,18 years,Rheumatoid Arthritis,Anti-CCP positive rheumatoid arthritis | On a stable regimen of medications | Moderate to severe disease activity by CDAI or DAS28 within 30 days of starting the study | At least one tender joint within 30 days of starting the study | At least one swollen joint within 30 days of starting the study | Ultrasound Doppler signal +2 or +3 in a joint within 30 days of starting the study | Ultrasound gray-scale synovitis +2 or +3 in a joint within 30 days of starting the study | Joint amenable to synovial biopsy | Clinician attribution that joint swelling and tenderness are due to rheumatoid arthritis,Current anticoagulation therapy | Active infection | Use of oral corticosteroids within 5 days of enrollment | Use of parenteral corticosteroids within 3 weeks of enrollment | Any history of joint infection | History of tuberculosis | History of coccidioidomycosis,(none),ALL,B,"Disease and stage/setting match (active moderate–severe RA), and prior biologic exposure is compatible with the trial. However, required anti-CCP positivity and ultrasound/biopsy criteria are not documented, so key eligibility requirements remain unknown.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,B,"No hard exclusions. Disease matches. One clear core anchor match (stage/setting: active moderate–severe RA). Biomarker (anti-CCP) and ultrasound/biopsy requirements are unknown, not mismatches. Line/prior exposure is compatible but not a required match. Thus B is appropriate; the grader’s reasoning aligns with the rubric.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT03517969,0.929232120513916,Castration-Resistant Prostate Cancer,"A Phase 2 Study of M6620 (VX-970, Berzosertib) in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer","This phase II trial studies how well berzosertib (M6620) and carboplatin with or without docetaxel works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from di...","{'id': 206612273, 'name': 'Berzosertib', 'description': 'Given IV', 'other_names': ['2-Pyrazinamine, 3-(3-(4-((Methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-', 'M 6620', 'M6620', 'VX 970', 'VX-970', 'VX970'], 'intervention_type': 'DRUG'}; {'id': 206612274, 'name': 'Carboplatin', 'description': 'Given IV', 'other_names': ['Blastocarb', 'Carboplat', 'Carboplatin Hexal', 'Carboplatino', 'Carboplatinum', 'Carbosin', 'Carbosol', 'Carbotec', 'CBDCA', 'Displata', 'Ercar', 'JM-8', 'JM8', 'Nealorin', 'Novoplatinum', 'Paraplatin', 'Paraplatin AQ', 'Paraplatine', 'Platinwas', 'Ribocarbo'], 'intervention_type': 'DRUG'}; {'id': 206612275, 'name': 'Docetaxel', 'description': 'Given IV', 'other_names': ['Docecad', 'RP 56976', 'RP-56976', 'RP56976', 'Taxotere', 'Taxotere Injection Concentrate'], 'intervention_type': 'DRUG'}; {'id': 206612276, 'name': 'Laboratory Biomarker Analysis', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}",PHASE2,18 years,Castration-Resistant Prostate Cancer (metastatic),"Histologically or cytologically confirmed prostate cancer with progressive disease (rising PSA or radiographic progression) | Metastatic disease on imaging and castrate testosterone < 50 ng/dL | Baseline PSA >= 2.0 ng/mL or measurable disease per RECIST 1.1 | Maintain castrate state (LHRH/GnRH therapy if no orchiectomy unless intolerant) | At least 2 prior treatments for castration-resistant prostate cancer | Prior progression or intolerance to at least one secondary hormonal therapy (e.g., abiraterone, enzalutamide, apalutamide, darolutamide, etc.) | Prior progression or intolerance to taxane-based chemotherapy | ECOG performance status <= 1 | Leukocytes >= 3,000/µL | Absolute neutrophil count >= 1,500/µL | Hemoglobin >= 9 g/dL | Platelets >= 150,000/µL | Total bilirubin <= 1.5 x ULN (except Gilbert syndrome) | AST <= 2.5 x ULN (<= 5 x ULN if liver metastases) | ALT <= 2.5 x ULN (<= 5 x ULN if liver metastases) | Creatinine clearance >= 40 mL/min | Prior treatment with mTOR inhibitors, TKIs, or biologic therapies allowed | Prior treatment with PARP inhibitors permitted | Lesion amenable to image-guided core biopsy for NGS prior to cycle 1 day 1 (may be waived per PI if required)","Chemotherapy or radiotherapy within 4 weeks prior to cycle 1 day 1 (6 weeks for nitrosoureas or mitomycin C) | Oral antineoplastic agents (including oral hormonal agents, PARP inhibitors, oral experimental agents) not discontinued >= 14 days prior to cycle 1 day 1 | Residual toxicities > grade 1 from prior therapy (except grade 2 anorexia, alopecia, neuropathy, or fatigue) | Concurrent treatment with other investigational agents | Known brain metastases or leptomeningeal disease | History of allergic reactions to compounds similar to berzosertib or carboplatin | Use of ototoxic or nephrotoxic medications that cannot be discontinued >= 7 days before first carboplatin dose and during study | Concomitant strong CYP3A4 inhibitors or inducers prohibited with berzosertib | Uncontrolled intercurrent illness (e.g., active infection, symptomatic CHF, unstable angina, significant arrhythmia, significant psychiatric illness) | Pregnant or nursing women | HIV-positive with detectable viral load and/or CD4 count <= 300/µL, or on interacting antiretroviral therapy | Prior platinum-containing regimen or prior ATR inhibitor for prostate cancer","Progression or intolerance to at least one secondary hormonal therapy required; Progression or intolerance to taxane-based chemotherapy required; Prior mTOR inhibitors, TKIs, or biologic therapies allowed; Prior PARP inhibitors permitted; Washout: chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to cycle 1 day 1 not allowed; Washout: oral antineoplastic agents discontinued >= 14 days prior to cycle 1 day 1",MALE,B,"Disease and setting (metastatic castration‑resistant prostate cancer) match, and he has progressed on secondary hormonal therapy. However, the trial requires prior progression or intolerance to taxane-based chemotherapy, which is not documented for this patient, so eligibility on that key criterion is uncertain.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,B,"No hard exclusions. Disease and metastatic setting match. Line/prior-exposure is uncertain due to missing documentation of prior taxane chemotherapy required by the trial, so not a clear match. Other anchors not applicable/unknown. Exactly one anchor matches → B per rubric. The grader’s reasoning aligns with this.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT03577418,1.0,Dementia,An Intervention to Reduce Discrepancy in Everyday Preferences,"Dementia is a disabling, progressive major neurocognitive disorder. Although cognitive symptoms drive the diagnosis of dementia, neuropsychiatric symptoms (NPS), such as depression, agitation/aggression, and psychosis, are common and associated with a number of significant adverse outcomes. There are currently extremely limited FDA (Food and Drug Administration)-approved treatments for NPS of dementia; there remains a critical need for safe and effective interventions for NPS that can be easi...","{'id': 206280969, 'name': 'Templated, clinician-facilitated intervention to align everyday living preferences assessment', 'description': 'In step 1, persons living with dementia or cognitive impairment (PLWD/CI) will complete the PELI (hereafter, ""assessment PELI-CI"" for Cognitive Impairment) to articulate their preferences. In step 2, care partners will consider the preferences of PLWD/CI; care partners will complete concurrent but separate proxy PELI assessments from the perspective of the PLWD/CI (i.e., as if acting as surrogate decision-makers; hereafter ""assessment PELI-CP"" for Care Partner). In the Intervention (step 3), the study clinician will ask the PLWD/CI to identify up to 3 ""social engagement"" preferences that matter most to them. Second, in discussion with the PLWD/CI and care partner, the study clinician will review areas where there is a difference in ratings between the PELI-CI and PELI-CP. The study clinician will then ask the PLWD/CI to identify up to 3 items of disagreement that are most important for the care partner to know about. A 1-page Preferences Priorities document will then be created.', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}",NA,55 years,Dementia; Mild Cognitive Impairment,Age >= 55 years | Community-dwelling | Primary diagnosis of mild cognitive impairment or mild to moderate dementia | Montreal Cognitive Assessment (MoCA) > 10 | Identified care partner (family member or close friend) with contact at least three times per week | Fluent in written and oral English,"No neuropsychiatric symptoms at baseline (NPI-Q score = 0) | Living in long-term care environments (e.g., nursing home, assisted living) | Comorbid active primary psychiatric illness (e.g., major depressive disorder, bipolar disorder, psychotic disorders)",(none),ALL,B,"Disease matches and stage/setting align (moderate dementia; age within range). MoCA >10 is required but not provided and there are no specific line/prior constraints, so only one core anchor is clearly satisfied.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,B,No hard exclusions. Disease matches and stage/setting (moderate dementia within mild–moderate) matches. Other core anchors are not applicable or unknown. Exactly one core anchor match without soft conflicts → B. The grader’s reasoning aligns with the rubric.,,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT03682081,1.0,Dementia,Impact of Novel Rehabilitative Approaches for Dysphagia in Patients With Alzheimer's Disease and Related Dementias,The overall purpose of this project is to develop effective dysphagia rehabilitative interventions for patients with Alzheimer's Disease and related dementias at risk for pneumonia development.,"{'id': 206388222, 'name': 'Isometric tongue strengthening facilitated by Iowa Oral Performance Instrument (IOPI)', 'description': 'An air-filled pressure bulb is placed on the surface of the oral tongue and pressed against the hard palate during exercise. Each patient is given a target pressure value to aim for as determined by the baseline one repetition maximum (1RM) lingual pressures. During week one of the regimen, the target value of each repetition will be 60% of the 1RM. For the remaining seven weeks, the target value will be increased to 80% of the 1RM. At weeks three, five, and seven, the baseline will be re-measured by phone and the 80% target value re-calculated.', 'other_names': ['Tongue strengthening'], 'intervention_type': 'DEVICE'}; {'id': 206388223, 'name': 'Biotene Oral Balance Gel', 'description': 'Participants will be instructed to apply an amount equivalent to about 1 cm of Biotene® Oral Balance Gel with a finger to the tongue and most intensely affected areas of the oral cavity three times a day after brushing their teeth for 8 weeks.', 'other_names': ['Saliva substitute'], 'intervention_type': 'DEVICE'}",NA,50 years to 99 years,Dysphagia; Alzheimer Disease,Age 50–99 | Diagnosis of dementia or cognitive impairment or memory loss | Clinical Dementia Rating (CDR) 0.5–2.0,Primary vascular dementia etiology | History of head and neck cancer | Structural oropharyngeal deformity affecting swallowing | Allergy to barium | Pregnant or breastfeeding or planning pregnancy,(none),ALL,B,"Disease matches (dementia is eligible) and stage/severity aligns with CDR 0.5–2.0 (moderate); other core anchors (prior therapy, biomarkers, metastatic pattern) are not specified. Age and sex fit and no listed exclusions apply.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,B,No hard exclusions. Disease matches since inclusion allows dementia broadly. One CORE ANCHOR (stage/severity aligning with CDR 0.5–2.0) matches; others are unspecified. Thus B is appropriate and the grader’s reasoning is consistent with the rubric.,,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT04104776,0.8482123017311096,Recurrent Clear Cell Ovarian Carcinoma,A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas,"The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.","{'id': 205951923, 'name': 'Tulmimetostat', 'description': 'Tulmimetostat dosed once per day orally in 28 day cycles', 'other_names': ['DZR123'], 'intervention_type': 'DRUG'}; {'id': 205951924, 'name': 'Enzalutamide', 'description': 'Enzalutamide dosed once per day orally in 28 day cycles', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,18 years,Urothelial Carcinoma; Ovarian Clear Cell Carcinoma; Endometrial Carcinoma; Peripheral T-Cell Lymphoma; Diffuse Large B-Cell Lymphoma; Malignant Mesothelioma; Prostate Cancer (metastatic castration-resistant),"Adults with locally advanced or metastatic solid tumors or lymphoma that relapsed/progressed after standard therapy or lack standard effective therapy (Phase 1) | ARID1A mutation by NGS, measurable disease per RECIST 1.1, and relapsed urothelial or other advanced/metastatic solid tumors (Cohort M1) | ARID1A mutation by NGS and ovarian clear cell carcinoma with measurable disease per RECIST 1.1 (Cohort M2) | ARID1A mutation by NGS and endometrial carcinoma with measurable disease per RECIST 1.1 (Cohort M3) | Relapsed or refractory PTCL (>=1 prior line) or DLBCL (>=2 prior lines) and not candidates for CAR-T or ASCT; includes GCB-DLBCL with EZH2 hotspot mutation (Cohort M4) | BAP1 loss and relapsed/refractory malignant pleural or peritoneal mesothelioma after >=1 prior line (Cohort M5) | mCRPC with measurable soft tissue disease (PCWG3), testosterone <= 50 ng/dL, ongoing surgical or medical castration, and progression after >=1 AR signaling inhibitor and >=1 taxane-based chemotherapy (Cohort M6) | Recurrent/advanced ARID1A wildtype endometrial carcinoma by NGS, measurable disease (RECIST 1.1), up to 2 prior systemic lines including platinum-based chemotherapy and PD-1/PD-L1 therapy unless contraindicated or not accessible (Cohort M7) | mCRPC with measurable soft tissue disease (PCWG3), testosterone <= 50 ng/dL, ongoing ADT; Part 1: abiraterone may have been received in mCRPC; Part 2: abiraterone must have been received in mCRPC; limited prior taxane regimens per part and evidence of progression (Cohort M8) | ECOG performance status <=1 | Adequate organ function","Prior solid organ or allogeneic hematopoietic cell transplantation | Symptomatic untreated brain metastases; CNS involvement by lymphoma (Cohort M4) | Recent MI or stroke within 3 months (6 months for Cohort M8) before Day 1 | Unstable angina within 3 months (6 months for Cohort M8) before Day 1 | NYHA Class 3 or 4 heart failure or cardiomyopathy | History of clinically significant ventricular arrhythmias | Uncontrolled hypertension despite 2 antihypertensives | QTcF > 480 msec (Cohorts M1–M6) | QTcF >= 450 msec (Cohorts M7 and M8) | Major surgery within 4 weeks or not recovered from prior surgery | Significant GI disorders affecting absorption (e.g., ulcerative colitis, malabsorption, refractory N/V, biliary shunt, significant bowel resection) | Uncontrolled active infection requiring IV antimicrobials within 14 days | Suspected pneumonitis or interstitial lung disease, or history of these conditions | Concurrent/second malignancy not meeting specified remission/low-risk exceptions; history of T-cell lymphoblastic lymphoma/leukemia | Active or chronic HIV, hepatitis B, or hepatitis C infection | Clinically active viral hepatitis or chronic liver disease | Any unstable or severe uncontrolled medical/psychiatric condition or significant abnormal labs increasing risk | Cohort M7: inability to remain fasted 2 hours before and 1 hour after dosing | Recent systemic anticancer therapy within 4 weeks or 5 half-lives (6 weeks for nitrosoureas/mitomycin C); prior PD-1/PD-L1 within >=4 weeks | Prior EZH2 inhibitor therapy | Radiation therapy (including RFA) within 4 weeks; single palliative fraction in 1 field allowed within 1 week | Stereotactic body radiation therapy within 2 weeks | Chemoembolization or radioembolization within 4 weeks | Concomitant strong CYP3A4/5 inducers or inhibitors within 7 days or 5 half-lives (except enzalutamide in Cohort M8) | Cohort M6: bone-only disease without nodal/visceral spread | Cohort M6: structurally unstable bone lesions at risk for fracture | Cohort M6: herbal products that may decrease PSA within 4 weeks and during study | Cohort M6: first-generation AR antagonists within 4 weeks; 5-alpha reductase inhibitors, ketoconazole, estrogens, or progesterones within 2 weeks | Cohort M6: planned palliative procedures for bone pain (e.g., RT or surgery) | Cohort M8 Part 1: prior enzalutamide | Cohort M8 Part 2: prior enzalutamide, apalutamide, darolutamide, or any investigational AR pathway inhibitor | Cohort M8: herbal products that may decrease PSA within 4 weeks and during study | Cohort M8: planned palliative procedures for bone pain (e.g., RT or surgery) | Cohort M8: investigational agent within 4 weeks before Day 1 | Cohort M8: prior irradiation to >25% of bone marrow | Cohort M8: active inflammatory GI disease, chronic diarrhea, diverticular disease, or prior gastric resection/lap band (PPI-treated GERD allowed) | Cohort M8: history of seizure, LOC, or TIA within 12 months, or conditions predisposing to seizure | Pregnancy or breastfeeding; plans to conceive/father children during and for 183 days after last dose | Inability or unwillingness to comply with protocol",PTCL: at least 1 prior line of therapy (Cohort M4); DLBCL: at least 2 prior lines of standard therapy; not candidates for CAR-T or ASCT (Cohort M4); Mesothelioma: progressed after at least 1 prior line of active therapy (Cohort M5); mCRPC: progressed after at least 1 androgen-receptor signaling inhibitor and at least 1 taxane-based chemotherapy (Cohort M6); Endometrial carcinoma (ARID1A WT): up to 2 prior systemic lines including platinum-based chemotherapy and PD-1/PD-L1 therapy unless contraindicated or not accessible (Cohort M7); mCRPC (Cohort M8): Part 1 may have received abiraterone in mCRPC; Part 2 must have received abiraterone in mCRPC; limited to no more than one prior taxane regimen as specified by part; Washout: no systemic anticancer therapy within 4 weeks or 5 half-lives (6 weeks for nitrosoureas/mitomycin C); PD-1/PD-L1 >= 4 weeks; radiation >= 4 weeks (single palliative fraction in 1 field allowed within 1 week); SBRT >= 2 weeks; chemoembolization/radioembolization >= 4 weeks,ALL,B,"Disease and stage/setting match for recurrent ovarian clear cell carcinoma, and prior therapy context is plausible. However, the cohort requires an ARID1A mutation and RECIST-measurable disease, both of which are not provided, so key eligibility elements are uncertain.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,B,"No hard exclusions. Disease matches and stage/setting (recurrent/advanced) aligns. Line/prior is not clearly required for the ovarian cohort, so only one clear CORE ANCHOR match. Required ARID1A mutation and measurable disease are unknown, preventing A. B is appropriate per rubric.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT04201873,0.8363864421844482,Recurrent Glioblastoma,Phase I Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the PD-1 Antibody Pembrolizumab With Autologous Tumor Lysate-Pulsed Dendritic Cell Vaccination in Patients With Surgically Accessible Recurrent/Progressive Glioblastoma,"This phase I trial studies the side effects and how well of pembrolizumab and a vaccine therapy (ATL-DC vaccine) work in treating patients with glioblastoma that has come back (recurrent) and can be removed by surgery (surgically accessible). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Vaccines, such as ATL-DC vaccine, may help the body build an effec...","{'id': 206076803, 'name': 'Dendritic Cell Tumor Cell Lysate Vaccine', 'description': 'Given ID', 'other_names': ['DC tumor cell lysate vaccine', 'dendritic cell-pulsed tumor cell lysate vaccine'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206076804, 'name': 'Pembrolizumab', 'description': 'Given IV', 'other_names': ['Keytruda', 'Lambrolizumab', 'MK-3475', 'SCH 900475'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206076805, 'name': 'Placebo Administration', 'description': 'Given IV', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206076806, 'name': 'Poly ICLC', 'description': 'Given IM', 'other_names': ['PolyI:PolyC with Poly-L-Lysine Stabilizer', 'Hiltonol', 'Poly I:Poly C with Poly-L-Lysine Stabilizer', 'poly-ICLC', 'Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose', 'Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose', 'Stabilized Polyriboinosinic/Polyribocytidylic Acid'], 'intervention_type': 'DRUG'}",PHASE1,18 years,Glioblastoma (recurrent),Histologically confirmed surgically accessible recurrent/progressive glioblastoma | First or second relapse | Undergoing clinically indicated surgery with expected ability to resect at least 2 g of tumor with low neurologic risk | MRI evidence of contrast-enhancing tumor progression per RANO within 14 days prior to randomization | Minimum tumor size 2 x 2 cm on MRI prior to surgery | At least 28 days from prior surgical resection before randomization | At least 7 days from prior stereotactic biopsy before randomization | At least 12 weeks from prior radiotherapy unless histologic confirmation of progression | At least 23 days from prior chemotherapy before randomization | At least 42 days from prior nitrosoureas before randomization | Karnofsky performance status >= 70 | Absolute neutrophil count >= 1500/µL within 14 days prior to start of study treatment | Platelets >= 100000/µL within 14 days prior to start of study treatment | Hemoglobin >= 9.0 g/dL within 14 days prior to start of study treatment without erythropoietin dependence and without PRBC transfusion within 2 weeks | Creatinine <= 1.5 x ULN or creatinine clearance >= 30 mL/min within 14 days prior to start of study treatment | Total bilirubin <= 1.5 x ULN or direct bilirubin <= ULN within 14 days prior to start of study treatment | AST <= 2.5 x ULN within 14 days prior to start of study treatment | ALT <= 2.5 x ULN within 14 days prior to start of study treatment | INR or PT <= 1.5 x ULN unless on anticoagulation with therapeutic range within 14 days prior to start of study treatment | aPTT <= 1.5 x ULN unless on anticoagulation with therapeutic range within 14 days prior to start of study treatment,"Positive pregnancy test within 72 hours prior to randomization | Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, or other T-cell co-inhibitory/stimulatory agents (e.g., CTLA-4, OX40, CD137) | Prior systemic anticancer therapy including investigational agents within 4 weeks prior to randomization | Not recovered from prior therapy adverse events to <= grade 1 (except <= grade 2 neuropathy) | Prior radiotherapy within 2 weeks of start of study treatment | Receipt of a live vaccine within 30 days prior to the first dose of study drug | Participation in another investigational study or use of an investigational device within 4 weeks prior to first dose | Diagnosis of immunodeficiency or chronic systemic steroid therapy > 10 mg prednisone equivalent daily or other immunosuppressive therapy within 7 days prior to first dose | Another malignancy that is progressing or requires active treatment within the past 3 years (except certain skin cancers or carcinoma in situ after curative therapy) | Tumor primarily localized to the brainstem or spinal cord | Severe hypersensitivity (>= grade 3) to pembrolizumab or its excipients | Active autoimmune disease requiring systemic treatment in the past 2 years | History of non-infectious pneumonitis requiring steroids or current pneumonitis | Active infection requiring systemic therapy | Known HIV infection | Known hepatitis B surface antigen positivity or active hepatitis C infection (HCV RNA detected) | Known active tuberculosis | Psychiatric or substance abuse disorder that would interfere with trial compliance | Pregnant or breastfeeding or planning to conceive/father children during treatment and for 120 days after last dose",At least 28 days since prior surgical resection; At least 7 days since prior stereotactic biopsy; At least 12 weeks since prior radiotherapy unless histologic confirmation of progression; At least 23 days since prior chemotherapy; At least 42 days since prior nitrosoureas; At first or second relapse after initial therapy,ALL,B,"Disease and line/prior-therapy fit (recurrent GBM at first relapse after chemoradiation; no prior PD-1), and age/sex meet criteria. However, key requirements such as surgically accessible disease with planned resection (≥2 g), tumor size, and KPS are not confirmed, so stage/setting cannot be fully matched.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,B,"No hard exclusions. Disease matches. Line/prior-exposure fits (first recurrence after chemoradiation; PD-1–naïve). Stage is recurrent, but key setting requirements (surgically accessible with planned resection ≥2 g, tumor size, KPS) are unknown, so the Stage/setting anchor cannot be confidently counted as a match. With exactly one confirmed core anchor and no soft conflicts, B is appropriate.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT04214392,0.8363864421844482,Recurrent Glioblastoma,A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for Patients With MMP2+ Recurrent or Progressive Glioblastoma,"This phase I trial studies the side effects and best dose of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain in treating patients with MPP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells.","{'id': 205806557, 'name': 'Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)', 'description': 'Given via ICT delivery', 'other_names': ['Chlorotoxin-CD28-CD3z-CD19t-expressing CAR T-cells'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205806558, 'name': 'Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)', 'description': 'Given via ICT/ICV dual delivery', 'other_names': ['Chlorotoxin-CD28-CD3z-CD19t-expressing CAR T-cells'], 'intervention_type': 'BIOLOGICAL'}",PHASE1,18 years,Glioblastoma (recurrent); Malignant Glioma (recurrent); WHO Grade II Glioma (recurrent); WHO Grade III Glioma (recurrent),"Karnofsky performance status >= 60% | ECOG <= 2 | Life expectancy >= 4 weeks | Histologically confirmed grade IV glioblastoma, or prior grade II/III malignant brain tumor with radiographic progression consistent with grade IV glioblastoma | Relapsed/progressive measurable disease after standard therapy and >= 12 weeks after completion of frontline radiation therapy | MMP2-positive tumor by IHC (>= 20% moderate/high staining) | No known contraindications to leukapheresis, steroids, or tocilizumab | WBC > 2000/µL or ANC >= 1000/µL (pre-leukapheresis) | Platelets >= 75,000/µL (pre-leukapheresis) | Hemoglobin >= 8 g/dL (pre-leukapheresis) | Total bilirubin <= 1.5 x ULN (pre-leukapheresis) | AST <= 2.5 x ULN (pre-leukapheresis) | ALT <= 2.5 x ULN (pre-leukapheresis) | Serum creatinine <= 1.6 mg/dL (pre-leukapheresis) | Oxygen saturation >= 95% on room air (pre-leukapheresis) | Seronegative for HIV Ag/Ab combo | Women of childbearing potential: negative pregnancy test | Females and males of childbearing potential agree to effective contraception or abstinence during study and for >= 3 months after last dose","Prior bevacizumab within 3 months before enrollment | Not recovered from toxicities of prior therapy | Uncontrolled seizure activity and/or clinically evident progressive encephalopathy | History of allergic reactions to compounds of similar composition to study agent | Active diarrhea | Clinically significant uncontrolled illness | Active infection requiring antibiotics | Known HIV, hepatitis B, or hepatitis C infection | Other active malignancy | Pregnant or breastfeeding | Any condition that, in the investigator's judgment, contraindicates participation due to safety concerns | Participant may be unable to comply with study procedures",Prior standard therapy required; >= 12 weeks since completion of frontline radiation therapy,ALL,B,"Disease and setting match (recurrent GBM post-standard therapy ≥12 weeks after radiation), and prior exposure, age, and ECOG fit trial criteria. Eligibility depends on required MMP2-positive tumor status and baseline labs/serologies, which are not provided.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),INCORRECT,A,"No hard exclusions. Disease matches, and both Stage/setting (recurrent post-standard therapy) and Line/prior (completed standard therapy and >12 weeks since RT implied by recurrence 3 months after adjuvant) match. MMP2 status is unknown and should not penalize per rubric. With ≥2 anchors matched and no soft conflicts, the correct grade is A, not B.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT05107674,0.8316181302070618,Castration-Resistant Prostate Cancer,"A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types","This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.","{'id': 206205261, 'name': 'NX-1607', 'description': 'Oral NX-1607', 'other_names': ['Cbl-b Inhibitor'], 'intervention_type': 'DRUG'}; {'id': 206205262, 'name': 'Paclitaxel', 'description': 'Paclitaxel IV', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,18 years,Cervical Cancer; Diffuse Large B-Cell Lymphoma; Gastric Cancer; Gastroesophageal Junction Cancer; Head and Neck Squamous Cell Carcinoma; Malignant Pleural Mesothelioma; Metastatic Castration-Resistant Prostate Cancer; Metastatic Urothelial Carcinoma; Melanoma (metastatic or unresectable); Microsatellite Stable Colorectal Carcinoma; Non-Small Cell Lung Cancer; Ovarian Cancer (epithelial); Richter Transformation; Triple Negative Breast Cancer,"Age >= 18 years | Measurable disease by disease-specific response criteria | Metastatic or unresectable disease and no suitable standard treatment options | ECOG performance status 0–1 | Minimum of 3 weeks or 5 half-lives (whichever is shorter) since last systemic cancer therapy | Minimum of 2 weeks since last radiotherapy | Minimum of 6 weeks since last nitrosoureas, antibody-drug conjugate, or radio-immuno-conjugate therapy | Adequate organ and bone marrow function without growth factors (limited exception for DLBCL) | Histologic/cytologic diagnosis of one of the specified malignancies (EOC, gastric/GEJ cancer, HNSCC, melanoma, NSCLC, mCRPC, MPM, TNBC, urothelial cancer, cervical cancer, MSS CRC, DLBCL including DLBCL-RT) | Accessible tumor (all cohorts) or lymph node (DLBCL only) for biopsy in Phase 1b","Active untreated brain metastases | Uncontrolled intercurrent illness (e.g., poorly controlled hypertension or diabetes, active infection requiring systemic therapy) | Primary refractory EOC (no response to first platinum regimen or relapse < 6 months after completion) | Psychiatric illness limiting compliance | Unresolved toxicities from prior therapy > Grade 1 (except Grade 2 alopecia or peripheral neuropathy, or patients on endocrine replacement therapy) | History of Grade >= 3 immune-related adverse events with prior immunotherapy | History of uveitis or active autoimmune disease requiring systemic treatment within 2 years (replacement therapy allowed) | Inability to swallow capsules or significant GI disease affecting absorption (e.g., malabsorption, resection of stomach/small bowel, ulcerative colitis, symptomatic IBD, bowel obstruction) | Known hypersensitivity to NX-1607 components | Pregnant or breastfeeding | Major surgery within 4 weeks before first dose or not fully recovered; planned major surgery during study or within 4 weeks after last dose | Live vaccine within 28 days or COVID-19 vaccine within 14 days prior to first NX-1607 dose | Active second malignancy except specified low-risk or remission conditions | HIV-1/2 infection unless well controlled (e.g., CD4 > 350/mm3 and undetectable viral load) | Active hepatitis A (IgM positive), hepatitis B (HBsAg positive), or hepatitis C (HCV RNA positive); HCV with undetectable virus after treatment is eligible; prior HBV exposure allowed if PCR negative | Systemic corticosteroids > 20 mg prednisone equivalent within 15 days (except prophylaxis for contrast reactions or with paclitaxel) or other immunosuppressive drugs within 30 days | Use of high-dose biotin (> 30 mcg/day) within 1 day prior to screening | Significant cardiovascular events within 6 months (myocardial infarction, unstable angina, symptomatic ischemic heart disease, NYHA Class III/IV heart failure, thromboembolic events, or other significant cardiac conditions) | Autologous or allogeneic stem cell transplant within 100 days prior to first dose | Receipt of an investigational product or device within 3 weeks or 5 half-lives (whichever is shorter) prior to first dose | Use of strong or moderate CYP3A4 inducers/inhibitors within specified windows (strong: within 14 days; moderate: within 7 days; or 5 half-lives, whichever is longer) | Prior CAR-T therapy within 30 days prior to first dose","Received and progressed after or are not candidates for standard treatments; Minimum washout: 3 weeks or 5 half-lives (whichever is shorter) since last systemic cancer therapy; Minimum washout: 2 weeks since last radiotherapy; Minimum washout: 6 weeks since last nitrosoureas, antibody-drug conjugate, or radio-immuno-conjugate therapy; Checkpoint inhibitor (PD-1/PD-L1/CTLA-4) washout >= 3 weeks before first dose; Autologous or allogeneic stem cell transplant washout >= 100 days before first dose; CAR-T therapy washout >= 30 days before first dose; Avoid strong CYP3A4 inducers for >= 14 days and moderate CYP3A4 inducers for >= 7 days (or 5 half-lives, whichever longer) before first dose; similar for inhibitors; mCRPC: at least 2 prior lines in advanced setting including androgen receptor-directed therapy and a taxane; MSS CRC: previously treated with >= 2 lines including a fluoropyrimidine, irinotecan, and/or oxaliplatin (and EGFR inhibitor if RAS wild-type)",ALL,B,"Disease and metastatic setting match the mCRPC cohort, and age/sex fit. Prior taxane exposure (required for mCRPC in this trial) and other key criteria (ECOG 0–1, measurable disease, washouts) are not provided, so line-of-therapy compatibility is uncertain but no explicit exclusion is evident.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),INCORRECT,D,"Disease and metastatic setting match, and no hard exclusions. However, the mCRPC cohort requires prior taxane exposure; the patient’s listed prior therapies do not include a taxane, which is a clear line/prior-exposure soft mismatch per the rubric. This should yield D rather than B.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05341947,1.0,Recurrent Glioblastoma,A Phase I Trial of Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma,"The purpose of this study is to examine the use of activated T cells (ATCs) to assess the safety and tolerability of autologous activated T cells, as measured by the number of Grade 3 or higher toxicities, the number of serious adverse events, and treatment-related toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of overall survival, rat...","{'id': 206453124, 'name': 'Activated T cells', 'description': 'Activated T cells (ATC) administered intravenously at one timepoint', 'other_names': [], 'intervention_type': 'BIOLOGICAL'}",PHASE1,18 years,Recurrent Glioblastoma,Recurrent glioblastoma | HLA-A1 positive | HLA-A2 positive | Complete resection of tumor,Clinically significant pulmonary disease | Clinically significant cardiac disease | Clinically significant systemic disease | Acute infection requiring active treatment with antibiotics or antivirals | Human immunodeficiency virus positivity or AIDS-related illness | Hepatitis B infection | Hepatitis C infection | Allergy to dimethyl sulfoxide (DMSO) | Allergy to gentamicin,(none),ALL,B,"Stage/setting matches recurrent glioblastoma and age/sex fit. However, eligibility hinges on required HLA-A1/A2 positivity and having a complete resection at enrollment, both of which are unknown for this patient.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,B,"No hard exclusions. Disease and stage/setting (recurrent GBM) match. Line/prior exposure compatibility is unspecified; biomarker (HLA-A1/A2) and resection-at-enrollment requirements are unknown, not mismatches. Exactly one core anchor confidently matches with no soft conflicts, which per rubric is a B.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05533372,1.0,Rheumatoid Arthritis,"Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IA-14069 in Healthy Subjects, With an Extension to Explore Any Drug-Drug Interaction Potential With Methotrexate (Part 1), and in Patients With Rheumatoid Arthritis, With Preliminary Assessment of Efficacy in Patients (Part 2)","The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending oral doses of IA-14069 in healthy subjects and in patients with RA on stable dosese of MTX, with preliminary assessment of efficacy in RA patients.","{'id': 206609588, 'name': 'IA-14069', 'description': 'IA-14069 for oral administration.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206609589, 'name': 'Placebo', 'description': 'Placebo for oral administration.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206609590, 'name': 'Methotrexate', 'description': 'Methotrexate for oral or SC administration.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206609591, 'name': 'Methotrexate', 'description': 'Methotrexate for oral administration.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,18 years to 70 years,Rheumatoid Arthritis,"Age 18–55 years for healthy subjects; 18–70 years for RA patients | BMI 18–32 kg/m2 for healthy subjects; 18–40 kg/m2 for RA patients | Weight >= 50 kg | Healthy status for Part 1; Rheumatoid arthritis for Part 2 | Females not pregnant or lactating at screening | Adequate contraception for females of childbearing potential and for non-sterilized males during study and for 90 days after last dose | Good physical and mental health based on history, exam, labs, ECG, and vital signs | Resting supine blood pressure without clinically relevant abnormalities | 12-lead ECG without clinically relevant abnormalities | Clinical laboratory tests within normal range or without clinically relevant deviations | RA patients: Methotrexate 5–25 mg weekly (oral or SC) as a DMARD for >=12 weeks prior to screening and stable dose for >=4 weeks before screening; expected to remain stable | RA patients: Active RA with >=6 swollen and >=6 tender joints and CRP >= ULN or ESR >= ULN","Use of any investigational drug or device within 30 days or 5 half-lives prior to admission | Any disease posing unacceptable risk in the opinion of the investigator | Pregnant or lactating females, or planning pregnancy within 90 days after last dose | Male participants with partners who are pregnant, lactating, or planning pregnancy within 90 days after last dose | History of relevant drug sensitivity or food allergies including anaphylaxis or hepatotoxicity | Allergy or hypersensitivity to the active ingredient or excipients | Tobacco or nicotine use within 60 days prior to dosing (Part 1) | Alcohol consumption exceeding 2 standard drinks per day on average within the previous 12 months | Positive drug or alcohol screen at screening or admission | Positive HBsAg, HCV antibodies, or HIV-1/2 antibodies | Donation or loss of >450 mL blood within 60 days prior to dosing or planned donation within 30 days after last dose | Plasma or platelet donation within 7 days prior to dosing through follow-up | Significant or acute illness within 5 days prior to dosing | Unsuitable veins for blood sampling | Chronic use of prescription or nonprescription drugs, vitamins, dietary or herbal supplements within 7–14 days or 5 half-lives prior to first dosing, except permitted medications | RA patients: Receiving a biologic DMARD or received within 6 weeks or 5 half-lives prior to screening | RA patients: Receiving a targeted synthetic DMARD or received within 6 weeks or 5 half-lives prior to screening | RA patients: Receiving a conventional synthetic DMARD (except methotrexate) or received within 6 weeks or 5 half-lives prior to screening | Strenuous activity, sunbathing, or contact sports within 48 hours prior to admission through follow-up | Consumption of grapefruit, pomelo, star fruit, or Seville orange products within 14 days prior to dosing and during the study | Receipt of SARS-CoV-2 or any other vaccine within 7 days prior to dosing | Healthy subjects: Clinically significant hepatic impairment based on LFTs or prothrombin time (Part 1) | Healthy subjects: Clinically significant renal impairment based on eGFR (CKD-EPI 2021) and proteinuria (Part 1) | RA patients: Any single ALT, AST, GGT, or ALP > 2.5 x ULN or total bilirubin > 1.5 x ULN, or more than one LFT parameter above ULN at screening and Day -3 (Part 2) | RA patients: eGFR (CKD-EPI 2021) < 60 mL/min/1.73m2 at screening and Day -3 (Part 2)",Methotrexate 5–25 mg weekly for >=12 weeks with stable dose for >=4 weeks prior to screening (RA patients),ALL,B,"Disease and age match, and the patient's active RA aligns with the trial’s RA cohort. However, eligibility hinges on being on stable methotrexate, meeting specific joint count/CRP-ESR criteria, and washout from recent biologic DMARDs—all unknown from the profile.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,B,"No hard exclusions. Disease matches and stage/setting (active RA cohort) matches. Line/prior-exposure compatibility (stable methotrexate background and biologic washout) is unknown, with no identified soft mismatch. Exactly one core anchor match → B.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05660369,1.0,Recurrent Glioblastoma,INCIPIENT: INtraventricular CARv3-TEAM-E T Cells for PatIENTs With GBM,The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).,"{'id': 206122343, 'name': 'CARv3-TEAM-E T cells', 'description': 'Autologous T lymphocyte population that contains cells transduced ex-vivo with a CARv3-TEAM-E lentiviral vector encoding a chimeric antigen receptor (CAR). Administered via Ommaya reservoir.', 'other_names': ['Autologous T lymphocyte'], 'intervention_type': 'DRUG'}",PHASE1,18 years,Glioblastoma; Recurrent Glioblastoma,"Histologically confirmed recurrent glioblastoma with EGFRvIII mutation (Arms: Safety Run-In and Arm 1) | First progression or recurrence and received prior radiation (Arms: Safety Run-In and Arm 1) | >=4 weeks since prior alkylating therapy or immunotherapy (Arms: Safety Run-In and Arm 1) | >=5 half-lives since another investigational agent (Arms: Safety Run-In and Arm 1) | Histologically confirmed newly diagnosed glioblastoma with EGFRvIII mutation and MGMT unmethylated (Arm 2) | Planned involved-field radiation alone without concomitant or sequential temozolomide (Arm 2) | Histologically confirmed recurrent glioblastoma, EGFRvIII negative with EGFR amplification (Arm 3) | First recurrence and received prior radiation (Arm 3) | >=4 weeks since prior alkylating therapy or immunotherapy (Arm 3) | >=5 half-lives since another investigational agent (Arm 3) | Measurable disease with at least one lesion >=10 mm on MRI | Leptomeningeal disease allowed | Resolution of prior therapy/radiotherapy adverse events to Grade 1 or baseline (except Grade 2 alopecia and Grade 2 sensory neuropathy) | Medically able and willing to undergo placement of an Ommaya reservoir | Steroid dose <=4 mg dexamethasone/day (or equivalent) at time of first infusion | Age >=18 years | Karnofsky >=60% | Able to undergo MRI with contrast | Life expectancy >3 months | Adequate organ and marrow function | Left ventricular ejection fraction >50%","Posterior fossa intraparenchymal disease | Intramedullary spinal disease as the only site of disease | Prior EGFRvIII-targeted therapies | Prior gene therapy or gene-modified cellular therapy | Chronic immunosuppressive treatment (e.g., cyclosporine or systemic steroids above physiologic dosing) | Unresolved toxicities from prior anti-cancer therapy > Grade 1 (except alopecia) | Concurrent treatment with other investigational agents | Allergy to compounds similar to CARv3-TEAM-E (e.g., cetuximab) | Uncontrolled intercurrent illness | HIV infection | Chronic hepatitis B virus infection or active hepatitis C virus infection | Psychiatric illness or social situations limiting compliance | Pregnancy or breastfeeding | Arm 2: Must have completed >=75% of planned 6 weeks of involved-field radiation without temozolomide prior to infusion | Arm 2: No prior cancer-directed therapy other than radiation",Recurrent arms: prior radiation required (first progression/recurrence); Washout: >=4 weeks from prior alkylating therapy or immunotherapy; Washout: >=5 half-lives from another investigational agent; Arm 2: planned involved-field radiation alone without temozolomide; Arm 2: completed >=75% of planned 6 weeks of radiation prior to infusion; Arm 2: no prior cancer-directed therapy other than radiation allowed,ALL,B,"The patient has recurrent glioblastoma with prior RT/TMZ and adequate washout, matching the trial’s disease and setting requirements. However, the trial requires specific EGFR alterations (EGFRvIII mutation or EGFR amplification with EGFRvIII negative) and first-recurrence status; these are not confirmed in the profile, making eligibility uncertain.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,B,"No hard exclusions. Disease matches. Stage/setting (recurrent) matches. Required biomarker (EGFRvIII or EGFR amplification) is unknown, so cannot satisfy the biomarker anchor; first-recurrence requirement is not confirmed, making the line/prior anchor uncertain. Thus exactly one anchor clearly matches → B. A is not possible because required biomarker is not confirmed. The grader’s reasoning aligns with this.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05718583,1.0,Rheumatoid Arthritis,A Pilot Proof of Concept Study of the Effects of Administration of a Short Chain Fatty Acid (SCFA) Supplement in Rheumatoid Arthritis Inadequate Responders (EASi-RAIR),"This study is a pilot, proof of concept study to determine the effects of administering an oral short-chain fatty acid (SCFA) supplement to Rheumatoid Arthritis (RA) patients with inadequate response to methotrexate (MTX). The study will include up to 35 participants to obtain a sample size of at least 25 participants taking the oral supplement. The researchers hypothesize that oral SCFA will change the participants' gut microbiome and regulatory immune responses. Clinical data to assess for ...","{'id': 205986714, 'name': 'Butyrate', 'description': 'Participants will self-administer the oral Short Chain Fatty Acid (SCFA) Butyrate supplement three times daily with meals for up to 2 months. The minimum duration necessary for an ""evaluable"" participant will be 2 weeks of SCFA supplementation.', 'other_names': ['Butyrate; butyric acid'], 'intervention_type': 'DIETARY_SUPPLEMENT'}",NA,18 years,Rheumatoid Arthritis,Rheumatoid arthritis meeting 2010 ACR/EULAR criteria or treating physician diagnosis | Inadequate response to methotrexate at maximum tolerated dose | Age >= 18 years,"Pregnant or breastfeeding | History of sensitivity to the study compound or excipients | Previous intolerance to short-chain fatty acids or related compounds | Current antibiotic treatment within 3 months of screening (at discretion of PI) | Current consumption of probiotics within 3 months of screening (at discretion of PI) | Severe hepatic impairment (e.g., ascites or clinical signs of coagulopathy) | Renal failure (eGFR < 30 mL/min or requiring dialysis) | History of other autoimmune disease (at discretion of PI) | Current immunodeficiency state (e.g., cancer, HIV, others)",Methotrexate inadequate response at maximum tolerated dose,ALL,B,"Disease matches and the patient is an adult with inadequate response to methotrexate, and prior biologic use is not excluded. Other exclusion factors (e.g., pregnancy/breastfeeding, recent antibiotics/probiotics, hepatic/renal status) are unknown, so only the line/prior-exposure anchor is clearly satisfied.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,B,"No hard exclusions. Disease matches and line/prior-exposure (inadequate response to methotrexate) clearly matches. Other anchors (stage/setting, biomarkers, mets pattern) are not applicable or unknown. With exactly one core anchor match and no soft conflicts, B is appropriate.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT06065462,0.8482123017311096,Recurrent Clear Cell Ovarian Carcinoma,Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100,To learn if the combination of dostarlimab and LB-100 can help to control ovarian clear cell carcinoma,"{'id': 206129471, 'name': 'Dostarlimab', 'description': 'Given by vein (IV)', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206129472, 'name': 'LB-100', 'description': 'GIven by vein (IV)', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,18 years,Ovarian Clear Cell Carcinoma,"Age 18–75 years | Recurrent clear cell ovarian, peritoneal, or fallopian tube carcinoma (mixed histology allowed if predominantly clear cell) | >=1 prior line of therapy for recurrent disease or platinum-resistant/refractory disease | Somatic mutation testing showing no PPP2R1A mutations | Measurable disease per modified RECIST v1.1 | ECOG performance status 0–1 | Life expectancy >=12 weeks | Adequate organ and marrow function (hemoglobin, ANC, platelets, bilirubin, AST/ALT, creatinine clearance per thresholds) | Post-menopausal status or negative serum pregnancy test with effective contraception","Participation in another interventional study with investigational product within 28 days | Prior treatment with anti-CTLA-4 or anti–PD-1/PD-L1 antibodies | Mismatch repair deficient (dMMR) or microsatellite instability-high tumors | Receipt of last anticancer therapy <=21 days before first dose (longer if required by prior agent) | Unresolved >= Grade 2 toxicity from prior therapy (except alopecia, vitiligo, and labs per inclusion) | Concurrent chemotherapy, immunotherapy, or hormonal cancer therapy | Major surgery within 28 days before first dose (palliative local surgery allowed) | History of allogeneic or solid organ transplantation | Active or prior autoimmune/inflammatory disorders (exceptions apply: vitiligo, alopecia, stable hypothyroidism, certain inactive conditions, celiac controlled by diet) | Uncontrolled intercurrent illness (e.g., active infection, CHF, uncontrolled hypertension, unstable angina, arrhythmia, ILD, COPD requiring systemic steroids/oxygen/hospitalization, serious GI conditions with diarrhea, psychiatric/social conditions limiting compliance) | Active infections: TB, hepatitis B (HBsAg+), hepatitis C unless HCV RNA negative, or HIV not meeting protocol control criteria | Another primary malignancy unless adequately treated and low risk of recurrence per protocol exceptions | History of leptomeningeal carcinomatosis | Untreated brain metastases or spinal cord compression (treated and stable allowed) | QTcF >=470 ms | Current or prior immunosuppressive medication within 14 days before first dose (protocol exceptions apply) | Live attenuated vaccine within 30 days before first dose and up to 90 days after last dose | Pregnant or breastfeeding, or of reproductive potential not using effective birth control | Allergy or hypersensitivity to study drugs or excipients | Unresolved partial or complete small or large bowel obstruction | Any condition making the patient unsuitable per investigator judgment",>=1 prior line of therapy for recurrent disease or platinum-resistant/refractory disease required; Washout >=21 days since last anticancer therapy before first dose,ALL,B,"Disease and stage/setting match (recurrent clear cell ovarian carcinoma) and age/sex fit. However, it’s unclear if she meets the required prior therapy for recurrent or platinum-resistant disease, PPP2R1A-negative status, and measurable disease.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,B,"No hard exclusions. Disease and recurrent setting match. Line/prior requirement (>=1 recurrent line or platinum-resistant) cannot be confirmed: no recurrent therapy documented and platinum-resistance status unknown → treat as unknown, not a soft mismatch. PPP2R1A-negative and measurable disease also unknown. Thus exactly one core anchor matches with no soft conflicts → B.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06079216,1.0,Dementia,Making Connections Thru Music: A Group Music Therapy-Based Intervention for Persons With Dementia,"Healthcare systems around the world, including within the United States, have long-established shortages of trained caregivers. The American Health Care Association states that ""the health care system has experienced a shortage of trained caregivers for critical roles for some time."" This scarcity directly impacts the 45,800 Long-Term Care (LTC) communities throughout the U.S. Concurrent with this staff shortage, more than half of LTC residents have some form of dementia. These two issues cre...","{'id': 206005259, 'name': 'Volunteer Led Making Connections Thru Music', 'description': 'Volunteer led Group music therapy-based intervention', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}; {'id': 206005260, 'name': 'Staff Led Making Connections Thru Music', 'description': 'Staff led Group music therapy-based intervention', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}",NA,18 years to 103 years,Alzheimer Disease; Dementia; Vascular Dementia,Dementia diagnosis (any type) | Age >= 65 years | Mini-Mental State Examination (MMSE) >= 10,Rapid physical decline | Rapid cognitive decline,(none),ALL,B,"Disease and eligibility match: dementia (any type), age ≥65, and MMSE ≥10 (patient MMSE 19); sex allowed. No exclusions are triggered, and stage/setting aligns, but other core anchors (line/prior therapy, biomarkers) are not specified, yielding one clear anchor match.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,B,"No hard exclusions. Disease matches and MMSE/setting aligns, while other anchors (line/prior, biomarkers, mets pattern) are not specified/applicable. Exactly one core anchor match → B per rubric.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06245499,1.0,Dementia,The Aging Brain Care Virtual Program,The program involves a virtual intervention to be delivered by RN or SW care coordinators over one year. Every care partner will receive monthly virtual visits during the first 3 months and then quarterly or more depending on assessed need. The intervention relies on a tailored approach in which patient and caregiver needs are identified during visits using validated assessment tools and addressed with standardized protocols. Protocols include management of behavioral/psychological symptoms o...,"{'id': 206509504, 'name': 'Aging Brain Care Virtual Program', 'description': 'The program involves a virtual intervention to be delivered by RN or SW care coordinators over one year. Every care partner will receive monthly virtual visits during the first 3 months and then quarterly or more depending on assessed need. The intervention relies on a tailored approach in which patient and caregiver needs are identified during visits using validated assessment tools and addressed with standardized protocols. Protocols include management of behavioral/psychological symptoms of dementia, caregiver stress, medication management, comorbidity management and advance care planning.', 'other_names': ['ABCV'], 'intervention_type': 'BEHAVIORAL'}",NA,18 years,Alzheimer Disease; Dementia,Age >= 65 years (patients) | Diagnosis of Alzheimer's disease or related dementias documented in primary care problem list (ICD-based) | Age >= 18 years (care partners),Enrolled in hospice at screening | Living in a long-term care nursing facility | Care partners who decline participation in the intervention,(none),ALL,B,"The patient meets the diagnosis (dementia) and age ≥65 criteria with no noted exclusions like hospice or nursing facility, satisfying the diagnostic/subtype anchor. Stage/setting and prior therapy requirements are not specified, so only one core anchor clearly matches.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),INCORRECT,C,"No hard exclusions. Disease matches, but none of the four core anchors are specified/match (no stage/setting, no line/prior, no required biomarker, no mets pattern). With 0 anchors and no soft conflicts, rubric calls for C. The grader incorrectly counted diagnosis as an anchor and gave B.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT06287463,1.0,Castration-Resistant Prostate Cancer,"A Master Protocol for the Multi-Cohort, Open-Label, Phase 1/2 Study of DCC-3084 as Monotherapy and in Combination With Other Antitumor Agents in Participants With Advanced Malignancies Driven by the MAPK Pathway","This is a multicenter, Phase 1/2 clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors. Additional modules exploring other cancers may be added to the master protocol at a later date. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion).","{'id': 205963212, 'name': 'DCC-3084', 'description': 'Administered orally', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,18 years,Solid Tumor; Castration-Resistant Prostate Cancer; Melanoma; Non-Small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma,"Able to take oral medication | Negative pregnancy test if female of childbearing potential and agrees to contraception requirements | Adequate organ function and electrolytes | ECOG performance status 0–1 | Life expectancy > 6 months | Pathologically confirmed solid cancer with KRAS, HRAS, NRAS, BRAF, CRAF, and/or NF1 mutation (ModA Part 1) | Exhausted all standard therapies known to provide benefit (ModA Part 1) | Documented BRAF mutation (ModA Part 2) | Pathologically confirmed diagnosis with progression after at least one prior line of therapy in the advanced or metastatic setting (ModA Part 2)","Prior treatment with certain BRAF dimer inhibitors | Pregnant or lactating | Use of medications or therapies prohibited with DCC-3084 within 14 days | Prior antitumor therapy or any investigational therapy within a protocol-specified timeframe before first dose | Allergy or hypersensitivity to any component of DCC-3084 | Invasive malignancy within 2 years other than the study indication or specified cancers treated with curative intent | Unresolved clinically relevant toxicities from prior therapy | Impaired cardiac function | Recent thrombotic or embolic events | Malabsorption syndrome or other condition that could affect oral absorption | Major surgery within 28 days before first dose | Cohort-specific exclusions as applicable | ModA Part 2: Known co-occurring mutation of KRAS, HRAS, NRAS, NF1, EGFR, PIK3CA, or PTEN",Exhausted standard of care therapies (ModA Part 1 requirement); Progression after at least one prior line of therapy in advanced/metastatic setting (ModA Part 2 requirement); Washout from prior antitumor or investigational therapy per protocol-specified timeframe,ALL,B,"Disease and metastatic setting match (metastatic CRPC). However, required MAPK-pathway mutation status and exhaustion of all standard therapies are not documented, making eligibility uncertain without an explicit conflict.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,B,"No hard exclusions apply. Disease matches and stage/setting (advanced/metastatic) matches. Biomarker requirement (MAPK/BRAF) is unknown, and line/exhaustion requirements depend on biomarker cohort, so anchor status is unknown rather than a mismatch. Exactly one anchor matches with no soft conflicts → Grade B per rubric.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06298474,1.0,Dementia,The BRAIN App (Phase 2 SBIR): Building Relationships Using Artificial Intelligence and Nostalgia,"There are currently 6.7 million Americans living with dementia and, without significant breakthroughs, this figure will double to 12.7 million by 2050. There are about 46,000 long-term care (LTC) facilities in the U.S. More than half of LTC residents have some form of dementia (Alzheimer's Association, 2018). Responsive behaviors and dysfunction of the dementia care triad-i.e., the PLWD, professional Care Partner (CP), and Family Member (FM)-are inexorably linked. The emergence of responsive ...","{'id': 206151678, 'name': 'The BRAIN App', 'description': ""The BRAIN App is digital engagement platform that uses AI to tailor activities to each person's specific interests / background."", 'other_names': [], 'intervention_type': 'BEHAVIORAL'}",NA,65 years,Alzheimer Disease; Dementia; Vascular Dementia,Age >= 65 years | Clinical diagnosis of dementia (any type) | Able to speak conversational English,Completely unable to communicate verbally | Serious visual or hearing impairments | Signs of rapid decline over the last 3 months (staff report),(none),ALL,B,"Disease and age match, and the stage/setting (clinical dementia without specified restrictions) aligns with the trial’s broad dementia population. No conflicts with exclusions are identified, while other core anchors (prior therapy requirements, biomarker requirements, metastatic pattern) are not specified.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,B,"No hard exclusions. Disease matches (dementia) and age fits ≥65. Exactly one CORE ANCHOR matches (stage/setting: clinical dementia appropriate). Other anchors (line/prior, biomarkers, mets pattern) are unspecified/irrelevant. Therefore B per rubric. Grader’s reasoning aligns.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT06493552,0.8805802464485168,Metastatic Urothelial Carcinoma,"A Modular, Open Label, Randomized Phase II/III Trial to Assess Efficacy of Combining sEphB4-HSA (EphrinB2 Inhibitor) With Immunotherapy Regimens in Patients With EphrinB2-High Solid Tumors","Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA. The primary objective of this study is to demonstrate additive therapeutic benefit for sEphB4-HSA. The secondary objectives are to determine whether the sEphB4-HSA containing regimen is safe and whether the oncological endpoints of importance in each cohort improve as a result of treatment with sEphB4-HSA containing regimen relative to a predefined thr...","{'id': 205832418, 'name': 'SEphB4-HSA', 'description': 'A recombinant protein comprised of the soluble form of human receptor EphB4 fused to human serum albumin.', 'other_names': ['sB4HSA'], 'intervention_type': 'DRUG'}; {'id': 205832419, 'name': 'Pembrolizumab', 'description': 'Antibody to human PD-1.', 'other_names': ['Keytruda'], 'intervention_type': 'DRUG'}; {'id': 205832420, 'name': 'Gemcitabine', 'description': 'A chemotherapy drug used to treat various types of cancer.', 'other_names': ['GEM, Gemzar'], 'intervention_type': 'DRUG'}; {'id': 205832421, 'name': 'Cisplatin', 'description': 'A type of chemotherapy drug called an alkylating agent used to treat various types of cancer.', 'other_names': ['CIS'], 'intervention_type': 'DRUG'}; {'id': 205832422, 'name': 'Enfortumab vedotin', 'description': 'Nectin-4-directed antibody and microtubule inhibitor conjugate.', 'other_names': ['EV, Padcev'], 'intervention_type': 'DRUG'}",PHASE2/PHASE3,18 years,Urothelial Carcinoma (metastatic); Bladder Cancer (muscle-invasive),"Age >= 18 years | Provide tumor tissue (cell block or >=15 slides) or archival tissue | Tumor molecular profiling required (commercial platform) including a PD-L1 assay | Tumor must express EphrinB2 (USC Norris Core Lab assessment) | ECOG <=1 | Adequate organ function | Urothelial carcinoma; variant histologies allowed; pure small cell excluded (Module A) | cT2–cT4a N0 M0 by TURBT or imaging (Module A) | No systemic therapy for cancer in the previous 12 months (Module A) | Control arm treatment choice declared prior to randomization; if cisplatin-ineligible or refusing, pembrolizumab must be insurance-approved before randomization (Module A) | Urothelial carcinoma; variant histologies allowed; pure small cell excluded (Module B) | Tumor must be Nectin4 non-amplified (Module B) | No systemic therapy for cancer in the previous 12 months (Module B) | Measurable disease per RECIST 1.1 (Module B)","Symptomatic brain metastases requiring systemic corticosteroids; prior treated brain metastases allowed if recovered, off corticosteroids >=4 weeks, and neurologically stable | History of or active autoimmune disease (e.g., Crohn's disease, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, Graves' disease) or other conditions compromising the immune system | Active infection including HBV, HCV, or HIV/AIDS-related illness | Uncontrolled adrenal insufficiency | Active chronic liver disease | Concurrent or active second malignancy requiring systemic therapy | Medical condition that increases risk or interferes with safety interpretation (e.g., severe diarrhea, acute diverticulitis) | Major surgery <6 weeks prior to first dose; minor surgery <4 weeks prior to first dose (vascular access device placement allowed if >=7 days before first dose) | History of severe hypersensitivity reaction to any monoclonal antibody",No systemic therapy for cancer in the previous 12 months,ALL,B,"Metastatic urothelial carcinoma matches the trial’s disease/setting. However, key requirements (EphrinB2-high expression, Nectin4 non-amplified, ECOG/organ function, and no systemic therapy within 12 months) are unknown, so only one core anchor clearly matches.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,B,"No hard exclusions apply. Stage/setting (metastatic UC) matches. Line/prior-therapy compatibility is uncertain due to the 12-month no-therapy requirement and unknown timing; required biomarkers (EphrinB2+, Nectin4 non-amplified) are unknown; no metastatic pattern constraints. With exactly one clear core anchor match and no soft mismatch, B is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06646757,0.6691051721572876,Fistulizing Crohn's Disease,Exploring Multiple Self-Help Interventions to Promote Self-Efficacy and Overcome Disability,"EMPOWER-IBD aims to identify behavioral interventions to strengthen patients' self-efficacy for self-management as a mechanism to reduce IBD-related disability. This multisite, randomized controlled trial with 16 arms will randomize adults with moderate-to-severe IBD-related disability to a combination of four multimodal behavioral interventions to test their clinical effectiveness in reducing IBD-related disability and improving self-efficacy. The interventions are four existing, publicly av...","{'id': 206045453, 'name': 'APP', 'description': ""1\\) My IBD Care (APP) is a free smartapp that supports patients' tracking of symptoms, medical appointments, and medications; self-paced behavioral change programs"", 'other_names': [], 'intervention_type': 'BEHAVIORAL'}; {'id': 206045454, 'name': 'CBT', 'description': '2\\) ""Coping with Crohn\'s and Colitis: A Patient and Clinician\'s Guide to CBT for IBD"" (CBT) is an IBD-specific cognitive behavioral therapy (CBT) workbook (e-book or hardcopy)', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}; {'id': 206045455, 'name': 'HELP', 'description': ""3\\) IBD Help Center (HELP) is a resource operated by the Crohn's and Colitis Foundation (CCF) for individuals to connect with an information specialist via email, call, or online live chat at no cost"", 'other_names': [], 'intervention_type': 'BEHAVIORAL'}; {'id': 206045456, 'name': 'PEER', 'description': ""4\\) Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \\& Colitis Foundation"", 'other_names': [], 'intervention_type': 'BEHAVIORAL'}",NA,18 years,Crohn Disease; Ulcerative Colitis,Age >= 18 years | Inflammatory Bowel Disease diagnosis | IBD Disability Index > 35,IBD Disability Index < 35,(none),ALL,B,"Disease (Crohn’s) and age match, and prior therapy exposure poses no restriction. The required IBD Disability Index > 35 is unknown and stage/setting is nonspecific, so only one core anchor (line/prior compatibility) clearly matches.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,B,"No hard exclusions. Disease and age are compatible. Among CORE ANCHORS, only line/prior-exposure is a clear match (no restrictions); stage/setting and required IBD Disability Index are unknown/not applicable, and no soft mismatch exists. That yields exactly 1 anchor match → Grade B.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06819852,1.0,Dementia,Skipping the Hospital: Acute Hospital Care at Home for People Living With Dementia,The investigators will perform a parallel-group multicenter randomized controlled trial of a 1-year pre-enrolled acute hospital care at home intervention vs usual care for people living with dementia. Patients will be randomized only after eligibility determination and after the family caregiver agrees to enroll; people living with dementia will assent when able. Patients will be allocated in a concealed fashion to the control and intervention groups in randomly selected block sizes of 4 or 6...,"{'id': 205727041, 'name': 'Acute hospital care at home', 'description': 'Home visit for a serious illness conversation. Acute illness evaluation on demand. Acute hospital care at home as needed.', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 205727042, 'name': 'Standard medical treatment', 'description': 'Standard acute and emergency care delivered in a brick-and-mortar hospital setting.', 'other_names': [], 'intervention_type': 'OTHER'}",NA,18 years,Dementia,Moderate or severe dementia (per Quick Dementia Rating System) | Resides in a private or assisted living residence with or nearby (<15 min travel time) to a family caregiver | Resides within the Mass General Brigham home hospital catchment area | At least 1 hospitalization in the last 12 months,"No functioning utilities (e.g., no working heat [October–April], no running water, or no electricity) | Resides in a skilled nursing facility | Resides in a group home | Domestic violence screen positive | In police custody | Family caregiver unable to initiate or maintain communication with care team | End-stage renal disease on hemodialysis | On methadone requiring daily pickup of medication | Active substance use disorder without a functioning treatment plan | Psychiatric diagnosis that would prohibit successful home hospital care | Acute delirium without explanation or without the ability to manage at home | Cancer requiring consistent hospital-based treatments | Cannot ambulate to bedside commode with assistance present in the home (if different from baseline), unless home-based aides are available",(none),ALL,B,"Disease (dementia) and severity (moderate) match the trial’s target population. Other required logistics (recent hospitalization, caregiver proximity, and catchment area) are unknown, with no explicit exclusions triggered.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,B,"No hard exclusions. Disease and stage (moderate dementia) match, fulfilling one core anchor (stage/setting). Other key inclusion logistics (recent hospitalization, caregiver proximity, catchment area) are unknown, not mismatches. Exactly one anchor match with no soft conflicts → B.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06976853,0.6691051721572876,Fistulizing Crohn's Disease,Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease,"The purpose of this research study is to evaluate what type of treatment will be beneficial for people with Crohn's disease and difficult to treat inflammation in the small bowel. Current therapies are used to control the inflammation due to Crohn's disease in your digestive tract. In some patients, those therapies are not sufficient to fully treat the disease. This objective of this study is to evaluate the efficacy of a different type of therapy, tirzepatide, that may promote healing of the...","{'id': 205796816, 'name': 'Tirzepatide', 'description': 'Addition of tirzepatide to current biological therapy', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205796817, 'name': 'Standard of care treatment', 'description': ""Intervention will be to change patient's current therapy to a 3rd or later advanced biologic patient have never been exposed to"", 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,18 years to 80 years,Crohn Disease,"Age 18 to 80 years | Confirmed diagnosis of Crohn disease based on endoscopy and histopathology | Active ileal or ileocolonic inflammation on colonoscopy: ileal SES-CD > 4 with ulcer subscore > 1 (ulcers > 5 mm) | Failure to respond (primary or secondary non-response) to at least 2 advanced class drugs, without evidence of immunogenicity for anti-TNF agents; on most recent therapy for >= 6 months optimized without corticosteroids | Post-surgical patients: >= 6 months post-operation with endoscopic evidence of ileal disease | Females: compliance with recommended birth control requirements","Age < 18 or > 80 years | Pregnant or breastfeeding | Diagnosis of ulcerative colitis, indeterminate colitis, microscopic colitis, ischemic colitis, radiation colitis, diverticular disease-associated colitis, toxic megacolon, active infectious colitis, or positive test for Clostridioides difficile toxin at screening | BMI < 25 | Current or previous diagnosis of anorexia nervosa | Type 1 or Type 2 diabetes | Use of concomitant hypoglycemic agents | Personal or family history of medullary thyroid carcinoma | History of multiple endocrine neoplasia | Known serious hypersensitivity to tirzepatide or any of its excipients | Functional or post-operative short-bowel syndrome | Intestinal resection <= 24 weeks prior to inclusion or other intra-abdominal surgeries <= 12 weeks prior to inclusion | Active treatment with corticosteroids | Positive stool test for parasites, C. difficile, or stool culture for pathogenic bacteria within 30 days prior to enrollment | Current stricture not passable with an endoscope | Impending need for surgery per investigator | Ileostomy or colostomy | Females: refusal to comply with recommended birth control requirements","Prior failure to at least 2 advanced class drugs after >= 6 months of optimized therapy without corticosteroids; Prior anti-TNF therapy (e.g., infliximab, adalimumab, certolizumab, golimumab); Prior anti-integrin therapy (vedolizumab); Prior anti-IL12/23 therapy (ustekinumab); Prior anti-IL23 therapy (e.g., risankizumab, guselkumab, mirikizumab); Prior JAK inhibitor therapy (upadacitinib)",ALL,B,"Disease matches Crohn’s and the patient has failed ≥2 advanced classes (infliximab, ustekinumab), with age within 18–80. However, the trial requires documented active ileal/ileocolonic inflammation (SES-CD >4) and other criteria (e.g., BMI ≥25, steroid-free, no anti-TNF immunogenicity) that are unknown for this patient.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,B,"No hard exclusions. Disease matches Crohn’s. One core anchor (line/prior exposure: failure of ≥2 advanced classes) matches. Stage/setting (ileal/ileocolonic active inflammation) and other requirements are unknown, with no soft mismatch identified. Thus B per rubric; grader’s reasoning is aligned.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT00611585,1.0,Rheumatoid Arthritis,"Birmingham Hip Resurfacing System (BHR) Post Approval Study: A Prospective, Multi-Centered Study of the Birmingham Hip Resurfacing System",The purpose of this study is to meet a PMA condition of approval of the BHR System. The study will evaluate the long term safety and effectiveness of the BHR system in patients with non-inflammatory and inflammatory arthritis.,"{'id': 206485319, 'name': 'Birmingham Hip Resurfacing', 'description': 'Hip resurfacing system: single use device for hybrid fixation in patients requiring primary hip resurfacing arthroplasty', 'other_names': ['BHR'], 'intervention_type': 'DEVICE'}",NA,21 years to 75 years,Osteoarthritis; Traumatic Arthritis; Avascular Necrosis; Hip Dysplasia; Rheumatoid Arthritis,Age >= 21 years | Skeletally mature | Requires primary hip resurfacing due to osteoarthritis | Requires primary hip resurfacing due to traumatic arthritis | Requires primary hip resurfacing due to avascular necrosis | Requires primary hip resurfacing due to hip dysplasia | Requires primary hip resurfacing due to rheumatoid arthritis,"Active infection or sepsis | Vascular insufficiency severe enough to compromise implant stability or postoperative recovery | Muscular atrophy severe enough to compromise implant stability or postoperative recovery | Neuromuscular disease severe enough to compromise implant stability or postoperative recovery | Female of child-bearing age | Bone stock inadequate to support the device | Moderate to severe renal insufficiency | Known or suspected metal hypersensitivity | Immunosuppressed state (e.g., AIDS) or receiving high doses of corticosteroids | Psychological or neurological conditions precluding participation | Severely overweight",(none),ALL,C,"Disease and age match, but this is a surgical device study requiring primary hip resurfacing due to RA, which is not established for the patient. Stage/setting and other device-specific criteria (e.g., child-bearing status, renal function, metal allergy, weight) are unknown, so no core anchors can be confirmed.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,C,"No hard exclusions apply. Disease matches (RA), age within window. Key requirement is need for primary hip resurfacing due to RA, which is unknown; other core anchors are not applicable/unknown. With 0 confirmed anchors and no soft mismatch identified, grade C is correct and the reasoning aligns with the rubric.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT02171104,0.42885035276412964,PMM2-CDG,"MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG","This single-institution, phase II study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) using busulfan- and fludarabine-based conditioning regimens with busulfan therapeutic drug monitoring (TDM) for patients with various inherited metabolic disorders (IMD) and severe osteopetrosis (OP).","{'id': 206253281, 'name': 'Stem Cell Transplantation', 'description': 'Infusion given on Day 0', 'other_names': [], 'intervention_type': 'BIOLOGICAL'}; {'id': 206253282, 'name': 'IMD Preparative Regimen', 'description': '* Anti-thymocyte Globulin (ATG)\n* Fludarabine\n* Busulfan', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206253283, 'name': 'Osteopetrosis Only Preparative Regimen', 'description': '* Anti-thymocyte Globulin (ATG)\n* Fludarabine\n* Busulfan\n* Thiotepa', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206253284, 'name': 'Osteopetrosis Haploidentical Only Preparative Regimen', 'description': '* Rituximab\n* Alemtuzumab\n* Busulfan\n* Fludarabine', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206253285, 'name': 'cALD SR-A (Standard-Risk, Regimen A)', 'description': 'N-acetylcysteine start day +1 through day +28', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206253286, 'name': 'cALD SR-B (Standard-Risk, Regimen B)', 'description': 'N-acetylcysteine start day +1through day +56', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206253287, 'name': 'cALD HR-D (High-Risk, Regimen C)', 'description': 'N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206253288, 'name': 'cALD HR-D (High-Risk, Regimen D)', 'description': 'N-acetylcysteine, celecoxib, vitamin E and alpha lipoic acid start day of admission (prior to conditioning regimen) and continue through day +100', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,up to 55 years,Acyl-CoA Oxidase Deficiency; Adrenoleukodystrophy (cerebral); Alpha-mannosidosis; Alpha-methylacyl-CoA Racemase Deficiency; Aspartylglucosaminuria; D-Bifunctional Enzyme Deficiency; Fucosidosis; Globoid Cell Leukodystrophy; Glycoprotein Metabolic Disorders; Hereditary Leukoencephalopathy With Axonal Spheroids; Hunter Syndrome; Hurler Syndrome; Infantile Refsum Disease; Inherited Metabolic Disorders; Maroteaux Lamy Syndrome; Metachromatic Leukodystrophy; Mitochondrial Neurogastrointestinal Encephalopathy; Mucopolysaccharidosis Disorders; Multifunctional Enzyme Deficiency; Neonatal Adrenoleukodystrophy; Niemann-Pick B; Niemann-Pick C Subtype 2; Peroxisomal Disorders; Recessive Leukodystrophies; Severe Osteopetrosis; Sly Syndrome; Sphingolipidoses; Sphingomyelin Deficiency; Zellweger Syndrome,"Age 0–55 years | Adequate graft available | Adequate organ function | MPS IH (Hurler syndrome) | MPS II (Hunter syndrome) with no or minimal symptomatic neurologic disease but expected neurologic phenotype | MPS VI (Maroteaux-Lamy syndrome) | MPS VII (Sly syndrome) | Alpha-mannosidosis | Fucosidosis | Aspartylglucosaminuria | Globoid cell leukodystrophy | Metachromatic leukodystrophy | Niemann-Pick disease type B (sphingomyelin deficiency) | Niemann-Pick C subtype 2 | Adrenoleukodystrophy (cerebral involvement) | Zellweger syndrome | Neonatal adrenoleukodystrophy | Infantile Refsum disease | Acyl-CoA oxidase deficiency | D-bifunctional enzyme deficiency | Multifunctional enzyme deficiency | Alpha-methylacyl-CoA racemase deficiency (AMACRD) | Mitochondrial neurogastrointestinal encephalopathy (MNGIE) | Severe osteopetrosis | Hereditary leukoencephalopathy with axonal spheroids (CSF1R mutation) | Other life-threatening lysosomal, peroxisomal or similar inherited disorders with white matter disease or neurologic manifestations where transplantation is rational (e.g., Wolman disease, GM1 gangliosidosis, I-cell disease, Tay-Sachs disease, Sandhoff disease) | Voluntary written consent","Pregnancy | Prior myeloablative chemotherapy within 4 months of start of conditioning | Uncontrolled bacterial, fungal, or viral infection including HIV | Active Aspergillus or other mold infection within 30 days",(none),ALL,C,"The patient's PMM2-CDG fits the trial’s broad category of glycoprotein/inherited metabolic disorders and age/sex are within allowed ranges with no explicit exclusions met. However, stage/setting and prior-therapy anchors are unspecified, and required transplant readiness details (e.g., graft availability, organ function) are unknown, so core anchors are insufficient to rate higher.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,C,"No hard exclusions apply. Disease broadly matches via glycoprotein/inherited metabolic disorders. Core anchors: stage/setting unknown, line/prior unknown, no applicable biomarker or metastatic constraints—so 0 anchors clearly match and no soft mismatches identified. Thus C is appropriate; the grader’s reasoning is consistent with the rubric.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT02171104,0.5901711583137512,Ornithine Transcarbamylase Deficiency,"MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG","This single-institution, phase II study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) using busulfan- and fludarabine-based conditioning regimens with busulfan therapeutic drug monitoring (TDM) for patients with various inherited metabolic disorders (IMD) and severe osteopetrosis (OP).","{'id': 206253281, 'name': 'Stem Cell Transplantation', 'description': 'Infusion given on Day 0', 'other_names': [], 'intervention_type': 'BIOLOGICAL'}; {'id': 206253282, 'name': 'IMD Preparative Regimen', 'description': '* Anti-thymocyte Globulin (ATG)\n* Fludarabine\n* Busulfan', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206253283, 'name': 'Osteopetrosis Only Preparative Regimen', 'description': '* Anti-thymocyte Globulin (ATG)\n* Fludarabine\n* Busulfan\n* Thiotepa', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206253284, 'name': 'Osteopetrosis Haploidentical Only Preparative Regimen', 'description': '* Rituximab\n* Alemtuzumab\n* Busulfan\n* Fludarabine', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206253285, 'name': 'cALD SR-A (Standard-Risk, Regimen A)', 'description': 'N-acetylcysteine start day +1 through day +28', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206253286, 'name': 'cALD SR-B (Standard-Risk, Regimen B)', 'description': 'N-acetylcysteine start day +1through day +56', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206253287, 'name': 'cALD HR-D (High-Risk, Regimen C)', 'description': 'N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206253288, 'name': 'cALD HR-D (High-Risk, Regimen D)', 'description': 'N-acetylcysteine, celecoxib, vitamin E and alpha lipoic acid start day of admission (prior to conditioning regimen) and continue through day +100', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,up to 55 years,Acyl-CoA Oxidase Deficiency; Adrenoleukodystrophy (cerebral); Alpha-mannosidosis; Alpha-methylacyl-CoA Racemase Deficiency; Aspartylglucosaminuria; D-Bifunctional Enzyme Deficiency; Fucosidosis; Globoid Cell Leukodystrophy; Glycoprotein Metabolic Disorders; Hereditary Leukoencephalopathy With Axonal Spheroids; Hunter Syndrome; Hurler Syndrome; Infantile Refsum Disease; Inherited Metabolic Disorders; Maroteaux Lamy Syndrome; Metachromatic Leukodystrophy; Mitochondrial Neurogastrointestinal Encephalopathy; Mucopolysaccharidosis Disorders; Multifunctional Enzyme Deficiency; Neonatal Adrenoleukodystrophy; Niemann-Pick B; Niemann-Pick C Subtype 2; Peroxisomal Disorders; Recessive Leukodystrophies; Severe Osteopetrosis; Sly Syndrome; Sphingolipidoses; Sphingomyelin Deficiency; Zellweger Syndrome,"Age 0–55 years | Adequate graft available | Adequate organ function | MPS IH (Hurler syndrome) | MPS II (Hunter syndrome) with no or minimal symptomatic neurologic disease but expected neurologic phenotype | MPS VI (Maroteaux-Lamy syndrome) | MPS VII (Sly syndrome) | Alpha-mannosidosis | Fucosidosis | Aspartylglucosaminuria | Globoid cell leukodystrophy | Metachromatic leukodystrophy | Niemann-Pick disease type B (sphingomyelin deficiency) | Niemann-Pick C subtype 2 | Adrenoleukodystrophy (cerebral involvement) | Zellweger syndrome | Neonatal adrenoleukodystrophy | Infantile Refsum disease | Acyl-CoA oxidase deficiency | D-bifunctional enzyme deficiency | Multifunctional enzyme deficiency | Alpha-methylacyl-CoA racemase deficiency (AMACRD) | Mitochondrial neurogastrointestinal encephalopathy (MNGIE) | Severe osteopetrosis | Hereditary leukoencephalopathy with axonal spheroids (CSF1R mutation) | Other life-threatening lysosomal, peroxisomal or similar inherited disorders with white matter disease or neurologic manifestations where transplantation is rational (e.g., Wolman disease, GM1 gangliosidosis, I-cell disease, Tay-Sachs disease, Sandhoff disease) | Voluntary written consent","Pregnancy | Prior myeloablative chemotherapy within 4 months of start of conditioning | Uncontrolled bacterial, fungal, or viral infection including HIV | Active Aspergillus or other mold infection within 30 days",(none),ALL,C,"The trial targets inherited metabolic disorders with age 0–55, which could encompass OTC deficiency, and there are no explicit exclusions met. However, OTC is not specifically listed and the inclusion emphasis is on lysosomal/peroxisomal disorders, so stage/setting and line/prior-therapy anchors are unclear, yielding no clear core anchor matches.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),INCORRECT,F,"Disease mismatch is a hard exclusion. The trial targets lysosomal/peroxisomal and related leukodystrophy-type inherited disorders; OTC (a urea cycle disorder) is not listed among diseases/cohorts. Per rubric, basket trials only count if the patient disease is explicitly listed. Therefore the correct grade is F, not C.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT02255383,1.0,Rheumatoid Arthritis,Persona The Personalized Knee System TKA Outcomes Study: Prospective Multicenter Study of the Persona Knee System,The primary objective of this study is to obtain implant survivorship and clinical outcomes data for commercially available Persona fixed bearing knee implants used in total knee arthroplasty. The assessment will include implant survivorship and clinical performance.,"{'id': 206152549, 'name': 'Zimmer Persona Total Knee System', 'description': 'Primary Total Knee Arthroplasty', 'other_names': ['Total Knee Arthroplasty', 'Total Knee Replacement'], 'intervention_type': 'DEVICE'}",NA,18 years to 75 years,Osteoarthritis; Rheumatoid Arthritis; Traumatic Arthritis; Polyarthritis; Avascular Necrosis of the Femoral Condyle,"Age 18-75 years | Severe knee pain/disability due to rheumatoid arthritis | Severe knee pain/disability due to osteoarthritis | Severe knee pain/disability due to traumatic arthritis | Severe knee pain/disability due to polyarthritis | Severe knee pain/disability due to collagen disorders | Severe knee pain/disability due to avascular necrosis of the femoral condyle | Post-traumatic loss of joint configuration (e.g., patellofemoral erosion/dysfunction or prior patellectomy) | Moderate valgus deformity | Moderate varus deformity | Moderate flexion deformity | Salvage of previously failed surgical attempts not including prior partial or total knee arthroplasty of the ipsilateral knee | Candidate for Persona fixed bearing knee components implanted per product labeling","Previous infection in the affected joint or other local/systemic infection that may affect the prosthetic joint | Insufficient bone stock on femoral or tibial surfaces | Skeletal immaturity | Neuropathic arthropathy | Osteoporosis compromising the affected limb | Loss of musculature or neuromuscular disease compromising the affected limb | Stable, painless arthrodesis in a satisfactory functional position | Severe instability due to absence of collateral ligament integrity | Rheumatoid arthritis with a skin ulcer or recurrent skin breakdown | Known or suspected sensitivity or allergy to implant materials | Pregnant | Prior partial or total knee arthroplasty of the ipsilateral knee",(none),ALL,C,"Disease and age match, and there are no explicit exclusions. However, this is a TKA surgical outcomes study requiring severe knee pain/disability and candidacy for a specific knee implant, which is not specified for the patient, leaving key stage/setting and line/prior anchors unknown.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,C,"No hard exclusions apply (age and sex fit; disease includes RA; exclusions not triggered). Key anchors like stage/setting (surgical TKA candidacy and severe knee pain) are unknown, and line/prior exposure is not constrained by the trial. With disease match but 0 clear anchor matches and no soft mismatch, C is appropriate.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT02356653,0.5412098169326782,Ornithine Transcarbamylase Deficiency,Expanded Access Protocol Using CD3+/CD19+ Depleted Unrelated Donor or Related Donor Peripheral Stem Cells,The goal of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease for which HSCT is indicated. These patients are not eligible for other Children's Hospital of Philadelphia IRB approved protocols that utilize CliniMACs technology for T depletion.,"{'id': 205978105, 'name': 'Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)', 'description': 'Processing of stem cells using the CliniMACs device to selectively deplete specific T cells to decrease risk of graft versus host disease when using donor stem cells which are not fully matched.', 'other_names': ['CliniMACs'], 'intervention_type': 'DEVICE'}",EARLY_PHASE1,up to 30 years,Bone Marrow Failure Syndrome; Immunodeficiency; Immunodysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome; Inborn Error of Metabolism; Leukemia; Lymphoma; Myelodysplastic Syndrome; Hemoglobinopathy; Metabolic Storage Disease,"Lacks a fully HLA-matched sibling and is a candidate for allogeneic HSCT not suitable for current institutional CliniMACs protocols | Metabolic storage disease correctable by HSCT | Bone marrow failure syndrome | Immunodeficiency or immune dysregulation syndromes (including HLH) | Hemoglobinopathy correctable and requiring HSCT | Other non-malignant blood, metabolic, or immune disorders for which HSCT is recommended | Acute leukemia | Chronic leukemia | Lymphoma | Myelodysplastic syndrome | Identified living donor (related or unrelated) meeting institutional and regulatory eligibility criteria | Unrelated donor meeting NMDP matching criteria at HLA-A, -B, -C, -DRB1, and -DQB1 (10/10, 9/10, or 8/10 if the mismatch is at DQB1) | Related donor suitable for mobilization and infectious disease screening per SOP (HIV, HepB, HepC PCR negative) | Unrelated donor identified through NMDP, willing and able to undergo mobilization and apheresis | Adequate hematologic and organ function per institutional SOP | Negative pregnancy test for participants of childbearing potential","Uncontrolled bacterial, viral, or fungal infection | Availability of a fully HLA-matched sibling donor | Donor unable to donate peripheral stem cells | Pregnant",(none),ALL,C,"The patient’s OTC deficiency fits the trial’s broad category of inborn errors of metabolism and age/sex are within limits. However, HSCT candidacy (including HSCT-correctable disease and donor/eligibility requirements) is unknown, and no stage/line anchors are specified.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,C,"No hard exclusions apply: disease category matches (inborn error of metabolism), gender ALL, age under max 30, and no explicit exclusions triggered. Core anchors are unknown: HSCT candidacy/setting not provided; line/prior exposure irrelevant/unspecified; required HSCT-correctable status unknown. With 0 anchors matched and no soft mismatch identified, C is appropriate. The grader’s reasoning aligns with the rubric.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03047213,0.8805802464485168,Metastatic Urothelial Carcinoma,"An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation",This pilot phase II trial studies how well sapanisertib works in treating patients with bladder cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic) with tuberous sclerosis (TSC)1 and/or TSC2 mutations (changes in deoxyribonucleic acid \[DNA\]). Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.,"{'id': 206192638, 'name': 'Sapanisertib', 'description': 'Given PO', 'other_names': ['INK-128', 'INK128', 'MLN-0128', 'MLN0128', 'TAK-228'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Urothelial Carcinoma (locally advanced); Urothelial Carcinoma (metastatic); Bladder Carcinoma (recurrent),"Measurable disease per RECIST 1.1 | Histologically confirmed urothelial (transitional cell) carcinoma that is locally advanced or metastatic | Tumor harbors a TSC1 or TSC2 mutation identified by a CLIA-certified laboratory | Progression during or after at least one prior platinum-containing regimen for inoperable locally advanced or metastatic disease, or ineligible for cisplatin-based chemotherapy | Cisplatin-ineligible if any: ECOG 2; creatinine clearance < 60 mL/min; hearing loss 25 dB at two contiguous frequencies; grade >= 2 peripheral neuropathy | ECOG performance status <= 2 (Karnofsky >= 60%) | Life expectancy > 12 weeks | Controlled diabetes allowed | Ability to swallow oral medications","Chemotherapy, immunotherapy, or investigational therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to first dose | Palliative radiotherapy within 2 weeks prior to first dose | Radiation therapy within the last 4 weeks or exposure > 30% of marrow area | Unresolved toxicities from prior anticancer therapy > grade 1 (except stable, controlled grade 2 per PI) | Symptomatic or untreated CNS metastases | History of CNS metastases unless treated, stable >= 3 months, no hemorrhage, off dexamethasone >= 4 weeks, and no ongoing corticosteroids or antiepileptics | Allergic reactions to compounds similar to MLN0128 (TAK-228) | Systemic corticosteroids or antiepileptic drugs for treated brain metastases | Use of strong CYP3A4, CYP2C19, or CYP2C9 inhibitors or inducers within 1 week prior to first dose | Uncontrolled intercurrent illness including active infection, symptomatic congestive heart failure, unstable angina, significant cardiac arrhythmia (excluding rate-controlled atrial fibrillation/flutter), or significant psychiatric illness | Pregnant or breastfeeding | HIV-positive on combination antiretroviral therapy with significant CYP450 inhibition (unless low CYP inhibition and adequate health status) | Baseline QTc > 480 ms, congenital long QT syndrome, or history of torsades de pointes | Active hepatitis B or C infection | Uncontrolled hypertension (> 180/95 mm Hg) | Pulmonary hypertension | Uncontrolled asthma or oxygen saturation < 90% on room air | Significant valvular heart disease (severe regurgitation or stenosis or valve replacement) | Medically significant symptomatic bradycardia | Malabsorption that may alter absorption of MLN0128 (TAK-228) | Concomitant proton pump inhibitor use (must discontinue >= 7 days prior to first dose) | Within 6 months: ischemic myocardial or cerebrovascular events (including TIA) or revascularization procedures | Within 6 months: requirement for inotropic support (excluding digoxin) or serious uncontrolled cardiac arrhythmia | Within 6 months: pulmonary embolism | Within 6 months: NYHA class III or IV heart failure | Within 6 months: pacemaker placement for rhythm control | Bisphosphonate therapy initiated < 30 days prior to first dose | Prior treatment with PI3K, AKT, or mTOR inhibitors","Progression after at least one prior platinum-containing chemotherapy regimen or cisplatin-ineligible; No restriction on number of prior therapy lines; Washout: >= 4 weeks from chemotherapy, immunotherapy, or investigational therapy (>= 6 weeks for nitrosoureas or mitomycin C); Washout: >= 2 weeks from palliative radiotherapy; Washout: >= 4 weeks from radiation therapy",ALL,C,"Stage/setting and line/prior exposure are compatible (metastatic urothelial carcinoma; cisplatin-ineligible by eGFR 35 mL/min), but the trial requires a TSC1/TSC2 mutation confirmed by a CLIA lab, which is unknown for this patient.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,C,"No hard exclusions. Disease matches; stage/setting and line/prior-exposure match. However, the trial requires a TSC1/TSC2 mutation and the patient’s status is unknown, preventing an A. With key biomarker information unknown and no soft mismatches, C is appropriate per rubric.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT03348631,0.8482123017311096,Recurrent Clear Cell Ovarian Carcinoma,"A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma","This phase II trial studies how well tazemetostat works in treating patients with ovarian or endometrial cancer that has come back (recurrent). Chemotherapy drugs, such as tazemetostat, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.","{'id': 206510694, 'name': 'Computed Tomography', 'description': 'Undergo CT scan', 'other_names': ['CAT', 'CAT Scan', 'Computed Axial Tomography', 'Computerized Axial Tomography', 'Computerized axial tomography (procedure)', 'Computerized Tomography', 'Computerized Tomography (CT) scan', 'CT', 'CT Scan', 'tomography'], 'intervention_type': 'PROCEDURE'}; {'id': 206510695, 'name': 'Magnetic Resonance Imaging', 'description': 'Undergo MRI', 'other_names': ['Magnetic Resonance', 'Magnetic Resonance Imaging (MRI)', 'Magnetic resonance imaging (procedure)', 'Magnetic Resonance Imaging Scan', 'Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance', 'MR', 'MR Imaging', 'MRI', 'MRI Scan', 'MRIs', 'NMR Imaging', 'NMRI', 'Nuclear Magnetic Resonance Imaging', 'sMRI', 'Structural MRI'], 'intervention_type': 'PROCEDURE'}; {'id': 206510696, 'name': 'Tazemetostat', 'description': 'Given PO', 'other_names': ['E 7438', 'E-7438', 'E7438', 'EPZ 6438', 'EPZ-6438', 'EPZ6438'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Ovarian Clear Cell Carcinoma; Ovarian Endometrioid Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma,"Histologically or cytologically confirmed recurrent or persistent ovarian endometrioid or clear cell carcinoma, or recurrent/persistent endometrioid endometrial adenocarcinoma | Only ovarian clear cell carcinoma patients with ARID1A pathogenic or likely pathogenic variant by NGS are eligible | Ovarian tumors must have at least 50% endometrioid or clear cell morphology (primary or recurrent lesion) | Measurable disease per RECIST v1.1 | Age >= 18 years | ECOG performance status 0-2 | 1 to 3 prior cytotoxic chemotherapy regimens for primary disease | Unlimited prior hormonal therapy, targeted therapy (including immunotherapy), or antiangiogenic therapy permitted | >= 28 days since last dose of cytotoxic chemotherapy | >= 6 weeks since last dose of nitrosoureas | >= 28 days since last dose of non-cytotoxic chemotherapy (e.g., small molecule inhibitor) | >= 28 days since last dose of monoclonal antibody | >= 28 days since last dose of immunotherapy | Radiotherapy washouts: >= 14 days since last local RT; >= 21 days since stereotactic radiosurgery; >= 12 weeks since craniospinal, >= 50% pelvic RT, or total body irradiation | Patients with CNS disease must show stabilization after the 28-day time point following definitive treatment | Measurable disease must be present outside prior radiation fields at registration | Platelets >= 100,000/µL | Absolute neutrophil count >= 1,500/µL | Hemoglobin >= 8 g/dL | Creatinine <= 1.5 x ULN | AST and ALT <= 3 x ULN | Total bilirubin <= 1.5 x ULN (direct bilirubin <= ULN if total bilirubin > 1.5 x ULN) | Able to swallow and retain oral medications","Prior treatment with an investigational EZH2 inhibitor | History of myeloid malignancy including myelodysplastic syndrome | Cytogenetic or molecular abnormalities associated with MDS or MPN (e.g., del(5q), chromosome 7 abnormalities, JAK2 V617F) | History of T-cell lymphoblastic lymphoma or T-cell acute lymphoblastic leukemia | Therapeutic paracentesis or thoracentesis within 8 weeks prior to registration | Clinical or radiographic evidence of bowel obstruction | Severe, active co-morbidity per investigator discretion | Pregnant or lactating | HIV-positive patients on combination antiretroviral therapy | Use of strong or moderate CYP3A inhibitors or inducers within 14 days of registration and during study treatment","Required: 1-3 prior cytotoxic chemotherapy regimens; Unlimited prior hormonal therapy allowed; Unlimited prior targeted therapy (including immunotherapy) allowed; Unlimited prior antiangiogenic therapy allowed; Washout: >= 28 days since cytotoxic chemotherapy; Washout: >= 6 weeks since nitrosoureas; Washout: >= 28 days since non-cytotoxic chemotherapy (small molecule inhibitor); Washout: >= 28 days since monoclonal antibody; Washout: >= 28 days since immunotherapy; Radiotherapy washout: >= 14 days local RT; >= 21 days stereotactic radiosurgery; >= 12 weeks craniospinal, >= 50% pelvic RT, or TBI",FEMALE,C,"Disease and setting match and prior therapy exposure appears compatible, but the trial requires an ARID1A pathogenic variant for ovarian clear cell patients, which is not provided for this patient. Measurable disease per RECIST is also not confirmed, making eligibility uncertain.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,C,"No hard exclusions. Disease and setting match; prior therapy count appears compatible (1 prior cytotoxic regimen). However, a required biomarker (ARID1A pathogenic variant) is unknown, and measurable disease is unconfirmed. With required biomarker not confirmed, A is not warranted; there’s no clear soft mismatch to justify D. Given uncertainty on a required biomarker anchor, C is appropriate.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT03643991,1.0,Dementia,Decreasing Agitation in Patients With Dementia Through the Use of Weighted Blankets: A Pilot Study,"The purpose of this research study is to determine whether the use of weighted blankets help reduce behavioral and psychological symptoms, including agitation in people with dementia.","{'id': 205588423, 'name': 'Weighted Blanket', 'description': 'Weighted blanket will be given to patients based on the patient weight (10% of patients body weight) for three nights while on inpatient unit.', 'other_names': [], 'intervention_type': 'OTHER'}",NA,60 years,Dementia,"Admitted to inpatient geriatric psychiatry unit, complex interventions unit, internal medicine service, or hospice GIP | Documented diagnosis of dementia or suspected major neurocognitive disorder | Agitation/aggression with CMAI-SV: score 3, 4, or 5 on at least one aggression item (items 1–4) | Legally Authorized Representative available to provide consent",Severe pain likely to be exacerbated by use of weighted blanket | Inability to remove blanket | Skin burns or open wounds | Admitted on 72-hour hold,(none),ALL,C,"Disease and age/sex match, but key required criteria (inpatient admission, documented agitation per CMAI-SV, and availability of a legally authorized representative) are unknown. With these setting/phenotype requirements unspecified, eligibility is uncertain without further details.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,C,"No hard exclusions apply (disease matches; age/sex within limits; no explicit exclusion triggered). Core anchors: stage/setting (inpatient), required phenotype (agitation per CMAI-SV), and LAR availability are all unknown; line/prior not applicable. With 0 anchors confirmed and no soft mismatches, rubric indicates C. Grader’s reasoning aligns with this.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT03726554,1.0,Rheumatoid Arthritis,Comprehensive Reverse Shoulder: Porous Augmented Glenoid Baseplate and Mini Humeral Tray Post-Market Clinical Follow-up Study,"This study is a multicenter, prospective, non-randomized, non-controlled, dual cohort post market surveillance study. The primary objective of this study is to confirm the safety and performance of the Comprehensive Reverse Shoulder System when used with the Comprehensive Porous Augmented Glenoid Baseplate and/or Comprehensive Mini Humeral Tray in primary and revision reverse shoulder arthroplasty.","{'id': 205956780, 'name': 'Comprehensive Reverse Porous Augmented Glenoid', 'description': 'Three glenoid baseplate options designed for various severities of glenoid erosion and deformity, the device promotes bony ingrowth while restoring natural human anatomy.', 'other_names': [], 'intervention_type': 'DEVICE'}; {'id': 205956781, 'name': 'Comprehensive Mini Humeral Tray', 'description': 'The mini humeral tray offers additional sizing options to the Comprehensive Shoulder line. The mini tray is designed to fit smaller anatomies.', 'other_names': [], 'intervention_type': 'DEVICE'}",NA,18 years,Shoulder Arthropathy; Rotator Cuff Deficiency; Shoulder Osteoarthritis; Post-Traumatic Arthritis; Rheumatoid Arthritis,Age >= 18 years | Anatomically and structurally suited to receive the implants | Functional deltoid | Grossly deficient rotator cuff with severe arthropathy | Previously failed shoulder joint replacement with a grossly deficient rotator cuff,Osteoporosis | Metabolic disorder that may impair bone formation | Osteomalacia | Distant foci of infection that may spread to the implant site | Rapid joint destruction | Marked bone loss | Bone resorption on radiograph,(none),ALL,C,"Rheumatoid arthritis is included in the trial’s disease list and the patient meets age/sex criteria. However, eligibility hinges on severe shoulder-specific pathology (gross rotator cuff deficiency with arthropathy or failed shoulder replacement and implant suitability), which is not documented, so no core anchors can be confirmed.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,C,"No hard exclusions apply. Disease includes Rheumatoid Arthritis; age/sex fit. Key inclusion (severe shoulder pathology/rotator cuff deficiency and implant suitability) is unknown, so no core anchors can be confirmed and there’s no soft mismatch identified. Grade C is appropriate per rubric.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03744793,0.8805802464485168,Metastatic Urothelial Carcinoma,A Phase II Trial to Evaluate Combination Therapy With Pemetrexed and Avelumab in Previously Treated Patients With MTAP-Deficient Advanced Urothelial Cancer,"This phase II trial studies how well pemetrexed and avelumab work in treating patients with MTAP-deficient urothelial cancer that has spread to other places in the body. Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pemetrexed and avelumab may work be...","{'id': 205882630, 'name': 'Avelumab', 'description': 'Given IV', 'other_names': ['Bavencio', 'MSB-0010718C', 'MSB0010718C'], 'intervention_type': 'DRUG'}; {'id': 205882631, 'name': 'Pemetrexed', 'description': 'Given IV', 'other_names': ['MTA', 'Multitargeted Antifolate'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Urothelial Carcinoma (metastatic),"Histologic confirmation of MTAP-deficient metastatic urothelial carcinoma verified by CLIA-certified IHC | Histologic variants (glandular, squamous, sarcomatoid, micropapillary, plasmacytoid, small cell changes) allowed if MTAP-deficient | Eligible as second-line after chemotherapy or PD-L1 inhibitor, or third-line after both chemotherapy and PD-L1 inhibitor | Prior intravesical therapy allowed and does not count as a prior line of therapy | Prior methotrexate-containing chemotherapy allowed if neoadjuvant or first-line given >= 12 months prior | Measurable disease per RECIST v1.1 | ECOG performance status <= 2 | AST <= 2.5 x ULN or <= 5 x ULN with liver metastases | ALT <= 2.5 x ULN or <= 5 x ULN with liver metastases | Total bilirubin <= 1.5 x ULN (<= 3.0 mg/dL allowed for Gilbert's syndrome or liver metastases) | ANC >= 1.5 x 10^9/L | Hemoglobin >= 9 g/dL (transfusion allowed) | Platelets >= 100 x 10^9/L | Normal serum creatinine or creatinine clearance >= 40 mL/min | Ability to interrupt NSAIDs around pemetrexed dosing | Ability to take folic acid, vitamin B12, and dexamethasone per protocol | Mild or well-controlled autoimmune conditions allowed (e.g., localized psoriasis, Hashimoto's on replacement, type 1 diabetes)","Primary CNS malignancies or active CNS metastases including leptomeningeal disease (treated, stable >= 4 weeks and off steroids allowed) | Other malignancy disease-free < 2 years except non-melanoma skin cancer, controlled localized prostate cancer, or in situ carcinoma | Pregnant or breastfeeding | Uncontrolled third space fluid (clinically significant pleural or peritoneal effusions not controlled by drainage) | Known or suspected autoimmune disease including inflammatory bowel disease, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, or autoimmune vasculitis | Systemic corticosteroids > 10 mg prednisone equivalents daily or other immunosuppressive medications within 14 days before first dose (except inhaled or replacement steroids > 10 mg without active autoimmune disease) | History of primary immunodeficiency | Prior organ transplantation including allogeneic stem-cell transplant | Vaccinations within 4 weeks of first avelumab dose and while on trial (except inactivated vaccines) | Active hepatitis A, B, or C | Known HIV infection or AIDS | Uncontrolled intercurrent illness including active infection, current pneumonitis, symptomatic heart failure, unstable angina, symptomatic arrhythmia, or interstitial lung disease | Clinically significant cardiovascular disease: stroke < 6 months, myocardial infarction < 6 months, unstable angina, heart failure >= NYHA class II, or serious arrhythmia requiring medication | Persisting toxicity from prior therapy > grade 1 (CTCAE v5.0) except alopecia, sensory neuropathy <= grade 2, or other <= grade 2 not posing safety risk | Uncontrolled psychiatric illness or social conditions limiting compliance or consent | Allergy or hypersensitivity to study drug formulations | Major surgery within 28 days prior to first dose or not recovered from prior surgery | Currently on dialysis",Eligible in second line after prior chemotherapy or PD-1/PD-L1 inhibitor; Eligible in third line after both chemotherapy and PD-1/PD-L1 inhibitor; Prior intravesical therapy allowed (does not count as a prior line); Prior methotrexate-containing chemotherapy allowed if >= 12 months since neoadjuvant or first-line,ALL,C,"Disease and metastatic setting align and prior exposure appears compatible, but the trial requires MTAP-deficient urothelial carcinoma and the patient’s MTAP status is unknown. Additionally, the trial requires creatinine clearance ≥40 mL/min whereas the patient’s eGFR is 35 mL/min, which may preclude eligibility.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),INCORRECT,B,"Disease matches; stage/setting and line/prior exposure match. Required MTAP biomarker is unknown (not a hard exclusion), which prevents A. The renal function shortfall is not a hard exclusion and not a CORE ANCHOR, so it shouldn’t reduce the grade. Thus B is appropriate, not C.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT03944447,0.6691051721572876,Fistulizing Crohn's Disease,Outcomes Mandate National Integration With Cannabis as Medicine,"This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.","{'id': 205395405, 'name': 'Cannabis, Medical', 'description': 'Patients will be given medical cannabis recommendations and certifications commensurate with the state law in which the encounter occurs. The variations in mechanisms between the states for recommending, registering, certifying, and developing mandated treatment plans or doses will be adhered to; however, variations in state law and cannabis programs should not cause variation in the study design because the end-result is still the same with patients being treated with medical cannabis.', 'other_names': ['Marijuana Medical', 'Marijuana Treatment'], 'intervention_type': 'DRUG'}; {'id': 205395406, 'name': 'RYAH-Medtech Inhaler', 'description': ""Our research study will involve incorporation of RYAH-Medtech company's devices into our protocols. They have an inhaler and a transdermal patch for both hemp-derived CBD and cannabis. RYAH has developed an integrated phone app for tracking product use and patient response. They are currently involved in clinical trials in Europe. OMNI Medical will integrate the partner with RYAH device for several reasons. Primary goals will involve using their integrated smart phone app to collect and secure large quantities of data. Secondary goals will include FDA approval as a medical device. The specific cannabis strain will be tracked using scannable QR codes programed into the smart phone app. This will allow us to track patient feedback and capture data on usage. OMNI Medical will have patients use RYAH's products as part of and FDA Investigational Device Exemption, which requires an IRB. Use of the devices would be completely voluntary by study participants."", 'other_names': [], 'intervention_type': 'DEVICE'}",PHASE2,7 years,Amyotrophic Lateral Sclerosis; Anxiety; Autism; Bipolar Disorder; COVID-19; Cancer; Chronic Pain; Chronic Pain Due to Injury; Chronic Pain Due to Trauma; Chronic Pain Syndrome; Chronic Traumatic Encephalopathy; Crohn Disease; Depression; Epilepsy; Fibromyalgia; Glaucoma; HIV/AIDS; Hepatitis C; Inflammatory Bowel Diseases; Insomnia; Multiple Sclerosis; Opioid-use Disorder; Parkinson Disease; Post Traumatic Stress Disorder; SARS-CoV Infection; Seizures; Sickle Cell Disease; Tourette Syndrome; Traumatic Brain Injury; Ulcerative Colitis,Clinical diagnosis of a qualifying condition for medical marijuana | Age >= 18 years or with parental/legal guardian consent per state law,Pregnancy | Breastfeeding | Active suicidality | Psychosis that could be exacerbated by cannabis,(none),ALL,C,"Disease matches (Crohn’s Disease/IBD listed) and the patient meets age/sex criteria with no explicit exclusions triggered. However, stage/setting and line/prior-therapy requirements are unspecified for this trial, so no core anchors can be confirmed.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,C,"No hard exclusions. Disease matches (Crohn’s/IBD listed). Core anchors: stage/setting not specified, line/prior not specified, no required biomarkers, no mets pattern—thus 0 confirmed matches and no soft conflicts. Grade C per rubric.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT04632628,1.0,Dementia,Web-based Cognitive Behavioral Treatment for Insomnia in Dementia Caregivers,"Over the next 30 years, more than 10 million persons living with dementia in the United States will receive care at home from an unpaid and untrained family caregiver. At home care is preferred by caregivers and persons with dementia alike, but increases the caregiver's risk of insomnia and related negative health outcomes, including depression, anxiety, cognitive disturbances and poor quality of life. Cognitive behavioral therapy for insomnia (CBT-I) is a highly effective and established evi...","{'id': 205904269, 'name': 'Web-based Cognitive Behavior Therapy for Insomnia (CBT-I)', 'description': 'Participants will complete 4 web-based CBT- I sessions. Lesson 1: Sleep Hygiene and Stimulus Control Lesson 2: Sleep Restriction and Relaxation Strategies Lesson 3: Identifying and Restructuring Dysfunction Thoughts Lesson 4: Practical Recommendations, Review, and Maintenance of Change', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}",NA,18 years,Dementia; Chronic Insomnia,"Age >= 18 years (caregivers) | Caregiver of a person with dementia living with the person with dementia | Insomnia diagnosis | Insomnia complaints for >= 6 months | Adequate opportunity and circumstances for sleep | At least one: difficulty falling asleep, difficulty staying asleep, or waking too early | Daytime dysfunction due to insomnia | Insomnia Severity Index score >= 11 or Insomnia Severity Index score 9-10 at screening | Baseline sleep diaries show > 30 minutes sleep onset latency or wake after sleep onset on >= 3 nights | Age >= 18 years (persons with dementia) | Person with dementia living with caregiver","Cognitive impairment in caregiver (TICS < 25 or MMSE < 26) | Sleep apnea with apnea-hypopnea index (AHI) > 15 | Bipolar disorder | Seizure disorder | Major psychopathology except depression or anxiety (e.g., suicidal ideation/intent, psychosis) | Severe untreated psychiatric comorbidity | Use of psychotropic or other medications that alter sleep | Concurrent non-pharmacological treatment for sleep or mood outside the trial","No current prescription or over-the-counter sleep medications, or must be on a stable dose for >= 6 weeks; No concurrent non-pharmacological treatment for sleep or mood",ALL,C,"Disease (dementia) is included, but the trial primarily enrolls caregiver–patient dyads and requires the caregiver to have diagnosed insomnia and cohabitation, which are unknown here. No clear stage/line requirements apply, so core anchors are largely unknown rather than mismatched.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,C,"No hard exclusions: dementia is included, age/sex fit, and no explicit exclusions apply. Core anchors (stage/setting, line, biomarkers, mets) are not applicable/unknown. Caregiver insomnia requirement is not a defined core anchor, so it doesn’t create a soft mismatch. With disease match and 0 anchor matches/unknown, grade C is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT04817969,1.0,Rheumatoid Arthritis,"Persona® Ti-Nidium® Personalized Total Knee System A Post-Market Clinical Follow-up Study to Provide Safety, Performance and Clinical Benefits Data Using the Persona Ti-Nidium Total Knee System and Instrumentation",The main objectives of this study are to evaluate overall clinical performance and safety of the Persona Ti-Nidium implant in total knee arthroplasty.,"{'id': 206003139, 'name': 'Zimmer Biomet Persona Ti-Nidium Total Knee System', 'description': 'Primary Knee Total Arthroplasty', 'other_names': [], 'intervention_type': 'DEVICE'}",NA,18 years,Rheumatoid Arthritis; Osteoarthritis; Traumatic Arthritis; Polyarthritis; Avascular Necrosis; Patellofemoral Osteoarthritis; Flexion Deformity of the Knee; Valgus Deformity; Varus Deformity; Knee Pain Chronic,"Skeletally mature adult. | Qualifies for total knee arthroplasty based on physical exam and medical history. | Indicated for the Persona Ti-Nidium Knee and Vivacit-E polyethylene articulating surface per product labeling. | Severe pain and disability due to rheumatoid arthritis, osteoarthritis, traumatic arthritis, or polyarthritis. | Collagen disorders and/or avascular necrosis of the femoral condyle. | Post-traumatic loss of joint configuration, particularly with patellofemoral erosion, dysfunction, or prior patellectomy. | Moderate valgus, varus, or flexion deformities.","Current or prior infection in the affected joint or other local/systemic infection that may affect the prosthetic joint. | Insufficient bone stock on femoral or tibial surfaces. | Skeletal immaturity. | Neuropathic arthropathy. | Osteoporosis or loss of musculature or neuromuscular disease that compromises the affected limb. | Stable, painless arthrodesis in a satisfactory functional position. | Severe instability due to absence of collateral ligament integrity. | Rheumatoid arthritis with a skin ulcer or history of recurrent skin breakdown. | Kinematic alignment technique contraindicated: >5° valgus deformity with medial collateral ligament insufficiency. | Currently participating in another surgical intervention or pain management study. | Pregnant.",(none),ALL,C,"Disease matches and age/sex are within range. However, candidacy for total knee arthroplasty and device-specific indications/exclusions are unknown, so stage/setting and prior-exposure anchors cannot be confirmed.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,C,"No hard exclusions (disease includes RA; age/sex fit; no explicit exclusion triggered). Stage/setting (TKA candidacy) is unknown; line/prior-exposure anchor not defined for this device trial; no biomarker or mets requirements. With disease match but no confirmed core anchor matches and no soft mismatch, C is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT04849884,1.0,Rheumatoid Arthritis,"A Prospective, Multi-Center, Post-Market Clinical Study to Evaluate the Performance of the CORI™ KNEE TENSIONER as an Accessory to the CORI™ Surgical System in Total Knee Arthroplasty Procedures.",To evaluate the performance of the CORI™ KNEE TENSIONER as an accessory to the CORI™ Surgical System.,"{'id': 205868145, 'name': 'CORI™ KNEE TENSIONER', 'description': 'Robotic TKA procedure with the REAL INTELLIGENCE™ CORI™ Surgical System including the use of the CORI™ KNEE TENSIONER accessory.', 'other_names': [], 'intervention_type': 'DEVICE'}",NA,18 years,Osteoarthritis; Rheumatoid Arthritis; Avascular Necrosis,Age >= 18 years | Suitable for the CORI Surgical System | Requires cemented primary total knee arthroplasty | Degenerative joint disease (osteoarthritis) as indication for TKA | Rheumatoid arthritis as indication for TKA | Avascular necrosis as indication for TKA | Requires correction of functional deformity | Fractures unmanageable by other techniques,"Contraindications or hypersensitivity to the CORI Surgical System | Need for revision TKA or complex implants other than standard TKA (e.g., stems, augments, custom devices) | Post-traumatic arthritis | Requires bilateral total knee arthroplasty | Active infection or sepsis | Body mass index > 40 | Advanced osteoarthritis | Joint disease | Vascular insufficiency | Muscular atrophy | Uncontrolled diabetes | Moderate to severe renal insufficiency | Neuromuscular disease | Mental illness or intellectual disability | Drug or alcohol abuse | Pregnant or nursing or women of child-bearing potential not using birth control",(none),ALL,C,"Disease (rheumatoid arthritis) matches and age/sex fit, but the trial specifically requires patients who need cemented primary total knee arthroplasty with the CORI system, which is not stated for this patient. Other eligibility details (e.g., surgical indication and listed comorbid exclusions) are unknown, with no explicit conflicts noted.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,C,"No hard exclusions. Disease matches RA; age/sex acceptable. Core anchors (stage/setting—TKA requirement, line/prior exposure, biomarkers, mets) are unknown/not applicable, with no soft mismatch identified. Thus 0 anchors match → Grade C per rubric.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT04862117,1.0,Rheumatoid Arthritis,Long Term Extension Study of the Safety and Efficacy of Neurostimulation Using a Vagus Nerve Stimulation Device in Patients With Rheumatoid Arthritis,"Long-term extension of a multi-site, first-in-human study to assess safety and efficacy of an active implantable Vagus Nerve Stimulation (VNS) device in adult patients with active moderate-to-severe rheumatoid arthritis who have had an incomplete response or intolerability to at least two biologic and/or targeted synthetic DMARDs having at least two different mechanisms of action","{'id': 206437859, 'name': 'SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System', 'description': 'Active Implantable Vagus Nerve Stimulation device.', 'other_names': ['SetPoint System'], 'intervention_type': 'DEVICE'}",NA,22 years to 75 years,Rheumatoid Arthritis,Completed 12 weeks of treatment in Study SPM-008 | Women of childbearing potential not pregnant and agree to use reliable contraception throughout the study,Inability to provide consent | Adverse event during Study SPM-008 that precludes participation | Any condition per investigator judgment that precludes participation,(none),ALL,C,"Disease and age/sex match the trial, but this is a long-term extension requiring completion of Study SPM-008, which is unknown for this patient. Without confirmation of prior SPM-008 participation, eligibility is uncertain.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,C,"No hard exclusions apply. The key requirement (completion of Study SPM-008) is unknown, which cannot trigger F or D per rubric. Core anchors are largely unknown/not applicable; with disease match and 0 anchors confirmed, the correct grade is C. The grader’s reasoning and assigned grade align with the rubric.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT04968405,1.0,Rheumatoid Arthritis,Analysis of the Performance and Safety of the Catalyst CSR Shoulder System - A Prospective Study,Evaluation of the performance and safety of the Catalyst CSR Shoulder System with clinical and radiographic results at multiple time points through 24 months postoperatively This study will be a prospective multi-center study conducted in the United States.,"{'id': 205961604, 'name': 'Catalyst CSR Total Shoulder System', 'description': 'The Catalyst CSR Shoulder System is a bone preserving total shoulder prosthesis designed for use in patients where the humeral head, neck and glenoid vault are of sufficient bone stock and there is an intact or reconstructable rotator cuff. The design requires minimal bone resection, thus giving the patient an alternative to other total shoulder designs where more bone is removed.', 'other_names': [], 'intervention_type': 'DEVICE'}",NA,18 years,Avascular Necrosis (humeral head); Shoulder Osteoarthritis; Rheumatoid Arthritis,Age >= 18 years | Skeletally mature with degenerative disease of the glenohumeral joint where hemi or total shoulder arthroplasty is indicated | Meets Catalyst CSR Shoulder System indications for use per approved labeling,"History of open surgery to the index shoulder (prior arthroscopic surgery allowed) | Full thickness rotator cuff tear or marked posterior glenoid wear | Local or systemic infection, or osteomyelitis of the proximal humerus or scapula | Inadequate or malformed bone precluding adequate fixation of the prosthesis | Osteoporosis | Neuromuscular disorders that do not allow control of the joint | Chronic instability, chronic dislocation, or deficient soft tissues/support structures (e.g., brachial plexus or deltoid) | Vascular insufficiency | Age, weight, or activity level expected to cause early failure of the system | Known sensitivity to cobalt-chromium-molybdenum alloys used in prosthetic devices | Any disease that could adversely affect implant function or longevity (e.g., metabolic disorders)",(none),ALL,C,"Disease (RA) and age match, and there are no explicit disqualifying prior therapies. However, the trial requires degenerative glenohumeral disease with an indication for shoulder arthroplasty, which is not specified for the patient, so key stage/setting details are unknown.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,C,"No hard exclusions apply. Disease (RA) and age are compatible, but the trial’s required stage/setting—degenerative glenohumeral disease needing shoulder arthroplasty—is not specified for the patient, yielding unknown on core anchors and no clear soft mismatch. Grade C is appropriate.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05007730,1.0,Dementia,Enhancing Health and Quality of Life for Individuals With Dementia Through Transitional-State Snacks,"Malnutrition significantly contributes to the disability and mortality associated with Alzheimer's disease and Alzheimer's disease-related dementias. Thus, nutritional status is one important, modifiable clinical factor for maintaining physical and cognitive health among persons with dementia (PWD). This project will pilot an innovative approach to enhancing nutrition through the use of transitional-state snack supplements, or foods that start as one texture and change to another. Specificall...","{'id': 206110881, 'name': 'Transitional-state food therapeutic nutrition supplement', 'description': 'Participants will consume at least one ""snack-sized"" package of the transitional-state food supplements per day across the intervention trial.', 'other_names': [], 'intervention_type': 'DIETARY_SUPPLEMENT'}",NA,18 years,Dementia,Medically stable | Medical diagnosis of dementia or possible dementia,"Requires 100% feeding assistance | NPO (nil per os) | Multiple food allergies | Requires a strict renal, low-fat, and/or no-salt diet | Deemed unsafe for transitional-state foods by a speech-language pathologist",(none),ALL,C,"Disease, age, and sex match, and there are no explicit exclusions identified. However, stage/setting and line/prior-therapy anchors are unspecified, and key inclusion/exclusion details (medical stability, feeding assistance, diet/allergies, SLP safety) are unknown, so no core anchors can be confirmed.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,C,"No hard exclusions. Disease, age, and sex match. Core anchors (stage/setting, line/prior, biomarker, mets pattern) are either not applicable or unspecified, yielding 0 confirmed matches and no soft mismatches. Grade C is appropriate per rubric.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05048966,1.0,Dementia,Comparison of Two Group Wellness Interventions for Individuals With Neurologic Conditions and Their Support Persons: A Randomized Clinical Trial,"Approximately 5.3 million people live with a long-term disability resulting from a traumatic brain injury (TBI) and between 5-8% of those older than 60 suffer from Alzheimer's disease or other forms of dementia (ADRD). Consequences of these conditions can result in dramatic and persistent changes in functioning, impacting not only the patients, but also loved ones who become informal support persons. Many existing services help the family in the moment, but do not address long-term wellness. ...","{'id': 205742752, 'name': 'Group Wellness Class 1', 'description': 'Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours.', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}; {'id': 205742753, 'name': 'Group Wellness Class 2', 'description': 'Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours.', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}",NA,18 years,Traumatic Brain Injury (moderate/severe); Mild Traumatic Brain Injury; Alzheimer's Disease; Dementia,Age 18-64 (moderate/severe TBI cohorts) | At least 1 year post-injury (moderate/severe TBI) | Age 18-64 (chronic mild TBI cohort) | At least 3 months post-injury (chronic mild TBI) | Age >= 65 years (ADRD cohort) | At least 1 year post-diagnosis (ADRD),"Prior stroke or neurological disease other than the target condition (TBI, mild TBI, or ADRD, respectively) | Unstable or uncontrolled seizures | Hospitalization for significant psychiatric illness (e.g., bipolar disorder, schizophrenia, psychosis) within the past 3 months | Current alcohol and/or drug use that interferes with ability to carry out common everyday functions",(none),ALL,C,"Disease and age match the ADRD cohort, but the trial requires ≥1 year post-diagnosis, which is not explicitly confirmed, and other core anchors are not specified. Therefore eligibility is uncertain without more details.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,C,"No hard exclusions. Disease and age fit the ADRD cohort; the ≥1 year post-diagnosis requirement is not explicitly confirmed, and other core anchors (stage/setting, line/prior, biomarkers, mets) are not applicable or unknown. With 0 clear anchor matches and no soft mismatch, C is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05144191,1.0,Rheumatoid Arthritis,"Insignia™ Hip Stem Outcomes Study - A Prospective, Post-market, Multi-center Evaluation of the Clinical Outcomes of the Insignia™ Hip Stem for Total Hip Replacement Surgery",The objective of this study is to evaluate the safety and effectiveness of the Insignia™ Hip Stem for global market access and post-market clinical follow-up up to 10 years postoperative.,"{'id': 206546266, 'name': 'Insignia uncemented Hip Stem', 'description': 'Device: Replacement of arthritic hip with Insignia uncemented Hip Stem', 'other_names': [], 'intervention_type': 'DEVICE'}",NA,18 years,Avascular Necrosis; Femoral Neck Fracture; Hip Osteoarthritis; Post-traumatic Osteoarthritis; Rheumatoid Arthritis; Trochanteric Fracture,Skeletally mature | Diagnosis of hip osteoarthritis | Diagnosis of avascular necrosis | Diagnosis of rheumatoid arthritis | Diagnosis of post-traumatic osteoarthritis | Correction of functional deformity indicated | Treatment of nonunion indicated | Femoral neck fracture | Trochanteric fracture | Candidate for primary or revision cementless total hip arthroplasty,"Pregnant or breastfeeding | Active or suspected latent infection in or about the affected hip joint | Mental or neuromuscular disorder increasing risk of prosthesis instability, fixation failure, or postoperative complications | Inadequate bone stock to support or fix the prosthesis | Immunologically suppressed or chronic systemic steroid use >30 days | Known sensitivity to device materials",(none),ALL,C,"Disease matches (rheumatoid arthritis) and age/sex fit, but the trial is for patients undergoing/candidates for cementless total hip arthroplasty, which is unknown for this patient. Stage/setting and prior-therapy anchors are not specified or not applicable, with no explicit exclusions triggered.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,C,"No hard exclusions apply. Disease matches (RA). Key anchor (stage/setting: candidacy for cementless THA) is unknown, and other anchors are not applicable/unknown. With 0 anchors matched and no soft mismatch identified, the rubric dictates grade C. The grader’s reasoning aligns with this.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05168423,0.8363864421844482,Recurrent Glioblastoma,"Phase 1, Open-label Study Evaluating the Safety and Feasibility of CART-EGFR-IL13Ra2 Cells in Patients With EGFR-Amplified Recurrent Glioblastoma","This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2 (referred to as ""CART-EGFR-IL13Ra2 cells"") in patients with EGFR-amplified glioblastoma, IDH-wildtype that has recurred following prior radiotherapy. This study will take place in two parts: an initial dose escalation phase followed by a dose exploration phase. In the dose expansion phase, the maximum tolerated dose (MTD) of C...","{'id': 206508711, 'name': 'CART-EGFR-IL13Ra2 Cells', 'description': 'autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR and a humanized scFv targeting IL13Ra2', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,18 years,Glioblastoma (recurrent),"Age >= 18 years | Glioblastoma, IDH-wildtype, recurrent after prior radiotherapy | EGFR amplification (wild-type EGFR) confirmed by NeoGenomics on tumor tissue | Surgical resection or biopsy clinically indicated | Serum creatinine <= 1.5 x ULN or creatinine clearance >= 30 mL/min and not on dialysis | AST <= 3 x ULN | ALT <= 3 x ULN | Total bilirubin <= 2.0 mg/dL (<= 3.0 mg/dL if Gilbert's syndrome) | Left ventricular ejection fraction >= 45% | Pulmonary reserve: dyspnea <= Grade 1 and oxygen saturation > 92% on room air | Karnofsky Performance Status >= 60% | Use of effective contraception if of reproductive potential","Active hepatitis B or hepatitis C infection | Any other active, uncontrolled infection | New York Heart Association class III or IV heart failure | Tumors primarily localized to the brain stem or spinal cord | Severe active comorbidity precluding study participation per investigator | Bevacizumab within 3 months prior to eligibility confirmation | Active autoimmune disease requiring systemic immunosuppression equivalent to >= 10 mg/day prednisone | Autoimmune neurological disease (e.g., multiple sclerosis, Parkinson's disease) | Pregnant or breastfeeding | History of hypersensitivity to human serum albumin, dimethyl sulfoxide (DMSO), or dextran 40",Prior radiotherapy required for glioblastoma,ALL,C,"The disease and recurrent setting match and prior radiotherapy is documented, but the trial requires EGFR amplification confirmed by NeoGenomics (and resection/biopsy being clinically indicated), which are not provided, so eligibility is uncertain.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,C,"No hard exclusions. Disease and recurrent setting match and prior RT is compatible. However, a required biomarker (EGFR amplification with NeoGenomics confirmation) is unknown, so required biomarkers are not satisfied—preventing an A. With key eligibility info missing and no soft mismatches, C (relevant/uncertain) is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05548972,1.0,Rheumatoid Arthritis,"Global, Multicenter and Prospective Post-Market Clinical Follow-Up Study of the G7® Dual Mobility Acetabular System With Vivacit-E® or Longevity® Poly Bearing & Instrumentation","This study is a global, multi-center, prospective, non-controlled, non-randomized, post-market clinical follow-up study. The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Dual Mobility Acetabular System when used with the Vivacit-E or Longevity polyethylene hip bearing and instrumentation in primary total and revision (total) hip arthroplasty","{'id': 206470196, 'name': 'G7 Dual Mobility with Vivacit-E bearing', 'description': 'hip arthroplasty with G7 Dual Mobility Vivacit-E bearing', 'other_names': [], 'intervention_type': 'DEVICE'}; {'id': 206470197, 'name': 'G7 Dual Mobility Longevity bearing', 'description': 'hip arthroplasty with G7 Dual Mobility Longevity bearing', 'other_names': [], 'intervention_type': 'DEVICE'}",NA,18 years to 80 years,Hip Osteoarthritis; Avascular Necrosis; Rheumatoid Arthritis; Femoral Neck Fracture; Trochanteric Fracture; Hip Dislocation,"Age 18 to 80 years | Skeletally mature | Qualifies for total hip arthroplasty based on exam and history | Non-inflammatory degenerative joint disease (including osteoarthritis and avascular necrosis) | Rheumatoid arthritis | Dislocation risk | Correction of functional deformity | Treatment of non-union, femoral neck fracture, or trochanteric fractures of the proximal femur with head involvement unmanageable by other techniques | Revision procedure where other treatment or devices have failed","Sepsis, active infection, or osteomyelitis at the affected joint | Significant osteoporosis (per treating surgeon) | Metabolic disorder(s) that may impair bone formation | Osteomalacia | Distant foci of infection that may spread to the implant site | Rapid joint destruction, marked bone loss, or bone resorption on pre-operative radiographs | Contralateral total hip arthroplasty within 3 months of index procedure or planned within 3 months | Simultaneous bilateral total hip arthroplasty | Vascular insufficiency, muscular atrophy at the implant site, or neuromuscular disease likely to jeopardize surgical outcome | Any concomitant disease likely to jeopardize the functioning or success of the implant | Pregnancy",(none),ALL,C,"Disease matches (rheumatoid arthritis) and age/sex fit, but the trial specifically enrolls patients who qualify for total hip arthroplasty, which is not stated for this patient. With stage/setting (surgical THA) and line/prior-therapy requirements unknown relative to the patient, there are no clear matches or exclusions.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,C,"No hard exclusions apply. Disease (RA) is listed in trial indications, but the key stage/setting requirement is qualifying for total hip arthroplasty, which is unknown for the patient; other anchors (line/prior, biomarkers, mets) are not applicable/unknown. With 0 clear anchor matches and no soft mismatch, grade C is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05587244,1.0,Rheumatoid Arthritis,"Multicenter, Prospective Post-Market Clinical Follow-Up Study of the G7® Freedom Constrained Vivacit-E® Liners","The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Freedom Constrained Vivacit-E Acetabular Liners in primary and revision total hip arthroplasty.","{'id': 206603610, 'name': 'Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners', 'description': 'Primary and/or Revision total hip arthroplasty with the G7 Freedom Constrained Vivacit-E Liners', 'other_names': [], 'intervention_type': 'DEVICE'}",NA,18 years to 80 years,Avascular Necrosis; Hip Dislocation; Femoral Neck Fracture; Fracture Nonunion; Hip Osteoarthritis; Rheumatoid Arthritis; Trochanteric Fracture,Age 18-80 years | Skeletally mature | Qualifies for unilateral total hip arthroplasty based on clinical assessment | Non-inflammatory degenerative joint disease (osteoarthritis or avascular necrosis) | Rheumatoid arthritis | High risk for hip dislocation | Undergoing revision hip arthroplasty | Correction of functional deformity | Need for treatment of non-union of the proximal femur with head involvement unmanageable by other techniques | Need for treatment of femoral neck fracture with head involvement unmanageable by other techniques | Need for treatment of trochanteric fracture of the proximal femur with head involvement unmanageable by other techniques,"Sepsis, active infection, or osteomyelitis at the affected joint | Significant osteoporosis (per treating surgeon) | Metabolic disorder(s) that may impair bone formation | Osteomalacia | Distant foci of infection that may spread to the implant site | Rapid joint destruction, marked bone loss, or bone resorption on pre-operative radiographs | Contralateral total hip arthroplasty within 3 months of planned index procedure | Planned contralateral total hip arthroplasty within 3 months of the index procedure | Simultaneous bilateral total hip arthroplasty | Vascular insufficiency at the implant site | Muscular atrophy at the implant site | Neuromuscular disease that might jeopardize surgical outcome | Concomitant disease likely to jeopardize the functioning or success of the implant (per investigator) | Pregnancy",(none),ALL,C,"The trial includes rheumatoid arthritis and the patient's age/sex fit, but it is a hip arthroplasty device study requiring candidates for (or undergoing) hip replacement, which is not specified for this patient. Line-of-therapy and other setting details are not provided, so eligibility cannot be confirmed.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,C,"No hard exclusions apply (disease includes RA; age/sex allowed; no explicit exclusion triggered). Core anchors: stage/setting (hip arthroplasty requirement) is unknown for the patient; line/prior not applicable; no required biomarkers; mets pattern not relevant. With 0 anchors matched and no soft mismatch identified, C is appropriate. The grader’s reasoning aligns with the rubric.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05630053,1.0,Rheumatoid Arthritis,Randomized Controlled Trial to Compare Persona OsseoTi Keel Cementless TKA vs Persona Keel Cemented TKA,"The main objective of this study is to evaluate the safety, performance, and clinical benefits of the Persona Keel cementless and cemented knee.","{'id': 205956803, 'name': 'Cementless Persona Knee System', 'description': 'The Persona Keel Knee system is a total knee system used in the replacement of the knee joint.', 'other_names': ['Persona PPS CoCr Cementless Femur', 'Persona PPS Femur', 'PPS Femur', 'OsseoTi 0° Spiked Keel Tibia', 'OsseoTi Tibia', 'OsseoTi Spiked Keel Tibia', 'Spiked Keel Tibia', 'Cementless Tibia'], 'intervention_type': 'DEVICE'}; {'id': 205956804, 'name': 'Cemented Persona Knee System', 'description': 'The Persona Keel Knee system is a total knee system used in the replacement of the knee joint.', 'other_names': ['Persona Keel Cemented Tibia', 'Keel Tibia'], 'intervention_type': 'DEVICE'}",NA,18 years,Osteoarthritis; Rheumatoid Arthritis; Traumatic Arthritis; Polyarthritis; Avascular Necrosis; Valgus Deformity; Varus Deformity; Flexion Deformity of Knee; Chronic Knee Pain,Skeletally mature adult. | Eligible for cemented or cementless total knee arthroplasty and meets indications for the Persona Keel Knee System.,"Pregnancy. | Concurrent participation in another surgical intervention or pain management study. | Neurologic or mental condition impairing ability to follow postoperative care instructions. | Planned simultaneous bilateral total knee arthroplasty. | Prior infection in the affected joint or active local/systemic infection that may affect the prosthetic joint. | Insufficient bone stock of femoral or tibial surfaces. | Neuropathic arthropathy. | Osteoporosis or loss of musculature/neuromuscular disease compromising the limb. | Stable, painless arthrodesis in satisfactory position. | Severe instability due to absent collateral ligament integrity. | Rheumatoid arthritis with skin ulcer or history of recurrent skin breakdown. | Valgus deformity >5° with MCL insufficiency where kinematic alignment is contraindicated.",(none),ALL,C,"Disease (rheumatoid arthritis) and age/sex match, but the trial requires eligibility for total knee arthroplasty and the patient’s TKA candidacy is unknown. No explicit exclusions are triggered based on available data.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,C,"No hard exclusions apply (RA included; age ≥18; gender allowed; no explicit conflicting exclusions). Stage/setting (TKA eligibility) is unknown, and other anchors (line/prior, biomarker, mets) are not applicable/unknown. With 0 anchors matched and no soft mismatch, rubric dictates C. Grader’s reasoning aligns.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05668013,0.6691051721572876,Fistulizing Crohn's Disease,"A Phase 2b, Randomized, Double-Blind Long-Term Extension Study to Evaluate Pharmacokinetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Treatment Phase of the Dose-Ranging Study (RELIEVE UCCD LTE)",The primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered every 4 weeks (Q4W) in adult participants with inflammatory bowel disease (IBD). Secondary objectives of the study are to: * evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD * evaluate the safety and tolerability of 2 different maintenance dose regimens of TEV-48574 sc a...,"{'id': 206417302, 'name': 'TEV-48574 Dose Regimen A', 'description': 'Subcutaneous (sc) administration using a commercial sc infusion system', 'other_names': ['duvakitug'], 'intervention_type': 'DRUG'}; {'id': 206417303, 'name': 'TEV-48574 Dose Regiment B', 'description': 'Subcutaneous (sc) administration using a commercial sc infusion system', 'other_names': ['duvakitug'], 'intervention_type': 'DRUG'}",PHASE2,18 years to 75 years,Ulcerative Colitis; Crohn Disease,Maintenance period: Achieved clinical response and/or clinical remission at week 14 of TV48574-IMM-20036 or in the re-induction period of this study | Re-induction: Did not achieve clinical response and/or clinical remission at week 14 of TV48574-IMM-20036,"Discontinued TV48574-IMM-20036 before the scheduled week 14 visit | Concomitant conditions or treatments that could interfere with study conduct, interpretation, or increase risk per investigator judgment | Anticipates requiring major surgery during the study | Currently pregnant or lactating, or planning pregnancy or lactation during the study or for at least 50 days after last dose",(none),ALL,C,"Disease and age/sex match, but this is a long-term extension limited to patients who completed the parent TEV-48574 study at week 14; the patient's participation in that study is unknown, so stage/setting and prior-exposure eligibility cannot be confirmed.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,C,"No hard exclusions apply; disease matches and age/sex fit. The LTE requires completion of a specific parent study and prior exposure/response status, which are unknown. With 0 confirmed core anchor matches and no soft mismatch identified, C is appropriate per the rubric.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05760898,1.0,Rheumatoid Arthritis,Improving Hypertension Control for Patients With Rheumatoid Arthritis,"Rheumatoid arthritis (RA) is a autoimmune disease associated with an increased risk of developing coronary artery disease (CAD) and premature death,. Traditional CAD risk factors like hypertension (HTN) are both very common and poorly controlled among RA patients. Patients with RA face significant challenges in controlling HTN. The goal of this project is to identify barriers to HTN care in patients with RA to reduce CAD events.","{'id': 206177379, 'name': 'Blood pressure intervention arm', 'description': 'The intervention will focus on empowering patients to actively participate in their HTN care, facilitating patient-provider communication, and creating a cohesive care team to close the coordination loop for HTN management. This pilot intervention will help achieve these goals by providing participants with home blood pressure monitors and teaching, improving patient-provider communication regarding blood pressure and RA management, and initiating care coordination between rheumatology and primary care providers.', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}",NA,18 years,Hypertension; Rheumatoid Arthritis,Age >= 18 years | Uncontrolled hypertension | History of rheumatoid arthritis,Age < 18 years | Cognitive impairment affecting capacity to consent | Pregnancy,(none),ALL,C,"The trial targets patients with rheumatoid arthritis, matching the patient's disease, but it requires uncontrolled hypertension, which is not documented for this patient; other core anchors (stage/setting, line/prior) are not specified.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,C,"No hard exclusions. Disease (RA) matches, but required uncontrolled hypertension status is unknown, and other core anchors (stage/setting, line/prior, mets) are unspecified. With 0 clear anchor matches and no soft mismatch, grade C is appropriate.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05820919,1.0,Dementia,Enhancing Sleep Quality for Nursing Home Residents With Dementia: Pragmatic Trial of an Evidence-Based Frontline Huddling Program,"This study seeks to improve clinical outcomes for an important, growing, and vulnerable population-nursing home residents with Alzheimer's disease or related dementias-by testing an evidence-based intervention to improve these residents' sleep. It will also examine the implementation and sustainment of this intervention.","{'id': 205418342, 'name': 'LOCK Sleep Program', 'description': 'The LOCK sleep program is a program that trains NH staff in a NH frontline staff huddling approach. It is derived from evidence supporting strengths-based learning, systematic observation, relationship-based teamwork, and efficiency. Staff learn how to work together as a team to collaboratively problem-solving about resident sleep challenges (e.g., evidence-based sleep promoting best practices and daytime meaningful activity best practices).', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}; {'id': 205418343, 'name': 'No intervention (control period/baseline data collection)', 'description': 'Each NH serves as its own control. During the control period, baseline data will be collected.', 'other_names': [], 'intervention_type': 'OTHER'}",NA,50 years,Alzheimer Disease; Dementia; Sleep Disorder,Age >= 50 years | Diagnosis of Alzheimer disease or related dementia | Identified by nursing home staff in frontline LOCK sleep huddles as having sleep problems,"High risk of obstructive sleep apnea not being treated for OSA | Persistent bilateral resting tremor or paralysis in both arms (e.g., subset of Parkinson's disease) interfering with actigraph measurements",(none),ALL,C,"Disease (dementia) and age match, with no explicit exclusions. However, eligibility appears to require nursing home residency and identification by staff for sleep problems, which are not provided, so key setting criteria are unknown.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,C,"No hard exclusions. Disease matches; age fits. Core anchors: stage/setting (nursing home with sleep problems) is unknown; line-of-therapy not applicable; no required biomarkers; mets pattern not relevant. With 0 clear anchor matches and no soft mismatches, C is appropriate. The grader’s reasoning correctly highlighted the unknown setting requirement.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05858996,1.0,Dementia,Testing the Pain Clinical Practice Guideline Using the Evidence Integration Triangle,"There are evidence based processes for assessment and management of pain using pharmacologic and nonpharmacological approaches. These were reviewed and included within the Pain Management Clinical Practice Guideline (Pain Management CPG) recently developed by AMDA: The Society for Post-Acute and Long-Term Care Medicine. There are, however, many challenges to translating the use of Clinical Practice Guidelines into clinical settings. To overcome these challenges we developed and previously tes...","{'id': 206422206, 'name': 'Pain-CPG-EIT', 'description': 'Following randomization champions and stakeholder team members from the communities will be identified. The investigators will recommend the following individuals to be members of the stakeholder team: a nurse in a leadership position (e.g., director of nursing); the designated champion(s); nursing home administrator; physician/medical director, nurse practitioner and/or physician assistant; unit nurse; nursing assistant; activity staff; social worker; pharmacist; and rehabilitation therapists.\n\nFollowing the first stakeholder team meeting, treatment communities will be provided with a research nurse facilitator to work 8 hours weekly during months one and two and then for four hours weekly starting in month three for a total of 12 months to provide the four components of the PAIN-CPG-EIT.', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}; {'id': 206422207, 'name': 'Pain-CPG-Education Only', 'description': 'The Pain-CPG-Education only group will be provided with the same education as used in Component II of the Pain-CPG-EIT intervention. The education will be provided based on the preferences of the community (this may be face-to-face; online; or via handouts).', 'other_names': ['EO'], 'intervention_type': 'OTHER'}",PHASE2,60 years,Dementia; Pain,"Resident living in a participating community | Age >= 60 years | Evidence of dementia: BIMS 0–12, or AD8 > 2, or CDR 0.5–2.0, and FAQ >= 9 to differentiate from mild cognitive impairment | Evidence of pain at recruitment: MDS item indicates pain occasionally/frequently/almost constantly, or staff report at same frequency, or receiving nonpharmacological or pharmacological pain treatment","Admitted for short-stay rehabilitation or other subacute needs (e.g., intravenous antibiotics) | Receiving hospice care",(none),ALL,C,"Disease (dementia) matches and age/sex fit, but key inclusion details are unknown—residency in a participating community, required pain evidence, and specific dementia scale thresholds (BIMS/AD8/CDR with FAQ ≥9)—so no CORE anchors can be confirmed.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,C,"No hard exclusions apply. Disease matches, but key required inclusion elements (residency in participating community, evidence of pain, specified dementia scales/FAQ) are unknown, so no CORE anchors can be confirmed. Thus C is appropriate per rubric.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06147999,1.0,Dementia,Impact of a Biophoton Therapy on Patients With Brain Disorders,"Previous clinical studies revealed that the newly developed biophoton therapy has been safe and effective in treating patients with Alzheimer's disease, dementia, stroke, traumatic brain injury, or Parkinson's disease. The current study is to confirm the previous clinical observation by conducting as a randomized, triple-blinded, placebo-controlled prospective intervention clinical research. About 80 patients with brain disorder (Alzheimer's disease, dementia, stroke, traumatic brain injury, ...","{'id': 206418721, 'name': 'Biophotonizer - a Biophoton Generator', 'description': 'A biophotonizer is a device producing strong biophoton field. These biophotons help the human body to gain self-healing capacity to heal many disorders, including brain disorders.', 'other_names': [], 'intervention_type': 'DEVICE'}",NA,18 years,Alzheimer's Disease; Dementia; Parkinson's Disease; Traumatic Brain Injury,Age >= 18 years | Clinical diagnosis of a brain disorder | Women of childbearing potential: pregnancy test required,"Untreated mental illness that would affect participation | Dependent on a ventilator | Implanted electronic devices (e.g., deep brain stimulator, pacemaker, other implanted electronics) | Comorbid conditions that would interfere with study activities or response (e.g., severe chronic pulmonary disease, history of uncontrolled seizures, severe diabetes, kidney failure, end-of-life prognosis) | Active infectious disease | Currently participating in another investigational drug or device trial | Pregnant",(none),ALL,C,"Disease matches (dementia) and age/sex fit broad criteria, with no explicit exclusions noted. However, the trial does not specify stage/setting, line of therapy, biomarkers, or metastasis-related constraints, leaving core anchors unknown.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,C,"No hard exclusions. Disease matches (Dementia). Core anchors: stage/setting not specified (unknown), line/prior exposure not specified (unknown), no required biomarker, and metastasis not applicable. Zero anchors match and no soft conflicts → C per rubric. The grader’s reasoning aligns.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT06186401,1.0,Recurrent Glioblastoma,Phase 1 Study of Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells in Adult Participants With EGFRvIII+ Glioblastoma,"This phase I trial tests the safety, side effects, and best dose of E-SYNC chimeric antigen receptor (CAR) T cells after lymphodepleting chemotherapy in treating patients with EGFRvIII positive (+) glioblastoma. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so the CAR T cells will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor t...","{'id': 205979940, 'name': 'E-SYNC T Cells', 'description': 'Given IV', 'other_names': ['Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR T Cells', 'Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR T Cells', 'Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ra2 CAR T Cells'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205979941, 'name': 'Cyclophosphamide (non-investigational)', 'description': 'Given IV', 'other_names': ['Cytoxan', 'Cytoxan Lyophilized', 'Neosar'], 'intervention_type': 'DRUG'}; {'id': 205979942, 'name': 'Fludarabine (non-investigational)', 'description': 'Given IV', 'other_names': ['Fludara', 'Oforta'], 'intervention_type': 'DRUG'}; {'id': 205979943, 'name': 'Leukapheresis', 'description': 'Undergo leukapheresis', 'other_names': ['Therapeutic Leukopheresis'], 'intervention_type': 'PROCEDURE'}; {'id': 205979944, 'name': 'Surgical resection', 'description': 'Undergo surgical resection of tumor tissue', 'other_names': ['Resection'], 'intervention_type': 'PROCEDURE'}",PHASE1,18 years,Glioblastoma; Recurrent Glioblastoma,Age >= 18 years | Karnofsky performance status >=70% | Adequate organ function | Absolute neutrophil count >=1000/µL | Platelet count >=100000/µL (transfusion independent >=7 days) | Absolute lymphocyte count >=300/µL and/or CD3 count >=150/µL | Creatinine clearance >=50 mL/min | Total bilirubin <=1.5 x ULN (except Gilbert's syndrome) | AST <=3 x ULN | ALT <=3 x ULN | Left ventricular ejection fraction >=40% | Pulse oximetry >92% on room air | Pathology: EGFRvIII-positive glioblastoma confirmed by CLIA-certified testing (NGS) or central review | MGMT promoter unmethylated or methylation index <3 (for newly diagnosed cohort) | Completed standard external beam radiotherapy as initial therapy | Able to receive E-SYNC T cell infusion within 12 weeks after completion of EBRT (cohort 1) | Off systemic steroids for >=3 days prior to leukapheresis | For cohort 2 Step 1: EGFRvIII H-score >=250 by central review | For cohort 2 Step 2: Radiographic progression per RANO | For cohort 2 Step 2: Recurrence surgically amenable with expected resection >=500 mg tissue | Negative serum pregnancy test for females of childbearing potential prior to study interventions | Contraception agreement during study and for >=6 months after last study intervention,"Investigational agents or chemotherapy targeting GBM within 4 weeks (>=23 days from last temozolomide or radiotherapy; >=6 weeks from last nitrosourea) | Pregnant or lactating | Known addiction to alcohol or illicit drugs | Prior EGFR-targeting therapy | Leptomeningeal disease | Known immunodeficiency (e.g., HIV) or autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy | Active hepatitis B (HBsAg+) or hepatitis C (PCR positive) | Prior solid organ or bone marrow transplantation | Uncontrolled intercurrent illness (e.g., active infection, symptomatic CHF, unstable angina, significant arrhythmia, active second malignancy requiring treatment, or psychiatric/social conditions limiting compliance) | Unable to return for required follow-up | For cohort 2 Step 2: Uncontrolled tumor mass effect by imaging or clinical assessment | For cohort 2 Step 2: Coagulation abnormalities unless on therapeutic anticoagulation",Completed standard external beam radiotherapy as initial therapy; Washout: >=4 weeks since investigational agents or chemotherapy targeting GBM; Washout: >=23 days since last temozolomide; Washout: >=23 days since radiotherapy; Washout: >=6 weeks since last nitrosourea,ALL,C,"Disease and setting (recurrent GBM) and prior standard chemoradiation are compatible, but the trial requires EGFRvIII-positive tumor (and for the recurrent cohort, likely resectable recurrence), which are unknown for this patient. No explicit exclusion is identified.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),INCORRECT,B,"No hard exclusions. Disease matches. One clear CORE ANCHOR match: prior exposure/line compatibility (standard chemoradiation with appropriate washout). Stage/setting is recurrent but resectability requirement is unknown, not a soft mismatch. EGFRvIII biomarker is required but unknown (precludes A, does not trigger D/F). With exactly one confirmed anchor and no soft conflicts, rubric calls for B, not C.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06370572,1.0,Dementia,Pragmatic Use of PAIN-Advanced Dementia Scale in Emergency Departments,The purpose of this study is to learn if the Pain in Advanced Dementia (PAINAD) scale can improve emergency pain care in persons living with dementia (PLWD). It is hypothesized that a PAINAD electronic health record (EHR) prompt that appears to emergency department (ED) staff will enable them to accurately assess pain levels and lead to better pain treatment for PLWD.,"{'id': 206043422, 'name': 'PAINAD EHR Prompt', 'description': 'Implementation of PAINAD EHR prompt in the ED workflow for PLWD presenting to the ED with hip pain', 'other_names': [], 'intervention_type': 'OTHER'}",NA,65 years,Dementia,Age >= 65 years | ED arrival complaint of hip pain | History of dementia in medical record or problem list,,(none),ALL,C,"Disease and age/sex match, but the trial requires an ED presentation with hip pain, which is not provided, and other core anchors (stage/setting specifics, prior therapy) are unspecified. Without confirmation of the ED hip pain criterion, fit is uncertain.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,C,"No hard exclusions: disease, age, and sex match; no explicit exclusions. Stage/setting (ED arrival with hip pain) is unknown from patient data, not a soft mismatch. Other anchors (line/prior, biomarkers) are not specified/relevant. With 0 anchors matched and no soft conflicts, C is appropriate and the grader’s reasoning aligns with the rubric.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06511752,1.0,Dementia,Educational Support Group Program for Carepartners of Bilingual and Spanish-speaking Persons With Progressive Forms of Aphasia and for Persons With Progressive Forms of Aphasia,"The current study aims to examine the benefits of an education/support group program for individuals with progressive aphasia (caused by various etiologies, diagnoses) and their carepartners. The current study utilizes pre-, post-treatment, and follow-up assessments to measure effects of a psychoeducational support group and an implementation/communication skills training phase on measures of psychosocial function, communicative effectiveness and speech/language function. Analysis of study-sp...","{'id': 205974891, 'name': 'Psychosocial educational, support group and implementation of strategies', 'description': 'Psychosocial educational, support group and implementation of strategies', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}",EARLY_PHASE1,18 years,Primary Progressive Aphasia; Alzheimer Disease; Dementia,"Diagnosis of progressive aphasia or language-led dementia with aphasia as a primary cause of difficulty with activities of daily living. | Awareness of language difficulties and willingness to discuss them. | Able to actively engage in group discussion and complete activities with minimal support. | Some ability to communicate and understand communication to participate in training sessions. | Functionally able to engage in training sessions (maintain some attention, minimal challenging behavior). | Care partner is a caregiver of an individual with progressive aphasia or language-led dementia.",,(none),ALL,C,"Disease and age/sex match, but the trial specifically requires progressive aphasia/language-led dementia and the ability to participate in group sessions, which are not documented for this patient. With these key subtype/functional requirements unknown, core anchors cannot be confirmed.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,C,"No hard exclusions: disease matches (dementia), age/sex allowed, no explicit exclusions. Required subtype (progressive aphasia/language-led dementia) and functional abilities are unknown, not definitively absent, so not F. Core anchors: stage/setting and line/prior not applicable/unknown; required subtype unknown; no mets pattern. With 0 confirmed anchors and no soft mismatch, grade C is appropriate. The grader’s reasoning aligns with the rubric.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06651281,0.6691051721572876,Fistulizing Crohn's Disease,A Phase 3 Extension Study to Evaluate the Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis,"Researchers want to learn more about tulisokibart (also known as MK-7240) in an extension study. Tulisokibart is a medicine designed to treat active, moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). An extension study is a type of study where people who received tulisokibart in certain other studies for CD or UC (called a parent study) may be able to join this study. The goals of this study are to learn about the safety of tulisokibart over time in people with CD or UC, an...","{'id': 205890482, 'name': 'Tulisokibart', 'description': 'Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously', 'other_names': ['MK-7240'], 'intervention_type': 'DRUG'}; {'id': 205890483, 'name': 'Placebo to tulisokibart', 'description': 'Placebo matching SC tulisokibart', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,Not specified,Crohn Disease; Ulcerative Colitis,Investigator determines the participant derives clinical benefit from continued tulisokibart | Not breastfeeding during the study intervention period and for at least 14 weeks after the last dose | Not pregnant with a negative highly sensitive pregnancy test within 24 hours (urine) or 72 hours (serum) before first dose | Participant of childbearing potential uses acceptable contraception or long-term abstinence,"Prematurely discontinued study intervention in the parent study | Received protocol-specified prohibited medications during the parent study | Known allergy, hypersensitivity, or intolerance to tulisokibart or its excipients",Participation in a qualifying Phase 2 or Phase 3 tulisokibart parent study for Crohn Disease or Ulcerative Colitis,ALL,C,"Disease (Crohn’s) matches and there are no explicit conflicts with age or sex. However, this is a long-term extension requiring prior participation in and ongoing clinical benefit from a tulisokibart parent study—details not provided—so key line/prior-exposure and setting anchors are unknown.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,C,"No hard exclusions. Disease (Crohn’s) matches. Extension study requires prior tulisokibart parent study participation and ongoing benefit—unknown for this patient—so stage/setting and line/prior-exposure anchors are unknown rather than mismatches. With 0 clear anchor matches and no soft conflicts, C is appropriate.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT06839456,0.5412098169326782,Ornithine Transcarbamylase Deficiency,Phase 1/2 Study: CD45RA Depleted Peripheral Stem Cell Addback to Prevent Viral and Fungal Infections Following Alternative Donor TCRab/CD19 Depleted Hematopoietic Stem Cell Transplant,"The major morbidities of allogeneic hematopoietic stem cell transplant (HSCT) using donors that are not human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life- threatening infections. T cell receptor alpha beta (TCRαβ) T lymphocyte depletion and CD19+ B lymphocyte depletion of alternative donor hematopoietic stem cell (HSC) grafts is effective in preventing GVHD, but immune reconstitution may be delayed, increasing the risk of infections. The central hypothes...","{'id': 205966256, 'name': 'Phase 1 Dose Level 1', 'description': 'Patients in the first dose level for the CD45RA depleted addback will receive 1 X 10\\^6 CD45RO+ T cells/kg. Once all patients in this dose group have been evaluated for acute GVHD at day 100, then we will advance to the next dose level if indicated by safety analysis.', 'other_names': [], 'intervention_type': 'DEVICE'}; {'id': 205966257, 'name': 'Phase 1 Dose Level 2', 'description': 'Patients in the second dose level for the CD45RA depleted addback will receive 2 X 10\\^6 CD45RO+ T cells/kg. Once all patients in this dose group have been evaluated for acute GVHD at day 100, then we will advance to the next dose level if indicated by safety analysis.', 'other_names': [], 'intervention_type': 'DEVICE'}; {'id': 205966258, 'name': 'Phase 1 Dose Level 3', 'description': 'Patients in the third and final dose level for the CD45RA depleted addback will receive 5 X 10\\^6 CD45RO+ T cells/kg. All patients in this dose group will be evaluated for acute GVHD at day 100. Based on these findings, the maximum tolerated dose (MTD) will be determined.\n\nOnce MTD for the addback cell dose has been determined in Phase 1, subjects with mismatched related donors will then enroll in Phase 2.', 'other_names': [], 'intervention_type': 'DEVICE'}; {'id': 205966259, 'name': 'Phase 2 Maximum Tolerated Dose determined in Phase 1', 'description': 'Patients with mismatched related donors will receive the CD45RA depleted addback at the maximum tolerated dose determined in the Phase 1 portion of the study.', 'other_names': [], 'intervention_type': 'DEVICE'}; {'id': 205966260, 'name': 'Phase 2 Established Dose from prior study, NCT03810196', 'description': 'Patients with unrelated donors will receive the CD45RA depleted addback at the dose 5 X 10\\^6 CD45RO+ T cells.', 'other_names': [], 'intervention_type': 'DEVICE'}",PHASE1/PHASE2,1 months to 25 years,Acquired Aplastic Anemia; Bone Marrow Failure; Hemophagocytic Lymphohistiocytosis; Hemoglobinopathy; High Risk Acute Lymphoblastic Leukemia; High Risk Acute Myeloid Leukemia; Immunodeficiency; Inborn Error of Metabolism; Inherited Bone Marrow Failure Syndrome; Myelodysplastic Syndrome; Primary Immune Regulatory Disorder; Relapsed Non-Hodgkin Lymphoma,Disease for which allogeneic hematopoietic stem cell transplant may be curative. | Age <= 25 years. | Remission status of hematologic malignancies per institutional standards. | Negative pregnancy test for participants of childbearing potential.,"Performance score less than 60. | No suitable donor available for mobilized peripheral stem cells. | Hodgkin lymphoma or non-Burkitt, non-lymphoblastic lymphoma. | Planned receipt of alemtuzumab during conditioning. | Available 10/10 HLA matched sibling donor. | Do not meet institutional disease, organ, or infectious criteria.",(none),ALL,C,"Disease category matches (OTC is an inborn error of metabolism) and age/sex fit the trial. However, the trial targets patients undergoing alternative donor allogeneic HSCT with specific graft manipulation, and the patient’s transplant setting/candidacy and related prior exposure are unknown, so core eligibility anchors cannot be confirmed.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,C,"No hard exclusions. Disease matches via inborn error of metabolism; age/sex fit. Core anchors: HSCT stage/setting is unknown for the patient, line/prior exposure unknown, no required biomarker or mets pattern specified. With 0 anchors confirmed and no soft mismatch identified, C is appropriate per rubric.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT01793519,1.0,Rheumatoid Arthritis,Stopping Tumor Necrosis Factor-Alpha Inhibitors in Rheumatoid Arthritis (STARA) Clinical Trial,"Background: * Rheumatoid arthritis (RA) is often treated with drugs known as tumor necrosis factor (TNF) inhibitors, that can help decrease joint pain and swelling and can even result in RA remission. However, TNF inhibitors may increase risk of serious infections or some types of cancer. * It is not clear if people whose RA has been in remission for a long time need to stay on the TNF inhibitor to remain in remission. If they can stop taking the TNF inhibitor without having their symptoms co...","{'id': 205272928, 'name': 'Etanercept', 'description': 'Subcutaneous', 'other_names': ['Enbrel'], 'intervention_type': 'DRUG'}; {'id': 205272929, 'name': 'Infliximab', 'description': 'Infusion', 'other_names': ['Remicade'], 'intervention_type': 'DRUG'}; {'id': 205272930, 'name': 'Adalimumab', 'description': 'Subcutaneous', 'other_names': ['Humira'], 'intervention_type': 'DRUG'}; {'id': 205272931, 'name': 'Placebo', 'description': 'Matching Placebo', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE4,18 years,Rheumatoid Arthritis,"Age >= 18 years | Rheumatoid arthritis per 1987 revised American College of Rheumatology criteria | Sustained clinical remission for the last 6 months while receiving etanercept, infliximab, or adalimumab plus >= 1 DMARD | DAS28 < 2.6 at each visit over the preceding 6 months, with at least one visit 2-4 months before enrollment; if no 6-month visit, the nearest visit in the 6-12 month period must have DAS28 < 2.6","Dose increase of anti-TNF agent or DMARD in the last 6 months | Change of anti-TNF agent or DMARD in the last 6 months | Current treatment with golimumab or certolizumab | Prednisone > 10 mg/day in the last 6 months | Prednisone > 5 mg/day in the last 3 months | Intramuscular or intravenous corticosteroids in the last 6 months for RA activity | Treatment with anakinra, abatacept, or tocilizumab in the last 6 months | Treatment with rituximab in the last 12 months | Treatment with an investigational RA drug in the last 6 months | Pregnant or lactating | No documentation of clinical remission for the last 6 months | Unwilling to discontinue anti-TNF agent | No documentation of negative tuberculin skin test, negative QuantiFERON-TB Gold test, or treatment for latent tuberculosis prior to starting anti-TNF therapy | Treatment of solid malignancy or non-melanoma skin cancer within the past 5 years, or any history of melanoma or hematologic or lymphoproliferative malignancy | No documentation of age-appropriate cancer screening at randomization | No documentation of negative hepatitis B serologies, completion of treatment for chronic hepatitis B, or suppressive antiviral treatment","On etanercept, infliximab, or adalimumab plus >= 1 DMARD for >= 6 months with sustained clinical remission; No dose increase of anti-TNF agent or DMARD within 6 months prior to screening; No change of anti-TNF agent or DMARD within 6 months prior to screening; No prednisone > 10 mg/day within 6 months prior to screening; No prednisone > 5 mg/day within 3 months prior to screening; No intramuscular or intravenous corticosteroids within 6 months for RA activity; No anakinra, abatacept, or tocilizumab within 6 months prior to screening; No rituximab within 12 months prior to screening; No investigational RA drug within 6 months prior to screening",ALL,D,"Disease matches, but the trial requires sustained clinical remission on a TNF inhibitor plus a DMARD (DAS28 < 2.6 for 6 months) to stop therapy, whereas the patient has active, refractory RA (DAS28 5.5) after methotrexate and prior biologics, conflicting with the setting/line requirements. Timing of tocilizumab exposure is unknown but could also be problematic per exclusions.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),INCORRECT,F,"Patient has active RA (DAS28 5.5) while the trial requires sustained clinical remission (DAS28 <2.6 for 6 months) on specific anti-TNF + DMARD. This is a required stage/setting the patient definitively lacks, which per rubric is a HARD EXCLUSION → F. The grader treated it as a soft mismatch (D). Other factors (e.g., tocilizumab timing) are unknown and do not change the hard exclusion.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT02642042,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies,"This phase II trial studies how well trametinib and docetaxel work in treating patients with stage IV KRAS mutation positive non-small cell lung cancer or cancer that has come back. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving tram...","{'id': 206081449, 'name': 'Docetaxel', 'description': 'Given IV', 'other_names': ['Docecad', 'RP 56976', 'RP-56976', 'RP56976', 'Taxotere', 'Taxotere Injection Concentrate'], 'intervention_type': 'DRUG'}; {'id': 206081450, 'name': 'Laboratory Biomarker Analysis', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206081451, 'name': 'Trametinib', 'description': 'Given PO', 'other_names': ['GSK 1120212', 'GSK 212', 'GSK-1120212', 'GSK-212', 'GSK1120212', 'GSK212', 'JTP 74057', 'JTP-74057', 'JTP74057', 'MEK Inhibitor GSK1120212'], 'intervention_type': 'DRUG'}",PHASE2,Not specified,Non-Small Cell Lung Cancer (metastatic),"KRAS mutation–positive non-small cell lung cancer that is stage IV or recurrent; KRAS subtype known; testing performed in a CLIA-certified laboratory | Measurable disease by RECIST 1.1 within 28 days (diagnostic-quality CT or MRI); non-measurable disease assessed within 42 days | Previously treated with 1–2 prior systemic regimens for advanced disease with documented progression; at least one prior platinum-based combination regimen | Zubrod performance status 0–2 | Absolute neutrophil count >= 1500/µL within 28 days | Platelet count >= 100,000/µL within 28 days | Hemoglobin >= 9 g/dL within 28 days | Total bilirubin <= 1.5 x ULN within 28 days | AST and ALT <= 2.5 x ULN (<= 5 x ULN if liver metastases) within 28 days | Serum creatinine <= 1.5 x ULN or creatinine clearance >= 40 mL/min within 28 days | Able to swallow oral medications; no condition expected to significantly alter absorption | Controlled brain metastases allowed if locally treated, asymptomatic >= 14 days, no residual neurological dysfunction, and off corticosteroids >= 2 days prior to registration | QTc <= 480 msec on ECG within 42 days; controlled atrial fibrillation allowed if stable > 30 days with repeat ECG showing stability | Left ventricular ejection fraction >= institutional lower limit of normal by ECHO or MUGA within 42 days","Active or uncontrolled brain metastases, leptomeningeal carcinomatosis, or spinal cord compression; residual neurological dysfunction; corticosteroid use within 2 days prior to registration | Receipt of chemotherapy, biologic therapy, or any investigational agent within 14 days prior to registration | Prior docetaxel therapy | Prior therapy with a MEK inhibitor or PI3K/AKT/mTOR pathway inhibitor | Gastrointestinal disorder with diarrhea as a major symptom or malabsorption/gastric resection that may alter drug absorption | History of interstitial lung disease or pneumonitis | Significant comorbid illness including NYHA class II congestive heart failure, uncontrolled hypertension, myocardial infarction, unstable angina, coronary angioplasty, stenting, or cerebrovascular accident within 6 months | QTc > 480 msec, clinically significant uncontrolled arrhythmias, or atrial fibrillation > grade 2 on screening ECG | Untreated or unresolved retinopathy or history/evidence of retinal vein occlusion | Immediate or delayed hypersensitivity to trametinib-related compounds, excipients, or DMSO | Known active hepatitis B or C infection or known HIV seropositivity | Another malignancy within 3 years except adequately treated basal/squamous cell skin cancer, in situ cervical cancer, adequately treated stage I–II cancer in complete remission, or localized prostate cancer on active surveillance | Pregnant or nursing | Major surgery within 28 days prior to registration","Progression after 1–2 prior systemic regimens for advanced NSCLC, including at least one platinum-based combination regimen; Prior immunotherapy or targeted therapy allowed and counts as a prior regimen; Maintenance therapy does not count as a separate regimen; Adjuvant or concurrent chemoradiation does not count as a prior regimen if recurrence occurred > 12 months after last chemotherapy dose; No chemotherapy, biologic therapy, or investigational agent within 14 days prior to registration (washout required); Prior radiation allowed if <= 25% bone marrow affected; >= 7 days since last radiation; at least one measurable lesion outside prior radiation field; Recovered from adverse effects of prior therapy to CTCAE grade <= 1 (except alopecia) before registration",ALL,D,"Stage/setting matches metastatic NSCLC, but the trial requires prior platinum-based chemotherapy (not received) and KRAS mutation positivity (status not provided), making the patient likely ineligible.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,D,"No hard exclusions apply. Disease and metastatic stage match, but there is a clear soft mismatch on line/prior exposure because the trial requires at least one prior platinum-based regimen, which the patient lacks. KRAS requirement is unknown (not a hard exclusion). Therefore D is appropriate and the grader’s reasoning aligns with the rubric.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT02812667,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,A Phase I Study of Nivolumab in Combination With Escalating Doses of Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC),"The purpose of the study is to determine whether plinabulin (also known as BPI-2358) has an effect on cancer and body in combination with nivolumab, a standard treatment for metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy. Plinabulin inhibits tumor growth by targeting both new and existing blood vessels going to the tumor as well as killing tumor cells. Plinabulin is an investigational drug, a drug that is not approved for use outside of...","{'id': 205852333, 'name': 'Nivolumab + Plinabulin', 'description': None, 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,18 years,Non-Small Cell Lung Cancer (metastatic),"Histologically or cytologically confirmed metastatic non-small cell lung cancer | Disease progressed during/after at least one platinum-containing chemotherapy regimen | At least 1 prior systemic therapy for metastatic disease | ECOG performance status <=1 | Life expectancy >=12 weeks | At least 1 measurable lesion per RECIST | Adequate hematopoietic, electrolyte, hepatic, and renal function | Prior chemotherapy completed >=4 weeks or >=5 half-lives before study drug, with AEs resolved to baseline or stabilized | Prior treated brain metastases allowed if no MRI progression for >=4 weeks and off systemic steroids for >=2 weeks before study drug | Prior definitive radiation completed >=4 weeks before study drug | Prior palliative radiotherapy completed >=2 weeks before study drug | No radiopharmaceuticals within 8 weeks before study drug | Prior major surgery completed >=4 weeks before study drug | Prior minor surgery completed >=1 week before study drug and recovered | Percutaneous biopsy completed >=10 days prior to study drug | Negative serum pregnancy test for women of childbearing potential","History of grade >=3 hypersensitivity reactions to monoclonal antibodies | History of cardiovascular illness | Uncontrolled hypertension: SBP >160 mmHg or DBP >100 mmHg | Symptomatic or untreated brain metastases | Leptomeningeal disease | Pulmonary conditions increasing risk of immunotherapy-related pulmonary toxicity | Active, non-infectious pneumonitis | Second malignancy (excluding non-melanoma skin cancer) unless in remission for 3 years | Active, known, or suspected autoimmune disease | History of ileus or significant gastrointestinal disorder predisposing to ileus or chronic bowel hypomotility | Prior microtubule destabilizing agents for NSCLC (e.g., vinorelbine) | Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibodies (or other T-cell co-stimulation pathway antibodies) | Known HIV infection | Active infection requiring therapy | Positive hepatitis B surface antigen | Positive hepatitis C RNA | Concurrent medical conditions that would make study drug hazardous or confound toxicity assessment | Concurrent medical condition requiring immunosuppressive medications or systemic steroids | Use of other investigational drugs within 28 days or >=5 half-lives before study drug | Pregnant or nursing",At least one prior systemic therapy for metastatic NSCLC; Prior platinum-containing chemotherapy required; Prior chemotherapy washout >=4 weeks or >=5 half-lives; Prior treated brain metastases allowed if stable and off steroids; Prior definitive radiation therapy washout >=4 weeks; Prior palliative radiotherapy washout >=2 weeks; No radiopharmaceuticals within 8 weeks; Prior major surgery washout >=4 weeks; minor surgery >=1 week; percutaneous biopsy >=10 days,ALL,D,"Stage/setting matches (metastatic NSCLC, ECOG 0), but the trial requires progression after prior platinum-containing chemotherapy, which the patient has not received (only osimertinib). Other criteria appear acceptable but do not overcome this specific line-of-therapy mismatch.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,D,"No hard exclusions apply. Disease and metastatic setting match, but the trial requires prior platinum-containing chemotherapy with progression, which the patient lacks (only osimertinib). This is a clear line-of-therapy/prior-exposure mismatch on a core anchor → D. The grader’s reasoning aligns with the rubric.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03176173,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL),This phase II trial studies how well radical-dose image guided radiation therapy works in treating patients with non-small cell lung cancer that has spread to other places in the body who are undergoing immunotherapy. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radical-dose image guided radiation therapy to patients with non-small cell lung cancer may help to improve response to immunotherapy anti-cancer treatment.,"{'id': 205284070, 'name': 'Image-guided Radiation Therapy', 'description': 'Ablative treatment as 50 Gy in 5 or 10 fractions.\n\nNon-ablative treatment as 27 Gy in 3 fractions, or 40 Gy in 10 fractions.', 'other_names': ['IGRT'], 'intervention_type': 'RADIATION'}; {'id': 205284071, 'name': ""Immunotherapy (physician's choice for standard of care immunotherapy)"", 'description': 'Continue regular medical care immunotherapy. Other than being an anti-PD-1 or anti-PD-L1 immunotherapy, the agent, dose, and schedule is not specified by protocol.', 'other_names': ['biologic therapy'], 'intervention_type': 'DRUG'}",NA,18 years,Non-Small Cell Lung Cancer (metastatic),"Stage IV non-small cell lung cancer, or initially stage I–III with distant metastatic recurrence | Age >= 18 | Receiving anti-PD-1 or anti-PD-L1 immunotherapy for >= 4 weeks | Restaging imaging after initiation of immunotherapy; CT or PET/CT of chest/upper abdomen within 4 weeks prior to registration | For patients with history of brain metastases, brain MRI or CT within 4 weeks of registration; otherwise brain MRI or CT within 12 weeks | Measurable disease per RECIST 1.1 | Expected to continue immunotherapy for at least 3 more months | Imaging shows response, stable disease, or modest progression | If modest progression, clinically stable in performance status and overall disease-related symptoms | At least one extracranial tumor safely treatable with radical-dose radiation therapy and not previously treated with radiation | ECOG performance status 0-2","Untreated brain metastases, if not planned to be treated in this course of radiation therapy | Pregnancy | Women of childbearing potential unwilling or unable to use contraception during protocol treatment",On anti-PD-1 or anti-PD-L1 immunotherapy for >= 4 weeks prior to enrollment,ALL,D,"Stage IV NSCLC matches, but the trial requires patients to be currently receiving anti–PD-1/PD-L1 immunotherapy for ≥4 weeks with plans to continue, whereas the patient is on osimertinib only. This line/prior-exposure mismatch makes the patient likely ineligible.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),INCORRECT,F,"The trial requires patients to be currently receiving anti–PD-1/PD-L1 therapy ≥4 weeks, which the patient definitively lacks (on osimertinib only). Per HARD EXCLUSIONS, a required setting the patient lacks → F. The grader treated this as a soft mismatch (D), but it should be a hard exclusion.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03274479,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,Phase I Trial of PBF-1129 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC),"Phase I clinical trial in Eastern Cooperative Oncology Group (ECOG) 0-1 patients with locally advanced or metastatic NSCLC to evaluate safety and tolerability of the compound PBF-1129, an Adenosine A2b receptor antagonist. The phase I dose escalation will be conducted 3+3 method. Pharmacokinetic (PK) data will be also obtained.","{'id': 205839293, 'name': 'PBF-1129', 'description': 'PBF-1129 once a day by oral administration', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,18 years,Non-Small Cell Lung Cancer (metastatic),"Histological or cytological diagnosis of metastatic non-small cell lung cancer (squamous or non-squamous). | Life expectancy >= 3 months. | Progressed on standard therapy, including platinum-based chemotherapy. | For tumors with EGFR, ALK, or ROS1 alterations: progressed on respective targeted therapy. | No limit to prior lines of systemic therapy. | ECOG performance status 0–1. | Measurable disease per RECIST v1.1. | Age > 18 years. | Adequate bone marrow, renal, and hepatic function.","Participation in another clinical study with an investigational product within 4 weeks or 5 half-lives before starting treatment. | Symptomatic and/or untreated or actively progressing CNS metastases or leptomeningeal disease (treated/stable CNS disease allowed per criteria). | Serious uncontrolled medical disorder or active infection that would impair ability to receive study treatment. | Concurrent use of other anticancer approved or investigational agents. | Active or prior autoimmune disease within the past 2 years (exceptions: vitiligo, Grave's disease, psoriasis not requiring systemic treatment). | Systemic corticosteroids >= 10 mg/day prednisone equivalent. | Current smoking not discontinued at least 7 days prior to study drug initiation. | Pregnancy or breastfeeding. | Prior malignancy within the past 2 years (with protocol-specified exceptions).",Progression after standard therapy including platinum-based chemotherapy required.; If EGFR/ALK/ROS1 positive: prior progression on corresponding targeted therapy required.; No limit to number of prior systemic therapy lines.,ALL,D,"Stage and ECOG match, and EGFR-targeted therapy progression is likely, but the trial requires progression after standard therapy including platinum-based chemotherapy, which the patient has not received.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,D,"No hard exclusions. Disease and stage match, but there is a clear soft mismatch on line/prior exposure: the trial requires progression after platinum-based chemotherapy and (for EGFR+) progression on EGFR therapy, which the patient has not had. This triggers a D per the rubric.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03319628,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,"A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b","First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks. Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) were enrolled in the expansion segment of this study. Patients with platinum-resistant, high-grade serous ovarian cancer were enrolled ...","{'id': 205231881, 'name': 'upifitamab rilsodotin', 'description': 'XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.\n\nFor sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536', 'other_names': ['XMT-1536', 'UpRi'], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic); Ovarian Cancer (platinum-resistant),"ECOG performance status 0–1 | Measurable disease per RECIST v1.1 | Resolution of acute toxic effects of prior therapy or surgery to <= Grade 1 (with specified exceptions) | Left ventricular ejection fraction >= 50% or >= lower limit of normal by Echo or MUGA | Adequate organ function per protocol laboratory criteria | AST and ALT <= 1.5 x ULN | Albumin >= 3.0 g/dL | Ovarian cancer (UPLIFT): High-grade serous ovarian, fallopian tube, or primary peritoneal cancer that is metastatic or recurrent | Ovarian cancer (UPLIFT): Platinum-resistant disease per protocol definition | Ovarian cancer (UPLIFT): One to 4 prior lines of systemic therapy for ovarian cancer | Ovarian cancer (UPLIFT): Prior bevacizumab required if 1–2 prior lines | Ovarian cancer (UPLIFT): Willing to provide archival tumor tissue or undergo new tumor biopsy","Major surgery within 28 days before starting study treatment | Systemic anticancer therapy within the lesser of 28 days or 5 half-lives before starting study treatment | Recent radiation therapy with unresolved toxicity or within a time window of potential toxicity | Untreated CNS metastases, history of leptomeningeal metastasis, or carcinomatous meningitis | Active infection with HIV, hepatitis B virus, or hepatitis C virus | Prior liver disease such as cirrhosis or hepatic fibrosis | Severe uncontrolled systemic disease or intercurrent illness that could interfere with study evaluations | Current use of supplemental oxygen therapy | History of suspected pneumonitis or interstitial lung disease | Pregnant or nursing women | History of other malignancy within 2 years except allowed in situ or skin cancers or malignancies with expected curative outcome | Active corneal disease or history of corneal disease within 12 months | Use of strong CYP3A inhibitors or inducers that cannot be discontinued while on treatment | Oxygen saturation on room air <93% | Ovarian cancer (UPLIFT): Low-grade, clear cell, endometrioid, mucinous, carcinosarcoma, germ-cell, mixed histology, or stromal tumors | Ovarian cancer (UPLIFT): Prior treatment with mirvetuximab soravtansine or another ADC containing an antitubulin payload | Ovarian cancer (UPLIFT): Primary platinum-resistant disease (no response or progression within 3 months after frontline platinum) | Ovarian cancer (UPLIFT): Participation in DES or EXP segments of this study | QTc sub-study: Use of strong CYP3A inducers | QTc sub-study: Uncontrolled cardiac arrhythmias (e.g., atrial fibrillation with ventricular rate >100 bpm at rest) or left bundle branch block | QTc sub-study: Cardiac valve abnormality greater than moderate severity | QTc sub-study: Not in sinus rhythm at screening with heart rate >45–<100 | QTc sub-study: Any ECG abnormality that can interfere with QT interval measurement",Ovarian cancer: One to 4 prior lines of systemic therapy required; Ovarian cancer: Prior platinum-based therapy with response then progression within <=6 months (platinum-resistant); Ovarian cancer: Prior bevacizumab required if 1–2 prior lines; No systemic anticancer therapy within 28 days or 5 half-lives before starting treatment,ALL,D,"Disease and performance status match (metastatic NSCLC, ECOG 0), but the trial excludes systemic anticancer therapy within 28 days/5 half-lives and the patient is currently on osimertinib. Measurable disease and other required labs are not provided.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),INCORRECT,B,"No hard exclusion applies. The trial allows metastatic NSCLC; stage/setting matches. Being currently on osimertinib is a washout/timing issue, not a core anchor mismatch or explicit exclusion per the rubric. Other anchors (line/prior requirements, biomarker, mets pattern constraints) are not specified or unknown. With exactly one core anchor match and no soft conflicts, the correct grade is B, not D.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT03389230,0.9556124806404114,Recurrent Glioblastoma,"Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a HER2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma",This phase I trial studies the side effects and best dose of memory-enriched T cells in treating patients with grade II-IV glioma that has come back (recurrent) or does not respond to treatment (refractory). Memory enriched T cells such as HER2(EQ)BBζ/CD19t+ T cells may enter and express its genes in immune cells. Immune cells can be engineered to kill glioma cells in the laboratory by inserting a piece of deoxyribonucleic acid (DNA) into the immune cells that allows them to recognize glioma ...,"{'id': 205789883, 'name': 'HER2(EQ)BBζ/CD19t+ T cells', 'description': 'Given via catheter', 'other_names': [], 'intervention_type': 'BIOLOGICAL'}; {'id': 205789884, 'name': 'Laboratory Biomarker Analysis', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 205789885, 'name': 'Leukapheresis', 'description': 'Undergo leukapheresis', 'other_names': ['Leukocytopheresis', 'Therapeutic Leukopheresis'], 'intervention_type': 'PROCEDURE'}",PHASE1,18 years to 75 years,Glioblastoma; Malignant Glioma; Recurrent Glioma; Refractory Glioma; WHO Grade III Glioma,"Histologically confirmed grade III or IV glioma, or prior grade II glioma with radiographic progression consistent with grade III or IV malignant glioma | Karnofsky performance status >= 60% | Life expectancy > 4 weeks | HER2 positive tumor by immunohistochemistry (>= 20%, 1+) confirmed by City of Hope Clinical Pathology | Appropriate venous access | Dexamethasone <= 2 mg TID on the day of PBMC collection | At least 2 weeks since last targeted agent, chemotherapy, or radiation before PBMC collection (PI discretion for locally delivered CSF investigational agents) | Creatinine < 1.6 mg/dL | White blood cell count > 2,000/µL or absolute neutrophil count > 1,000/µL | Platelets >= 100,000/µL | INR < 1.3 | Total bilirubin < 1.5 mg/dL | ALT and AST <= 2 x ULN | Released cryopreserved CAR T cell product available | No supplemental oxygen required to keep saturation > 95% and no progressive chest X-ray abnormalities | No history of CHF NYHA class III–IV, cardiomyopathy, myocarditis, or MI within 6 months; if risk factors present, EKG and echocardiogram within 42 days prior to registration | If new cardiac symptoms or cardiotoxic exposures: cardiac consultation, CPK, and troponin deem fit for study | Afebrile (<= 38.5 C), negative blood cultures within 48 hours prior to infusion, and no signs of meningitis | Serum creatinine < 1.8 mg/dL at infusion eligibility | Serum total bilirubin and transaminases <= 2 x ULN at infusion eligibility | Platelets > 100,000/µL (if 75,000–99,999/µL, may proceed after transfusion with post-transfusion >= 100,000/µL) | Dexamethasone <= 2 mg TID during CAR T cell therapy | Washouts before CAR T infusion: >= 6 weeks since nitrosourea; >= 23 days since temozolomide; >= 4 weeks since other non-nitrosourea cytotoxic chemotherapy; >= 2 weeks since last targeted agent (>= 4 weeks for bevacizumab)","Requires supplemental oxygen to maintain saturation > 95% and not expected to resolve within 2 weeks | History of CHF NYHA class III–IV within 6 months, cardiomyopathy, myocarditis, or MI; or significant cardiotoxic exposures without appropriate cardiac evaluation | Requires dialysis | Uncontrolled seizure activity and/or clinically evident progressive encephalopathy | Other active malignancies | Severe infection under treatment or recovering from major surgery until recovery is complete | Uncontrolled illness including ongoing or active infection | Known active hepatitis B or hepatitis C infection | Confirmed HIV positivity within 4 weeks of enrollment | Inability to understand the study or its risks/benefits (unless a legal guardian consents)","At least 2 weeks since last targeted therapy, chemotherapy, or radiation before PBMC collection; At least 6 weeks since nitrosourea chemotherapy before CAR T infusion; At least 23 days since temozolomide before CAR T infusion; At least 4 weeks since other non-nitrosourea cytotoxic chemotherapy before CAR T infusion; At least 2 weeks since last targeted agent before CAR T infusion (at least 4 weeks for bevacizumab)",ALL,D,"The disease and recurrent setting fit and prior therapy appears compatible, but the trial requires HER2-positive tumor by IHC (site-confirmed), which is not documented for this patient. KPS is also unspecified (only ECOG given), adding uncertainty.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),INCORRECT,A,"No hard exclusions. Disease and recurrent setting match; prior therapies compatible (washout likely satisfied). HER2 status is unknown (not a soft mismatch per rubric) and KPS vs ECOG is outside core anchors. With ≥2 core anchors matching (stage/setting and line/prior) and no soft conflicts, the correct grade is A, not D.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT03423628,0.8363864421844482,Recurrent Glioblastoma,"A Phase I, Multicentre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors.","This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of ascending doses of AZD1390 in combination with distinct regimens of radiation therapy","{'id': 205775756, 'name': 'Radiation Therapy', 'description': 'Arm A: 35 Gy of Intensity-modulated radiation therapy (IMRT) administered at daily fractions of 3.5 Gy over 10 fractions (2 weeks) Arm B: 30 Gy of whole brain radiation therapy (WBRT) or partial brain radiation therapy (PBRT) administered at daily fractions of 3 Gy over 10 fractions (2 weeks).\n\n\\*\\*Arm B has now closed to recruitment\\*\\* Arm C: 60 Gy of intensity-modulated radiation therapy (IMRT) administered at daily fractions of 2 Gy over 30 fractions (6 weeks)', 'other_names': ['Radiotherapy', 'Radiation treatment', 'RT'], 'intervention_type': 'RADIATION'}; {'id': 205775757, 'name': 'AZD1390', 'description': 'AZD1390 Administered in 3 Cycles depending on arm:\n\nCycle 0 (arms A and C): 1 dose prior to Radiation Therapy. For optional food effect assessment in Arm A, 2 doses prior to RT under both fed and fasted conditions. \\*Note: the optional food effect assessment is currently not open to recruitment\\*.\n\nCycle 1 (all arms): Intermittent or continuous dosing during Radiation Therapy (except for first 2 cohorts of Arm A).\n\nCycle 2 (arms A and C): 2 weeks adjuvant treatment after Radiation Therapy.', 'other_names': ['ATM inhibitor'], 'intervention_type': 'DRUG'}",PHASE1,18 years to 130 years,Glioblastoma (primary); Glioblastoma (recurrent); Brain Metastases; Leptomeningeal Disease,Provision of formalin-fixed paraffin embedded tumor tissue | Karnofsky Performance Status >= 60% | GBM histologically confirmed (Arm A/Japan) | Recurrent/relapsed or progressive disease by RANO (Arm A/Japan) | Completion of first-line radiation >= 6 months before Cycle 1 Day 1 (Arm A/Japan) | Tumor-induced seizures controlled on stable antiepileptic therapy (Arm A/Japan) | Willing to receive antiepileptic prophylaxis during study drug administration (Arms A/C) | Histologically confirmed solid tumor with MR-documented brain lesions (Arm B) | Not eligible for stereotactic radiosurgery for brain tumor (Arm B) | No prior brain radiation to the area to be irradiated; prior PBRT allowed if no significant field overlap (Arm B) | Non-CNS malignancy sufficiently controlled to allow required washout before therapy until 5 days after end of RT (Arm B) | Washout before first AZD1390 dose: 28 days for immune checkpoint inhibitors; 7 days for other agents (Arm B) | No radiation to lung fields within past 8 weeks (Arm B) | No history of seizures related to brain metastases or leptomeningeal disease (Arm B) | Receiving PBRT during Cycle 1 as standard of care for brain metastases (Arm B) | Primary GBM with unmethylated MGMT (Arm C) | MGMT promoter status determined by methylation-specific PCR or pyrosequencing (Arm C) | IDH1 mutation testing performed on tumor specimen; eligible regardless of IDH1 status (Arm C) | No history of uncontrolled seizures after surgery for primary GBM or need for >2 antiepileptic drugs (Arm C),"Chemotherapy or investigational drug within 28 days prior to first dose (Arms A/C) | Carmustine or lomustine within 6 weeks prior to first dose (Arms A/C) | Checkpoint inhibitor within 28 days before first dose (Arm B) | Any other systemic anticancer agent within 7 days before beginning study treatment (Arm B) | History of severe brain injury or stroke | Not eligible for sequential MRI evaluations | History of epileptic disorder or any seizure history unrelated to tumor | Use of strong CYP3A4 inhibitors or inducers within 2 weeks prior to study drug | Concurrent therapy with seizurogenic medications | Past or active interstitial lung disease, drug-induced ILD, or radiation pneumonitis requiring steroids; clinically active ILD | Concurrent severe/uncontrolled medical condition (e.g., severe COPD) | Prior pneumotoxic drugs (e.g., busulfan, bleomycin) within past year, or any prior pneumotoxic therapy with history of pulmonary toxicities; prior nitrosoureas allowed if no lung toxicity | History or presence of myopathy or creatine kinase > 5 x ULN on 2 occasions at screening | Cardiac dysfunction: myocardial infarction within 6 months, NYHA Class II–IV heart failure, unstable angina, unstable arrhythmias | Severe pulmonary infections (Japan: includes active TB, chronic active or uncontrolled HBV or HCV) | Unresolved toxicities from prior therapy > CTCAE v4.03 Grade 1 (chronic Grade 2 may be eligible per investigator) | Prior ATM inhibitor with concurrent radiation therapy (Arms A/Japan part) | Diabetes (Type I, Type II, or steroid-induced) for food effect assessment (not applicable to Japan part) | Undergoing systemic steroid treatment for food effect assessment (not applicable to Japan part)",Completion of first-line radiation >= 6 months before Cycle 1 Day 1 (Arm A/Japan); No prior brain radiation to the area to be irradiated; prior PBRT allowed if no significant overlap (Arm B); Washout before first AZD1390 dose: 28 days for immune checkpoint inhibitors (Arm B); Washout before first AZD1390 dose: 7 days for other systemic agents (Arm B); No radiation to lung fields within the past 8 weeks (Arm B),ALL,D,"Disease and recurrent setting match, but Arm A requires ≥6 months since completion of first-line radiation before starting study treatment, and the patient recurred only 3 months after adjuvant chemoradiation, making prior-therapy timing incompatible.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),INCORRECT,A,"No hard exclusions. Stage/setting matches (recurrent GBM). Line/prior exposure compatible (post–first-line RT; washout met). The grader misinterpreted the ≥6 months since completion of first-line radiation: recurrence 3 months after finishing adjuvant TMZ typically implies ≥9 months since RT, satisfying the criterion. With ≥2 anchors matching and no soft conflicts, the correct grade is A.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT03449108,0.7943270802497864,Recurrent Clear Cell Ovarian Carcinoma,Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types,"This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment (refractory) or that has come back (relapsed). LN-145 is made by collecting and growing specialized white blood cells (called T-cells) that are collected from the patient's tumor. LN-145-S1 ...","{'id': 205791947, 'name': 'Aldesleukin', 'description': 'Given IV', 'other_names': ['125-L-Serine-2-133-interleukin 2', 'Proleukin', 'r-serHuIL-2', 'Recombinant Human IL-2', 'Recombinant Human Interleukin-2'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205791948, 'name': 'Autologous Tumor Infiltrating Lymphocytes LN-145', 'description': 'Given IV', 'other_names': ['Autologous TILs LN-145', 'Autologous Tumor-infiltrating Lymphocytes LN-145', 'LN-145', 'LN145'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205791949, 'name': 'Autologous Tumor Infiltrating Lymphocytes LN-145-S1', 'description': 'Given IV', 'other_names': ['Autologous TILs LN-145-S1', 'Autologous Tumor-infiltrating Lymphocytes LN-145-S1', 'LN 145-S1', 'LN-145-S1', 'LN145-S1'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205791950, 'name': 'Cyclophosphamide', 'description': 'Given IV', 'other_names': ['Cytoxan', '(-)-Cyclophosphamide', '2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate', 'Carloxan', 'Ciclofosfamida', 'Ciclofosfamide', 'Cicloxal', 'Clafen', 'Claphene', 'CP monohydrate', 'CTX', 'CYCLO-cell', 'Cycloblastin', 'Cycloblastine', 'Cyclophospham', 'Cyclophosphamid monohydrate', 'Cyclophosphamide Monohydrate', 'Cyclophosphamidum', 'Cyclophosphan', 'Cyclophosphane', 'Cyclophosphanum', 'Cyclostin', 'Cyclostine', 'Cytophosphan', 'Cytophosphane', 'Fosfaseron', 'Genoxal', 'Genuxal', 'Ledoxina', 'Mitoxan', 'Neosar', 'Revimmune', 'Syklofosfamid', 'WR- 138719'], 'intervention_type': 'DRUG'}; {'id': 205791951, 'name': 'Fludarabine', 'description': 'Given IV', 'other_names': ['Fluradosa'], 'intervention_type': 'DRUG'}; {'id': 205791952, 'name': 'Ipilimumab', 'description': 'Given IV', 'other_names': ['Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody', 'BMS-734016', 'Ipilimumab Biosimilar CS1002', 'MDX-010', 'MDX-CTLA4', 'Yervoy'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205791953, 'name': 'Nivolumab', 'description': 'Given IV', 'other_names': ['BMS-936558', 'CMAB819', 'MDX-1106', 'NIVO', 'Nivolumab Biosimilar CMAB819', 'ONO-4538', 'Opdivo'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205791954, 'name': 'Quality-of-Life Assessment', 'description': 'Ancillary studies', 'other_names': ['Quality of Life Assessment'], 'intervention_type': 'OTHER'}; {'id': 205791955, 'name': 'Questionnaire Administration', 'description': 'Ancillary studies', 'other_names': [], 'intervention_type': 'OTHER'}",PHASE2,16 years to 70 years,Bone Sarcoma; Dedifferentiated Chondrosarcoma; Giant Cell Tumor of Bone; Giant Cell Tumor of Bone (malignant); Osteosarcoma (recurrent); Osteosarcoma (refractory); Soft Tissue Sarcoma; Ovarian Carcinosarcoma; Ovarian Carcinoma (platinum-resistant); Ovarian Carcinoma (recurrent); Anaplastic Thyroid Carcinoma; Poorly Differentiated Thyroid Carcinoma; Thyroid Gland Squamous Cell Carcinoma; Triple Negative Breast Cancer; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,"Age 18-70 years (16-70 years for osteosarcoma cohort) | ECOG performance status 0-1 | Tumor site amenable to excisional biopsy (separate from target lesion) for TIL generation | Discontinue prior antitumor therapy >= 28 days before enrollment for TIL preparation | Absolute neutrophil count >= 1000/µL | Hemoglobin >= 8.0 g/dL (transfusion allowed) | Platelet count >= 100,000/µL | AST <= 2.5 x ULN (<= 5 x ULN with liver metastases) | ALT <= 2.5 x ULN (<= 5 x ULN with liver metastases) | Total bilirubin <= 1.5 x ULN | Creatinine clearance >= 50 mL/min | PT and aPTT <= 1.5 x ULN (vitamin K correction allowed) | Negative serum pregnancy test (female of childbearing potential) | No confirmed HIV infection | 12-lead EKG without active ischemia and QTcF < 480 ms | Negative dobutamine stress echocardiogram or appropriate alternative cardiac evaluation per cardiology | Pulmonary function: FEV1 > 65% predicted or FVC > 65% predicted | Ovarian cancer cohort: high-grade non-mucinous histology (carcinosarcoma allowed) | Ovarian cancer cohort: failed at least two prior lines of chemotherapy and platinum-resistant disease | TIL-ICI ovarian cohort: criteria as per ovarian cancer cohort and enrolled after protocol version 2.0 activation | Osteosarcoma cohort: relapsed/refractory after conventional therapy including some combination of high-dose methotrexate, doxorubicin, cisplatin, and/or ifosfamide | Other bone and soft tissue sarcomas cohort: at least one prior line of therapy, or enrollment as initial therapy if no standard first-line exists | TIL-ICI sarcoma cohort: meets corresponding osteosarcoma/other sarcoma prior therapy criteria; enrolled after protocol version 2.0 activation | Anaplastic/poorly differentiated thyroid cohort: pathologic diagnosis consistent with anaplastic or poorly differentiated thyroid carcinoma | Anaplastic/poorly differentiated thyroid cohort: measurable distant metastatic disease by RECIST v1.1 | Anaplastic/poorly differentiated thyroid cohort: planned surgical resection or airway-stabilizing surgery, or resectable tumor for TIL manufacturing with stable airway | Anaplastic/poorly differentiated thyroid cohort: prior neck EBRT allowed if a separate measurable/biopsiable lesion remains | TNBC cohort: confirmed metastatic triple negative breast cancer (Stage IV or recurrent) | TNBC cohort: ER and PR < 10% and HER2 negative by ASCO/CAP | TNBC cohort: 1-3 prior lines of systemic therapy for metastatic disease | Resectable lesion minimum diameter 1.5 cm | Palliative therapy during screening allowed with PI approval for lesions not used for TIL generation or response assessment","Active or uncontrolled intercurrent illness including active infections, coagulation disorders, or major cardiovascular, respiratory, or immune system illnesses | Active viral hepatitis | Left ventricular ejection fraction < 45% | History of prior adoptive cell therapies | Persistent prior therapy-related toxicities > grade 2 (except peripheral neuropathy, alopecia, vitiligo) | History of grade >= 2 diarrhea/colitis from prior immunotherapy unless asymptomatic >= 6 months or normal colonoscopy after checkpoint therapy | Primary immunodeficiency | History of organ or hematopoietic stem cell transplant | Chronic steroid therapy > 10 mg/day prednisone equivalent | Pregnant or nursing | Significant psychiatric disease precluding informed consent | Clinically significant autoimmune disease (exceptions: resolved CPI side effects, vitiligo, psoriasis, type 1 diabetes, resolved childhood asthma/atopy, hypothyroidism on replacement, Sjogren's syndrome) | Clinically significant COPD, asthma, interstitial lung disease, or other chronic lung disease | Second malignancy within 5 years (exceptions: certain skin cancers and in situ cervical cancer; thyroid cohort allows indolent cancers per investigator) | Active CNS metastases or carcinomatous meningitis (treated/stable brain metastases allowed per protocol and off steroids >= 7 days before lymphodepletion) | Receipt of live vaccine within 30 days before lymphodepletion | Hypersensitivity to components/excipients of study drugs including cyclophosphamide, mesna, fludarabine, IL-2, aminoglycosides, HSA, dextran-40, nivolumab, or ipilimumab | Any condition that significantly increases risk in the investigator's judgment","Discontinue prior antitumor therapy >= 28 days before enrollment; Ovarian cancer: failed at least two prior lines of chemotherapy and platinum-resistant disease; Osteosarcoma: prior regimen including some combination of high-dose methotrexate, doxorubicin, cisplatin, and/or ifosfamide; Other bone and soft tissue sarcomas: at least one prior line of therapy unless no standard first-line therapy exists; TNBC: 1-3 prior lines of systemic therapy for metastatic disease; Thyroid cancer cohort: prior neck external beam radiation allowed if separate measurable/biopsiable lesion remains; Palliative therapy during screening allowed with PI approval for non-target/non-TIL lesions",ALL,D,"Disease and setting (recurrent ovarian carcinoma) align, but the trial’s ovarian cohort requires platinum-resistant disease and at least two prior lines of chemotherapy; the patient has only received adjuvant carboplatin/paclitaxel/bevacizumab with no evidence of ≥2 lines or platinum resistance.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,D,"No hard exclusions. Disease matches and setting (recurrent ovarian) aligns (1 anchor match). However, the ovarian cohort requires ≥2 prior lines and platinum-resistant disease; the patient has only one prior regimen, making a clear line-of-therapy mismatch (soft conflict). Platinum resistance status is unknown but not needed to trigger D. Thus D is appropriate.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT03579316,0.7943270802497864,Recurrent Clear Cell Ovarian Carcinoma,"EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition","This phase II trial studies how well adavosertib with or without olaparib work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent). Adavosertib and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.","{'id': 205883324, 'name': 'Adavosertib', 'description': 'Given PO', 'other_names': ['AZD-1775', 'AZD1775', 'MK-1775', 'MK1775'], 'intervention_type': 'DRUG'}; {'id': 205883325, 'name': 'Olaparib', 'description': 'Given PO', 'other_names': ['AZD 2281', 'AZD-2281', 'AZD2281', 'KU-0059436', 'Lynparza', 'PARP Inhibitor AZD2281'], 'intervention_type': 'DRUG'}; {'id': 205883326, 'name': 'Ceralasertib', 'description': 'Given PO', 'other_names': ['AZD6738'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Ovarian Carcinoma (recurrent); Primary Peritoneal Carcinoma (recurrent); Fallopian Tube Carcinoma (recurrent),"Histologically confirmed recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer with no curative options. | Progressive disease during PARP inhibitor therapy or within 6 months of completing PARP inhibitor therapy, with documented progression. | Prior PARP inhibitor allowed as treatment or maintenance. | At least one measurable lesion per RECIST v1.1. | Adequate archived tumor tissue collected before prior PARP therapy. | ECOG performance status 0-1 within 28 days of entry. | Adequate organ and marrow function. | ANC >=1500/µL. | Hemoglobin >=10 g/dL without transfusion in past 28 days. | Platelets >=100,000/µL without transfusion in past 28 days. | AST <=2.5 x ULN (<=5 x ULN with hepatic metastases). | ALT <=2.5 x ULN (<=5 x ULN with hepatic metastases). | Total bilirubin within normal limits (<=1.5 x ULN with liver metastases; <=3.0 x ULN with direct bilirubin normal in Gilbert's). | Creatinine clearance >=51 mL/min (estimated or measured). | Women of childbearing potential: negative serum pregnancy test within 3 days prior to treatment and agree to use effective contraception. | Predicted life expectancy >=16 weeks. | Age >=18 years. | Ceralasertib arm only: platinum-sensitive disease (recurrence >6 months after last platinum), prior response to last platinum and no progression on platinum. | Ceralasertib arm only: progression on prior PARP inhibitor in maintenance or treatment setting. | Ceralasertib arm only: germline or somatic BRCA mutation or HRD positive by a licensed test. | Ceralasertib arm only: clinical benefit from prior PARP inhibitor (>=6 months after >1 prior chemo line, or >=12 months if first-line maintenance). | Ceralasertib arm only: if prior olaparib, no significant toxicity or permanent dose reduction required. | Ceralasertib arm only: documented progression prior to study entry.","Insufficient washout from prior PARP inhibitor (minimum 10 days or 5 half-lives if longer, not to exceed 21 days). | Hormonal therapy for malignancy within 1 week prior to registration (HRT permitted). | Other anticancer therapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C). | Cytotoxic chemotherapy within 21 days of Cycle 1 Day 1. | Non-cytotoxic targeted agents within 30 days or <5 half-lives (whichever is shorter). | Immunotherapy within 42 days. | Palliative radiotherapy within 21 days (or wide-field radiation within 4 weeks) of Cycle 1 Day 1. | Systemic corticosteroids >10 mg prednisone/day (or equivalent) within 14 days prior to first dose, unless stable dose per CNS criteria. | Major surgery within 28 days or minor surgery within 7 days of starting treatment. | Residual toxicity > Grade 1 from prior therapy (except alopecia or anorexia). | Inability to swallow oral medications or significant GI disorders affecting absorption (including refractory N/V, significant bowel resection with sequelae); PEG tube or TPN use not allowed. | Symptomatic uncontrolled brain metastases; treated/stable CNS mets allowed per protocol criteria. | Concomitant use of sensitive CYP3A4 substrates or narrow therapeutic index CYP3A4 substrates, or moderate/strong CYP3A4 inhibitors/inducers that cannot be stopped per washout requirements; aprepitant/fosaprepitant prohibited. | Use of herbal supplements that significantly modulate CYP3A activity within 7 days prior to first dose. | Known hypersensitivity to adavosertib (AZD1775), ceralasertib, or olaparib. | NYHA class >=2 cardiac disease within 6 months (unstable angina, CHF, recent MI, uncontrolled conduction abnormalities, significant arrhythmias). | History of Torsades de pointes unless all risk factors corrected; ventricular arrhythmias or recent MI not studied with AZD1775. | Baseline QTcF >=480 msec or congenital long QT syndrome. | Risk factors for QT prolongation or arrhythmia (e.g., CHF, unstable angina, recent MI, hypokalemia, family history of long QT, uncontrolled conduction abnormality). | Pregnant or breastfeeding. | Serious active infection or serious underlying medical condition that would impair treatment; known HBV, HCV, or HIV infection; need for systemic anti-infectives. | Presence of other active invasive cancers. | Myelodysplastic syndrome or acute myeloid leukemia, or features suggestive of MDS/AML. | Previous allogeneic bone marrow transplant or double umbilical cord blood transplant. | Ceralasertib arm only: concomitant strong or moderate CYP3A inhibitors (2-week washout required). | Ceralasertib arm only: concomitant strong or moderate CYP3A inducers (5-week washout for enzalutamide/phenobarbital; 3 weeks for others). | Ceralasertib arm only: concomitant CYP3A4 and/or CYP2B6 substrates with narrow therapeutic index. | Ceralasertib arm only: risk of brain perfusion problems (e.g., carotid stenosis, presyncope/syncope, TIAs). | Ceralasertib arm only: uncontrolled hypertension (>= Grade 2) requiring intervention. | Ceralasertib arm only: diagnosis of ataxia telangiectasia. | Ceralasertib arm only: other malignancy active or treated within past 3 years (except specified in protocol). | Ceralasertib arm only: unresolved toxicities from prior therapy >= Grade 2 (except alopecia, Grade 2 neuropathy). | Ceralasertib arm only: relative hypotension (<90/60 mm Hg) or clinically relevant orthostatic hypotension (>20 mm Hg fall). | Ceralasertib arm only: non–leukocyte-depleted whole blood transfusion within 120 days before genetic sample collection.",Prior PARP inhibitor therapy with documented progression required.; Prior PARP inhibitor allowed as treatment or maintenance.; Minimum washout after prior PARP inhibitor: 10 days or 5 half-lives if longer (not to exceed 21 days).; Discontinue hormonal therapy for malignancy >=1 week before enrollment (HRT allowed).; Washout from other anticancer therapy >=3 weeks (>=6 weeks for nitrosoureas or mitomycin C).; No cytotoxic chemotherapy within 21 days before Cycle 1 Day 1.; For non-cytotoxic agents: >=30 days or >=5 half-lives (whichever is shorter) before Cycle 1 Day 1.; Minimum washout for immunotherapy: 42 days.; Palliative radiotherapy completed >=21 days prior (wide-field radiation >=4 weeks).; Avoid systemic corticosteroids >10 mg prednisone/day (or equivalent) within 14 days prior to first dose unless meeting CNS stability criteria.,ALL,D,"Disease and recurrent setting match, but the trial requires prior PARP inhibitor therapy with documented progression, which the patient has not had. Although BRCA1 positivity could fit an arm-specific biomarker, the prior PARP exposure requirement is unmet.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,D,"No hard exclusions apply (age/sex/disease match). Stage/setting (recurrent ovarian cancer) matches, but the trial requires prior PARP inhibitor exposure with progression, which the patient lacks—this is a clear soft mismatch on the Line/prior-exposure anchor, yielding D per the rubric.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03581487,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,Phase I/II Trial Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC,"This phase I/II trial studies the best dose of selumetinib and how well it works with durvalumab and tremelimumab in treating participants with stage IV non-small cell lung cancer or that has come back. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for ce...","{'id': 205722427, 'name': 'Durvalumab', 'description': 'Given IV', 'other_names': ['Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer', 'MEDI-4736', 'MEDI4736', 'Imfinzi'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205722428, 'name': 'Selumetinib', 'description': 'Given PO', 'other_names': ['ARRY-142886', 'AZD6244', 'MEK inhibitor AZD6244'], 'intervention_type': 'DRUG'}; {'id': 205722429, 'name': 'Tremelimumab', 'description': 'Given IV', 'other_names': ['Anti-CTLA4 Human Monoclonal Antibody CP-675,206', 'CP-675', 'CP-675,206', 'CP-675206', 'Ticilimumab'], 'intervention_type': 'BIOLOGICAL'}",PHASE1/PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic),"Histologically or cytologically confirmed recurrent non-small cell lung cancer not amenable to curative therapy or stage IV NSCLC | Known KRAS mutation status by CLIA-certified test | Documented progression after at least one prior line of chemotherapy or immunotherapy for metastatic or recurrent disease, or progression within 6 months of adjuvant or concurrent chemotherapy | Biopsy-accessible disease and willingness to undergo tumor biopsy | Measurable disease by RECIST 1.1 | Total body weight > 30 kg | ECOG performance status 0 or 1 | Ability to take oral medication | Brain metastases allowed if stable and not requiring anticonvulsants or escalating steroids","Investigational medicinal product or other systemic anticancer treatment within 4 weeks or within 5 half-lives prior to first dose | Concurrent enrollment in another interventional clinical study | Current or prior use of systemic immunosuppressive medication within 14 days before first durvalumab dose (with protocol-specified exceptions) | Any concurrent chemotherapy, immunotherapy, biologic, or hormonal anticancer therapy | Radiation therapy within 4 weeks prior to starting study treatment (limited palliative fields with protocol-specified exceptions) | Receipt of live attenuated vaccine within 30 days before study entry or within 30 days of durvalumab | Prior treatment with a MEK, RAS, or RAF inhibitor | Prior anti–PD-1, anti–PD-L1, or anti–CTLA-4 with toxicity leading to permanent discontinuation, unresolved AEs, >= grade 3 immune-related AE, immune-related neurologic or ocular AE, requirement for additional immunosuppression, AE recurrence on rechallenge, or current need for >10 mg/day prednisone equivalent | Unresolved >= grade 2 toxicity from prior anticancer therapy (except alopecia, vitiligo, and per protocol exceptions) | Known hypersensitivity to selumetinib, durvalumab, tremelimumab, or their excipients | Active or prior autoimmune or inflammatory disorders (with protocol-specified exceptions) | Active infection including tuberculosis, hepatitis B surface antigen positivity, hepatitis C with detectable RNA, or HIV infection | History of leptomeningeal carcinomatosis | Known or suspected brain metastases or spinal cord compression unless treated and stable off corticosteroids and anticonvulsants for >= 4 weeks | Known history of previous clinical diagnosis of tuberculosis | History of primary immunodeficiency | History of organ transplant requiring therapeutic immunosuppression | Significant cardiac conditions including QTcF > 450 ms, uncontrolled hypertension, recent acute coronary syndrome, uncontrolled angina, symptomatic heart failure NYHA II-IV, cardiomyopathy, LVEF below LLN or < 55%, severe valvular heart disease, or atrial fibrillation with ventricular rate > 100 bpm | Ophthalmologic conditions: RPED/CSR, retinal vein occlusion, intraocular pressure > 21 mmHg or uncontrolled glaucoma | Gastrointestinal disorders expected to limit absorption of selumetinib; refractory nausea/vomiting; chronic GI disease or significant bowel resection affecting absorption | Another primary malignancy within 5 years (except adequately treated basal/squamous cell skin cancer or carcinoma in situ of the cervix) | Major surgery within 4 weeks prior to starting study treatment (except vascular access) | Uncontrolled intercurrent illness including active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina, cardiac arrhythmia, interstitial lung disease, serious chronic GI conditions with diarrhea, or psychiatric/social conditions limiting compliance | Pregnant or breastfeeding | Systemic anticancer therapy within 4 weeks prior to starting study treatment (6 weeks for nitrosoureas, mitomycin, or suramin) | Patients of reproductive potential not using effective contraception from screening to 180 days after last dose of durvalumab and tremelimumab | Body weight <= 30 kg",Progression after >=1 prior line of systemic chemotherapy or immunotherapy for metastatic or recurrent NSCLC; Progression within 6 months of completing adjuvant or concurrent chemotherapy allowed,ALL,D,"Stage IV NSCLC and ECOG/age match, but the trial requires progression after at least one prior line of chemotherapy or immunotherapy, whereas the patient has only received osimertinib (EGFR TKI). KRAS mutation status is unspecified (not a hard exclusion but may require testing).",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,D,"No hard exclusions apply. Disease and stage match, but there is a clear soft mismatch on line/prior exposure: the trial requires progression after prior chemotherapy or immunotherapy, while the patient has only received osimertinib (EGFR TKI) with no qualifying prior chemo/IO. KRAS status is unknown and not an explicit exclusion here. Thus D is appropriate.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03589339,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy,"The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.","{'id': 205979917, 'name': 'NBTXR3', 'description': 'Single intra Tumoral injection', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205979918, 'name': 'SABR', 'description': 'Radiotherapy given as a definite number of fractions at the dose defined for each radiation field', 'other_names': ['Stereotaxic Ablative Radiotherapy', 'Stereotaxic Body Radiation Therapy'], 'intervention_type': 'RADIATION'}; {'id': 205979919, 'name': 'Nivolumab', 'description': 'Anti-PD-1 monotherapy', 'other_names': ['Opdivo'], 'intervention_type': 'DRUG'}; {'id': 205979920, 'name': 'Pembrolizumab', 'description': 'Anti-PD-1 monotherapy', 'other_names': ['Keytruda'], 'intervention_type': 'DRUG'}",PHASE1,18 years,Head and Neck Squamous Cell Carcinoma (recurrent/metastatic); Non-Small Cell Lung Cancer (metastatic); Melanoma (metastatic); Renal Cell Carcinoma (metastatic); Triple-Negative Breast Cancer (metastatic); Urothelial Carcinoma (metastatic); Cervical Cancer (metastatic); Hepatocellular Carcinoma (metastatic),"Biopsy-confirmed cancer indicated for anti-PD-1 therapy | Inoperable locoregional recurrent or recurrent/metastatic head and neck squamous cell carcinoma with a lesion amenable to irradiation (head and neck region, lung, or liver) | Metastatic disease to lung (including involved/mediastinal lymph nodes) or liver with a lesion in a previously non-irradiated field (dose escalation cohorts 2–3) | At least one measurable lesion per RECIST 1.1 that is amenable to intratumoral injection | Prior anti-PD-1 exposure status meeting cohort criteria (anti-PD-1 naive or primary/secondary resistance as specified) | ECOG performance status 0–2 | Life expectancy >12 weeks | Adequate organ and bone marrow function | Negative pregnancy test <= 7 days prior to NBTXR3 injection for women of child-bearing potential",History of immune-related adverse events from anti-PD-1/L1 that led to termination and precludes further PD-1 exposure | Symptomatic central nervous system metastases or carcinomatous meningitis | Active autoimmune disease requiring systemic treatment within the past 1 year | Known HIV infection | Active hepatitis B or hepatitis C infection | Active infection requiring intravenous antibiotics | Receipt of a live virus vaccine within 30 days prior to study treatment | History of pneumonitis requiring steroids or current pneumonitis | Extensive metastatic disease burden (>5 lesions overall including the primary tumor) | Locoregional recurrent HNSCC with ulceration | Prior checkpoint inhibitor within 2 weeks before NBTXR3 injection | Prior systemic anti-neoplastic therapy (including investigational agents) within 4 weeks before NBTXR3 injection | Unresolved adverse events from prior anti-neoplastic therapies and/or interventions (including radiation) > Grade 1 or not at baseline at screening | Clinically significant cardiac arrhythmias | NYHA Class III or IV heart failure within 6 months prior to screening | Pregnant or nursing female | Women of child-bearing potential and men who are sexually active not willing/able to use acceptable contraception | Any condition for which participation would not be in the participant's best interest,Prior anti-PD-1 therapy allowed; participants may be anti-PD-1 naive or have primary/secondary resistance per cohort; Expansion Cohorts 1 and 3 require prior anti-PD-1 primary or secondary resistance; Expansion Cohort 2 requires anti-PD-1 naive; Washout: no prior checkpoint inhibitor within 2 weeks before NBTXR3 injection; Washout: no prior systemic anti-neoplastic therapy (including investigational agents) within 4 weeks before NBTXR3 injection; Prior radiation allowed; injectable lesion may be in a previously irradiated field for specified HNSCC cohorts,ALL,D,"Disease and stage match NSCLC (metastatic), and anti–PD-1–naïve status is compatible with allowed cohorts. However, the trial excludes patients with extensive metastatic burden (>5 lesions); the patient has bone and liver metastases with a recent MRI showing numerous lesions, suggesting a lesion count likely exceeding the protocol limit, and the presence of an injection-amenable lesion is uncertain.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),INCORRECT,A,"Disease and stage match (metastatic NSCLC), and prior anti–PD-1 status is compatible with allowed cohorts—thus ≥2 core anchors match. The trial’s >5-lesion exclusion cannot be applied without a confirmed count; “numerous lesions” is ambiguous and should not be inferred into a mismatch per rubric. Uncertainty about an injection-amenable lesion is unknown, not a soft conflict. Therefore, absent a clear soft mismatch or hard exclusion, the grade should be A, not D.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03808337,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,PROMISE-005: A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Breast or Lung Cancer,This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.,"{'id': 206605534, 'name': 'Stereotactic Body Radiotherapy/SBRT', 'description': 'Radiation to each metastatic site should be delivered to a minimum dose of 30 Gy in 5 fractions (BED of 48 Gy10). The exact dose of radiotherapy will be determined by the treating radiation oncologist. Preferred regimens for lung metastases include 50 Gy in five fractions, 48 Gy in four fractions, or 54 Gy in three fractions, although lower doses may be employed to respect dose limits to critical structures such as the esophagus. Recommended SBRT dosing for other sites includes 27 to 30 Gy in three fractions or 24 Gy in one fraction for bone metastases.', 'other_names': [], 'intervention_type': 'RADIATION'}; {'id': 206605535, 'name': 'Systemic Therapy/Standard of Care', 'description': 'Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist. For patients randomized to receive SBRT, systemic therapy can be continued during SBRT at the discretion and concensus of treating physicians (medical oncologist and radiation oncologist). If the treating physicians recommend discontinuing systemic therapy during SBRT, general guidelines for stopping and reinitiating systemic regimen are as follows: Hormonal therapies and immunotherapy can be continued during SBRT. Consideration can be given to holding cytotoxic chemotherapy beginning 3 to 7 days prior to the initiation of SBRT until 3 to 7 days after the completion of SBRT. Similarly, consideration can be given to holding biologic agents during SBRT and for 0 to 3 days before and after.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,18 years,Breast Cancer (metastatic); Non-Small Cell Lung Cancer (metastatic),"Histologically confirmed metastatic disease on imaging | Metastatic breast cancer (all subtypes) | Non-small cell lung cancer without known targetable EGFR, ALK, or ROS1 alterations, or NSCLC with EGFR/ALK/ROS1 alterations after progression on first-line tyrosine kinase inhibitor | Newly diagnosed metastatic disease or non-progressive disease on systemic therapy for >= 3 months | Measurable disease at baseline (RECIST or PERCIST 2.0) | Five or fewer discrete disease sites amenable to SBRT | Brain metastases eligible if treated prior to enrollment | Palliative radiotherapy prior to enrollment allowed if at least one other non-irradiated lesion amenable to SBRT remains | ECOG 0–2 | Age >= 18 years | Adequate organ function to allow SBRT to relevant targets as determined by radiation oncologist",Serious medical comorbidities precluding radiotherapy | Pregnant or lactating | Other active malignancy within the last year | Clinical or radiologic spinal cord compression | Malignant pleural effusion or ascites | Enrollment causing unacceptable delay in planned management,NSCLC with EGFR/ALK/ROS1 alterations requires prior first-line tyrosine kinase inhibitor with documented progression; Ongoing systemic therapy allowed if non-progressive for >= 3 months before enrollment; Prior palliative radiotherapy allowed if at least one other lesion remains amenable to SBRT; Brain metastases must be treated prior to enrollment; Prior local therapy to primary or regional disease allowed (surgery or radiation); new local/regional recurrences must be technically treatable with SBRT or hypofractionated radiation,ALL,D,"Disease, age, and ECOG match, but the trial requires oligometastatic disease (≤5 SBRT-amenable lesions) while the patient has numerous lesions, which is a mismatch. Additionally, for EGFR-mutant NSCLC the trial requires documented progression on first-line TKI, which is not clearly established.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),INCORRECT,F,"The trial explicitly requires an oligometastatic state with ≤5 SBRT-amenable lesions. The patient’s “numerous lesions” definitively fails this required setting, which constitutes a hard exclusion per the rubric. The EGFR-TKI progression requirement is unclear and should not trigger F, but the oligometastatic requirement alone does. Therefore, the correct grade is F, not D.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03808558,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,A Phase 2 Multi-center Pharmacodynamics Study of TVB-2640 in KRAS Mutant Non-small Cell Lung Carcinomas,"This is a prospective one-arm, two-stage phase 2 trial of TVB-2640 in KRAS mutant NSCLC patients. 13 patients will be treated with a minimum of 1 cycle of TVB-2640 therapy over 8 weeks.","{'id': 205944212, 'name': 'TVB-2640', 'description': 'TVB-2640 will be administered 100mg/m2 orally once a day for 8 weeks.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic),"Metastatic or advanced, histologically or cytologically confirmed non-small cell lung cancer with oncogenic KRAS mutation | KRAS-mutant NSCLC refractory or relapsed and previously treated with doublet chemotherapy and an immune checkpoint inhibitor unless contraindicated | KRAS mutation documented by a CLIA-certified assay (tissue or blood-based) | EGFR mutation and ALK rearrangement status known; if positive, must have progressed after appropriate targeted therapy | Radiographic disease progression on most recent line of therapy | Measurable disease by RECIST v1.1 | Age >= 18 years | ECOG performance status 0–1 | Predicted life expectancy > 3 months | Adequate organ and marrow function | No significant ischemic heart disease or myocardial infarction within 6 months and adequate cardiac function","Inability to swallow oral medications or significant gastrointestinal disorder that may alter drug absorption | Risk factors for torsade de pointes including uncontrolled heart failure, severe hypokalemia (potassium < 3 mM/L), history of long QT syndrome, or requirement for concomitant QT-prolonging medications | Requirement for strong CYP3A4/5 agonists or inhibitors during study participation | Uncontrolled or severe intercurrent medical condition including uncontrolled brain metastases (stable treated or untreated brain metastases allowed under specified conditions) | Major surgery within 4 weeks before first dose | Receipt of cancer-directed therapy or investigational agent within 2 weeks (6 weeks for mitomycin C or nitrosoureas) or 5 half-lives, whichever is shorter, before first dose; unresolved toxicities > Grade 1 except specified | Pregnant or breastfeeding | Serious active infection requiring intravenous antibiotics | Known HIV infection or active hepatitis B or C infection | Important medical illness or abnormal laboratory finding increasing risk in the investigator's opinion | Prior or concurrent malignancy that may interfere with safety or efficacy assessment | History of clinically significant dry eye or other corneal abnormality, or contact lens wearer unwilling to abstain from use during treatment | Known allergy or hypersensitivity to components of TVB-2640 | Prior history of hypersensitivity, drug- or radiation-induced, or other immune-mediated pneumonitis","Prior platinum doublet chemotherapy required; Prior immune checkpoint inhibitor required unless contraindicated; If EGFR mutation or ALK rearrangement present, prior appropriate targeted therapy with progression required; Washout: No systemic anticancer therapy or investigational agent within 2 weeks (6 weeks for mitomycin C or nitrosoureas) or 5 half-lives, whichever is shorter; prior toxicities recovered to < Grade 1",ALL,D,"Stage and NSCLC diagnosis match, but the trial requires documented KRAS-mutant NSCLC and prior platinum doublet chemotherapy plus an immune checkpoint inhibitor; this patient has EGFR exon 19–mutant disease and has only received osimertinib.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,D,"No hard exclusion applies because KRAS status is not definitively known (cannot infer KRAS-wildtype from EGFR+ per rubric). Disease and metastatic setting match, but there are clear soft mismatches: trial requires KRAS-mutant NSCLC and prior platinum doublet plus immune checkpoint inhibitor, while the patient has EGFR-mutant disease and only prior osimertinib. Thus D is appropriate.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT04477200,0.8363864421844482,Recurrent Glioblastoma,Phase 0/I Dose Escalation Study of Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma,"This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma.","{'id': 206018706, 'name': 'Mycophenolate Mofetil', 'description': '500-2000mg orally twice daily, one week prior to re-resection (2 participants at each of 4 dose levels: 500mg, 1000mg, 1500mg and 2000mg)', 'other_names': ['MMF'], 'intervention_type': 'DRUG'}; {'id': 206018707, 'name': 'Radiation Therapy', 'description': '40.5 Gy in 15 fractions', 'other_names': ['RT'], 'intervention_type': 'RADIATION'}; {'id': 206018708, 'name': 'Re-resection (as part of standard of care)', 'description': 'Re-resection or biopsy of tumor as part of standard of care', 'other_names': [], 'intervention_type': 'PROCEDURE'}; {'id': 206018709, 'name': 'Temozolomide', 'description': 'Temozolomide capsules are an approved oral chemotherapeutic drug for the treatment of adult patients with newly diagnosed GBM/GS concomitantly with radiotherapy and then as adjuvant treatment. The dosing and timing of temozolomide therapy will be determined as per standard-of-care for the individual patient by the treating oncologist.', 'other_names': ['TMZ'], 'intervention_type': 'DRUG'}; {'id': 206018710, 'name': 'Mycophenolate Mofetil', 'description': '250-2000mg orally twice daily, one week prior to and concurrent with RT.', 'other_names': ['MMF'], 'intervention_type': 'DRUG'}; {'id': 206018711, 'name': 'Mycophenolate Mofetil', 'description': '250-2000mg orally twice daily, one week prior to and concurrent with RT and cyclic chemotherapy with temozolomide.', 'other_names': ['MMF'], 'intervention_type': 'DRUG'}; {'id': 206018712, 'name': 'Radiation Therapy', 'description': '60 Gy in 30 fractions', 'other_names': ['RT'], 'intervention_type': 'RADIATION'}",PHASE1,18 years,"Astrocytoma, Grade IV (newly diagnosed); Astrocytoma, Grade IV (recurrent); Glioblastoma (newly diagnosed); Glioblastoma (recurrent); Gliosarcoma (newly diagnosed); Gliosarcoma (recurrent)","Glioblastoma or gliosarcoma (recurrent or newly diagnosed) | Karnofsky Performance Status >= 60% | Phase 0: Candidate for clinically indicated re-resection or biopsy | Phase 1, Recurrent: Candidate for clinically indicated re-irradiation | Phase 1, Recurrent: No more than one prior course of radiation for GBM | Phase 1, Newly Diagnosed: Candidate for upfront standard-of-care chemoradiation | ANC >= 1,500 /µL","No histopathological diagnosis of the tumor | Gliomatosis cerebri pattern (involvement of 3 or more lobes) | Leptomeningeal disease | Use of bevacizumab within 8 weeks of enrollment | Known history of HIV | Active hepatitis B infection | Active hepatitis C infection | Active systemic infection | Active central nervous system infection | Grade 4 lymphopenia | Creatinine clearance < 25 mL/min | History of organ transplantation | Known hypoxanthine-guanine phosphoribosyltransferase deficiency | Serious intercurrent disease | Allergic reaction or hypersensitivity to mycophenolate mofetil or mycophenolic acid | Medical contraindication to mycophenolate mofetil per treating physician | Known immunosuppressive condition from autoimmune disease, immune deficiency syndrome, or chronic immunosuppressive therapy | Inability to undergo brain MRI with and without contrast | Pregnant or lactating | Known phenylketonuria | Phase 0: Biopsy patients unlikely to have sufficient tissue to spare for research | Phase 1: Increase in steroid requirement within 7 days of enrollment | Phase 1, Recurrent: Radiation within 6 months prior to enrollment | Phase 1, Recurrent: Surgery within 4 weeks of planned re-irradiation | Phase 1, Newly Diagnosed: History of hypersensitivity to temozolomide or dacarbazine | Phase 1, Newly Diagnosed: Prior chemotherapy or radiation therapy for glioblastoma or gliosarcoma",No more than one prior course of radiation for GBM (recurrent cohort); No bevacizumab within 8 weeks prior to enrollment; No radiation within 6 months prior to enrollment (recurrent cohort); No surgery within 4 weeks before re-irradiation (recurrent cohort),ALL,D,"Disease and recurrent setting match, but the recurrent Phase 1 cohort excludes patients who had radiation within 6 months prior to enrollment; the patient relapsed 3 months after completing adjuvant radiation, creating a timing conflict. Eligibility for the Phase 0 surgical cohort is unknown.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),INCORRECT,B,"No hard exclusion is established. The grader misread the timeline (recurrence was 3 months after adjuvant temozolomide, not after radiation), so the “radiation within 6 months” conflict is unknown, not a soft mismatch. Disease and recurrent setting match; other anchors (line/prior specifics like re-irradiation candidacy and 6‑month RT interval) are unknown. With exactly one confirmed anchor and no soft conflicts, the correct grade is B.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04514484,1.0,Castration-Resistant Prostate Cancer,Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection,"This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and who are undergoing treatment for human immunodeficiency virus (HIV). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune ...","{'id': 206423463, 'name': 'Biospecimen Collection', 'description': 'Undergo blood sample collection', 'other_names': ['Biological Sample Collection', 'Biospecimen Collected', 'Specimen Collection'], 'intervention_type': 'PROCEDURE'}; {'id': 206423464, 'name': 'Cabozantinib S-malate', 'description': 'Given PO', 'other_names': ['BMS-907351', 'Cabometyx', 'Cometriq', 'XL 184', 'XL-184', 'XL184'], 'intervention_type': 'DRUG'}; {'id': 206423465, 'name': 'Computed Tomography', 'description': 'Undergo CT', 'other_names': ['CAT', 'CAT Scan', 'Computed Axial Tomography', 'Computerized Axial Tomography', 'Computerized axial tomography (procedure)', 'Computerized Tomography', 'Computerized Tomography (CT) scan', 'CT', 'CT Scan', 'Diagnostic CAT Scan', 'Diagnostic CAT Scan Service Type', 'tomography'], 'intervention_type': 'PROCEDURE'}; {'id': 206423466, 'name': 'Magnetic Resonance Imaging', 'description': 'Undergo MRI', 'other_names': ['Magnetic Resonance', 'Magnetic Resonance Imaging (MRI)', 'Magnetic resonance imaging (procedure)', 'Magnetic Resonance Imaging Scan', 'Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance', 'MR', 'MR Imaging', 'MRI', 'MRI Scan', 'MRIs', 'NMR Imaging', 'NMRI', 'Nuclear Magnetic Resonance Imaging', 'sMRI', 'Structural MRI'], 'intervention_type': 'PROCEDURE'}; {'id': 206423467, 'name': 'Nivolumab', 'description': 'Given IV', 'other_names': ['ABP 206', 'BCD-263', 'BMS 936558', 'BMS-936558', 'BMS936558', 'CMAB819', 'MDX 1106', 'MDX-1106', 'MDX1106', 'NIVO', 'Nivolumab Biosimilar ABP 206', 'Nivolumab Biosimilar BCD-263', 'Nivolumab Biosimilar CMAB819', 'ONO 4538', 'ONO-4538', 'ONO4538', 'Opdivo'], 'intervention_type': 'BIOLOGICAL'}",PHASE1,18 years,Kaposi Sarcoma; Renal Cell Carcinoma; Hepatocellular Carcinoma; Medullary Thyroid Carcinoma; Melanoma; Non-Small Cell Lung Cancer; Head and Neck Carcinoma; Urothelial Carcinoma; Small Cell Lung Cancer; Differentiated Thyroid Cancer (radioiodine-refractory); Ovarian Cancer; Castration-Resistant Prostate Cancer; Triple-Negative Breast Cancer,"Age >= 18 years | Histologically or cytologically confirmed advanced solid tumor that is metastatic or recurrent and requires palliative systemic treatment | For safety cohort: tumor types with FDA indications or phase 2 activity for cabozantinib or nivolumab (e.g., RCC, HCC, MTC, melanoma, NSCLC, head and neck cancer, urothelial carcinoma, SCLC, radioiodine-refractory differentiated thyroid cancer, ovarian cancer, CRPC, TNBC) | Expansion cohort: Kaposi sarcoma with histologic/cytologic/pathologic confirmation | Progressed, intolerant, or declined systemic therapy associated with clinically significant survival benefit if checkpoint blockade is not an approved/accepted treatment | Any number of prior cancer therapies permitted; treatment naive subjects allowed (with KS caveats) | ECOG performance status 0-1 (Karnofsky >= 80%) | For non-KS tumors: evaluable disease | Absolute neutrophil count >= 1,000/µL | Platelets >= 75,000/µL | Total bilirubin <= 1.5 x ULN (<= 3 x ULN with Gilbert's or ARV-related unconjugated hyperbilirubinemia) | AST <= 3 x ULN | ALT <= 3 x ULN | Creatinine <= 1.5 x ULN or creatinine clearance >= 50 mL/min | Hemoglobin >= 9 g/dL | CD4 count >= 50/µL | Documented HIV infection; on appropriate ART that is not strongly CYP3A4 inhibiting or converted to such a regimen before therapy | Life expectancy >= 12 weeks | Chronic HBV: undetectable HBV viral load on suppressive therapy if indicated | HCV: treated and cured, or if on treatment, undetectable HCV viral load | Prior/concurrent malignancy allowed if it will not interfere with assessment of safety or efficacy","Safety run-in cohort: prior cabozantinib, PD-1/PD-L1 inhibitor, or VEGFR inhibitor (allowed in KS expansion cohort) | Use of potent CYP3A4 inhibitors (e.g., ritonavir, cobicistat, certain azoles/macrolides, etc.) | Cytotoxic chemotherapy or biologic agents within 3 weeks; nitrosoureas/mitomycin C within 6 weeks; unresolved toxicities from prior therapy > 4 weeks | Recent radiation: thorax/abdomen/pelvis within 4 weeks; bone or brain within 14 days; any other site within 21 days; unresolved complications from prior radiation | Concurrent investigational agents | Systemic corticosteroids > 10 mg prednisone daily (or equivalent) or not stable/decreasing for >= 2 weeks (inhaled/topical allowed) | Allergic reactions to compounds similar to nivolumab or cabozantinib | PT/INR or PTT >= 1.3 x ULN within 7 days before first dose | Primary brain tumor, active brain metastases or epidural disease (exceptions for treated/stable or small asymptomatic lesions per protocol) | Prohibited anticoagulation: warfarin, dabigatran, betrixaban, clopidogrel (LMWH or rivaroxaban/edoxaban/apixaban allowed under conditions) | Clinically significant GI bleeding within 6 months; hemoptysis >= 2.5 mL within 3 months; signs of pulmonary hemorrhage within 3 months | Radiographic cavitating pulmonary lesions | Tumor in contact with, invading, or encasing major blood vessels | Tumor invading GI tract or endotracheal/endobronchial tree within 28 days | Uncontrolled cardiovascular disorders: NYHA class III/IV CHF; uncontrolled hypertension > 140/90 mm Hg; QTcF > 500 ms; within 6 months: unstable angina, significant arrhythmias, stroke, myocardial infarction, thromboembolic event; presence of venous filter | High-risk GI conditions: active symptomatic PUD or diverticulitis, intra-abdominal abscess, GI obstruction within 28 days; abdominal fistula, GI perforation, bowel or gastric outlet obstruction within 6 months; PEG tube placement within 3 months | Active autoimmune disease or history likely to recur requiring immunosuppression (exceptions include vitiligo, endocrine deficiencies on replacement, controlled RA/Sjogren's/psoriasis, etc.) | Major surgery within 2 weeks or minor surgery within 10 days; incomplete wound healing or ongoing complications | Unable to swallow tablets | History of organ transplant or stem cell transplant | Uncontrolled intercurrent illness | Psychiatric/social conditions limiting compliance | Pregnant or breastfeeding","Any number of prior cancer therapies permitted; treatment naive allowed (with KS-specific allowances); Must have progressed, been intolerant of, or declined systemic therapy associated with survival benefit if checkpoint blockade is not approved; Washout: cytotoxic chemotherapy or biologics within 3 weeks; nitrosoureas/mitomycin C within 6 weeks; Radiation washout: thorax/abdomen/pelvis within 4 weeks; bone or brain within 14 days; other sites within 21 days",ALL,D,"Although the patient has metastatic CRPC and prior therapy exposure aligns, the trial requires documented HIV infection with ART, which is not provided for this patient, making eligibility likely mismatched. Other labs/performance status requirements are also unknown.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),INCORRECT,A,"HIV status is unknown and should be treated as neutral per rubric, not as a soft mismatch. Disease matches; stage/setting and prior-therapy anchors both match; no identified soft conflicts. Therefore grade should be A, not D.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT04637594,0.8805802464485168,Metastatic Urothelial Carcinoma,Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: a Randomized Phase 3 Non-Inferiority Trial (IMAGINE),"This phase III trial compares survival in urothelial cancer patients who stop immune checkpoint inhibitor treatment after being treated for about a year to those patients who continue treatment with immune checkpoint inhibitors. Immunotherapy with monoclonal antibodies, such as avelumab, durvalumab, pembrolizumab, atezolizumab, and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stopping immune checkpoint in...","{'id': 205962726, 'name': 'Pembrolizumab', 'description': 'Given IV', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205962727, 'name': 'Nivolumab', 'description': 'Given IV', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205962728, 'name': 'Atezolizumab', 'description': 'Given IV', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205962729, 'name': 'Durvalumab', 'description': 'Given IV', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205962730, 'name': 'Avelumab', 'description': 'Given IV', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,18 years,Urothelial Carcinoma (locally advanced); Urothelial Carcinoma (metastatic),"Histologically or cytologically confirmed urothelial carcinoma with predominantly transitional-cell features | Locally advanced or metastatic disease prior to starting immune checkpoint blockade | Primary tumor site: bladder, renal pelvis, ureter, urethra, or prostate | Received at least one cycle of FDA-approved PD-1/L1 ICI-containing standard-of-care therapy for locally advanced or metastatic urothelial carcinoma | No progressive disease by RECIST 1.1 after 12–15 months of ICI (CR, PR, or SD) | Age >= 18 years | ECOG performance status 0–2 | Adequate bone marrow and organ function to continue PD-1/L1 ICI as judged by treating physician | CNS metastases allowed if radiographically stable, clinically asymptomatic, and any prior local therapy completed > 6 months before registration | Resolved HBV (anti-HBc positive, HBsAg negative) eligible | HCV antibody positive eligible if HCV RNA PCR negative | HIV eligible if on HAART with normal CD4 count and undetectable viral load","Progressive disease by RECIST 1.1 after 12–15 months of ICI | Toxicity from ICI therapy that makes continuation clinically unacceptable | History of tuberculosis | Active hepatitis B infection | Active hepatitis C infection | Uncontrolled HIV infection | History of allogeneic organ transplantation | Current systemic immunosuppressive medication > 10 mg/day prednisone equivalent | Another primary malignancy with active disease, except malignancy treated with curative intent and no active disease for >= 2 years, or adequately treated non-melanoma skin cancer or carcinoma in situ | Pregnant or breastfeeding | Patients of reproductive potential unwilling to use effective contraception",At least one cycle of FDA-approved PD-1/L1 ICI-containing standard-of-care therapy; Completed 12–15 months of PD-1/L1 ICI with CR/PR/SD at registration,ALL,D,"Disease/setting matches metastatic urothelial carcinoma, but the trial requires patients with CR/PR/SD after 12–15 months of ongoing PD-1/L1 therapy; this patient has progressed after second-line therapy and there’s no evidence of 12–15 months non-progression on ICI, creating a line/prior-exposure mismatch.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,D,"No hard exclusions apply (age, sex, disease match). However, the trial requires 12–15 months of ongoing PD-1/L1 therapy with CR/PR/SD, which the patient clearly lacks due to progression after second-line therapy. This is a clear soft mismatch on line/prior-exposure, so D is appropriate.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT04896775,1.0,Dementia,"NiteCAPP: Web-based Interventions for Insomnia in Rural Dementia Caregivers: Examination of Sleep, Arousal, Mood, Cognitive, and Immune Outcomes","The goal of this project evaluate the efficacy of NiteCAPP in improving insomnia in a rural dementia caregiver sample (n of 100 caregiver and PWD dyads). We will measure both the short term (post-treatment) and long term (6 and 12 months) effects of the intervention on CG sleep, arousal, inflammation, health, mood, burden and cognitive function, and PWD sleep.","{'id': 206503744, 'name': 'NiteCAPP CARES', 'description': 'Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on sleep education, sleep hygiene, and stimulus control. Session 2 focuses on sleep compression, relaxation, and problem solving. Session 3 focuses on coping and stress management and cognitive therapy. Session 4 focuses on a review of skills and plan for maintenance of behavior change.', 'other_names': ['Web CBT-I'], 'intervention_type': 'BEHAVIORAL'}; {'id': 206503745, 'name': 'NiteCAPP SHARES', 'description': 'Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on expanded sleep education and sleep hygiene. Session 2 focuses insomnia education and sleep hygiene support. Session 3 focuses on targeted sleep education and sleep in dementia. Session 4 focuses on a review of skills and plan for maintenance of behavior change. Boosters review skills, encourage practice, and troubleshoot issues.', 'other_names': ['Web Sleep Hygiene and Related Education (Web-SHARE)'], 'intervention_type': 'BEHAVIORAL'}",NA,18 years,Dementia; Insomnia,"Age >= 18 years (caregiver) | Insomnia diagnosis (caregiver) | Insomnia duration >= 6 months (caregiver) | Adequate opportunity and circumstances for sleep (caregiver) | Insomnia symptoms: difficulty falling asleep, staying asleep, or early morning awakening (>=1) (caregiver) | Daytime dysfunction due to insomnia (caregiver) | Baseline sleep diary: sleep onset latency or wake after sleep onset > 30 minutes on >= 3 nights (caregiver) | Probable/possible Alzheimer's disease (person with dementia) | Nighttime Behavior Inventory: >=1 problem on >= 3 nights/week (person with dementia) | Sleep Apnea questionnaire score < 32 (person with dementia)","Cognitive impairment: Telephone Interview for Cognitive Status (TICS) < 25 (caregiver) | Sleep disorder other than insomnia, including sleep apnea (AHI > 15) (caregiver) | Bipolar disorder (caregiver) | Seizure disorder (caregiver) | Major psychopathology except depression or anxiety (e.g., suicidal, psychotic) (caregiver) | Severe untreated psychiatric comorbidity (caregiver) | Use of psychotropic or other medications that alter sleep (e.g., beta-blockers) (caregiver) | Non-pharmacological treatment for sleep or mood outside the trial (caregiver)",No prescribed or over-the-counter sleep medications for >= 1 month or stable dose for >= 6 months (caregiver); No sleep medications for >= 1 month or stable dose for >= 6 months (person with dementia),ALL,D,"Age/sex and dementia status align, and no conflicting prior therapies are noted, but the trial requires the person with dementia to have probable/possible Alzheimer’s disease and to be part of a caregiver-insomnia dyad. The patient’s amyloid-negative profile suggests non-AD and there is no evidence of the required caregiver/insomnia criteria, making this a likely subtype/setting mismatch rather than a definitive exclusion.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,D,"No hard exclusion applies: disease includes dementia, age/sex OK, and required AD subtype/caregiver status are not definitively contradicted. However, there is a specific soft mismatch: trial requires probable/possible AD while patient is amyloid-negative (implied biomarker miss) and the setting targets caregiver–insomnia dyads, which the patient likely does not meet. This fits a D under the rubric.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04969315,0.9614679217338562,Castration-Resistant Prostate Cancer,"Phase I/II First-in-Human Study of TT-10 (PORT-6), an Adenosine 2A Receptor Antagonist, and PORT-7, an Adenosine 2B Receptor Antagonist, as Single Agents and in Combination in Participants With Advanced Selected Solid Tumors","The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of care. The main questions it aims to answer are: 1. To evaluate the safety and tolerability of TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) 2. To determine the maximum tolerated dose or the recommended phase 2 dose of TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) 3. To obtain a preliminary estimate...","{'id': 206088250, 'name': 'TT-10', 'description': 'TT-10 orally administered BID', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206088251, 'name': 'TT-4', 'description': 'TT-4 is orally administered QD', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,18 years,Castrate-Resistant Prostate Cancer; Colorectal Cancer; Endometrial Cancer; Head and Neck Squamous Cell Carcinoma; Non-Small Cell Lung Cancer; Ovarian Cancer; Renal Cell Carcinoma,"Histologically or cytologically confirmed advanced solid tumors per cohort definitions | RCC: locally advanced or metastatic with >=2 prior systemic regimens including VEGF-targeted therapy and checkpoint inhibitor therapy | CRPC: metastatic disease with prior second-generation hormonal agent and a taxane-based chemotherapy | SCCHN: advanced/metastatic, incurable by surgery or radiotherapy, progressed during/after platinum-based chemotherapy and/or checkpoint inhibitor therapy | NSCLC: metastatic, intolerant or resistant to standard therapy or no standard therapy available | CRC: metastatic, intolerant or resistant to standard therapy or no standard therapy available | Endometrial Cancer: metastatic, intolerant or resistant to standard therapy or no standard therapy available | Ovarian Cancer: metastatic, intolerant or resistant to standard therapy or no standard therapy available | ECOG 0–1 | Measurable disease per RECIST 1.1; CRPC may enroll with non-measurable disease if screening PSA >= 2.0 ng/mL with sponsor approval | Adequate hematologic, hepatic, and renal function | Consent to baseline biopsy or provision of recent archival tissue as specified | Able to swallow capsules","Major surgery within 4 weeks prior to screening | Active CNS metastases; treated/stable off corticosteroids allowed; leptomeningeal metastases excluded | Prior radiotherapy within 2 weeks of start; 1-week washout permitted for palliative radiotherapy (<= 2 weeks) to non-CNS disease | Prior anti-cancer therapy within 4 weeks (2 weeks for short-acting TKIs); unresolved treatment-related toxicities > Grade 1 | HIV infection | HBsAg positive unless on antiviral therapy >= 4 weeks with undetectable HBV viral load; must remain on therapy per guidelines | History of HCV infection unless curatively treated with undetectable viral load at screening | Requires immunosuppressive therapy including systemic steroids >= 10 mg prednisone equivalent daily or other immunosuppressants/biologics | Requires strong inhibitors or inducers of CYP3A4, CYP2C9, or CYP2C19 | Requires drugs that modify gastric pH (PPIs or H2 blockers); antacids allowed with dose separation | Ongoing systemic bacterial, fungal, or viral infection | Live vaccine within 6 weeks of first dose (mRNA COVID-19 vaccines permitted) | Baseline QTcF > 470 ms (average of triplicate) | Prior surgery or gastrointestinal dysfunction that may affect drug absorption (e.g., gastric bypass, gastrectomy) | Pregnant or breastfeeding | Concurrent active malignancy other than non-melanoma skin cancer, carcinoma in situ of the cervix, or prostate intraepithelial neoplasia | Past medical history of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonitis requiring steroids; or clinically active interstitial lung disease | History of peptic ulcer or gastrointestinal bleed within 6 months | History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring treatment within 6 months | Unstable or severe uncontrolled medical condition that increases study risk",RCC: prior >= 2 systemic regimens including VEGF-targeted therapy and checkpoint inhibitor therapy; CRPC: prior second-generation hormonal therapy and taxane-based chemotherapy; SCCHN: prior platinum-based chemotherapy and/or checkpoint inhibitor with progression; NSCLC/CRC/Endometrial/Ovarian Cancer: intolerant or resistant to standard therapy or no standard therapy available; Washout from prior anti-cancer therapy >= 4 weeks (>= 2 weeks for short-acting TKIs) before start; Washout from radiotherapy >= 2 weeks (>= 1 week for short palliative courses <= 2 weeks),ALL,D,"Disease and stage match (metastatic CRPC; age and sex eligible), but the CRPC cohort requires prior taxane-based chemotherapy in addition to second-generation hormonal therapy, and the patient’s history lists abiraterone/enzalutamide without a taxane, creating a likely line-of-therapy mismatch.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,D,"No hard exclusions apply. Disease and stage match, but the CRPC cohort requires prior taxane-based chemotherapy in addition to second-generation hormonal therapy, which the patient lacks—this is a clear soft mismatch on the Line/prior anchor, yielding D per rubric.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05098652,1.0,Dementia,Coaching Dementia Caregivers to Master Care-Resistant Behavior and Improve Coping Strategies,"266 family caregivers will be randomly assigned to either immediate intervention or delayed intervention groups. All caregivers will complete baseline surveys and 3 weeks of daily diaries. The immediate intervention group will receive 12 weeks of CuRB-IT. They will complete 3 rounds of 3-week daily diaries followed by an intermittent survey at 12 week intervals for the next 33 weeks. The delayed intervention group will receive 12 weeks of attention, complete 1 round of 3-week daily diaries fo...","{'id': 206065737, 'name': 'CuRB-IT', 'description': '9 1-hour coaching sessions delivered over a videoconferencing platform (Zoom); 6 delivered weekly, 3 delivered biweekly', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}",NA,18 years to 95 years,Dementia,"Age >= 18 years | Provides unpaid caregiving | Care recipient is spouse/partner, sibling, parent, or grandparent (including in-law) aged >= 60 years | Lives with or shares cooking facilities with the care recipient | Care recipient has mild cognitive impairment or dementia per Quick Dementia Rating System | Provides help with >= 2 instrumental activities of daily living or >= 1 activity of daily living | Care recipient is resistant to assistance with at least one instrumental or activity of daily living",Unable to speak/read English | No reliable access to a smartphone or internet,(none),ALL,D,"Disease area aligns (dementia), but the trial enrolls unpaid caregivers of persons with dementia. The patient is the care recipient, not a caregiver, creating a clear setting/inclusion mismatch.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),INCORRECT,F,"The trial explicitly requires the participant to be an unpaid caregiver; the patient is the care recipient. This is a required setting/role the patient definitively lacks, which per HARD EXCLUSIONS (“Required biomarker/subtype/stage/setting mismatch”) should trigger an F. The grader correctly identified the mismatch but misclassified it as a soft mismatch (D) instead of a hard exclusion.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT05226507,0.8482123017311096,Recurrent Clear Cell Ovarian Carcinoma,A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer,The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.,"{'id': 206418506, 'name': 'NXP800', 'description': 'NXP800 is an anti-neoplastic, oral small molecule.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,18 years,Solid Tumor; Ovarian Clear Cell Carcinoma; Ovarian Endometrioid Carcinoma,"Age >= 18 years | Life expectancy >= 12 weeks | Histologically or cytologically confirmed advanced/metastatic/progressive solid tumor with no effective therapy available or appropriate (Part A) | Measurable disease per RECIST 1.1 | ECOG performance status <=2 (Part A) | ARID1A-mutated clear cell ovarian carcinoma (>=50% clear cell, no serous differentiation) or endometrioid ovarian carcinoma (Part B) | Disease progression within 6 months after completion of platinum-based therapy (Part B) | If BRCA mutation present, prior treatment with a PARP inhibitor required (Part B) | 1 to 3 prior systemic lines of therapy, including at least one line containing bevacizumab (Part B) | ECOG performance status 0–1 (Part B)","Radiotherapy, endocrine therapy, chemotherapy, or investigational agent within 28 days (42 days for nitrosoureas or mitomycin-C) before first dose | Ongoing toxicities from prior therapy > Grade 2 (except alopecia in Part B) | Active/progressive brain metastases; treated brain metastases must be stable for >= 28 days (Part A) or >= 12 weeks off corticosteroids (Part B) | Pregnancy or lactation","Washout >= 28 days for radiotherapy, endocrine therapy, chemotherapy, or investigational agents (>= 42 days for nitrosoureas or mitomycin-C) before first dose; May continue bisphosphonates for bone metastases; May continue GnRH agonists for prostate cancer; Progression within 6 months after completion of platinum-based therapy required (Part B); At least 1 and no more than 3 prior systemic lines required (Part B); Prior bevacizumab-containing line required (Part B); If BRCA mutation, prior PARP inhibitor required (Part B)",ALL,D,"Disease and advanced/recurrent setting match, but the ovarian expansion cohort (Part B) requires prior PARP inhibitor use for BRCA-mutated patients (not given here) and ARID1A mutation (status unknown). The solid-tumor dose-escalation (Part A) requires no effective therapy available, yet given BRCA1 positivity and no prior PARP, a standard PARP therapy is available, making eligibility likely mismatched.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,D,"No hard exclusions. Disease matches and setting is advanced/recurrent. However, Part B requires prior PARP use for BRCA-mutated patients (patient lacks this), creating a clear line/prior-exposure mismatch; ARID1A requirement is unknown (not an F). Part A’s ‘no effective therapy available’ likely not met given BRCA1 with available PARP therapy. Thus a specific soft mismatch → D.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT05281471,0.8482123017311096,Recurrent Clear Cell Ovarian Carcinoma,"A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase I...","{'id': 206513728, 'name': 'olvimulogene nanivacirepvec', 'description': 'Olvi-Vec is an engineered oncolytic vaccinia virus', 'other_names': ['GL-ONC1 and GLV-1h68'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206513729, 'name': 'Platinum chemotherapy: carboplatin (preferred) or cisplatin', 'description': 'Administered according to local practice', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206513730, 'name': ""Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin"", 'description': 'Administered according to local practice', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206513731, 'name': 'Bevacizumab (or biosimilar)', 'description': 'Administered according to local practice', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,18 years,High-Grade Serous Ovarian Cancer; Endometrioid Ovarian Cancer; Ovarian Clear Cell Carcinoma; Fallopian Tube Cancer; Primary Peritoneal Cancer,"Histologically confirmed non-resectable ovarian, fallopian tube, or primary peritoneal cancer | High-grade serous (including MMMT with high-grade epithelial carcinoma, FIGO grades 2–3), endometrioid, or clear-cell ovarian cancer | ECOG performance status 0–1 | Life expectancy >= 6 months | Received >= 3 prior lines of systemic therapy | Platinum-refractory disease: platinum-free interval (PFI) < 1 month (including progression on platinum-based therapy) | Platinum-resistant disease: PFI 1–6 months | Received >= 2 doses of platinum in the most recent platinum-based line | Prior bevacizumab (or biosimilar) treatment | No contraindication to carboplatin, cisplatin, or bevacizumab (or biosimilar) | Radiographic disease progression after last prior line of therapy before randomization | At least 1 measurable target lesion per RECIST 1.1 on abdominal/pelvis imaging at screening | Evidence of disease in the peritoneal cavity by CT and/or PET or physical exam | Adequate renal, hepatic, bone marrow, coagulation, and immune function by lymphocyte count","Mucinous, low-grade serous, squamous cell, small cell neuroendocrine subtypes, MMMT without epithelial component on recent biopsy, or non-epithelial ovarian cancers (e.g., germ cell tumors, sex-cord tumors) | Bowel obstruction within 3 months prior to screening | Active urinary tract infection, pneumonia, or other systemic infections | Active gastrointestinal bleeding | Known current central nervous system metastasis | Inflammatory bowel disease | History of HIV infection | Active hepatitis B virus or hepatitis C virus within 4 weeks prior to study | History of thromboembolic event within the prior 3 months | Contraindications to intraperitoneal catheter placement (e.g., bowel obstruction with distended abdomen, rigid abdomen with bulky anterior wall carcinomatosis, abdominal wall hernia mesh precluding laparoscopic entry) | Clinically significant cardiac disease (NYHA Class III/IV) | Acute cerebrovascular accident or transient ischemic attack within previous 6 months | Oxygen saturation < 90% | Prior virus-based gene therapy or therapy with cytolytic virus of any type | Receiving concurrent antiviral agent | Active prior malignancy within 3 years except curable localized cancers (e.g., basal/squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of cervix or breast, other stage I/II local malignancies) | Chemotherapy, radiotherapy, or other anti-cancer biologic therapies within 4 weeks prior to planned treatment | Surgery within 4 weeks prior to first study treatment or insufficient recovery from surgical trauma/wound healing | Receiving immunosuppressive therapy or chronic steroids (except <= 20 mg/day prednisolone equivalent for acute medical management) | Symptomatic malignant ascites or pleural effusions requiring frequent paracentesis > once every 14 days | Known hypersensitivity to gentamicin",">= 3 prior lines of systemic therapy required; Prior bevacizumab required; Prior platinum-based therapy with >= 2 doses in the most recent line required; Washout: no chemotherapy, radiotherapy, or anti-cancer biologics within 4 weeks prior to planned treatment",FEMALE,D,"Disease, sex, and age match, but the trial requires platinum‑resistant/refractory disease and ≥3 prior systemic lines; the patient has only had one adjuvant platinum/bevacizumab regimen, and platinum-free interval status is unspecified, making eligibility unlikely.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,D,"No hard exclusions apply. Disease, sex, and age match. There is a clear soft mismatch on line-of-therapy: trial requires ≥3 prior systemic lines and platinum-resistant/refractory status, while the patient has only one adjuvant platinum/bevacizumab regimen and PFI is unknown. This fits a D per the rubric.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05284643,0.8363864421844482,Recurrent Glioblastoma,"Pilot Trial of Spectroscopic MRI-guided, Dose-Escalated Proton Radiation Therapy and Bevacizumab for Recurrent Glioblastoma",The purpose of this research is to find hidden cancer with an experimental magnetic resonance imaging (MRI) scan called spectroscopic magnetic resonance imaging (sMRI). That spectroscopic MRI scan will be used to increase the area of the brain receiving radiation and then the dose of radiation in attempt to kill more of the cancer. Proton radiotherapy and bevacizumab (Avastin) are used to minimize the possible side effects of this approach.,"{'id': 206024059, 'name': 'Intensity Modulated Proton Therapy (IMPT)', 'description': 'Participants will receive radiation therapy delivered via intensity modulated proton therapy (IMPT) simultaneous integrated boost technique over a period of 10 days, 5 days per week for approximately 2 weeks.', 'other_names': [], 'intervention_type': 'RADIATION'}; {'id': 206024060, 'name': 'Bevacizumab', 'description': 'Bevacizumab will be administered intravenously (IV), beginning at a dose of 10 mg/kg every 2-3 weeks until disease progression.', 'other_names': ['Avastin'], 'intervention_type': 'DRUG'}",NA,18 years,Glioblastoma (recurrent),"Recurrent glioblastoma or variants (e.g., gliosarcoma) confirmed by MRI outside initial high-dose RT field, biopsy/resection, or advanced imaging (PET, perfusion MRI, MR spectroscopy). | Pathologic diagnosis of glioblastoma (or gliosarcoma) by 2021 WHO criteria (initial and/or re-resection; reclassification allowed). | Total enhancing recurrence on T1 post-contrast MRI with maximum linear measurement <= 6 cm. | Prior brain radiation therapy for glioma with conventional fractionation (1.8–2 Gy/fraction), total dose <= 63 Gy. | Elapsed time from prior brain radiation: >= 4 months for marginal/out-of-field failures; >= 6 months for in-field failures. | Washout from prior agents before study treatment: >= 28 days or 5 half-lives (whichever shorter) for experimental agents; >= 28 days for cytotoxics (>= 14 days for vincristine; >= 21 days for procarbazine and temozolomide). | Age >= 18 years. | Able to undergo MRI scans. | Life expectancy > 12 weeks. | ECOG performance status 0-2. | ANC >= 1500/µL. | Platelets >= 75000/µL. | Hemoglobin >= 9.0 g/dL (transfusion allowed). | Total bilirubin <= 2 mg/dL. | AST (SGOT) <= 2.5 x ULN. | Serum creatinine <= 1.8 mg/dL. | Urine protein/creatinine ratio < 1.0 or urine dipstick protein <= 2+ (if >2+, require UPC < 1.0 or 24-hour urine protein <= 1 g). | If on full-dose anticoagulation: no active high-risk bleeding condition and stable in-range INR (typically 2–3) or stable LMWH.","Brain malignancies other than glioblastoma or variants by 2021 WHO (benign lesions like meningioma allowed). | Glioma without prior standard first-line therapies including an initial course of radiation therapy. | History of a second course of brain radiation therapy. | Multifocal disease across multiple brain lobes (multiple nodules in same region allowed if total linear diameter <= 6 cm). | Prior treatment with bevacizumab. | Concurrent chemotherapy with study therapy other than bevacizumab. | Recurrent glioblastoma located in regions with known sMRI artifact: temporal lobe below floor of third ventricle, orbitofrontal cortex, prefrontal cortex, medial frontal gyrus, brainstem, or cerebellum. | Pregnant or breastfeeding. | Prior invasive malignancy (except non-melanoma skin cancer) unless disease-free >= 1 year (non-invasive tumors allowed). | Unstable angina or CHF requiring hospitalization within 6 months. | Transmural myocardial infarction within 6 months. | Stroke or TIA within 6 months. | Significant vascular disease or clinically significant peripheral vascular disease. | Acute bacterial or fungal infection requiring IV antibiotics at registration. | COPD exacerbation or other respiratory illness requiring hospitalization or precluding therapy at registration. | Hepatic insufficiency with clinical jaundice and/or coagulation defects. | AIDS (per CDC definition). | Unwilling/unable to use acceptable contraception if of childbearing potential and sexually active. | Allergic reaction to bevacizumab. | History of hypertensive crisis or hypertensive encephalopathy. | Non-healing wound, ulcer, or bone fracture within 90 days. | CTCAE v4 grade >= 3 hemorrhage within 30 days. | Major surgery, open biopsy, or significant traumatic injury within 28 days (except craniotomy). | Concurrent investigational agents.","Prior standard first-line therapy for glioma including a first course of brain radiation (conventional fractionation 1.8–2 Gy/fx, total dose <= 63 Gy) required.; Interval from prior brain radiation: >= 4 months (marginal/out-of-field failures) or >= 6 months (in-field failures) before study treatment.; Washout prior to study: >= 28 days or 5 half-lives from experimental agents; >= 28 days from cytotoxic agents (>= 14 days from vincristine; >= 21 days from procarbazine and temozolomide).",ALL,D,"Disease and setting match (recurrent glioblastoma; age 40; ECOG 1), but the trial requires ≥4–6 months since prior brain radiation before study treatment, and the patient recurred 3 months after completing adjuvant chemoradiation, making timing a likely mismatch.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),INCORRECT,A,"No hard exclusion is triggered. Disease and setting match; prior standard therapy aligns and no prior bevacizumab. The grader’s cited timing issue is inferred and misread: “3 months after completing adjuvant therapy” is not the interval from last radiation to study start. Time-from-RT requirement is unknown and should be neutral, not a soft mismatch. With ≥2 core anchors matching (stage/setting and line/prior), the correct grade is A.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT05300048,0.8482123017311096,Recurrent Clear Cell Ovarian Carcinoma,A Phase 1b Study of Serabelisib in Combination with an Insulin Suppressing Diet (Study ISD) and with or Without Nab-paclitaxel in Adult Subjects with Advanced Solid Tumors with PIK3CA Mutations with or Without PTEN Loss,This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side effects and enhancing anticancer activity.,"{'id': 205985282, 'name': 'Serabelisib', 'description': 'serabelisib administered orally', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205985283, 'name': 'Insulin Suppressing Diet', 'description': '3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 205985284, 'name': 'Nab paclitaxel', 'description': 'nab-paclitaxel administered intravenously weekly', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,18 years,Colorectal Cancer; Endometrial Cancer; Ovarian Clear Cell Carcinoma; Ovarian Endometrioid Carcinoma,"Age >= 18 years | Histologically or cytologically confirmed recurrent solid tumor (cohort-specific: any extracranial solid tumor; endometrial cancer; ovarian clear cell or ovarian endometrioid carcinoma; colorectal adenocarcinoma) | Tumor harbors an activating PIK3CA mutation (with or without PTEN loss) | At least one measurable lesion per RECIST 1.1 | Life expectancy >= 3 months | ECOG performance status 0–1 | Adequate bone marrow function: ANC threshold per cohort and platelets and hemoglobin as specified | Adequate hepatic function: AST and ALT <= 2.5 x ULN (<= 5 x ULN with liver metastases), total bilirubin <= 1.5 x ULN (<= 3 x ULN with Gilbert syndrome) | INR <= 1.5 x ULN or within therapeutic range if on anticoagulants | Albumin >= 3.0 mg/dL or >= lower limit of normal | Renal: serum creatinine <= 2 x ULN | Ability to take oral medication and adhere to the insulin suppressing diet | Cohort 1a: Failed, intolerant of, ineligible for, or refused <= 3 prior lines of therapy for advanced/metastatic disease or refused standard of care | Cohort 2 (colorectal cancer): Failed no more than two prior lines of therapy for metastatic CRC | Cohort 1b and Cohort 3 (endometrial cancer): No more than three prior chemotherapeutic regimens; prior hormonal therapy does not count | Cohort 1b and Cohort 4 (ovarian clear cell or endometrioid): No more than three prior chemotherapeutic regimens; prior hormonal therapy does not count | Women of childbearing potential: negative pregnancy tests at screening and baseline and use of approved contraception during treatment and for the specified post-treatment period | Men must be surgically sterile or use approved contraception during treatment and for 90 days post last dose","Primary malignant brain tumor | Prior treatment with serabelisib, alpelisib, or other PI3K inhibitors | Leptomeningeal disease or symptomatic/untreated brain metastases | Another malignancy within 2 years requiring treatment (with specified exceptions) | Therapeutic radiation or chemotherapy within 21 days prior to first dose or unresolved clinically significant toxicities > Grade 1 | Nitrosoureas or mitomycin C within 6 weeks prior to first dose | Monoclonal antibody therapy within 1 half-life or < 4 weeks prior to first dose | Chronic systemic glucocorticoids > 5 mg prednisone equivalent daily (except replacement for adrenal insufficiency) | Diabetes mellitus requiring insulin or insulin secretagogues | Poorly controlled diabetes: HbA1c > 7.5% or fasting blood sugar > 160 mg/dL | Clinically significant impaired cardiac function or cardiac disease | QTcF > 470 msec at screening | Myocardial infarction, cardiac stent placement, or unstable angina within 6 months | Clinically significant peripheral vascular disease | Malabsorption syndromes | Other clinically significant comorbidities per investigator | Pregnant or breastfeeding | Use of strong CYP3A4 inducers or inhibitors within 7 days prior to first serabelisib dose or requirement for concomitant CYP3A4 inducers/inhibitors | Untreated or poorly controlled gastroesophageal reflux disease | Use of H2 receptor antagonists within 12 hours prior to first serabelisib dose | Use of proton pump inhibitors within 7 days or 5 half-lives prior to first serabelisib dose or anticipated need during study | Use of neutralizing antacids within 4 hours prior to first serabelisib dose or anticipated frequent use during study | Poorly controlled HIV, HBV, or HCV infection | Known allergy to nab-paclitaxel, serabelisib, their excipients, or the insulin suppressing diet | Severe, uncontrolled gout | BMI < 18.5 kg/m2 or severe/refractory cachexia or anorexia limiting adherence to the diet | Inability to adequately chew, swallow, digest, or tolerate the study diet | History of severe nephrolithiasis requiring urologic intervention | Participation in a diet or weight loss plan within 10 days prior to first study drug | Severe constipation or history where exacerbation of constipation is inadvisable (e.g., small bowel obstruction) | History of anaphylaxis from food allergy or conditions requiring avoidance of particular foods (e.g., celiac disease) | Diagnosed eating disorder within the past 10 years | Unwilling to take a non-vegan or non-vegetarian diet | Peripheral neuropathy >= Grade 2","Failed, intolerant of, ineligible for, or refused standard-of-care therapy for advanced/metastatic disease (cohort-specific limits apply); Cohort 1a: <= 3 prior lines of therapy for advanced/metastatic disease; Cohort 2 (colorectal cancer): <= 2 prior lines of therapy for metastatic CRC; Cohort 1b and Cohort 3 (endometrial cancer): <= 3 prior chemotherapy regimens; prior hormonal therapy does not count; Cohort 1b and Cohort 4 (ovarian clear cell or endometrioid): <= 3 prior chemotherapy regimens; prior hormonal therapy does not count; Washout: >= 21 days from prior chemotherapy or radiotherapy before first study dose; Washout: >= 6 weeks from nitrosoureas or mitomycin C before first study dose; Washout: >= 1 half-life or >= 4 weeks (whichever is shorter) from monoclonal antibody therapy before first study dose",ALL,D,"Disease and recurrent setting match the ovarian clear cell cohort, and prior chemotherapy count appears within limits, but the trial requires an activating PIK3CA mutation (status not provided) and enrollment generally after failure/refusal/ineligibility of standard therapy for advanced disease, whereas the patient has only had adjuvant therapy. This creates a likely line-of-therapy mismatch despite otherwise relevant disease fit.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,D,"No hard exclusions. Disease and recurrent setting match. However, the trial generally requires failure/ineligibility/refusal of standard therapy for advanced/metastatic disease, while the patient has only received adjuvant therapy—this is a soft line-of-therapy mismatch, warranting D. PIK3CA mutation is required but status is unknown, which should not trigger F.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT05335941,0.8805802464485168,Metastatic Urothelial Carcinoma,A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma,"This is a Phase 2 open-label, single-arm trial for patients with MTAP-deficient advanced urothelial cancer who had received prior immunotherapy. This is a single site study at the University of Texas MD Anderson Cancer Center. This study will allow patients in second line of treatment for advanced urothelial ca or beyond. All patients must have been previously treated with immune checkpoint inhibitor (ICI) therapy as per current standard of care.","{'id': 206136741, 'name': 'Pemetrexed', 'description': 'Given by vein (IV)', 'other_names': ['LY23151', 'Alimta®', 'MTA', 'Multitargeted Antifolate', 'NSC-698037'], 'intervention_type': 'DRUG'}; {'id': 206136742, 'name': 'Zimberelimab', 'description': 'Given by vein (IV)', 'other_names': ['AB122'], 'intervention_type': 'DRUG'}; {'id': 206136743, 'name': 'Etrumadenant', 'description': 'Given by PO', 'other_names': ['AB928', 'Etruma'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Urothelial Carcinoma (metastatic),"Age >= 18 years | Histologic confirmation of MTAP-deficient metastatic urothelial carcinoma by CLIA-certified IHC or NGS showing MTAP copy number loss | Second-line therapy or beyond after prior PD-(L)1 immune checkpoint inhibitor | Measurable disease per RECIST v1.1 | ECOG performance status <= 2 | AST <= 2.5 x ULN (<= 5 x ULN with liver metastases) | ALT <= 2.5 x ULN (<= 5 x ULN with liver metastases) | Total bilirubin <= 1.5 x ULN (<= 3.0 mg/dL with Gilbert's syndrome or liver metastases) | ANC >= 1.5 x 10^9/L | Hemoglobin >= 9 g/dL (transfusion allowed) | Platelets >= 100 x 10^9/L | Creatinine clearance >= 45 mL/min or normal serum creatinine | Negative pregnancy test for women of childbearing potential | Use of effective contraception during treatment and for specified durations after last doses | Ability to interrupt NSAIDs around pemetrexed dosing and to take folic acid, vitamin B12, and dexamethasone | Mild or well-controlled autoimmune conditions permitted as specified | Prior anti-PD-1/PD-L1 therapy is mandatory","QTc >= 480 msec (Fridericia) | Concomitant oral BCRP substrates with a narrow therapeutic window within 4 weeks or 5 half-lives | Concomitant oral P-gp substrates with a narrow therapeutic window within 4 weeks or 5 half-lives | Concomitant strong CYP3A4 inducers within 4 weeks or 5 half-lives | Concomitant strong CYP3A4 inhibitors within 4 weeks or 5 half-lives | Gastrointestinal conditions precluding oral medications (e.g., malabsorption, severe nausea/vomiting, dysphagia) | Prior treatment with an agent targeting the adenosine pathway | History of severe allergic reactions to chimeric or humanized antibodies or fusion proteins | Primary CNS malignancies or active CNS metastases; previously treated brain metastases allowed only if stable >= 4 weeks and no ongoing steroids | Another malignancy within 2 years, except non-melanoma skin cancer, controlled localized prostate cancer, controlled papillary thyroid carcinoma, or in situ carcinoma | Pregnant or breastfeeding | Uncontrolled large third-space fluid (e.g., pleural or peritoneal effusion) not amenable to drainage | Active inflammatory bowel disease | Active autoimmune disorders such as rheumatoid arthritis, systemic sclerosis, systemic lupus erythematosus, or autoimmune vasculitis | Systemic corticosteroids > 10 mg prednisone equivalents daily or other immunosuppressive medications within 14 days (except allowed uses) | History of primary immunodeficiency | Prior organ transplantation, including allogeneic stem-cell transplant | Live vaccines within 4 weeks prior to first dose and while on trial (COVID-19 vaccines allowed) | Active hepatitis A, B, or C | Known HIV infection or AIDS | Uncontrolled intercurrent illness (e.g., active infection, current pneumonitis, symptomatic congestive heart failure, unstable angina, symptomatic arrhythmia, interstitial lung disease) | Uncontrolled psychiatric illness or social situations limiting compliance | Known allergy or hypersensitivity to study drug formulations | Major surgery within 28 days prior to first dose or not fully recovered | Current dialysis | Prior checkpoint inhibitor therapy discontinued due to grade 4 toxicity | Prior antifolate therapy in neoadjuvant or metastatic setting",Prior PD-1/PD-L1 therapy required; Eligible in second line or beyond after immune checkpoint inhibitor; Prior intravesical therapy allowed and does not count as a prior line,ALL,D,"Disease and setting match and the patient is post–PD-1, but the trial requires MTAP-deficient tumors (status not provided) and a creatinine clearance ≥45 mL/min while the patient’s eGFR is 35 mL/min, making eligibility unlikely. No explicit exclusion is triggered, but renal function and biomarker requirements pose soft mismatches.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),INCORRECT,A,"No hard exclusions per rubric. Disease, metastatic setting, and line/prior-exposure (post–PD-1) all match; required biomarker (MTAP) is unknown, which should be treated as neutral, not a soft mismatch. Renal function does not fall under the core anchors and is not listed as a hard exclusion. With ≥2 core anchors matching and no core-anchor soft mismatch, the correct grade is A.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05377840,0.6691051721572876,Fistulizing Crohn's Disease,Effect Cognitive Behavioral Therapy (CBT) in the Treatment of Anxiety and Depression in Patients With Inflammatory Bowel Disease,"This is a prospective, single center, randomized treatment study to assess if anxiety and depression in participants with IBD can be improved with CBT compared to those treated with SKY.","{'id': 205958465, 'name': 'Psychologist-administered Cognitive Behavioral Therapy', 'description': 'CBT is a combined psycho-social intervention that aims to improve overall mental health focusing on developing coping strategies. For psychologist-administered CBT: Participants will have individual weekly sessions (virtually) lasting 60 minutes each over an 8-week period with 1 follow-up maintenance session at week 12.', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}; {'id': 205958466, 'name': 'Self-Administered Cognitive Behavioral Therapy', 'description': 'CBT is a combined psycho-social intervention that aims to improve overall mental health focusing on developing coping strategies. For self-administered CBT: Participants will be given a book written for patients on CBT for IBD with instructions on how to self-administer CBT.', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}",NA,18 years,Crohn Disease; Ulcerative Colitis,"Verified inflammatory bowel disease (Crohn disease or ulcerative colitis) | Stable IBD treatment regimen with no evidence of active intestinal inflammation by normal C-reactive protein and/or fecal calprotectin, imaging, or endoscopy | Meets criteria for anxiety and/or depression based on screening questionnaires | On stable doses of anxiety and/or depression medications for >=12 weeks and willing to maintain the same dose during the study","Evidence of active intestinal inflammation by elevated C-reactive protein and/or fecal calprotectin, imaging, or endoscopy | Non-English speaking | Suicidal ideation or severe mental illness requiring urgent psychiatric care",Stable IBD treatment regimen required; Stable doses of anxiety and/or depression medications >=12 weeks permitted and must remain unchanged during study,ALL,D,"Disease matches (Crohn’s), but the trial requires quiescent IBD with no active intestinal inflammation, while the patient has moderate-to-severe fistulizing disease with an active draining perianal fistula and recent abscess—suggesting a likely mismatch though not an explicit exclusion without labs/imaging. Additionally, the required anxiety/depression criterion is unknown.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),INCORRECT,F,"Disease matches, but the trial explicitly requires no active intestinal inflammation and excludes patients with evidence of active inflammation. The patient definitively has active, moderate-to-severe fistulizing Crohn’s (draining fistula, recent abscess), satisfying a hard exclusion (required setting mismatch and explicit exclusion). Therefore the correct grade is F, not D.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05644262,1.0,Dementia,Life's End Benefits of cannaBidiol and tetrahYdrocannabinol (LiBBY),This is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) compared to placebo over 12 weeks. This study is designed to test the hypothesis that treatment with an oral combination of THC/CBD will reduce agitation hospice care-eligible patients with agitation and dementia as measured by the Cohen Mansfield Agitation Inventory (CMAI) when compared to placebo at 2 weeks. This study will enroll approxim...,"{'id': 206280766, 'name': 'T2:C100', 'description': 'The active study intervention, T2:C100, is an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in a digestible oil. T2:C100 is a full spectrum oral solution with five non-reactive ingredients: delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), a pharmaceutical grade medium chain triglyceride (MCT) oil, and two flavoring agents (lemon and peppermint).\n\nDuring the double-blind treatment period, participants will receive 1mL study drug (T2:C100) twice daily for Baseline - Day 7 (approximately 1 week), and then will increase to 2mL study drug twice for the remainder of the double-blind treatment period (Day 7 - Week 12 (approximately 11 weeks)).\n\nParticipants who enter the Open Label Extension will receive 1mL study drug (T2:C100) twice daily for Week 12 - Week 13 (approximately 1 week), and will then increase to 2mL study drug twice daily for the remainder of the Open Label Extension (Week 13 - Week 26 (approximately 23 weeks)).', 'other_names': ['TRC/CBD oral combination'], 'intervention_type': 'DRUG'}; {'id': 206280767, 'name': 'Placebo', 'description': 'Matching placebo in a digestible oil. The placebo contains only three non-reactive ingredients: medium chain triglyceride (MCT) oil and two flavoring agents (lemon and peppermint).\n\nDuring the double-blind treatment period, participants will receive 1mL placebo twice daily for Baseline - Day 7 (approximately 1 week), and then will increase to 2mL placebo twice for the remainder of the double-blind treatment period (Day 7 - Week 12 (approximately 11 weeks)).', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,40 years,Dementia,Age >= 40 years | DSM-5 Major Neurocognitive Disorder | Clinically significant agitation with NPI-agitation subscale >= 4 at screening | Meets at least one: enrolled in hospice care; FAST stage 6d; ADEPT (Mitchell Index) score >= 12 | Able to take or be administered liquid medication,"Cannabinoid or marijuana use within 3 weeks prior to baseline | Hypersensitivity to cannabinoids or formulation components | Treatment with another investigational drug or intervention within 30 days or 5 half-lives, whichever is longer | Any condition that makes the participant unsuitable for inclusion in the opinion of the investigator",No cannabinoid use during the first 12 weeks of the study; No cannabinoid or marijuana use within 3 weeks prior to baseline; No investigational drugs or interventions within 30 days or 5 half-lives before baseline,ALL,D,"The trial targets advanced/end-of-life dementia with clinically significant agitation and requires hospice enrollment, FAST stage 6d, or ADEPT ≥12, while the patient is moderate-stage (MMSE 19) with no documentation of agitation or those criteria, indicating a stage/setting mismatch. No hard exclusions are triggered (age/sex/disease match and no prohibited prior cannabinoid use).",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,D,"No hard exclusions apply (disease matches; age/sex OK; cannabinoid use unknown). There is a clear soft mismatch on stage/setting: trial targets advanced/end-of-life dementia with required agitation and end-stage criteria (hospice/FAST 6d/ADEPT≥12), while the patient is described as moderate-stage with no evidence of those criteria. That warrants grade D per rubric.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05748613,1.0,Dementia,Treatment of Stress and Anxiety in Mild Cognitive Impairment/Mild Alzheimer's Disease and Related Dementias - RCT,The goal of this clinical trial is to test the effectiveness of a computerized anxiety sensitivity treatment (CAST) compared to a health education control (HEC) in older adults with mild cognitive impairment (MCI) or mild Alzheimer's Disease and related dementias (ADRD) and their care partners. The main questions it aims to answer are: 1. Efficacy of CAST in reducing anxiety and related symptoms among those with MCI/mild ADRD 2. Efficacy of CAST in reducing care partner burden among care part...,"{'id': 205994659, 'name': 'Computerized Anxiety Sensitivity Treatment', 'description': 'Brief computerized treatment for anxiety sensitivity', 'other_names': ['CAST'], 'intervention_type': 'BEHAVIORAL'}; {'id': 205994660, 'name': 'Health Education Control', 'description': 'Brief computerized presentation on healthy behaviors', 'other_names': ['HEC, Physical Health Education Training ,PHET'], 'intervention_type': 'BEHAVIORAL'}",NA,60 years,Mild Cognitive Impairment; Alzheimer Disease; Dementia; Anxiety,Patient age >=60 years | Care partner age >=18 years | Has a care partner who will participate | PROMIS-Anxiety short form score >=20 (patient) OR | SSASI score >=5 (patient) OR | NIH Toolbox Perceived Stress Scale score >=31 (patient) | MoCA score 17–26 (patient) OR | Memory Complaint Scale score >=3 (patient) OR | Care partner Quick Dementia Rating Scale score 2–12.5,"Vision or hearing impairment preventing participation in computerized presentations (patient or care partner) | Medical conditions precluding participation (patient or care partner) | Severe mental illness (e.g., schizophrenia, unmedicated bipolar disorder) (patient or care partner)",(none),ALL,D,"Although dementia and age match, the trial targets MCI/mild AD/related dementias (e.g., MoCA 17–26 or QDRS 2–12.5), while the patient has moderate-stage dementia (MMSE 19), indicating a likely severity mismatch. Required anxiety/stress thresholds and a participating care partner are also unknown.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,D,"No hard exclusions apply (disease includes dementia; age ≥60; gender ALL). The key CORE ANCHOR is stage/setting: trial focuses on MCI/mild dementia ranges, while patient is moderate dementia (MMSE 19), a soft stage mismatch → D. Other requirements (anxiety/stress thresholds, care partner) are unknown and thus neutral. The grader’s reasoning and grade align with the rubric.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05846984,1.0,Dementia,Learning Skills Together: A Randomized Controlled Trial of a Complex Care Skills Intervention to Improve AD/ADRD Caregiver Self-Efficacy,"Learning Skills Together (LST) is a 6-week psychoeducational intervention focused on complex care (nursing) tasks completed by family caregivers to persons living with Alzheimer's Disease and related dementias. This study aims to test the efficacy of LST at reducing caregiver depression and negative appraisal of behavioral symptoms of dementia by building caregiver self-efficacy. To do this, eligible participants will be randomized into an intervention group (LST) or a control group condition...","{'id': 205962222, 'name': 'Learning Skills Together Intervention', 'description': ""Learning Skills Together is a 6-week psychoeducational intervention developed to improve caregivers' confidence when completing complex care tasks (e.g., using a gait belt). Participants are asked to attend six 1.5-hour Zoom-delivered group discussion sessions once per week, which cover topics such as how to communicate with someone who is living with dementia, medication management, and home safety. Participants are also provided with a workbook that accompanies each lesson, and includes short readings, videos, additional resources, as well as weekly practice and reflection exercises."", 'other_names': [], 'intervention_type': 'BEHAVIORAL'}; {'id': 205962223, 'name': 'Caregiver Healthy Living Intervention', 'description': 'Participants in the Caregiver Healthy Living Intervention will participate in a 6-week educational intervention to help improve caregiver health behaviors (e.g., getting enough sleep). Participants are asked to attend six 1.5-hour Zoom-delivered group discussion sessions once per week, which cover topics such as how to eat a healthy diet, getting enough physical activity, and taking care of mental health. Participants are also provided a workbook that includes short readings and additional resources.', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}",NA,18 years,Alzheimer Disease; Dementia,Age >= 18 years | Family member or family of choice to an individual with Alzheimer’s disease or related dementia diagnosed by a physician | Provides assistance with at least two instrumental activities of daily living or one activity of daily living | Care recipient Global Deterioration Scale (GDS) rating 4 to 6,Unable to read and speak English | Prior participation in Learning Skills Together | Plans to place the care recipient in a skilled nursing facility within the next 9 months | Diagnosed with depression and/or started or significantly altered depression treatment in the previous 3 months,(none),ALL,D,"This trial enrolls family caregivers of individuals with AD/ADRD, whereas the patient is the person with dementia, not a caregiver. Although the disease area is relevant, the target population is a stage/setting mismatch, making the patient likely ineligible.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,D,"No hard exclusions apply (disease listed; age/sex fit; no explicit exclusion). However, the trial enrolls caregivers, not patients with dementia, creating a clear stage/setting/population mismatch on a core anchor. That warrants a D per rubric. The grader’s reasoning aligns with this.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05956158,0.6691051721572876,Fistulizing Crohn's Disease,RISE: A Remote Study of Insomnia Treatment in Crohn's Disease,"The purpose of this study is to assess whether the investigators can treat insomnia in people with Crohn's disease, and if insomnia treatment can make other things better, like pain or inflammation.","{'id': 205509002, 'name': 'Behavioral Treatment', 'description': 'This treatment is designed to help participants make changes to behavior patterns and thoughts that contribute to insomnia.', 'other_names': ['Cognitive Behavioral Therapy for Insomnia', 'CBT-I'], 'intervention_type': 'BEHAVIORAL'}; {'id': 205509003, 'name': 'Sleep Education Treatment', 'description': ""This treatment is designed to help participants understand the relationships among sleep, pain, and Crohn's disease and to make changes to insomnia-related behaviors."", 'other_names': [], 'intervention_type': 'BEHAVIORAL'}",NA,18 years,Crohn Disease; Insomnia,Mild to moderate Crohn disease | Insomnia Severity Index score >= 8 | Sleep onset latency or wake after sleep onset >= 30 minutes | Stable sleep and Crohn disease medications for >= 3 months,"PHQ-9 depression score >= 15 | GAD-7 anxiety score >= 15 | Unstable major psychiatric condition (e.g., bipolar disorder, psychotic disorder) | Current alcohol or substance abuse | Current opioid use for pain control | Current systemic corticosteroid use | Pregnancy or nursing | Ileostomy or colostomy | Seizure disorder | Sleep apnea or positive WatchPAT screen | Restless legs syndrome or positive Cambridge-Hopkins RLSq screen | Night shift or rotating shift work | Frequent travel outside of time zone",Stable sleep and Crohn disease medications for >= 3 months,ALL,D,"Disease category matches, but the trial requires mild-to-moderate Crohn’s disease while the patient has moderate-to-severe fistulizing disease, creating a stage/severity mismatch. Insomnia criteria and medication stability are unknown, but the severity requirement likely makes the patient ineligible.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),INCORRECT,F,"The trial requires mild-to-moderate Crohn’s disease; the patient has severe (CDAI 350) fistulizing Crohn’s, which is a required stage/severity mismatch and a hard exclusion under the rubric. Insomnia and medication stability are unknown and do not affect the hard exclusion. Correct grade is F, not D.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT06193486,1.0,Castration-Resistant Prostate Cancer,A Phase I Clinical Trial of an Infusion of Autologous Gamma Delta T Cells Genetically Engineered With a Chimeric Receptor to Target the Prostate Stem Cell Antigen in Patients With Metastatic Castration Resistant Prostate Cancer,This is a phase 1 single center clinical trial for patients with end stage Metastatic Castration Resistant Prostate Cancer who have progressed through standard of care treatment options and are on zoledronate for bone metastases. This clinical trial includes a dose-escalation phase and dose-expansion phase to assess the safety and preliminary efficacy of treatment with autologous T cells genetically modified to express Prostate stem cell antigen.,"{'id': 206149371, 'name': 'MSGV1-PSCA-8T28Z', 'description': 'Autologous Gamma Delta T Cells Genetically Engineered with a Chimeric Receptor to Target the Prostate Stem Cell Antigen.', 'other_names': [], 'intervention_type': 'BIOLOGICAL'}; {'id': 206149372, 'name': 'Fludarabine', 'description': 'Fludarabine is an antimetabolite given prior to lymphodepletion.', 'other_names': ['Fludara'], 'intervention_type': 'DRUG'}; {'id': 206149373, 'name': 'Cyclophosphamide', 'description': 'Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,18 years,Castration-Resistant Prostate Cancer,"Men with metastatic castration-resistant prostate cancer to bone with imaging progression per PCWG3 | Prior therapy including >=1 line of chemotherapy and >=1 androgen receptor–targeted therapy (abiraterone, enzalutamide, apalutamide, or darolutamide) | Bone-targeted agent requirements: zoledronic acid dosing as specified; if on denosumab, switch to zoledronic acid and receive at least 1 dose prior to lymphodepletion; if not on either, receive at least 2 doses of zoledronic acid prior to lymphodepletion | Age >= 18 years | ECOG performance status <=2 or Karnofsky >=70% | Adequate organ and marrow function | Life expectancy >= 6 months","Active hepatitis B infection, history of hepatitis C, or HIV infection | Dental issues such as osteonecrosis of the jaw precluding zoledronic acid use | NYHA class 3 or 4 heart disease or symptomatic congestive heart failure | Myocardial infarction < 6 months prior to enrollment | History of clinically significant ventricular arrhythmia or unexplained non-vasovagal syncope | Severe non-ischemic cardiomyopathy with ejection fraction < 20% | Baseline ECG/ECHO findings requiring intervention before anticancer therapy | Active autoimmune disease (except stable autoimmune thyroid disease) | Known or suspected leptomeningeal disease | Brain stem, midbrain, pons, or medulla metastases | Untreated brain metastases; previously irradiated brain lesions eligible only if >4 weeks from radiation and >3 weeks off corticosteroids | Prior clinically significant seizure disorder | Concurrent active malignancy requiring therapy other than observation | Serious uncontrolled medical illness within 28 days of first study treatment | Active uncontrolled infection (except uncomplicated UTI) within 28 days of first study treatment | Prior history of pancreatitis | Any condition which, in the opinion of the investigator, makes the patient ineligible","Required: prior >=1 line of chemotherapy and >=1 androgen receptor–targeted therapy; Washout: no anticancer therapy (chemotherapy, biologic therapy, radiation, or immunotherapy) within 3 weeks before T cell infusion with resolution of hematologic effects; Washout: no radium-223 or lutetium-177 vipivotide tetraxetan (Puvicto) within 3 months before T cell infusion; Washout: no checkpoint inhibitor therapy (PD-1/PD-L1/CTLA-4 or similar) within 6 months before T cell infusion with resolution of clinically significant related side effects",MALE,D,"Disease/setting match (male mCRPC with bone metastases) and prior AR-targeted therapy are satisfied, but the trial requires ≥1 prior line of chemotherapy, which is not documented for this patient, making likely ineligibility.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),INCORRECT,A,"No hard exclusions. Stage/setting (mCRPC) matches and metastatic pattern requirement (bone mets) matches. Prior chemo is not documented, so per rubric treat as unknown, not a soft mismatch. With ≥2 anchors matched and no soft conflicts, correct grade is A, not D.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT06730347,0.8482123017311096,Recurrent Clear Cell Ovarian Carcinoma,A Phase 2 Multicohort Study to Evaluate Lorigerlimab in Participants With Advanced Solid Tumors,"Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 60 participants will be enrolled. The study will assess the efficacy and safety of lorigerlimab in participants with PROC or CCGC. Participants will receive lorigerlimab by intravenous (IV) infusion on Day 1 of every 21-day treatment cycle. Treatment cycles will continue until progression of cancer, unacceptable side eff...","{'id': 206501587, 'name': 'Lorigerlimab', 'description': 'Bispecific DART protein binding PD-1 and CTLA-4', 'other_names': ['MGD019'], 'intervention_type': 'BIOLOGICAL'}",PHASE2,18 years,"Ovarian Cancer (platinum-resistant, high-grade serous); Primary Peritoneal Carcinoma (platinum-resistant, high-grade serous); Fallopian Tube Carcinoma (platinum-resistant, high-grade serous); Ovarian Clear Cell Carcinoma; Endometrial Cancer (clear cell); Vaginal Cancer (clear cell); Vulvar Cancer (clear cell); Cervical Cancer (clear cell); Primary Peritoneal Carcinoma (clear cell); Fallopian Tube Carcinoma (clear cell)","Histologically confirmed high-grade serous epithelial ovarian cancer, including primary peritoneal or fallopian tube cancer, that is platinum-resistant | Histologically confirmed clear cell ovarian, endometrial, vaginal, vulvar, or cervical cancer (including primary peritoneal and fallopian tube) | Persistent or recurrent disease with documented progression | Measurable disease per RECIST v1.1 | Available archival tumor tissue or willingness to undergo biopsy for fresh tumor sample | PROC cohort: received 1 to 3 prior lines of therapy for platinum-resistant ovarian cancer | CCGC cohort: received at least 1 prior line of therapy for clear cell gynecologic cancer | Participants with known BRCA mutation must have received a PARP inhibitor (if available) with progression or intolerance | Acceptable physical condition and laboratory values","Primary platinum-refractory disease (no response or progression within 3 months of last dose of first-line platinum chemotherapy) | Prior treatment with a checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4) | Active brain metastases or leptomeningeal metastases | Prior stem cell, tissue, or solid organ transplant | Another malignancy requiring treatment within the past 3 years, except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix or breast | Any underlying medical or psychiatric condition that would impair the ability to receive, tolerate, or comply with study treatment or procedures",Prior platinum-based chemotherapy with platinum-resistant disease; PROC cohort: 1 to 3 prior lines of therapy for PROC; CCGC cohort: at least 1 prior line of therapy for CCGC; BRCA-mutated participants: prior PARP inhibitor with progression or intolerance if available,FEMALE,D,"Disease and recurrent setting match the clear cell gynecologic cancer cohort with ≥1 prior line. However, BRCA-mutated participants must have received a PARP inhibitor (if available), and her history lacks PARP exposure, making her likely ineligible unless PARP therapy was unavailable.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),INCORRECT,A,"No hard exclusions. Disease matches the clear cell cohort. Stage/setting (recurrent) matches, and patient has ≥1 prior systemic line. The BRCA-mutated prior PARP requirement is conditional (“if available”); availability is unknown, so it is not a clear soft mismatch per rubric. With ≥2 anchors matched and no soft conflicts, the correct grade is A, not D.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06962111,1.0,Dementia,Early-Stage Partner in Care-Living Alone (EPIC-LA),"EPICLA+ (Early-Stage Partners in Care Living Alone Plus) is a research project designed to assist people with early-stage memory loss who live alone in the community by providing early-stage related education and skill-training sessions, held via Zoom, designed to reduce stress, enhance well-being, manage challenges, and plan for the future. Researchers will gather feedback from individuals about their experience to continue to improve programs for early-stage memory loss.","{'id': 206177252, 'name': 'Psychoeducational skills training intervention', 'description': 'This protocol is a minimal risk care values clarification /care planning and psychoeducational skills training intervention, delivered as a workshop series plus one in-home session for people in the early stages of memory loss who live alone. In addition, during this intervention, participants will have access to general and personalized virtual resources with materials for use during and after the intervention.', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}",NA,60 years,Alzheimer Disease; Dementia; Mild Cognitive Impairment,"Age >= 60 years | Able to participate in English or Spanish | US resident | Able to provide consent verbally and in writing | At least 2 of 8 changes on the AD8 screening tool | Diagnosis of early-stage ADRD or MMSE 20-26 (high school graduates), or MMSE 17-26 (without high school), or MMSE >= 27 with confirmed early-stage dementia or MCI | Able to participate in EPIC-LA workshops via Zoom",Inability to participate via telephone or online video conferencing | Unwilling to participate | Insufficient time to attend the training | Lack of computer skills that precludes participation | Unstable internet connection to use the video platform | Hearing or visual impairment that precludes participation,(none),ALL,D,"Disease matches, but the trial targets early-stage ADRD/MCI; the patient has moderate-stage dementia and MMSE 19 (which would only meet criteria if no high school, education unknown). Other required logistics (AD8 score, US residency, Zoom capability) are unknown, so this is a likely mismatch rather than a clear exclusion.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,D,"No hard exclusions: disease, age, and sex match; education status and logistics unknown. Core anchors show a clear soft mismatch on stage/setting (trial targets early-stage ADRD/MCI; patient is moderate-stage). That warrants D per rubric. The grader’s reasoning aligns with this and appropriately avoids F since eligibility via MMSE-education pathway is uncertain, not definitively excluded.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT01050855,0.5830909013748169,Ornithine Transcarbamylase Deficiency,Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders,"This is a Phase II pilot study to evaluate engraftment and toxicity of patients with non-malignant diseases using a reduced intensity conditioning regimen in the setting of allogeneic transplant for non malignant diseases. Bone Marrow or cord blood will be acceptable as a stem cell source. Recently, reduced intensity conditioning (RIC) regimens have been used for both adult patients with leukemias and pediatric patients with non-malignant diseases. These regimens are better tolerated, resulti...","{'id': 205786695, 'name': 'RIC: Distal Campath', 'description': 'Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)', 'other_names': ['Reduced Intensity Conditioning Regimen'], 'intervention_type': 'DRUG'}; {'id': 205786696, 'name': 'RIC:Intermediate Campath', 'description': 'Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)', 'other_names': ['Reduced Intensity Conditioning Regimen'], 'intervention_type': 'DRUG'}; {'id': 205786697, 'name': 'RIC: Mini Busulfan', 'description': 'Campath, Fludarabine, Busulfan, Cyclosporine, Cellcept (MMF)', 'other_names': ['Reduced Intensity Conditioning Regimen'], 'intervention_type': 'DRUG'}",PHASE2,6 months to 25 years,IPEX Syndrome; Sickle Cell Disease; Thalassemia Major; Bone Marrow Failure; Hemophagocytic Lymphohistiocytosis; Langerhans Cell Histiocytosis; Severe Combined Immunodeficiency; Adenosine Deaminase Deficiency; Common Variable Immunodeficiency; Wiskott-Aldrich Syndrome,Age >6 months to 25 years | Immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome | Sickle cell disease | Thalassemia major | Bone marrow failure | Hemophagocytic lymphohistiocytosis or other macrophage activation syndromes | Severe Langerhans cell histiocytosis | Severe combined immunodeficiency | Adenosine deaminase deficiency | Common variable immunodeficiency | Wiskott-Aldrich syndrome | Echocardiogram shortening fraction >27% | Serum creatinine <1.5 x ULN for age | Liver function tests <5 x ULN | No active infections,"Uncontrolled bacterial, fungal, or viral infections",(none),ALL,F,"Disease mismatch: the trial does not include ornithine transcarbamylase deficiency among its eligible diseases. Additionally, the patient is 3 months old, below the trial’s minimum age of 6 months.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Correct: The trial does not include OTC deficiency among eligible diseases (hard exclusion), and the patient is below the trial’s minimum age of 6 months (hard exclusion). F is appropriate.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT01171898,0.8099971413612366,Castration-Resistant Prostate Cancer,"An Open-Label, Phase 1/2, Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Patients With Progressive Advanced Castration-Resistant Prostate Cancer","The purpose of this study is to assess the safety and activity of ARN-509 in men with advanced castration resistant prostate cancer. Patients will first be enrolled into Phase 1 of the study to identify a tolerable dose for the Phase 2 portion of the study. In the Phase 2, 3 different cohorts of patients will be enrolled to evaluate the safety and activity of ARN-509.","{'id': 206631394, 'name': 'ARN-509 (Phase 1)', 'description': 'ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206631395, 'name': 'ARN-509 (Phase 2)', 'description': 'ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,18 years,Prostate Cancer (castration-resistant),Histologically or cytologically confirmed prostate cancer | Non-metastatic CRPC with PSA >= 8 ng/mL (within 3 months) | Non-metastatic CRPC with PSA doubling time <= 10 months | Progressive metastatic CRPC by PSA progression | Progressive metastatic CRPC by radiographic progression | Ongoing androgen deprivation therapy with a GnRH analog/inhibitor or orchiectomy | Serum testosterone <= 50 ng/dL | ECOG 0-1 | Life expectancy >= 3 months | Prior abiraterone therapy >= 6 months before progression (post-abiraterone cohort),"Distant metastases including CNS, vertebral, or meningeal involvement (for non-metastatic cohort) | Brain metastases or untreated spinal cord compression | Prior treatment with enzalutamide (MDV3100) | Prior treatment with abiraterone | Prior treatment with ketoconazole | Concurrent treatment with medications known to have seizure potential | Concurrent corticosteroids (must taper off as soon as possible if already on) | QTc > 450 msec | History of seizure or condition predisposing to seizure | Severe or uncontrolled systemic disease | HIV infection",Ongoing androgen deprivation therapy required; Prior abiraterone therapy >= 6 months required for post-abiraterone cohort,MALE,F,"The trial explicitly excludes patients with prior treatment with enzalutamide (MDV3100), which this patient received. All other factors aside, this hard exclusion renders the patient ineligible.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,F,"The trial explicitly excludes prior enzalutamide (MDV3100). The patient has progressed on enzalutamide, triggering a hard exclusion. Other factors (disease, age, sex) align, but the explicit exclusion mandates grade F per rubric.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT01522976,0.44208985567092896,PMM2-CDG,A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML),"This randomized phase II/III trial studies how well azacitidine works with or without lenalidomide or vorinostat in treating patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Lenalidomide may stop the growth of cancer cells by stopping blood flow to the can...","{'id': 206204129, 'name': 'Azacitidine', 'description': 'Given SC or IV', 'other_names': ['5 AZC', '5-AC', '5-Azacitidine', '5-Azacytidine', '5-AZC', 'Azacytidine', 'Azacytidine, 5-', 'Ladakamycin', 'Mylosar', 'U-18496', 'Vidaza'], 'intervention_type': 'DRUG'}; {'id': 206204130, 'name': 'Laboratory Biomarker Analysis', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206204131, 'name': 'Lenalidomide', 'description': 'Given PO', 'other_names': ['CC-5013', 'CC5013', 'CDC 501', 'Revlimid', 'CC 5013'], 'intervention_type': 'DRUG'}; {'id': 206204132, 'name': 'Vorinostat', 'description': 'Given PO', 'other_names': ['L-001079038', 'MSK-390', 'SAHA', 'Suberanilohydroxamic Acid', 'Suberoylanilide Hydroxamic Acid', 'Zolinza'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Myelodysplastic Syndrome; Myelodysplastic Syndrome With Excess Blasts; Myelodysplastic Syndrome With Excess Blasts-1; Chronic Myelomonocytic Leukemia; Chronic Myelomonocytic Leukemia-1; Chronic Myelomonocytic Leukemia-2,"Diagnosis of myelodysplastic syndrome (MDS) meeting FAB RAEB (5-20% marrow blasts) or WHO RAEB-1 (5-9% marrow blasts) or RAEB-2 (10-19% marrow blasts and/or 5-19% blood blasts) | Diagnosis of chronic myelomonocytic leukemia (CMML) meeting FAB criteria (10-19% marrow blasts and/or 5-19% blood blasts) or WHO CMML-1 (<10% marrow blasts and/or <5% blood blasts) or CMML-2 (10-19% marrow blasts and/or 5-19% blood blasts) | IPSS risk intermediate-2 (1.5-2.0 points) or high (>= 2.5 points); intermediate-1 (0.5-1.0 points) allowed only if >= 5% myeloblasts | Baseline disease assessment specimens obtained within 30 days prior to registration | Zubrod performance status 0-2 | Females of childbearing potential: negative pregnancy test within 10-14 days prior to registration; if assigned lenalidomide, second test within 24 hours prior to cycle 1 and adherence to dual contraception; men agree to condom use with FCBP | Pretreatment cytogenetics required within 30 days prior to registration per cooperative group specifications","Acute myeloid leukemia (AML) | Prior treatment with lenalidomide, azacitidine, vorinostat, or decitabine | Prior radiation therapy, chemotherapy, or other cytotoxic therapy for conditions other than MDS within 12 months | Prior allogeneic stem cell or bone marrow transplantation (autologous transplant permitted) | Use of histone deacetylase (HDAC) inhibitor agents for anticancer treatment | Use of valproic acid for epilepsy within 30 days prior to registration | Pre-existing neurotoxicity/neuropathy >= grade 2, or prior >= grade 3 allergic reaction/hypersensitivity or rash to thalidomide not resolved to < grade 2 | Serious medical condition, laboratory abnormality, or psychiatric illness that poses unacceptable risk or prevents informed consent | History of thromboembolic event or condition requiring current anticoagulation with warfarin or low molecular-weight heparin | Known or suspected hypersensitivity to mannitol | White blood cell count > 30,000/µL at registration | Active second malignancy within 3 years, except adequately treated basal/squamous cell skin cancer or in situ cervical cancer",Hematopoietic growth factors stopped >= 14 days before registration; Prior low-dose cytarabine for MDS allowed if discontinued >= 28 days before registration; Prior hydroxyurea for CMML allowed if discontinued >= 7 days before registration,ALL,F,"Disease mismatch: the trial is for MDS/CMML, not PMM2-CDG. Additionally, the patient is 8 years old, which is below the trial’s minimum age of 18.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"Correct: There is a hard exclusion due to disease mismatch (trial is for MDS/CMML; patient has PMM2-CDG), and also an age hard exclusion (trial minimum age 18; patient is 8). Either suffices for grade F.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT01708954,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,"A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib Plus Cabozantinib as 2nd or 3rd Line Therapy in Patients With EGFR Wild-Type NSCLC",This randomized phase II trial studies how well giving erlotinib hydrochloride and cabozantinib-s-malate alone or in combination works as second or third line therapy in treating patient with stage IV non-small cell lung cancer. Erlotinib hydrochloride and cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving erlotinib hydrochloride together with cabozantinib-s-malate is more effective than erlotinib...,"{'id': 206205240, 'name': 'Cabozantinib S-malate', 'description': 'Given PO', 'other_names': ['BMS-907351', 'Cabometyx', 'Cometriq', 'XL 184', 'XL-184', 'XL184'], 'intervention_type': 'DRUG'}; {'id': 206205241, 'name': 'Erlotinib Hydrochloride', 'description': 'Given PO', 'other_names': ['Cp-358,774', 'CP358', 'OSI 774', 'OSI-774', 'OSI774', 'Tarceva', 'CP 358', 'CP-358'], 'intervention_type': 'DRUG'}; {'id': 206205242, 'name': 'Laboratory Biomarker Analysis', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}",PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic),"Non-small cell lung carcinoma confirmed cytologically or histologically | Predominant non-squamous histology; small cell components excluded | Stage IV or recurrent disease by AJCC 7th edition | Measurable disease per RECIST v1.1 | Tumor tissue available for MET IHC testing | One to two prior lines of chemotherapy for advanced disease | Any prior chemotherapy completed per required washout | Discontinued investigational agents >= 4 weeks before registration | Recovered to baseline or CTCAE v4.0 <= grade 1 from prior therapy toxicities (except alopecia and non-clinically significant AEs) | Brain metastases status meeting protocol criteria (stable if present); baseline brain imaging per protocol | Radiation-related toxicities resolved to <= grade 1 | ECOG performance status 0-2 | Anticipated life expectancy > 3 months | Acceptable bone marrow, renal, and hepatic function within 2 weeks prior to registration | QTcF <= 500 ms within 28 days before registration | Able to swallow tablets | Step 2: Radiographic progressive disease after >= 2 courses on Arm A or Arm B | Step 2: Registered within 4 weeks of last dose from Step 1 | Step 2: ECOG performance status 0-2 | Step 2: Recovered to baseline (pre-Step 1) or CTCAE v4.0 <= grade 1 from prior therapy toxicities","Insufficient tumor pathology material (tumor block or 10 unstained slides) for required testing | Prior erlotinib or other EGFR tyrosine kinase inhibitor therapy | Prior VEGFR tyrosine kinase inhibitor therapy | Prior MET tyrosine kinase inhibitor therapy or MET monoclonal antibody | Radiation therapy to thoracic cavity, abdomen, or pelvis within 3 months; to bone or brain within 14 days; or to any other site within 28 days prior to registration | Clinically significant gastrointestinal bleeding within 6 months | Hemoptysis >= 2.5 mL within 3 months | Other signs of pulmonary hemorrhage within 3 months | Tumor invading the gastrointestinal tract or endotracheal/endobronchial tumor within 28 days prior to registration | Cavitating pulmonary lesion(s) within 28 days prior to registration | Tumor in contact with, invading, or encasing major blood vessels within 28 days prior to registration | History of major thrombotic events (deep vein thrombosis or pulmonary embolism) within 6 months | Therapeutic anticoagulation or antiplatelet therapy (except low-dose aspirin <= 81 mg/day and prophylactic LMWH) | Concomitant strong CYP3A4 inducers | Congestive heart failure NYHA class III or IV | Uncontrolled hypertension | History of congenital long QT syndrome | Unstable angina within 6 months | Clinically significant cardiac arrhythmias within 6 months | Stroke or transient ischemic attack or other ischemic event within 6 months | Myocardial infarction within 6 months | Gastrointestinal disorders with high risk of perforation or fistula | High risk of fistula including PEG tube placement within 3 months | Uncontrolled, significant intercurrent or recent illness | Prior malignancy within 2 years requiring systemic treatment or currently active | Pregnant or breastfeeding | HIV infection on antiretroviral therapy | Chronic active hepatitis B | Step 2: Intervening anticancer treatment or major surgery between Step 1 and Step 2 (except palliative bone radiation finished >= 2 weeks before Step 2 registration) | Step 2: Central nervous system progression | Step 2: Intercurrent illness or complication limiting ability to safely tolerate erlotinib plus cabozantinib",Required: 1-2 prior lines of chemotherapy for advanced NSCLC; Prior adjuvant chemotherapy allowed if > 12 months before first-line systemic therapy (otherwise counts as one line); Discontinue investigational agents >= 4 weeks before registration,ALL,F,"The trial explicitly excludes patients with prior EGFR tyrosine kinase inhibitor therapy, and the patient has received osimertinib (an EGFR TKI). Additionally, the trial requires 1–2 prior lines of chemotherapy for advanced disease, which the patient has not had.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Correct: The trial explicitly excludes prior EGFR TKI therapy, and the patient received osimertinib (an EGFR TKI), which is a hard exclusion → F. The noted lack of required prior chemotherapy further disfavors eligibility but is not needed for the F. Additionally, the trial targets EGFR wild-type, while the patient has an EGFR exon 19 deletion, another hard exclusion.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT01961843,0.8099971413612366,Castration-Resistant Prostate Cancer,"Investigator-Initiated, Pilot Translational Study of Circulating Tumor Cells to Identify Predictive Factors of Response to Abiraterone Acetate in Men With Castration-Resistant Prostate Cancer",This research study is a Pilot clinical trial. Pilot clinical trials often examine new tests (such as laboratory or radiology tests) in patients who receive either standard cancer treatments or new treatments that have been well-tested in many patients on other trials. It is often difficult to determine how prostate cancer is going to behave when a new treatment is started. Physicians have no way to predict how a patient's tumor will respond to treatment. Although scientists have learned abou...,"{'id': 205279743, 'name': 'Abiraterone', 'description': 'Abiraterone acetate is an orally bioavailable inhibitor of steroid synthesis, specifically testosterone synthesis.', 'other_names': ['Abiraterone acetate', 'Zytiga'], 'intervention_type': 'DRUG'}; {'id': 205279744, 'name': 'Prednisone', 'description': 'Prednisone is a synthetic corticosteroid that is co-administered with abiraterone acetate to offset the hypokalemia and hypertension side effects of abiraterone acetate.', 'other_names': [], 'intervention_type': 'DRUG'}",NA,18 years,Prostate Cancer (castration-resistant),Histologically or cytologically confirmed adenocarcinoma of the prostate | Able to swallow tablets whole | Willing to take abiraterone on an empty stomach | Willing to use effective birth control with barrier protection | Metastatic disease documented by positive bone scan or metastatic lesions other than liver or visceral metastasis on CT or MRI | Asymptomatic or mildly symptomatic from prostate cancer | Surgically or medically castrated | Previous anti-androgen therapy with progression after withdrawal | Life expectancy >= 6 months,"Active infection or other condition contraindicating corticosteroid use | Uncontrolled hypertension | Severe hepatic impairment | History of pituitary or adrenal dysfunction | Clinically significant heart disease (myocardial infarction or arterial thrombotic events within 6 months, severe or unstable angina, or NYHA Class III or IV heart failure) | Poorly controlled diabetes | Gastrointestinal disorders that may interfere with absorption of study agents | Pre-existing condition requiring long-term corticosteroid use in excess of study dose | Allergy, hypersensitivity, or intolerance to abiraterone or prednisone or their excipients | Pathology consistent with small cell carcinoma of the prostate | Liver, visceral organ, or brain metastasis | Prior cytotoxic chemotherapy or biologic therapy for treatment of CRPC | Radiation therapy for primary tumor within 6 weeks of Cycle 1 Day 1 | Radiation therapy for metastatic CRPC within 2 weeks of Cycle 1 Day 1 | Radionuclide therapy for metastatic CRPC within 6 weeks of Cycle 1 Day 1 | Previous ketoconazole for prostate cancer for > 7 days | Prior systemic treatment with an azole drug | Prior flutamide within 4 weeks of Cycle 1 Day 1 | Prior bicalutamide or nilutamide within 6 weeks of Cycle 1 Day 1 | Active or symptomatic viral hepatitis or chronic liver disease | History of a different malignancy unless disease-free for >= 5 years or non-melanoma skin cancer treated within 5 years | Administration of an investigational therapeutic within 30 days of Cycle 1 Day 1",Castration (surgical or medical) required; Prior anti-androgen therapy with progression after withdrawal required; Washout: flutamide >= 4 weeks before Cycle 1 Day 1; Washout: bicalutamide or nilutamide >= 6 weeks before Cycle 1 Day 1; Washout: radiation therapy to primary tumor >= 6 weeks before Cycle 1 Day 1; Washout: radiation therapy to metastases >= 2 weeks before Cycle 1 Day 1; Washout: radionuclide therapy >= 6 weeks before Cycle 1 Day 1; Washout: investigational therapy >= 30 days before Cycle 1 Day 1,MALE,F,"The trial explicitly excludes patients with liver or other visceral metastases, and this patient has PSMA PET-avid liver metastases; therefore they are ineligible.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with liver or other visceral metastases, and the patient has PSMA PET-avid liver metastases. This is a hard exclusion, so grade F is correct.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02068794,0.7943270802497864,Recurrent Clear Cell Ovarian Carcinoma,Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer,"This phase I/II trial studies the side effects and best dose of oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) infected mesenchymal stem cells and to see how well it works in treating patients with ovarian, primary peritoneal or fallopian tube cancer that has come back. Mesenchymal stem cells may be able to carry tumor-killing substances directly to ovarian, primary peritoneal and fallopian tube cancer cells.","{'id': 206344252, 'name': 'Laboratory Biomarker Analysis', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206344253, 'name': 'Mesenchymal Stem Cell Transplantation', 'description': 'Given IP', 'other_names': [], 'intervention_type': 'PROCEDURE'}; {'id': 206344254, 'name': 'Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter', 'description': 'Given IP', 'other_names': ['MV-NIS'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206344255, 'name': 'Echocardiography', 'description': 'Undergo ECHO', 'other_names': ['Echocardiograph (EC)', 'echocardiograph', 'ECHO'], 'intervention_type': 'PROCEDURE'}; {'id': 206344256, 'name': 'Multigated Acquisition Scan', 'description': 'Undergo MUGA', 'other_names': ['Blood Pool Scan', 'Equilibrium Radionuclide Angiography', 'Gated Blood Pool Imaging', 'Gated Heart Pool Scan', 'MUGA', 'MUGA Scan', 'Multi-Gated Acquisition Scan', 'Radionuclide Ventriculogram Scan', 'Radionuclide ventriculography', 'Radionuclide Ventriculography (RNVG)', 'Synchronized Multigated Acquisition Scanning', 'RNVG', 'SYMA Scanning'], 'intervention_type': 'PROCEDURE'}; {'id': 206344257, 'name': 'Biospecimen Collection', 'description': 'Undergo blood sample collection', 'other_names': ['Biological Sample Collection', 'Biospecimen Collected', 'Blood Sample Collection', 'Specimen Collection'], 'intervention_type': 'PROCEDURE'}; {'id': 206344258, 'name': 'Chest Radiography', 'description': 'Undergo chest X-ray', 'other_names': ['chest x-ray'], 'intervention_type': 'PROCEDURE'}; {'id': 206344259, 'name': 'Single Photon Tomography and Computed Tomography Scan', 'description': 'Undergo SPECT/CT', 'other_names': ['SPECT/CT', 'SPECT/CT SCAN'], 'intervention_type': 'PROCEDURE'}; {'id': 206344260, 'name': 'Computed Tomography', 'description': 'Undergo CT', 'other_names': ['CAT', 'CAT Scan', 'Computed Axial Tomography (CAT)', 'computerized axial tomography', 'Computerized axial tomography (procedure)', 'Computerized Tomography', 'CT', 'CT SCAN', 'tomography'], 'intervention_type': 'PROCEDURE'}; {'id': 206344261, 'name': 'Magnetic Resonance Imaging', 'description': 'Undergo MRI', 'other_names': ['Magnetic Resonance', 'Magnetic Resonance Imaging (MRI)', 'Magnetic resonance imaging (procedure)Q', 'Magnetic Resonance Imaging Scan', 'Medical Imaging', 'Magnetic Resonance / Nuclear Magnetic Resonance', 'MR', 'MR Imaging', 'MRI Scan', 'MRIs', 'NMRI', 'nuclear magnetic resonance imaging', 'sMRI', 'Structural MRI'], 'intervention_type': 'PROCEDURE'}",PHASE1/PHASE2,18 years,Ovarian Carcinoma (recurrent); Primary Peritoneal Carcinoma (recurrent); Fallopian Tube Carcinoma (recurrent),"Recurrent or progressive ovarian, primary peritoneal, or fallopian tube cancer after prior platinum and taxane therapy | Histologic confirmation of the original primary tumor | Prior bilateral oophorectomy | Eligible epithelial histologies: serous, endometrioid, mucinous, undifferentiated, clear cell, mixed epithelial, transitional cell, malignant Brenner tumor, or adenocarcinoma NOS | ECOG performance status 0–2 | Normal cardiac function by MUGA or echocardiogram | Life expectancy >= 12 weeks | Measurable disease by exam or CT, or CA-125 elevation/microscopic residual with willingness for laparoscopy if no radiographic progression after 6 cycles | CD4 count >= 200/µL or >= 15% of peripheral blood lymphocytes","Epithelial tumors of low malignant potential, stromal tumors, or germ cell tumors of the ovary | Known standard therapy that is potentially curative or capable of extending life expectancy; first relapse > 6 months after adjuvant chemotherapy | Active infection <= 5 days prior to registration | History of tuberculosis or positive PPD | History of other malignancy within 5 years (except non-melanoma skin cancer, cervical CIS, or DCIS) | Chemotherapy within 3 weeks prior to registration | Immunotherapy within 4 weeks prior to registration | Biologic therapy within 4 weeks prior to registration | Extensive abdominal surgery including enterotomy(ies) within 3 weeks prior to registration | Any prior viral or gene therapy | Radiation therapy to the abdomen or pelvis | NYHA class III or IV heart failure, symptomatic coronary artery disease, cardiac arrhythmias (atrial fibrillation or SVT) | Other significant cardiac or pulmonary disease that may impair treatment safety | Requirement for blood product support | CNS metastases or seizure disorder | HIV infection or other immunodeficiency | History of organ transplantation | Chronic hepatitis B or C | Concurrent chemotherapy, immunotherapy, radiotherapy, or other investigational ancillary therapy | Intra-abdominal disease > 8 cm, intrahepatic disease, or disease beyond the abdominal cavity (except intra-abdominal lymph nodes) | Systemic corticosteroid therapy (except topical or inhaled steroids) | Household contacts <= 15 months old or household contact with known immunodeficiency | Allergy to measles vaccine or severe reaction to prior measles vaccination | Allergy to iodine (excluding IV contrast reactions) | Any other condition deemed to negatively impact treatment safety",Prior platinum- and taxane-based chemotherapy required; Chemotherapy washout >= 3 weeks before registration; Immunotherapy washout >= 4 weeks before registration; Biologic therapy washout >= 4 weeks before registration; Extensive abdominal surgery washout >= 3 weeks before registration,ALL,F,"Explicit exclusion applies: the trial excludes disease beyond the abdominal cavity, and the patient has cytology-positive pleural effusion (thoracic). While the disease type and prior platinum/taxane exposure match, this exclusion renders the patient ineligible.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,F,"The trial explicitly excludes disease beyond the abdominal cavity; the patient has a cytology-positive pleural effusion (thoracic), which is a direct conflict. This is a hard exclusion, so F is appropriate despite other apparent matches.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02122185,0.8482123017311096,Recurrent Clear Cell Ovarian Carcinoma,"A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction With Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer","This randomized phase II trial studies how well metformin hydrochloride and combination chemotherapy works in treating patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Metformin hydrochloride may help carboplatin, paclitaxel and docet...","{'id': 206547048, 'name': 'metformin hydrochloride', 'description': 'Given PO', 'other_names': ['Glucophage'], 'intervention_type': 'DRUG'}; {'id': 206547049, 'name': 'placebo', 'description': 'Given PO', 'other_names': ['PLCB'], 'intervention_type': 'DRUG'}; {'id': 206547050, 'name': 'Chemotherapy', 'description': 'Participants will received standard chemotherapy (6-8 cycles). Specific regimen to be given is at the discretion of their treating physician.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,18 years,Ovarian Epithelial Cancer (Stage III–IV); Fallopian Tube Cancer (Stage III–IV); Primary Peritoneal Cancer (Stage III–IV); Ovarian Serous Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Clear Cell Carcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Undifferentiated Adenocarcinoma; Brenner Tumor,"Age >= 18 years | ECOG performance status <= 2 | Leukocytes >= 3,000/µL | Absolute neutrophil count >= 1,500/µL | Platelets >= 100,000/µL | Total bilirubin <= 1 x ULN (Gilbert syndrome allowed) | AST <= 2.0 x ULN | ALT <= 2.0 x ULN | Creatinine <= 1 x ULN or creatinine clearance >= 60 mL/min | Fasting blood glucose <= 126 mg/dL or nonfasting glucose <= 140 mg/dL | Histologically confirmed carcinoma consistent with ovarian, fallopian tube, or primary peritoneal carcinoma | Stage III or IV disease with gross macroscopic residual disease after primary debulking surgery | For planned neoadjuvant chemotherapy: cytology or biopsy showing adenocarcinoma and CA-125 > 250 or CA-125:CEA ratio > 25 or CA-125 <= 250 with no evidence of GI cancer; presumed stage III or IV based on carcinomatosis/effusions/ascites | Agreement to receive 6–8 cycles of an allowed standard chemotherapy regimen as specified | Women of child-bearing potential agree to use effective non-hormonal contraception during the study","Known diabetes mellitus or fasting glucose > 126 mg/dL or random glucose > 140 mg/dL | Current use of metformin, sulfonylureas, thiazolidinediones, or insulin | Use of other investigational agents | Comorbidities with expected survival < 2 years unrelated to ovarian cancer | Concurrent active invasive malignancy or prior malignancy with > 30% risk of recurrence within 2 years | Allergy to metformin or compounds of similar composition | NYHA class III or IV heart failure | History of any acidosis | Alcoholic liver disease | Habitual intake of >= 3 alcoholic beverages per day | Uncontrolled intercurrent illness (e.g., active major infection, unstable angina, symptomatic CHF, significant arrhythmia, psychiatric illness limiting compliance) | Pregnant or nursing | Mucinous adenocarcinoma or borderline tumors | Planned intraperitoneal chemotherapy | Neoadjuvant chemotherapy without planned interval debulking surgery (assuming adequate response) | Planned chemotherapy regimens not specified in the protocol | Participation in other interventional trials to reduce ovarian cancer recurrence or planned off-protocol maintenance therapy (e.g., paclitaxel or bevacizumab)",(none),FEMALE,F,"The trial is for newly diagnosed stage III–IV patients starting first-line chemotherapy (with gross residual after primary debulking or planned neoadjuvant). This patient has recurrent disease after prior adjuvant carboplatin/paclitaxel/bevacizumab, so the required setting is not met.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Female; Age 36 years; Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion (recurrent disease); BRCA1 positive; Prior optimal debulking surgery; Prior adjuvant carboplatin + paclitaxel + bevacizumab,(none),Optimal debulking surgery; Adjuvant carboplatin + paclitaxel + bevacizumab,Stage III,,36,years,female,(none),CORRECT,F,"The trial requires a frontline advanced setting (newly diagnosed Stage III–IV with gross residual after primary debulking or planned neoadjuvant). The patient has recurrent disease after prior adjuvant therapy, definitively lacking the required setting. This is a hard exclusion per the rubric (“requires marker/stage/setting the patient definitively lacks”), so F is correct.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT02411448,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,"A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer",The main purpose of this study is to evaluate the efficacy and safety of ramucirumab in combination with erlotinib as compared to placebo in combination with erlotinib in previously untreated participants with stage IV non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation (Exon 19-Del and Exon 21 L858R). Safety and tolerability of ramucirumab in combination with erlotinib will be assessed in Part A before proceeding to Part B. The purpose ...,"{'id': 206168693, 'name': 'Ramucirumab', 'description': 'Administered IV.', 'other_names': ['LY3009806'], 'intervention_type': 'DRUG'}; {'id': 206168694, 'name': 'Placebo', 'description': 'Administered IV.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206168695, 'name': 'Erlotinib', 'description': 'Administered orally.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206168696, 'name': 'Gefitinib', 'description': 'Administered orally.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206168697, 'name': 'Osimertinib', 'description': 'Administered orally.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,18 years,Non-Small Cell Lung Cancer (metastatic),Histologically or cytologically confirmed Stage IV non-small cell lung cancer | Eligible for first-line erlotinib based on activating EGFR mutation (exon 19 deletion or exon 21 L858R) | Provision of adequate archived tissue sample (optional for Part C) | At least one measurable lesion | Life expectancy >= 3 months,"Known EGFR T790M mutation (not applicable for Part C Period 2) | Known leptomeningeal carcinomatosis, uncontrolled or unstable spinal cord compression, or brain metastases | Serious illness or medical condition | Ongoing treatment with CYP3A4 inducers or strong inhibitors | Ongoing therapy with nonsteroidal anti-inflammatory drugs for more than 2 months | History of gross hemoptysis | Significant bleeding disorders | Radiologic evidence of major blood vessel invasion or encasement by tumor | Radiographic evidence of intratumor cavitation | History of gastrointestinal perforation within 6 months | History of bowel obstruction, inflammatory enteropathy, or extensive intestinal resection | History of any arterial thrombotic event within 6 months prior to enrollment | Significant ophthalmologic abnormalities of the surface of the eye",(none),ALL,F,"The trial requires previously untreated, first-line EGFR-mutant metastatic NSCLC eligible for first-line erlotinib, but the patient has received prior systemic therapy (osimertinib) for metastatic disease. This is a hard line-of-therapy/setting mismatch.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),INCORRECT,D,"Disease and biomarker match; age/sex OK. The trial requires first-line/previously untreated therapy, while the patient has prior osimertinib—this is a clear line-of-therapy soft mismatch per CORE ANCHORS, not a listed HARD EXCLUSION (it’s in inclusion, not an explicit exclusion criterion). Thus grade should be D, not F.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT02453282,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,"A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).","This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC","{'id': 206132916, 'name': 'MEDI4736 (Durvalumab)', 'description': None, 'other_names': [], 'intervention_type': 'BIOLOGICAL'}; {'id': 206132917, 'name': 'MEDI4736 (Durvalumab)+Tremelimumab', 'description': None, 'other_names': [], 'intervention_type': 'BIOLOGICAL'}; {'id': 206132918, 'name': 'Paclitaxel + Carboplatin', 'description': 'Chemotherapy Agents', 'other_names': ['Platinum based Standard of Care Chemotherapy'], 'intervention_type': 'DRUG'}; {'id': 206132919, 'name': 'Gemcitabine + Cisplatin', 'description': 'Chemotherapy Agents', 'other_names': ['Platinum based Standard of Care Chemotherapy'], 'intervention_type': 'DRUG'}; {'id': 206132920, 'name': 'Gemcitabine + Carboplatin', 'description': 'Chemotherapy Agents', 'other_names': ['Platinum based Standard of Care Chemotherapy'], 'intervention_type': 'DRUG'}; {'id': 206132921, 'name': 'Pemetrexed + Cisplatin', 'description': 'Chemotherapy Agents', 'other_names': ['Platinum based Standard of Care Chemotherapy'], 'intervention_type': 'DRUG'}; {'id': 206132922, 'name': 'Pemetrexed + Carboplatin', 'description': 'Chemotherapy Agents', 'other_names': ['Platinum based Standard of Care Chemotherapy'], 'intervention_type': 'DRUG'}; {'id': 206132923, 'name': 'Tremelimumab', 'description': None, 'other_names': [], 'intervention_type': 'BIOLOGICAL'}",PHASE3,18 years to 130 years,Non-Small Cell Lung Cancer (metastatic),Age >= 18 years | Stage IV non-small cell lung cancer | No sensitizing EGFR mutation | No ALK rearrangement | No prior systemic therapy for recurrent/metastatic NSCLC | WHO performance status 0-1,"Mixed small-cell and NSCLC histology or sarcomatoid variant | Brain metastases or spinal cord compression unless asymptomatic, treated, and stable without steroids | Prior exposure to immunomodulatory therapy (CTLA-4, PD-1, PD-L1, or PD-L2 antibodies), excluding therapeutic anticancer vaccines | Active or prior autoimmune or inflammatory disorders (e.g., colitis or Crohn's disease)",No prior systemic therapy for recurrent/metastatic NSCLC,ALL,F,"Hard exclusion: the trial requires no sensitizing EGFR mutation and no prior systemic therapy for metastatic disease, while the patient has an EGFR exon 19 deletion and has received osimertinib.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Trial requires no sensitizing EGFR mutation and no prior systemic therapy for metastatic disease; patient has EGFR exon 19 deletion and prior osimertinib. These are hard exclusions, so F is correct.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT02516241,0.8805802464485168,Metastatic Urothelial Carcinoma,"A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Cancer","A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer","{'id': 206511605, 'name': 'MEDI4736 (Durvalumab)', 'description': 'IV infusion', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206511606, 'name': 'Tremelimumab', 'description': 'IV infusion', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206511607, 'name': 'Cisplatin', 'description': 'IV infusion', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206511608, 'name': 'Carboplatin', 'description': 'IV infusion', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206511609, 'name': 'Gemcitabine', 'description': 'IV infusion', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,18 years to 130 years,Urothelial Carcinoma (metastatic),"Histologically or cytologically confirmed unresectable Stage IV transitional cell carcinoma of the urothelium. | No prior first-line chemotherapy for metastatic disease. | Patients may be cisplatin-eligible or cisplatin-ineligible. | Definition of cisplatin ineligibility includes: creatinine clearance < 60 mL/min, CTCAE Grade >= 2 hearing loss, CTCAE Grade >= 2 peripheral neuropathy, or NYHA Class >= III heart failure. | Tumor PD-L1 status known by IHC prior to randomization.","Prior exposure to immune-mediated therapy including CTLA-4, PD-1, PD-L1, or PD-L2 antibodies, or therapeutic anticancer vaccines. | History of allogeneic organ transplantation requiring immunosuppression. | Active or prior autoimmune or inflammatory disorders (with protocol-specified exceptions). | Untreated or unstable brain metastases or spinal cord compression, or requirement for steroids within 14 days prior to treatment. | Active infection including tuberculosis, hepatitis B, hepatitis C, or HIV. | Current or prior use of systemic immunosuppressive medication within 14 days before first dose (with protocol-specified exceptions). | Receipt of live attenuated vaccine within 30 days prior to first dose.",No prior first-line chemotherapy for metastatic disease.; Prior intravesical chemotherapy or immunotherapy allowed if completed >= 28 days before start of study treatment.,ALL,F,"The trial excludes any prior PD-1/PD-L1/CTLA-4 exposure, and the patient received pembrolizumab (PD-1) with enfortumab vedotin. Additionally, the study is for first-line metastatic therapy, while the patient is post–second-line.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,F,"Explicit exclusion applies: the trial excludes prior PD-1/PD-L1/CTLA-4 therapy and the patient received pembrolizumab. That alone mandates F. The first-line setting requirement also mismatches the patient’s post–second-line status, but the PD-1 exclusion is sufficient for a hard F.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT02542293,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,"A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).","This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC.","{'id': 206132243, 'name': 'Durvalumab +Tremelimumab', 'description': None, 'other_names': [], 'intervention_type': 'BIOLOGICAL'}; {'id': 206132244, 'name': 'Paclitaxel + carboplatin', 'description': 'Chemotherapy Agents', 'other_names': ['Platinum based Standard of Care Chemotherapy'], 'intervention_type': 'DRUG'}; {'id': 206132245, 'name': 'Gemcitabine + cisplatin', 'description': 'Chemotherapy Agents', 'other_names': ['Platinum based Standard of Care Chemotherapy'], 'intervention_type': 'DRUG'}; {'id': 206132246, 'name': 'Gemcitabine + carboplatin', 'description': 'Chemotherapy Agents', 'other_names': ['Platinum based Standard of Care Chemotherapy'], 'intervention_type': 'DRUG'}; {'id': 206132247, 'name': 'Pemetrexed + cisplatin', 'description': 'Chemotherapy Agent', 'other_names': ['Platinum based Standard of Care Chemotherapy'], 'intervention_type': 'DRUG'}; {'id': 206132248, 'name': 'Pemetrexed + carboplatin', 'description': 'Chemotherapy Agent', 'other_names': ['Platinum based Standard of Care Chemotherapy'], 'intervention_type': 'DRUG'}",PHASE3,18 years to 130 years,Non-Small Cell Lung Cancer (metastatic),Age >= 18 years | Stage IV non-small cell lung cancer | No activating EGFR mutation | No ALK rearrangement,"Mixed small cell lung cancer and NSCLC histology | Sarcomatoid variant | Brain metastases or spinal cord compression unless stable and off steroids >= 14 days prior to treatment | Active or prior autoimmune or inflammatory disorders (e.g., Crohn's disease, ulcerative colitis)","No prior systemic therapy for recurrent/metastatic NSCLC; No prior immune checkpoint inhibitor therapy (anti-CTLA-4, anti-PD-1, anti-PD-L1, anti-PD-L2); Therapeutic anticancer vaccines allowed",ALL,F,"Hard exclusions apply: the trial requires no activating EGFR mutation and no prior systemic therapy for metastatic NSCLC, but the patient has an EGFR exon 19 deletion and has received osimertinib.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Trial requires no activating EGFR mutation and no prior systemic therapy for metastatic NSCLC; patient has EGFR exon 19 deletion and received osimertinib. These are hard exclusions per rubric, so F is correct.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT02629159,1.0,Rheumatoid Arthritis,"A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)","The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to severely active rheumatoid arthritis (RA) who are on a stable background of methotrexate (MTX and who have an inadequate response to MTX.","{'id': 206512567, 'name': 'Placebo for Adalimumab', 'description': 'Administered by subcutaneous injection once every other week', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206512568, 'name': 'Adalimumab', 'description': 'Administered by subcutaneous injection once every other week', 'other_names': ['Humira'], 'intervention_type': 'DRUG'}; {'id': 206512569, 'name': 'Placebo for Upadacitinib', 'description': 'Tablets taken orally once a day', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206512570, 'name': 'Upadacitinib', 'description': 'Tablets taken orally once a day', 'other_names': ['ABT-494'], 'intervention_type': 'DRUG'}",PHASE3,18 years,Rheumatoid Arthritis,Age >= 18 years | Rheumatoid arthritis diagnosis >= 3 months | On methotrexate >= 3 months and stable dose >= 15–25 mg/week (>= 10 mg/week if intolerant of >= 12.5 mg/week) for >= 4 weeks before first dose | Folic acid or folinic acid supplementation throughout study participation | >= 6 swollen joints (66-joint count) at Screening and Baseline | >= 6 tender joints (68-joint count) at Screening and Baseline | Radiographic evidence of >= 3 bone erosions on x-ray at Screening | OR >= 1 bone erosion and positive rheumatoid factor at Screening | OR >= 1 bone erosion and positive anti-cyclic citrullinated peptide antibodies at Screening | Prior exposure to only one bDMARD (excluding adalimumab) allowed (up to 20% of participants) if intolerance or limited exposure (< 3 months) with required washout | Discontinue all csDMARDs except methotrexate,"Prior exposure to any Janus kinase (JAK) inhibitor (e.g., tofacitinib, baricitinib, filgotinib) | Prior exposure to adalimumab | Inadequate response to bDMARD therapy as determined by the investigator | History of inflammatory joint disease other than rheumatoid arthritis (secondary Sjogren's syndrome permitted)",Stable methotrexate 15–25 mg/week (>= 10 mg/week if intolerant) for >= 4 weeks prior to first dose; Folic acid or folinic acid supplementation required; Discontinue csDMARDs except methotrexate before enrollment; Up to one prior bDMARD (excluding adalimumab) allowed if intolerance or < 3 months exposure; washout required,ALL,F,"Although disease and age match, the trial explicitly excludes any prior adalimumab exposure and allows at most one prior bDMARD (excluding adalimumab). The patient previously received adalimumab and tocilizumab, so this is a hard exclusion.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,F,"Trial explicitly excludes prior adalimumab exposure and limits prior bDMARDs to one (excluding adalimumab). Patient has received adalimumab and tocilizumab. This is a hard exclusion, so F is correct.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT02703623,0.8316181302070618,Castration-Resistant Prostate Cancer,A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer,"This randomized phase II trial studies the side effects and how well abiraterone acetate, prednisone, and apalutamide work with or without ipilimumab or cabazitaxel and carboplatin in treating patients with castration-resistant prostate cancer that has spread to other places in the body. Androgens can cause the growth of prostate cancer cells. Drugs, such as abiraterone acetate and apalutamide may lessen the amount of androgens made by the body. Immunotherapy with monoclonal antibodies, such ...","{'id': 205943227, 'name': 'Abiraterone Acetate', 'description': 'Given PO', 'other_names': ['CB7630', 'Zytiga'], 'intervention_type': 'DRUG'}; {'id': 205943228, 'name': 'Apalutamide', 'description': 'Given PO', 'other_names': ['ARN 509', 'ARN-509', 'ARN509', 'JNJ 56021927', 'JNJ-56021927'], 'intervention_type': 'DRUG'}; {'id': 205943229, 'name': 'Cabazitaxel', 'description': 'Given IV', 'other_names': ['Jevtana', 'RPR-116258A', 'Taxoid XRP6258', 'XRP-6258'], 'intervention_type': 'DRUG'}; {'id': 205943230, 'name': 'Carboplatin', 'description': 'Given IV', 'other_names': ['Nealorin', 'Novoplatinum', 'Paraplatin', 'Paraplatin AQ', 'Paraplatine', 'Platinwas', 'Blastocarb', 'Carboplat', 'Carboplatin Hexal', 'Carboplatino', 'Carbosin', 'Carbosol', 'Carbotec', 'CBDCA', 'Displata', 'Ercar', 'JM-8', 'Ribocarbo'], 'intervention_type': 'DRUG'}; {'id': 205943231, 'name': 'Ipilimumab', 'description': 'Given IV', 'other_names': ['Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody', 'BMS-734016', 'MDX-010', 'MDX-CTLA4', 'Yervoy'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205943232, 'name': 'Laboratory Biomarker Analysis', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 205943233, 'name': 'Prednisone', 'description': 'Given PO', 'other_names': ['.delta.1-Cortisone', '1, 2-Dehydrocortisone', 'Adasone', 'Cortancyl', 'Dacortin', 'DeCortin', 'Decortisyl', 'Decorton', 'Delta 1-Cortisone', 'Delta-Dome', 'Deltacortene', 'Deltacortisone', 'Deltadehydrocortisone', 'Deltasone', 'Deltison', 'Deltra', 'Econosone', 'Lisacort', 'Meprosona-F', 'Metacortandracin', 'Meticorten', 'Ofisolona', 'Orasone', 'Panafcort', 'Panasol-S', 'Paracort', 'PRED', 'Predicor', 'Predicorten', 'Prednicen-M', 'Prednicort', 'Prednidib', 'Prednilonga', 'Predniment', 'Prednisonum', 'Prednitone', 'Promifen', 'Servisone', 'SK-Prednisone'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Metastatic Castration-Resistant Prostate Cancer,"Male >=18 years | Histologically or cytologically confirmed prostate adenocarcinoma | Metastatic disease on imaging (bone scan, CT and/or MRI) | Progressive disease by PSA, RECIST 1.1 for soft tissue, or bone scan per PCWG3 | Surgically or medically castrated; testosterone <=50 ng/dL (<=2.0 nM) | ECOG <=2 | Hemoglobin >=7.5 g/dL (with bone marrow involvement; independent of transfusion/growth factors within 3 months) | Platelet count >=100,000/µL (independent of transfusion/growth factors within 3 months) | Serum albumin >=3.0 g/dL | Discontinue seizure-threshold–lowering medications >=4 weeks prior to entry | Absolute neutrophil count >=1,500/µL | Creatinine clearance >=40 mL/min | Serum potassium >= LLN | Serum magnesium >= LLN | Total bilirubin <1.5 x ULN (except Gilbert's) | AST or ALT <2.5 x ULN (<=5 x ULN allowed with liver metastases) | Able to swallow tablets/capsules whole","Prior treatment with ipilimumab | Systemic therapy for prostate cancer within 28 days before Cycle 1 Day 1 (except LHRH agonists/antagonists for testosterone suppression, sipuleucel-T, and bisphosphonates or RANK-ligand inhibitors) | Investigational product within 28 days before Cycle 1 Day 1 | Medications listed as prohibited (e.g., those that lower seizure threshold) within 28 days before Cycle 1 Day 1 | Treatment within 12 months before Cycle 1 Day 1 with any CYP17-lyase inhibitor, any 2nd-generation AR antagonist (e.g., enzalutamide), cabazitaxel, or carboplatin | Disease progression while on, or within 3 months of discontinuing, a CYP17-lyase inhibitor, 2nd-generation AR antagonist, cabazitaxel, or carboplatin (unless >12 months prior and without progression) | Disease refractory to >2 lines of chemotherapy | Flutamide within 4 weeks before Cycle 1 Day 1; bicalutamide or nilutamide within 6 weeks before Cycle 1 Day 1 (shorter 3-day washout allowed under specified conditions) | Radiation therapy to the primary tumor within 6 weeks before Cycle 1 Day 1 (palliative RT allowed if recovered) | Chronic condition requiring >10 mg prednisone/prednisolone daily | Active infection requiring therapy or contraindicating corticosteroid use; known HIV/AIDS | Other malignancy requiring radiotherapy or systemic treatment within 5 years or with >=30% 24-month recurrence risk (except non-melanoma skin cancer or Ta urothelial carcinoma) | Uncontrolled hypertension (systolic >=140 mmHg or diastolic >=90 mmHg) | QTc >=450 msec | Active or symptomatic viral hepatitis or chronic liver disease | Clinically significant heart disease (MI or arterial thrombotic events within 6 months, severe/unstable angina, significant ventricular arrhythmias, NYHA class III–IV, or LVEF <40%) | Autoimmune disease (e.g., IBD, rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis, scleroderma, SLE, vasculitis, autoimmune neuropathies); vitiligo and controlled endocrine deficiencies allowed | History or risk factors for bowel perforation (e.g., acute diverticulitis, intra-abdominal abscess, GI obstruction, abdominal carcinomatosis) | History of seizure or conditions predisposing to seizure (e.g., recent stroke or LOC, AVM, intracranial masses causing edema or mass effect) | GI disorder affecting absorption | Untreated symptomatic spinal cord compression","Surgical or ongoing medical castration (LHRH agonist/antagonist) required; No systemic therapy for prostate cancer within 28 days before Cycle 1 Day 1 (LHRH therapy, sipuleucel-T, bisphosphonates/RANK-ligand inhibitors allowed); No investigational agents within 28 days before Cycle 1 Day 1; Discontinue seizure-threshold–lowering medications >=4 weeks before study entry; Flutamide washout >=4 weeks; bicalutamide or nilutamide washout >=6 weeks (or >=3 days if early progression documented)",MALE,F,"Explicit exclusion: the trial excludes patients with disease progression on a 2nd‑generation AR antagonist; this patient progressed on enzalutamide. Although disease, age, and sex match, the exclusion criterion applies.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with disease progression while on a 2nd‑generation AR antagonist (e.g., enzalutamide). The patient progressed on enzalutamide, so this is a hard exclusion. Despite disease, age, and sex matching, F is appropriate per the rubric.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT02807805,0.8099971413612366,Castration-Resistant Prostate Cancer,A Phase II Study With a Lead-in Safety Phase of Abiraterone in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC),"This phase II trial studies the side effects and how well abiraterone acetate, niclosamide, and prednisone work in treating patients with hormone-resistant prostate cancer. Androgens can cause the growth of prostate cells. Hormone therapy using abiraterone acetate may fight prostate cancer by lowering the amount of androgen the body makes. Niclosamide is a drug that may block another signal that can cause prostate cancer cell growth. Prednisone is a drug that can help lessen inflammation. Giv...","{'id': 205969373, 'name': 'Abiraterone Acetate', 'description': 'Given PO', 'other_names': ['CB7630', 'Zytiga'], 'intervention_type': 'DRUG'}; {'id': 205969374, 'name': 'Niclosamide', 'description': 'Given PO', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205969375, 'name': 'Prednisone', 'description': 'Given PO', 'other_names': ['.delta.1-Cortisone', '1, 2-Dehydrocortisone', 'Adasone', 'Cortancyl', 'Dacortin', 'DeCortin', 'Decortisyl', 'Decorton', 'Delta 1-Cortisone', 'Delta-Dome', 'Deltacortene', 'Deltacortisone', 'Deltadehydrocortisone', 'Deltasone', 'Deltison', 'Deltra', 'Econosone', 'Metacortandracin', 'Meticorten', 'Ofisolona', 'Orasone', 'Panafcort', 'Panasol-S', 'Paracort', 'Predicor', 'Predicorten', 'Prednicen-M', 'Prednicort', 'Prednidib', 'Prednilonga', 'Predniment', 'Prednisonum', 'Prednitone', 'Promifen', 'Servisone'], 'intervention_type': 'DRUG'}",PHASE2,19 years,Prostate Cancer (castration-resistant),"Histologically or cytologically confirmed prostate cancer | Castration-resistant disease despite androgen deprivation per progression criteria | Measurable disease not required | If PSA is the only indicator of disease and no metastatic disease, PSA >= 5.0 ng/mL | Surgically or medically castrated; willing to continue LHRH agonist or antagonist | Serum testosterone < 50 ng/dL within 3 months prior to registration | ECOG <=2 (Karnofsky >=70%) | Life expectancy > 6 months | Leukocytes >= 3000/µL | Absolute neutrophil count >= 1500/µL | Platelets >= 100000/µL | Total bilirubin <= 1 x ULN | AST and ALT <= 1.5 x ULN | Creatinine <= 1.5 x ULN","Chemotherapy or radiotherapy within 4 weeks prior to enrollment or unresolved toxicities from prior therapy | Receipt of other investigational agents within 4 weeks prior to enrollment | Use of herbs or alternative medicines for prostate cancer (e.g., saw palmetto, PC-SPES) | Prior abiraterone or ketoconazole for prostate cancer | Other malignancy within the past 3 years except adequately treated basal/squamous cell skin cancer or other stage 0–I cancers | Known brain metastases | Allergic reactions to compounds similar to abiraterone or niclosamide | Uncontrolled intercurrent illness (including active infection, symptomatic CHF, unstable angina, cardiac arrhythmia, or significant psychiatric illness) | HIV-positive on combination antiretroviral therapy | Significant gastrointestinal impairment that may alter drug absorption (e.g., ulcerative disease, uncontrolled nausea/vomiting/diarrhea, malabsorption, small bowel resection) | Active bleeding diathesis | History of noncompliance to medical regimens | Unable or unwilling to comply with the protocol | Symptomatic metastatic prostate cancer (e.g., moderate to severe pain, impaired organ function, or spinal cord compression) unless adequately managed","Prior hormonal therapy (bicalutamide, enzalutamide, flutamide, nilutamide) allowed; Prior chemotherapy (docetaxel, cabazitaxel, mitoxantrone) allowed; No chemotherapy or radiotherapy within 4 weeks before enrollment; No investigational agents within 4 weeks before enrollment",MALE,F,"The trial explicitly excludes patients with prior abiraterone use, and the patient previously received abiraterone (Zytiga). Other factors (male, age 66, CRPC) match, but this is a hard exclusion.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with prior abiraterone; the patient received abiraterone (Zytiga). This is a hard exclusion per the rubric, so grade F is correct. Other matches (male, age, CRPC) do not override the exclusion.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT02888743,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC,"This randomized phase II trial studies the side effects of durvalumab and tremelimumab and to see how well they work with or without high or low-dose radiation therapy in treating patients with colorectal or non-small cell lung cancer that has spread to other parts of the body (metastatic). Immunotherapy with durvalumab and tremelimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to...","{'id': 206613843, 'name': 'Durvalumab', 'description': 'Given IV', 'other_names': ['Imfinzi', 'Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer', 'MEDI 4736', 'MEDI-4736', 'MEDI4736'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206613844, 'name': 'Radiation Therapy', 'description': 'Undergo radiation therapy', 'other_names': ['Radiation', 'Cancer Radiotherapy', 'Energy Type', 'ENERGY_TYPE', 'Irradiate', 'Irradiated', 'Irradiation', 'Radiation Therapy, NOS', 'Radiotherapeutics', 'Radiotherapy', 'RT', 'Therapy, Radiation'], 'intervention_type': 'RADIATION'}; {'id': 206613845, 'name': 'Tremelimumab', 'description': 'Given IV', 'other_names': ['Anti-CTLA4 Human Monoclonal Antibody CP-675,206', 'CP 675', 'CP 675206', 'CP-675', 'CP-675,206', 'CP-675206', 'CP675', 'CP675206', 'Imjudo', 'Ticilimumab', 'Tremelimumab-actl'], 'intervention_type': 'BIOLOGICAL'}",PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic); Colorectal Cancer (metastatic),"Histologically or cytologically confirmed non-small cell lung cancer (cohort 1) or colorectal cancer (cohort 2) | Measurable disease per RECIST: >=20 mm by conventional imaging or >=10 mm by spiral CT/MRI/clinical calipers | Progressive disease after prior therapy: NSCLC requires progression on prior PD-1/PD-L1 therapy; CRC requires progression on >=1 line of chemotherapy | >=21 days since prior systemic therapy (chemotherapy or radiation) | ECOG performance status <=1 (Karnofsky >=60%) | Normal organ and marrow function without recent transfusion or growth factor support | Hemoglobin >=9 g/dL | Absolute neutrophil count >=1500/µL | Platelets >=100,000/µL | Total bilirubin <=1.5 x ULN (except Gilbert syndrome) | AST and ALT <=2.5 x ULN (<=5 x ULN with hepatic metastases) | Creatinine clearance >40 mL/min (measured or Cockcroft-Gault) | At least one non-previously irradiated lesion suitable for protocol-specified palliative radiation; not CNS and not the only measurable lesion | Women of childbearing potential: negative pregnancy test and agreement to use highly effective contraception; men and partners agree to contraception per protocol durations | Body weight >30 kg | Life expectancy >=12 weeks | Cohort 1: ability to undergo fresh tumor biopsy or provide recent archival tissue if biopsy not feasible | Cohort 2: ability to undergo fresh tumor biopsy or provide recent archival tissue if biopsy not feasible | Cohort 2: Microsatellite stable (MSS) tumor by IHC (no loss of MLH1, MSH2, PMS2, MSH6) or PCR (no MSI)","Systemic therapy (chemotherapy, biologic therapy) or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) | Prior radiotherapy or conditions leading to excessive cumulative normal tissue dose | Unresolved toxicities from prior therapy > grade 1 (except alopecia/vitiligo) | Concurrent investigational agents | Untreated brain metastases, spinal cord compression, or leptomeningeal disease; or unstable/active CNS disease | Allergic reactions to durvalumab, tremelimumab, or similar agents; prior PD-1/PD-L1 toxicity leading to discontinuation | Prior exposure to immune-mediated therapy including anti-CTLA-4 (not allowed); NSCLC may have prior PD-1/PD-L1 only | Uncontrolled intercurrent illness (active infection, symptomatic CHF, unstable angina, significant arrhythmia, severe psychiatric illness) | Pregnant or breastfeeding | HIV-positive | Concurrent anticancer chemotherapy, immunotherapy, biologic, or hormonal therapy | Immunosuppressive medication within 14 days before first dose (except physiologic-dose steroids and local/inhaled/topical steroids) | Major surgery within 28 days before first dose (palliative local surgery allowed) | History of allogeneic organ transplantation | Active or prior autoimmune or inflammatory disorders within 3 years (with protocol-listed exceptions) | Another active malignancy unless treated with curative intent and disease-free >=5 years or specified in situ/skin cancers | QTc >=470 ms | Active primary immunodeficiency | History of tuberculosis | Active hepatitis B (HBsAg positive) or active hepatitis C (HCV RNA positive) | Live attenuated vaccine within 30 days before first dose and during treatment/30 days after | Any condition that interferes with evaluation of treatment or safety assessment | Unresolved >= grade 2 toxicity from prior anticancer therapy (with specified exceptions) | NSCLC: prior immunotherapy-related AEs not meeting protocol safety resolution criteria | NSCLC: eligibility for approved EGFR, ROS1, or ALK targeted therapy should be evaluated",NSCLC cohort: prior PD-1/PD-L1 therapy with documented progression; Colorectal cohort: progressed on >=1 prior line of chemotherapy; >=21 days washout from prior systemic therapy or radiation before enrollment,ALL,F,"Disease and stage match, but the NSCLC cohort requires prior PD-1/PD-L1 therapy with documented progression, which the patient lacks (only prior osimertinib). This unmet required prior-exposure criterion is a hard exclusion.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),INCORRECT,D,"Patient has metastatic NSCLC (disease/stage match), but lacks the trial’s required prior PD-1/PD-L1 exposure with progression. Per rubric, unmet prior-exposure is a CORE ANCHOR soft mismatch (Line/prior), not a listed hard exclusion. Therefore grade should be D, not F.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT02917993,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer,The purpose of this study is to evaluate the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).,"{'id': 205850342, 'name': 'Itacitinib', 'description': 'In Phase 1, itacitinib at a protocol-defined starting dose, with subsequent dose escalation based on protocol-specific criteria. In Phase 2, itacitinib at the recommended dose from Phase 1.', 'other_names': ['INCB039110'], 'intervention_type': 'DRUG'}; {'id': 205850343, 'name': 'Osimertinib', 'description': 'Osimertinib 80 mg once daily (QD)', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic),"Age >= 18 years | Histologically or cytologically confirmed unresectable locally advanced (Stage IIIB) or metastatic (Stage IV) non-small cell lung cancer | Documented somatic activating EGFR mutation (e.g., G719X, exon 19 deletion, L858R, L861Q) in tumor tissue or plasma | Phase 1: Prior EGFR TKI therapy with documented disease progression | Phase 2: No more than 1 prior line of therapy for advanced disease; first-line EGFR TKI with documented disease progression | Eligible if progression > 6 months after completion of neoadjuvant/adjuvant chemotherapy or chemoradiation, provided EGFR TKI was given as first-line for advanced NSCLC | Evidence of EGFR T790M mutation in tumor or plasma obtained after progression on EGFR TKI (sample available for central analysis) | Radiographically measurable or evaluable disease per RECIST v1.1","Active or progressive CNS metastases or new neurological symptoms attributable to CNS metastases | Use of corticosteroids for CNS metastases not on a stable or decreasing dose for >= 4 weeks before first dose | Laboratory parameters outside protocol-defined ranges | Clinically significant ECG abnormalities | Clinically significant or uncontrolled cardiac disease | Past history of interstitial lung disease, drug-induced ILD, or radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD | Current or previous other malignancy within 2 years except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive malignancy | Concurrent anticancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or hormonal therapy) | Any previous use of a JAK inhibitor | Any previous use of osimertinib | Any previous use of other EGFR-directed therapy for T790M-mutant NSCLC",Prior EGFR TKI with documented progression (Phase 1); No more than 1 prior line for advanced disease; first-line EGFR TKI with progression (Phase 2),ALL,F,"The trial explicitly excludes any previous use of osimertinib, and the patient has been on osimertinib for 2 years. Additionally, the trial requires post-EGFR TKI T790M mutation, which is not documented for this patient.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Correct F due to explicit hard exclusion: trial excludes any prior osimertinib use, and the patient has taken osimertinib for 2 years. The mention of T790M as an additional requirement is not needed and should not drive F when status is unknown, but the hard exclusion alone justifies F.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT02935205,0.8099971413612366,Castration-Resistant Prostate Cancer,A Phase I/II Study of Enzalutamide in Combination With Indomethacin in Castration-Resistant Prostate Cancer (CRPC),"This phase I/II trial studies the side effects of enzalutamide and indomethacin and to see how well they work in treating patients with prostate cancer that does not respond to treatment with hormones, has come back, or has spread from where it started to other places in the body. Androgens can cause the growth of prostate cancer cells. Hormone therapy using enzalutamide and indomethacin may fight prostate cancer by lowering the amount of androgen the body makes and/or blocking the use of and...","{'id': 205448610, 'name': 'Enzalutamide', 'description': 'Given PO', 'other_names': ['ASP9785', 'MDV3100', 'Xtandi'], 'intervention_type': 'DRUG'}; {'id': 205448611, 'name': 'Indomethacin', 'description': 'Given PO', 'other_names': ['Indocin', 'Indometacin'], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,19 years,Prostate Cancer (castration-resistant),"Histologically or cytologically confirmed prostate cancer | Castration-resistant disease | Disease progression by measurable or evaluable criteria or rising PSA | Measurable disease not required | If PSA is the only indicator and no metastases, PSA >= 5.0 ng/mL | Surgically or medically castrated; continue LHRH agonist/antagonist if applicable | Serum testosterone < 50 ng/dL within 3 months | ECOG <= 2 (Karnofsky >= 60%) | Life expectancy > 6 months | Leukocytes >= 3000/µL | Absolute neutrophil count >= 1500/µL | Platelets >= 100000/µL | Total bilirubin <= 1 x ULN | AST/ALT <= 1.5 x ULN | Creatinine <= 1.5 x ULN","Chemotherapy or radiotherapy within 4 weeks or unresolved toxicities from prior therapy | Use of other investigational agents within 4 weeks | Use of herbs or alternative medicines for prostate cancer (e.g., saw palmetto, PC-SPES) | Prior enzalutamide or ketoconazole for prostate cancer | Other malignancy within 3 years except adequately treated basal/squamous cell skin cancer or stage 0/I cancers | Known brain metastases | Hypersensitivity to enzalutamide or indomethacin or similar compounds | Uncontrolled intercurrent illness (e.g., active infection, symptomatic CHF, unstable angina, significant arrhythmia, severe psychiatric illness) | HIV-positive on combination antiretroviral therapy | Significant gastrointestinal impairment affecting drug absorption | Active bleeding diathesis | History of noncompliance to medical regimens | Symptomatic metastatic prostate cancer unless adequately managed (e.g., moderate-severe pain, impaired organ function, spinal cord compression) | History of seizure disorder, brain injury with loss of consciousness, TIA within 12 months, cerebrovascular accident, brain arteriovenous malformation | History of peptic ulcer disease or gastrointestinal bleeding","Ongoing androgen deprivation therapy with LHRH agonist or antagonist required; Washout >= 4 weeks since chemotherapy or radiotherapy; Washout >= 4 weeks since investigational agents; Prior hormonal therapy allowed (e.g., bicalutamide, abiraterone, flutamide, nilutamide); Prior chemotherapy allowed (e.g., docetaxel, cabazitaxel, mitoxantrone)",MALE,F,"The trial explicitly excludes patients with prior enzalutamide exposure, and the patient has progressed on enzalutamide. Therefore, he is ineligible.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,F,"The trial explicitly excludes prior enzalutamide use, and the patient has progressed on enzalutamide. This is a hard exclusion per the rubric, so grade F is correct.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT02971501,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,A Phase II Trial of Osimertinib (AZD9291) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases,This phase II trial studies how well osimertinib with or without bevacizumab works in treating patients with EGFR positive non-small cell lung cancer that has spread to the brain (brain metastases). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab may stop or slow non-small cell lung cancer by blocking the growth of new blood vessels necessary for tumor growth. Giving osimertinib with or without bevacizumab may work better in t...,"{'id': 206420147, 'name': 'Bevacizumab', 'description': 'Given IV', 'other_names': ['ABP 215', 'ABP-215', 'ABP215', 'Alymsys', 'Anti-VEGF', 'Anti-VEGF Humanized Monoclonal Antibody', 'Anti-VEGF Monoclonal Antibody SIBP04', 'Anti-VEGF rhuMAb', 'Avastin', 'Avzivi', 'Aybintio', 'BAT 1706', 'BAT-1706', 'BAT1706', 'BAT1706 Biosimilar', 'Bevacizumab awwb', 'Bevacizumab Biosimilar ABP 215', 'Bevacizumab Biosimilar BAT1706', 'Bevacizumab Biosimilar BEVZ92', 'Bevacizumab Biosimilar BI 695502', 'Bevacizumab Biosimilar CBT 124', 'Bevacizumab Biosimilar CT-P16', 'Bevacizumab Biosimilar FKB238', 'Bevacizumab Biosimilar GB-222', 'Bevacizumab Biosimilar HD204', 'Bevacizumab Biosimilar HLX04', 'Bevacizumab Biosimilar IBI305', 'Bevacizumab Biosimilar LY01008', 'Bevacizumab Biosimilar MB02', 'Bevacizumab Biosimilar MIL60', 'Bevacizumab Biosimilar Mvasi', 'Bevacizumab Biosimilar MYL-1402O', 'Bevacizumab Biosimilar QL 1101', 'Bevacizumab Biosimilar QL1101', 'Bevacizumab Biosimilar RPH-001', 'Bevacizumab Biosimilar SCT501', 'Bevacizumab Biosimilar Zirabev', 'Bevacizumab-adcd', 'Bevacizumab-awwb', 'Bevacizumab-aybi', 'Bevacizumab-bvzr', 'Bevacizumab-equi', 'Bevacizumab-maly', 'Bevacizumab-onbe', 'Bevacizumab-tnjn', 'BP102', 'BP102 Biosimilar', 'CT P16', 'CT-P16', 'CTP16', 'Equidacent', 'FKB 238', 'FKB-238', 'FKB238', 'HD204', 'Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer', 'MB 02', 'MB-02', 'MB02', 'Mvasi', 'MYL-1402O', 'Onbevzi', 'Oyavas', 'PF 06439535', 'PF-06439535', 'PF06439535', 'QL1101', 'Recombinant Humanized Anti-VEGF Monoclonal Antibody', 'rhuMab-VEGF', 'SCT501', 'SIBP 04', 'SIBP-04', 'SIBP04', 'Vegzelma', 'Zirabev'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206420148, 'name': 'Biopsy Procedure', 'description': 'Undergo tumor biopsy', 'other_names': ['Biopsy', 'BIOPSY_TYPE', 'Bx'], 'intervention_type': 'PROCEDURE'}; {'id': 206420149, 'name': 'Biospecimen Collection', 'description': 'Undergo blood sample collection', 'other_names': ['Biological Sample Collection', 'Biospecimen Collected', 'Specimen Collection'], 'intervention_type': 'PROCEDURE'}; {'id': 206420150, 'name': 'Computed Tomography', 'description': 'Undergo CT scan', 'other_names': ['tomography', 'CAT', 'CAT Scan', 'Computed Axial Tomography', 'Computerized Axial Tomography', 'Computerized axial tomography (procedure)', 'Computerized Tomography', 'Computerized Tomography (CT) scan', 'CT', 'CT Scan', 'Diagnostic CAT Scan', 'Diagnostic CAT Scan Service Type'], 'intervention_type': 'PROCEDURE'}; {'id': 206420151, 'name': 'Magnetic Resonance Imaging', 'description': 'Undergo MRI', 'other_names': ['Magnetic Resonance', 'Magnetic Resonance Imaging (MRI)', 'Magnetic resonance imaging (procedure)', 'Magnetic Resonance Imaging Scan', 'Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance', 'MR', 'MR Imaging', 'MRI', 'MRI Scan', 'MRIs', 'NMR Imaging', 'NMRI', 'Nuclear Magnetic Resonance Imaging', 'sMRI', 'Structural MRI'], 'intervention_type': 'PROCEDURE'}; {'id': 206420152, 'name': 'Osimertinib', 'description': 'Given PO', 'other_names': ['AZD 9291', 'AZD-9291', 'AZD9291', 'Mereletinib'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic); Brain Metastases,"Non-small cell lung cancer with an activating EGFR mutation (exon 19 deletion, L858R, or other EGFR TKI–sensitive mutation) documented in CLIA-certified testing | At least one measurable asymptomatic, untreated CNS lesion >= 5 mm by brain MRI | Measurable systemic disease not required; if present must meet standard radiographic size criteria | Age >= 18 years | ECOG performance status <= 2 | Life expectancy > 3 months | Stable dose anticonvulsants with no seizures for >= 2 weeks prior to therapy","Symptomatic brain metastases or symptomatic leptomeningeal disease | Brain metastases for which complete surgical resection is clinically appropriate | Prior treatment with any EGFR TKI | Prior treatment with VEGF pathway inhibitors, including bevacizumab | Current or recent use of corticosteroids for cerebral edema or neurologic symptoms (unless off for >= 3 days without recurrent symptoms) | Use of other investigational agents or participation in another investigational study within 5 half-lives or 3 months (whichever is greater) | Unresolved toxicities from prior therapy > CTCAE grade 1 (except alopecia and grade 2 platinum-related neuropathy) | Concurrent active malignancy (except non-melanoma skin cancers) | Contraindication to MRI | History of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonitis requiring steroids, or evidence of active interstitial lung disease | Hypersensitivity to osimertinib, bevacizumab, or similar compounds (including CHO-derived products) | Proteinuria >= 1000 mg/24 h | Serious or non-healing wound, ulcer, or bone fracture | Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months | Major surgery, open biopsy, or significant traumatic injury within 28 days; core biopsy within 7 days; anticipated need for major surgery | Significant vascular disease (e.g., aortic aneurysm, recent peripheral arterial thrombosis) within 6 months | Inadequately controlled hypertension (SBP > 160 mmHg and/or DBP > 90 mmHg despite medication) | Cerebrovascular accident within 6 months | Myocardial infarction or unstable angina within 6 months | NYHA class II or greater congestive heart failure | Serious or inadequately controlled cardiac arrhythmia | Clinically significant peripheral vascular disease | QTcF > 470 ms or clinically important ECG abnormalities (e.g., complete LBBB, second/third degree heart block) | Risk factors for QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, congenital long QT, family history of long QT or unexplained sudden death < 40 years) | Bleeding diathesis or coagulopathy, including clinically significant hemoptysis | Refractory nausea/vomiting, chronic GI disease, inability to swallow, or prior bowel resection precluding adequate absorption of osimertinib | Known hypersensitivity to recombinant human antibodies | Use of potent CYP3A4 inducers within at least 3 weeks prior to first dose or inability to avoid them | Severe or uncontrolled systemic disease or active infection (including hepatitis B, hepatitis C, or HIV) | ANC < 1.5 x 10^9/L | Platelets < 100 x 10^9/L | Hemoglobin < 90 g/L | AST > 2.5 x ULN (or > 5 x ULN with liver metastases) | ALT > 2.5 x ULN (or > 5 x ULN with liver metastases) | Total bilirubin > 1.5 x ULN (or > 3 x ULN with Gilbert's syndrome or liver metastases) | Serum creatinine > 1.5 x ULN with creatinine clearance < 50 mL/min",Prior chemotherapy allowed,ALL,F,"The trial explicitly excludes patients with prior treatment with any EGFR TKI, and the patient has received osimertinib. Additionally, the trial requires untreated, asymptomatic brain metastases, which are not documented for this patient.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Hard exclusion applies: the trial excludes any prior EGFR TKI, and the patient has been on osimertinib. That alone mandates F per rubric. The note about untreated brain metastases is ancillary and not required to justify F.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03137771,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial,"This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without local consolidation therapy works in treating patients with stage IV non-small cell lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Local consolidation ther...","{'id': 205962931, 'name': '3-Dimensional Conformal Radiation Therapy (3D-CRT)', 'description': 'Undergo 3DCRT', 'other_names': ['3-dimensional conformal radiation therapy', '3-dimensional radiation therapy', '3D CONFORMAL RADIATION THERAPY', '3D CRT', '3D-CRT', 'Conformal Therapy', 'Radiation Conformal Therapy'], 'intervention_type': 'RADIATION'}; {'id': 205962932, 'name': 'Docetaxel', 'description': 'Given IV', 'other_names': ['Docecad', 'RP56976', 'Taxotere', 'Taxotere Injection Concentrate'], 'intervention_type': 'DRUG'}; {'id': 205962933, 'name': 'Gemcitabine', 'description': 'Given IV', 'other_names': ['dFdC', 'dFdCyd', 'Difluorodeoxycytidine'], 'intervention_type': 'DRUG'}; {'id': 205962934, 'name': 'Intensity-Modulated Radiation Therapy (IMRT)', 'description': 'Undergo IMRT', 'other_names': ['IMRT', 'Intensity Modulated RT', 'INTENSITY-MODULATED RADIATION THERAPY', 'Intensity-Modulated Radiotherapy'], 'intervention_type': 'RADIATION'}; {'id': 205962935, 'name': 'Pemetrexed Disodium', 'description': 'Given IV', 'other_names': ['Alimta', 'LY231514', 'N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt'], 'intervention_type': 'DRUG'}; {'id': 205962936, 'name': 'Stereotactic Body Radiation Therapy (SBRT)', 'description': 'Undergo SBRT', 'other_names': ['SBRT', 'stereotactic body radiation therapy'], 'intervention_type': 'RADIATION'}; {'id': 205962937, 'name': 'Erlotinib Hydrochloride', 'description': 'Given PO', 'other_names': ['Tarceva'], 'intervention_type': 'DRUG'}; {'id': 205962938, 'name': 'Pembrolizumab', 'description': 'Given IV', 'other_names': ['Keytruda'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic),"Pathologically confirmed non-small cell lung cancer with metastatic (stage IV) disease and limited metastases (<=3 sites) | Imaging confirmation of limited metastatic disease and response/stable disease on CT chest through adrenals or PET/CT within 30 days | Zubrod performance status 0–2 within 30 days | AST <= 2.5 x ULN (<= 5 x ULN with liver metastases) | ALT <= 2.5 x ULN (<= 5 x ULN with liver metastases) | Total bilirubin <= 1.5 x ULN | Absolute neutrophil count >= 500/µL | Platelets >= 50,000/µL | Creatinine <= 1.5 x ULN or creatinine clearance > 45 mL/min if creatinine > 1.5 x ULN | Received first-line/induction systemic therapy with immunotherapy and/or platinum-based chemotherapy for 4–5 cycles with stable disease or partial response | For nivolumab + chemotherapy regimens: total of 4–5 doses of nivolumab (with ipilimumab as specified) acceptable to meet induction requirement | Residual disease site(s) (primary and/or up to 3 metastases) amenable to local consolidative therapy after induction | Prior systemic/adjuvant/neoadjuvant therapy for stage I–III NSCLC permitted | Previously treated/resolved brain metastases allowed without evidence of progression prior to registration | Palliative radiotherapy prior to registration allowed if at least one other lesion remains amenable to local consolidative therapy | HIV-infected patients on effective antiretroviral therapy with undetectable viral load within 6 months are eligible","Untreated or progressive brain metastases after induction therapy | Cutaneous metastasis of NSCLC | Metastatic disease invading esophagus, stomach, intestines, or mesenteric lymph nodes if not a surgical candidate | Prior invasive malignancy (except specified low-risk cancers) unless disease-free for >= 1 year | Metastases within 3 cm of previously irradiated critical structures when not a surgical candidate and prior doses exceed tolerance (e.g., spinal cord > 40 Gy, brachial plexus > 50 Gy, bowel/stomach > 45 Gy, brainstem > 50 Gy, lung prior V20 > 35%) | Receiving first-line targeted therapy (non-cytotoxic systemic therapy) for NSCLC | Driver mutations with available targeted therapies (e.g., EGFR mutant, ALK positive) | Requirement for re-irradiation of prior high-dose regions for progressing primary disease | Malignant pleural effusion not resolved after first-line systemic therapy | More than 3 discrete extracranial metastatic locations after first-line therapy requiring more than 3 radiation/surgery plans | Acute bacterial or fungal infection requiring intravenous antibiotics | Pregnancy or breastfeeding | Participation in an investigational cancer drug study within 4 weeks | For patients who received immunotherapy during induction: chronic steroids or active autoimmune disease requiring systemic treatment within the previous 2 years | Active interstitial lung disease or history of pneumonitis treated with glucocorticoids | Use of bevacizumab or other antiangiogenic therapy in first-line or planned maintenance therapy",Completed 4–5 cycles of first-line induction immunotherapy and/or platinum-based chemotherapy with stable disease or partial response; Nivolumab plus ipilimumab regimens allowed if totaling 2 doses of ipilimumab and 4–5 doses of nivolumab; nivolumab + 2 cycles chemotherapy allowed if 4–5 total nivolumab doses; Prior systemic/adjuvant/neoadjuvant therapy for stage I–III NSCLC permitted; Prior radiotherapy for brain metastases permitted; Palliative radiotherapy prior to registration permitted if another lesion remains for local consolidative therapy; No investigational cancer therapy within 4 weeks prior to registration,ALL,F,"The trial explicitly excludes patients with EGFR driver mutations and those receiving first-line targeted therapy; this patient has an EGFR exon 19 deletion and has been on first-line osimertinib. Additionally, the trial requires induction chemo/immunotherapy and limited metastases (<=3), which are not met.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with EGFR driver mutations and those receiving first-line targeted therapy; the patient has EGFR exon 19 and is on first-line osimertinib. This is a hard exclusion, so F is correct. Other mismatches (induction chemo/immunotherapy requirement and limited metastases ≤3) further support ineligibility but are not needed for the F.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT03162432,0.6691051721572876,Fistulizing Crohn's Disease,High Dose Interval Vitamin D Supplementation in Patients With IBD Receiving Remicade,The goal of this study will be to assess the safety and efficacy of high-dose interval Vitamin D3 therapy in children and young adults with Inflammatory Bowel Disease being treated with serial Remicade infusions.,"{'id': 205625786, 'name': 'Vitamin D3', 'description': 'Oral Vitamin D3 therapy.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,7 years to 25 years,Crohn Disease; Ulcerative Colitis,Existing diagnosis of inflammatory bowel disease | Age 0–25 years | Serum 25-OH vitamin D level 15–29 ng/mL within the last 8 weeks with no changes in vitamin D supplementation in the interim,"Pregnant | History of underlying kidney disease | History of granulomatous disease | Inability to take oral vitamin D | History of hypercalcemia | History of hypercalciuria | Currently taking an anti-epileptic medication | History of pre-existing liver disease (excluding primary sclerosing cholangitis, non-alcoholic fatty liver disease, or steatohepatitis)",(none),ALL,F,"Although the disease (Crohn's disease) matches, the trial restricts age to 7–25 years and the patient is 32, which is a hard exclusion. Other required criteria (e.g., vitamin D level 15–29 ng/mL) are unknown but do not overcome the age mismatch.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Patient age 32 exceeds trial’s maximum age 25, which is a hard exclusion per rubric. Disease matches and other criteria (e.g., vitamin D level) are unknown and do not override the age exclusion. The grader’s F is correct.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03164616,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,"A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)","This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.","{'id': 206152505, 'name': 'Durvalumab', 'description': 'IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until disease progression or other discontinuation criteria', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206152506, 'name': 'Tremelimumab', 'description': 'IV infusions every 3 weeks for 12 weeks (4 cycles). An additional dose of tremelimumab will be administered in the week 16.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206152507, 'name': 'Abraxane + carboplatin', 'description': 'Standard of care chemotherapy (squamous and non-squamous patients): Abraxane 100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle. Carboplatin Area under the plasma drug concentration-time curve (AUC) 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206152508, 'name': 'Gemcitabine + cisplatin', 'description': 'Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206152509, 'name': 'Gemcitabine + carboplatin', 'description': 'Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206152510, 'name': 'Pemetrexed + carboplatin', 'description': 'Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \\[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\\] until objective disease progression.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206152511, 'name': 'Pemetrexed + cisplatin', 'description': 'Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \\[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\\] until objective disease progression.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,18 years to 130 years,Non-Small Cell Lung Cancer (metastatic),Age >= 18 years | Histologically or cytologically confirmed Stage IV NSCLC | Confirmed tumor PD-L1 status prior to randomization | Tumors lack activating EGFR mutations and ALK fusions | No prior chemotherapy or other systemic therapy for metastatic NSCLC | ECOG 0-1 | No prior exposure to immune-mediated therapy (excluding therapeutic anticancer vaccines),"Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant | Active or prior documented autoimmune or inflammatory disorders | Untreated or unstable brain metastases or spinal cord compression; requires stability off steroids | Active infection including tuberculosis, hepatitis B, hepatitis C, or HIV",No prior systemic therapy for metastatic NSCLC; No prior exposure to immune-mediated therapy (excluding therapeutic anticancer vaccines),ALL,F,The trial requires tumors to lack activating EGFR mutations and excludes any prior systemic therapy for metastatic NSCLC; the patient has an EGFR exon 19 deletion and has received osimertinib. These are hard exclusions.,Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"The trial requires EGFR-wildtype (lack of activating EGFR mutations) and no prior systemic therapy for metastatic NSCLC. The patient has an EGFR exon 19 deletion and has received osimertinib. Both are explicit hard exclusions, so F is correct.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03391869,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR),"This phase III trial studies how well nivolumab and ipilimumab works with or without local consolidation therapy in treating patients with stage IV non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Local consolidation therapy, such as surgery or radiation therapy, may improve survival outcomes in patients with non-smal...","{'id': 206435839, 'name': 'Ipilimumab', 'description': 'Given IV', 'other_names': ['Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody', 'BMS-734016', 'Ipilimumab Biosimilar CS1002', 'MDX-010', 'MDX-CTLA4', 'Yervoy'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206435840, 'name': 'Local Consolidation Therapy', 'description': 'Undergo radiation and/or surgery', 'other_names': ['LCT', 'Local Consolidative Therapy'], 'intervention_type': 'PROCEDURE'}; {'id': 206435841, 'name': 'Nivolumab', 'description': 'Given IV', 'other_names': ['BMS-936558', 'MDX-1106', 'NIVO', 'ONO-4538', 'Opdivo'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206435842, 'name': 'Quality-of-Life Assessment', 'description': 'Ancillary studies', 'other_names': ['Quality of Life Assessment'], 'intervention_type': 'OTHER'}; {'id': 206435843, 'name': 'Radiation Therapy', 'description': 'Undergo radiation', 'other_names': ['Cancer Radiotherapy', 'ENERGY_TYPE', 'Irradiate', 'Irradiated', 'Irradiation', 'Radiation', 'Radiation Therapy, NOS', 'Radiotherapeutics', 'Radiotherapy', 'RT', 'Therapy, Radiation'], 'intervention_type': 'RADIATION'}; {'id': 206435844, 'name': 'Therapeutic Conventional Surgery', 'description': 'Undergo surgery', 'other_names': [], 'intervention_type': 'PROCEDURE'}",PHASE3,18 years,Non-Small Cell Lung Cancer (metastatic),"Histologically or cytologically confirmed non-small cell lung cancer; neuroendocrine carcinomas (e.g., small cell, carcinoid) excluded; carcinomas with neuroendocrine differentiation eligible | Stage IV measurable disease per RECIST 1.1 | For lung adenocarcinoma: absence of EGFR sensitizing mutation and ALK fusion when standard therapies are available; testing by CLIA-certified tumor or plasma assay | One prior line of chemotherapy and/or targeted therapy for metastatic disease permitted (frontline, including maintenance); prior antiangiogenic therapy permitted if used frontline | ECOG performance status 0–1 | Adequately treated brain metastases or asymptomatic small (<=1 cm) brain metastases allowed if neurologically stable and off corticosteroids or on <=10 mg daily prednisone (or equivalent) for >=2 weeks | For cohort 1: prior palliative radiotherapy allowed if at least one other non-irradiated lesion amenable to LCT remains | Cohort 2: radiologic progression during induction phase prior to randomization | Cohort 2: start platinum doublet plus immune checkpoint inhibitor within 6 weeks after last day of prior immune checkpoint inhibitor therapy | Cohort 2: willingness to undergo pre-treatment and on-treatment tumor biopsies (or archival tissue if unsafe to biopsy) | Cohort 2: radiotherapy for symptomatic metastases at time of progression permitted | WBC >= 2000/µL | Neutrophils >= 1500/µL | Platelets >= 100000/µL | Hemoglobin > 9.0 g/dL | Serum creatinine <= 1.5 x ULN or creatinine clearance >= 50 mL/min | AST <= 3 x ULN | ALT <= 3 x ULN | Total bilirubin <= 1.5 x ULN (Gilbert syndrome allowed if total bilirubin < 3.0 mg/dL)","Prior systemic immunotherapy for metastatic NSCLC (e.g., PD-1/PD-L1 or CTLA-4 inhibitors) | Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to study treatment (except hormone-replacement therapy or oral contraceptives) | Prior pneumonitis requiring corticosteroids within 60 days before first dose of nivolumab | Active, known, or suspected autoimmune disease (exceptions: vitiligo, type I diabetes, residual hypothyroidism on replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur) | Systemic immunosuppressive treatment >10 mg/day prednisone equivalents within 14 days of study drug administration (with specified exceptions) | Positive hepatitis B surface antigen or positive hepatitis C indicating acute or chronic infection | Known HIV infection or AIDS | History of severe hypersensitivity to monoclonal antibodies or allergy to study drug components | Women must not be breastfeeding","One prior line of chemotherapy and/or targeted therapy for metastatic disease permitted (frontline, including maintenance); Prior antiangiogenic therapy permitted if used in frontline setting",ALL,F,"The trial requires absence of EGFR sensitizing mutations for lung adenocarcinoma, but the patient has an EGFR exon 19 deletion. Therefore, this is a required biomarker mismatch and a hard exclusion.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),INCORRECT,A,"The EGFR-wildtype requirement is specified only for lung adenocarcinoma; histology is not provided, so per rubric you cannot assume adenocarcinoma and cannot invoke a hard exclusion. With no definitive hard exclusions, stage/setting and prior-exposure/line anchors both match (metastatic NSCLC; immunotherapy-naive; one prior targeted line permitted). Thus the correct grade is A, not F.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT03406611,0.5332883596420288,Ornithine Transcarbamylase Deficiency,"A Double Blind, Randomized, Placebo-controlled, Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effects on Clinical Outcomes of Pegtibatinase (TVT-058), Administered Subcutaneously in Patients with Cystathionine Beta-Synthase Deficient Homocystinuria (COMPOSE)","Homocystinuria caused by Cystathionine Beta-Synthase (CBS) Deficiency is a rare autosomal-recessive metabolic condition characterized by an excess of homocysteine (Hcy) in the plasma, tissues and urine. It is due to reduced or absent activity of the CBS enzyme, and is also known as classical homocystinuria. The symptoms associated with homocystinuria are variable in severity and time of onset across patients. Some affected individuals may have mild signs of the disorder; others may have multi...","{'id': 205349560, 'name': 'Pegtibatinase', 'description': 'Pegtibatinase sterile solution for subcutaneous injection', 'other_names': ['TVT-058', 'OT-58', 'PEG modified CBS, PEG htCBS C15S, htCBS C15S ME-200GS'], 'intervention_type': 'DRUG'}; {'id': 205349561, 'name': 'Placebo', 'description': 'Normal saline for subcutaneous injection', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,12 years to 65 years,Homocystinuria,Genetic confirmation of cystathionine beta-synthase deficient homocystinuria | Plasma total homocysteine >= 50 micromoles/L with prior documented total homocysteine >= 80 micromoles/L,"Previous exposure to pegtibatinase or prior participation in a pegtibatinase trial | Use of injectable polyethylene glycol (PEG)–containing drugs within 3 months prior to screening and during study participation | Known hypersensitivity to PEG-containing products or any components of pegtibatinase | Positive test for HIV antibody, hepatitis B surface antigen, or hepatitis C antibody | History of organ transplantation | Chronic immunosuppressive therapy | Substance abuse | Pregnant or breastfeeding or planning pregnancy/breastfeeding during the study | Concurrent disease or condition that would interfere with study participation or safety in the opinion of the investigator | Planned major surgery during the study period | High risk of poor treatment compliance or not completing the study in the investigator's opinion",No investigational product or investigational medical device within 30 days prior to screening,ALL,F,"Disease mismatch: the trial targets cystathionine beta-synthase–deficient homocystinuria, while the patient has OTC deficiency. Additionally, the patient is 3 months old, which is outside the trial’s 12–65 year age range, and the required CBS biomarker is not met.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Correct: There is a hard disease mismatch (OTC deficiency vs CBS-deficient homocystinuria), a hard age window conflict (3 months vs 12–65 years), and a required biomarker mismatch (CBS required, patient has OTC). Any one warrants F; multiple are present.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03410043,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,Randomized Phase II Trial of Osimertinib With or Without Local Consolidation Therapy (LCT) for Patients With EGFR-Mutant Metastatic NSCLC (NORTHSTAR),"This phase II trial studies how well osimertinib, surgery, and radiation therapy work in treating patients with stage IIIB or IV non-small cell lung cancer with EGFR mutations. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving osimertinib, surgery, and radiation therapy may work better at treating non-small cell lung cancer with EGFR mutations.","{'id': 205798390, 'name': 'Osimertinib', 'description': 'Given PO', 'other_names': ['AZD-9291', 'AZD9291', 'Mereletinib', 'Tagrisso'], 'intervention_type': 'DRUG'}; {'id': 205798391, 'name': 'Radiation Therapy', 'description': 'Undergo radiation therapy', 'other_names': ['Cancer Radiotherapy', 'ENERGY_TYPE', 'Irradiate', 'Irradiated', 'Irradiation', 'Radiation', 'Radiation Therapy, NOS', 'Radiotherapeutics', 'Radiotherapy', 'RT', 'Therapy, Radiation'], 'intervention_type': 'RADIATION'}; {'id': 205798392, 'name': 'Therapeutic Conventional Surgery', 'description': 'Undergo surgery', 'other_names': [], 'intervention_type': 'PROCEDURE'}",PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic),"Histologically or cytologically confirmed non-small cell lung cancer | Stage IIIB/IV or recurrent NSCLC not amenable to curative therapy | EGFR exon 19 deletion or L858R mutation and TKI naive, or acquired EGFR T790M after progression on erlotinib/gefitinib/afatinib with no prior third-generation EGFR TKI (CLIA-certified test) | ECOG <=1 | Measurable disease per RECIST 1.1 | Candidate for local consolidative therapy to at least one site | Ability to take oral medication | Life expectancy >= 12 weeks | For randomization: no progression after 6–12 weeks of osimertinib per RECIST 1.1 with required body and brain imaging | For randomization: target lesions amenable to LCT","Prior treatment with osimertinib or any third-generation EGFR TKI | Use of potent CYP3A4 inducers within 3 weeks prior to first dose | Symptomatic or neurologically unstable CNS metastases | Unresolved toxicities from prior therapy > CTCAE grade 1 (except alopecia grade 2) | Severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diathesis, or active infection (hepatitis B, hepatitis C, HIV) | Refractory nausea/vomiting, chronic GI disease, inability to swallow, or prior significant bowel resection impairing absorption | History of interstitial lung disease, drug-induced ILD, radiation pneumonitis requiring steroids, or active ILD | Pregnant or breastfeeding | Hypersensitivity to osimertinib or its excipients | QTcF > 470 msec, clinically important ECG abnormalities, or risk factors/medications predisposing to QT prolongation or arrhythmia | Excluded from randomization: complete response to induction osimertinib or prior treatment to all visible lesions leaving none amenable to LCT","TKI naive required for EGFR exon 19 deletion or L858R cohort; Prior erlotinib, gefitinib, or afatinib allowed if acquired EGFR T790M present; No prior third-generation EGFR TKI; No prior osimertinib; Palliative radiation to urgent lesions (including CNS) allowed before randomization if at least one site remains amenable to LCT; Induction osimertinib for 6–12 weeks required before randomization",ALL,F,"The trial explicitly excludes patients with prior osimertinib or any third-generation EGFR TKI; this patient has been on osimertinib for 2 years, constituting a hard exclusion.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"The trial explicitly excludes any prior osimertinib or third-generation EGFR TKI, while the patient has been on osimertinib for 2 years. This is a hard exclusion per rubric, so F is correct regardless of other matches.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT03419234,1.0,Castration-Resistant Prostate Cancer,Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial,"This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with docetaxel that has spread to other parts of the body. Androgens can cause the growth of prostate cancer cells. Hormone therapy using abiraterone acetate and antiandrogen therapy may fight prostate cancer by lowering and/or blocking the use of androgens by the tumor c...","{'id': 206556660, 'name': 'Abiraterone Acetate', 'description': 'Given PO', 'other_names': ['CB7630', 'Zytiga'], 'intervention_type': 'DRUG'}; {'id': 206556661, 'name': 'Antiandrogen Therapy', 'description': 'Receive standard of care antiandrogen therapy with either LHRH agonist or antagonist', 'other_names': ['ADT', 'Androgen Deprivation Therapy', 'Anti-androgen Therapy', 'Anti-androgen Treatment', 'Antiandrogen Treatment', 'Hormone Deprivation Therapy', 'Hormone-Deprivation Therapy'], 'intervention_type': 'DRUG'}; {'id': 206556662, 'name': 'Cabazitaxel', 'description': 'Given IV', 'other_names': ['Jevtana', 'RPR-116258A', 'Taxoid XRP6258', 'XRP-6258'], 'intervention_type': 'DRUG'}; {'id': 206556663, 'name': 'Laboratory Biomarker Analysis', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206556664, 'name': 'Orchiectomy', 'description': 'Undergo standard of care surgical castration with bilateral orchiectomy', 'other_names': ['Castration', 'Male Castration', 'Male Gonadectomy', 'orchidectomy'], 'intervention_type': 'PROCEDURE'}; {'id': 206556665, 'name': 'Pharmacological Study', 'description': 'Correlative studies', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206556666, 'name': 'Prednisone', 'description': 'Given PO', 'other_names': ['.delta.1-Cortisone', '1, 2-Dehydrocortisone', 'Adasone', 'Cortancyl', 'Dacortin', 'DeCortin', 'Decortisyl', 'Decorton', 'Delta 1-Cortisone', 'Delta-Dome', 'Deltacortene', 'Deltacortisone', 'Deltadehydrocortisone', 'Deltasone', 'Deltison', 'Deltra', 'Econosone', 'Lisacort', 'Meprosona-F', 'Metacortandracin', 'Meticorten', 'Ofisolona', 'Orasone', 'Panafcort', 'Panasol-S', 'Paracort', 'PRED', 'Predicor', 'Predicorten', 'Prednicen-M', 'Prednicort', 'Prednidib', 'Prednilonga', 'Predniment', 'Prednisonum', 'Prednitone', 'Promifen', 'Servisone', 'SK-Prednisone'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Castration-Resistant Prostate Cancer,"Histologically confirmed adenocarcinoma of the prostate | Prior >= 3 cycles of docetaxel for hormone-sensitive metastatic prostate cancer | Metastatic disease on imaging (soft tissue and/or bone) | Receiving androgen deprivation therapy (surgical castration or LHRH agonist/antagonist) and will continue during study | Castrate serum testosterone < 50 ng/dL | PSA progression on ADT: >= 2 consecutive rises with final value >= 2.0 ng/mL | Measurable disease progression per RECIST 1.1 (> 20% increase in sum of diameters or new measurable lesions; lymph node short axis > 15 mm to assess change) | Bone disease progression on ADT: >= 2 new lesions on bone scan or NaF PET/CT | ECOG performance status 0–2 | Absolute neutrophil count >= 1500/µL | Hemoglobin >= 9.0 g/dL | Platelets >= 100,000/µL | Creatinine < 2.0 mg/dL | Treated brain metastases allowed if steroids <= 10 mg prednisone daily (or equivalent)","Any prior chemotherapy or androgen receptor-directed therapy for castration-resistant prostate cancer (e.g., docetaxel, cabazitaxel, mitoxantrone, abiraterone, ketoconazole, enzalutamide); prior radium-223 or sipuleucel-T allowed | Pure small cell or other non-adenocarcinoma prostate cancer histology inappropriate for abiraterone | Concurrent therapeutic investigational agents or anticancer therapy other than standard ADT; bone-protective agents allowed if initiated prior to entry | Contraindication to prednisone (corticosteroids) | Total bilirubin > ULN (unless Gilbert’s syndrome with normal direct bilirubin) | ALT > 1.5 x ULN | AST > 1.5 x ULN | Active infection requiring antibiotics | History of adrenal insufficiency or hypoaldosteronism | Myocardial infarction or arterial thrombotic event within 6 months | Heart failure NYHA class II or higher | Uncontrolled angina | Severe uncontrolled ventricular arrhythmia | External beam radiation therapy within 4 weeks of registration | History of allergic reactions to G-CSF | History of allergic reactions to docetaxel or to polysorbate 80–containing medications | Active malignancy within 3 years except adequately treated non-melanoma skin cancer or bladder carcinoma in situ | Life expectancy < 12 months | Neuropathy grade >= 2",Received >= 3 cycles of docetaxel for hormone-sensitive metastatic prostate cancer; Receiving ongoing androgen deprivation therapy (LHRH agonist/antagonist or bilateral orchiectomy) throughout study; Prior nonsteroidal antiandrogen allowed with washout (>= 4 weeks for flutamide; >= 6 weeks for bicalutamide or nilutamide) and PSA progression after discontinuation,MALE,F,"The trial explicitly excludes patients with any prior androgen receptor–directed therapy for castration-resistant prostate cancer (e.g., enzalutamide/abiraterone), which this patient received with progression on enzalutamide. Additionally, the required prior docetaxel for hormone-sensitive disease is not documented.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,F,"Correct: Trial explicitly excludes any prior AR-directed therapy for CRPC (e.g., abiraterone, enzalutamide), which the patient has (progressed on enzalutamide). The missing documentation of prior docetaxel should not drive the grade, but the hard exclusion already warrants F.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03459846,0.8805802464485168,Metastatic Urothelial Carcinoma,"A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer","A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer","{'id': 206514661, 'name': 'Durvalumab', 'description': 'Durvalumab 1500 mg IV q4w', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206514662, 'name': 'Olaparib', 'description': ""Olaparib PO 300 mg BID adjusted based on patient's creatinine clearance."", 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206514663, 'name': 'Placebo', 'description': 'Matching placebo for oral tablet BID', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,18 years to 130 years,Urothelial Carcinoma (metastatic),"Histologically or cytologically confirmed urothelial carcinoma of the renal pelvis, ureter, urinary bladder, or urethra | Unresectable Stage IV disease | No prior systemic therapy for unresectable Stage IV disease | Platinum-ineligible: unfit for carboplatin and meeting at least one of the following: creatinine clearance <60 mL/min, CTCAE grade >=2 hearing loss, CTCAE grade >=2 peripheral neuropathy, NYHA class III heart failure, or ECOG 2 | Known tumor HRR mutation status prior to randomization | ECOG performance status 0–2 | At least one RECIST 1.1 target lesion at baseline | Ability to swallow oral medications | Postmenopausal status or negative pregnancy test for premenopausal females","Active or prior autoimmune or inflammatory disorders | Other invasive malignancy within 5 years before first dose | Major surgery within 28 days before first dose | Active brain metastases or spinal cord compression unless stable and off steroids for >=14 days | History of active primary immunodeficiency | Active infection including tuberculosis | History of allogeneic organ transplantation | Uncontrolled intercurrent illness | Prior exposure to a PARP inhibitor or immune-mediated therapy | Concurrent chemotherapy, investigational product, biologic, or hormonal anticancer therapy | Use of immunosuppressive medication within 14 days before first dose | Radiation therapy not meeting allowed exceptions (only definitive >=12 months prior or specified limited palliative RT allowed) | Receipt of live attenuated vaccine within 30 days before first dose | Known hypersensitivity to durvalumab, olaparib, or excipients | Pregnant or breastfeeding | Patients of reproductive potential unwilling to use effective birth control for the protocol-specified duration",No prior systemic therapy for unresectable Stage IV disease; Prior definitive radiation allowed if >=12 months before first dose; Palliative brain radiation allowed if clinically stable and off steroids per protocol; Palliative radiation to painful bony lesions or symptomatic pelvic soft tissue allowed if <30% bone marrow treated,ALL,F,"The trial is for first-line unresectable Stage IV disease and excludes any prior systemic therapy and prior immune-mediated therapy; the patient has already received enfortumab vedotin plus pembrolizumab for metastatic disease, violating both requirements.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,F,Hard exclusions apply: the trial requires no prior systemic therapy for unresectable Stage IV (patient is post-second line) and explicitly excludes prior immune-mediated therapy (patient received pembrolizumab). Either condition alone warrants F. The grader’s reasoning correctly identified these.,,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT03531736,0.450744092464447,PMM2-CDG,Allogeneic Hematopoietic Stem Cell Transplantation of α/β T-Lymphocyte Depleted Graft Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia,"The main purpose of this study is to learn if a new combination of chemotherapy, in combination with low-dose radiation, will be safe for the patient, and at the same time provide the best opportunity to cure the bone marrow cancer. The combination of chemotherapy and radiation described in the study is considered 'low intensity.' Although the chemotherapy agents used in this study and for transplant are FDA approved, the chemotherapy treatment and conditioning regimens or combinations listed...","{'id': 206116061, 'name': 'Antithymocyte globulin (Rabbit)', 'description': 'ATG (2 mg/kg/d IV on days-8 through -7)', 'other_names': ['ATG'], 'intervention_type': 'DRUG'}; {'id': 206116062, 'name': 'fludarabine', 'description': 'fludarabine (30 mg/m2/d on days -5 through -2)', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206116063, 'name': 'total body irradiation', 'description': 'TBI 200 cGy (days -2 and -1) given post stem cell infusion', 'other_names': ['TBI'], 'intervention_type': 'RADIATION'}; {'id': 206116064, 'name': 'cyclophosphamide', 'description': 'cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4)', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206116065, 'name': 'Rituxan', 'description': 'Rituxan (200 mg/m2) will be given to reduce the risk of EBV viremia', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206116066, 'name': 'Allogeneic Hematopoietic Stem Cell Transplantation', 'description': 'Allogeneic Hematopoietic Stem Cell Transplantation', 'other_names': [], 'intervention_type': 'PROCEDURE'}",PHASE1,18 years,Acute Myeloid Leukemia; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; MDS/MPN Overlap Syndrome; Chronic Myelomonocytic Leukemia; Chronic Myeloid Leukemia; Severe Aplastic Anemia; Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma; Multiple Myeloma,"Age >= 18 years | Bone marrow blasts <= 5% prior to conditioning | Acute Myeloid Leukemia in first complete remission with intermediate or high-risk features (non-good-risk cytogenetics) | Therapy-related Acute Myeloid Leukemia with history of prior antineoplastic therapy | Acute Myeloid Leukemia with normal karyotype and high-risk mutations (FLT3, RUNX1, TP53, ASXL1 or other high risk) | Acute Myeloid Leukemia in >= 2nd remission | Myelodysplastic Syndrome with IPSS INT-2 or high risk | Myelodysplastic Syndrome of any risk with life-threatening cytopenia | Myelodysplastic Syndrome with high-risk cytogenetic/genomic features (e.g., chromosome 7 or 3 abnormalities, TP53 mutation, complex or monosomal karyotype) | Myeloproliferative Neoplasm with high-risk features per protocol | MDS/MPN overlap syndrome with high-risk features per protocol | Chronic Myelomonocytic Leukemia | Chronic Myeloid Leukemia failed or intolerant to BCR-ABL tyrosine kinase inhibitors | Chronic Myeloid Leukemia with BCR-ABL mutation predicting poor TKI response (e.g., T351l) | Severe Aplastic Anemia | Chronic Lymphocytic Leukemia with high-risk disease per EBMT consensus criteria | Non-Hodgkin Lymphoma responding to therapy prior to enrollment | Non-Hodgkin Lymphoma with relapse after prior autologous transplant or ineligible for autologous transplant | Multiple Myeloma relapsed after autologous stem cell transplantation with at least partial response after additional chemotherapy | Multiple Myeloma with high-risk cytogenetics at diagnosis (complex karyotype, del17p, t(4;14), t(14;16) by FISH and/or del13 by karyotype) and at least partial response after autologous transplant | Karnofsky performance status >= 70% | Cardiac function: asymptomatic or, if symptomatic, LVEF >= 40% and improves with exercise | Hepatic function: ALT < 5 x ULN | Hepatic function: total bilirubin < 2 x ULN (unless congenital benign hyperbilirubinemia) | Renal function: creatinine clearance > 30 mL/min | Pulmonary function: DLCO > 50% predicted (hemoglobin-corrected)","Prior allogeneic hematopoietic stem cell transplantation | Prior total body irradiation >= 400 cGy | Bone marrow fibrosis with reticulin stain > 1/3 | Active and uncontrolled infection at time of transplantation | HIV infection | Seropositivity for HTLV-1 | Inadequate performance status or organ function | Pregnancy or breastfeeding | Unable to give informed consent or comply with protocol, supportive care, follow-up, or research tests",Therapy-related AML with prior antineoplastic therapy; CML: failed or intolerant to BCR-ABL tyrosine kinase inhibitors; Non-Hodgkin Lymphoma: responding to therapy prior to enrollment; Non-Hodgkin Lymphoma: relapsed after prior autologous transplant or ineligible for autologous transplant; Multiple Myeloma: prior autologous stem cell transplantation; Multiple Myeloma: at least partial response after additional chemotherapy,ALL,F,"Disease mismatch: the trial targets adult hematologic malignancies/aplastic anemia, not PMM2-CDG. Additionally, the trial requires age ≥18, while the patient is 8 years old.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,Disease mismatch (PMM2-CDG not among trial diseases) and age <18 vs trial minimum age 18 are both hard exclusions. Grade F is correct per rubric.,,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03567642,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,"Phase 1 Study of Combination Osimertinib, Platinum, Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers With Concurrent RB1 and TP53 Alterations","The purpose of this study is to test the safety of combining Osimertinib with either Cisplatin or Carboplatin (at different dose levels) and Etoposide, to find out what effects, if any, this combination of drugs has on people with EGFR mutant lung cancer.","{'id': 206070236, 'name': 'Osimertinib', 'description': 'Osimertinib 80mg daily', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206070237, 'name': 'Platinum', 'description': 'Cisplatin 60mg/m2 or Cisplatin 45mg/m2 Carboplatin AUC 5 or Carboplatin AUC 4', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206070238, 'name': 'Etoposide', 'description': 'Etoposide 100mg/m2 or Etoposide 80mg/m2', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,18 years,Non-Small Cell Lung Cancer (metastatic),Metastatic non-small cell lung cancer (biopsy-proven) | Somatic activating EGFR mutation in tumor or cfDNA | Concurrent TP53 alteration by IHC or NGS | Concurrent RB1 alteration by IHC or NGS | Measurable disease per RECIST 1.1 with a non-irradiated indicator lesion | Karnofsky >= 70% | Age > 18 years,"Pregnant or lactating | Prior EGFR TKI other than osimertinib or osimertinib started > 9 weeks before enrollment | Radiotherapy within 1 week prior to protocol treatment | Major surgery within 1 week prior to protocol treatment | Active clinically significant interstitial lung disease | Unresolved > grade 1 toxicity from previous treatment | Pure small cell lung cancer histology | QTcF > 475 msec or clinically significant ECG rhythm, conduction, or morphology abnormalities | Cisplatin-specific: creatinine clearance < 60 mL/min | Cisplatin-specific: hearing impairment requiring assistive device | Cisplatin-specific: neuropathy | Cisplatin-specific: provider deems patient unsuitable for cisplatin",Osimertinib allowed if started within the last 9 weeks; No prior EGFR TKI other than osimertinib,ALL,F,"The trial explicitly excludes patients who started osimertinib more than 9 weeks before enrollment, and this patient has been on osimertinib for 2 years. Additionally, the trial requires concurrent TP53 and RB1 alterations, which are not documented for this patient.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Explicit exclusion applies: trial excludes patients who started osimertinib >9 weeks before enrollment, while the patient has been on osimertinib for 2 years. That alone mandates F. Mention of missing TP53/RB1 is not needed but does not change the outcome.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03575013,0.8805802464485168,Metastatic Urothelial Carcinoma,A Phase 1b Study of Combination of Avelumab and Taxane Based Chemotherapy in Platinum Refractory or Ineligible Metastatic Urothelial Cancer,"This study evaluates the safety and efficacy of the combination of Avelumab, (a fully human anti-programmed death ligand 1 (PD-L1) IgG1 antibody) in combination with a taxane chemotherapy (docetaxel) in patients with metastatic urothelial cancer who are either ineligible to receive cisplatin based chemotherapy, refractory to cisplatin in first line setting or have disease relapse after receiving cisplatin based chemotherapy within a year in the neoadjuvant or adjuvant setting.","{'id': 205955735, 'name': 'Avelumab', 'description': 'Avelumab is a fully human anti-programmed death ligand 1 (PD-L1) IgG1 antibody', 'other_names': ['MSB0010718C'], 'intervention_type': 'DRUG'}; {'id': 205955736, 'name': 'Docetaxel', 'description': 'Docetaxel is a antineoplastic agent belonging to the taxoid family', 'other_names': ['Taxotere'], 'intervention_type': 'DRUG'}",PHASE1,18 years,Urothelial Carcinoma (metastatic),"Age 18–85 years | Histologically or cytologically confirmed locally advanced or metastatic urothelial (transitional cell) carcinoma; mixed histologies allowed if urothelial is predominant | Progressed after at least 1 prior platinum-containing regimen for inoperable locally advanced/metastatic urothelial carcinoma or recurrence, or cisplatin-ineligible by renal, hearing, or neuropathy criteria, or progression within 12 months of neoadjuvant/adjuvant chemotherapy | Biopsy material available (archival acceptable if fresh not feasible) | ECOG performance status 0–1 | Estimated life expectancy >= 3 months | At least one measurable lesion per RECIST v1.1 | Adequate hematologic function | Adequate hepatic function | Adequate renal function (creatinine clearance > 30 mL/min)","Concurrent anticancer treatment | Prior therapy with any drug targeting T cell coregulatory proteins | Major surgery within 4 weeks or not fully recovered within 4 weeks | Concurrent systemic corticosteroids or other immunosuppressive agents (short-term steroids for allergic reactions or on-study immune AEs allowed) | Use of any investigational drug within 28 days before starting trial drug | Active central nervous system metastases (appropriately treated CNS metastases allowed) | Previous malignant disease within 5 years except basal/squamous cell skin cancer, cervical carcinoma in situ, or prostate adenocarcinoma Gleason 6–7, pT2b | Prior organ transplantation including allogeneic stem-cell transplantation | Known HIV infection or active HBV or HCV infection | Active or history of autoimmune disease or immune deficiencies (type 1 diabetes, vitiligo, psoriasis, or thyroid disease not requiring immunosuppression allowed) | Known monoclonal antibody hypersensitivity, history of anaphylaxis, or uncontrolled asthma | Persisting toxicity from prior therapy > grade 1 (grade <= 2 sensory neuropathy allowed) | Pregnancy or lactation | Clinically significant cardiovascular disease (stroke < 6 months, myocardial infarction < 6 months, unstable angina, congestive heart failure >= NYHA class II, or serious arrhythmia requiring medication) | Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis, or psychiatric conditions including recent or active suicidal ideation or behavior",Prior platinum-containing chemotherapy for locally advanced or metastatic urothelial carcinoma with progression; Progression within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy,ALL,F,"Explicit exclusion: the trial prohibits prior therapy with T cell coregulatory inhibitors (PD-1/PD-L1), and the patient received pembrolizumab.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,F,"The trial explicitly excludes prior therapy targeting T cell coregulatory proteins; the patient received pembrolizumab (PD-1). This is a hard exclusion per rubric, so F is correct.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03600701,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer,"This phase II trial studies how well atezolizumab and cobimetinib work in treating patients with non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (metastatic), has come back (recurrent), or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cobimetinib...","{'id': 206421350, 'name': 'Atezolizumab', 'description': 'Given IV', 'other_names': ['MPDL 3280A', 'MPDL 328OA', 'MPDL-3280A', 'MPDL3280A', 'MPDL328OA', 'RG 7446', 'RG-7446', 'RG7446', 'RO 5541267', 'RO-5541267', 'RO5541267', 'Tecentriq'], 'intervention_type': 'DRUG'}; {'id': 206421351, 'name': 'Biopsy Procedure', 'description': 'Undergo biopsy', 'other_names': ['Biopsy', 'BIOPSY_TYPE', 'Bx'], 'intervention_type': 'PROCEDURE'}; {'id': 206421352, 'name': 'Biospecimen Collection', 'description': 'Undergo collection of blood', 'other_names': ['Biological Sample Collection', 'Biospecimen Collected', 'Specimen Collection'], 'intervention_type': 'PROCEDURE'}; {'id': 206421353, 'name': 'Cobimetinib', 'description': 'Given PO', 'other_names': ['Cotellic', 'GDC 0973', 'GDC-0973', 'GDC0973', 'MEK Inhibitor GDC-0973', 'XL 518', 'XL-518', 'XL518'], 'intervention_type': 'DRUG'}; {'id': 206421354, 'name': 'Computed Tomography', 'description': 'Undergo CT scan', 'other_names': ['CAT Scan', 'Computed Axial Tomography', 'Computerized Axial Tomography', 'CAT', 'Computerized axial tomography (procedure)', 'Computerized Tomography', 'Computerized Tomography (CT) scan', 'CT', 'CT Scan', 'Diagnostic CAT Scan', 'Diagnostic CAT Scan Service Type', 'tomography'], 'intervention_type': 'PROCEDURE'}; {'id': 206421355, 'name': 'Magnetic Resonance Imaging', 'description': 'Undergo MRI', 'other_names': ['NMRI', 'Nuclear Magnetic Resonance Imaging', 'sMRI', 'Structural MRI', 'Magnetic Resonance', 'Magnetic Resonance Imaging (MRI)', 'Magnetic resonance imaging (procedure)', 'Magnetic Resonance Imaging Scan', 'Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance', 'MR', 'MR Imaging', 'MRI', 'MRI Scan', 'MRIs', 'NMR Imaging'], 'intervention_type': 'PROCEDURE'}",PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic); Non-Small Cell Lung Cancer (recurrent); Non-Small Cell Lung Cancer (refractory),"Histologically or cytologically confirmed metastatic or recurrent non-small cell lung cancer | KRAS mutation required for cohort 1 (CLIA-approved assay) | KRAS wild type required for cohort 2 (KRAS status must be known) | Primary resistance to anti-PD-1 or anti-PD-L1 therapy with progressive disease within 6 months of initiating PD-1/PD-L1 inhibitor | Patients with sensitizing EGFR, ALK or ROS1 alterations eligible if progressed on or intolerant to the corresponding approved inhibitor | Disease amenable to core biopsy and willingness to undergo research biopsies | Measurable disease with at least one lesion: >= 20 mm by chest x-ray or >= 10 mm by CT/MRI/clinical calipers | Age >= 18 years | ECOG performance status <= 2 (Karnofsky >= 60%) | HIV on effective antiretroviral therapy with undetectable viral load within 6 months eligible","Unresolved clinically significant adverse events from prior anti-cancer therapy (except alopecia) | Investigational agent within 4 weeks prior to cycle 1 day 1 | Systemic immunosuppressive medications within 2 weeks prior to cycle 1 day 1 (except permitted low-dose/inhale/mineralocorticoids) | Symptomatic central nervous system metastases | Concurrent malignancy expected to require active treatment within 2 years or interfere with study assessments | Hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies | Allergic reactions to compounds similar to atezolizumab or cobimetinib | Congenital long QT syndrome or QTcF > 450 ms within 28 days of cycle 1 day 1 | Left ventricular ejection fraction below institutional LLN or < 50% within 4 weeks of cycle 1 day 1 | Retinal pathology posing risk for neurosensory retinal detachment, central serous chorioretinopathy, retinal vein occlusion, or neovascular macular degeneration | Any grade >= 3 hemorrhage or bleeding event within 4 weeks prior to treatment | History of stroke, reversible ischemic neurologic deficit, or transient ischemic attack within 6 months prior to treatment | Use of strong or moderate CYP3A4 inhibitors or inducers (including St. John's wort or grapefruit juice) | Clinically significant liver disease (active hepatitis, cirrhosis, fatty liver, or inherited liver disease) | History or risk of autoimmune disease requiring systemic therapy (with specified exceptions) | Idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia, or active pneumonitis on screening CT | Significant active infection requiring treatment within 14 days prior to cycle 1 day 1 | Major surgical procedure within 28 days prior to cycle 1 day 1 or anticipated during study | Live attenuated vaccine within 4 weeks before cycle 1 day 1 or planned during study and up to 5 months after last atezolizumab dose | Uncontrolled pleural or pericardial effusion or ascites requiring recurrent drainage | Uncontrolled intercurrent illness (including active TB, symptomatic CHF, unstable angina, significant arrhythmia, or psychiatric/social conditions limiting compliance) | Pregnant or breastfeeding | Inability or unwillingness to swallow pills | History of malabsorption syndrome or condition interfering with enteral absorption","Prior anti-PD-1 or anti-PD-L1 therapy required; Progressive disease within 6 months of initiating PD-1/PD-L1 inhibitor; If EGFR, ALK, or ROS1 sensitizing alteration present: prior progression on or intolerance to corresponding approved inhibitor; No investigational agents within 4 weeks prior to cycle 1 day 1; No systemic immunosuppressive medications within 2 weeks prior to cycle 1 day 1",ALL,F,"The trial requires prior anti–PD-1/PD-L1 therapy with progression within 6 months of initiation, but the patient has only received osimertinib (no prior PD-1/PD-L1), so the required treatment setting is not met. KRAS status is also unspecified, but the prior PD-1 requirement alone is disqualifying.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,The trial explicitly requires prior anti–PD-1/PD-L1 therapy with progression within 6 months (a required setting the patient definitively lacks). This constitutes a hard exclusion per the rubric. Other factors (KRAS status unknown) are neutral. Therefore F is correct and the grader’s reasoning is appropriate.,,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT03613532,0.4264147877693176,PMM2-CDG,"A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap Syndromes","This clinical trial involves individuals who have been diagnosed with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), or MDS/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable) and are planning to have an allogeneic hematopoietic stem cell transplant (""bone marrow transplant""). The goal of this research study is to (1) test the safety of adding the study drug, Venetoclax, to a standard of care conditioning regimen for bone ...","{'id': 206249842, 'name': 'Venetoclax', 'description': 'Part 1: 6-7 total doses depending on dose level assigned', 'other_names': ['ABT199'], 'intervention_type': 'DRUG'}; {'id': 206249843, 'name': 'Fludarabine', 'description': 'Given once daily for 4 days', 'other_names': ['Fludara'], 'intervention_type': 'DRUG'}; {'id': 206249844, 'name': 'Busulfan', 'description': 'Given twice daily for 4 days', 'other_names': ['Busulfex', 'Myleran'], 'intervention_type': 'DRUG'}; {'id': 206249845, 'name': 'Venetoclax', 'description': 'Part 2, Part 3, and Part 4: 14 doses for 8-12 cycles depending on dose level assigned', 'other_names': ['ABT199'], 'intervention_type': 'DRUG'}; {'id': 206249846, 'name': 'Azacitidine', 'description': 'Part 2 and Part 4: 5 doses for 8-12 cycles depending on dose level assigned', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206249847, 'name': 'Decitabine/cedazuridine', 'description': 'Part 3: 3 doses for 8 cycles', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,18 years,Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; MDS/MPN-Unclassifiable,"Age >= 18 years | High-risk Myelodysplastic Syndrome as defined (e.g., IPSS Int-2 or higher; TP53 mutation; RAS pathway mutation [NRAS, KRAS, PTPN11, CBL, NF1, RIT1, FLT3, KIT]; therapy-related MDS) | High-risk Acute Myeloid Leukemia as defined (e.g., ELN adverse risk features including TP53, RUNX1, ASXL1 mutations; KMT2A rearrangement; BCR-ABL1; inv(3)/t(3;3) [GATA2, MECOM(EVI1)]; t(6;9) [DEK-NUP214]; -5/del(5q); -7; -17/abn(17p); complex or monosomal karyotype; wild-type NPM1 with FLT3-ITD high; secondary AML; or ‘secondary-type’ AML gene mutations) | High-risk CMML or MDS/MPN-unclassifiable defined by trisomy 8, chromosome 7 abnormalities, complex karyotype, or ASXL1 mutation | AML with measurable residual disease by flow cytometry >= 0.1% despite morphologic remission (per PI review) eligible | Candidate for reduced-intensity conditioning allo-HCT with peripheral blood stem cell source | Matched related or 8/8 matched unrelated donor available | ECOG performance status <=2 | Total bilirubin <= 2 x ULN (Gilbert syndrome exception allowed) | AST <= 3 x ULN | ALT <= 3 x ULN | Creatinine clearance >= 30 mL/min (Cockcroft-Gault) | Part 2/3: No DLT from venetoclax addition prior to maintenance | Part 2/3: No morphologic relapse (blasts <5%) on marrow after day +28 prior to maintenance | Part 2/3: ANC >= 1.0 K/uL without growth factor and platelets >= 50 K/uL without transfusion within 7 days of starting maintenance | Part 2/3: Total bilirubin <= 2 x ULN (unless Gilbert’s) | Part 2/3: AST and ALT <= 3 x ULN | Part 2/3: Creatinine clearance >= 30 mL/min | Part 2/3: Absence of overall grade II–IV acute GVHD or after its resolution; prednisone <= 0.5 mg/kg/day allowed | Part 4: Left ventricular ejection fraction >= 45% within 3 months prior to first dose | No concurrent illnesses preventing oral therapy or interfering with safety assessment","Chemotherapy, radiotherapy, or investigational therapy within 14 days prior to first study dose (exceptions: hydroxyurea and/or dexamethasone) | Ongoing venetoclax within 3 days prior to first study dose | Use of BCR-ABL, IDH, or FLT3 inhibitors within 5 days prior to first study dose | MDS or MDS/MPN with >10% morphologic blasts on bone marrow biopsy | AML with >5% morphologic blasts on bone marrow biopsy | Candidates recommended for myeloablative conditioning regimen | Prior allogeneic stem cell transplantation | Symptomatic or untreated known CNS involvement of disease | Active heart disease (NYHA class 3–4) or unstable angina, stroke, or myocardial infarction within 6 months before first dose | Consumption of grapefruit, Seville oranges, or starfruit within 3 days prior to treatment or use of strong/moderate CYP inducers within 7 days before first dose | Malabsorption syndrome or significant condition precluding enteral administration | Other severe acute/chronic medical or psychiatric condition or lab abnormality increasing study risk or interfering with interpretation | Active hepatitis B infection (unless on effective therapy with undetectable HBV DNA and no liver complications) | Active hepatitis C infection (unless successfully treated or antibody positive with undetectable HCV RNA) | Known active HIV infection (due to potential drug-drug interactions with HAART) | Pregnant or breastfeeding or intending pregnancy during study or within 3 months after final dose | Live attenuated vaccine within 4 weeks prior to initiation or anticipated during study | Uncontrolled infection at time of first dose (antimicrobials allowed if hemodynamically stable) | Part 2/3/4: Recommended to receive FLT3 inhibitor or any other antileukemic maintenance post allo-HCT","No minimum or limit on prior therapy for advanced myeloid malignancy; Prior exposure to venetoclax allowed; Washout >=14 days from chemotherapy, radiotherapy, or investigational therapy (except hydroxyurea and/or dexamethasone) before first dose; BCR-ABL, IDH, and FLT3 inhibitors may continue until 5 days prior to first dose; If on venetoclax pre-transplant, require 3-day washout before first study dose",ALL,F,"Disease mismatch: the trial enrolls high-risk AML/MDS/CMML patients, not PMM2-CDG. Age mismatch: minimum age is 18, while the patient is 8 years old.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,Correct: There is a hard disease mismatch (PMM2-CDG vs AML/MDS/CMML/MDS-MPN) and an age hard exclusion (trial min age 18 vs patient age 8). Either warrants F per rubric.,,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT03635892,0.5362953543663025,Ornithine Transcarbamylase Deficiency,A Phase 2 Open-Label Study of Nivolumab Combined With Cabozantinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (CA209-9KU),The purpose of this study is to compare any good and bad effects of using a combination of nivolumab (Opdivo®) and cabozantinib (Cabometyx®) in people with metastatic kidney cancer.,"{'id': 207608718, 'name': 'cabozantinib', 'description': 'cabozantinib 40mg, self administered orally once daily on a continuous schedule (days 1-28) Patients will continue to take cabozantinib until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.', 'other_names': ['CABOMETYX®'], 'intervention_type': 'DRUG'}; {'id': 207608719, 'name': 'nivolumab', 'description': 'Patients will receive an intravenous infusion of nivolumab, per institutional standards, at 240 mg on Cycle 1, Day 1 and will return to the center approximately every two weeks (14 ± 3 days) for subsequent infusions until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.', 'other_names': ['Opdivo'], 'intervention_type': 'DRUG'}",PHASE2,18 years,"Renal Cell Carcinoma (non-clear cell, metastatic)",Histologically confirmed unresectable advanced or metastatic non-clear cell RCC | 0–1 prior systemic therapies allowed | Measurable disease per RECIST 1.1 | Age >= 18 years | Karnofsky >= 70% | Toxicities from prior therapy <= Grade 1 | Adequate hematologic and organ function | Creatinine clearance >= 30 mL/min | Urine protein/creatinine ratio <= 1 mg/mg | Serum albumin >= 2.8 g/dL,"Prior PD-1, PD-L1, CTLA-4, or high-dose IL-2 | Prior cabozantinib for non-clear cell RCC | Small molecule kinase inhibitor within 2 weeks | Anticancer antibodies, cytotoxic therapy, or investigational agents within 4 weeks | Active brain, spinal cord, or leptomeningeal metastases | Systemic corticosteroids > 10 mg prednisone equivalents or immunosuppressants within 14 days | Uncontrolled pleural, pericardial effusion, or ascites | Uncontrolled hypercalcemia | Another malignancy within 2 years (exceptions apply) | Pregnant or breastfeeding | HIV infection | Active or chronic hepatitis B or C | Significant cardiovascular disease or EF < 50% | Uncontrolled hypertension > 150/100 mmHg | Recent stroke or TIA within 6 months | Significant vascular disease within 6 months | Bleeding diathesis or significant coagulopathy | GI obstruction or abdominal free air | Recent abdominal fistula, perforation, or intraabdominal abscess | Serious non-healing wounds or fractures | Moderate to severe hepatic impairment (Child-Pugh B or C) | QTcF > 500 ms | Inability to swallow tablets or capsules | Allergy to study drug components | Clinically significant recent bleeding | Cavitating pulmonary lesions or endobronchial disease | Tumor invading major vessels or GI tract | Recent radiation within protocol-defined windows | Concomitant warfarin or prohibited anticoagulants",0 or 1 prior systemic therapies allowed; Washout: small molecule kinase inhibitors >= 2 weeks; Washout: antibodies/cytotoxic/investigational agents >= 4 weeks,ALL,F,"Disease mismatch: the patient has OTC deficiency, while the trial targets advanced/metastatic non-clear cell renal cell carcinoma. Additionally, the patient is 3 months old, below the trial’s minimum age of 18 years.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,Hard exclusions apply: disease mismatch (OTC deficiency vs non-clear cell RCC) and age below minimum (3 months vs ≥18). F is correct per rubric.,,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03682068,0.9586746692657471,Metastatic Urothelial Carcinoma,"A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer.","This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (in...","{'id': 206328398, 'name': 'Durvalumab', 'description': 'Durvalumab IV (intravenous infusion)', 'other_names': ['MEDI4736'], 'intervention_type': 'DRUG'}; {'id': 206328399, 'name': 'Tremelimumab', 'description': 'Tremelimumab IV (intravenous infusion)', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206328400, 'name': 'Cisplatin + Gemcitabine', 'description': 'Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206328401, 'name': 'Carboplatin + Gemcitabine', 'description': 'Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,18 years to 130 years,Metastatic Urothelial Cancer; Unresectable Locally Advanced Urothelial Cancer,"Histologically or cytologically confirmed unresectable locally advanced or metastatic urothelial carcinoma (transitional cell or mixed histology) of renal pelvis, ureter, bladder, or urethra | No prior first-line chemotherapy for advanced/metastatic disease | Prior definitive chemoradiation, adjuvant, or neoadjuvant therapy allowed if progression occurred >12 months from last therapy or surgery | At least 1 measurable target lesion per RECIST 1.1 not previously irradiated | ECOG performance status 0–1 | Adequate organ and marrow function | Life expectancy >=12 weeks | Postmenopausal status or negative pregnancy test for premenopausal females","Prior exposure to immune-mediated therapy (anti-CTLA-4, anti-PD-1, anti-PD-L1, anti-PD-L2), except prior Bacillus Calmette-Guerin and therapeutic anticancer vaccines | Requires systemic immunosuppression for severe concomitant condition | Untreated CNS metastases or carcinomatous meningitis | Eligible for or being considered for radical resection during the study | Medical contraindications to platinum doublet chemotherapy or hypersensitivity to study drugs or excipients | Prior intravesical chemotherapy or immunotherapy must be completed >=28 days before study treatment","Prior definitive chemoradiation, adjuvant, or neoadjuvant therapy allowed if relapse/progression >12 months from last therapy or surgery; Prior intravesical chemotherapy or immunotherapy allowed if completed >=28 days before study treatment; Prior Bacillus Calmette-Guerin allowed; Prior therapeutic anticancer vaccines permitted",ALL,F,"Explicit exclusion: the trial prohibits prior anti–PD-1/PD-L1 therapy, and the patient received pembrolizumab. Additionally, the study is first-line while the patient is post–second-line.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,F,"The trial explicitly excludes prior PD-1/PD-L1 therapy, and the patient received pembrolizumab, which is a hard exclusion → F. The trial is also first-line while the patient is post–second-line, reinforcing ineligibility. The grader correctly applied the rubric.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03707938,0.8648536205291748,Metastatic Non-Small Cell Lung Cancer,BRIGHTSTAR: A Pilot Trial of Local Consolidative Therapy (LCT) With Brigatinib in Tyrosine Kinase Inhibitor-Naive ALK-Rearranged Advanced NSCLC,"This early phase I trial studies the side effects and how well local consolidative therapy (LCT) and brigatinib works in treating patients with non-small cell lung cancer that is stage IV or has come back (recurrent). Giving LCT, such as surgery and/or radiation, after initial treatment may kill any remaining tumor cells. Brigatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving LCT and brigatinib may work better in treating patients with non...","{'id': 206475207, 'name': 'Brigatinib', 'description': 'Given PO', 'other_names': ['Alunbrig', 'AP 26113', 'AP-26113', 'AP26113'], 'intervention_type': 'DRUG'}; {'id': 206475208, 'name': 'Local Consolidation Therapy', 'description': 'Undergo local consolidative therapy', 'other_names': ['LCT', 'Local Consolidative Therapy'], 'intervention_type': 'PROCEDURE'}",PHASE1,18 years,Non-Small Cell Lung Cancer (metastatic),"Histologically or cytologically confirmed stage IV or recurrent non-small cell lung cancer not a candidate for definitive multimodality therapy | Documented ALK rearrangement by FISH, IHC, tissue NGS, or cfDNA NGS | Tyrosine kinase inhibitor naive or <= 8 weeks of first-line brigatinib without disease progression | Candidate for local consolidative therapy to at least one site of residual disease | ECOG performance status 0-2 | Age >= 18 years | QTcF <= 450 msec (males) or <= 470 msec (females)","Another primary malignancy (exceptions: adequately treated non-melanoma skin cancer or cervical carcinoma in situ; definitively treated non-metastatic prostate cancer; or malignancy relapse-free for >= 2 years) | Prior TKI therapy including ALK-targeted TKIs (except ongoing first-line brigatinib per inclusion) | More than 1 prior regimen of chemotherapy or immunotherapy for locally advanced or metastatic disease | Symptomatic CNS metastases or escalating corticosteroid dose for CNS disease within 7 days before enrollment | Current spinal cord compression | Pulmonary interstitial disease, drug-related pneumonitis, or radiation pneumonitis at screening | Known or suspected hypersensitivity to brigatinib or its excipients | Malabsorption syndrome or other GI condition that could affect oral absorption of brigatinib | Pregnant or breastfeeding | Significant, uncontrolled, or active cardiovascular disease (e.g., MI within 6 months, unstable angina within 6 months, decompensated CHF within 6 months, clinically significant atrial arrhythmia or bradyarrhythmia, any ventricular arrhythmia, stroke or TIA within 6 months) | Uncontrolled hypertension | Ongoing or active infection, including need for IV antibiotics | Known HIV infection | Any condition that would compromise patient safety or interfere with study evaluations",TKI naive or <= 8 weeks of first-line brigatinib without progression; <= 1 prior regimen of chemotherapy or immunotherapy for advanced disease allowed; Prior consolidative immunotherapy after concurrent chemoradiotherapy for locally advanced disease allowed,ALL,F,"The trial requires ALK-rearranged NSCLC and TKI-naive or ≤8 weeks on first-line brigatinib, but the patient has EGFR exon 19–mutated disease and prior osimertinib exposure. This is a required biomarker mismatch and conflicts with the trial’s prior TKI exclusion.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; ECOG 0; De novo metastatic disease; Metastases to bone and liver; EGFR exon 19 deletion; On osimertinib for 2 years with complete response; Recent MRI shows numerous lesions; No past medical issues,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Hard exclusion applies: trial explicitly excludes patients with any prior TKI therapy, and the patient received osimertinib. While ALK status is not provided (so biomarker mismatch alone shouldn’t trigger F), the prior-TKI exclusion is sufficient for an F. The grader’s final grade is correct.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT03808103,0.6691051721572876,Fistulizing Crohn's Disease,"A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of EcoActive on Intestinal Adherent Invasive Escherichia Coli (AIEC) in Patients With Inactive Crohn's Disease (CD)",This study will evaluate the safety of oral administration of EcoActive to patients with inactive Crohn's disease and how it affects the levels of AIEC in stool.,"{'id': 206469424, 'name': 'Placebo', 'description': 'Orally, twice a day, for a period of fifteen days', 'other_names': ['0.9% saline'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206469425, 'name': 'Bacteriophage preparation', 'description': 'Orally, twice a day, for a period of fifteen days', 'other_names': ['EcoActive'], 'intervention_type': 'BIOLOGICAL'}",PHASE1/PHASE2,18 years,Crohn Disease,Age >= 18 years | Inactive Crohn's disease in clinical and objective remission with Harvey-Bradshaw Index (HBI) < 4 | Permitted Crohn's disease medications expected to remain stable during the study | Crohn's disease history >= 6 months | CRP within normal range at screening | Fecal calprotectin <= 150 µg/g at screening | Adherent-invasive Escherichia coli (AIEC) detected in stool | Females of childbearing potential must use effective contraception during the study | Negative pregnancy test for women of childbearing potential,"Active Crohn's disease with HBI >= 4 | Ongoing gastrointestinal pathology: colorectal tumor or gastrointestinal bleeding | Active malignancy or any malignant disease within the past 5 years | Indeterminate colitis or ulcerative colitis | Colectomy or partial colectomy (less than ileo-transverse colonic anastomosis) | Colonic or small bowel stoma | Active perianal lesions | Pregnant or nursing, or planning pregnancy during the study | Severe uncontrolled diseases including heart disease, congestive heart failure, hypertension, lung disease, endocrine disease, clinically significant renal disease (glomerular filtration rate < 60 mL/min), hepatic disease, or hematological disorders | Use of supplemental probiotics (pills or tablets) | History of or planned procedures aimed at modifying the gastrointestinal microbiota within the past year | Topical gastrointestinal treatment (e.g., enemas) within 2 weeks prior to screening or planned during the study | Bowel cleansing or preparation for endoscopy, CT/MRI within 4 weeks prior to screening or planned during the study | Receipt of antibiotics within 4 weeks prior to screening or planned during the study | Known allergy or hypersensitivity to an excipient in the study drug or placebo | Receipt of mesalamine-based therapies within 4 weeks prior to screening | Severe psychiatric, psychological, or neurological disorders | Alcohol, drug, or medication abuse within the past year",Stable dose of permitted Crohn's disease medications during the study,ALL,F,"The trial requires inactive Crohn’s disease and explicitly excludes active perianal lesions; the patient has active, draining perianal fistulizing Crohn’s disease with a seton in place. These explicit exclusions make the patient ineligible.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Hard exclusion applies: the trial explicitly excludes active perianal lesions, while the patient has an active draining perianal fistula. Therefore F is correct. Other mismatches (inactive disease required) also support ineligibility but are not needed to justify F.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT03816345,1.0,Rheumatoid Arthritis,A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO),"This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.","{'id': 206207512, 'name': 'Biospecimen Collection', 'description': 'Undergo collection of blood, CSF, tissue, stool and urine samples', 'other_names': ['Biological Sample Collection', 'Biospecimen Collected', 'Specimen Collection'], 'intervention_type': 'PROCEDURE'}; {'id': 206207513, 'name': 'Nivolumab', 'description': 'Given IV', 'other_names': ['ABP 206', 'BCD-263', 'BMS 936558', 'BMS-936558', 'BMS936558', 'CMAB819', 'MDX 1106', 'MDX-1106', 'MDX1106', 'NIVO', 'Nivolumab Biosimilar ABP 206', 'Nivolumab Biosimilar BCD-263', 'Nivolumab Biosimilar CMAB819', 'ONO 4538', 'ONO-4538', 'ONO4538', 'Opdivo'], 'intervention_type': 'BIOLOGICAL'}",PHASE1,18 years,Dermatomyositis; Systemic Scleroderma; Rheumatoid Arthritis; Systemic Lupus Erythematosus; Multiple Sclerosis; Sjogren Syndrome; Psoriasis; Psoriatic Arthritis; Crohn Disease; Ulcerative Colitis; Melanoma; Non-Small Cell Lung Cancer; Merkel Cell Carcinoma; Bladder Cancer; Renal Cell Carcinoma; Gastric Cancer; Hepatocellular Carcinoma; Cervical Cancer; Head and Neck Cancer; Hodgkin Lymphoma; Small Cell Lung Cancer,"Histologically confirmed malignancy that is radiologically evaluable and metastatic or unresectable, or a malignancy for which PD-1/PD-L1 inhibitor is approved in the adjuvant setting | Eligible tumor types include solid tumors and malignancies with known activity to single-agent PD-1/PD-L1 antibodies (e.g., melanoma, NSCLC, Merkel cell carcinoma, bladder cancer, RCC, gastric cancer, HCC, cervical cancer, head and neck cancer, Hodgkin lymphoma, metastatic SCLC, MSI-high solid tumor) | Age >= 18 years | ECOG performance status 0-2 (Karnofsky >= 60) | Life expectancy > 12 weeks | Leukocytes >= 1,000/µL | Absolute neutrophil count >= 500/µL | Platelets >= 50,000/µL | Total bilirubin <= 2 x ULN | AST <= 5 x ULN | ALT <= 5 x ULN | Creatinine <= 1 x ULN or GFR >= 30 mL/min | HIV-infected patients on effective antiretroviral therapy with undetectable viral load within 6 months are eligible | Chronic HBV infection allowed if HBV viral load undetectable on suppressive therapy if indicated | History of HCV infection allowed if treated with undetectable HCV viral load | Active brain or leptomeningeal metastases allowed if no immediate CNS-specific treatment required and unlikely to be required for >= 4 weeks, and risk-benefit assessment favors trial participation | Patients with more than one autoimmune disease are eligible; treating physician determines dominant autoimmune disease","Chemotherapy or radiotherapy within 2 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C) or unresolved/stabilized adverse events from prior therapy | Prior therapy with anti-PD-1 or anti-PD-L1 | Prior allogeneic hematologic transplant | Receiving other anticancer investigational agents | Uncontrolled intercurrent illness including ongoing or active infection, symptomatic congestive heart failure, unstable angina, clinically significant cardiac arrhythmia, or psychiatric illness/social conditions limiting compliance",Prior high-dose interleukin-2 allowed with washout >= 4 weeks; Prior interferon allowed with washout >= 4 weeks; Prior CTLA-4 inhibitor allowed with washout >= 6 weeks,ALL,F,"This study requires a histologically confirmed metastatic/unresectable malignancy eligible for PD‑1 therapy. The patient has rheumatoid arthritis without any reported malignancy, failing a required setting.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,F,"The trial requires a histologically confirmed advanced or unresectable malignancy (a required setting). The patient profile shows rheumatoid arthritis only with no malignancy, which fails a required criterion and constitutes a hard exclusion. Age and sex fit, and prior PD-1 exposure is absent, but the missing malignancy makes the F appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT03816345,0.6691051721572876,Fistulizing Crohn's Disease,A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO),"This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.","{'id': 206207512, 'name': 'Biospecimen Collection', 'description': 'Undergo collection of blood, CSF, tissue, stool and urine samples', 'other_names': ['Biological Sample Collection', 'Biospecimen Collected', 'Specimen Collection'], 'intervention_type': 'PROCEDURE'}; {'id': 206207513, 'name': 'Nivolumab', 'description': 'Given IV', 'other_names': ['ABP 206', 'BCD-263', 'BMS 936558', 'BMS-936558', 'BMS936558', 'CMAB819', 'MDX 1106', 'MDX-1106', 'MDX1106', 'NIVO', 'Nivolumab Biosimilar ABP 206', 'Nivolumab Biosimilar BCD-263', 'Nivolumab Biosimilar CMAB819', 'ONO 4538', 'ONO-4538', 'ONO4538', 'Opdivo'], 'intervention_type': 'BIOLOGICAL'}",PHASE1,18 years,Dermatomyositis; Systemic Scleroderma; Rheumatoid Arthritis; Systemic Lupus Erythematosus; Multiple Sclerosis; Sjogren Syndrome; Psoriasis; Psoriatic Arthritis; Crohn Disease; Ulcerative Colitis; Melanoma; Non-Small Cell Lung Cancer; Merkel Cell Carcinoma; Bladder Cancer; Renal Cell Carcinoma; Gastric Cancer; Hepatocellular Carcinoma; Cervical Cancer; Head and Neck Cancer; Hodgkin Lymphoma; Small Cell Lung Cancer,"Histologically confirmed malignancy that is radiologically evaluable and metastatic or unresectable, or a malignancy for which PD-1/PD-L1 inhibitor is approved in the adjuvant setting | Eligible tumor types include solid tumors and malignancies with known activity to single-agent PD-1/PD-L1 antibodies (e.g., melanoma, NSCLC, Merkel cell carcinoma, bladder cancer, RCC, gastric cancer, HCC, cervical cancer, head and neck cancer, Hodgkin lymphoma, metastatic SCLC, MSI-high solid tumor) | Age >= 18 years | ECOG performance status 0-2 (Karnofsky >= 60) | Life expectancy > 12 weeks | Leukocytes >= 1,000/µL | Absolute neutrophil count >= 500/µL | Platelets >= 50,000/µL | Total bilirubin <= 2 x ULN | AST <= 5 x ULN | ALT <= 5 x ULN | Creatinine <= 1 x ULN or GFR >= 30 mL/min | HIV-infected patients on effective antiretroviral therapy with undetectable viral load within 6 months are eligible | Chronic HBV infection allowed if HBV viral load undetectable on suppressive therapy if indicated | History of HCV infection allowed if treated with undetectable HCV viral load | Active brain or leptomeningeal metastases allowed if no immediate CNS-specific treatment required and unlikely to be required for >= 4 weeks, and risk-benefit assessment favors trial participation | Patients with more than one autoimmune disease are eligible; treating physician determines dominant autoimmune disease","Chemotherapy or radiotherapy within 2 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C) or unresolved/stabilized adverse events from prior therapy | Prior therapy with anti-PD-1 or anti-PD-L1 | Prior allogeneic hematologic transplant | Receiving other anticancer investigational agents | Uncontrolled intercurrent illness including ongoing or active infection, symptomatic congestive heart failure, unstable angina, clinically significant cardiac arrhythmia, or psychiatric illness/social conditions limiting compliance",Prior high-dose interleukin-2 allowed with washout >= 4 weeks; Prior interferon allowed with washout >= 4 weeks; Prior CTLA-4 inhibitor allowed with washout >= 6 weeks,ALL,F,"This trial requires a histologically confirmed metastatic/unresectable malignancy eligible for PD-1/PD-L1 therapy, whereas the patient has fistulizing Crohn’s disease with no malignancy reported. This fails a required stage/setting criterion.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"The trial requires a histologically confirmed metastatic/unresectable (or adjuvant-eligible) malignancy. The patient has only Crohn’s disease with no malignancy, definitively lacking a required stage/setting. This is a hard exclusion per the rubric, so F is correct.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT03847467,0.6691051721572876,Fistulizing Crohn's Disease,Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in Pediatric and Young Adult IBD Patients Receiving Stable Maintenance Anti-TNF Therapy,"Randomized, placebo-controlled dose-ranging study of 2'-FL in IBD, Crohn's Disease (CD) and ulcerative colitis (UC). The overarching hypothesis is that 2'-FL supplementation in IBD will be safe and well tolerated, while increasing fecal Bifidobacterium abundance and butyrate in a dose dependent manner. The investigators will test 1, 5, or 10 gm 2'-FL compared to 2 gm dextrose placebo as a daily dietary supplement in pediatric and young adult IBD participants in stable remission receiving infl...","{'id': 206410695, 'name': ""2'-Fucosyllactose"", 'description': 'Human milk oligosaccharide prebiotic dietary supplement', 'other_names': [""2'-FL""], 'intervention_type': 'DRUG'}; {'id': 206410696, 'name': 'Placebo', 'description': 'Dextrose', 'other_names': [], 'intervention_type': 'OTHER'}",PHASE1/PHASE2,11 years to 25 years,Crohn Disease; Ulcerative Colitis,"Age 11-25 years. | Diagnosed with Crohn Disease or Ulcerative Colitis. | Disease in remission: Adult CD (18-25): CDAI < 150; Pediatric CD (11-17): wPCDAI < 12.5; Adult UC (18-25): Modified Mayo stool frequency sub-score=0 and rectal bleeding sub-score=0; Pediatric UC (11-17): PUCAI < 10. | Not receiving corticosteroids. | Stable anti-TNF maintenance therapy (adalimumab, infliximab, or infliximab-dyyb) for >=12 weeks prior to enrollment (infliximab/infliximab-dyyb 5 mg/kg q8w to 10 mg/kg q4w; adalimumab 20 mg q2w to 40 mg q7d). | If on mesalamine, mercaptopurine, azathioprine, or methotrexate, stable dose for >=12 weeks prior to enrollment. | Agreement to not make major dietary changes during the study (e.g., vegan, SCD, EEN). | Crohn Disease patients may have had one ileo-colic resection if no more colon resected than cecum and ascending colon and >=6 months post-surgery.","Active IBD clinical disease during the previous 6 months as determined by the investigator. | Use of antibiotics during the previous month. | Use of probiotics or prebiotics during the previous month. | Diagnosis of celiac disease, diabetes, or other exclusionary comorbidity. | Treatment with another investigational drug or other intervention within 4 weeks. | Treatment with other biologic medication for IBD within prior 12 weeks. | Problem with lactose breakdown. | Pregnant or breastfeeding. | Crohn Disease with more than one IBD-related surgery or sub-total colectomy. | Ulcerative Colitis with colectomy or IBD-related surgery. | Concomitant use of anti-diarrheal medications.","Stable maintenance anti-TNF therapy (adalimumab, infliximab, or infliximab-dyyb) for >=12 weeks required.; Stable mesalamine, mercaptopurine, azathioprine, or methotrexate for >=12 weeks allowed.",ALL,F,"Age 32 exceeds the trial’s 11–25 years window (hard exclusion). Additionally, the trial requires disease remission on stable anti-TNF and no recent antibiotics, conflicting with this patient’s active disease and recent IV antibiotics.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Age 32 is outside the trial’s 11–25 year window, which is a hard exclusion and mandates grade F. Other cited conflicts (remission requirement, recent antibiotics) are not needed to determine the grade.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03854474,0.8805802464485168,Metastatic Urothelial Carcinoma,A Pilot Study of Tazemetostat and Pembrolizumab (MK-3475) in Advanced Urothelial Carcinoma,"This phase I/II trial studies the side effects and best dose of tazemetostat and how well it works when given together with pembrolizumab in treating patients with urothelial carcinoma that has spread to nearby tissue or lymph nodes (locally advanced ) or from where it first started (primary site) to other places in the body (metastatic). Tazemetostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pe...","{'id': 206423206, 'name': 'Biospecimen Collection', 'description': 'Undergo collection of blood samples', 'other_names': ['Biological Sample Collection', 'Biospecimen Collected', 'Specimen Collection'], 'intervention_type': 'PROCEDURE'}; {'id': 206423207, 'name': 'Computed Tomography', 'description': 'Undergo CT', 'other_names': ['CAT', 'CAT Scan', 'Computed Axial Tomography', 'Computerized Axial Tomography', 'Computerized axial tomography (procedure)', 'Computerized Tomography', 'Computerized Tomography (CT) scan', 'CT', 'CT Scan', 'Diagnostic CAT Scan', 'Diagnostic CAT Scan Service Type', 'tomography'], 'intervention_type': 'PROCEDURE'}; {'id': 206423208, 'name': 'Magnetic Resonance Imaging', 'description': 'Undergo MRI', 'other_names': ['Magnetic Resonance', 'Magnetic Resonance Imaging (MRI)', 'Magnetic resonance imaging (procedure)', 'Magnetic Resonance Imaging Scan', 'Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance', 'MR', 'MR Imaging', 'MRI', 'MRI Scan', 'MRIs', 'NMR Imaging', 'NMRI', 'Nuclear Magnetic Resonance Imaging', 'sMRI', 'Structural MRI'], 'intervention_type': 'PROCEDURE'}; {'id': 206423209, 'name': 'Pembrolizumab', 'description': 'Given IV', 'other_names': ['BCD-201', 'GME 751', 'GME751', 'Keytruda', 'Lambrolizumab', 'MK 3475', 'MK-3475', 'MK3475', 'Pembrolizumab Biosimilar BCD-201', 'Pembrolizumab Biosimilar GME751', 'Pembrolizumab Biosimilar QL2107', 'Pembrolizumab Biosimilar RPH-075', 'Pembrolizumab Biosimilar SB27', 'QL2107', 'RPH 075', 'RPH-075', 'RPH075', 'SB 27', 'SB-27', 'SB27', 'SCH 900475', 'SCH-900475', 'SCH900475'], 'intervention_type': 'BIOLOGICAL'}; {'id': 206423210, 'name': 'Tazemetostat', 'description': 'Given PO', 'other_names': ['E 7438', 'E-7438', 'E7438', 'EPZ 6438', 'EPZ-6438', 'EPZ6438'], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,18 years,Urothelial Carcinoma (locally advanced); Urothelial Carcinoma (metastatic),Pathologically confirmed urothelial carcinoma | Locally advanced or metastatic disease | Arm A: Disease progression during or within 12 months after platinum-based chemotherapy (cisplatin or carboplatin) | Arm B: Platinum-ineligible or chemotherapy-ineligible status per investigator | Measurable disease per RECIST v1.1 | Naive to prior PD-1/PD-L1/PD-L2 or EZH2 inhibitors | Age >= 18 years | ECOG performance status <= 2 | Leukocytes >= 3000/µL | Absolute neutrophil count >= 1500/µL | Platelets >= 100000/µL | Hemoglobin >= 9 g/dL | Creatinine <= 1.5 x ULN or creatinine clearance >= 30 mL/min | Total bilirubin <= 1.5 x ULN or direct bilirubin <= ULN if total bilirubin > 1.5 x ULN | AST and ALT <= 2.5 x ULN (<= 5 x ULN with liver metastases) | INR or PT <= 1.5 x ULN unless on therapeutic anticoagulation | aPTT <= 1.5 x ULN unless on therapeutic anticoagulation | HIV-infected patients eligible if on effective ART and undetectable viral load within 6 months,"Disease suitable for local therapy with curative intent | Chemotherapy, targeted small molecule therapy, or radiotherapy within 4 weeks before first dose | Unresolved toxicities from prior therapy > grade 1 (exceptions: <= grade 2 neuropathy, <= grade 2 alopecia, <= grade 3 audiometric hearing loss) | Participation in another interventional study with receipt of study therapy or investigational device within 4 weeks | Transfusion of blood products or administration of colony-stimulating factors within 4 weeks before first dose | Diagnosis of immunodeficiency or systemic steroid/immunosuppressive therapy within 7 days before first dose | Grade 3 thrombocytopenia, neutropenia, or anemia | Cytogenetic or sequencing abnormalities associated with MDS/MPN (e.g., del(5q), chromosome 7 abnormalities, JAK2 V617F) | Ongoing or untreated hematologic malignancy or myeloproliferative disorder, or prior history of hematologic malignancy/myeloproliferative disorder | Prior PD-1/PD-L1/PD-L2 or EZH2 inhibitor therapy | Prior monoclonal antibody within 4 weeks before day 1 | Active second invasive malignancy within 5 years (except curatively treated basal or squamous cell skin cancer or carcinoma in situ of the cervix) or receiving treatment for another cancer | Known brain metastases or carcinomatous meningitis (unless previously treated and stable >= 4 weeks, no new/enlarging lesions, and off steroids >= 7 days) | Allergic reactions to compounds similar to pembrolizumab or tazemetostat | Active autoimmune disease requiring systemic treatment in the past 2 years | History of non-infectious pneumonitis requiring steroids or current pneumonitis | QTcF > 450 msec | Major surgery within 3 weeks before first dose | Use of strong or moderate CYP3A inhibitors or inducers within 14 days before first dose | Inability to take oral medication or malabsorption/uncontrolled gastrointestinal condition that may impair tazemetostat bioavailability | Uncontrolled intercurrent illness (active infection, interstitial lung disease, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, uncontrolled hypertension, stroke within 6 months, or psychiatric/social conditions limiting compliance) | Pregnant or breastfeeding; planning to conceive or father children or donate sperm during treatment and for 6 months after last dose | Known hepatitis B surface antigen positivity or detectable hepatitis C virus RNA | Receipt of a live vaccine within 30 days before treatment start","Arm A requires prior platinum-based chemotherapy with progression on or within 12 months; No chemotherapy, targeted therapy, or radiotherapy within 4 weeks prior to first dose; No investigational agents or devices within 4 weeks prior to first dose; No monoclonal antibody therapy within 4 weeks prior to first dose; No transfusion of blood products or colony-stimulating factors within 4 weeks prior to first dose; No systemic corticosteroids or other immunosuppressive therapy within 7 days prior to first dose; No live vaccines within 30 days prior to treatment start",ALL,F,"Although the disease and setting match, the trial explicitly excludes patients with prior PD-1/PD-L1 therapy. The patient previously received pembrolizumab (a PD-1 inhibitor), which is a hard exclusion.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,F,"The trial explicitly requires PD-1/PD-L1 naïvety and excludes prior PD-1 exposure. The patient received pembrolizumab (PD-1), which is a hard exclusion per the rubric example. Therefore F is correct regardless of other matches.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT03893487,0.8363864421844482,Recurrent Glioblastoma,"A Target Validation Study of Fimepinostat in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG)","This trial studies how well fimepinostat works in treating patients with newly diagnosed diffuse intrinsic pontine glioma, or medulloblastoma, or high-grade glioma that have come back. Fimepinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.","{'id': 205947918, 'name': 'Fimepinostat', 'description': 'Fimepinostat capsules', 'other_names': ['CUDC-907'], 'intervention_type': 'DRUG'}; {'id': 205947919, 'name': 'Therapeutic Conventional Surgery', 'description': 'Undergo surgery', 'other_names': [], 'intervention_type': 'PROCEDURE'}",EARLY_PHASE1,3 years to 39 years,Diffuse Intrinsic Pontine Glioma; Medulloblastoma (recurrent); Anaplastic Astrocytoma (recurrent); Glioblastoma (recurrent); Malignant Glioma (recurrent),"Newly diagnosed diffuse intrinsic pontine glioma (WHO grade II–IV); biopsy feasible; may enroll before or after standard-of-care radiation; no prior therapy before fimepinostat except temozolomide during radiation or prior radiation; if post-radiation, enroll within 14 weeks of completion | Recurrent medulloblastoma (WHO grade IV), any molecular subtype; locally recurrent or disseminated disease allowed if resection/biopsy clinically indicated | Recurrent high-grade glioma including anaplastic astrocytoma (WHO grade III) and glioblastoma (WHO grade IV); locally recurrent or disseminated disease allowed if resection/biopsy clinically indicated | Recurrent DIPG eligible if biopsy/resection feasible outside the pons (e.g., cerebellar extension or metastatic site) | Able to swallow intact fimepinostat capsules or mini-tabs without chewing or crushing | Body surface area >= 0.5 m^2 | Tumor tissue collection required as part of standard of care (minimum equivalent to ~4–6 stereotactic core biopsies) | Prior therapy allowed for recurrent medulloblastoma and recurrent HGG (surgery, chemotherapy, radiation); must have recovered from acute side effects of prior anti-cancer therapies | Myelosuppressive chemotherapy washout: >= 21 days (>= 42 days if prior nitrosourea) | Hematopoietic growth factor washout: >= 14 days after long-acting or >= 7 days after short-acting growth factors | Biologic anti-neoplastic agent washout: >= 7 days | Monoclonal antibody washout: >= 21 days | Radiotherapy washout: >= 2 weeks after local palliative RT; >= 3 months after craniospinal RT or RT to > 50% pelvis | Major surgery washout: >= 21 days | Dexamethasone on a stable or decreasing dose for >= 7 days prior to enrollment if receiving | Absolute neutrophil count >= 1000/µL | Platelet count >= 100000/µL (transfusion independent for >= 7 days) | Creatinine clearance or GFR >= 70 mL/min/1.73 m^2 or age/sex-specific serum creatinine within limits | Total bilirubin <= 1.5 x ULN for age | ALT (SGPT) <= 110 U/L | Serum albumin >= 2 g/dL | Seizure disorder permitted if well controlled | Diarrhea < grade 2 (CTCAE v5.0) | Non-fasting glucose < 125 mg/dL without antihyperglycemics, or fasting glucose <= 160 mg/dL without antihyperglycemics if non-fasting > 125 mg/dL | QTc < 480 msec | Women of childbearing potential and men agree to use adequate contraception during study and for 30 days after last dose","Not recovered from acute adverse events due to prior therapies administered > 4 weeks earlier | Prior therapy with single-agent or combination histone deacetylase (HDAC) and PI3K inhibitors | Receiving any other investigational agent | History of allergic reaction to compounds of similar chemical or biological composition to fimepinostat | Uncontrolled intercurrent illness (e.g., active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia) or psychiatric/social condition limiting compliance | Active HIV infection with potential life-threatening consequences associated with immunosuppressive therapy | History of type 1 or type 2 diabetes mellitus | Gastrointestinal condition that could interfere with absorption or metabolism of fimepinostat","Recurrent medulloblastoma and recurrent high-grade glioma: prior surgery, chemotherapy, and radiation allowed; Newly diagnosed DIPG: no prior therapy before fimepinostat except temozolomide during radiation or prior radiation; Recovered from acute toxicities of prior anti-cancer therapy; Washout: myelosuppressive chemotherapy >= 21 days (>= 42 days if nitrosourea); Washout: hematopoietic growth factors >= 14 days (long-acting) or >= 7 days (short-acting); Washout: biologic anti-neoplastic agents >= 7 days; Washout: monoclonal antibodies >= 21 days; Washout: radiotherapy >= 2 weeks (local palliative) or >= 3 months (craniospinal or > 50% pelvis); Washout: major surgery >= 21 days",ALL,F,"Although the disease (recurrent glioblastoma) matches a trial cohort, the patient is 40 years old, which exceeds the trial’s maximum age of 39—a hard age window exclusion.",Recurrent Glioblastoma,IDH wildtype,Recurrent glioblastoma; IDH wildtype; ECOG 1; Age 40; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide; Recurrence three months after completing adjuvant therapy; No other medical issues,(none),Prior gross total resection; Prior radiation therapy with concurrent temozolomide; Prior adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,F,"Patient is 40 years old, exceeding the trial’s maximum age of 39, which is a hard age-window exclusion. Disease matches but hard exclusion dictates grade F. Grader’s reasoning aligns with the rubric.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT03926520,0.7645418643951416,Dementia,Effect and Safety of Electroconvulsive Therapy Plus Usual Care for the Acute Management of Severe Agitation in Dementia,"This study will explore the effect of ECT treatments plus usual care (ECT+UC) in reducing severe agitation in patients with moderate to severe dementia including Alzheimer's Disease, Vascular dementia, Frontotemporal dementia, and Dementia with Lewy Bodies. The study will also determine the tolerability/safety outcomes of ECT+UC.","{'id': 205456480, 'name': 'Electroconvulsive Therapy (ECT)', 'description': 'Stimulus method of delivery will be RUL electrode placement, and ultra-brief (UB) pulse width (0.25-0.37ms). At the first ECT session, seizure threshold (ST) will be determined by titration with the empirical dose titration method and subsequent treatments will be approximately 6 times the ST. Following other NIMH sponsored multicenter ECT studies (PRIDE, U01 MH055495), stimulus settings will be adjusted as needed during the ECT course based on seizure quality and treatment efficacy. Participants will be administered anesthesia.', 'other_names': [], 'intervention_type': 'DEVICE'}",NA,40 years,Alzheimer Dementia; Vascular Dementia; Frontotemporal Dementia; Dementia with Lewy Bodies,"Diagnosis of Alzheimer's dementia per NIA-AA criteria | Diagnosis of vascular dementia with MRI evidence of microvascular ischemic disease and no clinical/radiologic evidence of stroke | Diagnosis of frontotemporal dementia | Diagnosis of dementia with Lewy bodies | Mini-Mental State Examination (MMSE) <= 15 | Cohen-Mansfield Agitation Inventory (CMAI) threshold for severe agitation as specified | At least one failed pharmacological intervention to manage behavioral symptoms | Medically stable for safe ECT based on physical exam, urinalysis, and serum chemistries (and brain imaging when indicated) | Comprehension of English | Authorized legal representative able and willing to provide informed consent | Age >= 40 years","Current co-morbid delirium by Confusion Assessment Method (CAM) or clinical diagnosis | Vascular dementia due to stroke (abrupt onset, step-wise decline, MRI evidence of hemorrhagic/embolic stroke, or exam consistent with current/prior stroke) | Schizophrenia | Bipolar disorder | Schizoaffective disorder | Active substance use disorder within the past 6 months | Treatment with ECT, transcranial magnetic stimulation, or vagal nerve stimulation within the past 3 months",At least one failed pharmacological intervention for behavioral symptoms,ALL,F,"The trial requires MMSE ≤ 15, while the patient’s MMSE is 19, which fails a mandatory inclusion criterion. Other required features (severe agitation with prior failed pharmacologic management) are unknown but the MMSE mismatch alone is a hard exclusion.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"The trial requires MMSE ≤ 15, and the patient has MMSE 19, which is a definitive failure of a required stage/severity criterion—treated as a hard exclusion per the rubric. Thus F is appropriate regardless of other unknowns (e.g., severe agitation, prior failed pharmacologic management).",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT04004442,0.8805802464485168,Metastatic Urothelial Carcinoma,Phase I Study of Avelumab in Combination With AXL Inhibitor AVB-S6-500 in Patients With Advanced Urothelial Carcinoma,The purpose of this research study is to test the safety of avelumab and AVB-S6-500 and see what effects (good and bad) this combination treatment has on patients with advanced urothelial carcinoma.,"{'id': 205991076, 'name': 'Avelumab', 'description': 'Avelumab: 800 mg IV every two weeks (on days 1 and 15 of a 28-day cycle)', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205991077, 'name': 'AVB-S6-500', 'description': 'AVB-S6-500: 10mg/kg IV every 2 weeks (on days 1 and 15 of a 28-day cycle) Potential dose reduction: AVB-S6-500: 5mg/kg IV weekly (on days 1, 8, 15 and 22 of a 28-day cycle)', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,18 years,Urothelial Carcinoma (metastatic),"Age >= 18 years | Histologically confirmed locally advanced unresectable (T4b or N2/N3) or metastatic urothelial carcinoma (renal pelvis, ureter, bladder, or urethra) | Progressed after at least 1 prior platinum-containing regimen for advanced/unresectable or metastatic disease OR progression/recurrence within 12 months of completing neoadjuvant or adjuvant cisplatin-based chemotherapy OR ineligible for cisplatin (ECOG 2, neuropathy >= 2, GFR < 60 mL/min, hearing loss >= 2, or NYHA class III+ heart failure) OR declined platinum-based chemotherapy | Available pretreatment tumor specimen or willingness to undergo biopsy | ECOG performance status <= 2 | At least one measurable lesion per RECIST 1.1 | Adequate hematologic and end-organ function | Women of childbearing potential: negative pregnancy test at screening | Agreement to use highly effective contraception or remain abstinent during treatment and for at least 30 days after last dose","Concurrent systemic anticancer treatment or investigational drug within 28 days (palliative radiation allowed if measurable disease exists outside the field) | Prior therapy with PD-1 or PD-L1 inhibitors | Systemic corticosteroids > 10 mg prednisone equivalent or other immunosuppressive agents within 28 days before start (short-term <= 7 days, replacement doses <= 10 mg, topical/intranasal/inhaled allowed) | Untreated or symptomatic central nervous system metastases (eligible >= 4 weeks after surgery/radiation with stable/improved follow-up imaging) | Active second malignancy or malignancy within 3 years except basal/squamous cell skin cancer, cervical carcinoma in situ, or pT2 prostate adenocarcinoma with Gleason <= 7 (no dominant pattern 4) | Prior organ transplantation including allogeneic stem-cell transplantation | Known hepatitis B virus infection or untreated hepatitis C (treated HCV eligible) | Hypersensitivity to monoclonal antibodies or biologic drugs, history of anaphylaxis, or uncontrolled asthma | Persisting toxicity from prior therapy > grade 1 (grade <= 2 sensory neuropathy allowed) | Pregnant or lactating | Active autoimmune disease requiring systemic immunosuppression (type 1 diabetes, vitiligo, psoriasis, or thyroid disorders not requiring systemic immunosuppression allowed) | History of interstitial lung disease/pneumonitis (including drug-induced) or evidence of active pneumonitis (radiation fibrosis allowed) | Active infection requiring systemic therapy | Severe infections within 4 weeks prior to first dose (including hospitalization for infection, bacteremia, or severe pneumonia) | Live or attenuated vaccine within 4 weeks prior to first dose, within 5 months after last dose, or anticipated need during the study | Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormalities, that increase risk or may interfere with study participation or interpretation",Progression after at least one prior platinum-containing chemotherapy regimen for advanced/unresectable or metastatic disease; Progression or recurrence within 12 months after completing neoadjuvant or adjuvant cisplatin-based chemotherapy; Cisplatin-ineligible per protocol criteria; Declined platinum-based chemotherapy; No systemic anticancer therapy within 28 days before starting study treatment,ALL,F,"The trial explicitly excludes patients with prior PD-1/PD-L1 therapy, and the patient received pembrolizumab (PD-1). Although the disease stage matches, this hard exclusion makes the patient ineligible.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,F,"Trial explicitly excludes prior PD-1/PD-L1 therapy; patient received pembrolizumab (PD-1). This is a hard exclusion, so F is correct.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT04098393,0.450744092464447,PMM2-CDG,"A Pilot Study of Condensed Busulfan, Melphalan, and Fludarabine Conditioning Prior to Ex-vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation","The purpose of this study is to see if a condensed version of the chemotherapy regimen busulfan, melphalan, fludarabine (bu/mel/flu) and the drug antithymocyte globulin (ATG-also referred to as rATG or thymoglobulin) can have the same or fewer number of severe side effects in people with various blood cancers 30 days after they receive an allogeneic hematopoietic cell transplantation.","{'id': 206019838, 'name': 'Busulfan 3.2 mg/kg/day', 'description': 'Busulfan 3.2 mg/kg/day, with dose adjustments made according to pharmacokinetic (PK) levels.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206019839, 'name': 'Fludarabine', 'description': 'Fludarabine (25mg/m2/ day) administered on days -6, -5, -4, -3, and -2.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206019840, 'name': 'Melphalan', 'description': 'Melphalan (70mg/m2/day) administered on days -6 and -5.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206019841, 'name': 'Antithymocyte globulin (ATG)', 'description': ""ATG will be given based on a dynamic nomogram based on the patient's absolute lymphocyte count at the start of conditioning and can result in 2 or 3 days of ATG administration."", 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206019842, 'name': 'Busulfan 0.8 mg/kg', 'description': 'Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206019843, 'name': 'Allogeneic hematopoietic cell transplantation (Allo-HCT)', 'description': 'Allogeneic hematopoietic cell transplantation following the conditioning regimen.', 'other_names': [], 'intervention_type': 'PROCEDURE'}",PHASE1,18 years,Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Acute Leukemias of Ambiguous Lineage; Chronic Myeloid Leukemia; Myelodysplastic Syndromes; Myeloproliferative Neoplasms; MDS/MPN Overlap Syndrome; Chronic Myelomonocytic Leukemia; Severe Aplastic Anemia; Hodgkin Lymphoma; Non-Hodgkin Lymphoma; Multiple Myeloma,"Age >= 18 years | Acute myeloid leukemia in CR1 with intermediate/high-risk features or relapsed AML in >= CR2 | Acute leukemias of ambiguous lineage in >= CR1 | Acute lymphoblastic leukemia in CR1 with high-risk features or ALL in >= CR2 | Chronic myeloid leukemia with failed/intolerant TKI therapy, or BCR-ABL mutation with poor TKI response (e.g., T315I), or in accelerated/blast phase with <10% blasts after therapy, or in second chronic phase | Myelodysplastic syndromes, myeloproliferative neoplasms, or MDS/MPN overlap meeting intermediate-or-higher risk, life-threatening cytopenias, high-risk cytogenetics/genomics (e.g., chr 7 or 3 abnormalities, TP53 mutation, complex or monosomal karyotype), or therapy-related/evolving disease | Chronic myelomonocytic leukemia (CMML-1 or CMML-2) | Severe aplastic anemia | Relapsed Hodgkin lymphoma responding to therapy and relapsed after autologous HCT or ineligible for autologous HCT | Relapsed non-Hodgkin lymphoma responding to therapy and relapsed after autologous HCT or ineligible for autologous HCT | High-risk multiple myeloma following autologous HCT or relapsed multiple myeloma following autologous HCT with chemosensitive disease | Serum bilirubin <= 2 mg/dL (unless specified exceptions) | AST < 3 x ULN | ALT < 3 x ULN | Alkaline phosphatase < 3 x ULN | Creatinine clearance >= 50 mL/min | Left ventricular ejection fraction >= 45% | FEV1 >= 50% predicted | DLCO (corrected) >= 50% predicted | ECOG <=2",Active extramedullary disease | Active central nervous system malignancy | Active or uncontrolled infection at time of allo-HCT | Prior allogeneic hematopoietic cell transplantation | Prior autologous HCT within the last 6 months (except high-risk multiple myeloma patients) | HIV I/II or HTLV I/II seropositivity | Pregnant or breastfeeding | Unwilling to use contraception during the study period | Unable to give informed consent or comply with protocol,Failed or intolerant prior BCR-ABL tyrosine kinase inhibitor therapy for CML; Relapse after autologous hematopoietic cell transplant (Hodgkin or non-Hodgkin lymphoma); Prior autologous hematopoietic cell transplant for multiple myeloma (high-risk or relapsed),ALL,F,"Hard exclusions apply: the patient's disease (PMM2-CDG) is not among the trial’s eligible hematologic conditions, and the patient is 8 years old while the trial requires participants to be ≥18.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"Hard exclusions apply: the patient’s disease (PMM2-CDG) is not among the trial’s eligible conditions, and the patient is 8 years old while the trial requires ≥18. The grader correctly assigned F and provided appropriate reasoning.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT04223856,0.8805802464485168,Metastatic Urothelial Carcinoma,"An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer",This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this study will have cancer that has spread from their urinary system to other parts of their body.,"{'id': 206107588, 'name': 'Enfortumab vedotin', 'description': 'Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle', 'other_names': ['ASG-22CE', 'ASG-22ME', 'PADCEV'], 'intervention_type': 'DRUG'}; {'id': 206107589, 'name': 'Pembrolizumab', 'description': 'IV infusion on Day 1 of every 3-week cycle', 'other_names': ['Keytruda'], 'intervention_type': 'DRUG'}; {'id': 206107590, 'name': 'Cisplatin', 'description': 'administered as IV infusion on Day 1 of each 3-week cycle', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206107591, 'name': 'Carboplatin', 'description': 'Dosed according to local guidelines and will be administered as IV infusion on Day 1 of each 3-week cycle', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206107592, 'name': 'Gemcitabine', 'description': 'IV infusion on Days 1 and 8 of every 3 week cycle', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,18 years,Urothelial Carcinoma (metastatic),"Histologically documented, unresectable locally advanced or metastatic urothelial carcinoma | Measurable disease per RECIST v1.1 | If prior definitive radiotherapy, measurable disease outside the radiation field or progression since completion | No prior systemic therapy for locally advanced or metastatic urothelial carcinoma | Prior neoadjuvant chemotherapy allowed if recurrence >12 months from completion | Prior adjuvant chemotherapy allowed if recurrence >12 months from completion | Eligible for cisplatin- or carboplatin-containing chemotherapy per investigator judgment | Archival tumor tissue or metastatic biopsy provided for PD-L1 testing prior to randomization | ECOG performance status 0–2 | Adequate hematologic and organ function","Prior enfortumab vedotin or other MMAE-based antibody-drug conjugate | Prior PD-1 or PD-L1 inhibitor for any malignancy | Prior agent directed to another stimulatory or coinhibitory T-cell receptor | Anticancer treatment (chemotherapy, biologics, or investigational agents) not completed >=4 weeks prior to first dose | Uncontrolled diabetes | Estimated life expectancy <12 weeks | Active central nervous system metastases | Clinically significant toxicities from prior therapy not resolved to <= Grade 1 or baseline | Active systemic infection requiring antimicrobial treatment at randomization | Known active hepatitis B, active hepatitis C, or HIV infection | Another invasive malignancy within 3 years or residual disease from prior malignancy | Cerebrovascular event, unstable angina, myocardial infarction, or NYHA Class IV symptoms within 6 months | Radiotherapy within 2 weeks prior to randomization | Major surgery within 4 weeks prior to randomization | Severe (>= Grade 3) hypersensitivity to enfortumab vedotin excipients | Active keratitis or corneal ulcerations | Autoimmune disease requiring systemic treatment in the past 2 years | History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or active pneumonitis on screening CT | Prior allogeneic stem cell or solid organ transplant | Live attenuated vaccine within 30 days prior to randomization",No prior systemic therapy for locally advanced or metastatic urothelial carcinoma; Prior neoadjuvant or adjuvant chemotherapy allowed if recurrence >12 months from completion; Washout >=4 weeks since prior anticancer therapy; Radiotherapy washout >=2 weeks; Major surgery washout >=4 weeks,ALL,F,"The trial excludes patients with prior enfortumab vedotin and prior PD-1/PD-L1 therapy, and requires no prior systemic therapy for metastatic disease; this patient previously received enfortumab vedotin plus pembrolizumab and is post–second line.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,F,"Explicit hard exclusions apply: the trial excludes prior enfortumab vedotin and prior PD-1/PD-L1 therapy, and requires no prior systemic therapy for locally advanced/metastatic disease. The patient received enfortumab vedotin plus pembrolizumab post–second line. Therefore F is correct.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT04224558,0.6691051721572876,Fistulizing Crohn's Disease,Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease,"Unfortunately, some patients with Crohn's disease (CD) fail to respond to the best clinical treatments and some only experience temporary benefit. For severe Crohn's disease, there is an experimental treatment called ""high dose immunoablation"" followed by autologous hematopoietic stem cell transplantation (HSCT). This study removes over active lymphocytes (immunoablation) and replaces them using blood stem cells that have been taken from the patient's own body. The aim of the study is to rese...","{'id': 205995114, 'name': 'Mesna', 'description': 'Stem Cell Mobilization: Infused according to institutional guidelines;\n\nPost-PBSC Infusion Conditioning: Mesna provided with Cytoxan according to institutional protocol.', 'other_names': ['Mesnex'], 'intervention_type': 'DRUG'}; {'id': 205995115, 'name': 'Cyclophosphamide', 'description': 'Stem Cell Mobilization:\n\nCyclophosphamide (CY) infused intravenously over 1 hour: 50 mg/kg (25 mg/kg/day on 2 consecutive days)', 'other_names': ['Cytoxan', 'Neosar'], 'intervention_type': 'DRUG'}; {'id': 205995116, 'name': 'Filgrastim', 'description': 'Stem Cell Mobilization: Filgrastim (G-CSF) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapheresis;\n\nPost-PBSC Infusion Conditioning: Filgrastim administered intravenously 5 mcg/kg IV starting day + 5, continue until ANC of \\>1000/μL', 'other_names': ['Neupogen', 'Granix'], 'intervention_type': 'DRUG'}; {'id': 205995117, 'name': 'Apheresis catheter placement', 'description': 'Subjects will require placement of an Apheresis catheter by Intervention Radiologists on the day of collection of stem cells.', 'other_names': [], 'intervention_type': 'PROCEDURE'}; {'id': 205995118, 'name': 'Leukapheresis', 'description': 'Leukapheresis will be performed on a continuous flow separator machine according to institutional guidelines to target 3-8 x 10\\^6 CD34+ cells/kg body weight.', 'other_names': [], 'intervention_type': 'PROCEDURE'}; {'id': 205995119, 'name': 'Fludarabine', 'description': 'Preparative/Conditioning Regime Fludarabine given as 30 mg/m2 per dose x 4 days, beginning on day -6.', 'other_names': ['Fludara'], 'intervention_type': 'DRUG'}; {'id': 205995120, 'name': 'Methylprednisolone', 'description': 'Preparative/Conditioning Regime r-ATG pre-medication according to institutional guidelines', 'other_names': ['solu-medrol'], 'intervention_type': 'DRUG'}; {'id': 205995121, 'name': 'Diphenhydramine', 'description': 'Preparative/Conditioning Regime r-ATG premedication according to institutional guidelines', 'other_names': ['Benadryl'], 'intervention_type': 'DRUG'}; {'id': 205995122, 'name': 'Acetaminophen', 'description': 'Preparative/Conditioning Regime r-ATG premedication according to institutional guidlines', 'other_names': ['Tylenol'], 'intervention_type': 'DRUG'}; {'id': 205995123, 'name': 'anti-thymocyte globulin (rabbit)', 'description': 'Preparative/Conditioning Regime r-ATG administered intravenously: 2.5 mg/kg/dose IV over 6 hours on specified days (day -6,-4,-2); ); total 3 doses=7.5 mg/kg.', 'other_names': ['thymoglobulin'], 'intervention_type': 'DRUG'}; {'id': 205995124, 'name': 'lymphocyte immune globulin', 'description': 'Preparative/Conditioning Regime In patients who develop severe allergic reactions to rATG (Thymoglobulin), it may be substituted by horse ATG (hATG, ATGAM, Pharmacia \\& Upjohn, Kalamazoo, MI). The recommended dose of hATG is 25 mg/kg/day for 3 doses.', 'other_names': ['ATGAM'], 'intervention_type': 'DRUG'}; {'id': 205995125, 'name': 'Peripheral Blood Stem Cell Infusion', 'description': 'PBSC (peripheral blood stem cell) infusion on day 0 as per institutional guidelines.', 'other_names': [], 'intervention_type': 'BIOLOGICAL'}; {'id': 205995126, 'name': 'Cytoxan', 'description': 'Post-PBSC Infusion Conditioning Cytoxan infused intravenously: 50mg/kg/day x 2 days. Infused over 2 hours with adequate hydration or according to institutional guidelines.', 'other_names': ['Cyclophosphamide'], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,13 years to 28 years,Crohn Disease,"Age 13–28 years. | Confirmed Crohn disease for >= 6 months prior to screening. | Active disease at registration: PCDAI > 30 plus at least two of the following: elevated CRP; endoscopic evidence of active disease confirmed by histology; active small bowel Crohn disease on CT or MR enterography. | Refractory course despite >= 3 immunosuppressive/biologic agents (e.g., azathioprine, methotrexate, infliximab/adalimumab/certolizumab) or intolerance/toxicity to these drugs. | Current problems unsuitable for surgery or at risk for short bowel syndrome.","Pregnancy or unwillingness to use adequate contraception. | Renal impairment: creatinine clearance < 30 mL/min. | Cardiac disease: refractory congestive heart failure; left ventricular ejection fraction < 40%; chronic atrial fibrillation requiring oral anticoagulation; uncontrolled ventricular arrhythmia; pericardial effusion with hemodynamic consequences. | Pulmonary impairment: diffusion capacity < 40%. | Psychiatric disorders including active drug or alcohol abuse. | Concurrent or recent malignancy (excluding non-melanoma skin cancer). | Uncontrolled hypertension: resting systolic blood pressure >= 140 mmHg and/or diastolic >= 90 mmHg despite at least 2 antihypertensive agents. | Infection with HIV, HTLV-1/2, hepatitis viruses, or other infection considered a contraindication. | Current clinically relevant abscess or significant active infection. | Perianal fistula without free drainage (seton or natural free drainage required). | History of tuberculosis or increased risk; positive TB testing (e.g., Quantiferon Gold) or other evidence of active TB. | Abnormal chest X-ray consistent with active infection or neoplasm. | Significant malnutrition: BMI <= 18 kg/m^2 or serum albumin < 20 g/L. | Other chronic disease causing significant organ failure. | Previous poor compliance. | Concurrent enrollment in another protocol using an investigational drug or hematopoietic growth factor within 4 weeks before entry.","Refractory to >= 3 immunosuppressive/biologic agents (e.g., azathioprine, methotrexate, anti-TNF agents).",ALL,F,"The patient is 32 years old, which is outside the trial’s eligible age range of 13–28 years, constituting a hard exclusion.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Age is a hard exclusion: patient is 32 while the trial requires 13–28 years. Disease matches, but hard exclusion applies, so F is correct.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT04411654,0.4309793710708618,PMM2-CDG,"An Open-label, Phase 1/2 Study to Evaluate the Safety and Efficacy of Single-dose LY3884961 in Infants With Type 2 Gaucher Disease","J3Z-MC-OJAB is an open-label, Phase 1/2, multicenter study to evaluate the safety and efficacy of single-dose LY3884961 (formerly PR001) in infants diagnosed with Type 2 Gaucher disease (GD2). For each patient, the study will be approximately 5 years in duration. During the first 12 months after dosing, patients will be evaluated for the effects of LY3884961 on safety, tolerability, immunogenicity, biomarkers, and efficacy. Patients will be followed up for an additional 4 years to monitor saf...","{'id': 205795602, 'name': 'LY3884961', 'description': 'Participants will receive a single dose of LY3884961 administered intracisternally.', 'other_names': [], 'intervention_type': 'GENETIC'}; {'id': 205795603, 'name': 'Methylprednisolone', 'description': 'Single IV pulse administered as concomitant medication.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205795604, 'name': 'Sirolimus', 'description': 'Loading dose, followed by maintenance doses, followed by dose tapering; administered as concomitant medication.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205795605, 'name': 'Prednisone', 'description': 'Administered orally as concomitant medication, followed by dose tapering.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,0 months to 24 months,Gaucher Disease Type 2,Bi-allelic GBA1 mutations consistent with Gaucher Disease Type 2 confirmed by central laboratory | Clinical diagnosis of Gaucher Disease Type 2,"Significant CNS disease other than Gaucher Disease Type 2 | Achieved independent gait | Severe peripheral symptoms of Gaucher Disease posing unacceptable risk or interfering with study conduct | Concomitant disease, condition, or treatment posing unacceptable risk or interfering with study conduct | Use of any substrate reduction therapy for Gaucher Disease treatment | Use of prohibited medications, herbal, or over-the-counter agents | Any prior gene or cell therapy | Use of systemic immunosuppressant or corticosteroid therapy other than protocol-specified immunosuppression | Participation in another investigational drug or device study within the past 3 months | Brain MRI/MRA showing clinically significant abnormality that contraindicates intracisternal injection | Clinically significant laboratory test result abnormalities at screening | Contraindications or intolerance to MRI, MRA, CT, or contrast agents | Contraindications to general anesthesia or sedation",No investigational drug or device within 3 months,ALL,F,"The trial targets Gaucher Disease Type 2 with required bi-allelic GBA1 mutations and an age limit of ≤24 months, while the patient has PMM2-CDG with PMM2 variants and is 8 years old. This constitutes disease, biomarker, and age window mismatches, which are hard exclusions.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"Clear hard exclusions: disease mismatch (PMM2-CDG vs Gaucher Type 2), required biomarker mismatch (PMM2 vs required GBA1), and age outside max (8 years vs ≤24 months). Grade F is appropriate per rubric.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT04486781,0.8805802464485168,Metastatic Urothelial Carcinoma,A Phase II Trial of Pembrolizumab as Standard of Care + sEphB4-HSA in Chemotherapy Ineligible or Chemotherapy Refusing Patients With Metastatic Urothelial Carcinoma,sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to evaluate the combination of Pembrolizumab + sEphB4-HSA in the population of patients with previously untreated advanced (metastatic or recurrent) urothelial carcinoma who are chemotherapy ineligible or who refuse chemotherapy.,"{'id': 205816255, 'name': 'Pembrolizumab + sEphB4-HSA', 'description': 'sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,18 years,Urothelial Carcinoma (metastatic),Age >= 18 years | Pathologically proven urothelial carcinoma that is advanced (metastatic or recurrent) | Treatment naive for advanced disease (progression >12 months after last dose of platinum-based neoadjuvant or adjuvant chemotherapy is eligible) | ECOG performance status 0–1 | Adequate organ function | Ineligible for chemotherapy in frontline setting or refusing chemotherapy | Planned to begin pembrolizumab per standard of care; enroll before second dose and prior to restaging imaging | Measurable disease per RECIST 1.1,"Known history of HIV infection | Diagnosis of immunodeficiency or receipt of systemic steroid therapy or other immunosuppressive therapy within 7 days prior to first dose | Active hepatitis B or active hepatitis C infection | Known history of active tuberculosis | Active autoimmune disease requiring systemic treatment within the past 2 years (replacement therapy allowed) | Additional malignancy that is progressing or requires active treatment (except basal cell carcinoma potentially cured after surgery or controlled prostate cancer on hormonal therapy) | Active CNS metastases or carcinomatous meningitis (treated brain metastases allowed) | Pregnant or breastfeeding, or expecting to conceive or father children during and for 120 days after treatment | NYHA class 3 or 4 heart failure, recent myocardial infarction or acute coronary syndrome, diabetes mellitus with ketoacidosis, or COPD requiring hospitalization in the preceding 6 months | Any intercurrent medical condition that contraindicates treatment with sEphB4-HSA or pembrolizumab or places the patient at undue risk | Receipt of a live vaccine within 30 days prior to start of study therapy | Uncontrolled hypertension (systolic >140 mmHg or diastolic >90 mmHg)",No prior systemic therapy for advanced urothelial carcinoma (prior platinum-based neoadjuvant/adjuvant allowed if relapse >12 months after last dose); Receiving or planned to receive pembrolizumab as standard of care; must enroll before the second dose,ALL,F,"The trial requires patients to be treatment-naive for advanced/metastatic disease and to be starting first-line pembrolizumab, but the patient has already received enfortumab vedotin plus pembrolizumab and is post–second line. This is an explicit line-of-therapy exclusion.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),INCORRECT,D,"The patient’s disease matches and age/sex are eligible, but there is a clear line-of-therapy/prior exposure mismatch (trial requires treatment-naive frontline pembrolizumab; patient is post–second line with prior pembrolizumab). Per the rubric, this is a soft mismatch on a core anchor → D, not a hard exclusion F, since it’s not listed under trial_exclusion_criteria.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT04578392,0.6691051721572876,Fistulizing Crohn's Disease,MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES),Study description - Patients will be randomized according to post-operative recurrence risk to either a high ligation of ileocolic artery or mesenteric sparing ileocolic resection for terminal ileal Crohn's disease. The primary endpoint 6-month endoscopic recurrence. Endpoints - Primary endpoint; 6 months Secondary endpoints at 1 and 5 years post ileocecal resection Study population - Adult Crohn's disease patients with medically refractory terminal ileal Crohn's disease undergoing a primary ...,"{'id': 205948391, 'name': 'high ligation of ileocolic artery', 'description': 'Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing', 'other_names': [], 'intervention_type': 'PROCEDURE'}; {'id': 205948392, 'name': 'mesenteric sparing', 'description': 'Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing', 'other_names': [], 'intervention_type': 'PROCEDURE'}",NA,18 years to 65 years,Crohn Disease,Age 18-65 years | Isolated ileocolic Crohn's disease <30 cm in length | Medically refractory disease or intolerance to ongoing medical therapy,"Age <18 years | Repeat ileocolic resection | Concurrent Crohn's disease in other locations requiring additional intraoperative intervention beyond ileocolic resection | Terminal ileal disease >30 cm | Planned ileal resection only (disease spares distal ileum and ileocecal valve) | Anastomosis diverted intra-operatively with a loop or end ileostomy | Clinically significant cardiac or other medical conditions within 6 months (e.g., myocardial infarction, active angina, congestive heart failure) that compromise safety | Evidence of hepatitis B, hepatitis C, or HIV | History of cancer including melanoma (except localized skin cancers) | Emergent indication for operation | Pregnant or breastfeeding | History of clinically significant autoimmunity other than Crohn's disease or any previous fat-directed autoimmunity",Concurrent corticosteroids permitted; Concurrent 5-ASA permitted; Concurrent thiopurines permitted; Concurrent methotrexate permitted; Concurrent antibiotics permitted; Concurrent anti-TNF therapy permitted; Concurrent vedolizumab permitted; Concurrent ustekinumab permitted,ALL,F,"The trial requires isolated ileocolic Crohn’s disease (<30 cm) for ileocolic resection, whereas the patient has active perianal fistulizing Crohn’s disease (non-isolated), failing the required disease location/setting. Age and prior therapies are compatible, but the mandatory subtype/setting mismatch is a hard exclusion.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"The trial requires isolated ileocolic Crohn’s disease; the patient has active perianal fistulizing disease, so they definitively lack the required subtype/location. This is a hard exclusion per the rubric. Age/sex and prior therapies are compatible but irrelevant once a hard exclusion applies. The grader’s F is correct.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT04701918,0.8805802464485168,Metastatic Urothelial Carcinoma,"A Multicenter, Single-Arm Open Label Phase II Trial of Cryoablation in Combination With Pembrolizumab or Avelumab in Patients With Metastatic Urothelial Carcinoma","This research study is examining the effectiveness of pembrolizumab plus cryoablation or aveluma plus cryoablation on people with urothelial carcinoma, including bladder cancer, that has spread.","{'id': 205515642, 'name': 'Pembrolizumab', 'description': 'Intravenous injection through a vein (IV) every 3 weeks', 'other_names': ['Keytruda'], 'intervention_type': 'DRUG'}; {'id': 205515643, 'name': 'Cryoablation', 'description': 'Needle inserted through the skin and into the tumor using CT guidance', 'other_names': [], 'intervention_type': 'PROCEDURE'}; {'id': 205515644, 'name': 'Avelumab', 'description': 'Intravenous injection through a vein (IV) every 2 weeks', 'other_names': ['Bavencio'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Bladder Cancer; Urothelial Carcinoma (metastatic),"Age > 18 years | Histologically or cytologically confirmed metastatic (M1, Stage IV) urothelial carcinoma (renal pelvis, ureters, urinary bladder, urethra) | Measurable metastatic disease with at least one lesion > 2 cm amenable to percutaneous image-guided cryoablation | Measurable disease by RECIST v1.1 independent of the lesion to be ablated | Life expectancy > 12 weeks | ECOG performance status 0–1 | ANC > 1 x 10^9/L | Platelets > 75 x 10^9/L | ALT < 5 x ULN | AST < 5 x ULN | Total bilirubin < 3 mg/dL | INR < 1.7 | Creatinine clearance > 30 mL/min","Target lesion for cryoablation previously treated with radiation therapy or other locoregional therapy | Inability to lie flat for the cryoablation procedure | Significant immunodeficiency or CD4+ T cells < 200/µL | History of autoimmune disease (e.g., myasthenia gravis, myositis, autoimmune hepatitis, SLE, RA, IBD, vasculitis, Sjogren's, Guillain-Barre, MS, glomerulonephritis) | Ongoing adverse events from prior chemotherapy (except Grade 1 toxicities such as alopecia) | Systemic corticosteroids > 10 mg/day prednisone equivalent or other systemic immunosuppressive medications within 2 weeks prior to Day 1 or anticipated during trial | Anticoagulant or antiplatelet therapy that cannot be interrupted prior to cryoablation | Pregnant or lactating | Severe allergic, anaphylactic, or hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins | Other significant disease or laboratory abnormality that contraindicates investigational drug use or increases risk | Prior therapy with immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, anti-PD-L1) | Systemic immunostimulatory agents (e.g., IFNs, IL-2) within 6 weeks or five half-lives prior to Day 1 | Clinically significant infection within 2 weeks prior to Day 1 | Any systemic anti-cancer treatment (including investigational agents) within 4 weeks prior to first dose; not fully recovered to <= Grade 1 from prior therapy (<= Grade 2 neuropathy allowed)",Washout: systemic immunostimulatory agents >= 6 weeks or 5 half-lives prior to Day 1; Washout: systemic anti-cancer therapy >= 4 weeks prior to first dose,ALL,F,"The trial explicitly excludes patients with prior immune checkpoint inhibitor therapy, and the patient previously received pembrolizumab. Although the disease and metastatic setting match, this hard exclusion makes the patient ineligible.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,F,"The trial explicitly excludes prior immune checkpoint inhibitor therapy, and the patient previously received pembrolizumab (anti-PD-1). This is a hard exclusion per the rubric example, so F is correct despite other matches.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT04706013,0.5606189966201782,Ornithine Transcarbamylase Deficiency,Study of Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency,"The proposed clinical study is intended to evaluate oral P5P for the treatment of patients confirmed to have Pyridox(am)ine 5'-Phosphate Oxidase (PNPO) deficiency via genetic analysis. There is an unmet clinical need for pharmaceutical grade P5P, as to date none has been made commercially available. Patients will receive pharmaceutical grade P5P according to their normal oral P5P dosing regimen, as previously established by their physicians.","{'id': 205843194, 'name': 'Pyridoxal Phosphate', 'description': 'Oral tablets 50 mg', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,Not specified,Pyridox(am)ine 5'-Phosphate Oxidase Deficiency,Confirmed PNPO deficiency by genetic analysis | Seizures typically controlled on oral pyridoxal phosphate with multiple daily doses | On pyridoxal phosphate therapy for >=30 days prior to enrollment | Previous failed treatment on pyridoxine allowed; off pyridoxine for >=24 hours,Any condition or abnormality that may compromise patient safety or ability to comply with study procedures | Known or suspected allergy to pyridoxal phosphate or related drugs | Participation in an interventional clinical research study within 4 weeks prior to screening or prior enrollment in this study,On pyridoxal phosphate therapy for >=30 days before enrollment; Prior pyridoxine allowed with washout >=24 hours,ALL,F,"Disease mismatch: the trial targets PNPO deficiency and requires confirmed PNPO deficiency, while the patient has OTC deficiency. This is a hard exclusion.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,Clear disease mismatch: trial requires PNPO deficiency while patient has OTC deficiency. This is a hard exclusion per rubric (disease mismatch and required biomarker/subtype mismatch). Grade F is correct.,,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT04713475,0.4418357014656067,PMM2-CDG,"Phase 1/2 Open-Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered Into the Cisterna Magna of Pediatric Type 1 (Early Onset) and Type 2a (Late Onset) Infantile GM1 Gangliosidosis","PBGM01 is a gene therapy for GM1 gangliosidosis intended to deliver a functional copy of the GLB1 gene to the brain and peripheral tissues. This study will assess in a 2 part design the safety, tolerability and efficacy of PBGM01 in patients with early onset infantile (Type 1) and late onset infantile (Type 2a) GM1 gangliosidosis","{'id': 206391577, 'name': 'PBGM01', 'description': 'AAVhu68 viral vector', 'other_names': [], 'intervention_type': 'BIOLOGICAL'}",PHASE1/PHASE2,1 months to 24 months,"GM1 Gangliosidosis, Type I; GM1 Gangliosidosis, Type 2",Documented GM1 gangliosidosis with 2 pathogenic GLB1 mutations and beta-galactosidase enzyme deficiency | Type 1 (early onset infantile): age >= 1 month and < 12 months at enrollment; symptom onset < 6 months; specified minimum developmental milestones remaining | Type 2a (late onset infantile): age >= 6 months and <= 24 months at enrollment; symptom onset between 6 and 18 months; specified minimum developmental milestones remaining including ability to sit independently per WHO-MGRS (sit unsupported with head erect for >= 10 seconds),"Clinically significant neurocognitive deficit not attributable to GM1 gangliosidosis or that may confound study results | Acute illness requiring hospitalization within 30 days prior to enrollment | History of ventilation-assisted respiratory support or need for tracheostomy; chronic invasive or noninvasive mechanical ventilation | Intractable seizures or uncontrolled epilepsy, including status epilepticus or seizures requiring hospitalization within 30 days prior to dosing | Contraindication to intra-cisterna magna administration, fluoroscopic imaging, or anesthesia, or conditions increasing ICM procedure risk (e.g., mass effect/increased intracranial pressure, posterior fossa/foramen magnum space-occupying lesion, aberrant vascular or venous anatomy, Chiari malformation) | Contraindication to MRI or lumbar puncture | Prior gene therapy | Use of miglustat within 48 hours prior to dosing; miglustat prohibited during study | Use of enzyme replacement therapy or other investigational therapy within 5 half-lives prior to dosing; enzyme replacement prohibited during study | Receipt of a vaccine within 14 days prior to dosing or scheduled vaccine within 30 days after dosing | eGFR < 30 mL/min based on creatinine | Coagulopathy: INR > 1.5 or aPTT > 40 seconds | Platelet count < 100,000/µL | AST > 3 x ULN or ALT > 3 x ULN | Total bilirubin > 1.5 x ULN | Cardiomyopathy (screening troponin above ULN) | Peripheral neuropathy | Medical conditions or abnormal labs/vital signs increasing risk from ICM injection, anesthesia, fluoroscopy, LP, and/or MRI (e.g., temperature > 38°C, oxygen saturation < 95% on room air or baseline oxygen requirement, abnormal heart or respiratory rate for age, abnormal blood pressure for age, evidence of infection) | Any condition that would put the subject at undue risk during the procedure or interfere with evaluation of PBGM01 or interpretation of safety or results",Discontinue miglustat >= 48 hours before dosing; prohibited during study; No enzyme replacement therapy or other investigational therapy within 5 half-lives before dosing; enzyme replacement prohibited during study; No vaccines within 14 days before dosing and none scheduled within 30 days after dosing,ALL,F,"Disease mismatch: the trial is for GM1 gangliosidosis with GLB1 mutations in infants (1–24 months), whereas the patient has PMM2-CDG with PMM2 variants and is 8 years old. These constitute hard exclusions (disease, biomarker, and age window).",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"Clear hard exclusions: disease mismatch (PMM2-CDG vs GM1 gangliosidosis), required biomarker mismatch (GLB1 required vs PMM2), and age window conflict (trial 1–24 months vs patient 8 years). F is correct per rubric.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT04724018,0.8805802464485168,Metastatic Urothelial Carcinoma,Combinations of Sacituzumab Govitecan Plus Enfortumab Vedotin and Pembrolizumab for Metastatic Urothelial Carcinoma: the Double Antibody Drug Conjugate (DAD) and Double Antibody Drug Conjugate With Immunotherapy (DAD-IO) Phase I/II Trial,"Phase I of this research study will assess what doses of Sacituzumab Govitecan and Enfortumab Vedotin can be safely combined in the treatment of metastatic urothelial carcinoma (mUC). In Phase II of the study, patients in one of the two cohorts will receive Sacituzumab Govitecan, Enfortumab Vedotin, and Pembrolizumab to assess the efficacy of this drug combination. The names of the study drugs in these investigational combinations are: * Enfortumab Vedotin * Sacituzumab Govitecan * Pembrolizumab","{'id': 205800492, 'name': 'Sacituzumab Govitecan (SG)', 'description': 'Intravenous infusion', 'other_names': ['Trodelvy'], 'intervention_type': 'DRUG'}; {'id': 205800493, 'name': 'Enfortumab vedotin-ejfv (EV)', 'description': 'Intravenous infusion', 'other_names': ['Padcev'], 'intervention_type': 'DRUG'}; {'id': 205800494, 'name': 'Pembrolizumab', 'description': 'Intravenous infusion', 'other_names': ['Keytruda'], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,18 years,Urothelial Carcinoma (metastatic),"Histologically confirmed predominant urothelial carcinoma (bladder, renal pelvis, ureter, or urethra); urothelial component >50% if mixed; small-cell carcinoma excluded; locally advanced unresectable allowed | Age >= 18 years | ECOG performance status 0–1 | Measurable disease by RECIST 1.1 | Adequate organ and marrow function | HIV on effective antiretroviral therapy with undetectable viral load within 6 months allowed | Chronic HBV allowed if viral load undetectable on suppressive therapy | HCV treated/cured or on treatment with undetectable viral load | Cardiac function NYHA class 2B or better | Cohort A: Cisplatin-eligible must have received prior platinum therapy and a PD-1/PD-L1 inhibitor for advanced disease or within 12 months of perioperative therapy | Cohort A: Cisplatin-ineligible must have progressed on or since one prior line of therapy for advanced disease or within 12 months of perioperative therapy | Cohort A: Disease progressing on or since most recent therapy | Cohort B: No prior systemic therapy for metastatic urothelial carcinoma; prior immunotherapy allowed if > 6 months from last dose in the perioperative setting","Pregnant or lactating | Prior anti-cancer biologic agent (including immune checkpoint inhibitors) within 4 weeks or chemotherapy/targeted therapy/radiation within 2 weeks before C1D1 (Cohort A) | Prior chemotherapy or anti-cancer biologic agent within 26 weeks before C1D1 (Cohort B) | Unresolved toxicities from prior therapy > Grade 1 (except per protocol allowances) | Major surgery without adequate recovery | Prior exposure to topoisomerase I inhibitors, sacituzumab govitecan, or enfortumab vedotin | Active second malignancy (exceptions for completely treated with no evidence of disease for 3 years or low risk of recurrence) | Active CNS metastases or carcinomatous meningitis; previously treated brain metastases allowed if stable >= 4 weeks, symptoms at baseline, no new/enlarging lesions, and prednisone <= 20 mg/day (Cohort A) or <= 10 mg/day (Cohort B) | Myocardial infarction or unstable angina within 6 months prior to C1D1 | Serious ventricular arrhythmia, high-grade AV block, or other significant arrhythmias requiring anti-arrhythmic therapy; history of QT prolongation | NYHA Class III or greater heart failure or LVEF < 40% | Active inflammatory bowel disease or GI perforation within 6 months | Active serious infection requiring antibiotics | Other uncontrolled medical or psychiatric conditions that could confound study or prevent completion | Requirement for > 10 mg/day prednisone (or equivalent) or other systemic immunosuppression (inhaled/topical steroids allowed without active autoimmune disease) | History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced or idiopathic pneumonitis, or active pneumonitis on screening CT | Concurrent investigational agents | Allergy to pembrolizumab, enfortumab vedotin, sacituzumab govitecan, or excipients (including MES, histidine, trehalose dihydrate, polysorbate 80 or 20) | Uncontrolled intercurrent illness | Psychiatric illness/social situations limiting compliance | Uncontrolled diabetes (HbA1c > 8% or 7–8% with unexplained diabetes symptoms) | Uncontrolled tumor-related bone pain or impending spinal cord compression | Cohort B: History of autoimmune disease requiring systemic treatment in the past 2 years (with protocol-specified exceptions)",Cohort A (cisplatin-eligible): prior platinum-containing therapy and prior PD-1/PD-L1 inhibitor required; Cohort A (cisplatin-ineligible): progressed on or since at least one prior line of therapy for advanced disease or within 12 months of perioperative therapy; Cohort A: disease must be progressing on or since the most recent therapy; Cohort B: no prior systemic therapy for metastatic urothelial carcinoma; prior immunotherapy allowed if > 6 months from last dose in perioperative setting; Washout (Cohort A): >= 4 weeks from prior anti-cancer biologic agent; >= 2 weeks from prior chemotherapy/targeted therapy/radiation before C1D1; Washout (Cohort B): no prior chemotherapy or anti-cancer biologic agent within 26 weeks before C1D1,ALL,F,"The trial explicitly excludes patients with prior exposure to enfortumab vedotin, which this patient has received. Therefore, despite disease and setting alignment, this is a hard exclusion.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,F,"The trial explicitly excludes prior exposure to enfortumab vedotin, and the patient has received enfortumab vedotin plus pembrolizumab. This is a hard exclusion per the rubric, so grade F is correct regardless of other matches.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT04835506,0.6691051721572876,Fistulizing Crohn's Disease,Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial,The OPTIMIZE Trial compares whether iDose dashboard-driven infliximab dosing (iDose-driven dosing) is more effective and safer than standard infliximab dosing for inducing and maintaining disease remission in inflammatory bowel disease.,"{'id': 205978593, 'name': 'Infliximab', 'description': 'infliximab', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE4,16 years,Crohn Disease; Ulcerative Colitis,"Age 16 to 80 years | Diagnosis of inflammatory bowel disease (Crohn disease or ulcerative colitis) by standard endoscopic, histologic, or radiologic criteria | Moderately to severely active Crohn disease: CDAI 220–450 | Moderately to severely active ulcerative colitis: partial Mayo Score > 4 with rectal bleeding subscore >= 1 | Elevated C-reactive protein (> ULN) | Fecal calprotectin > 250 µg/g | Crohn disease endoscopic activity: SES-CD > 6 (or > 3 for isolated ileal disease) | Ulcerative colitis endoscopic activity: Mayo endoscopic subscore >= 2 | Physician intends to prescribe infliximab as part of usual care | No previous infliximab use, except 1 prior dose allowed within 2.5 weeks of enrollment if all eligibility criteria were met and dosing per protocol | Males or nonpregnant, nonlactating females","Abdominal or pelvic abscess, including perianal | Presence of stoma, ileal pouch-anal anastomosis, or ostomy | Isolated perianal disease | Obstructive disease such as obstructive stricture | Short gut syndrome | Toxic megacolon or other complications requiring surgery or confounding assessment of disease activity | Total colectomy | History or current diagnosis of ulcerative proctitis (extent < 15 cm from anal verge) | Acute severe (fulminant) ulcerative colitis | Hospitalized intravenous steroid-refractory ulcerative colitis | Indeterminate colitis | Microscopic colitis | Ischemic colitis | Colonic mucosal dysplasia | Untreated bile acid malabsorption | Current bacterial or parasitic enteric infection (including Clostridioides difficile) | Active or latent tuberculosis | Known hepatitis B virus infection | Known hepatitis C virus infection | Known HIV infection | Sepsis | Active abscess | Opportunistic infection within 6 months prior to screening | Any infection requiring antimicrobial therapy within 2 weeks prior to screening | More than 1 episode of herpes zoster or any episode of disseminated zoster | Any infection requiring hospitalization or intravenous antimicrobials within 4 weeks prior to screening | Malignancy or lymphoproliferative disorder (except nonmelanoma skin cancer or cervical carcinoma in situ) unless treated with no recurrence within 5 years | Primary or secondary immunodeficiency | Primary nonresponse to adalimumab (no objective benefit after 14 weeks) | Failure to a prior biologic (primary nonresponse or secondary loss of response) excluded once a cap of approximately 40% of enrollment with prior biologic failure is reached | Concomitant oral corticosteroids exceeding prednisone 40 mg/day, budesonide 9 mg/day, or equivalent unless taper planned to be off by Week 14 | Any contraindication to infliximab per product label | Clinically significant, serious, unstable, or uncontrolled comorbidity that may confound results or increase risk | Pregnant or lactating | Known intolerance or hypersensitivity to infliximab or other murine proteins",No prior infliximab (<= 1 prior dose within 2.5 weeks allowed if eligibility met and dosing per protocol),ALL,F,"The trial requires no prior infliximab use (except ≤1 recent dose), whereas the patient is refractory to infliximab, which explicitly conflicts with eligibility.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"The trial explicitly excludes prior infliximab use (except ≤1 recent dose). The patient is refractory to infliximab, indicating prior exposure beyond what’s allowed. This is a hard exclusion per the rubric, so F is correct.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT04863885,0.8805802464485168,Metastatic Urothelial Carcinoma,Phase I/II Study of Ipilimumab Plus Nivolumab (IPI-NIVO) Combined With Sacituzumab Govitecan (SG)as First-line Treatment for Cisplatin-ineligible Metastatic Urothelial Carcinoma,The purpose of this study is to see how well the study drugs called Ipilimumab plus Nivolumab (IPI-NIVO) work when added to another study drug called Sacituzumab Govitecan for people who have metastatic bladder cancer.,"{'id': 206179201, 'name': 'Ipilimumab', 'description': 'Participants will receive Ipilimumab 3 mg/kg', 'other_names': ['Yervoy'], 'intervention_type': 'DRUG'}; {'id': 206179202, 'name': 'Nivolumab', 'description': 'Participants will receive Nivoumab 1mg/kg', 'other_names': ['Opdivo'], 'intervention_type': 'DRUG'}; {'id': 206179203, 'name': 'Sacituzumab govitecan', 'description': 'Participants will be treated at 1 of 2 dose levels of Sacituzumab govitecan, either at 8 mg/kg, 10 mg/kg, or 6 mg/kg.', 'other_names': ['Trodelvy'], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,18 years,Urothelial Carcinoma (metastatic),Age >= 18 years | ECOG performance status 0–1 | Histologically documented locally advanced or metastatic urothelial carcinoma | Mixed histology allowed if urothelial carcinoma is predominant (>=50%) | Cisplatin-ineligible: creatinine clearance < 60 mL/min | Cisplatin-ineligible: CTCAE v5.0 hearing loss > Grade 1 | Cisplatin-ineligible: CTCAE v5.0 neuropathy > Grade 1 | Cisplatin-ineligible: NYHA cardiac dysfunction > Class II | Adequate organ function per protocol | Measurable disease by RECIST 1.1 | Women: post-menopausal or negative pregnancy test as specified | Women of childbearing potential: agree to dual contraception during treatment and for >=5 months after last dose | Men: agree to adequate contraception during treatment and for 7 months after last dose,"Pregnant or lactating | Participation in another investigational study or device use within 4 weeks prior to first dose | Prior chemotherapy for metastatic urothelial carcinoma | Small-cell carcinoma component | Prior chemotherapy for localized urothelial carcinoma completed within 12 months before registration | Prior anti-PD-1/PD-L1 therapy unless given in earlier stage and completed >3 months before registration | Prior therapy with sacituzumab govitecan, irinotecan, any topoisomerase I-containing regimen, or any topoisomerase I antibody-drug conjugate | Radiation for bone metastasis within 2 weeks prior to first dose | Any other radiation therapy within 4 weeks prior to first dose | Systemic radionuclide therapy within 6 weeks prior to first dose | Requires concomitant medication interfering with ABCA1 transporter or UGT1A1 | Gilbert's disease | Active second malignancy (exceptions for completely treated/low-risk tumors as specified) | Known active CNS metastases or carcinomatous meningitis (treated, stable brain mets allowed under specified conditions) | Active cardiac disease as defined in protocol | Active inflammatory bowel disease (ulcerative colitis, Crohn's disease) or history of bowel obstruction | History of clinically significant bleeding, intestinal obstruction, or GI perforation within 6 months | High-dose systemic corticosteroids within 2 weeks prior to first dose (<=10 mg prednisone equivalent daily allowed for non-CNS reasons if stable >=4 weeks) | Active infection requiring systemic antibiotics within 2 weeks prior to initiation | Active autoimmune disease requiring systemic treatment or condition precluding IPI-NIVO | Live vaccine within 30 days prior to first dose | History or evidence of interstitial lung disease or non-infectious pneumonitis | HIV-1/2 with uncontrolled viral load and on medications that may interfere with SN-38 metabolism | Active hepatitis B or hepatitis C (HBcAb positive with detectable HBV DNA excluded) | Other significant medical or psychiatric conditions that could confound study or prevent completion","No prior chemotherapy for metastatic urothelial carcinoma; Prior anti–PD-1/PD-L1 allowed only if neoadjuvant/adjuvant and completed >3 months before registration; No prior sacituzumab govitecan, irinotecan, topoisomerase I–containing regimens, or topoisomerase I ADCs; Radiation washout: bone metastasis >=2 weeks; other radiation >=4 weeks; systemic radionuclides >=6 weeks before first dose; Investigational agents/devices: >=4-week washout before first dose; High-dose systemic corticosteroids: at least 2 weeks since last use before first dose (<=10 mg prednisone equivalent daily permitted if stable >=4 weeks for non-CNS reasons); Live vaccines: not within 30 days before first dose; Systemic antibiotics for active infection: not within 2 weeks before initiation of study treatment; Recovered adequately from major surgery before starting therapy",ALL,F,"This is a first-line trial that explicitly excludes prior anti–PD-1/PD-L1 therapy and prior systemic treatment for metastatic disease. The patient received pembrolizumab (PD-1) with enfortumab vedotin for metastatic urothelial carcinoma, triggering a hard exclusion.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,F,"The trial explicitly excludes prior anti–PD-1/PD-L1 therapy unless limited to earlier-stage and completed >3 months before registration. The patient received pembrolizumab in the metastatic setting, triggering a hard exclusion. Thus, grade F is correct.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT04878029,0.8805802464485168,Metastatic Urothelial Carcinoma,"A Phase I/Ib Open Label, Single-Arm Study of Cabozantinib in Combination with Enfortumab Vedotin (EV) in the Treatment of Locally Advanced or Metastatic Urothelial Cancer","This phase I/Ib trial seeks to find out the best dose, possible benefits and/or side effects of cabozantinib in combination with enfortumab vedotin in treating urothelial cancer that has spread to nearby tissues and lymph nodes (locally advanced) or other parts of the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to a toxic agent called vedotin. Enfortum...","{'id': 206011720, 'name': 'Cabozantinib S-malate', 'description': 'Given PO', 'other_names': ['BMS-907351', 'Cabometyx', 'Cometriq', 'XL-184', 'XL184'], 'intervention_type': 'DRUG'}; {'id': 206011721, 'name': 'Enfortumab Vedotin', 'description': 'Given IV', 'other_names': ['AGS 22ME', 'AGS-22M6E', 'Anti-Nectin 4 ADC ASG-22CE', 'Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E', 'ASG-22CE', 'Enfortumab Vedotin-ejfv', 'Padcev'], 'intervention_type': 'DRUG'}; {'id': 206011722, 'name': 'Quality-of-Life Assessment', 'description': 'Ancillary studies', 'other_names': ['Quality of Life Assessment'], 'intervention_type': 'OTHER'}; {'id': 206011723, 'name': 'Questionnaire Administration', 'description': 'Ancillary studies', 'other_names': [], 'intervention_type': 'OTHER'}",PHASE1,18 years,Urothelial Carcinoma (metastatic); Urothelial Carcinoma (locally advanced); Urothelial Carcinoma (unresectable); Bladder Urothelial Carcinoma (squamous differentiation),Histologically confirmed urothelial carcinoma (squamous differentiation or mixed histology allowed if urothelial carcinoma present) | Metastatic or unresectable locally advanced disease | Prior checkpoint inhibitor (PD-1 or PD-L1) therapy required | Prior platinum chemotherapy or platinum-ineligible at enrollment | Recovery to baseline or <= grade 1 from prior therapy toxicities (unless clinically nonsignificant/stable on supportive therapy) | Tumor tissue available or willing to undergo repeat biopsy | Measurable disease per RECIST v1.1 | ECOG performance status <=2 | Age >=18 years,"Prior cabozantinib treatment | Prior enfortumab vedotin or other MMAE-based ADCs | Small molecule kinase inhibitor within 2 weeks before first dose | Cytotoxic/biologic/other systemic anticancer therapy within 2 weeks before first dose | Radiation therapy within 2 weeks before first dose; radionuclide therapy within 6 weeks | Known brain metastases or cranial epidural disease unless adequately treated and stable >=4 weeks and off corticosteroids | Concurrent anticoagulation with warfarin, dabigatran, betrixaban, or platelet inhibitors (clopidogrel) | Uncontrolled hypertension (>140/90 mm Hg despite therapy) | NYHA class 3 or 4 heart failure, unstable angina, serious arrhythmias | Stroke/TIA, myocardial infarction, other ischemic or thromboembolic event within 6 months | High-risk GI disorders (e.g., tumor invading GI tract, active peptic ulcer, IBD, diverticulitis, cholecystitis, symptomatic cholangitis, appendicitis, acute pancreatitis, duct obstruction, gastric outlet obstruction) | Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months | Clinically significant bleeding (e.g., hematuria, hematemesis, hemoptysis >2.5 mL) within 12 weeks | Cavitating pulmonary lesions or endotracheal/endobronchial disease | Lesions invading or encasing major blood vessels | Sensory or motor neuropathy grade >=2 | Serious non-healing wound, ulcer, or bone fracture | Uncompensated/symptomatic hypothyroidism | Moderate to severe hepatic impairment (Child-Pugh B or C) | Uncontrolled diabetes mellitus (HbA1c >=8%) | Major surgery within 2 weeks or minor surgery within 10 days before first dose; incomplete wound healing | QTcF >500 ms on ECG (confirmation per protocol) | Pregnant or lactating | Inability to swallow tablets | Hypersensitivity to study drug components | Other active malignancy requiring treatment within 3 years (except specified curable cancers)",Prior PD-1 or PD-L1 inhibitor required; Prior platinum chemotherapy or platinum-ineligible,ALL,F,"Disease and setting match, but the trial explicitly excludes patients with prior enfortumab vedotin exposure. This patient has received enfortumab vedotin plus pembrolizumab.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with prior enfortumab vedotin exposure, which the patient has. This is a hard exclusion per the rubric, so F is correct.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT04881617,0.7164024710655212,Dementia,Establishing Evidence-based Treatment for Speech and Language in Primary Progressive Aphasia,"Primary progressive aphasia (PPA) is a progressive neurological disorder that causes a gradual decline in communication ability as a result of selective neurodegeneration of speech and language networks in the brain. PPA is a devastating condition affecting adults as young as their 40's or 50's, depriving them of the ability to communicate and function in society. There has been significant progress in discovering the neurobiological mechanisms that underlie PPA and in identifying its clinica...","{'id': 205697628, 'name': 'Lexical Retrieval Training (LRT)', 'description': 'In person or via teletherapy: Participants work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) sessions per week with a clinician plus daily home practice exercises.', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}; {'id': 205697629, 'name': 'Video-Implemented Script Training for Aphasia (VISTA)', 'description': 'In person or via teletherapy: Participants work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes 30 minutes per day of home practice, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts. Biweekly (one hour each) sessions with a clinician target clear and accurate script production, script memorization, and conversational usage of scripts.', 'other_names': [], 'intervention_type': 'BEHAVIORAL'}",NA,Not specified,Primary Progressive Aphasia; Logopenic Progressive Aphasia; Nonfluent Progressive Aphasia; Semantic Dementia,"Primary Progressive Aphasia diagnosis per Gorno-Tempini et al., 2011 criteria | Mini-Mental State Examination score >= 15","Other neurological or psychiatric diagnosis contributing to cognitive-linguistic deficits | Significant uncorrected visual or hearing impairment that would interfere with participation | Mini-Mental State Examination score < 15 | Prominent initial non-speech-language impairment (cognitive, behavioral, or motoric)",(none),ALL,F,"Disease mismatch: the trial requires a diagnosis of Primary Progressive Aphasia (including its variants), while the patient is described as having dementia without a specified PPA diagnosis.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"The trial specifically requires a diagnosis of Primary Progressive Aphasia (PPA) or its variants, while the patient is only described as having dementia without a PPA diagnosis. This is a disease mismatch, which is a hard exclusion per the rubric. The assigned grade F is correct.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT04899310,0.5627489686012268,Ornithine Transcarbamylase Deficiency,"A Global, Phase 1/2, Open-Label, Dose Optimization Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency","This is a study of mRNA-3705 in participants with isolated elevated methylmalonic acid (MMA) due to methylmalonyl-coenzyme A (CoA) mutase (MUT) deficiency. The main goal of the study is to assess safety, pharmacokinetics, and pharmacodynamics of mRNA-3705.","{'id': 205978917, 'name': 'mRNA-3705', 'description': 'A sterile liquid for injection', 'other_names': ['modified mRNA encoding human', 'methylmalonyl-coenzyme A mutase'], 'intervention_type': 'BIOLOGICAL'}",PHASE1/PHASE2,1 years,Methylmalonic Acidemia,Body weight >= 11.0 kg | Diagnosis of isolated methylmalonic acidemia due to MUT deficiency confirmed by molecular genetic testing | Blood vitamin B12 level >= lower limit of normal; elevated B12 allowed if due to supplementation per Investigator | Willing and able to provide informed consent/assent and comply with study procedures | Sexually active females of childbearing potential and males of reproductive potential agree to use highly effective contraception during the study and for 3 months after last dose | (Part 2 only) At least 1 documented metabolic decompensation event in the 12 months before consent,"Diagnosis of isolated MMA cblA, cblB, or cblD subtypes, methylmalonyl-CoA epimerase deficiency, or combined MMA with homocystinuria | Prior gene therapy for the treatment of MMA | History of organ transplantation or planned organ transplantation during study participation | Active, unstable, or clinically significant medical condition not related to MMA that could increase risk, interfere with results, or limit participation (including relevant allergies; cardiovascular, central nervous system, gastrointestinal, infectious disease; clinically significant pathology; or history of cancer) | (Part 2 only) History of hepatitis B surface antigen positivity, hepatitis C virus infection, or HIV infection; participants with resolved HBV (HBcAb positive, HBsAg negative) are eligible; HCV antibody positive allowed only if HCV RNA PCR is negative",(none),ALL,F,"Disease mismatch: the trial targets methylmalonic acidemia (MUT deficiency), while the patient has ornithine transcarbamylase deficiency. Additionally, the patient is 3 months old, which is outside the trial’s minimum age of 1 year.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Correct: There is a hard disease mismatch (OTC deficiency vs MMA due to MUT), and also an age hard exclusion (3 months vs minimum 1 year). Either triggers F per rubric.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT04909801,1.0,Rheumatoid Arthritis,"A Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatment With Subcutaneous Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive Rheumatoid Arthritis Who Have ""Shared Epitope"" HLA Class II Risk Alleles and Have an Inadequate Response to Methotrexate","The purpose of this study is to evaluate the superiority in efficacy of abatacept compared with adalimumab, on background methotrexate, in adults with early, seropositive, and shared epitope-positive rheumatoid arthritis and an inadequate methotrexate response.","{'id': 205984602, 'name': 'Abatacept', 'description': 'Abatacept SC (125 mg) once weekly', 'other_names': ['BMS-188667', 'Orencia®'], 'intervention_type': 'DRUG'}; {'id': 205984603, 'name': 'Adalimumab', 'description': 'Adalimumab SC (40 mg) once every 2 weeks', 'other_names': ['Humira®'], 'intervention_type': 'DRUG'}; {'id': 205984604, 'name': 'Methotrexate', 'description': 'Methotrexate oral/parenteral maximum tolerated dose (minimum 15 mg and maximum 25 mg weekly)', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,18 years,Rheumatoid Arthritis,"Early rheumatoid arthritis with symptom onset <= 12 months before screening and meeting ACR/EULAR 2010 RA classification criteria within that period | Naive to any targeted (biologic or nonbiologic) DMARDs, conventional synthetic DMARDs other than methotrexate, or investigational therapies for RA | Treated with methotrexate for >= 12 weeks with a stable dose for >= 4 weeks prior to randomization | Anti-CCP-2 > 3 x ULN and rheumatoid factor positive by central laboratory at screening | DAS28-CRP >= 3.2 at screening | >= 3 tender and >= 3 swollen joints at screening and at randomization","Women who are breastfeeding | Autoimmune disease other than rheumatoid arthritis or currently active fibromyalgia | History of or current inflammatory joint disease other than rheumatoid arthritis (e.g., psoriatic arthritis, gout, reactive arthritis, Lyme disease) | At risk for tuberculosis | Recent acute infection | History of chronic or recurrent bacterial infection (e.g., chronic pyelonephritis, osteomyelitis, bronchiectasis) | History of infection of a joint prosthesis or artificial joint | History of systemic fungal infections (e.g., histoplasmosis, blastomycosis, coccidioidomycosis) | History of primary immunodeficiency | Current clinical findings or history of a demyelinating disorder | Five or more joints cannot be assessed for tenderness or swelling | Prior targeted/nonbiologic DMARDs (other than methotrexate) or investigational therapies for RA",Methotrexate for >= 12 weeks with stable dose for >= 4 weeks prior to randomization,ALL,F,"Explicit exclusion: the trial requires RA patients naïve to targeted/biologic DMARDs (other than methotrexate), but the patient previously received adalimumab and tocilizumab. This directly conflicts with the trial’s exclusion criteria.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,F,"Explicit exclusion applies: the trial requires no prior targeted/biologic DMARDs beyond methotrexate, while the patient previously received adalimumab and tocilizumab. This triggers a hard exclusion per the rubric.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT04941456,0.5186926126480103,PMM2-CDG,Is Ambulation Distance on the Six-minute Walk Test Improved With the Use of Passy-Muir Valve for Patients With Tracheostomy Compared to Patients With an Open Tracheostomy?,The purpose of this study is to determine if the use of the Passy-Muir Valve improves endurance for patients in the Long Term Acute Care setting as measured with the Six- Minute Walk Test.,"{'id': 205828602, 'name': 'Open Tracheostomy', 'description': 'Participants will perform the six minute walk test with an open tracheostomy. Participants will complete 1 to 3 session over approximately three-weeks.', 'other_names': ['Standard'], 'intervention_type': 'OTHER'}; {'id': 205828603, 'name': 'PMV in place', 'description': 'Participants will perform the six minute walk test with a PMV in place. Participants will complete 1 to 3 sessions over approximately three-weeks.', 'other_names': ['PMV', 'Passy-Muir Valve'], 'intervention_type': 'DEVICE'}",NA,18 years,PMV; Exercise Endurance; Tracheostomy,Tracheostomy present | Able to tolerate daily 30-minute physical therapy with PMV | Oxygen saturation >=88% with exertion | Able to ambulate >=10 feet (with or without assistive device or physical assistance),Active seizures | Pregnancy | Uncontrolled hypertension | Cognitive deficits that preclude informed consent | Enteric infection control precautions | Ongoing orthostasis | Currently on decannulation protocol | Medical instability warranting hold of therapy program,(none),ALL,F,"Disease mismatch: the trial targets tracheostomy/PMV use rather than PMM2-CDG. Additionally, the patient is 8 years old, below the trial’s minimum age of 18.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"Two hard exclusions apply: (1) Disease mismatch—the trial targets tracheostomy/PMV rather than PMM2-CDG; (2) Age window conflict—the patient is 8, below the trial minimum age of 18. Either triggers an F. The grader correctly assigned F and provided appropriate reasoning.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05003986,0.42564189434051514,PMM2-CDG,"A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases","To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.","{'id': 205792842, 'name': 'Sparsentan', 'description': 'Population 1: 800 mg Sparsentan (oral suspension)', 'other_names': ['RE-021'], 'intervention_type': 'DRUG'}; {'id': 205792843, 'name': 'Sparsentan', 'description': 'Population 2: 400 mg Sparsentan (oral suspension)', 'other_names': ['RE-021'], 'intervention_type': 'DRUG'}; {'id': 205792844, 'name': 'Sparsentan', 'description': 'Population 3: 400 mg Sparsentan (tablets)', 'other_names': ['RE-021'], 'intervention_type': 'DRUG'}",PHASE2,1 years to 17 years,Alport Syndrome; Focal Segmental Glomerulosclerosis; IgA Vasculitis; Immunoglobulin A Nephropathy; Minimal Change Disease,"eGFR >=30 mL/min/1.73 m2 at screening | Mean seated blood pressure between the 5th and 95th percentile for sex and height | Population 1: Age >=1 year and <18 years at Day 1 | Population 1: UP/C >=1.5 g/g at screening | Population 1: Kidney biopsy-proven FSGS or MCD histological patterns consistent with primary disease, or genetic podocyte mutation associated with FSGS or MCD, or FSGS histological pattern with maladaptive cause | Population 2: Age >=2 years and <18 years at Day 1 | Population 2: UP/C >=0.6 g/g at screening | Population 2: Kidney biopsy-confirmed IgAN, IgAV, or AS, or AS diagnosis by qualifying COL4A3/COL4A4/COL4A5 pathogenic mutations (including digenic) | Population 3: Age >=8 years and <18 years at Day 1 | Population 3: UP/C >=1.0 g/g at screening | Population 3: Kidney biopsy-confirmed IgAN | Population 3: Weight >=40 kg | Population 3: On ACE inhibitor and/or ARB therapy for at least 12 weeks prior to screening","Weight <7.3 kg at screening | FSGS or MCD secondary to viral infections, drug toxicities, or malignancies | IgA glomerular deposits not due to primary IgAN or IgAV | Acute onset or relapse of glomerular disease requiring new or different class of immunosuppressive treatment within 6 months before screening | Chronic immunosuppressive medications (including systemic steroids) not on a stable dose for >=1 month before screening | Requires prohibited concomitant medications | Any prior organ transplantation other than corneal transplant | History of congenital or acquired heart failure (modified Ross Class II–IV) or prior hospitalization for heart failure or symptoms (unexplained dyspnea, orthopnea, paroxysmal nocturnal dyspnea, ascites, peripheral edema) | Hemodynamically significant cardiac valvular disease | Clinically significant congenital vascular disease | Jaundice, hepatitis, or known hepatobiliary disease, or ALT >2 x ULN or AST >2 x ULN at screening | History of malignancy within the past 2 years | Hematocrit <27% at screening | Hemoglobin <9 g/dL at screening | Potassium >5.5 mEq/L at screening | Any clinically significant abnormal laboratory value per investigator | History of allergic response to angiotensin II antagonists or endothelin receptor antagonists (including sparsentan) or hypersensitivity to excipients | Pregnant, planning pregnancy during the study, or breastfeeding | Females of childbearing potential not agreeing to required contraception and testing schedule | Participation in another investigational study within 28 days before screening or planning to participate during this study | Prior exposure to sparsentan | Inability to adhere to study requirements per investigator judgment | Population 3: Unable to swallow tablets whole",ACE inhibitor and/or angiotensin receptor blocker for >=12 weeks prior to screening (Population 3),ALL,F,"Disease mismatch: the trial targets pediatric proteinuric glomerular diseases (Alport, FSGS, IgAN/IgAV, MCD), whereas the patient has PMM2-CDG. Therefore the patient does not meet the disease criteria.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"Disease mismatch is a hard exclusion: the trial enrolls specific pediatric proteinuric glomerular diseases (Alport, FSGS, IgAN/IgAV, MCD), while the patient has PMM2-CDG. Thus F is correct regardless of other factors.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05038592,0.44208985567092896,PMM2-CDG,Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes,"This phase I/II trial studies the side effects, best dose, and effect of tagraxofusp and decitabine in treating patients with chronic myelomonocytic leukemia. Tagraxofusp consists of human interleukin 3 (IL3) linked to a toxic agent called DT388. IL3 attaches to IL3 receptor positive cancer cells in a targeted way and delivers DT388 to kill them. Chemotherapy drugs, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them fro...","{'id': 206230934, 'name': 'Decitabine', 'description': 'Given IV', 'other_names': [""5-Aza-2''-deoxycytidine"", 'Dacogen', 'Decitabine for Injection', 'Deoxyazacytidine', 'Dezocitidine'], 'intervention_type': 'DRUG'}; {'id': 206230935, 'name': 'Tagraxofusp-erzs', 'description': 'Given IV', 'other_names': ['Diphtheria Toxin(388)-Interleukin-3 Fusion Protein', 'DT(388)-IL3 Fusion Protein', 'DT388IL3 fusion protein', 'Elzonris', 'IL3R-targeting Fusion Protein SL-401', 'SL-401', 'Tagraxofusp', 'Tagraxofusp ERZS'], 'intervention_type': 'BIOLOGICAL'}",PHASE1/PHASE2,18 years,Chronic Myelomonocytic Leukemia; Chronic Myelomonocytic Leukemia-1; Chronic Myelomonocytic Leukemia-2; Myelodysplastic/Myeloproliferative Neoplasm; Myelodysplastic Syndrome (high-risk),"Age >= 18 years | Diagnosis of myelodysplastic/myeloproliferative neoplasm per WHO | CMML-1 or CMML-2 or higher-risk MDS (IPSS-R > 3.5 or TP53 mutation) with > 5% blasts, or MDS/MPN (other than CMML) with > 5% bone marrow blasts | Relapsed cohort: no response after 6 cycles of azacitidine, decitabine, guadecitabine, or decitabine-cedazuridine (ASTX727), or relapse/progression after any number of cycles | HMA-naive cohort: previously untreated CMML-1 or CMML-2 with intermediate-2 or high-risk IPSS, or higher-risk MDS (IPSS-R > 3.5 or TP53 mutation) with > 5% blasts, or MDS/MPN (other than CMML) with > 5% bone marrow blasts | ECOG performance status 0-2 | Left ventricular ejection fraction >= 50% | Serum creatinine <= 1.5 mg/dL | Serum albumin >= 3.2 g/dL (no IV albumin within 72 hours) | Total bilirubin <= 1.5 mg/dL | AST and ALT <= 2.5 x ULN | Creatine kinase <= 2.5 x ULN | Women of childbearing potential: negative pregnancy test prior to treatment | Agrees to use acceptable contraception during study and for 2 months after last tagraxofusp dose","Persistent clinically significant toxicities >= Grade 2 from prior therapy (excluding alopecia, nausea, fatigue) | Chemotherapy, wide-field radiation, or biologic therapy within 14 days prior to study entry | Investigational agent within 14 days prior to study entry or concurrent investigational therapy | Prior treatment with tagraxofusp or hypersensitivity to its components | Active malignancy requiring therapy (except non-melanoma skin cancer, carcinoma in situ including superficial bladder cancer, cervical intraepithelial neoplasia, or organ-confined prostate cancer without progression) | Clinically significant cardiovascular disease (e.g., uncontrolled or NYHA Class 3 or 4 heart failure, uncontrolled angina, recent myocardial infarction, unstable angina, stroke within 6 months, uncontrolled hypertension, or significant arrhythmias not controlled by medication) | Uncontrolled, clinically significant pulmonary disease (e.g., COPD, pulmonary hypertension) posing significant risk | Known or suspected CNS involvement; if suspected, must be ruled out by imaging and/or CSF examination | Receiving immunosuppressive therapy (except <= 10 mg prednisone equivalent and tacrolimus for GVHD prophylaxis); active GVHD therapy must be stopped >= 14 days before study drug and no evidence of >= Grade 2 GVHD | Uncontrolled intercurrent illness including uncontrolled infection, disseminated intravascular coagulation, or psychiatric illness limiting compliance | Pregnant or breastfeeding | Known HIV infection | Active or chronic hepatitis B or hepatitis C infection | Oxygen-dependent | Any condition placing patient at unacceptably high risk for toxicities | Hydroxyurea permitted only if receiving prior to study entry and only during Cycle 1; use after Cycle 1 only with PI approval","Relapsed cohort: prior hypomethylating agent (azacitidine, decitabine, guadecitabine, or decitabine-cedazuridine) >= 6 cycles with no response, or relapse/progression after any number of cycles; HMA-naive cohort allowed; Washout: no chemotherapy, wide-field radiation, biologic therapy, or investigational agents within 14 days prior to study entry; Hydroxyurea permitted during Cycle 1 only if patient was receiving it prior to study entry",ALL,F,"Disease mismatch: the trial targets CMML/MDS/MPN, not PMM2-CDG. Additionally, the patient is 8 years old while the trial requires age ≥18.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"There is a hard exclusion due to disease mismatch (trial targets CMML/MDS/MPN, not PMM2-CDG) and another hard exclusion for age (trial requires ≥18; patient is 8). Under the rubric, any hard exclusion results in grade F. The grader correctly assigned F and cited appropriate reasons.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT05077709,0.8805802464485168,Metastatic Urothelial Carcinoma,"A Phase II Multi-Arm (Basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination With Pembrolizumab, as First-Line Treatment for Patients With Metastatic NSCLC, SCCHN, or Metastatic mUBC","A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)","{'id': 205822618, 'name': 'IO102-IO103 in combination with pembrolizumab', 'description': 'The experimental drug IO102-IO103 is for SC injection and consist of IDO and PD-L1 peptides', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic); Head and Neck Squamous Cell Carcinoma (metastatic); Urothelial Carcinoma (metastatic),"Histologically or cytologically confirmed metastatic NSCLC (Arm A), no prior systemic therapy for metastatic disease | No known sensitizing EGFR or ALK mutations (NSCLC) | Recurrent or metastatic SCCHN considered incurable by local therapies, no prior therapy (Arm B) | Documented HPV status for oropharyngeal cancer (SCCHN) | Advanced/unresectable or metastatic urothelial carcinoma of renal pelvis, ureter, bladder, or urethra; transitional cell histology dominant if mixed (Arm C) | Metastatic UBC not eligible for any cisplatin therapy (Arm C) | All solitary metastases biopsied to confirm metastasis from primary indication | PD-L1 TPS >= 50% (NSCLC, Arm A) | PD-L1 CPS >= 20 (SCCHN, Arm B) | PD-L1 CPS >= 10 (mUBC, Arm C) | Age >= 18 years | Measurable disease per RECIST 1.1 | Provision of blood sample and archival or new tumor tissue (non-irradiated lesion preferred) | ECOG performance status 0–1 | Recovered from major surgery prior to starting treatment | Adequate organ function per protocol","Positive pregnancy test or pregnant/breastfeeding | Prior anti–PD-1/PD-L1/PD-L2 or other T-cell co-regulatory agent used in adjuvant/neoadjuvant setting with discontinuation due to >= Grade 3 immune-related adverse event | Prior systemic anti-cancer therapy in the first-line metastatic setting (neoadjuvant/adjuvant allowed if completed >= 6 months before metastatic diagnosis) | Unresolved toxicities from prior therapies > Grade 1 (except <= Grade 2 neuropathy) | Prior radiotherapy to the lung > 30 Gy within 6 months before start; radiation-related AEs not recovered; steroid requirement; or history of radiation pneumonitis | Life expectancy < 3 months or rapidly progressing disease | Live or live-attenuated vaccine within 30 days prior to first dose | Participation in a trial with an investigational agent within 30 days prior to entry or investigational device within 6 months (unless in follow-up and >= 6 months since last dose) | Immunodeficiency | Systemic or topical corticosteroids at immunosuppressive doses within 2 weeks prior to treatment initiation (> 10 mg/day hydrocortisone or > 5 mg/day prednisone equivalent) | Another malignancy that is progressing or required active treatment within the past 2 years (exceptions: certain in situ or skin cancers) | Active CNS metastases and/or carcinomatous meningitis (unless previously treated and radiologically and clinically stable without steroids >= 14 days) | Severe hypersensitivity (>= Grade 3) to IO102, IO103, pembrolizumab, or excipients | Active autoimmune disease requiring systemic treatment in past 2 years (replacement therapy allowed) | History of non-infectious pneumonitis requiring steroids or current pneumonitis | Active infection requiring systemic therapy | Known HIV infection | Adrenal insufficiency (basal cortisol < 140 nmol/L or < 5 µg/dL) | Known chronic Hepatitis B (HBsAg reactive) or active Hepatitis C infection (HCV RNA detected) | Any condition, therapy, or lab abnormality that may confound results or is not in the patient’s best interest per investigator | Psychiatric or substance abuse disorders interfering with trial requirements | Planning to conceive or father children during treatment and required post-treatment period | History of allogeneic tissue/solid organ transplant | Progressive disease within 6 months of completion of curatively intended systemic treatment for locoregionally advanced SCCHN | Nasopharyngeal tumors (any histology) excluded (SCCHN)",No prior systemic therapy for metastatic disease; Neoadjuvant/adjuvant therapy allowed if completed >= 6 months before metastatic diagnosis; No prior anti–PD-1/PD-L1/PD-L2 or other T-cell co-regulatory agent leading to discontinuation for >= Grade 3 immune-related AE; Not eligible for any cisplatin therapy (mUBC); Palliative radiotherapy (<= 2 weeks) to non-CNS disease allowed with >= 1-week washout; No investigational agents within 30 days prior to study entry,ALL,F,"This trial is first-line only and explicitly excludes patients with any prior systemic therapy for metastatic disease; the patient received enfortumab vedotin plus pembrolizumab and is post–second line. Additionally, the trial requires PD-L1 CPS ≥10 for mUBC, which is unknown here but the prior therapy already disqualifies.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,F,"Hard exclusion applies: the trial explicitly excludes anyone with prior systemic therapy for metastatic disease (first-line setting only), while the patient is post–second line with prior enfortumab vedotin plus pembrolizumab. PD-L1 status being unknown is not needed to trigger F. The grader’s F is correct.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT05092958,0.8805802464485168,Metastatic Urothelial Carcinoma,MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer,"This phase III trial compares the effect of adding cabozantinib to avelumab versus avelumab alone in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of...","{'id': 206422368, 'name': 'Avelumab', 'description': 'Given IV', 'other_names': ['Bavencio', 'MSB 0010718C', 'MSB-0010718C', 'MSB0010718C'], 'intervention_type': 'DRUG'}; {'id': 206422369, 'name': 'Biospecimen Collection', 'description': 'Undergo collection of blood and urine samples', 'other_names': ['Biological Sample Collection', 'Biospecimen Collected', 'Specimen Collection'], 'intervention_type': 'PROCEDURE'}; {'id': 206422370, 'name': 'Bone Scan', 'description': 'Undergo bone scan', 'other_names': ['Bone Scintigraphy'], 'intervention_type': 'PROCEDURE'}; {'id': 206422371, 'name': 'Cabozantinib S-malate', 'description': 'Given PO', 'other_names': ['BMS-907351', 'Cabometyx', 'Cometriq', 'XL 184', 'XL-184', 'XL184'], 'intervention_type': 'DRUG'}; {'id': 206422372, 'name': 'Computed Tomography', 'description': 'Undergo CT', 'other_names': ['CAT', 'CAT Scan', 'Computed Axial Tomography', 'Computerized Axial Tomography', 'Computerized axial tomography (procedure)', 'Computerized Tomography', 'Computerized Tomography (CT) scan', 'CT', 'CT Scan', 'Diagnostic CAT Scan', 'Diagnostic CAT Scan Service Type', 'tomography'], 'intervention_type': 'PROCEDURE'}; {'id': 206422373, 'name': 'Magnetic Resonance Imaging', 'description': 'Undergo MRI', 'other_names': ['Magnetic Resonance', 'Magnetic Resonance Imaging (MRI)', 'Magnetic resonance imaging (procedure)', 'Magnetic Resonance Imaging Scan', 'Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance', 'MR', 'MR Imaging', 'MRI', 'MRI Scan', 'MRIs', 'NMR Imaging', 'NMRI', 'Nuclear Magnetic Resonance Imaging', 'sMRI', 'Structural MRI'], 'intervention_type': 'PROCEDURE'}; {'id': 206422374, 'name': 'Quality-of-Life Assessment', 'description': 'Ancillary studies', 'other_names': ['Quality of Life Assessment'], 'intervention_type': 'OTHER'}; {'id': 206422375, 'name': 'Questionnaire Administration', 'description': 'Ancillary studies', 'other_names': [], 'intervention_type': 'OTHER'}",PHASE3,18 years,Urothelial Carcinoma (metastatic),"Histologically or cytologically confirmed advanced or metastatic urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra (excluding small-cell histology). | Received 4–6 cycles of first-line platinum-based chemotherapy (gemcitabine-cisplatin, gemcitabine-carboplatin, MVAC or ddMVAC). | No more than 1 prior line of chemotherapy for metastatic or locally advanced disease. | Neoadjuvant or adjuvant chemotherapy allowed if given >= 12 months prior to registration. | Tumor response of CR, PR, or SD after completion of first-line platinum-based chemotherapy by treating physician assessment. | Last dose of first-line chemotherapy 3–10 weeks before randomization. | Age >= 18 years. | ECOG performance status 0–1. | Not pregnant and not nursing. | HIV-infected patients on effective antiretroviral therapy with undetectable viral load within 6 months are eligible. | Autoimmune/rheumatologic conditions controlled without systemic immunosuppression (<= 10 mg prednisone equivalent) are eligible; stable endocrine disorders and type 1 diabetes are eligible.","Prior immunotherapy with IL-2, IFN-alpha, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or CTLA-4 (including ipilimumab), or other agents targeting T-cell co-stimulation or immune checkpoints. | Use of systemic immunosuppressive medication within 7 days before randomization (except inhaled/topical/local steroids, physiologic doses <= 10 mg/day prednisone equivalent, or premedication for hypersensitivity). | Active autoimmune disease that might deteriorate with anti–PD-L1 therapy. | Symptomatic central nervous system metastases or CNS metastases not meeting stability criteria (post-treatment, recovered, off steroids >= 2 weeks, neurologically stable). | Major surgery within 4 weeks prior to randomization or unresolved postoperative complications. | Palliative radiotherapy within 48 hours prior to randomization. | Hemoptysis >= 0.5 teaspoon (2.5 mL) of red blood, clinically significant hematuria, hematemesis, coagulopathy, or other significant bleeding within 3 months before randomization. | Known cavitating pulmonary lesions or endobronchial disease. | Receipt of a live attenuated vaccine within 30 days prior to randomization. | Congestive heart failure NYHA class III or IV. | Uncontrolled hypertension: sustained BP > 150/90 mm Hg despite optimal therapy. | QTcF > 500 ms (unless resolved on repeat testing) or any history of congenital long QT syndrome. | Stroke, TIA, myocardial infarction, other symptomatic ischemic event, or thromboembolic event (e.g., DVT/PE) within 6 months before randomization (with specified allowances for stable incidental events). | Significant gastrointestinal disorders with high risk of perforation/fistula or obstruction (e.g., unresolved active peptic ulcer disease, cholecystitis, diverticulitis, symptomatic cholangitis or appendicitis, malabsorption) within 28 days. | Active infection requiring systemic treatment within 14 days before randomization. | Serious non-healing wound, ulcer, or bone fracture within 28 days before randomization. | History of organ or allogeneic stem cell transplant. | Persisting > grade 2 toxicity from prior therapy that poses safety risk. | Another malignancy within 3 years, except adequately treated localized cancers as specified. | Concomitant anticoagulation with warfarin, dabigatran, betrixaban, or platelet inhibitors such as clopidogrel (with specified allowances for LMWH or certain factor Xa inhibitors).","First-line platinum-based chemotherapy required (4–6 cycles).; No more than 1 prior line of chemotherapy for metastatic or locally advanced disease.; Neoadjuvant or adjuvant chemotherapy permitted if given >= 12 months before registration.; Last dose of first-line chemotherapy must be 3–10 weeks before randomization.; Objective response of CR, PR, or SD required after completion of first-line chemotherapy.",ALL,F,"The trial explicitly excludes patients with prior anti–PD-1/PD-L1 therapy, and the patient received pembrolizumab. Additionally, this is a maintenance study immediately after first-line platinum with response, which does not fit this post–second-line, progressed setting.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,F,"Correct: The trial explicitly excludes prior anti–PD-1/PD-L1 therapy, and the patient received pembrolizumab. That is a HARD EXCLUSION → F. The noted maintenance-setting mismatch further supports ineligibility but is not needed once the hard exclusion applies.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT05144256,0.5519946813583374,Ornithine Transcarbamylase Deficiency,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Regularly Transfused, Followed by a 5-Year Open-label Extension Period","ACTIVATE-KidsT (AG348-C-022) is a multicenter study designed to evaluate the efficacy and safety of treatment with mitapivat compared with placebo in pediatric participants with pyruvate kinase deficiency (PK deficiency) who are regularly receiving blood transfusions. Participants will be randomized 2:1 to receive either mitapivat or matching placebo. Randomization will be stratified by age (1 to \< 6 years, 6 to \< 12 years, 12 to \< 18 years) and splenectomy status. Participants will be dos...","{'id': 205807314, 'name': 'Mitapivat', 'description': 'Tablets or granules', 'other_names': ['AG-348', 'AG-348 sulfate hydrate', 'Mitapivat sulfate'], 'intervention_type': 'DRUG'}; {'id': 205807315, 'name': 'Mitapivat-matching placebo', 'description': 'Tablets or granules', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,1 years to 17 years,Pyruvate Kinase Deficiency,"Age 1 to <18 years (12–24 months must weigh >=7 kg) | Clinical laboratory confirmation of pyruvate kinase deficiency with >=2 mutant PKLR alleles, including >=1 missense mutation | Received 6 to 26 red blood cell transfusion episodes in the 52 weeks prior to consent/assent | Complete transfusion records for the prior 52 weeks (dates, volumes, and pre-transfusion hemoglobin for >=80% of transfusions) | Receiving folic acid supplementation for >=21 days before first dose and continued during study participation | Post-menarche females or Tanner stage 2 breast development: abstinent or using 2 forms of contraception (>=1 highly effective) during study and for 28 days after last dose","Pregnant or breastfeeding | PKLR genotype homozygous R479H or two nonmissense mutations without another missense mutation | History of malignancy | Active and/or uncontrolled cardiac or pulmonary disease or clinically relevant QT prolongation within 6 months | Liver disease with histopathological evidence of cirrhosis or severe fibrosis | Clinically symptomatic cholelithiasis or cholecystitis (unless prior cholecystectomy) | History of drug-induced cholestatic hepatitis | AST >2.5 x ULN (unless due to hemolysis and/or hepatic iron deposition) | ALT >2.5 x ULN (unless due to hepatic iron deposition) | Estimated glomerular filtration rate <60 mL/min/1.73 m^2 | Nonfasting triglycerides >440 mg/dL (5 mmol/L) | Active uncontrolled infection requiring systemic antimicrobial therapy | Known active hepatitis B virus infection | Known hepatitis C virus infection | Known HIV infection | Major surgery (including splenectomy) within 6 months or planned during screening or double-blind period | Current enrollment or past participation in another interventional study within 90 days or 5 half-lives (whichever longer) before first dose | Prior exposure to gene therapy | Prior bone marrow or stem cell transplantation | Currently receiving hematopoietic stimulating agents (last dose <28 days or <5 half-lives before randomization) | Use of strong CYP3A4/5 inhibitors within <5 days or <5 half-lives before randomization | Use of strong CYP3A4 inducers within <28 days or <5 half-lives before randomization | Use of anabolic steroids, including testosterone, within <28 days before randomization | Allergy or contraindication to mitapivat or its excipients | Receiving a pyruvate kinase activator within <52 weeks before consent/assent",Received 6–26 RBC transfusion episodes in the prior 52 weeks; Folic acid supplementation for >=21 days before first dose; Hematopoietic stimulating agents stopped >=28 days or >=5 half-lives before randomization; Strong CYP3A4/5 inhibitors stopped >=5 days or >=5 half-lives before randomization; Strong CYP3A4 inducers stopped >=28 days or >=5 half-lives before randomization; Anabolic steroids (including testosterone) stopped >=28 days before randomization; Prior pyruvate kinase activator stopped >=52 weeks before consent/assent; No investigational drug/device within 90 days or >=5 half-lives before first dose,ALL,F,"Disease mismatch: the trial targets pyruvate kinase deficiency with PKLR mutations, while the patient has ornithine transcarbamylase deficiency. Additionally, the patient is 3 months old, below the trial’s minimum age of 1 year.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Disease mismatch (OTC vs pyruvate kinase deficiency) is a hard exclusion. Patient is also below the trial’s minimum age (3 months vs ≥1 year), another hard exclusion. The grader correctly assigned F and identified the key factors.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT05175105,0.5519946813583374,Ornithine Transcarbamylase Deficiency,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Not Regularly Transfused, Followed by a 5-Year Open-label Extension Period","Study ACTIVATE-Kids (AG348-C-023) will evaluate the efficacy and safety of orally administered mitapivat as compared with placebo in pediatric participants with pyruvate kinase deficiency (PKD) who are not regularly receiving blood transfusions. Participants will be randomized 2:1 to receive either mitapivat or matching placebo. Randomization will be stratified by age (1 to \< 6 years, 6 to \< 12 years, 12 to \< 18 years). Participants will be dosed by age and weight during a double-blind per...","{'id': 206116729, 'name': 'Mitapivat', 'description': 'Tablets or granules', 'other_names': ['AG-348', 'AG-348 sulfate hydrate', 'Mitapivat sulfate'], 'intervention_type': 'DRUG'}; {'id': 206116730, 'name': 'Mitapivat-matching placebo', 'description': 'Tablets or granules', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,1 years to 17 years,Pyruvate Kinase Deficiency,"Age 1 to <18 years; if 12–24 months old, weight >=7 kg | Clinical laboratory confirmation of PK deficiency: >=2 PKLR mutant alleles with >=1 missense mutation (central genotyping) | No more than 5 RBC transfusions in the 52 weeks prior to consent/assent and none within <=12 weeks before first dose | Hemoglobin <=10 g/dL (age 12 to <18 years) or <=9 g/dL (age 1 to <12 years) based on >=2 measurements >=7 days apart during screening | Receiving folic acid supplementation for >=21 days prior to first dose and to be continued during the study | Females post-menarche/Tanner stage >=2: abstinent or using 2 forms of contraception (>=1 highly effective) during study and for 28 days after last dose","Pregnant or breastfeeding | PKLR genotype: homozygous R479H or two nonmissense mutations without another missense mutation | History of malignancy | Active and/or uncontrolled cardiac or pulmonary disease or clinically relevant QT prolongation within 6 months | Liver disease with histopathological evidence of cirrhosis or severe fibrosis | Clinically symptomatic cholelithiasis or cholecystitis (prior cholecystectomy allowed) | History of drug-induced cholestatic hepatitis | AST >2.5 x ULN (unless due to hemolysis or hepatic iron deposition) | ALT >2.5 x ULN (unless due to hepatic iron deposition) | Renal dysfunction: eGFR <60 mL/min/1.73 m^2 | Nonfasting triglycerides >440 mg/dL (5 mmol/L) | Active uncontrolled infection requiring systemic antimicrobial therapy | Known active hepatitis B virus infection | Known hepatitis C virus infection | Known HIV infection | Major surgery (including splenectomy) within <=6 months prior to consent/assent or planned during screening or double-blind period | Participation in another interventional study with an investigational drug or device within 90 days or 5 half-lives (whichever longer) prior to first dose | Prior exposure to gene therapy | Prior bone marrow or stem cell transplantation | Currently receiving hematopoietic stimulating agents or within 28 days (or 5 half-lives, whichever longer) before randomization | Use of strong CYP3A4/5 inhibitors without >=5-day (or 5 half-lives) washout before randomization | Use of strong CYP3A4 inducers without >=28-day (or 5 half-lives) washout before randomization | Use of anabolic steroids, including testosterone, without >=28-day washout before randomization | Allergy or contraindication to mitapivat or its excipients | Receiving a pyruvate kinase activator within <52 weeks prior to consent/assent | Any medical, hematologic, psychological, or behavioral condition or prior/current therapy that may confer unacceptable risk or confound data interpretation per investigator",RBC transfusions: <=5 in the prior 52 weeks and none within 12 weeks before first dose; No pyruvate kinase activator within >=52 weeks prior to consent/assent; No hematopoietic stimulating agents within >=28 days (or 5 half-lives) before randomization; Washout for strong CYP3A4/5 inhibitors >=5 days (or 5 half-lives) before randomization; Washout for strong CYP3A4 inducers >=28 days (or 5 half-lives) before randomization; No anabolic steroids within >=28 days before randomization; No investigational study drug within 90 days or 5 half-lives (whichever longer),ALL,F,"Disease mismatch: the trial targets pyruvate kinase deficiency, not ornithine transcarbamylase deficiency. Additionally, the patient is 3 months old, below the trial’s minimum age of 1 year.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,Correct: There is a hard disease mismatch (OTC vs PK deficiency) and an age hard exclusion (3 months < trial minimum of 1 year). Either triggers an F per rubric.,,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT05295433,0.5627489686012268,Ornithine Transcarbamylase Deficiency,"A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705",The primary objective of this study is to evaluate the long-term safety of mRNA-3705 administered to participants with isolated methylmalonic acidemia (MMA) due to methylmalonyl-coenzyme A mutase (MUT) deficiency who have previously participated in other clinical studies of mRNA-3705.,"{'id': 206078269, 'name': 'mRNA-3705', 'description': 'A sterile liquid for injection', 'other_names': ['modified mRNA encoding human', 'methylmalonyl-coenzyme A mutase'], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,1 years,Methylmalonic Acidemia,Completed the assigned dose regimen treatment period in another mRNA-3705 clinical study or eligible for early transition due to >3 consecutive missed doses from COVID-19 vaccination during mRNA-3705-P101. | Completed the End of Treatment visit in mRNA-3705-P101 within 10 days of first dose in the current study.,"Not expected to receive clinical benefit from continued mRNA-3705, in the Investigator’s opinion. | Any clinical or laboratory abnormality or medical condition that may increase risk, at Investigator’s discretion. | History of liver and/or kidney transplant.",Completed prior treatment period with mRNA-3705 in a previous clinical study.; Prior participation in mRNA-3705-P101 with EOT visit completed within 10 days before first dose in current study.,ALL,F,"Disease mismatch: the trial targets methylmalonic acidemia, while the patient has OTC deficiency; additionally, the patient is 3 months old, below the trial’s minimum age of 1 year.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"There is a hard exclusion due to disease mismatch (trial is for methylmalonic acidemia; patient has OTC deficiency). Additionally, the patient is below the trial’s minimum age (3 months vs ≥1 year). Either hard exclusion warrants an F. The grader’s reasoning and grade are correct.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT05345171,1.0,Ornithine Transcarbamylase Deficiency,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Adeno-associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Patients With Late-onset OTC Deficiency",The primary objective is to evaluate the efficacy of DTX301 on the improvement of ornithine transcarbamylase (OTC) function by maintaining safe plasma ammonia levels.,"{'id': 205772634, 'name': 'DTX301', 'description': 'non-replicating, self-complementary recombinant adeno-associated virus serotype 8 (AAV8) vector', 'other_names': ['avalotcagene ontaparvovec'], 'intervention_type': 'GENETIC'}; {'id': 205772635, 'name': 'Placebo', 'description': 'normal saline infusion', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 205772636, 'name': 'Oral Corticosteroids', 'description': 'Participants who receive DTX301 solution will receive oral corticosteroids.', 'other_names': ['Prednisolone'], 'intervention_type': 'DRUG'}; {'id': 205772637, 'name': 'Placebo for oral corticosteroids', 'description': 'Participants who receive Placebo will receive placebo corticosteroids to maintain the study blind', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205772638, 'name': 'Sodium Acetate', 'description': 'A tracer for the Ureagenesis Rate Test (URT)', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,12 years,Ornithine Transcarbamylase Deficiency,"Confirmed clinical diagnosis of late-onset ornithine transcarbamylase (OTC) deficiency by enzymatic, biochemical, or molecular testing | Free from symptomatic hyperammonemia and no emergent active intervention for hyperammonemia within 4 weeks before screening/baseline | If on ongoing daily ammonia scavenger therapy, on a stable daily dose for >= 4 weeks prior to screening | If on a protein-restricted diet, stable total daily protein intake with <= 20% variability for >= 4 weeks prior to screening | Females of childbearing potential and fertile males agree to use highly effective contraception from consent through Visit 28","Significant hepatic inflammation or cirrhosis | Estimated glomerular filtration rate < 60 mL/min/1.73 m2 at screening | Active hepatitis B or hepatitis C infection (HBsAg positive or HCV RNA positive, or current antiviral therapy for HBV or HCV) | Active infection (viral or bacterial) | Detectable pre-existing antibodies to the AAV8 capsid | Any condition that would interfere with participation, pose undue risk, or confound interpretation of results in the opinion of the Investigator | Current or prior participation in another gene transfer study",Ammonia scavenger therapy allowed if on a stable daily dose for >= 4 weeks,ALL,F,"Hard exclusions: the trial requires late-onset OTC while the patient has neonatal-onset disease, and the minimum age is 12 years whereas the patient is 3 months old.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"The trial has hard exclusions: minimum age is 12 years while the patient is 3 months old, and the trial requires late-onset OTC whereas the patient has neonatal-onset. Either alone warrants an F. The grader correctly identified these and assigned F.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05367609,0.4273300766944885,PMM2-CDG,Personalized Perioperative Analgesia Platform (PPAP) for Pediatric Spine Fusion Surgery (sIRB),The purpose of this collaborative CTSA application is to develop an innovative perioperative precision analgesia platform (PPAP) to improve analgesia and reduce serious immediate and long-term adverse outcomes of perioperative opioids in children undergoing painful surgery.,"{'id': 205896586, 'name': 'Preoperative Genotyping', 'description': 'Genotype based risk prediction and personalized pain management', 'other_names': [], 'intervention_type': 'DIAGNOSTIC_TEST'}",NA,10 years to 21 years,PPAP; Spine Fusion,Age 10-21 years | ASA physical status 1-3 | Undergoing posterior-lateral spinal fusion | Receives inpatient opioids | Prescribed opioids at discharge,Serious illness | Preoperative severe pain | Preoperative opioid use or misuse,(none),ALL,F,"Disease mismatch: the trial targets perioperative analgesia for pediatric spine fusion, not PMM2-CDG. Additionally, the patient is 8 years old, below the trial's minimum age of 10.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"There is a clear hard exclusion: disease mismatch (trial is for perioperative analgesia in pediatric spine fusion, not PMM2-CDG). Additionally, the patient is below the trial’s minimum age (8 vs 10). Either hard exclusion warrants an F. The grader’s reasoning and assigned grade are correct.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05402332,0.4538046717643738,PMM2-CDG,"A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Crossover, Trial Assessing the Efficacy, Safety, and Tolerability of AVTX-801 in Subjects with Phosphoglucomutase 1 Deficiency Related Congenital Disorders of Glycosylation (PGM1-CDG)",This is a clinical trial to evaluate the efficacy of AVTX-801 (D-galactose) on the clinical manifestations of PGM1-CDG in participants currently taking D-galactose.,"{'id': 205973053, 'name': 'AVTX-801', 'description': 'D-Galactose medical grade supplement - 1.5g/kg/day (not to exceed 50 g/day)', 'other_names': ['D-Galactose'], 'intervention_type': 'DRUG'}; {'id': 205973054, 'name': 'Placebo', 'description': 'placebo equivalent', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,18 years to 60 years,Phosphoglucomutase 1-Related Congenital Disorder of Glycosylation,Age 18 to 60 years | Genetically confirmed PGM1-CDG | Currently on a stable dose of D-galactose therapy | Non-pregnant (females of childbearing potential) | Non-lactating (females of childbearing potential) | Women of childbearing potential and non-sterile men agree to use highly effective contraception during the study and follow-up,"Aldolase B deficiency | Galactosemia | Hemolytic uremic syndrome | Severe anemia | History of galactose intolerance that precludes participation (per investigator) | Severe diarrhea from oral galactose | Severe, recurrent vomiting from oral galactose | Constipation from oral galactose | Galactosuria from oral galactose | Increased liver glycogen storage from oral galactose | Liver failure | ALT > 8 x ULN | AST > 8 x ULN | Use of investigational compounds within the previous 6 months or current enrollment in another investigational trial | Pregnancy | Hepatic impairment that would require a dose adjustment (per investigator)",Stable D-galactose therapy,ALL,F,"The trial targets PGM1-CDG and requires ages 18–60, while the patient has PMM2-CDG and is 8 years old; this is a disease mismatch and an age window conflict, both hard exclusions.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,Disease mismatch (PMM2-CDG vs PGM1-CDG) and age window conflict (8 vs 18–60) are hard exclusions. The grader correctly assigned F and cited appropriate reasons.,,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT05402345,0.5601659417152405,Ornithine Transcarbamylase Deficiency,"A Phase II Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Effect Of GlcNAc On Tear Production In Individuals With NGLY1-CDDG","In patients with NGLY1-CDDG, the disorder can lead to eye damage due to not being able to produce enough tears. This study is being done to see if the dietary supplement, GlcNAc, improves tear production in patients with NGLY1-CDDG.","{'id': 205791965, 'name': 'GlcNAc-GlcN', 'description': 'GlcNAc powder - weight-dependent dose', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205791966, 'name': 'Placebo', 'description': 'Placebo xylose', 'other_names': [], 'intervention_type': 'OTHER'}",PHASE2,1 years to 60 years,NGLY1 Deficiency,"Molecularly confirmed NGLY1-CDDG | Age 1–60 years | Non-pregnant, non-lactating females of childbearing potential must use highly effective contraception during the study; contraception not required if sterilized or postmenopausal","Hypersensitivity to any components of the placebo | Treatment with GlcNAc within 28 days prior to Visit 1 | Participation in another therapeutic drug trial during the blinded phase or within 28 days prior to Visit 1 | Shellfish allergy | Planned eye surgery within 3 months of enrollment | Pregnant, nursing, less than 6 months postpartum, or attempting to conceive",No GlcNAc within 28 days prior to Visit 1 (washout required); No participation in another therapeutic drug trial during the blinded phase and within 28 days prior to Visit 1,ALL,F,"Disease mismatch: the trial targets NGLY1 deficiency and requires molecularly confirmed NGLY1-CDDG, while the patient has OTC deficiency. The patient is also 3 months old, below the trial’s minimum age of 1 year.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Correct: There is a hard exclusion due to disease mismatch (trial requires NGLY1-CDDG; patient has OTC deficiency). Additionally, the patient is below the minimum age (3 months vs 1 year), another hard exclusion. F is appropriate.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05532657,1.0,Dementia,Long-term Effects of Hearing Intervention on Brain Health in the Aging and Cognitive Health Evaluation in Elders Randomized Study,The ACHIEVE Brain Health Follow-Up Study is a 3-year follow-up to the Aging and Cognitive Health Evaluation in Elders (ACHIEVE) randomized study to determine the long-term effect of hearing intervention vs. successful aging/delayed hearing intervention on rates of cognitive decline and incident mild cognitive impairment or dementia.,"{'id': 205600748, 'name': 'Hearing intervention', 'description': 'The hearing intervention is best practices hearing rehabilitation treatment program, consisting of fitting with hearing aids and other hearing assistive technologies along with comprehensive, individualized hearing rehabilitation sessions with a study audiologist spaced over the 2-3 months post-fitting designed to provide all the active components of the intervention. Participants also received semi-annual booster sessions with the study audiologist for 3 years and will continue to receive hearing healthcare from the study audiologist and complete semi-annual sessions for 3 additional years.', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 205600749, 'name': 'Successful aging/delayed hearing intervention', 'description': 'The successful aging health education program follows the protocol and materials developed for the 10 Keys to Healthy Aging program. The program involved individualized sessions with a study health educator, with initial sessions spaced over the 2-3 months post-randomization and semi-annual sessions for 3 years. Upon completion of the ACHIEVE trial, these participants are offered the best practices hearing rehabilitative treatment program with comprehensive, individualized sessions post-fitting and will receive semi-annual booster sessions with the study audiologist for 3 years.', 'other_names': [], 'intervention_type': 'OTHER'}",PHASE3,73 years,Dementia; Hearing Loss; Mild Cognitive Impairment,"Prior participation in the ACHIEVE trial | Age 70–84 years | Community dwelling, fluent English speaker | Adult-onset hearing impairment with four-frequency PTA (0.5–4 kHz, better ear) >= 30 dB HL and <= 70 dB HL | Speech recognition in quiet >= 60% in better ear | MMSE >= 23 for high school degree or less | MMSE >= 25 for some college or more","Disability in >= 2 activities of daily living | Vision impairment worse than 20/63 on the Minnesota Near Vision Card | Self-reported use of a hearing aid in the past 1 year | Medical contraindication to use of hearing aids (e.g., draining ear) | Unwilling to wear hearing aids daily | Conductive hearing impairment with air-bone gap > 15 dB in two or more contiguous frequencies in both ears",(none),ALL,F,"Hard exclusion: the patient is 68, which is below the trial’s minimum age (≥73; criteria also specify 70–84). The patient also fails the required MMSE threshold (MMSE 19 vs required ≥23–25).",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"Age is a hard exclusion: trial minimum age is 73, patient is 68 → F. While the grader also cited MMSE below threshold, MMSE is not specified as a hard exclusion in the rubric, but the age conflict alone justifies F. Overall grade is correct.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT05549219,0.5490809679031372,Ornithine Transcarbamylase Deficiency,"A Phase 2, Randomized, Open-Label, 24-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult, Adolescent, and Pediatric Participants With PMM2-CDG","This is a Phase 2, randomized, open-label, 24-week treatment study to evaluate the potential pharmacodynamic (PD) activity, safety, tolerability, and pharmacokinetics (PK) of GLM101 in adult, adolescent, and pediatric, patients with a confirmed diagnosis of PMM2-CDG. The planned doses of GLM101 to be investigated are 10, 20, and 30 mg/kg. The study will consist of a Screening Period, a 24-week (6-month) Treatment Period, and a 30-day (1-month) Follow-Up Period.","{'id': 205716428, 'name': 'GLM101', 'description': 'GLM101 IV Infusion', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,2 years to 65 years,Phosphomannomutase 2 Deficiency,"Age 2–65 years (cohort dependent) | Molecularly confirmed PMM2-CDG (biallelic pathogenic/likely pathogenic PMM2 variants, or bi-allelic variants plus deficient PMM2 enzyme activity)","Diagnosis of a congenital disorder of glycosylation other than PMM2-CDG | Active infection requiring parenteral antibiotics/antivirals/antifungals or systemic steroids within 7 days prior to screening | Active COVID-19 or positive SARS-CoV-2 test at screening | ALT >3 x ULN | AST >3 x ULN | Total bilirubin >2 x ULN | INR >1.5 | History of severe allergic reaction to GLM101 or its excipients | Known poor venous access | History of liver transplant | Drug or alcohol use disorder within 12 months | Major surgery within 30 days prior to screening | Clinically significant lab abnormalities not related to PMM2-CDG | Positive pregnancy test (female) | Breastfeeding (female) | Hepatitis B surface antigen positive or hepatitis C antibody positive | Any illness that might impact infusion safety or evaluability per investigator/medical monitor | QTc >=450 ms or clinically significant ECG abnormalities | Uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric, or other significant disease | Participation in another interventional study or investigational product within 30 days or 5 half-lives | Weight >75 kg",(none),ALL,F,"Disease mismatch: the trial is for PMM2-CDG, while the patient has OTC deficiency. Additionally, the patient is 3 months old, below the trial's minimum age of 2 years.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Disease mismatch (OTC vs PMM2-CDG) is a hard exclusion, and patient age (3 months) is below trial minimum (2 years), another hard exclusion. Grade F is correct and reasoning aligns with rubric.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05583942,0.42564189434051514,PMM2-CDG,A Pilot Randomized Clinical Trial of Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Steroid Resistant Nephrotic Syndrome in Children,"Children with steroid resistant nephrotic syndrome (SRNS) are exposed to prolonged courses of immunosuppressant medications. Given the adverse side effect profiles and variable efficacy of these medications, there is an urgent need to identify novel and safe therapies to treat nephrotic syndrome in children. Stimulation of the vagus nerve, which can be activated noninvasively by transcutaneous auricular vagus nerve stimulation (taVNS), has immunomodulatory effects mediated by the inflammatory...","{'id': 205221477, 'name': 'trascutaneous auricular vagus nerve stimulation', 'description': 'The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.', 'other_names': ['Roscoe TENS 7000'], 'intervention_type': 'DEVICE'}; {'id': 205221478, 'name': 'Sham device', 'description': 'The device will appear to function but no electrical stimulation will be delivered.', 'other_names': ['Roscoe TENS 7000'], 'intervention_type': 'DEVICE'}",NA,3 years to 17 years,Focal Segmental Glomerulosclerosis; Minimal Change Disease; Nephrotic Syndrome,Steroid resistant nephrotic syndrome | Age 3-17 years | eGFR >= 30 mL/min/1.73 m2 | Minimal Change Disease or Focal Segmental Glomerulosclerosis diagnosis per biopsy | Urine protein:creatinine ratio > 1.0 | Stable immunosuppression and ACE inhibitor/angiotensin receptor blocker regimen for >= 3 months | Evidence of B-cell repletion if previously exposed to rituximab,"Secondary causes of nephrotic syndrome (e.g., genetic, congenital, infectious) | Steroid sensitive nephrotic syndrome | Known genetic defects causing nephrotic syndrome (e.g., NPHS2, NPHS1, PLCE1, WT1) | Any known inflammatory condition | History of cardiac disease (arrhythmias, structural/functional abnormalities) | Implantable electronic devices (pacemakers, defibrillators, hearing aids, cochlear implants, deep brain stimulators) | Chronic rash or skin breakdown of the left ear at the cymba concha | Pregnancy",Stable immunosuppression for >= 3 months; Stable ACE inhibitor or angiotensin receptor blocker for >= 3 months; Prior rituximab allowed with B-cell repletion,ALL,F,"Disease mismatch: the trial targets steroid-resistant nephrotic syndrome (MCD/FSGS), while the patient has PMM2-CDG. Therefore, the patient does not meet the trial’s disease criteria.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"Disease mismatch is a hard exclusion: the trial targets steroid-resistant nephrotic syndrome (MCD/FSGS), while the patient has PMM2-CDG. Assigning F is correct per rubric.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05588063,0.42564189434051514,PMM2-CDG,A Pilot Randomized Clinical Trial of Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Frequently Relapsing Nephrotic Syndrome in Children,"Children with frequently relapsing nephrotic syndrome (FRNS) are exposed to prolonged courses of steroids and other immunosuppressant medications. Given the adverse side effect profiles and variable efficacy of these medications, there is an urgent need to identify novel and safe therapies to treat nephrotic syndrome in children. Stimulation of the vagus nerve, which can be activated non invasively by transcutaneous auricular vagus nerve stimulation (taVNS), has immunomodulatory effects media...","{'id': 205411115, 'name': 'Transcutaneous auricular vagus nerve stimulation', 'description': 'The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.', 'other_names': ['Roscoe TENS 7000'], 'intervention_type': 'DEVICE'}; {'id': 205411116, 'name': 'Sham device', 'description': 'The device will appear to function but no electrical stimulation will be delivered.', 'other_names': ['Roscoe TENS 7000'], 'intervention_type': 'DEVICE'}",NA,3 years to 17 years,Nephrotic Syndrome; Minimal Change Disease; Focal Segmental Glomerulosclerosis,Frequently relapsing nephrotic syndrome (FRNS) | Age 3-17 years | eGFR >= 30 mL/min/1.73 m2 | Minimal change disease or focal segmental glomerulosclerosis (clinical or biopsy diagnosis) | Steroid-sensitive nephrotic syndrome (prior remission within 4 weeks of steroid therapy) | In remission at enrollment (urine protein/creatinine ratio < 0.2 or negative dipstick for 3 consecutive days),"Secondary forms of nephrotic syndrome | Steroid-resistant nephrotic syndrome | Steroid-dependent nephrotic syndrome (relapse within 14 days of stopping steroids or while on steroids) | Exposure to steroids within 14 days of enrollment | Receiving any standing immunosuppression | Any known inflammatory condition (e.g., systemic lupus erythematosus) | History of cardiac disease (arrhythmias, structural or functional abnormalities) | Implantable electronic devices | Pregnancy | Potential non-compliance with study schedules or procedures in the opinion of the investigator",Off systemic steroids >= 14 days before Day 1; Prior immunosuppression allowed if > 2 months before enrollment and/or after B-cell repletion,ALL,F,"Disease mismatch: the trial targets frequently relapsing nephrotic syndrome (minimal change disease or focal segmental glomerulosclerosis), while the patient has PMM2-CDG. This is a hard exclusion.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"Correct: The patient’s disease (PMM2-CDG) is not among the trial’s targeted diseases (FRNS/MCD/FSGS), which is a hard exclusion per the rubric. An F is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05660746,0.6691051721572876,Fistulizing Crohn's Disease,Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's Disease,"Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease (CD). There are limited treatment options approved for use in children and adults with Crohn's disease. Physicians need better ways to inform decisions on treatment. The main reason for this research study is to determine if a computer program that calculates an individualized dose based on a patient's blood testing results (precision dosing) can better achieve the be...","{'id': 205970604, 'name': 'RoadMAB', 'description': 'The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.', 'other_names': [], 'intervention_type': 'DEVICE'}; {'id': 205970605, 'name': 'Infliximab', 'description': 'Conventional dosing. Induction: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance: 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.\n\nPrecision dosing. Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool.', 'other_names': ['Avsola', 'Inflectra', 'Ixifi', 'Remicade', 'Renflexis'], 'intervention_type': 'DRUG'}",PHASE2/PHASE3,6 years to 22 years,Crohn Disease,"Age 6–22 years | Diagnosis of Crohn disease within the last 90 days | Anti-TNF naive and starting infliximab | Clinical activity: PCDAI >=10 (<18 years) or CDAI >=150 (>=18 years) within the last 60 days | Endoscopic or biomarker activity: SES-CD >6 (or >3 for isolated ileal disease) within 60 days, or report of large intestinal ulcerations, or fecal calprotectin >250 μg/g within 75 days | C-reactive protein >1.0 mg/dL within the last 30 days and/or fecal calprotectin >250 μg/g within the last 75 days | Negative tuberculosis interferon-gamma release test | Negative urine pregnancy test for females of childbearing potential","Ulcerative colitis or inflammatory bowel disease-unspecified | Prior use of anti-TNF therapy (infliximab, adalimumab, certolizumab pegol, or golimumab) | Internal abdominal or pelvic penetrating fistulae in the last 180 days | Intra-abdominal abscess, phlegmon, or inflammatory mass in the last 180 days | Active perianal abscess (receiving oral antibiotics for <7 days) | Intestinal stricture with pre-stenotic dilation >3 cm and surgery planned in the next 90 days | Positive stool assay for Clostridium difficile toxin or other intestinal pathogens within 14 days of screening unless repeat is negative and no ongoing infection | Current hospitalization for complications of severe Crohn disease | Planned use of methotrexate or 6-mercaptopurine (azathioprine) during the induction phase | Current ileostomy, colostomy, ileoanal pouch, previous extensive small bowel resection (>35 cm), or any Crohn disease surgery planned within the next 90 days | History of autoimmune hepatitis, primary sclerosing cholangitis, thyroiditis, or juvenile idiopathic arthritis | Treatment with another investigational drug in the last 4 weeks | History of malignancy (including lymphoma or leukemia) | Currently receiving treatment for histoplasmosis | History of tuberculosis, HIV, immunodeficiency syndrome, central nervous system demyelinating disease, heart failure, or receiving intravenous antibiotics in the last 14 days for any infection | Currently pregnant, breastfeeding, or plans to become pregnant in the next 1 year",(none),ALL,F,"The patient is 32 years old (trial ages 6–22) and has prior anti-TNF exposure (refractory to infliximab), which is explicitly excluded as the trial requires anti-TNF–naive participants.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Hard exclusions apply: patient age 32 exceeds trial max age 22, and prior anti-TNF (infliximab) exposure contradicts the trial’s anti-TNF–naive requirement/explicit exclusion. Thus F is correct and reasoning aligns with rubric.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05665530,0.450744092464447,PMM2-CDG,"A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies","This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate the safety, tolerability, recommended phase 2 dose (PR2D), and preliminary efficacy of PRT2527 as a monotherapy and in combination with zanubrutinib or venetoclax.","{'id': 205972163, 'name': 'PRT2527', 'description': 'PRT2527 will be administered by intravenous infusion once weekly.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205972164, 'name': 'Zanubrutinib', 'description': 'Zanubrutinib will be provided in capsules for oral administration once or twice daily.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205972165, 'name': 'Venetoclax', 'description': 'Venetoclax will be provided in tablet for oral administration once daily', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,18 years,Aggressive B-Cell Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Richter's Syndrome; T-Cell Lymphoma; Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome; MDS/MPN Overlap Syndrome,"Histologically or cytologically confirmed aggressive B-cell lymphoma subtypes, mantle cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (including Richter's syndrome), T-cell lymphoma (monotherapy only), acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome, or MDS/MPN overlap syndrome that are relapsed, refractory, or ineligible for standard therapy | ECOG 0–1 | Adequate hematologic, renal, and hepatic function | Left ventricular ejection fraction >= 50%","Active central nervous system involvement by malignancy | Uncontrolled intercurrent illness | Active infection requiring systemic therapy | Hematopoietic stem cell transplant within 90 days or graft-versus-host disease grade > 1 | Severe pulmonary disease with hypoxemia | History of another malignancy except adequately treated non-melanoma skin cancer or lentigo maligna, superficial bladder cancer, carcinoma in situ of the cervix without evidence of disease, and asymptomatic prostate cancer without known metastatic disease and no requirement for therapy | Concurrent treatment with strong CYP3A4 inhibitors or within 15 days of starting study treatment | Prior exposure to a CDK9 inhibitor | Receipt of investigational or approved anticancer therapies within 5 half-lives or 14 days prior to start of study treatment (whichever is shorter) | Mean corrected QT interval > 470 msec or history of long QT syndrome | T-cell leukemias",Washout from prior investigational or approved anticancer therapy: >= 5 half-lives or 14 days before study treatment (whichever is shorter),ALL,F,"Disease mismatch: the trial is for relapsed/refractory hematologic malignancies, not PMM2-CDG. Additionally, the patient is 8 years old, below the trial’s minimum age of 18.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,Correct: There is a clear hard exclusion due to disease mismatch (trial is for specific hematologic malignancies; patient has PMM2-CDG) and an age conflict (trial min age 18 vs patient age 8). Either warrants an F per the rubric.,,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT05684965,0.9614679217338562,Castration-Resistant Prostate Cancer,"A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors","This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.","{'id': 206552153, 'name': 'XTX301', 'description': 'XTX301 monotherapy', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1/PHASE2,18 years,Head and Neck Squamous Cell Carcinoma; Melanoma; Non-Small Cell Lung Cancer; Ovarian Cancer; Castrate-Resistant Prostate Cancer; Triple-Negative Breast Cancer; Cervical Cancer; Colorectal Cancer (MSI-H/dMMR); Endometrial Cancer (MSI-H/dMMR),"Locally advanced or metastatic solid tumor that has failed standard therapy, lacks survival benefit from standard therapy, or for which standard therapy is not available (Phase 1A) | Select advanced solid tumors for Part 1B: melanoma, NSCLC, HNSCC, TNBC, cervical cancer, MSI-H/dMMR colorectal cancer, or MSI-H/dMMR endometrial cancer | Measurable disease per RECIST 1.1 (Phase 2) | HNSCC (Cohort 2A): locally recurrent or metastatic; previously treated with 1–2 lines; unless contraindicated, prior PD-1/PD-L1 inhibitor and/or platinum-based chemotherapy required | Melanoma (Cohort 2B): unresectable or metastatic; previously treated with 1–2 lines; unless contraindicated, prior PD-1/PD-L1 inhibitor required; if BRAF V600 mutation present, prior targeted therapy required; uveal melanoma excluded | NSCLC (Cohort 2C): locally advanced or metastatic; previously treated with 1–2 lines; unless contraindicated, prior PD-1/PD-L1 inhibitor and platinum-based regimen required; if actionable driver present (e.g., EGFR, ALK, ROS1, NTRK, BRAF V600E), prior targeted therapy required | Ovarian cancer (Cohort 2D): epithelial ovarian, fallopian tube, or primary peritoneal cancer with platinum-resistant disease; prior response to first-line platinum lasting >= 180 days; platinum-intolerant also eligible; unless contraindicated, if BRCA mutation known, prior PARP inhibitor required | Castrate-resistant prostate cancer (Cohort 2E): metastatic CRPC; prior androgen receptor pathway inhibitor and/or chemotherapy; surgical or ongoing medical castration maintained | Triple-negative breast cancer (Cohort 2F): metastatic TNBC with relapse after 2–4 prior lines (neoadjuvant/adjuvant counts as 1) | ECOG performance status 0–2 (Phase 1) | ECOG performance status 0–1 (Phase 2) | Adequate organ function | Part 1B: lesions amenable to biopsy and willingness to provide fresh tumor biopsies pre- and on-treatment | Recovered from recent major surgery with no ongoing complications prior to study drug","Prior treatment with IL-12 therapy (any form, including recombinant, prodrug, or intratumoral) | Known liver metastasis on imaging | Ongoing non-disease-related necrosis such as active ulcer, nonhealing wound, or intercurrent bone fracture | Active primary CNS malignancy, CNS metastases, or carcinomatous meningitis | Active autoimmune disease | History of Grade >= 3 immune-related adverse events from prior immunotherapy unless resolved with therapy within 14 days | Immunodeficiency diagnosis or chronic systemic immunosuppression exceeding prednisone 10 mg daily (or equivalent) within 7 days before first dose | Active hepatitis B infection | Active hepatitis C infection | Prior treatment with gene therapy | History of organ transplant | History of hematopoietic stem-cell transplant","Failed, no benefit from, or no available standard therapy (Phase 1); HNSCC: prior PD-1/PD-L1 inhibitor and/or platinum-based chemotherapy unless contraindicated; Melanoma: prior PD-1/PD-L1 inhibitor; if BRAF V600 mutated, prior BRAF-targeted therapy; NSCLC: prior PD-1/PD-L1 inhibitor and platinum-based chemotherapy; prior targeted therapy if actionable driver present (e.g., EGFR, ALK, ROS1, NTRK, BRAF V600E); Ovarian cancer: prior response to first-line platinum >= 180 days; prior PARP inhibitor if BRCA mutated; platinum-intolerant eligible; CRPC: prior androgen receptor pathway inhibitor and/or chemotherapy; ongoing surgical or medical castration; TNBC: 2–4 prior lines in the metastatic setting; neoadjuvant/adjuvant counts as 1 line",ALL,F,"While the disease type (mCRPC) and prior AR-targeted therapies fit, the trial explicitly excludes patients with known liver metastasis on imaging, and the patient has liver metastases.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with known liver metastases on imaging, and the patient has PSMA PET–avid liver metastases. This is a hard exclusion, so grade F is correct.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT05734196,0.5502394437789917,Ornithine Transcarbamylase Deficiency,"The ENERGY Study: An Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Infants With Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1 (ENPP1) Deficiency or ATP-binding Cassette Sub-family C Member 6 (ABCC6) Deficiency",The primary purpose of Study INZ701-104 (the ENERGY study) is to assess the safety and tolerability of INZ-701 in infants with ENPP1 Deficiency or with ABCC6 Deficiency.,"{'id': 205958414, 'name': 'INZ-701', 'description': 'Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.', 'other_names': ['(rhENPP1-Fc).'], 'intervention_type': 'DRUG'}",PHASE1,up to 1 years,ENPP1 Deficiency; ABCC6 Deficiency; Generalized Arterial Calcification of Infancy,Confirmed post-natal molecular genetic diagnosis of ENPP1 Deficiency or ABCC6 Deficiency with biallelic mutations | Clinical manifestations of Generalized Arterial Calcification of Infancy (GACI) or GACI-2 | Age from birth to <1 year at Baseline (Day 1) | Weight >=0.5 kg at first dose,"Clinically significant disease or laboratory abnormality unrelated to ENPP1 or ABCC6 deficiency that may preclude participation, including uncontrolled thyroid disease or unrelated connective tissue, bone, mineral, or muscle disease | Care withdrawn or receiving end of life care or hospice only | Known malignancy | Known intolerance to INZ-701 or any excipients | Concurrent participation in another non-Inozyme interventional study | Receipt of any non-Inozyme investigational new drug within 5 half-lives or within 4 weeks prior to first dose, whichever is longer, or use of an investigational device",No investigational drug within 5 half-lives or 4 weeks prior to first dose,ALL,F,"Disease mismatch: the trial enrolls infants with ENPP1 or ABCC6 deficiency (GACI), whereas the patient has genetically confirmed OTC deficiency. Therefore the patient does not meet the required disease/biomarker cohort.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Correct: The patient has OTC deficiency, while the trial only includes ENPP1 or ABCC6 deficiency (GACI). This is a hard disease/required biomarker mismatch, triggering an F regardless of other factors.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05781152,0.6691051721572876,Fistulizing Crohn's Disease,"Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease","Crohn's disease (CD) is a condition that causes inflammation (swelling, redness) of the lining and wall of the small intestine, large intestine, or both. CD may be associated with abdominal cramps/pain, diarrhea, blood in the stool, weight loss, or delayed growth in children. While the exact cause of CD is not certain it is thought that the immune system located in the intestine reacts abnormally to the large number of bacteria contained there. The investigators think that diet, exposure to a...","{'id': 206227805, 'name': 'Anti-TNF therapy', 'description': ""Use of anti-TNF therapy for children and adolescents with newly diagnosed Crohn's disease guided by a clinical decision support tool"", 'other_names': ['Remicade, Inflectra, Renflexis, Avsola, Humira, Amgevita, Hulio, Hadlima, Hyrimoz, Idacio'], 'intervention_type': 'DRUG'}",PHASE4,6 years to 17 years,Crohn Disease,"Age >= 6 years and < 18 years | Suspected Crohn disease at initial evaluation (Phase 1) | Negative stool culture for enteric pathogens and negative Clostridium difficile toxin if presenting with diarrhea | History of C. difficile requires >= 6 weeks from treatment start and negative repeat stool for C. difficile toxin | Diagnosed with macroscopic Crohn disease involving terminal ileum and/or colon by endoscopy and/or MRE (Phase 2) | Received at least one initial therapy upon diagnosis: corticosteroids, immunomodulator, aminosalicylic acids (5-ASA), defined nutritional therapy, or anti-TNF (adalimumab or infliximab) (Phase 2) | Commenced adalimumab or infliximab as first therapy or within 180 days of diagnosis, with or without concomitant immunomodulator (Phase 2) | Ileal and rectal biopsies obtained, or acceptable alternatives with documented terminal ileum inflammation by MRE and endoscopic findings (Phase 2)","Diagnosis of Crohn disease following abdominal resectional surgery/appendectomy at initial presentation | High likelihood (>50%) of needing bowel resection within 3 months of diagnosis (e.g., perforation, obstructive stricture) | Use of oral corticosteroids for non-gastrointestinal indications within 4 weeks prior to diagnostic assessment and biosampling | Use of any investigational drug within 4 weeks prior to diagnostic assessment and sampling | Pregnancy | Poorly controlled medical conditions (e.g., diabetes, congestive heart failure) | Previous treatment with immunomodulators within 1 year of enrollment for other medical conditions | Previous treatment with anti-TNF therapy within 2 years of enrollment for other medical conditions | Previous treatment with non-anti-TNF biologics or small molecules for non-IBD indications within 6 months (except dupilumab) | Inability to undergo MRE | Diagnosis of Crohn disease using video capsule endoscopy only with normal ileocolonoscopy and normal MRE (Phase 2) | Orofacial Crohn disease only (Phase 2) | Esophageal, gastric, duodenal, and/or jejunal Crohn disease only (Phase 2) | Severe complex fistulizing perianal disease +/- abscess or perianal disease requiring ongoing surgical intervention (seton placement or I&D alone not exclusionary) (Phase 2) | Perianal Crohn disease only without luminal disease (Phase 2) | Internal fistulizing disease at diagnosis (Phase 2) | Initial IBD treatment with non-anti-TNF biologic or small molecule therapy (Phase 2) | Received any anti-TNF agent other than adalimumab or infliximab (Phase 2) | Unlikely to return for clinical, endoscopic, or MRE follow-up (Phase 2) | Baseline endoscopy video unavailable for central reading without approved alternative documentation (Phase 2) | Underwent bowel resection within 3 months of diagnosis (Phase 2)","Initial therapy upon diagnosis may include corticosteroids, immunomodulator, 5-ASA, defined nutritional therapy, or anti-TNF; Commenced adalimumab or infliximab as first therapy or within 180 days of diagnosis, with or without concomitant immunomodulator; Washout from investigational drug >= 4 weeks prior to diagnostic assessment",ALL,F,"Age window conflict: the trial enrolls participants aged 6–17, while the patient is 32. Additionally, the study focuses on newly diagnosed pediatric Crohn’s, not a refractory adult case.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Age window conflict (patient 32 vs trial 6–17) is a hard exclusion, so F is correct. The grader’s added note about newly diagnosed pediatric setting further supports ineligibility but the age alone triggers F.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05814627,1.0,Rheumatoid Arthritis,"A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and Who Had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH)","Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in adult participants with inadequate response or intolerance to one TNF-inhibitor who are on a stable dose of methotrexate (MTX). Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for the treatment of RA. This study is dou...","{'id': 206410659, 'name': 'Upadacitinib', 'description': 'Oral Tablets', 'other_names': ['RINVOQ'], 'intervention_type': 'DRUG'}; {'id': 206410660, 'name': 'Adalimumab', 'description': 'Subcutaneous Injection', 'other_names': ['Humira'], 'intervention_type': 'DRUG'}; {'id': 206410661, 'name': 'Upadacitinib Matching Placebo', 'description': 'Oral Tablets', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206410662, 'name': 'Adalimumab Matching Placebo', 'description': 'Subcutaneous Injection', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,18 years,Rheumatoid Arthritis,"Rheumatoid Arthritis diagnosed for >= 3 months per 2010 ACR/EULAR criteria. | Prior treatment with exactly one TNF inhibitor for >= 3 consecutive months with inadequate response or intolerance. | On methotrexate for >= 3 consecutive months. | Stable methotrexate dose 15–25 mg/week (>= 10 mg/week if intolerant) for >= 4 weeks prior to first dose; >= 7.5 mg/week acceptable in Chinese, Japanese, Korean, or Taiwanese participants. | Folic acid or folinic acid supplementation required during study participation. | Swollen joints >= 6 (66-joint count) at screening and baseline. | Tender joints >= 6 (68-joint count) at screening and baseline. | High-sensitivity C-reactive protein (hsCRP) >= 3 mg/L at screening.","History of arthritis with onset before age 17 years or current inflammatory joint disease other than rheumatoid arthritis. | Prior exposure to any JAK inhibitor. | Prior exposure to adalimumab. | Prior exposure to any TNF inhibitor other than infliximab, etanercept, certolizumab pegol, or golimumab. | Prior exposure to any non-TNFi biologic DMARD or targeted synthetic DMARD.",Prior treatment with one TNF inhibitor for >= 3 months with inadequate response or intolerance.; Methotrexate for >= 3 months with a stable dose 15–25 mg/week (>= 10 mg/week if intolerant; >= 7.5 mg/week allowed regionally) for >= 4 weeks prior.; Folic acid or folinic acid supplementation.,ALL,F,"Explicit exclusion: the trial disallows prior exposure to adalimumab and to any non-TNFi biologic DMARD; the patient previously received adalimumab and tocilizumab. Age and disease match, but these exclusions make the patient ineligible.",Rheumatoid Arthritis,(none),Seropositive rheumatoid arthritis; Active disease (DAS28 = 5.5); Refractory to methotrexate and two prior biologic agents,(none),Methotrexate; Adalimumab; Tocilizumab,,,55,years,female,(none),CORRECT,F,"The trial explicitly excludes prior exposure to adalimumab and to any non-TNFi biologic DMARD; the patient received adalimumab and tocilizumab. This is a hard exclusion, so grade F is correct.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05817643,1.0,Dementia,"A Randomized, Open-label, 2-period, Crossover, Pilot Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers",This project is developing a novel disease-modifying compound for Alzheimer's disease (AD).,"{'id': 205789250, 'name': 'BMS-984923', 'description': 'Oral capsule', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE1,50 years to 80 years,Alzheimer Disease; Dementia,"Age 50–80 years inclusive | No history of cognitive impairment | Capable of providing written informed consent and willing to comply with study procedures | Not pregnant, lactating, or of childbearing potential","Body mass index >38 kg/m2 or body weight <50 kg | Significant cerebrovascular disease | Any significant neurologic disease | Current DSM-5 diagnosis of active major depression, schizophrenia, or bipolar disorder | Clinically significant or unstable medical condition | Any disorder or medication that could interfere with absorption, distribution, metabolism, or excretion of drugs | History of cholecystectomy | History of acute or chronic hepatitis B or C, or carriers of hepatitis B (HBsAg positive) or anti-HCV antibody positive | Use of psychoactive medications | Use of medications with potential drug-drug interactions | Use of another investigational agent | Clinically significant abnormalities in screening laboratories | Any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale | Acceptable Geriatric Depression Scale (GDS) score",(none),ALL,F,"Explicit exclusion applies: the trial requires healthy older adults with no cognitive impairment and excludes any significant neurologic disease, while the patient has moderate dementia with cognitive decline. Although age and sex fit, these criteria make the patient ineligible.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,Hard exclusion applies: trial requires healthy volunteers with no cognitive impairment and explicitly excludes significant neurologic disease; patient has moderate dementia with cognitive decline. Age/sex fit but explicit exclusion → F.,,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05818553,0.4252880811691284,PMM2-CDG,"A Phase 2,Double-Blind,Randomized Clinical Trial to Explore the Safety,Tolerability,Efficacy, and Pharmacokinetics of PRAX-562 in Pediatric Participants With Developmental and Epileptic Encephalopathies Followed by Open-Label Extension(OLE)","This is a Phase 2, double-blind, randomized clinical trial to explore the safety, tolerability, efficacy, and pharmacokinetics of PRAX-562 in pediatric participants who have seizures associated with early-onset SCN2A-DEE and SCN8A-DEE.","{'id': 205993485, 'name': 'PRAX-562', 'description': 'Once daily oral or G-tube treatment.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2/PHASE3,2 years to 18 years,SCN2A Encephalopathy; SCN8A Encephalopathy,"Documented rare missense variant in SCN2A with seizure onset in the first 3 months of life, or documented de novo missense variant in SCN8A with seizure onset in the first 6 months of life. | At least 8 countable motor seizures in the 4 weeks immediately prior to Screening. | At least 8 countable motor seizures during the 28-day Baseline Observation Period.","Clinically significant or known pathogenic/likely pathogenic genetic variant other than in SCN2A or SCN8A, or a genetic variant that may explain or contribute to epilepsy and/or developmental disorder. | Documented, functionally characterized loss-of-function missense variant, or presumed loss-of-function variant (nonsense or frameshift), or clinical evidence that prior exposure to a sodium channel blocker worsened seizures. | Two or more episodes of convulsive status epilepticus requiring hospitalization and intubation in the 6 months prior to Screening.",(none),ALL,F,"Disease mismatch: the trial is for SCN2A/SCN8A encephalopathy and requires SCN2A or SCN8A variants, while the patient has PMM2-CDG with PMM2 variants. The trial also explicitly excludes participants with other pathogenic variants explaining a developmental disorder.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"Hard exclusion applies: disease mismatch (trial targets SCN2A/SCN8A encephalopathy, patient has PMM2-CDG). Additionally, explicit exclusion for pathogenic variants other than SCN2A/SCN8A would exclude this patient. The assigned grade F is correct.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT05845814,0.8805802464485168,Metastatic Urothelial Carcinoma,"A Phase 1/2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination With Investigational Agents Versus Pembrolizumab Plus EV, as First-Line Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04B",This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the efficacy and safety of coformulated favezelimab/pembrolizumab plus EV and coformulated vibostolimab/pembrolizumab plus EV relative to pembrolizumab plus EV. There will be no comparison of coformulated favezelimab/pembrolizumab plus EV versus coformulated vibostolimab/pembrolizumab plus EV. If ORR and/or DRR are substantially better...,"{'id': 205889897, 'name': 'Coformulated favezelimab/pembrolizumab', 'description': 'Coformulated favezelimab/pembrolizumab (800 mg/200 mg) IV infusion', 'other_names': ['MK-4280A'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205889898, 'name': 'Coformulated vibostolimab/pembrolizumab', 'description': 'Coformulated vibostolimab/pembrolizumab (200 mg/200 mg) IV infusion', 'other_names': ['MK-7684A'], 'intervention_type': 'BIOLOGICAL'}; {'id': 205889899, 'name': 'EV', 'description': '1.25 mg/kg IV infusion', 'other_names': ['Padcev', 'ASG-22CE', 'ASG-22ME'], 'intervention_type': 'COMBINATION_PRODUCT'}; {'id': 205889900, 'name': 'Pembrolizumab', 'description': '200 mg IV infusion', 'other_names': ['MK-3475', 'KEYTRUDA®'], 'intervention_type': 'BIOLOGICAL'}",PHASE1/PHASE2,18 years,Urothelial Carcinoma (metastatic),"Histologically documented locally advanced or metastatic urothelial carcinoma | Mixed histology eligible if urothelial component >=50% and plasmacytoid component <10% | No prior systemic therapy for locally advanced/metastatic urothelial carcinoma | Provide archival tumor tissue or newly obtained core/excisional biopsy adequate for biomarker evaluation | Adverse events from prior anticancer therapies recovered to <= Grade 1 or baseline (endocrine AEs on replacement or < Grade 2 neuropathy allowed) | Central nervous system metastases allowed if clinically stable >=4 weeks, baseline imaging shows no new/enlarged lesions, on stable dose of prednisone <=10 mg/day (or equivalent) for >=2 weeks if needed, and no leptomeningeal disease",Tumors with any neuroendocrine component | Additional malignancy without curative therapy or with recurrence within 3 years | Live or live-attenuated vaccine within 30 days prior to first dose | Investigational agent or device within 4 weeks prior to first dose | Immunodeficiency or chronic systemic steroid/immunosuppressive therapy within 7 days prior to first dose (except physiologic replacement or inhaled/topical steroids) | Active keratitis or corneal ulcerations (superficial punctate keratitis allowed if adequately treated) | Active autoimmune disease requiring systemic treatment in past 2 years (except replacement therapy) | History of uncontrolled diabetes | History of noninfectious pneumonitis requiring steroids or current pneumonitis | Active infection requiring systemic therapy | Known HIV infection | Hepatitis B or hepatitis C virus infection | Major surgery within 4 weeks prior to first dose | Prior allogeneic tissue or solid organ transplant | Leptomeningeal disease,No prior systemic therapy for locally advanced/metastatic urothelial carcinoma; Prior neoadjuvant or adjuvant chemotherapy permitted; Prior PD-1 or PD-L1 therapy for earlier-stage disease permitted if progression/recurrence >12 months after completion,ALL,F,This study requires first-line treatment with no prior systemic therapy for locally advanced/metastatic urothelial carcinoma. The patient is post–second line and has already received enfortumab vedotin plus pembrolizumab for metastatic disease.,Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,F,"The trial explicitly requires no prior systemic therapy for locally advanced/metastatic urothelial carcinoma (first-line only). The patient is post–second line and previously received EV+pembrolizumab for metastatic disease. This is a hard exclusion under the rubric, so grade F is correct.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05885412,0.48481565713882446,PMM2-CDG,A Phase 1 Dose Escalation Trial Evaluating an Intravenously Administered Recombinant Adeno-Associated Virus Serotype rh.74 (AAVrh.74) Vector Containing the Human Plakophilin-2a (PKP2a) Coding Sequence (RP-A601; AAVrh.74-PKP2a) in Subjects With Arrhythmogenic Cardiomyopathy Arising From Pathogenic PKP2 Variants (PKP2-ACM),This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.,"{'id': 205407141, 'name': 'RP-A601', 'description': 'RP-A601 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, human plakophilin 2 (PKP2), transcript variant 2a (PKP2a)', 'other_names': [], 'intervention_type': 'GENETIC'}",PHASE1,18 years,Arrhythmogenic Cardiomyopathy (PKP2),Age >= 18 years | Clinical diagnosis of arrhythmogenic cardiomyopathy per 2010 revised Task Force Criteria | Pathogenic or likely pathogenic truncating variant in PKP2 | Implantable cardioverter-defibrillator in place for >= 6 months | Premature ventricular contraction frequency >= 500 per 24 hours by ambulatory monitoring | Left ventricular ejection fraction >= 50%,Anti-AAVrh.74 neutralizing antibody titer > 1:40 | Cardiomyopathy due to a genetic etiology other than PKP2 truncating variant | Previous participation in a gene transfer or gene editing study | Severe right ventricular dysfunction | New York Heart Association Class IV heart failure,(none),ALL,F,"The trial is for adult arrhythmogenic cardiomyopathy with pathogenic PKP2 variants (age ≥18). The patient has PMM2-CDG with PMM2 variants and is 8 years old, failing disease, biomarker, and age requirements.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"Disease mismatch (PMM2-CDG vs PKP2-ACM), age below minimum (8 < 18), and required biomarker mismatch (PKP2 truncating variant required) are all hard exclusions. Grade F is correct.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT05907746,0.5548418164253235,Ornithine Transcarbamylase Deficiency,A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency,"Background: People with GATA2 deficiency have a mutation on the GATA2 gene. This gene affects immune function. People with this disease are prone to serious infections; in time, they may develop blood cancers. A hematopoietic stem cell (HSC) transplant can cure GATA2 deficiency, but using stem cells donated by other people can cause serious side effects. Objective: To test a new drug (Briquilimab) to see if it can make HSC transplants safer. Eligibility: People aged 6 to 70 years who have GAT...","{'id': 206555416, 'name': 'Mycophenolate Mofetil', 'description': '15 mg/kg IV three times per day starting on day +5 until approximately day +30 (+/- 2 days)', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206555417, 'name': 'Tacrolimus', 'description': '0.02 mg/kg IV daily starting on day +5', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206555418, 'name': 'Post-Transplant Cyclophosphamide', 'description': '50 mg/kg IV daily on days +3 and +4', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206555419, 'name': 'Total Body Irradiation', 'description': '200cGy on day -1', 'other_names': [], 'intervention_type': 'RADIATION'}; {'id': 206555420, 'name': 'Hematopoietic Cell Transplant', 'description': 'stem cell transplant on day 0', 'other_names': [], 'intervention_type': 'PROCEDURE'}; {'id': 206555421, 'name': 'Briquilimab', 'description': 'Single 0.6 mg/kg IV infusion administered between days -13 and day -10', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206555422, 'name': 'Cyclophosphamide', 'description': '14.5 mg/kg IV daily on days -6 and -5; for 7/8 Unrelated or Haploidentical Donor, prior to transplant.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206555423, 'name': 'Fludarabine', 'description': '30 mg/m2 IV over 30 minutes daily. For 8/8 Matched Related or Unrelated Donor, fludarabine dose will be on days -4, -3, and -2. For 7/8 Unrelated or Haploidentical Donor, fludarabine dose will be on days -6, -5, -4, -3, and -2.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,6 years to 70 years,GATA2 Deficiency,"Age 6–70 years | Germline deleterious mutation in GATA2 confirmed by targeted sequencing | Clinical manifestations consistent with GATA2 deficiency (e.g., severe/recurrent infections; monocytes <190/µL, B cells <61/µL, NK cells <126/µL; myelodysplastic syndrome by WHO) | Early-stage GATA2 deficiency: hypocellular marrow for age, <5% blasts, and normal/favorable cytogenetics (good/very good risk groups plus trisomy 8) | Availability of suitable donor: 8/8 HLA-matched related or unrelated, 7/8 HLA-matched unrelated, or haploidentical related donor | Karnofsky or Lansky performance status >= 40% | Left ventricular ejection fraction > 40% | Total bilirubin <= 2.5 x ULN | AST and ALT <= 5 x ULN | Adult creatinine <= 2.0 mg/dL and creatinine clearance >= 30 mL/min | Pediatric creatinine < 1.5 mg/dL and creatinine clearance > 30 mL/min/1.73m^2 | Pulmonary function: FEV1 and adjusted DLCO > 30%; if unable to perform due to age, no dyspnea at rest and no supplemental oxygen requirement | HBV or HCV seropositive allowed if HBV DNA <100 IU/mL or HCV RNA undetectable and hepatology approval","Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) score > 8 | Receipt of investigational agents within 4 weeks before treatment initiation (except virus-specific T cells for treatment of viral infection/reactivation prior to allogeneic HCT) | History of hematologic malignancy (e.g., AML, CMML); MDS allowed | History of allergic reactions to compounds similar to study agents (fludarabine, cyclophosphamide, tacrolimus, mycophenolate, G-CSF) | Presence of active malignancy (virus-driven malignancies allowed); MDS allowed | HIV infection | Pregnancy | Uncontrolled intercurrent illness or social situations limiting compliance with study requirements",No investigational agents within 4 weeks before treatment initiation (except virus-specific T cells for viral infection/reactivation),ALL,F,"Disease mismatch: the trial targets GATA2 deficiency, not OTC deficiency. Additionally, the trial requires age 6–70 years and a confirmed GATA2 germline mutation, while the patient is 3 months old with an OTC mutation.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Clear hard exclusions: disease mismatch (GATA2 vs OTC), age below minimum (3 months vs 6 years), and required GATA2 mutation absent. F is appropriate and the reasoning aligns with the rubric.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT05923190,0.8805802464485168,Metastatic Urothelial Carcinoma,A Pilot Trial of Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma,This is a non-randomized two arm open-label phase 2 pilot study in adult subjects with locally advanced or metastatic urothelial cancer. The study will investigate an alternative administration schedule of EV given as monotherapy and in combination with pembrolizumab.,"{'id': 206015742, 'name': 'Enfortumab vedotin', 'description': 'EV will be administered at standard dose of 1.25 mg/kg IV on days 1 and 8 with pembrolizumab 200 mg IV on day 1 of a 21-day cycle for 6 cycles', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206015743, 'name': 'Pembrolizumab', 'description': 'Pembrolizumab will be administered on day 1 of a 21-day cycle', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,18 years,Urothelial Carcinoma (locally advanced); Urothelial Carcinoma (metastatic),Histologically and radiographically confirmed locally advanced or metastatic urothelial carcinoma | Measurable disease per RECIST v1.1 | ECOG performance status 0-2 | Age >= 18 years | Prior systemic therapy completed >= 14 days before treatment | Normal organ and marrow function,"Prior monomethyl auristatin E (MMAE)-based antibody-drug conjugate for urothelial cancer | Baseline sensory or motor neuropathy grade >= 2 | Uncontrolled diabetes (HbA1c > 8%) | Uncontrolled or untreated central nervous system metastases | Leptomeningeal disease | Active untreated infection requiring systemic antimicrobial therapy | Symptomatic congestive heart failure, unstable angina, or uncontrolled cardiac arrhythmia | Psychiatric illness or social situation limiting compliance with study requirements | Another invasive malignancy within 3 years requiring treatment or with residual disease requiring treatment (adjuvant endocrine therapy for breast cancer allowed) | Known HIV-positive on combination antiretroviral therapy | History of interstitial lung disease or pneumonitis (including drug-induced) or active pneumonitis on screening CT | Prior allogeneic stem cell or solid organ transplant | Active tuberculosis | Pregnant or breastfeeding | EV/pembrolizumab arm: prior immunotherapy with immune-related adverse event requiring cessation or immunosuppression | EV/pembrolizumab arm: active autoimmune disease requiring systemic treatment within the past 2 years | EV/pembrolizumab arm: receiving high-dose steroids > 20 mg/day prednisone or equivalent at enrollment",Prior systemic therapy completed >= 14 days before treatment,ALL,F,"The trial explicitly excludes patients with prior MMAE-based antibody-drug conjugate therapy for urothelial cancer, and the patient received enfortumab vedotin (an MMAE-based ADC). Although the disease and setting match, this hard exclusion makes the patient ineligible.",Metastatic Urothelial Carcinoma,(none),Metastatic urothelial carcinoma; Progression after second-line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Received enfortumab vedotin plus pembrolizumab; Bone and liver metastases; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD; Age 55 years; Male sex,(none),Neoadjuvant gemcitabine/cisplatin (4 cycles); Enfortumab vedotin plus pembrolizumab,metastatic,post-second line,55,years,male,(none),CORRECT,F,"The trial explicitly excludes prior MMAE-based ADC exposure; the patient previously received enfortumab vedotin (MMAE-based), which is a hard exclusion per the rubric. Thus F is correct.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT06046820,0.5367637276649475,Ornithine Transcarbamylase Deficiency,"The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children With Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency",The primary purpose of Study INZ701-106 (The ENERGY 3 Study) is to assess the efficacy and safety of INZ-701 in children with ENPP1 Deficiency.,"{'id': 206007959, 'name': 'INZ-701', 'description': 'Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.', 'other_names': ['(rhENPP1-Fc).'], 'intervention_type': 'DRUG'}; {'id': 206007960, 'name': 'Control Arm (Conventional Therapy)', 'description': 'Conventional therapy is defined as oral phosphate supplements and calcitriol or other active forms of vitamin D3 (or analogs). No other agents for treatment of ENPP1 Deficiency are allowed in the control arm.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,1 years to 12 years,Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency,Biallelic ENPP1 mutations confirmed by a CAP/CLIA-certified (or regional equivalent) laboratory | Age >=1 and <13 years at Study Day 1 | Open growth plates of the distal femur and proximal tibia in both legs | Plasma pyrophosphate (PPi) <1400 nM at screening | 25-hydroxyvitamin D >=12 ng/mL at screening | Radiographic evidence of skeletal abnormalities with RSS >=2 | Negative serum pregnancy test for females of childbearing potential | Use of highly effective contraception for participants of childbearing potential during the study,"Clinically significant disease or laboratory abnormality not associated with ENPP1 Deficiency that would preclude participation or confound results | Use of prohibited medications: systemic corticosteroids >5 mg prednisone equivalent per day, anti-FGF23 agents, or oral/IV bisphosphonates | Unable or unwilling to discontinue calcitriol or other active vitamin D analogs within 7 days prior to Study Day 1 | Unable or unwilling to discontinue oral phosphate supplements within 36 hours prior to Study Day 1 if randomized to INZ-701 | Planned orthopedic surgery during the 52-week randomized treatment period | Known intolerance to INZ-701 or its excipients | Positive COVID-19 test within 5 days prior to randomization (if required per local policy) | Previous treatment with INZ-701 | Concurrent participation in another interventional clinical study or receipt of an investigational drug within 5 half-lives or 4 weeks prior to randomization (whichever is longer), or use of an investigational device",Discontinue calcitriol or other active vitamin D analogs >=7 days prior to Study Day 1; Discontinue oral phosphate supplements >=36 hours prior to Study Day 1; No investigational drugs within 5 half-lives or 4 weeks prior to randomization (whichever is longer),ALL,F,"The trial targets ENPP1 deficiency with required biallelic ENPP1 mutations and age ≥1 year, whereas the patient has OTC deficiency and is 3 months old. This is a disease mismatch and an age outside the permitted range, both hard exclusions.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,Clear hard exclusions: disease mismatch (ENPP1 deficiency trial vs patient with OTC deficiency) and age below trial minimum (3 months vs ≥1 year). Grader correctly assigned F and explained appropriately.,,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT06067802,0.5343823432922363,Ornithine Transcarbamylase Deficiency,"A Phase II, Escalating Dose, Open Label Study to Evaluate the Safety of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)","This is a medical research study to test a medication in adult patients with a disease called medium-chain acyl-CoA dehydrogenase deficiency (MCADD). The medication is triheptanoin, which is currently FDA approved for the treatment of Long-Chain Fatty Acid Oxidation Disorders. Previous research suggests that triheptanoin may also be effective in the treatment MCADD. This study will investigate the safety and efficacy (how well it works) of triheptanoin in patients with MCADD.","{'id': 206417174, 'name': 'Triheptanoin', 'description': 'Open-label design with doses of triheptanoin up to 1.0 gm/kg triheptanoin', 'other_names': ['Dojolvi'], 'intervention_type': 'DRUG'}",PHASE2,16 years,Medium-Chain Acyl-CoA Dehydrogenase Deficiency,"Diagnosis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency with molecular confirmation. | Age >= 16 years. | Negative pregnancy test for females of childbearing potential. | Effective contraception required for females of childbearing potential and males, or abstinence.","Use of any investigational drug within 30 days of screening. | Active infection (viral or bacterial) or other intercurrent illness at screening. | Evidence of liver disease: AST or ALT > 1.5 x ULN at screening. | Pregnant, planning to become pregnant, breastfeeding, or lactating. | Diagnosis of pancreatic insufficiency or use of pancreatic lipase inhibitors (e.g., orlistat). | Type 1 or type 2 diabetes, or use of medications that can cause hypoglycemia. | Any clinical or laboratory abnormality or medical condition that increases risk in the investigator's judgment.",No investigational drugs within 30 days prior to screening.,ALL,F,"Disease mismatch: the trial targets MCAD deficiency, while the patient has OTC deficiency. Additionally, the patient is 3 months old and the trial requires age ≥16 years.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,Clear hard exclusions: disease mismatch (OTC vs MCAD) and age below minimum (3 months vs ≥16 years). The grader correctly applied the rubric and assigned F with appropriate reasoning.,,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT06069375,0.5343823432922363,Ornithine Transcarbamylase Deficiency,"A Phase 2, Open-Label, Fixed Dose Study to Evaluate the Use of Sodium Phenylbutyrate (ACER-001) in the Treatment of Pediatric and Adult Patients With MCAD Deficiency Caused by the Common ACADM c.985 A>G (K304E) Mutation","This is a medical research study to test a medication in patients 10 years of age and older with a disease called medium-chain acyl-CoA dehydrogenase deficiency (MCADD) caused by the common ACADM c.985 A\>G (K304E) mutation. The medication is sodium phenylbutyrate (ACER-001), which is currently FDA approved for the treatment of Urea Cyle Disorders. Previous research suggests that sodium phenylbutyrate may also be effective in the treatment MCADD. This study will investigate the safety and eff...","{'id': 206451534, 'name': 'Sodium phenylbutyrate', 'description': 'Open-label design with doses of sodium phenylbutyrate up to 4.0 g/m2/day', 'other_names': ['Olpruva'], 'intervention_type': 'DRUG'}",PHASE2,10 years,Medium-Chain Acyl-CoA Dehydrogenase Deficiency,Diagnosis of medium-chain acyl-CoA dehydrogenase deficiency (MCADD) with molecular confirmation of at least one ACADM c.985A>G mutation. | Age >=16 years (cohort 1) or 10-15 years (cohort 2). | Negative pregnancy test for females of childbearing potential. | Females of childbearing age and sexually active males must use acceptable contraception during the study.,"Use of any investigational drug within 30 days of Day 1. | Active infection (viral or bacterial) or other intercurrent condition at screening. | Any clinical or laboratory abnormality of Grade >=3 per CTCAE v5.0. | Grade 3 elevations in liver enzymes (ALT, AST, or GGT 5-20 x ULN) in a clinically stable subject. | Use of medications that significantly affect renal clearance (e.g., probenecid), increase protein catabolism (e.g., corticosteroids), or increase ammonia levels (e.g., valproic acid or haloperidol) within 48 hours prior to Day 1 and throughout the study. | Renal insufficiency: eGFR <60 mL/min/1.73 m2. | Use of sodium benzoate within one week of Day 1. | Known hypersensitivity to PAA or PBA. | Breastfeeding or lactating females. | At risk of hypokalemia due to pre-existing diagnosis or on medications that can cause hypokalemia. | Type 1 or type 2 diabetes, or use of medications that can cause hypoglycemia.","No investigational drugs within 30 days prior to Day 1.; No sodium benzoate within 1 week prior to Day 1.; Avoid medications affecting renal clearance (e.g., probenecid), increasing protein catabolism (e.g., corticosteroids), or increasing ammonia (e.g., valproic acid, haloperidol) within 48 hours prior to Day 1 and during the study.",ALL,F,Hard exclusions: Disease mismatch (trial is for MCAD with ACADM c.985A>G; patient has OTC deficiency). Age window conflict (trial minimum age is 10 years; patient is 3 months old).,Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Disease mismatch (OTC vs MCAD with ACADM c.985A>G) is a hard exclusion, and the patient is far below the trial’s minimum age (10 years). Either alone warrants F; together confirm the grade. The grader applied the rubric correctly.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT06199531,0.5601659417152405,Ornithine Transcarbamylase Deficiency,"A Phase 1/2/3 Open-label, Single Arm, Dose-finding Study to Investigate Long-term Safety, Tolerability and Efficacy of GS-100, an Adeno-associated Virus Serotype 9 (AAV9) Vector-mediated Gene Transfer of Human NGLY1, in Patients With NGLY1 Deficiency","A non-randomized, open-label, dose escalation study of a single intracerebroventricular (ICV) administration of a gene replacement therapy in subjects who are 2 to 18 years old with NGLY1 Deficiency.","{'id': 206280756, 'name': 'GS-100', 'description': 'A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.', 'other_names': ['Recombinant, single-stranded adeno-associated virus serotype 9 (AAV9) vector that encodes a full-length version of human NGLY1'], 'intervention_type': 'GENETIC'}",PHASE1/PHASE2,2 years to 18 years,NGLY1 Deficiency,Age 2 to 18 years at consent | Documented NGLY1 Deficiency with biallelic NGLY1 variants by molecular genetic sequencing | Elevated GlcNAc-Asn (GNA) may be considered alongside genetic and clinical data for diagnosis confirmation | Two or more of the following typical features of NGLY1 Deficiency: global developmental delay/intellectual disability; hyperkinetic movement disorder; transient elevation of transaminases; (hypo)alacrima; peripheral neuropathy | For epilepsy: stable anti-seizure medication regimen for >=28 days prior to enrollment | Females of childbearing potential: negative serum pregnancy test at screening and agree to highly effective contraception through end of study,"Level 5 on both GMFCS E&R and CFCS scales | Contraindication to corticosteroids or condition that could worsen with corticosteroid therapy | Signs or symptoms of increased intracranial pressure, history of space-occupying lesion, or ventricular shunt that would preclude ICV procedures or safety assessments | Medical or behavioral condition that may adversely affect safety, study completion, or data interpretation | Blood pressure >99th percentile for age/height/sex per NHLBI guidelines | Fever: body temperature >=38.0°C | Abnormal age-based respiratory rate ranges (toddler 24-40; preschooler 22-34; school-aged 18-30; adolescent 12-16 breaths/min) | Oxygen saturation on room air <92% | Allergy or hypersensitivity to GS-100 formulation | Prior treatment with gene therapy | Treatment with any investigational product within 30 days or 5 half-lives (whichever is longer) before screening; ongoing AEs from prior IP must be resolved before screening | Concurrent enrollment in another interventional clinical study | Coagulation dysfunction: INR >=1.4 x ULN | Current hepatitis B infection (HBsAg and/or HBcAb positive); isolated HBsAb with negative HBV DNA is allowed | Prior or current hepatitis C infection (HCV antibody positive with confirmatory RNA PCR positive) | Hemoglobin <9 g/dL | Absolute neutrophil count <1000/µL | Platelet count <100,000/µL | Creatinine >1.25 x ULN | Planned major surgery (including major dental) during screening through 52 weeks post-infusion | Pregnant or breastfeeding | Elevated ACTH >=1.5 x ULN requiring endocrinology evaluation and management for possible adrenal insufficiency prior to enrollment",Investigational product washout >=30 days or 5 half-lives before screening; Stable anti-seizure medication regimen >=28 days before enrollment,ALL,F,"Disease mismatch: the trial enrolls patients with NGLY1 deficiency, while the patient has OTC deficiency. The patient is also 3 months old, outside the trial's 2–18 year age range.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"There is a clear hard exclusion: disease mismatch (patient has OTC deficiency; trial requires NGLY1 deficiency). Additionally, the patient is 3 months old, outside the trial’s 2–18 year age range. Either hard exclusion warrants an F. The grader’s reasoning and grade are correct.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06216899,0.6691051721572876,Fistulizing Crohn's Disease,Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial,"This study will compare the tolerability and efficacy of conventional formula Exclusive Enteral Nutrition (EEN) and whole-food blended smoothie EEN by enrolling a total of 60 participants with newly diagnosed pediatric Crohn's disease (CD). Participants will be provided either commercial formula or guided on the preparation of the home-blended smoothie. These participants will be given a specific recipe, blender, and be provided the food components to the smoothie. The study will total 8 week...","{'id': 206418259, 'name': 'Whole-food based smoothie', 'description': 'The smoothies will be based upon the concept of reverse-engineering of exclusive enteral nutrition and provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.', 'other_names': [], 'intervention_type': 'OTHER'}; {'id': 206418260, 'name': 'Formula', 'description': 'Conventional formula (Boost, Ensure, Modulen) as per the direction of their primary Gastroenterology team to provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.', 'other_names': [], 'intervention_type': 'OTHER'}",NA,8 years to 21 years,Crohn Disease,"Age 8–21 years | Crohn disease diagnosis within 24 months | Elevated inflammatory markers at enrollment: C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), or fecal calprotectin | Active Crohn disease with Pediatric Crohn's Disease Activity Index (PCDAI) >=10",History of surgery for Crohn disease | Perianal disease phenotype | Corticosteroid use within 4 weeks | Immunomodulator dose adjustment within 8 weeks | Azathioprine use within 4 weeks prior to final study visit | Methotrexate start or dose adjustment within 3 weeks prior to final study visit | Prior use of biologic medication | Prior exclusive enteral nutrition (EEN) or other dietary therapy for Crohn disease | Prior antibiotic treatment for Crohn disease | Allergy to any smoothie components | Hospital admission due to Crohn disease severity,(none),ALL,F,"Patient is 32 (trial requires age 8–21), has perianal fistulizing disease (excluded), and has prior biologic and antibiotic therapy—explicit exclusions.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Age 32 exceeds trial’s 8–21 window (hard exclusion). Trial also explicitly excludes perianal phenotype and prior biologic/antibiotic use, all present in the patient. Grader correctly applied hard exclusions → F.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT06247085,0.5332883596420288,Ornithine Transcarbamylase Deficiency,"A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study To Assess The Efficacy And Safety Of Pegtibatinase Administered Subcutaneously In Addition To Standard Of Care In Participants With Classical Homocystinuria Due To Cystathionine Beta Synthase Deficiency (HARMONY)",The purpose of this study is to measure efficacy and safety of pegtibatinase treatment compared with placebo in participants with classical HCU receiving standard of care who have not achieved tHcy target levels. Study details include: * Total Study duration: up to 38 weeks * Screening: * Initial Screening duration: up to 4 weeks * Pre-treatment Diet Standardization Period duration: up to 6 weeks * Blinded Treatment Duration: 24 weeks * 2-week blinded dose titration period * 22-week blinded a...,"{'id': 205916698, 'name': 'Pegtibatinase', 'description': 'Full Target Dose of pegtibatinase BIW', 'other_names': ['OT-058', 'TVT-058'], 'intervention_type': 'DRUG'}; {'id': 205916699, 'name': 'Placebo', 'description': 'volume-matched saline SC BIW', 'other_names': [], 'intervention_type': 'OTHER'}",PHASE3,12 years to 65 years,Homocystinuria,"Age 12–65 years | Diagnosis of classical homocystinuria due to cystathionine beta synthase (CBS) deficiency by clinical, biochemical, and/or genetic testing | Plasma total homocysteine >= 80 µM at screening (allowance for up to 18 participants with 50 to <80 µM) | Willing to maintain a generally stable diet during the study | Willing to maintain generally stable intake and doses of betaine, pyridoxine, and methionine-free formula during the study",Diagnosis of Marfan syndrome | Diagnosis of methylenetetrahydrofolate reductase (MTHFR) deficiency | Diagnosis of a disorder of cobalamin metabolism | Clinically significant concurrent disease that would interfere with participation or safety | History of major thrombotic event within the previous 6 months | Body weight >= 160 kg | Use or planned use of any injectable drugs containing polyethylene glycol (PEG) (excluding PEG-containing vaccines) | Previous exposure to pegtibatinase | Previous participation in a study with pegtibatinase or pegtarviliase | Prior severe immune reaction to a PEG-containing product,Stable dose of betaine; Stable pyridoxine; Stable methionine-free formula,ALL,F,"Disease mismatch: the trial targets classical homocystinuria due to CBS deficiency, not OTC deficiency. Additionally, the patient is 3 months old, while the trial requires ages 12–65.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Correct: There is a hard disease mismatch (trial is for classical homocystinuria/CBS deficiency, patient has OTC deficiency) and also an age hard exclusion (patient 3 months vs trial 12–65 years). Either triggers F per rubric.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT06422351,0.5519946813583374,Ornithine Transcarbamylase Deficiency,A Phase 2 Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced With a Lentiviral Vector Carrying the Codon Optimized Red Cell Pyruvate Kinase (coRPK) Gene in Subjects With Pyruvate Kinase Deficiency,This is an open-label Phase II trial to evaluate the efficacy of a hematopoietic cell-based gene therapy for patients with Pyruvate Kinase Deficiency (PKD).,"{'id': 205277980, 'name': 'RP-L301', 'description': 'Autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKLR (Pyruvate Kinase L/R) gene', 'other_names': ['Intervention/Treatment'], 'intervention_type': 'BIOLOGICAL'}",PHASE2,8 years to 55 years,Pyruvate Kinase Deficiency,"Pyruvate Kinase Deficiency with confirmed PKLR mutation | Hemoglobin <9.5 g/dL on >=2 assessments in prior 12 months plus transfusion burden (>=6 RBC transfusion episodes in prior 12 months or >=3 RBC transfusion episodes each year for 2 years) | OR Hemoglobin <8.5 g/dL on >=2 assessments irrespective of transfusions | OR Hemoglobin <10.0 g/dL on >=2 assessments with fatigue limiting activities (CTCAE grade 3) or grade 2 not responsive to therapy, or icterus limiting activities not responsive to therapy | Age 8–55 years | Prior splenectomy | Adequate cardiac, pulmonary, renal, and hepatic function | Negative serum pregnancy test (females of childbearing potential)","Other known causes of hemolysis in addition to PKD | Venous thromboembolism or arteriothromboembolic event within the prior 12 months | Bridging fibrosis, cirrhosis, or active hepatitis on liver biopsy | Cardiac T2* <10 ms by MRI | Left ventricular ejection fraction <45% | Severe iron overload warranting exclusion per investigator | Documented HIV infection | Active viral hepatitis | Poorly controlled hypertension | Pulmonary hypertension | Cardiac arrhythmia | Congestive heart failure | Stroke or myocardial infarction within the prior 12 months | Active hematologic or solid organ malignancy (except non-melanoma skin cancer or carcinoma in situ) | History of malignancy without evidence of disease for <3 years | Uncontrolled seizure disorder | ALT >2.5 x ULN | AST >2.5 x ULN | Serum creatinine > ULN unless eGFR >=60 mL/min/1.73m2 | Need for supplemental oxygen in the prior 2 weeks (in absence of acute infection) | Clinically significant pulmonary disease impairing ability to tolerate procedures | Contraindication to leukapheresis | Karnofsky Index <70% (>=16 years) or Lansky <70% (<16 years) | Participation in another clinical trial with an investigational drug within 14 days before consent | Pregnant, breastfeeding, or planning pregnancy within 24 months; inadequate contraception | Previous allogeneic or other hematopoietic stem cell transplant",No investigational drugs within 14 days prior to consent; Mitapivat discontinued >=90 days before start of mobilization,ALL,F,"Disease mismatch: the trial targets Pyruvate Kinase Deficiency, while the patient has Ornithine Transcarbamylase deficiency. Additionally, the patient is 3 months old, below the trial’s 8–55 year age range.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Disease mismatch (OTC vs PKD) is a hard exclusion; additionally, the patient’s age (3 months) is below the trial’s 8–55 years range. Either hard exclusion warrants F. The grader’s reasoning and grade are correct.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT06430385,0.4585214853286743,PMM2-CDG,"A Phase 1-2, Double-Blind, Sham-Controlled Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Patients With MECP2 Duplication Syndrome",The primary purpose of this study is to evaluate the safety and tolerability of ION440.,"{'id': 206066900, 'name': 'ION440', 'description': 'ION440 will be administered by intrathecal bolus (ITB) injection.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206066901, 'name': 'Sham procedure', 'description': 'An LP will be performed with CSF collection but will not be followed by the administration of study treatment by ITB injection.', 'other_names': [], 'intervention_type': 'PROCEDURE'}",PHASE1/PHASE2,2 years to 65 years,MECP2 Duplication Syndrome,Males age 2 to 65 years (cohort-dependent; Group A: 8–65 years; Group B: 2–7 years). | Documented MECP2 Duplication Syndrome with genetic confirmation of MECP2 duplication. | Stable doses of concomitant medications for >= 3 months prior to baseline (or per investigator judgment). | Completed Part 1/MAD to enroll in Part 2.,"Complex MECP2 duplication/triplication or clinical features suggesting complex variant if structure unknown (e.g., seizures onset < age 5 for those >=5 years, oxygen dependence, microcephaly). | Clinically significant vital sign or ECG abnormality at screening (e.g., HR < 45 bpm; SBP < 90 mmHg; confirmed BP > 170/105 mmHg). | Known brain or spinal disease interfering with lumbar puncture, CSF circulation, or safety of the procedure. | Any concomitant disease/condition or finding making participation unsuitable or posing unacceptable risk, per investigator. | Treatment with an investigational drug/biologic/device within 30 days or 5 half-lives, whichever is longer. | Previous treatment with an oligonucleotide (including siRNA) within 4 months (single dose) or 12 months (multiple doses); centrally administered ASOs require >= 12 months washout. | Currently enrolled in another clinical trial of an investigational agent/device or used any investigational agent within 5 half-lives. | History of gene therapy, cell transplantation, or experimental brain surgery. | Active infection requiring systemic antiviral/antimicrobial therapy not completed before baseline. | Status epilepticus within the past 6 months.","Washout from investigational agents: 30 days or 5 half-lives, whichever is longer.; Washout from oligonucleotides (including siRNA): >= 4 months after single dose; >= 12 months after multiple doses; centrally administered ASOs: >= 12 months.",MALE,F,"Disease mismatch: the trial targets MECP2 Duplication Syndrome, while the patient has PMM2-CDG. Additionally, the trial enrolls males only, and the patient is female.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"Hard exclusions apply: disease mismatch (PMM2-CDG vs MECP2 Duplication Syndrome) and sex restriction (trial male-only, patient female). F is correct per rubric.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT06431893,0.5332883596420288,Ornithine Transcarbamylase Deficiency,"An Open-Label, Phase 3 Long-Term Extension (LTE) Study To Assess The Safety, Tolerability, And Efficacy Of Treatment With Pegtibatinase In Participants With Classical Homocystinuria (HCU) Due To Cystathionine Beta Synthase Deficiency (ENSEMBLE)",The goal of this long-term extension (LTE) study is to evaluate the safety and efficacy of pegtibatinase in patients with classical homocystinuria (HCU). Patients who are active in the Phase 1/2 COMPOSE study or those who complete the 24 weeks of treatment in the Phase 3 HARMONY are eligible to participate. Participants will be in this clinical study for up to about 13 months including: * a treatment period of up to 104 weeks * a 4-week safety follow-up period,"{'id': 205841030, 'name': 'Pegtibatinase', 'description': 'Full Target Dose of pegtibatinase BIW', 'other_names': ['OT-58', 'TVT-058'], 'intervention_type': 'DRUG'}",PHASE3,5 years to 65 years,Homocystinuria,Active in the COMPOSE pegtibatinase study or completed the 24-week blinded period on the full target dose in the Phase 3 HARMONY study,Permanently discontinued pegtibatinase in a previous study due to serious adverse event or intolerance,Prior participation in the COMPOSE pegtibatinase study; Completed 24-week blinded period on full target dose in the HARMONY study,ALL,F,"The trial targets classical homocystinuria due to CBS deficiency and requires prior participation in COMPOSE/HARMONY, whereas the patient has OTC deficiency. Additionally, the patient is 3 months old, below the 5–65 year age range.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Hard exclusions apply: disease mismatch (OTC deficiency vs trial for classical homocystinuria/CBS deficiency) and age below minimum (3 months vs ≥5 years). Therefore F is correct, and the grader’s reasoning correctly identified key factors.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT06462547,0.5502394437789917,Ornithine Transcarbamylase Deficiency,"The ADAPT Study: An Open-label, Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency",The purpose of this study (Study INZ701-304 \[ADAPT\]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical study and choose to continue dosing for the potential treatment of their condition.,"{'id': 205772472, 'name': 'INZ-701', 'description': 'INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).', 'other_names': ['rhENPP1-Fc'], 'intervention_type': 'DRUG'}",PHASE2,1 years,ENPP1 Deficiency; ABCC6 Deficiency,Age >1 year | Completed protocol-required safety and PK/PD and/or efficacy period(s) of a previous INZ-701 clinical study in ENPP1 or ABCC6 deficiency | Females of childbearing potential use 1 highly effective contraception method from >=1 month before first dose through 30 days after last dose | No ova donation from first dose through 30 days after last dose | Sexually active males use condoms from first dose through 30 days after last dose | No sperm donation from first dose through 30 days after last dose,"Clinically significant disease or laboratory abnormality not associated with ENPP1 or ABCC6 deficiency that may preclude participation or confound results | Known intolerance to INZ-701 or its excipients | Concurrent participation in another interventional study or receipt of an investigational drug (other than INZ-701) within 5 half-lives or 4 weeks before first dose (whichever is longer), or use of an investigational device | Pregnant, trying to become pregnant, or breastfeeding | Male participant trying to father a child",Prior INZ-701 treatment in a previous clinical study (required),ALL,F,"Disease mismatch: the trial targets ENPP1 or ABCC6 deficiency, not OTC deficiency. The patient is also below the minimum age (3 months vs ≥1 year) and lacks required prior INZ-701 study participation.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion (trial is for ENPP1/ABCC6, patient has OTC). Additionally, patient is below minimum age and lacks required prior INZ-701 study participation. Any one of these triggers F; grader’s F and reasoning are correct.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT06466135,0.42564189434051514,PMM2-CDG,"Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of WAL0921 in Patients With Glomerular Kidney Diseases and Proteinuria","This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and proteinuria, including diabetic nephropathy and rare glomerular kidney diseases (primary focal segmental glomerulosclerosis \[FSGS\], treatment-resistant minimal change disease \[TR MCD\], primary immunoglobulin A nephropathy \[IgAN\], and primary membranous nephropat...","{'id': 205823471, 'name': 'WAL0921', 'description': 'Investigational drug WAL0921 Participants receive an intravenous infusion of WAL0921 investigational drug once every 2 weeks for 7 total infusions.', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 205823472, 'name': 'Placebo', 'description': 'Placebo product Participants receive an intravenous infusion of placebo once every 2 weeks for 7 total infusions.', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,18 years to 75 years,Diabetic Nephropathy; Primary Focal Segmental Glomerulosclerosis; Minimal Change Disease; Primary IgA Nephropathy; Primary Membranous Nephropathy,Age 18-75 years | Diagnosis of one of: diabetic nephropathy; primary focal segmental glomerulosclerosis; treatment-resistant minimal change disease; primary IgA nephropathy; primary membranous nephropathy | eGFR >= 30 mL/min/1.73 m2,Currently pregnant or planning to become pregnant | History of organ transplantation | History of alcohol or substance use disorder | Acute dialysis or acute kidney injury within 6 months of screening | Any condition that would prevent safe participation or completion of study requirements in the investigator's judgment,(none),ALL,F,"Disease mismatch: the trial targets specific glomerular kidney diseases, not PMM2-CDG. Additionally, the patient is 8 years old, below the trial’s minimum age of 18.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"Correct: There is a clear hard exclusion due to disease mismatch (trial targets specific glomerular kidney diseases, not PMM2-CDG) and an age conflict (patient 8 < min 18). Either warrants an F per rubric. The grader’s reasoning aligns with the rubric.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT06488313,1.0,Ornithine Transcarbamylase Deficiency,"A Phase 2a, Open-label, Multiple Ascending Dose Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency",Evaluate the safety and pharmacodynamics of multiple doses of ARCT-810 in adolescent and adult participants with OTC deficiency.,"{'id': 205976007, 'name': 'ARCT-810', 'description': 'ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) messenger RNA (mRNA) formulated in a lipid nanoparticle (LNP).', 'other_names': [], 'intervention_type': 'BIOLOGICAL'}",PHASE2,12 years,Ornithine Transcarbamylase Deficiency,"Age >= 12 years | Documented clinical diagnosis of ornithine transcarbamylase deficiency | History of symptomatic hyperammonemia or elevated plasma ammonia or glutamine with clinical stability for >= 1 month | Stable management for OTC deficiency with protein-restricted diet, dietary supplements, and/or ammonia scavenger regimen for >= 28 days | Good general health with no clinically significant abnormal findings (including plasma ammonia within participant's historical range)","Uncontrolled hypertension | Symptoms of infection within 7 days prior to dosing | Malignancy within 5 years except adequately treated basal or squamous cell skin cancer or cervical carcinoma in situ | History of any OTC gene therapy | History of liver-derived stem cell therapy within the past 2 years | History of any organ transplant | History of severe allergic reaction to a liposomal or PEG-containing product | History of congenital or acquired cardiac disorders | Abuse of medications, illicit drugs, or alcohol | INR > 1.5 | eGFR < 60 mL/min/1.73 m2 | Positive test for HIV | Positive test for HBV | Positive test for HCV | Inadequately controlled diabetes | Clinically significant anemia | Changes in maintenance therapies for OTC deficiency within 28 days prior to dosing | Medical history requiring continuous or intermittent systemic corticosteroid administration | Receipt of inhibitors of urea synthesis or drugs that significantly affect renal clearance | Recent treatment with another investigational drug, biological agent, or device | Treatment with any oligonucleotide (siRNA or mRNA) within 6 months prior to screening | Any other condition that would interfere with participation in the opinion of the investigator","Stable management for OTC deficiency with protein-restricted diet, dietary supplements and/or ammonia scavenger regimen for >= 28 days",ALL,F,"Although the disease matches, the trial requires participants to be ≥12 years old, and the patient is 3 months old, which is a hard age-window exclusion.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Age window conflict: trial requires ≥12 years while patient is 3 months old. This is a hard exclusion per rubric. Disease matches, but age alone warrants F. Grader’s reasoning aligns with rubric.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT06500702,0.42564189434051514,PMM2-CDG,"A Parallel-group Treatment, Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Umbrella Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, and Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)","This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD). The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, SAR442970, or rilzabrutinib compared with placebo in participants with primary FSGS or primary MCD aged 16 to 75 years. Study details for each participant include: The study duration ...","{'id': 206501942, 'name': 'frexalimab', 'description': 'frexalimab treatment', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206501943, 'name': 'SAR442970', 'description': 'SAR442970 treatment', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206501944, 'name': 'rilzabrutinib', 'description': 'rilzabrutinib treatment', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206501945, 'name': 'placebo', 'description': 'placebo treatment', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,16 years to 75 years,Focal Segmental Glomerulosclerosis; Minimal Change Disease,Biopsy-proven primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD). | Urine protein-to-creatinine ratio (UPCR) >= 3 g/g at screening. | Estimated glomerular filtration rate (eGFR) >= 45 mL/min/1.73 m^2 at screening. | Documented history of >= 40% reduction in UPCR in response to corticosteroid or other immunosuppressive therapy when pre-treatment UPCR was >= 3.5 g/g. | Prednisone or equivalent <= 10 mg/day and stable for >= 1 week prior to randomization. | On a stable dose of renin-angiotensin-aldosterone system (RAAS) inhibitor for >= 4 weeks prior to screening (if applicable). | On a stable dose of SGLT2 inhibitor for >= 4 weeks prior to screening (if applicable). | Body weight 45 to 120 kg (inclusive) at screening.,Genetic or secondary FSGS or MCD (APOL1 risk alleles eligible). | Collapsing variant of FSGS. | End-stage kidney disease requiring dialysis or kidney transplantation.,Documented >= 40% UPCR reduction in response to corticosteroid or other immunosuppressive therapy when baseline UPCR was >= 3.5 g/g.; Stable prednisone or equivalent <= 10 mg/day for >= 1 week prior to randomization.; Stable RAAS inhibitor for >= 4 weeks prior to screening (if applicable).; Stable SGLT2 inhibitor for >= 4 weeks prior to screening (if applicable).,ALL,F,"The trial is for FSGS or MCD and requires ages 16–75, whereas the patient has PMM2-CDG and is 8 years old. This is a disease mismatch and an age window conflict, both hard exclusions.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"Correct. The patient’s disease (PMM2-CDG) is not among the trial diseases (FSGS/MCD), and the patient is 8 years old while the trial requires 16–75. Both are hard exclusions, so grade F is appropriate.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06619327,1.0,Dementia,Resilient Together for Dementia: a Live Video Resiliency Dyadic Intervention for Persons with Dementia and Their Care-partners Early After Diagnosis,"This study will evaluate the feasibility and preliminary efficacy of the novel Resilient Together for Dementia (RT-D) intervention for couples following dementia diagnoses. The primary target is emotional distress, and the program aims to prevent chronic distress in at-risk couples.","{'id': 206013416, 'name': 'Resilient Together for Dementia', 'description': 'RT-D has been developed based on feedback from couples and dementia clinicians as well as prior successful dyadic interventions. RT-D was developed based on the Recovering Together (RT) dyadic intervention for acute neurological illnesses and is being adapted to address the needs of couples navigating new dementia diagnoses.', 'other_names': ['RT-D'], 'intervention_type': 'BEHAVIORAL'}; {'id': 206013417, 'name': 'MEUC', 'description': 'The MEUC condition was also developed based on the comparison trial in the Recovering Together dyadic intervention, and was adapted based on feedback from prior studies. The program is self-guided and provides educational information similar to the RT-D condition, but with no skills practice or weekly sessions with a therapist.', 'other_names': ['Minimally enhanced usual care'], 'intervention_type': 'BEHAVIORAL'}",NA,18 years,Dementia,Recent (~3 months) chart-documented Alzheimer’s disease and related dementias (ADRD) diagnosis | ADRD symptom onset after age 65 | Early stage dementia with Clinical Dementia Rating (CDR) score 0.5 or 1.0 | Cognitive awareness of problems and ability to understand study protocol as determined by standardized teach-back assessment | English-speaking adults (>=18 years) in a dyad | Dyad lives together | At least one partner with clinically significant emotional distress at screening: >7 on Hospital Anxiety and Depression Scale subscales or <5 on the Geriatric Depression Scale,"Patient deemed inappropriate by the neurology team | Either partner has a co-occurring terminal illness | Diagnosis of dementia with clinical profile that would preclude participation (e.g., frontotemporal dementia-behavioral variant) as determined by treatment team",(none),ALL,F,"The trial requires early-stage dementia (CDR 0.5–1.0) soon after diagnosis, whereas the patient has moderate-stage dementia (MMSE 19), indicating they do not meet the required stage/setting.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"The trial requires early-stage dementia (CDR 0.5–1.0) shortly after diagnosis. The patient has moderate-stage dementia (MMSE 19), definitively lacking the required stage/setting. Per rubric, a required stage/setting mismatch is a hard exclusion → F. The grader’s reasoning correctly identified this.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT06717438,0.5156362056732178,PMM2-CDG,"A Phase 2 Randomized, Double-blind, Placebo-controlled, Study of Zatolmilast (BPN14770) in Subjects With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome)",The primary objective of this study is to assess the safety and tolerability of BPN14770 in participants aged 9 to 45 years with JS.,"{'id': 205851641, 'name': 'BPN14770', 'description': 'Capsules for oral administration', 'other_names': ['Zatolmilast'], 'intervention_type': 'DRUG'}; {'id': 205851642, 'name': 'Placebo', 'description': 'Capsules for oral administration', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,9 years to 45 years,PPP2R5D Neurodevelopmental Disorder,Age 9–45 years | Confirmed PPP2R5D Neurodevelopmental Disorder | Current treatment with no more than 3 prescribed psychotropic medications,"Body weight <25 kg | Clinically significant abnormalities in safety laboratory tests, vital signs, or ECG at screening | Concurrent major psychiatric condition (e.g., major depressive disorder, schizophrenia, bipolar disorder); autism spectrum disorder or anxiety disorder allowed | Planning to commence psychotherapy or cognitive behavior therapy during the study or initiated within 4 weeks prior to screening",No psychotherapy or cognitive behavior therapy initiated within 4 weeks prior to screening; Concomitant use of <=3 prescribed psychotropic medications allowed,ALL,F,"The trial is for PPP2R5D neurodevelopmental disorder requiring confirmed PPP2R5D, while the patient has PMM2-CDG with PMM2 variants. Additionally, the patient is 8 years old, below the trial’s minimum age of 9.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,Hard exclusions apply: disease mismatch (PMM2-CDG vs PPP2R5D disorder) and age below minimum (8 < 9). The grader correctly assigned F and identified key reasons.,,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT06773026,0.5343823432922363,Ornithine Transcarbamylase Deficiency,"A Phase 2, Open-label, Fixed-dose Study to Assess the Efficacy of Sodium Phenylbutyrate (ACER-001) in Treating Pediatric and Adult Patients With Medium Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency Resulting From the Prevalent ACADM c.985 A>G (K304E) Mutation","This is a medical research study to test a medication in patients 4 years of age and older with a disease called medium-chain acyl-CoA dehydrogenase deficiency (MCADD) caused by the common ACADM c.985 A\>G (K304E) mutation. The medication is sodium phenylbutyrate (ACER-001), which is currently FDA approved for the treatment of Urea Cyle Disorders. Previous research suggests that sodium phenylbutyrate may also be effective in the treatment MCADD. This study will investigate the safety and effi...","{'id': 205945706, 'name': 'Sodium phenylbutyrate', 'description': 'Open-label design with doses of sodium phenylbutyrate at 4.0 g/m2/day', 'other_names': ['Olpruva'], 'intervention_type': 'DRUG'}",PHASE2,4 years,Medium-Chain Acyl-CoA Dehydrogenase Deficiency,Diagnosis of medium-chain acyl-CoA dehydrogenase deficiency (MCADD) with molecular confirmation of at least one copy of ACADM c.985A>G. | Age >= 4 years. | Negative pregnancy test for females of childbearing potential. | Use of effective contraception for females of childbearing potential and sexually active males during the study.,"Use of any investigational drug within 30 days before Day 1. | Active viral or bacterial infection. | Any clinical or laboratory abnormality of CTCAE v5.0 grade >= 3, including AST/ALT 5–20 x ULN. | Any condition that increases risk per investigator judgment. | Use within 48 hours before Day 1 and during the study of medications that significantly affect renal clearance (e.g., probenecid). | Use within 48 hours before Day 1 and during the study of medications that increase protein catabolism (e.g., corticosteroids). | Use within 48 hours before Day 1 and during the study of medications known to increase ammonia levels (e.g., valproic acid, haloperidol). | Renal insufficiency (eGFR < 60 mL/min/1.73m2). | Use of sodium benzoate within 1 week before Day 1. | Known hypersensitivity to PAA or PBA. | Breastfeeding or lactating. | At risk of hypokalemia due to pre-existing diagnosis or medications. | Type 1 or type 2 diabetes, or use of medications that can cause hypoglycemia. | Positive urine drug screen for non-prescribed drugs. | Use of antimetabolite drugs (e.g., hydroxyurea, 5-fluorouracil, methotrexate).","No investigational drugs within 30 days before Day 1.; No sodium benzoate within 1 week before Day 1.; No medications significantly affecting renal clearance (e.g., probenecid) within 48 hours before Day 1 and during the study.; No corticosteroids within 48 hours before Day 1 and during the study.; No valproic acid or haloperidol within 48 hours before Day 1 and during the study.; No antimetabolite chemotherapy (e.g., hydroxyurea, 5-fluorouracil, methotrexate) during the study.",ALL,F,"Disease mismatch: the trial targets MCAD deficiency with ACADM c.985A>G, while the patient has OTC deficiency. Additionally, the patient is 3 months old, below the trial’s minimum age of 4 years.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,Correct: There is a hard disease mismatch (OTC vs MCAD with ACADM c.985A>G) and an age hard exclusion (3 months vs trial minimum 4 years). Either triggers F per rubric.,,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT06842498,0.8316181302070618,Castration-Resistant Prostate Cancer,A Phase 2 Dose Optimization Trial Evaluating a CD46-Targeted Antibody-Drug Conjugate (FG-3246) in Patients With Metastatic Castration-Resistant Prostate Cancer,"The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second-generation androgen receptor signaling inhibitor (ARSI) in any setting and no prior taxane therapy in the mCRPC setting.","{'id': 205982990, 'name': 'FG-3246', 'description': 'FG-3246 will be administered per schedule specified in the arm description.', 'other_names': ['FOR46'], 'intervention_type': 'DRUG'}",PHASE2,18 years,Metastatic Castration-Resistant Prostate Cancer,"Histologic and/or cytologic confirmation of prostate adenocarcinoma | Agree to tumor biopsy of a primary or metastatic lesion during screening or provide archival biopsy obtained after development of castration resistance within 1 year prior to randomization | Serum testosterone <50 ng/dL during screening | Progressed on one prior second-generation androgen receptor signaling inhibitor (abiraterone, enzalutamide, apalutamide, or darolutamide) | Progressive metastatic castration-resistant prostate cancer at screening | At least 1 metastatic lesion on CT, MRI, or bone scan obtained within 28 days prior to randomization | Adequate organ function at screening and reconfirmed on Study Day -1 or Day 1","Prior treatment with a therapeutic targeting CD46 | Small cell neuroendocrine carcinoma (pure or mixed) or any non-adenocarcinoma component on histology | More than one prior second-generation ARSI in any setting | Receipt of any systemic anticancer therapy within 28 days prior to randomization | Receipt of any prior radiation therapy within 28 days prior to randomization | Known actionable mutation or gene alteration (e.g., BRCA1) with available approved therapies unless not appropriate or patient refuses such therapy | CTCAE Grade >=2 peripheral neuropathy at screening from any etiology | Any prior chemotherapy; exception: one prior taxane-based chemotherapy in the castration-sensitive setting allowed if completed >12 months before randomization | Known hypersensitivity to FG-3246 components or analogs or history of allergic/anaphylactic reaction to human, humanized, or chimeric monoclonal antibodies | Diagnosis of any other malignancy within the past 5 years except adequately treated basal cell or squamous cell carcinoma of the skin | Requires treatment with a strong CYP3A4 inhibitor or inducer that cannot be safely discontinued","Required: exactly one prior second-generation ARSI (abiraterone, enzalutamide, apalutamide, or darolutamide); Allowed: one prior taxane-based chemotherapy in the castration-sensitive setting if completed >12 months before randomization; Washout: no systemic anticancer therapy within 28 days prior to randomization; Washout: no prior radiation therapy within 28 days prior to randomization",MALE,F,"The trial explicitly excludes patients with more than one prior second-generation ARSI; this patient received both abiraterone and enzalutamide. Therefore, they fail a hard exclusion despite otherwise matching mCRPC, age, and sex.",Castration-Resistant Prostate Cancer,PSMA PET avid,Male sex; Age 66 years; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid liver and bone metastases,(none),Androgen deprivation therapy (leuprolide); Abiraterone (Zytiga); Enzalutamide (progression on),metastatic,,66,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with more than one prior second-generation ARSI; the patient had both abiraterone and enzalutamide. This is a hard exclusion, so F is correct despite matches on disease, age, and sex.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT06892288,0.5490809679031372,Ornithine Transcarbamylase Deficiency,"A Phase 2b, Multicenter, Double-blind, Randomized, Placebo Controlled Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 Administered Intravenously to Participants With PMM2-CDG (POLAR Trial)","This study is evaluating the safety, effectiveness, and how the body absorbs, distributes, and eliminates GLM101, for participants with PMM2-CDG, including children, adolescents, and adults. Researchers will compare participants receiving GLM101 to those receiving a placebo to see if GLM101 improves symptoms of PMM2-CDG. The study includes two treatment parts: a 24-week double blind placebo-controlled treatment period (Part A), and a 24-week open-label phase where every participant will recei...","{'id': 206615058, 'name': 'GLM101 (Part A, Double-blind)', 'description': 'IV infusions, 30 mg/kg once weekly for 24 weeks, for participants randomized to GLM101 in Part A', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206615059, 'name': 'Placebo (Part A, Double-blind)', 'description': 'IV infusions, 30 mg/kg once weekly for 24 weeks, for participants randomized to Placebo in Part A', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206615060, 'name': 'GLM101 (Part B, Open-label)', 'description': 'IV infusions, 30 mg/kg once weekly from week 25 to 48, to all participants', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2/PHASE3,4 years,Phosphomannomutase 2 Deficiency,"Age >= 4 years at consent | Molecular diagnosis of PMM2-CDG with biallelic pathogenic/likely pathogenic variants or biallelic variants plus PMM2 enzyme activity consistent with PMM2-CDG | Able to complete the full ICARS assessment | Screening ICARS total score >= 20 and <= 80 | Women of childbearing potential: negative serum pregnancy test and use of effective contraception during treatment and for 50 days after last infusion | Females of non-childbearing potential: premenarchal, surgically sterile, or ovarian dysfunction with FSH > 40 IU/L and amenorrhea for 12 months | Sexually active males with female partners: use effective contraception during treatment and for 50 days after last infusion | Males agree to refrain from donating sperm during the study and for 50 days after last infusion","Uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric, or other significant disease per investigator | Diagnosis of a CDG other than PMM2-CDG | History of liver transplant | Active infection requiring parenteral antibiotics, antivirals, antifungals, or systemic steroids within 7 days prior to screening | History of drug or alcohol use disorder within 12 months prior to screening | Major surgical procedure within 30 days prior to screening or planned major surgery | Previous GLM101 administration | Participation in another interventional study or investigational drug/device use within 30 days or 5 half-lives before enrollment | Use of products or supplements containing mannose or biotin within 2 weeks prior to screening | ALT > 3 x ULN, AST > 3 x ULN, or total bilirubin > 2 x ULN, or INR > 1.5 | Screening laboratory value(s) clinically significant and not related to PMM2-CDG per investigator | Hepatitis B surface antigen positive or hepatitis C antibody positive | QTcF >= 450 ms or other clinically significant ECG abnormalities | Any illness that may impact GLM101 infusion safety or evaluability per investigator/Medical Monitor | Body weight > 75 kg | Known or suspected hypersensitivity to GLM101 or its components | Any other condition making the participant unsuitable per investigator",No investigational drug or device within 30 days or 5 half-lives (whichever is longer) before enrollment; No mannose or biotin supplements within 2 weeks prior to screening,ALL,F,"Disease mismatch: the trial targets PMM2-CDG, while the patient has OTC deficiency. Additionally, the patient is 3 months old, below the trial’s minimum age of 4 years.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,Hard exclusions apply: clear disease mismatch (OTC vs PMM2-CDG) and age below minimum (3 months vs ≥4 years). The grader correctly assigned F and cited appropriate reasons.,,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06919926,1.0,Dementia,"A Randomized, Within-subject, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101 (Low-dose Levetiracetam, 220 mg, Extended Release Tablet) for the Treatment of Hippocampal Overactivity in the Elderly","This randomized, crossover, placebo controlled clinical study will assess the efficacy and safety of a slow release form of levetiracetam (AGB101) in the treatment of cognitively normal adults by measuring change in several imaging measures over the course of a two week treatment period.","{'id': 205742393, 'name': 'AGB101', 'description': 'low-dose levetiracetam, 220 mg, extended release tablet', 'other_names': ['levetiracetam'], 'intervention_type': 'DRUG'}; {'id': 205742394, 'name': 'Placebo', 'description': 'placebo capsule', 'other_names': ['sugar pill'], 'intervention_type': 'DRUG'}",PHASE2,50 years to 80 years,Dementia; Hippocampal Overactivity,"Age 50–80 years | Good general health | Study partner with contact >= 2 hours/week | Mini-Mental State Examination (MMSE) 27–30 | No memory complaint from subject or study partner | Normal memory function on Buschke Selective Reminding Test (Immediate and Delayed Recall) or equivalent | Clinical Dementia Rating (CDR) global score 0 with memory box score 0 | Antidepressants at a stable dose for >= 1 month prior to screening | Able to undergo repeated 3T MRI with no contraindications | Willing to allow blood collection for apolipoprotein E genotyping | Willing to undergo Tau PET scan with 18F MK-6240 tracer | Adequate visual and auditory acuity for neuropsychological testing | Proficient fluency in native local language for testing | If of childbearing potential (participant or partner), agrees to use effective contraception during study and for 4 days after","Use of anticonvulsant medications within 1 month prior to baseline | Use of anticoagulant medications within 1 month prior to baseline | Participation in a therapeutic clinical study within 1 month prior to screening or during the study | History of hypersensitivity or lack of tolerability to levetiracetam | Severe renal impairment (creatinine clearance < 30 mL/min) or undergoing hemodialysis | Significant neurological disease that could interfere with the study (e.g., Parkinson's disease, Alzheimer's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder [excluding infant febrile seizures], subdural hematoma, multiple sclerosis, significant head trauma with persistent deficits, structural brain abnormalities) | Major depression within the last 3 years | Prior diagnosis of schizophrenia, bipolar disorder, or other psychotic disorder | MRI contraindications (e.g., pacemaker, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in body) | Alcohol or substance abuse or dependence within the past 3 years | Significant systemic illness or unstable medical condition that could impede compliance | Unstable medical condition likely to require new treatment during the study that may affect efficacy data collection | Current suicidal ideation | Pregnant or lactating | Any other condition that, in the investigator's opinion, would confound study interpretation",Antidepressants at stable dose >= 1 month prior to screening,ALL,F,"Fails a hard requirement: the trial requires cognitively normal participants (MMSE 27–30, CDR 0, no memory complaints), while the patient has moderate dementia with MMSE 19. Thus the required stage/setting is definitively not met.",Dementia,Elevated p-tau; Amyloid PET negative; CSF amyloid negative,Male; Age 68 years; Two-year history of progressive cognitive decline; MMSE 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"The trial explicitly requires cognitively normal participants (MMSE 27–30, CDR 0, no memory complaints), which the patient definitively does not meet (MMSE 19, moderate dementia). This is a required stage/setting mismatch qualifying as a hard exclusion per the rubric. Grade F is appropriate.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT06937658,0.4612867832183838,PMM2-CDG,Remote Alert Pathway To Optimize CaRe of Cardiac Implantable Electrical Devices,"The Remote Alert Pathway to Optimize Care of Cardiac Implantable Electrical Devices (RAPTOR-CIED) Study is a pragmatic, multi-center, randomized trial with 1:1 patient-level randomization comparing the safety and effectiveness of alert-driven care versus guideline-based care for patients with wireless cardiac implantable electrical devices (CIEDs). The study will be conducted in 2 phases: a Feasibility Phase and a Main Phase. This registration outlines the goals and design features of the Fea...","{'id': 205704112, 'name': 'Alert-based care', 'description': 'Alert-based care is an alternative strategy for longitudinal management of patients with wireless pacemakers and implantable defibrillators', 'other_names': [], 'intervention_type': 'DEVICE'}; {'id': 205704113, 'name': 'Guideline-based care', 'description': 'Guideline-based care is the current typical standard for longitudinal management of patients with wireless pacemakers and implantable defibrillators', 'other_names': [], 'intervention_type': 'DEVICE'}",NA,18 years,Pacemaker DDD; Implantable Defibrillator User,"Age > 18 years | Clinically stable | Has a wireless cardiac implantable electronic device (pacemaker or implantable cardioverter-defibrillator), including single, dual-chamber, biventricular, subcutaneous/extravascular, or leadless systems | Device from Medtronic, Boston Scientific, Abbott, or Biotronik | Currently enrolled in remote monitoring | Primary clinical electrophysiology follow-up at the enrolling center",Presence of an insertable cardiac monitor (alone or in combination with any other CIED) | Listed for cardiac transplantation prior to enrollment,(none),ALL,F,"Disease mismatch: the trial targets patients with cardiac implantable electronic devices (pacemaker/ICD), not PMM2-CDG. Additionally, the patient is 8 years old while the trial requires age ≥18.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"Correct: There is a hard disease mismatch (trial targets CIED users, not PMM2-CDG) and an age hard exclusion (trial requires ≥18; patient is 8). Either warrants F.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT06983028,0.42564189434051514,PMM2-CDG,A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER),The purpose of this study is to evaluate the safety and tolerability of atacicept in adult and adolescent participants and to measure the effect in reducing proteinuria and preserving renal function.,"{'id': 206212166, 'name': 'Atacicept', 'description': 'Atacicept 150 mg SC QW via pre-filled syringe', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE2,10 years,IgA Nephropathy; Primary Membranous Nephropathy; Minimal Change Disease; Focal Segmental Glomerulosclerosis; Nephrotic Syndrome,"Weight >= 40 kg | On a stable standard-of-care treatment regimen | Systolic blood pressure <= 160 mmHg and diastolic blood pressure <= 90 mmHg at screening (for ages >= 10 to < 18 years: average of 3 readings < 95th percentile for age, gender, and height) | Diagnosis of IgA nephropathy, IgA vasculitis nephritis, primary membranous nephropathy, minimal change disease, focal segmental glomerulosclerosis, or primary nephrotic syndrome | IgAN/IgAVN cohorts: Age >= 10 years | IgAN/IgAVN cohorts: Biopsy-proven IgA nephropathy or IgA vasculitis nephritis | IgAN/IgAVN cohorts: UPCR >= 0.5 g/g | IgAN/IgAVN cohorts: eGFR >= 20 mL/min/1.73m2 | pMN cohorts: Age >= 18 years | pMN cohorts: Biopsy-proven primary membranous nephropathy | pMN cohorts: Anti-PLA2R antibodies >= 25 RU/mL | pMN cohorts: UPCR >= 1.5 g/g | pMN cohorts: Low risk for spontaneous remission (based on severity or duration) | Nephrotic syndrome cohorts (MCD, FSGS, or pediatric idiopathic): Age >= 10 years | Nephrotic syndrome cohorts (MCD, FSGS, or pediatric idiopathic): eGFR >= 30 mL/min/1.73m2 | Nephrotic syndrome cohorts (adults): Biopsy diagnosis of primary minimal change disease or focal segmental glomerulosclerosis | Nephrotic syndrome cohorts (children): Frequently relapsing, steroid-dependent, or steroid-resistant course | Nephrotic syndrome cohorts: UPCR >= 1.0 g/g | Nephrotic syndrome cohorts: Evidence of anti-nephrin antibodies",Rapidly progressive glomerulonephritis with loss of >= 50% of eGFR within 3 months prior to and at screening | Active viral or bacterial infections | Clinically significant conditions or laboratory abnormalities that may interfere with participation | Receipt of live or live-attenuated vaccines within 30 days prior to enrollment | Known hypersensitivity to atacicept or any component of its formulation,(none),ALL,F,"Hard exclusions: The trial targets autoimmune glomerular kidney diseases (e.g., IgA nephropathy, membranous nephropathy), not PMM2-CDG, and the minimum age is 10 years while the patient is 8.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"Correct: The patient’s disease (PMM2-CDG) is not among the trial’s targeted diseases, which is a hard exclusion. Additionally, the patient is 8 years old while the trial minimum age is 10, another hard exclusion. Therefore F is appropriate.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT06995521,0.5412098169326782,Ornithine Transcarbamylase Deficiency,"Use of Vorinostat as GVHD Prophylaxis in Children, Adolescents, and Young Adults With Non-Malignant Disorders Undergoing Allogeneic Blood and Marrow Transplantation","This is a single-arm, open label, phase 2 study to determine the safety and efficacy of vorinostat without serotherapy as GVHD prophylaxis when combined with either tacrolimus and methotrexate or post-transplant cyclophosphamide, tacrolimus, and mycophenolate in patients aged 1 to 26 years of age with non-malignant disorders undergoing bone marrow transplant following myeloablative conditioning.","{'id': 205795907, 'name': 'Vorinostat', 'description': 'For Matched sibling and matched unrelated donor transplant recipients: Vorinostat will be given orally at a dose of 60 milligrams per square meter two times a day (BID) (120 mg/m2/day) from day -10 to day 30 post-transplant. The maximum dose will be 100 mg BID.\n\nHaploidentical donor transplant recipients:\n\nVorinostat will be given orally at a dose of 60 mg/m2 BID (120 mg/m2/day) from day +5 (at least 24 hours after completion of the day +4 cyclophosphamide) through day 30 post-transplant. The maximum dose will be 100 mg BID.\n\nDosing may be rounded by +/- 10%. Patients that are able to take capsules and whose calculated dose is ≥91 mg may take 100 mg capsules.', 'other_names': ['Zolinza'], 'intervention_type': 'DRUG'}",PHASE2,1 years to 26 years,Graft-Versus-Host Disease; Primary Immunodeficiency; Inborn Error of Metabolism; Hemoglobinopathy; Inherited Bone Marrow Failure Syndrome,"Non-malignant condition amenable to allogeneic HSCT | Primary immunodeficiency/primary immune regulatory disorder | Inborn error of metabolism | Red blood cell disorder/hemoglobinopathy (per protocol) | Inherited bone marrow failure syndrome | Suitable donor available: matched sibling, matched unrelated, or haploidentical | Adequate pulmonary function: DLCO, FEV1, FVC >=50% predicted | Adequate renal function: GFR >=50 mL/min | Adequate liver function: AST/ALT <3 x ULN; total bilirubin <=2.5 mg/dL unless Gilbert syndrome or disease-related | Adequate cardiac function: EF >=50% or FS >=26% | Performance status Karnofsky/Lansky >=70% | HIV and HTLV I/II seronegative | Transfusion-dependent anemias: liver MRI to document hepatic iron content | Effective contraception required during treatment and post-treatment (per protocol) | If receiving investigational therapy for underlying disorder, must discontinue prior to initiation of conditioning regimen","Fanconi anemia, dyskeratosis congenita, telomere biology disorders, or inherited DNA repair/radiosensitivity disorders | Idiopathic severe aplastic anemia | Severe combined immunodeficiency syndrome | Malignancy within the last 5 years | Epstein-Barr virus-driven lymphoproliferative disorder within the last 5 years | Uncontrolled bacterial, viral, or fungal infection at enrollment | HIV or HTLV seropositive | Active hepatitis B or hepatitis C | Pregnancy or breastfeeding | Inability to take oral medications | Allergy to vorinostat, related compounds, or drugs used in conditioning or GVHD prophylaxis | Transfusion-dependent anemia with liver iron content >8 mg Fe/g dry weight or bridging fibrosis/cirrhosis on biopsy | Enrollment on another GVHD-prevention clinical trial | Receipt of an ex vivo T cell-depleted or CD34-selected graft | Prior treatment with a histone deacetylase inhibitor within 30 days | History of prolonged QTc syndrome | Uncontrolled intercurrent illness (e.g., symptomatic heart failure, unstable angina, significant arrhythmia, psychiatric illness/social issues limiting compliance)",Must discontinue other investigational therapies for the underlying disorder prior to initiation of conditioning regimen,ALL,F,"The patient is 3 months old, below the trial's minimum age of 1 year, which is a hard exclusion. While OTC deficiency fits the inborn error of metabolism category, the age window conflict renders the patient ineligible.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Patient is 3 months old, below the trial’s minimum age of 1 year, which is a hard exclusion per rubric. Grader correctly applied age window conflict leading to F; disease category match is irrelevant once a hard exclusion applies.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT07015671,0.42657917737960815,PMM2-CDG,Bioavailability and Bioequivalence (BA/BE) Study of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Subjects,"This study examines the bioavailability and bioequivalence of single dose of a Fixed Dose Combination (FDC) tablet (12 mg Extended-Release Torsemide and 15mg Spironolactone). The goal of this study is to determine PK/PD effects of the FDC, 10 mg Torsemide alone, 25mg Aldactone® (Spironolactone) alone, and 10 mg Torsemide and 25 mg Aldactone® (Spironolactone) taken together in healthy subjects.","{'id': 206524209, 'name': '10 mg Torsemide tablet', 'description': 'Single dose 10 mg Torsemide tablet', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206524210, 'name': '25 mg Aldactone (Spironolactone) tablet', 'description': 'Single dose 25 mg Aldactone® (Spironolactone) tablet', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206524211, 'name': 'FDC (12 mg ER Torsemide + 15mg Spironolactone) tablet', 'description': 'Single dose FDC (12 mg ER Torsemide + 15 mg Spironolactone) tablet', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,18 years to 45 years,Bioequivalence Study in Healthy Subjects; PK/PD,"Age 18–45 years | Weight: men >=50 kg; women >=45 kg; BMI 18.50–29.99 kg/m2 | Non-smoker (abstinent >=1 year) and no tobacco use | Healthy with no significant disease and no clinically significant abnormalities on history, exam, labs, ECG, and chest X-ray | Negative for HIV 1/2, hepatitis B, hepatitis C, and syphilis | Women of childbearing potential and male participants agree to use two effective contraceptive methods during the study and for 2 weeks after last dose; postmenopausal or surgically sterile women eligible","Significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, musculoskeletal, or psychiatric disease | History of asthma, urticaria, or allergic-type reactions after taking torsemide, spironolactone, or other drugs; gastric/duodenal ulcer; gastrointestinal bleeding; jaundice within past 6 months; internal bleeding | Hypersensitivity or allergy to torsemide, spironolactone, or excipients | Alcohol or drug abuse within the past year | Family history of bleeding disorders | History of urinary retention, difficulty voiding, or incontinence | Blood donation >=500 mL within 90 days before first dose | Difficulty with venous access for cannulation or blood sampling | Positive breath alcohol test at screening/check-in | Positive urine drug screen at screening/check-in | Positive screening for hepatitis B, hepatitis C, HIV, or syphilis | Difficulty swallowing tablets | Use of any medication (including OTC) or herbal products within 14 days before first dose | Use of enzyme-modifying drugs within 30 days before first dose | History of dehydration from diarrhea or vomiting within 24 hours before first check-in | Consumption of xanthine-containing products (chocolate, tea, coffee, cola) within 48 hours before first check-in | Consumption of grapefruit or its products within 48 hours before first check-in | Pregnant or lactating females",No medications (including OTC) or herbal products within 14 days before first dose; No enzyme-modifying drugs within 30 days before first dose,ALL,F,"This is a bioequivalence study restricted to healthy adults aged 18–45 and does not target PMM2-CDG. The patient is 8 years old with PMM2-CDG, failing both disease match and age eligibility.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"Hard exclusions apply: the trial enrolls healthy adults (18–45) and does not target PMM2-CDG, while the patient is 8 years old with PMM2-CDG. Both disease mismatch and age window conflict trigger an F. The grader’s reasoning aligns with the rubric.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT07019922,0.4252880811691284,PMM2-CDG,"A Randomized, Multi-Center, Double-Blind, Sham-Procedure-Controlled Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy","A Randomized, Multi-Center, Double-Blind, Sham-Procedure-Controlled Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy","{'id': 206401901, 'name': '1mg elsunersen', 'description': '24 weeks every 4 weeks intrathecally', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206401902, 'name': 'sham procedure', 'description': '24 weeks of sham-procedure every 4 weeks', 'other_names': [], 'intervention_type': 'PROCEDURE'}; {'id': 206401903, 'name': '0.5mg elsunersen', 'description': '24 weeks every 4 weeks intrathecally', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,1 days to 18 years,Epileptic Encephalopathy; SCN2A Encephalopathy,Documented gain-of-function SCN2A variant confirmed by genetic testing. | Onset of seizures prior to 3 months of age. | Seizure frequency of >=4 countable motor seizures per 28 days during the baseline observation period.,"Clinically significant or pathogenic genetic variant other than in SCN2A, or a variant that may explain or contribute to the epilepsy and/or developmental disorder. | Bone, spine (e.g., kyphosis, scoliosis), bleeding, or other significant disorder. | Received any experimental or investigational drug, device, or other therapy within 30 days or 5 half-lives prior to screening, including any prior use of gene therapy. | Currently pregnant or breastfeeding or planning to become pregnant during the trial.",Washout from investigational therapies: >=30 days or >=5 half-lives before screening.,ALL,F,"The trial targets SCN2A developmental and epileptic encephalopathy and requires a gain-of-function SCN2A variant; the patient has PMM2-CDG with PMM2 variants, so disease and biomarker requirements are not met. The trial also explicitly excludes participants with a pathogenic variant other than SCN2A that may explain the disorder.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,Hard exclusion applies: disease mismatch (PMM2-CDG vs SCN2A encephalopathy) and explicit exclusion for non-SCN2A pathogenic variants. The grader correctly assigned F and gave appropriate reasoning.,,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT07054515,0.4909437298774719,PMM2-CDG,"18-month Double-blind, Randomized, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease and in Late-infantile and Juvenile-onset Forms of GM1 Gangliosidosis or GM2 Gangliosidosis","An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease and in late-infantile and juvenile-onset forms of GM1 gangliosidosis or GM2 gangliosidosis","{'id': 206422840, 'name': 'AZ-3102', 'description': 'Oral dispersible tablets', 'other_names': ['nizubaglustat'], 'intervention_type': 'DRUG'}; {'id': 206422841, 'name': 'Placebo', 'description': 'A matching placebo will be administered in the same regimen as the intervention', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,4 years,GM1 Gangliosidosis; GM2 Gangliosidosis; Niemann-Pick Type C Disease,"Age >= 4 years | Diagnosis of Niemann-Pick type C disease (late-infantile or juvenile form) | Diagnosis of GM1 gangliosidosis (late-infantile or juvenile onset) | Diagnosis of GM2 gangliosidosis (Tay-Sachs, Sandhoff, or GM2AB variant; late-infantile or juvenile onset)",,(none),ALL,F,"Disease mismatch: the trial enrolls Niemann-Pick type C, GM1, or GM2 gangliosidosis, while the patient has PMM2-CDG, which is not included. Although age and sex fit, the disease requirement is not met.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"Correct: The patient’s disease (PMM2-CDG) is not among the trial’s included diseases (NPC, GM1, GM2), which is a hard exclusion per rubric, yielding an F. Age/sex compatibility doesn’t override disease mismatch.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT07059130,0.6691051721572876,Fistulizing Crohn's Disease,Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis: A Phase IV Multicenter Interventional Study,"This research study looks at how safe and effective a medicine called Mirikizumab is for treating older adults (aged 60 and above) who have moderate to severe Crohn's disease (CD) or ulcerative colitis (UC). These two conditions, known as inflammatory bowel diseases (IBD), cause inflammation (swelling and irritation) in the digestive tract. Older adults with these conditions often have other health issues and face increased risks and complications, making it challenging for them to use certai...","{'id': 206259044, 'name': 'Mirikizumab', 'description': ""Mirikizumab will be administered to participants according to FDA-approved dosing guidelines for moderate-to-severe Crohn's Disease and Ulcerative Colitis. Participants will receive scheduled doses throughout the study period at predefined intervals. Clinical assessments, patient-reported outcomes, biomarker analyses, and safety monitoring will occur at baseline and at Weeks 12, 24, and 48."", 'other_names': ['Mirikizumab Treatment Group'], 'intervention_type': 'BIOLOGICAL'}",PHASE4,60 years to 99 years,Crohn Disease; Ulcerative Colitis,Age >= 60 years | Moderate-to-severe Crohn's disease (CDAI >= 220) or moderate-to-severe ulcerative colitis (Mayo Score >= 6) | Able to provide informed consent,"Major gastrointestinal surgery within 3 months | Active infection requiring antibiotic or antiviral treatment | Active malignancy or history of malignancy within 5 years (except fully resected basal cell or squamous cell skin cancer with no metastatic disease for >= 3 years) | Participation in another clinical trial with investigational therapy within 30 days | Contraindication or known hypersensitivity to biologic medications, specifically mirikizumab | Unstable angina, myocardial infarction, or cardiovascular procedures within the past 6 months | Uncontrolled hypertension (systolic >= 160 mmHg or diastolic >= 100 mmHg despite treatment) | Congestive heart failure (NYHA Class III or IV) | Clinically significant arrhythmias or other unstable cardiovascular conditions",(none),ALL,F,"The trial requires age 60–99, but the patient is 32, which is outside the allowed window. Although the disease (Crohn’s disease) matches, the age criterion is a hard exclusion.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active draining perianal fistula with seton in place; Recently completed IV antibiotics for perianal abscess,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Patient is 32, while trial minimum age is 60. Age window conflict is a hard exclusion per rubric, so F is correct. Disease otherwise matches; no need to assess anchors once hard exclusion applies.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT07082543,0.4909437298774719,PMM2-CDG,"18-month Double-blind, Randomized, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease and in Late-infantile and Juvenile-onset Forms of GM1 Gangliosidosis or GM2 Gangliosidosis","An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of GM1 gangliosidosis or GM2 gangliosidosis","{'id': 206423285, 'name': 'AZ-3102', 'description': 'Nizubaglustat', 'other_names': [], 'intervention_type': 'DRUG'}; {'id': 206423286, 'name': 'Placebo', 'description': 'Placebo', 'other_names': [], 'intervention_type': 'DRUG'}",PHASE3,4 years,GM1 Gangliosidosis; GM2 Gangliosidosis,"Confirmed GM1 gangliosidosis or Tay-Sachs, Sandhoff, or GM2AB variant | Age >= 4 years | Neurologic symptom onset between 1 and 10 years of age | Ataxic disturbances with total SARA score >= 3 and <= 30 at Baseline | Females of childbearing potential who are sexually active willing to follow contraceptive guidance | Male participants with a female partner of childbearing potential willing to follow contraceptive guidance",Medical conditions other than GM1 or GM2 gangliosidosis that would confound scientific rigor or interpretation | Body weight < 10 kg | Another neurologic disease present | Moderate or severe hepatic impairment | Moderate or severe renal impairment | Platelet count < 100 x10^9/L | Anti-epileptic treatment dose not stable within previous 3 months or new anti-epileptic treatment within 1 month before Baseline | Prior investigational drug use within 3 months before Screening | Prior participation in a clinical study involving gene therapy or stem cell transplantation within 2 years prior to Screening | Positive serum pregnancy test (women of childbearing potential),(none),ALL,F,"Disease mismatch: the trial enrolls GM1/GM2 gangliosidosis (Tay-Sachs/Sandhoff/GM2AB) while the patient has PMM2-CDG, which is not included.",PMM2-CDG,PMM2 (biallelic pathogenic variants),Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; Moderate cerebellar dysfunction; ICARS score 35; Age 8 years; Female sex,(none),(none),,,8,years,female,(none),CORRECT,F,"Disease mismatch is a hard exclusion. The trial enrolls GM1/GM2 gangliosidosis, while the patient has PMM2-CDG. Therefore F is correct regardless of other anchors.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT07097311,0.5343823432922363,Ornithine Transcarbamylase Deficiency,"A Phase II, Open Label Study to Evaluate the Safety of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)","This is a medical research study to test a medication in patients 4 years of age and older with a disease called medium-chain acyl-CoA dehydrogenase deficiency (MCADD). The medication is triheptanoin, which is currently FDA approved for the treatment of long chain fatty acid oxidation disorders (FAODs). Previous research suggests that triheptanoin may also be effective in the treatment MCADD. This study will investigate the safety and efficacy (how well it works) of triheptanoin patients with...","{'id': 206413892, 'name': 'Triheptanoin', 'description': 'Open-label design with doses of triheptanoin up to 1.0 gm/kg/day. The dose will be titrated from Day 1-24.', 'other_names': ['Dojolvi'], 'intervention_type': 'DRUG'}",PHASE2,4 years,Medium-Chain Acyl-CoA Dehydrogenase Deficiency,Diagnosis of MCADD with molecular confirmation | Age >= 4 years | Negative pregnancy test for females of childbearing potential | Use of effective contraception during the study (females of childbearing age and sexually active males),"Use of any investigational drug within 30 days before screening | Active infection (viral or bacterial) or other intercurrent illness at screening | Any clinically significant abnormality or condition increasing risk in the investigator's judgment | Known hypersensitivity to triheptanoin | Breastfeeding or lactating | Type 1 or type 2 diabetes | Use of medications that can cause hypoglycemia | Use of antimetabolite medications (e.g., hydroxyurea, 5-fluorouracil, methotrexate)",(none),ALL,F,"Disease mismatch: the trial targets MCADD, while the patient has OTC deficiency. Additionally, the patient is 3 months old, below the trial’s minimum age of 4 years.",Ornithine Transcarbamylase Deficiency,OTC,Genetically confirmed Ornithine Transcarbamylase (OTC) deficiency; Age 3 months; Male; History of severe neonatal hyperammonemic crisis; Stable on dietary protein restriction and ammonia scavengers,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"There is a hard exclusion due to disease mismatch (OTC vs MCADD). Additionally, the patient is below the trial’s minimum age (3 months vs ≥4 years). Either hard exclusion warrants grade F. The grader’s F and reasoning are correct.",,
